BINDING PROTEINS AGAINST VEGF, PDGF, AND/OR THEIR RECEPTORS

Abstract

Binding proteins that bind one or more of VEGF, PDGF and/or their receptors, including antibodies, CDR-grafted antibodies, humanized antibodies, binding fragments, fusion proteins, and bispecific or multispecific proteins thereof are disclosed. Also disclosed are methods of making and using the binding proteins.

Description

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Aug. 5, 2016, is named 12252_0202-00000_SL.txt and is 4,068,254 bytes in size.

FIELD

The invention relates to antibodies and antigen-binding fragments thereof, as well as multivalent and multispecific binding proteins, that bind vascular endothelial growth factor (VEGF) and/or platelet-derived growth factor (PDGF), as well as their receptors, and methods of making, and using the constructs in the diagnosis, prevention, and/or treatment of acute and chronic inflammatory diseases, cancer, and other disorders.

BACKGROUND

Angiogenesis, the formation of new blood vessels from pre-existing vasculature, plays a role in the pathogenesis of many diseases, including ocular diseases such as age-related macular degeneration (AMD) or diabetic macular edema (DME). Vascular endothelial growth factor (VEGF) plays a role in the regulation of normal and abnormal angiogenesis (Ferrara et al, (1997) Endoer. Rev. 18:4-25). Several anti-VEGF agents are provided in the art, e.g., in U.S. Pat. No. 7,169,901, which discloses VEGF antibodies for inhibiting VEGF-induced cell proliferation, and U.S. Pat. No. 7,070,959, which discloses isolated nucleic acid molecules encoding fusion proteins capable of binding VEGF.

Targeting VEGF with currently available therapeutics is not effective in all patients or for all diseases associated with inflammation and/or angiogenesis. A significant population of non-responders present following anti-VEGF monotherapy, and the disease prevalence will only increase as the aging population increases globally.

A currently preferred treatment for wet AMD consists of intravitreal injections of an anti-VEGF agent. However, although anti-VEGF therapy reduces choroidal neovascularization, it does not have an effect on regression of the mature vasculature. Also, current agents do not provide an anti-fibrotic effect, so that once scarring of the retina occurs; visual acuity cannot be recovered. Other limitations of the existing treatments regimens include patient discomfort, the need for repeat injections with inherent complications including endophthalmitis, retinal tear and detachment, intraocular hemorrhage, and cataract formation. There is a substantial time burden on ophthalmologists to provide monthly intravitreal treatment and optical coherence tomography (OCT) measurements on a large volume patients. As a result, there is a significant medical and economic need for an AMD therapeutic with greater efficacy, or that can be delivered less frequently and still achieve optimal efficacy.

Platelet-derived growth factor (PDGF) is a growth factor involved in the regulation of blood vessels from pre-existing vessel tissue. PDGF binds to receptors on pericytes in newly-forming abnormal blood vessels. This may contribute to neovascularization of abnormal blood vessels by providing a protective perictye coating, for example, during ocular disorders such as wet AMD.

Engineered proteins, such as antibodies, fragments, and multispecific binding proteins capable of binding two or more antigens, are known in the art. Such multispecific binding proteins can be generated using cell fusion, chemical conjugation, or recombinant DNA techniques. There are a variety of multispecific binding protein structures known in the art and many structures and methods have distinct disadvantages.

Bispecific antibodies have been produced using quadroma technology. Bispecific antibodies can also be produced by chemical conjugation of two different mAbs. Other approaches include coupling of two parental antibodies with a hetero-bifunctional crosslinker, production of tandem single-chain Fv molecules, diabodies, bispecific diabodies, single-chain diabodies, and di-diabodies. In addition, a multivalent antibody construct comprising two Fab repeats in the heavy chain of an IgG and capable of binding four antigen molecules has been described (see PCT Publication No. WO 01/77342 and Miller et al. (2003) J. Immunol. 170(9):4854-61).

U.S. Pat. No. 7,612,181 (incorporated herein by reference in its entirety) provides a novel family of binding proteins capable of binding two or more antigens with high affinity, which are called dual variable domain binding proteins (DVD-Ig binding protein) or dual variable domain immunoglobulins (DVD-Ig). DVD-Ig molecules are binding proteins that may be used to bind two distinct epitopes on the same molecule or two different molecules simultaneously. DVD-Ig molecules are unique binding proteins comprised of two variable domains fused to N-terminal constant regions. The variable domains may be directly fused to one another or connected via synthetic peptide linkers of assorted length and amino acid composition. DVD-Ig binding proteins may be engineered with intact and functional Fc domains, or otherwise modified constant domains, allowing them to mediate appropriate effector functions and exhibit other desired properties. The DVD-Ig format, due to its flexibility of choice of variable domain pair, orientation of two antigen-binding domains, and the length of the linker that joins them, may provide novel therapeutic modalities.

Accordingly, while VEGF monotherapy has had some success in the art, there remains a need for constructs exhibiting better targeting, efficiency, and/or efficacy in binding to VEGF, as well as improved targeting of other pathways involved in inflammation (such as ocular inflammation), e.g., the PDGF pathway. Improved targeting of either of these molecules, alone or in combination, may lead to improvements in, e.g., preventing, diagnosing, and/or treating disorders such as angiogenic, inflammatory, and/or ocular disorders. Also, while a variety of structures have been provided in the art, with various advantages and disadvantages, new variable domain sequences can further improve the properties of binding proteins targeting VEGF and/or PDGF, or their cognate receptors.

SUMMARY

Disclosed herein are binding proteins capable of binding VEGF and/or PDGF, and/or their cognate receptors. In some embodiments, the binding proteins are antibodies to VEGF and/or PDGF, or antigen-binding fragments thereof. In some embodiments, the binding proteins are bispecific and capable of binding VEGF and PDGF. In some embodiments, the binding proteins comprise one or more sequences from any one of Tables A, 27-30, 38-42, 46-50, or 56-58, or the CDR amino acid residues from those sequences.

In various embodiments, the binding proteins are bispecific or multispecific binding proteins capable of binding one or more of VEGF and/or PDGF, and/or their cognate receptors. In some embodiments, the binding proteins are dual variable domain immunoglobulins (DVD-Igs or DVD-Ig binding proteins) using the binding protein framework disclosed in U.S. Pat. No. 7,612,181 (incorporated herein by reference in its entirety).

In some embodiments, the DVD-Ig binding proteins contain particular first and second polypeptide chains, each comprising first and second variable domains comprising sequences (e.g., sequences selected from those listed in Tables A, 27-30, 38-42, 46-50, or 56-58, or the CDR amino acid residues from those sequences) that form functional binding sites for binding targets such as VEGF and/or PDGF, or their cognate receptors. In some embodiments, the first and second polypeptide chains of the binding protein each independently comprise VD1-(X1)n-VD2-C-X2, wherein VD1 is a first variable domain; VD2 is a second variable domain; C is a constant domain; X1 is a linker; X2 is an Fc region that is either present or absent; n is 0 or 1, and wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site for VEGF, PDGF, or a cognate receptor, and the VD2 domains on the first and second polypeptide chains form a second functional target binding site for VEGF, PDGF, or a cognate receptor. In some embodiments, (a) the first polypeptide chain of the binding protein comprises VD1-(X1)n-VD2-C-X2, wherein VD1 is a first heavy chain variable domain; VD2 is a second heavy chain variable domain; C is a heavy chain constant domain; X1 is a linker; X2 is an Fc region; and n is 0 or 1 (i.e., X1 and X2 are either present or absent, depending on whether n is independently chosen to be 0 or 1 for each position); and (b) the second polypeptide chain of the binding protein comprises VD1-(X1)n-VD2-C-X2, wherein VD1 is a first light chain variable domain; VD2 is a second light chain variable domain; C is a light chain constant domain; X1 is a linker; X2 is an Fc region; and n is 0 or 1 for X1 and n is 0 for X2 (i.e., the Fc region is absent on the second polypeptide chain); and (c) wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site for VEGF, PDGF, or a cognate receptor, and the VD2 domains on the first and second polypeptide chains form a second functional target binding site for VEGF, PDGF, or a cognate receptor. In some embodiments, the VD1 position forms a binding site for VEGF and the VD2 position forms a binding site for PDGF. In some embodiments, the CDR and/or variable domains at the VD1 and VD2 positions are antibody variable domains and the constant domains are antibody constant domains. Any of the CDR and/or variable domain and/or first and second polypeptide chain sequences disclosed herein may be incorporated in these DVD-Ig binding protein structures to form binding domains for VEGF and/or PDGF, and/or their cognate receptors.

In some embodiments, both the first and second binding sites of a DVD-Ig construct disclosed herein target VEGF. In some embodiments, both the first and second binding sites target PDGF. In some embodiments, the first binding site targets VEGF and the second binding site targets PDGF. In some embodiments, the first binding site targets PDGF and the second binding site targets VEGF. In some embodiments, an Fc domain is present on one polypeptide chain and absent on the other, or absent on both polypeptide chains. In some embodiments, the sequences of the first and second variable domains on each polypeptide chain (i.e., the VD1 and VD2 positions) are independently selected from the sequences in Table A, 27-30, 38-42, 46-50, or 56-58 to form functional binding sites. In some embodiments, the sequences of the first and second variable domains each contain the three complementarity determining regions (i.e., CDRs 1-3) from the selected sequences listed in Tables A, 27-30, 38-42, 46-50, or 56-58, and are arranged in the same order as shown in the Tables, thereby forming functional binding sites (i.e., the binding domains are capable of binding to their target antigen, VEGF or PDGF). In some embodiments, the paired variable domain sequences on the first and second polypeptide chains (i.e., the VD1 sequence on the first chain paired with the VD1 sequence on the second chain and the VD2 sequence on the first chain paired with the VD2 sequence on the second chain) form functional binding sites for binding targets VEGF and/or PDGF using the sequences in the Tables. In some embodiments, the binding proteins are capable of binding to VEGF and/or PDGF with improved binding affinity and/or neutralization potency, improved in vivo efficacy, improved expression, and/or improved drug-like properties (e.g., thermal stability, storage stability, solubility, etc.).

Also disclosed herein are methods of making and using the claimed binding proteins, e.g., in the detection, inhibition, reduction, prevention, and/or treatment of cancers, tumors, fibrosis, renal disease, inflammation, age-related macular degeneration (AMD), wet AMD, diabetic retinopathy, other angiogenesis-dependent diseases, or angiogenesis-independent diseases characterized by aberrant VEGF and/or PDGF expression or activity.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A and FIG. 1B are schematic representations of a Dual Variable Domain (DVD) binding protein construct.

FIG. 2A and FIG. 2B show the reactivity of anti-PDGF-BB antibodies and anti-VEGF-A/anti-PDGF-BB DVD-Ig molecules to ECM-associated PDGF-BB.

FIG. 3 illustrates the inhibition of sprouting from a HUVEC/MSC co-culture sprouting assay by anti-VEGF-A/anti-PDGF-BB DVD-Ig molecules.

FIG. 4 is a bar graph showing the area of subretinal neovascularization in Rho/huVEGF transgenic mice.

FIG. 5 is a bar graph showing the area of choroidal neovascularization in Rho/huVEGF transgenic mice.

FIG. 6 is a bar graph comparing choroidal neovascularization in the untreated eye among the different treatment groups.

FIG. 7 is a bar graph showing number of partial, total, and undetached eyes in Tet/opsin/VEGF mice.

DETAILED DESCRIPTION

Vascular endothelial growth factor (VEGF) is a signal protein that regulates physiological angiogenesis during embryogenesis, skeletal growth, and reproductive functions. Aberrant expression of VEGF is implicated in pathological angiogenesis and is associated with tumors, intraocular neovascular disorders, and other diseases. The VEGF family members include VEGF-A, placenta growth factor (PGF), VEGF-B, VEGF-C, and VEGF-D. Multiple isoforms of VEGF-A exist that result from alternative splicing of a single, 8-exon VEGFA gene. The biological effects of VEGF are mediated by various receptors, including two receptor tyrosine kinases, VEGF receptor-1 (VEGFR1) and VEGF receptor-2 (VEGFR2), which differ in their signaling properties. When cells are deficient in oxygen, they produce hypoxia-inducible factor (HIF) which releases VEGF and other mediators triggering a tyrosine kinase pathway leading to angiogenesis (Ferrara et al. (2003) Nat. Med. 9:669-676). In various embodiments, the binding proteins disclosed herein can bind one or more of the VEGF family members, including alternate isoforms, and/or can bind one or more of the cognate VEGF receptors.

Platelet-derived growth factor (PDGF) is a protein that stimulates growth, survival, and motility of mesenchymal cells and certain other cell types. It has significant functions during embryonal development and in the control of blood vessel formation as an adult. PDGF is composed of a dimeric glycoprotein made up of two A (-AA), two B (-BB) chains, or a combination of the two (-AB). There are five different isoforms of PDGF that moderate cellular responses through two receptors, alpha (PDGFRA) and beta (PDGFRB) (Heldin (2013) Cell Commun Sig. 11:97). PDGF plays an important role in driving the proliferation of undifferentiated mesenchyme and some progenitor populations. Overactivity or inappropriate PDGF signaling is associated with the development of certain malignant diseases, as well as non-malignant diseases characterized by excessive cell proliferation and other inflammatory disorders. In various embodiments, the binding proteins disclosed herein can bind one or more of the PDGF isoforms, and/or can bind one or more of the cognate PDGF receptors.

Binding Proteins

Disclosed herein are binding proteins capable of binding one or more of VEGF, PDGF, and their cognate receptors. In some embodiments, the binding protein is an antibody or an antigen-binding fragment thereof. In an embodiment, the binding protein is an antibody, a monoclonal antibody, a murine antibody, a human antibody, a humanized antibody, a bispecific antibody, a chimeric antibody, a Fab, a Fab′, a F(ab′)₂, an ScFv, an SMIP, an affibody, an avimer, a versabody, a nanobody, a fynomab, a domain antibody, or an antigen binding fragment of any of the foregoing. In an embodiment, the binding protein comprises antibody heavy chain variable domain sequences and antibody light chain variable domain sequences that are capable of binding one or more of VEGF, PDGF, and their cognate receptors. In an embodiment, the binding protein comprises the paired heavy and light chain variable domain sequences of any of the binding sites disclosed in Tables 27-30, 38-42, 46-50, or the CDR sequences from those variable domains. The CDR sequences of the variable domains in the Tables are identified in bold.

In some embodiments, the binding proteins disclosed herein is bispecific or multispecific. The bispecific or multispecific construct may be monovalent or bivalent. Various bispecific or multispecific constructs are known in the art (see e.g., Spiess et al. (2015) Mol. Immunol. 67; 95-106). Bispecific or multispecific constructs include, but are not limited to, an asymmetric bispecific antibody, an asymmetric bispecific IgG4, a CrossMab binding protein, a bispecific antibody, a bispecific binding protein, a multispecific binding protein, a DAF (dual action Fab antibody; two-in-one), a DAF (dual action Fab antibody; four-in-one), a DutaMab, a DT-IgG, a knobs-in-holes binding protein, a Charge pair binding protein, a Fab-arm exchange binding protein, a SEEDbody, a Triomab (Triomab quadroma bispecific or removab bispecific), a LUZ-Y, a Fcab, a κλ-body, an iMab (innovative multimer), and an Orthogonal Fab. In some embodiments, the bispecific or multispecific construct is a DVD-Ig binding protein, an IgG(H)-scFv, an scFv-(H)IgG, an IgG(L)-scFv, an scFv-(L)IgG, an IgG(L, H)-Fv, an IgG(H)-V, a V(H)-IgG, an IgG(L)-V, a V(L)-IgG, a KIH IgG-scFab, a 2scFv-IgG, an IgG-2scFv, an scFv4-Ig, a Zybody, or a DVI-IgG (four-in-one). In some embodiments, the bispecific or multispecific construct also can be a nanobody (or VHH), a bispecific tandem nanobody, a bispecific trivalent tandem nanobody, a nanobody-HSA, a BiTE (bispecific T-cell engager) binding protein, a Diabody, a DART (dual affinity retargeting) binding protein, a TandAb (tetravalent bispecifc tandem antibody), an scDiabody, an scDiabody-CH3, a Diabody-CH3, a Triple Body, a Miniantibody, a Minibody, a TriBi minibody, an scFv-CH3 KIH, a Fab-scFv, an scFv-CH-CL-scFv, a F(ab′)2, a F(ab′)2 scFv2, an scFv-KIH, a Fab-scFv-Fc, a Tetravalent HCAb, an scDiabody-Fc, a Diabody-Fc, a Tandem scFv-Fc, a Fabsc, a bsFc-1/2, a CODV-Ig (cross-over dual variable immunoglobulin), a biclonics antibody or an Intrabody. Bispecific or multispecific constructs also include, for example, a Dock and Lock binding protein, an ImmTAC, an HSAbody, an scDiabody-HSA, a Tandem scFv-Toxin, an IgG-IgG binding protein, a Cov-X-Body, and an scFv1-PEG-scFv2. In some embodiments, the bispecific or multispecific construct is a DVD-Ig binding protein, a CrossMab binding protein, a diabody, a tandem single-chain Fv molecule, a bispecific diabody, a single-chain diabody molecule, or a di-diabody. In some embodiments, the binding protein is a DVD-Ig binding protein. See, e.g., U.S. Pat. No. 7,612,181 (incorporated herein by reference in its entirety). The bispecific or multispecific construct may comprise one or more binding sites for VEGF, PDGF, and/or their receptors. The bispecific or multispecific construct may comprise binding sites only for VEGF, PDGF, and/or their receptors, or may comprise additional binding sites for other antigen targets. The bispecific or multispecific construct may comprise binding sites for more than one epitope on VEGF, PDGF, and/or their receptors, e.g., using different CDR sets or variable domains from those disclosed herein to form binding sites targeting different epitopes.

In various embodiments, the binding protein is capable of binding VEGF, and comprises CDRs 1-3 from SEQ ID NO: 17 and CDRs 1-3 from SEQ ID NO: 18, CDRs 1-3 from SEQ ID NO: 19 and CDRs 1-3 from SEQ ID NO: 20, CDRs 1-3 from SEQ ID NO: 21 and CDRs 1-3 from SEQ ID NO: 22, CDRs 1-3 from SEQ ID NO: 23 and CDRs 1-3 from SEQ ID NO: 24, CDRs 1-3 from SEQ ID NO: 25 and CDRs 1-3 from SEQ ID NO: 26, CDRs 1-3 from SEQ ID NO: 27 and CDRs 1-3 from SEQ ID NO: 28, CDRs 1-3 from SEQ ID NO: 29 and CDRs 1-3 from SEQ ID NO: 30, CDRs 1-3 from SEQ ID NO: 31 and CDRs 1-3 from SEQ ID NO: 32, CDRs 1-3 from SEQ ID NO: 33 and CDRs 1-3 from SEQ ID NO: 34, CDRs 1-3 from SEQ ID NO: 35 and CDRs 1-3 from SEQ ID NO: 36, CDRs 1-3 from SEQ ID NO: 37 and CDRs 1-3 from SEQ ID NO: 38, CDRs 1-3 from SEQ ID NO: 39 and CDRs 1-3 from SEQ ID NO: 40, CDRs 1-3 from SEQ ID NO: 41 and CDRs 1-3 from SEQ ID NO: 42, or CDRs 1-3 from SEQ ID NO: 43 and CDRs 1-3 from SEQ ID NO: 44. In an embodiment, the binding protein is capable of binding VEGF, and comprises SEQ ID NO: 17 and SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, SEQ ID NO: 21 and SEQ ID NO: 22, SEQ ID NO: 23 and SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 26, SEQ ID NO: 27 and SEQ ID NO: 28, SEQ ID NO: 29 and SEQ ID NO: 30, SEQ ID NO: 31 and SEQ ID NO: 32, SEQ ID NO: 33 and SEQ ID NO: 34, SEQ ID NO: 35 and SEQ ID NO: 36, SEQ ID NO: 37 and SEQ ID NO: 38, SEQ ID NO: 39 and SEQ ID NO: 40, SEQ ID NO: 41 and SEQ ID NO: 42, or SEQ ID NO: 43 and SEQ ID NO: 44. Any of said binding proteins capable of binding VEGF may also be capable of binding PDGF, and may comprise any of the PDGF binding sequences as described herein.

In various embodiments, the binding protein is capable of binding PDGF, and comprises CDRs 1-3 from SEQ ID NO: 1 and CDRs 1-3 from SEQ ID NO: 2, CDRs 1-3 from SEQ ID NO: 3 and CDRs 1-3 from SEQ ID NO: 4, CDRs 1-3 from SEQ ID NO: 5 and CDRs 1-3 from SEQ ID NO: 6, CDRs 1-3 from SEQ ID NO: 7 and CDRs 1-3 from SEQ ID NO: 8, CDRs 1-3 from SEQ ID NO: 9 and CDRs 1-3 from SEQ ID NO: 10, CDRs 1-3 from SEQ ID NO: 11 and CDRs 1-3 from SEQ ID NO: 12, CDRs 1-3 from SEQ ID NO: 13 and CDRs 1-3 from SEQ ID NO: 14, CDRs 1-3 from SEQ ID NO: 15 and CDRs 1-3 from SEQ ID NO: 16, or CDRs 1-3 from SEQ ID NO: 211 and CDRs 1-3 from SEQ ID NO: 212. In an embodiment, the binding protein is capable of binding PDGF, and comprises SEQ ID NO: 1 and SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16, or SEQ ID NO: 211 and SEQ ID NO: 212. Any of said binding proteins capable of binding PDGF may also be capable of binding VEGF, and may comprise any of the VEGF binding sequences as described herein.

In an embodiment, the binding protein is a bispecific or multispecific antibody capable of binding one or more of VEGF, PDGF, and their cognate receptors, or another multispecific construct capable of binding the targets. In certain embodiments, the treatment is with bispecific antibodies that have been produced by quadroma technology (Milstein and Cuello (1983) Nature 305(5934): 537-40), by chemical conjugation of two different monoclonal antibodies (Staerz et al. (1985) Nature 314(6012): 628-31), or by knob-into-hole or similar approaches which introduces mutations in the Fc region (Holliger et al. (1993) Proc. Natl. Acad. Sci. USA 90(14): 6444-6448). In some embodiments, the multispecific binding protein is a dual variable domain immunoglobulin (DVD-Ig), e.g., as disclosed in U.S. Pat. No. 7,612,181 (incorporated herein by reference in their entirety). In an embodiment, the DVD-Ig binding protein comprises one or more binding sites comprising the paired heavy and light chain variable domain sequences of any of the binding sites disclosed in Tables 27-30, 38-42, 46-50, or 56-58, or the CDR sequences from those variable domains. For instance, a binding site for VEGF can comprise a paired set of heavy and light chain variable domain sequences from any one of Tables 27 or 38-42, or the CDR regions from those sequences, while the PDGF can comprise the paired heavy and light chain variable domain sequences in Tables 28 or 46-50, or the CDR regions from those sequences. The CDR regions of some of these sequences are shown in Table A and in Table 57.

In some embodiments, a multispecific binding protein disclosed herein is capable of binding VEGF and PDGF, and allows for fewer injections or a lower concentration of active agent, as compared to combination antibody therapy.

In some embodiments, the DVD-Ig binding protein comprises first and second polypeptide chains, each independently comprising VD1-(X1)n-VD2-C-X2, wherein: VD1 is a first variable domain; VD2 is a second variable domain; C is a constant domain; X1 is a linker; X2 is an Fc region that is either present or absent; n is independently 0 or 1 on the first and second chains, and wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site. In some embodiments, the binding protein is capable of binding one or more of VEGF, PDGF, and their cognate receptors, e.g., using a paired set of sequences from any one of Tables 27-30, 38-42, 46-50, or 56-58. In some embodiments, the binding protein comprises VD1 sequences on the first and second polypeptide chains (i.e., a VD1 sequence on the first chain paired with a VD1 sequence on the second chain) that together form a binding domain capable of binding a target selected from VEGF, PDGF, and their cognate receptors. In some embodiments, the binding protein is capable of binding VEGF at both the VD1 and VD2 positions. In some embodiments, the binding protein is capable of binding PDGF at both the VD1 and VD2 positions. In some embodiments, the binding protein is capable of binding VEGF at the VD1 position and PDGF at the VD2 position. In some embodiments, the binding protein is capable of binding PDGF at the VD1 position and VEGF at the VD2 position.

When a binding protein comprises the CDRs from a sequence selected from any one of Tables 27-30, 38-42, 46-50, or 56-58, the CDRs are arranged in the order specified by the sequence in the Table and separated by suitable framework sequences to form a functional binding site. The paired sequences selected from the Tables that form a functional binding site for a target (e.g., a binding site for VEGF and/or PDGF), or the CDRs from those sequences, may be placed in either the VD1 or VD2 positions on the first and second polypeptide chains to form a binding site at either the VD1 or VD2 domain.

The binding proteins disclosed herein comprise VD1 and VD2 binding domains that are capable of binding to first and second target antigens. As used herein, a VD1 domain or a VD2 domain, or a VD1 position or VD2 position, may refer to either the variable domain sequence on one polypeptide chain (e.g., a VD1 heavy chain sequence) or to the variable domain sequences on both the first and second polypeptide chain (e.g., a VD1 heavy chain sequence and a VD1 light chain sequence) that together form the functional binding site, as indicated by the context in which it is discussed.

In some embodiments, a DVD-Ig binding protein can comprise two first and two second polypeptide chains forming four functional binding sites on two arms of the construct. An example of a four chain structure having two arms, each arm comprising a first and second polypeptide chain and two functional binding sites, is shown in FIG. 1.

In an embodiment, the DVD-Ig binding protein is capable of binding VEGF and PDGF, wherein the binding site for VEGF comprises CDRs 1-3 from SEQ ID NO: 17 and CDRs 1-3 from SEQ ID NO: 18, CDRs 1-3 from SEQ ID NO: 19 and CDRs 1-3 from SEQ ID NO: 20, CDRs 1-3 from SEQ ID NO: 21 and CDRs 1-3 from SEQ ID NO: 22, CDRs 1-3 from SEQ ID NO: 23 and CDRs 1-3 from SEQ ID NO: 24, CDRs 1-3 from SEQ ID NO: 25 and CDRs 1-3 from SEQ ID NO: 26, CDRs 1-3 from SEQ ID NO: 27 and CDRs 1-3 from SEQ ID NO: 28, CDRs 1-3 from SEQ ID NO: 29 and CDRs 1-3 from SEQ ID NO: 30, CDRs 1-3 from SEQ ID NO: 31 and CDRs 1-3 from SEQ ID NO: 32, CDRs 1-3 from SEQ ID NO: 33 and CDRs 1-3 from SEQ ID NO: 34, CDRs 1-3 from SEQ ID NO: 35 and CDRs 1-3 from SEQ ID NO: 36, CDRs 1-3 from SEQ ID NO: 37 and CDRs 1-3 from SEQ ID NO: 38, CDRs 1-3 from SEQ ID NO: 39 and CDRs 1-3 from SEQ ID NO: 40, CDRs 1-3 from SEQ ID NO: 41 and CDRs 1-3 from SEQ ID NO: 42, or CDRs 1-3 from SEQ ID NO: 43 and CDRs 1-3 from SEQ ID NO: 44. In an embodiment, the binding site for VEGF comprises SEQ ID NO: 17 and SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, SEQ ID NO: 21 and SEQ ID NO: 22, SEQ ID NO: 23 and SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 26, SEQ ID NO: 27 and SEQ ID NO: 28, SEQ ID NO: 29 and SEQ ID NO: 30, SEQ ID NO: 31 and SEQ ID NO: 32, SEQ ID NO: 33 and SEQ ID NO: 34, SEQ ID NO: 35 and SEQ ID NO: 36, SEQ ID NO: 37 and SEQ ID NO: 38, SEQ ID NO: 39 and SEQ ID NO: 40, SEQ ID NO: 41 and SEQ ID NO: 42, or SEQ ID NO: 43 and SEQ ID NO: 44.

In an embodiment, a DVD-Ig binding protein is disclosed that is capable of binding VEGF and PDGF, wherein the binding site for PDGF comprises CDRs 1-3 from SEQ ID NO: 1 and CDRs 1-3 from SEQ ID NO: 2, CDRs 1-3 from SEQ ID NO: 3 and CDRs 1-3 from SEQ ID NO: 4, CDRs 1-3 from SEQ ID NO: 5 and CDRs 1-3 from SEQ ID NO: 6, CDRs 1-3 from SEQ ID NO: 7 and CDRs 1-3 from SEQ ID NO: 8, CDRs 1-3 from SEQ ID NO: 9 and CDRs 1-3 from SEQ ID NO: 10, CDRs 1-3 from SEQ ID NO: 11 and CDRs 1-3 from SEQ ID NO: 12, CDRs 1-3 from SEQ ID NO: 13 and CDRs 1-3 from SEQ ID NO: 14, CDRs 1-3 from SEQ ID NO: 15 and CDRs 1-3 from SEQ ID NO: 16, or CDRs 1-3 from SEQ ID NO: 211 and CDRs 1-3 from SEQ ID NO: 212. In an embodiment, the binding site for PDGF comprises SEQ ID NO: 1 and SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16, or SEQ ID NO: 211 and SEQ ID NO: 212.

In an embodiment, the DVD-Ig binding protein is capable of binding VEGF and PDGF, wherein the binding site for VEGF comprises CDRs 1-3 from SEQ ID NO: 17 and CDRs 1-3 from SEQ ID NO: 18, CDRs 1-3 from SEQ ID NO: 19 and CDRs 1-3 from SEQ ID NO: 20, CDRs 1-3 from SEQ ID NO: 21 and CDRs 1-3 from SEQ ID NO: 22, CDRs 1-3 from SEQ ID NO: 23 and CDRs 1-3 from SEQ ID NO: 24, CDRs 1-3 from SEQ ID NO: 25 and CDRs 1-3 from SEQ ID NO: 26, CDRs 1-3 from SEQ ID NO: 27 and CDRs 1-3 from SEQ ID NO: 28, CDRs 1-3 from SEQ ID NO: 29 and CDRs 1-3 from SEQ ID NO: 30, CDRs 1-3 from SEQ ID NO: 31 and CDRs 1-3 from SEQ ID NO: 32, CDRs 1-3 from SEQ ID NO: 33 and CDRs 1-3 from SEQ ID NO: 34, CDRs 1-3 from SEQ ID NO: 35 and CDRs 1-3 from SEQ ID NO: 36, CDRs 1-3 from SEQ ID NO: 37 and CDRs 1-3 from SEQ ID NO: 38, CDRs 1-3 from SEQ ID NO: 39 and CDRs 1-3 from SEQ ID NO: 40, CDRs 1-3 from SEQ ID NO: 41 and CDRs 1-3 from SEQ ID NO: 42, or CDRs 1-3 from SEQ ID NO: 43 and CDRs 1-3 from SEQ ID NO: 44; and the binding site for PDGF comprises CDRs 1-3 from SEQ ID NO: 1 and CDRs 1-3 from SEQ ID NO: 2, CDRs 1-3 from SEQ ID NO: 3 and CDRs 1-3 from SEQ ID NO: 4, CDRs 1-3 from SEQ ID NO: 5 and CDRs 1-3 from SEQ ID NO: 6, CDRs 1-3 from SEQ ID NO: 7 and CDRs 1-3 from SEQ ID NO: 8, CDRs 1-3 from SEQ ID NO: 9 and CDRs 1-3 from SEQ ID NO: 10, CDRs 1-3 from SEQ ID NO: 11 and CDRs 1-3 from SEQ ID NO: 12, CDRs 1-3 from SEQ ID NO: 13 and CDRs 1-3 from SEQ ID NO: 14, CDRs 1-3 from SEQ ID NO: 15 and CDRs 1-3 from SEQ ID NO: 16, or CDRs 1-3 from SEQ ID NO: 211 and CDRs 1-3 from SEQ ID NO: 212. In an embodiment, the binding site for VEGF comprises SEQ ID NO: 17 and SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, SEQ ID NO: 21 and SEQ ID NO: 22, SEQ ID NO: 23 and SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 26, SEQ ID NO: 27 and SEQ ID NO: 28, SEQ ID NO: 29 and SEQ ID NO: 30, SEQ ID NO: 31 and SEQ ID NO: 32, SEQ ID NO: 33 and SEQ ID NO: 34, SEQ ID NO: 35 and SEQ ID NO: 36, SEQ ID NO: 37 and SEQ ID NO: 38, SEQ ID NO: 39 and SEQ ID NO: 40, SEQ ID NO: 41 and SEQ ID NO: 42, or SEQ ID NO: 43 and SEQ ID NO: 44; and the binding site for PDGF comprises SEQ ID NO: 1 and SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16, or SEQ ID NO: 211 and SEQ ID NO: 212.

In various embodiments, the DVD-Ig binding protein is capable of binding VEGF and PDGF, wherein the binding site for VEGF comprises CDRs 1-3 from SEQ ID NO: 35 and CDRs-1-3 from SEQ ID NO: 36, and the binding site for PDGF comprises CDRs 1-3 from SEQ ID NO: 15 and CDRs-1-3 from SEQ ID NO: 16. In an embodiment, the binding site for VEGF comprises SEQ ID NO: 35 and SEQ ID NO: 36, and the binding site for PDGF comprises SEQ ID NO: 15 and SEQ ID NO: 16. In any of these embodiments, the binding site for VEGF may be the outer binding domain or VD1 position as described herein, and the binding site for PDGF may be the inner domain or VD2 position as described herein. In various embodiments, any of the DVD-Ig binding proteins disclosed herein can comprise one or more of the X1 linkers shown in Table 55. In an embodiment, the X1 linker on the heavy chain is a GS-H10 linker and the X1 linker on the light chain is a GS-L10(dR) linker. In an embodiment, the X1 linker on the heavy chain is a GS-H10 linker and the X1 linker on the light chain is a GS-L10 linker. In an embodiment, the X1 linker on the heavy chain is an HG-short linker and the X1 linker on the light chain is an LK-long linker.

In various embodiments, any of the antibodies, binding proteins, or DVD-Ig binding proteins disclosed herein can comprise a human IgG (e.g., an IgG1) heavy chain constant region on the first polypeptide chain comprising substitutions of leucines at positions 234 and 235 with alanines, and optionally also (or alternatively) a substitution of histidine at position 435 with alanine, wherein the amino acid positions are numbered using EU index numbering. In various embodiments, the antibody, binding protein, or DVD-Ig binding protein can also comprise a human kappa or lambda light chain constant region on the second polypeptide chain. In an embodiment, the light chain comprises a wild-type human kappa light chain constant region sequence.

In an embodiment, the DVD-Ig binding protein is capable of binding VEGF and PDGF, and comprises PR-1610561 (comprising SEQ ID NOs: 131 and 132). In an embodiment, the binding protein comprises a heavy chain constant region on the first polypeptide chain comprising a human IgG1 heavy chain sequence modified by one or more amino acid changes, wherein the changes comprise substitution of leucines at positions 234 and 235 with alanines, and optionally also comprising a substitution of histidine at position 435 with alanine, wherein the amino acid positions are numbered using EU index numbering; and a light chain constant region on the second polypeptide chain comprising a human kappa light chain constant region sequence. In an embodiment, the binding protein comprises an IgG1 constant region with substitution of leucines at positions 234 and 235 with alanines, and a substitution of histidine at position 435 with alanine, wherein the amino acid positions are numbered using EU index numbering; and a light chain constant region on the second polypeptide chain comprising a human kappa light chain constant region sequence. In some embodiments, the L234A, L235A, and H435 mutations are present in a DVD-Ig binding protein comprising PR-1610561 (comprising SEQ ID NOs: 131 and 132). In some embodiments, the binding protein carrying the constant region mutations has increased ocular duration over an antibody, but is rapidly cleared from systemic circulation (e.g., by altering FcRn recognition), as compared to an antibody or as compared to the same binding protein lacking the constant region mutations. In some embodiments, the high ocular duration allows for less frequent administration and/or fewer overall injections while achieving a comparable or improved efficacy as compared to administration of a combination of anti-VEGF and anti-PDGF antibodies or as compared to administration of the binding protein lacking the constant region mutations. In some embodiments, the binding protein carrying the constant region mutations has decreased ADCC and CDC effector functions mediated by binding to extracellular matrix-associated VEGF-A and/or PDGF-BB, as compared to administration of the binding protein lacking the constant region mutations. In some embodiments, the binding protein carrying the constant region mutations does not bind to one or more Fc-gamma receptors. In some embodiments, systemic levels of the binding protein in a patient drops below detectable levels after less than 20, 25, 30, 35, or 40 hours following administration at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 mg/kg, or more (or any concentration in between) in an intravenous bolus dose.

In an embodiment, the DVD-Ig binding protein is capable of binding VEGF and PDGF, wherein the binding site for VEGF comprises CDRs 1-3 from SEQ ID NO: 17 and CDRs-1-3 from SEQ ID NO: 18, and the binding site for PDGF comprises CDRs 1-3 from SEQ ID NO: 1 and CDRs-1-3 from SEQ ID NO: 2. In an embodiment, the binding site for VEGF comprises SEQ ID NO: 17 and SEQ ID NO: 18, and the binding site for PDGF comprises SEQ ID NO: 1 and SEQ ID NO: 2. In an embodiment, the DVD-Ig binding protein is capable of binding VEGF and PDGF, wherein the binding site for VEGF comprises CDRs 1-3 from SEQ ID NO: 39 and CDRs-1-3 from SEQ ID NO: 40, and the binding site for PDGF comprises CDRs 1-3 from SEQ ID NO: 15 and CDRs-1-3 from SEQ ID NO: 16. In an embodiment, the binding site for VEGF comprises SEQ ID NO: 39 and SEQ ID NO: 40, and the binding site for PDGF comprises SEQ ID NO: 15 and SEQ ID NO: 16. In any of these embodiments, the binding site for VEGF may be the outer binding domain or VD1 sequence as described herein, and the binding site for PDGF may be the inner domain or VD2 sequence as described herein. In various embodiments, the binding proteins can comprise one or more of the X1 linkers shown in Table 55. In an embodiment, the X1 linker on the heavy chain is a GS-H10 linker and the X1 linker on the light chain is a GS-L10(dR) linker. In an embodiment, the X1 linker on the heavy chain is a GS-H10 linker and the X1 linker on the light chain is a GS-L10 linker. In an embodiment, the X1 linker on the heavy chain is an HG-short linker and the X1 linker on the light chain is an LK-long linker. In an embodiment, the binding protein is capable of binding VEGF and PDGF, and comprises PR-1572102 (comprising SEQ ID NOs: 88 and 89) or PR-1572105 (comprising SEQ ID NOs: 94 and 95) or PR1611292 (comprising SEQ ID NOs: 141 and 142). In an embodiment, the binding protein comprises a heavy chain constant region on the first polypeptide chain comprising a human IgG1 heavy chain sequence modified by one or more amino acid changes, wherein the changes comprise substitution of leucines at positions 234 and 235 with alanines, and optionally also comprising a substitution of histidine at position 435 with alanine, wherein the amino acid positions are numbered using EU index numbering; and a light chain constant region on the second polypeptide chain comprising a human kappa light chain constant region sequence.

In an embodiment, the DVD-Ig binding protein comprises the first and second polypeptide chains of any of the DVD-Ig binding proteins disclosed in Tables 56-58. The CDR sequences of the variable domains in Tables 56-58 are in bold and the linker sequences are italicized.

In an embodiment, the DVD-Ig binding protein comprises the first and second polypeptide chains of PR-1563988 (comprising SEQ ID NOs: 45 and 46), PR-1563990 (comprising SEQ ID NOs: 47 and 48), PR-1563998 (comprising SEQ ID NOs: 49 and 50), PR-1564009 (comprising SEQ ID NOs: 51 and 52), PR-1564010 (comprising SEQ ID NOs: 53 and 54), PR-1564011 (comprising SEQ ID NOs: 55 and 56), PR-1564012 (comprising SEQ ID NOs: 57 and 58), PR-1564013 (comprising SEQ ID NOs: 59 and 60), PR-1565031 (comprising SEQ ID NOs: 76 and 77), PR-1565032 (comprising SEQ ID NOs: 78 and 79), PR-1565035 (comprising SEQ ID NOs: 80 and 81), PR-1572102 (comprising SEQ ID NOs: 88 and 89), PR-1572103 (comprising SEQ ID NOs: 90 and 91), PR-1572104 (comprising SEQ ID NOs: 92 and 93), PR-1572105 (comprising SEQ ID NOs: 94 and 95), PR-1572106 (comprising SEQ ID NOs: 96 and 97), PR-1575832 (comprising SEQ ID NOs: 99 and 100), PR-1575834 (comprising SEQ ID NOs: 101 and 102), PR-1575835 (comprising SEQ ID NOs: 103 and 104), PR-1577165 (comprising SEQ ID NOs: 105 and 106), PR-1577166 (comprising SEQ ID NOs: 107 and 108), PR-1577547 (comprising SEQ ID NOs: 109 and 110), PR-1577548 (comprising SEQ ID NOs: 111 and 112), PR-1577550 (comprising SEQ ID NOs: 113 and 114), PR-1578137 (comprising SEQ ID NOs: 116 and 117), PR-1610560 (comprising SEQ ID NOs: 129 and 130), PR-1610561 (comprising SEQ ID NOs: 131 and 132), PR-1610562 (comprising SEQ ID NOs: 133 and 134), PR-1610563 (comprising SEQ ID NOs: 135 and 136), PR-1611291 (comprising SEQ ID NOs: 139 and 140), PR-1611292 (comprising SEQ ID NOs: 141 and 142), PR-1612489 (comprising SEQ ID NOs: 161 and 162), PR-1612491 (comprising SEQ ID NOs: 163 and 164), PR-1612492 (comprising SEQ ID NOs: 165 and 166), PR-1612495 (comprising SEQ ID NOs: 171 and 172), PR-1612496 (comprising SEQ ID NOs: 173 and 174), PR-1612499 (comprising SEQ ID NOs: 177 and 178), PR-1612500 (comprising SEQ ID NOs: 179 and 180), PR-1612501 (comprising SEQ ID NOs: 181 and 182), PR-1612502 (comprising SEQ ID NOs: 183 and 184), PR-1613183 (comprising SEQ ID NOs: 185 and 186), PR-1613184 (comprising SEQ ID NOs: 187 and 188), PR-1613185 (comprising SEQ ID NOs: 189 and 190), PR-1613190 (comprising SEQ ID NOs: 199 and 200), PR-1565040 (comprising SEQ ID NOs: 3844 and 3845), PR-1565042 (comprising SEQ ID NOs: 3837 and 3838), PR-1565044 (comprising SEQ ID NOs: 213 and 214), PR-1565051 (comprising SEQ ID NOs: 215 and 216), PR-1565083 (comprising SEQ ID NOs: 217 and 218), PR-1565084 (comprising SEQ ID NOs: 219 and 220), PR-1565085 (comprising SEQ ID NOs: 221 and 222), PR-1565086 (comprising SEQ ID NOs: 223 and 224), PR-1571821 (comprising SEQ ID NOs: 225 and 226), PR-1571823 (comprising SEQ ID NOs: 227 and 228), PR-1575521 (comprising SEQ ID NOs: 229 and 230), PR-1571824 (comprising SEQ ID NOs: 231 and 232), PR-1571825 (comprising SEQ ID NOs: 233 and 234), PR-1571826 (comprising SEQ ID NOs: 235 and 236), PR-1571827 (comprising SEQ ID NOs: 237 and 238), PR-1571828 (comprising SEQ ID NOs: 239 and 240), PR-1571830 (comprising SEQ ID NOs: 241 and 242), PR-1571831 (comprising SEQ ID NOs: 243 and 244), PR-1571832 (comprising SEQ ID NOs: 245 and 246), PR-1571836 (comprising SEQ ID NOs: 247 and 248), PR-1577053 (comprising SEQ ID NOs: 249 and 250), or PR-1577056 (comprising SEQ ID NOs: 251 and 252.

In some embodiments, a binding protein, including a DVD-Ig binding protein, antibody, or fragment thereof, is capable of binding VEGF and/or PDGF and has at least about 80%, 90%, 95%, or 99% homology to CDRs 1-3 or to the full variable domains of any of the sequences in Tables 27, 28, 38-42, or 46-50. As used herein, the term percent (%) homology defines the percentage of residues in the amino acid sequence variant that are identical after aligning the sequences and introducing gaps and other spacing, e.g., using the BLAST alignment software.

In an embodiment, the binding protein has an on rate constant (K_on) to one or more targets of at least about 10²M⁻¹s⁻¹; at least about 10³M⁻¹s⁻¹; at least about 10⁴M⁻¹s⁻¹; at least about 10⁵M⁻¹s⁻¹; or at least about 10⁶M⁻¹s⁻¹, as measured by surface plasmon resonance. In an embodiment, the binding protein has an on rate constant (K_on) to one or more targets from about 10²M⁻¹s⁻¹ to about 10³M⁻¹s⁻¹; from about 10³M⁻¹s⁻¹ to about 10⁴M⁻¹s⁻¹; from about 10⁴M⁻¹s⁻¹ to about 10⁵M⁻¹s⁻¹; or from about 10⁵M⁻¹s⁻¹ to about 10⁶M⁻¹s⁻¹, as measured by surface plasmon resonance.

In an embodiment, the binding protein has an off rate constant (K_off) for one or more targets of at most about 10⁻³s⁻¹; at most about 10⁻⁴s⁻¹; at most about 10⁻⁵s⁻¹; or at most about 10⁻⁶s⁻¹, as measured by surface plasmon resonance. In an embodiment, the binding protein has an off rate constant (K_off) to one or more targets of about 10⁻³s⁻¹ to about 10⁻⁴s⁻¹; of about 10⁻⁴s⁻¹ to about 10⁻⁵s⁻¹; or of about 10⁻⁵s⁻¹ to about 10⁻⁶s⁻¹, as measured by surface plasmon resonance.

In an embodiment, the binding protein has a dissociation constant (K_d) to one or more targets of at most about 10⁻⁷M; at most about 10⁻⁸M; at most about 10⁻⁹M; at most about 10⁻¹⁰ M; at most about 10⁻¹¹M; at most about 10⁻¹²M; or at most 10⁻¹³M. In an embodiment, the binding protein has a dissociation constant (K_d) to its targets of about 10⁻⁷M to about 10⁻⁸M; of about 10⁻⁸M to about 10⁻⁹M; of about 10⁻⁹M to about 10⁻¹⁰ M; of about 10⁻¹⁰ M to about 10⁻¹¹M; of about 10⁻¹¹M to about 10⁻¹²M; or of about 10⁻¹² to M about 10⁻¹³M.

In an embodiment, the binding protein is a conjugate further comprising an agent. In an embodiment, the agent is an immunoadhesion molecule, an imaging agent, a therapeutic agent, or a cytotoxic agent. In an embodiment, the imaging agent is a radiolabel, an enzyme, a fluorescent label, a luminescent label, a bioluminescent label, a magnetic label, or biotin. In another embodiment, the radiolabel is ³H, ¹⁴C, ³⁵S, ⁹⁰Y, ⁹⁹Tc, ¹¹¹In, ¹²⁵I, ¹³¹I, ¹⁷⁷Lu, ¹⁶⁶Ho, or ¹⁵³Sm. In yet another embodiment, the therapeutic or cytotoxic agent is an anti-metabolite, an alkylating agent, an antibiotic, a growth factor, a cytokine, an anti-angiogenic agent, an anti-mitotic agent, an anthracycline, toxin, or an apoptotic agent, or an immunosuppressive agent.

In an embodiment, the binding protein is a crystallized binding protein and exists as a crystal. In an embodiment, the crystal is a carrier-free pharmaceutical controlled release crystal. In another embodiment, the crystallized binding protein has a greater half-life in vivo than the soluble counterpart of the binding protein. In yet another embodiment, the crystallized binding protein retains biological activity.

In certain embodiments, a binding protein disclosed herein can compete for binding to VEGF, PDGF, and/or a cognate receptor with any of the antibodies, binding proteins, or bispecific antibodies disclosed herein. In certain embodiments, a binding protein disclosed herein can compete for binding with an antibody, binding protein, or bispecific antibody comprising CDRs and/or variable domains selected from those identified in Tables 27, 28, 38-42, or 46-50. In certain embodiments, a binding protein disclosed herein can compete for binding with PR-1610561 (comprising SEQ ID NOs: 131 and 132) or a binding protein comprising the CDRs and/or variable domains of PR-1610561. In certain embodiments, a binding protein disclosed herein can compete for binding with PR-1572102 (comprising SEQ ID NOs: 88 and 89) or PR-1572105 (comprising SEQ ID NOs: 94 and 95) or PR1611292 (comprising SEQ ID NOs: 141 and 142).

According to certain embodiments, a binding protein disclosed herein can bind to the same epitope of VEGF, PDGF, and/or a cognate receptor as any of the antibodies, binding proteins, or bispecific antibodies disclosed herein. In certain embodiments, a binding protein disclosed herein can bind to the same epitope of VEGF, PDGF, and/or a cognate receptor bound by an antibody, binding protein, or bispecific antibody comprising CDRs and/or variable domains selected from those identified in Tables 27, 28, 38-42, or 46-50. In certain embodiments, a binding protein disclosed herein can bind to the same epitope as PR-1610561 (comprising SEQ ID NOs: 131 and 132) or a binding protein comprising the CDRs and/or variable domains of PR-1610561. In certain embodiments, a binding protein disclosed herein binds to the same epitope as PR-1572102 (comprising SEQ ID NOs: 88 and 89) or PR-1572105 (comprising SEQ ID NOs: 94 and 95) or PR1611292 (comprising SEQ ID NOs: 141 and 142).

In certain embodiments, competitive binding can be evaluated using a cross-blocking assay, such as the assay described in ANTIBODIES, A LABORATORY MANUAL, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1^st edition 1988, 2^nd edition 2014). In some embodiments, competitive binding is identified when a test antibody or binding protein reduces binding of a reference antibody or binding protein (e.g., a binding protein comprising CDRs and/or variable domains selected from those identified in Tables 27, 28, 38-42, or 46-50) to VEGF, PDGF, and/or a cognate receptor by at least about 50% in the cross-blocking assay (e.g., 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.5%, or more, or any percentage in between), and/or vice versa. In some embodiments, competitive binding can be due to shared or similar (e.g., partially overlapping) epitopes, or due to steric hindrance where antibodies or binding proteins bind at nearby epitopes. See, e.g., Tzartos, Methods in Molecular Biology, vol. 66, Epitope Mapping Protocols, pages 55-66, Humana Press Inc. (1998). In some embodiments, competitive binding can be used to sort groups of binding proteins that share similar epitopes, e.g., those that compete for binding can be “binned” as a group of binding proteins that have overlapping or nearby epitopes, while those that do not compete are placed in a separate group of binding proteins that do not have overlapping or nearby epitopes

In an embodiment, the binding protein described herein is glycosylated. For example, the glycosylation pattern may be a human glycosylation pattern.

In various embodiments, a pharmaceutical composition comprising a binding protein disclosed herein and a pharmaceutically acceptable carrier is provided. In a further embodiment, the pharmaceutical composition comprises at least one additional agent such as a therapeutic agent for treating a disorder or a diagnostic agent. For example, the additional agent may be a therapeutic agent, an imaging agent, a cytotoxic agent, an angiogenesis inhibitor (including but not limited to an anti-VEGF antibody or a VEGF-trap), a kinase inhibitor (including but not limited to a KDR and a TIE-2 inhibitor), a co-stimulation molecule blocker (including but not limited to anti-B7.1, anti-B7.2, CTLA4-Ig, anti-CD20), an adhesion molecule blocker (including but not limited to an anti-LFA-1 antibody, an anti-E/L selectin antibody, a small molecule inhibitor), an anti-cytokine antibody or functional fragment thereof (including but not limited to an anti-IL-18, an anti-TNF, and an anti-IL-6/cytokine receptor antibody), methotrexate, cyclosporin, rapamycin, FK506, a detectable label or reporter, a TNF antagonist, an antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteriod, an anabolic steroid, an erythropoietin, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an antidepressant, an antipsychotic, a stimulant, an asthma medication, a beta agonist, an inhaled steroid, an epinephrine or analog, a cytokine, or a cytokine antagonist.

In various embodiments, a binding protein disclosed herein binds to VEGF and comprises CDRs and/or variable domains selected from those identified in Tables A, 2.4.1-2.4.9, 27, and 38-42. In some embodiments, the binding protein comprises a CDR set of heavy chain CDRs 1-3 and paired light chain CDRs 1-3 selected from any of the CDR sets listed in Tables A, 2.4.1-2.4.9, 27, and 38-42. In some embodiments, the binding protein comprises a heavy chain variable domain and paired light chain variable domain selected from any of the variable domains listed in Tables A, 2.4.1-2.4.9, 27, and 38-42. In some embodiments, the binding protein is a bispecific or multispecific binding protein, comprising CDRs and/or variable domains selected from Tables A, 2.4.1-2.4.9, 27, and 38-42. The binding protein may further comprise heavy and light chain constant domains selected from Table 3. In some embodiments, the binding protein is also capable of binding to PDGF.

In some embodiments, a binding protein disclosed herein binds to PDGF and comprises CDRs and/or variable domains selected from those identified in Tables A, 1.4.1-1.4.7, 28, and 46-50. In some embodiments, the binding protein comprises a CDR set of heavy chain CDRs 1-3 and paired light chain CDRs 1-3 selected from any of the CDR sets listed in Tables A, 1.4.1-1.4.7, 28, and 46-50. In some embodiments, the binding protein comprises a heavy chain variable domain and paired light chain variable domain selected from any of the variable domains listed in Tables A, 1.4.1-1.4.7, 28, and 46-50. In some embodiments, the binding protein is a bispecific or multispecific binding protein, comprising CDRs and/or variable domains selected from Tables A, 1.4.1-1.4.7, 28, and 46-50. The binding protein may further comprise heavy and light chain constant domains selected from Table 3. In some embodiments, the binding protein is also capable of binding to VEGF.

In some embodiments, a binding protein disclosed herein binds to VEGF and PDGF, wherein the binding site for VEGF comprises CDRs and/or variable domains selected from those identified in Tables A, 2.4.1-2.4.9, 27, and 38-42 and the binding site for PDGF comprises CDRs and/or variable domains selected from those identified in Tables A, 1.4.1-1.4.7, 28, and 46-50. In some embodiments, the binding sites for VEGF and PDGF comprises CDRs and/or variable domains selected from any of the variable domains listed in Tables 56-59, 95, and 96. In some embodiments, binding proteins disclosed herein comprise binding sites for VEGF and PDGF comprising the paired CDRs and/or variable domains from any one of the bispecific binding proteins selected from Tables 56-59, 95, and 96. In some embodiments, the binding proteins are DVD-Ig binding proteins, or any of the other bispecific or multispecific formats disclosed herein. The binding protein described herein may further comprise one or more linkers between the VEGF and PDGF binding sites, wherein the linkers comprise sequences that are selected from Table 55. The binding protein described herein may also comprise heavy and light chain constant domains selected from Table 3.

In some embodiments, a binding protein is capable of binding VEGF and PDGF, wherein the binding site for VEGF comprises CDRs 1-3 from SEQ ID NO: 17 and CDRs-1-3 from SEQ ID NO: 18, and the binding site for PDGF comprises a CDR set of heavy chain CDRs 1-3 and paired light chain CDRs 1-3 selected from any of Tables A, 1.4.1-1.4.7, 28, and 46-50. In some embodiments, the binding site for VEGF comprises CDRs 1-3 from SEQ ID NO: 35 and CDRs-1-3 from SEQ ID NO: 36, and the binding site for PDGF comprises a CDR set of heavy chain CDRs 1-3 and paired light chain CDRs 1-3 selected from any of Tables A, 1.4.1-1.4.7, 28, and 46-50. In some embodiments, the binding site for VEGF comprises CDRs 1-3 from SEQ ID NO: 39 and CDRs-1-3 from SEQ ID NO: 40, and the binding site for PDGF comprises a CDR set of heavy chain CDRs 1-3 and paired light chain CDRs 1-3 selected from any of Tables A, 1.4.1-1.4.7, 28, and 46-50. In some embodiments, the binding site for VEGF comprises SEQ ID NO: 17 and SEQ ID NO: 18, and the binding site for PDGF comprises a heavy chain variable domain and paired light chain variable domain selected from any of the variable domains listed in Tables A, 1.4.1-1.4.7, 28, and 46-50. In some embodiments, the binding site for VEGF comprises SEQ ID NO: 35 and SEQ ID NO: 36, and the binding site for PDGF comprises a heavy chain variable domain and paired light chain variable domain selected from any of the variable domains listed in Tables A, 1.4.1-1.4.7, 28, and 46-50. In some embodiments, the binding site for VEGF comprises SEQ ID NO: 39 and SEQ ID NO: 40, and the binding site for PDGF comprises a heavy chain variable domain and paired light chain variable domain selected from any of the variable domains listed in Tables A, 1.4.1-1.4.7, 28, and 46-50. The binding protein described herein may further comprise one or more linkers between the VEGF and PDGF binding sites, wherein the linkers comprise sequences that are selected from Table 55. The binding protein described herein may also comprise heavy and light chain constant domains selected from Table 3.

In some embodiments, a binding protein is capable of binding VEGF and PDGF, wherein the binding site for PDGF comprises CDRs 1-3 from SEQ ID NO: 1 and CDRs-1-3 from SEQ ID NO: 2, and the binding site for VEGF comprises a CDR set of heavy chain CDRs 1-3 and paired light chain CDRs 1-3 selected from any of Tables A, 2.4.1-2.4.9, 27, and 38-42. In some embodiments, the binding site for PDGF comprises CDRs 1-3 from SEQ ID NO: 15 and CDRs-1-3 from SEQ ID NO: 16, and the binding site for VEGF comprises a CDR set of heavy chain CDRs 1-3 and paired light chain CDRs 1-3 selected from any of Tables A, 2.4.1-2.4.9, 27, and 38-42. In some embodiments, the binding site for PDGF comprises SEQ ID NO: 1 and SEQ ID NO: 2, and the binding site for VEGF comprises a heavy chain variable domain and paired light chain variable domain selected from any of the variable domains listed in Tables A, 2.4.1-2.4.9, 27, and 38-42. In some embodiments, the binding site for PDGF comprises SEQ ID NO: 15 and SEQ ID NO: 16, and the binding site for VEGF comprises a heavy chain variable domain and paired light chain variable domain selected from any of the variable domains listed in Tables A, 2.4.1-2.4.9, 27, and 38-42. The binding protein described herein may further comprise one or more linkers between the VEGF and PDGF binding sites, wherein the linkers comprise sequences that are selected from Table 55. The binding protein described herein may also comprise heavy and light chain constant domains selected from Table 3.

In some embodiments, a binding protein is capable of binding VEGF and PDGF, wherein the binding site for VEGF comprises CDRs 1-3 from SEQ ID NO: 17 and CDRs-1-3 from SEQ ID NO: 18, and the binding site PDGF comprises CDRs 1-3 from SEQ ID NO: 1 and CDRs-1-3 from SEQ ID NO: 2. In some embodiments, the binding site for VEGF comprises CDRs 1-3 from SEQ ID NO: 35 and CDRs-1-3 from SEQ ID NO: 36, and the binding site for PDGF comprises CDRs 1-3 from SEQ ID NO: 15 and CDRs-1-3 from SEQ ID NO: 16. In some embodiments, the binding site for VEGF comprises CDRs 1-3 from SEQ ID NO: 39 and CDRs-1-3 from SEQ ID NO: 40, and the binding site for PDGF comprises CDRs 1-3 from SEQ ID NO: 15 and CDRs-1-3 from SEQ ID NO: 16. The binding protein described herein may further comprise one or more linkers between the VEGF and PDGF binding sites, wherein the linkers comprise sequences that are selected from Table 55. The binding protein described herein may also comprise heavy and light chain constant domains selected from Table 3.

In some embodiments, a binding protein is capable of binding VEGF and PDGF, wherein the binding site for VEGF comprises SEQ ID NO: 17 and SEQ ID NO: 18, and the binding site PDGF comprises SEQ ID NO: 1 and SEQ ID NO: 2. In some embodiments, the binding site for VEGF comprises SEQ ID NO: 35 and SEQ ID NO: 36, and the binding site for PDGF comprises SEQ ID NO: 15 and SEQ ID NO: 16. In some embodiments, the binding site for VEGF comprises SEQ ID NO: 39 and SEQ ID NO: 40, and the binding site for PDGF comprises SEQ ID NO: 15 and SEQ ID NO: 16. The binding protein described herein may further comprise one or more linkers between the VEGF and PDGF binding sites, wherein the linkers comprise sequences that are selected from Table 55. The binding protein described herein may also comprise heavy and light chain constant domains selected from Table 3.

In some embodiments, the binding protein is a DVD-Ig binding protein, capable of binding VEGF and PDGF. In some embodiment, the heavy chain of the binding protein comprises a DVD-Ig heavy chain variable domain and paired DVD-Ig light chain variable domain selected from Tables 56-59, 95, and 96. In some embodiments, the binding protein comprises DVD-Ig heavy and light chain variable domains of SEQ ID NO: 131 and SEQ ID NO: 132. In some embodiments, the binding protein comprises DVD-Ig heavy and light chain variable domains of SEQ ID NO: 88 and SEQ ID NO: 89. In some embodiments, the binding protein comprises DVD-Ig heavy and light chain variable domains of SEQ ID NO: 94 and SEQ ID NO: 95. In some embodiments, the binding protein comprises DVD-Ig heavy and light chain variable domains of SEQ ID NO: 141 and SEQ ID NO: 142. The DVD-Ig binding protein described herein may further comprise heavy and light chain constant domains selected from Table 3.

In certain embodiments, a binding protein disclosed herein is a DVD-Ig binding protein, comprising first and second polypeptide chains of SEQ ID NO: 131 and SEQ ID NO: 132. In some embodiments, the DVD-Ig binding protein comprises first and second polypeptide chains of SEQ ID NO: 88 and SEQ ID NO: 89. In some embodiments, the DVD-Ig binding protein comprises first and second polypeptide chains of SEQ ID NO: 94 and SEQ ID NO: 95. In some embodiments, the DVD-Ig binding protein comprises first and second polypeptide chains of SEQ ID NO: 141 and SEQ ID NO: 142.

Binding Protein Properties

The development and production of a binding protein for use as a human therapeutic agent, e.g., as an anti-inflammatory agent or oncologic agent, may require more than the identification of a binding protein capable of binding to a desired target or targets. The binding proteins disclosed herein exhibit favorable properties in one or more of the following categories (a) the binding kinetics (on-rate, off-rate and affinity) for both the inner and outer antigen-binding domains, (b) potencies in various biochemical and cellular bioassays, (c) in vivo efficacies in relevant tumor models, (d) pharmacokinetic and pharmacodynamics properties, (e) manufacturability, including protein expression level in selected cell lines, scalability, post-translational modification, physicochemical properties such as monomer percentage, solubility, and stability (intrinsic, freeze/thaw, storage stability, etc.), (f) formulation properties, (g) potential immunogenicity risk, (h) toxicological properties, and (i) binding mode and valency. Binding mode and valency may affect binding properties and cellular potencies of a molecule.

The binding proteins disclosed herein exhibit favorable properties in some or each of the categories listed above, including surprisingly high binding affinity at both the VD1 and VD2 positions.

In some embodiments a binding protein or binding proteins disclosed herein targeting VEGF and PDGF serve to both reduce choroidal neovascularization and increase regression of mature vasculature, e.g., in ocular conditions such as AMD. In some embodiments a binding protein or binding proteins disclosed herein targeting VEGF and PDGF neutralize VEGF and PDGF simultaneously. In some embodiments, the binding protein exhibits one or more of high potency to VEGF and/or PDGF, extended ocular duration, and rapid clearance from systemic circulation. In some embodiments, the binding protein is a bispecific and allows for a single injection of an agent to both targets (VEGF and PDGDF), reducing injection volume/frequency while still retaining the drug-like products of a traditional antibody.

In some embodiments, the disclosed binding protein exhibits superior in vivo efficacy (e.g., in a preclinical model of choroidal neovascularization or AMD) as compared to existing treatments for AMD (e.g., Elyea™ and/or Lucentis™). In some embodiments, the disclosed binding protein is a DVD-Ig binding protein and exhibits a high ocular duration. In some embodiments, the DVD-Ig binding protein may be, e.g., 150-200 kDa in weight or greater, and may provide for a longer ocular duration as compared to lower weight agents such as monoclonal antibodies. In some embodiments, the binding protein disclosed herein is a DVD-Ig binding protein and has an ocular half life of at least about 4 days, or at least about 4. 6 days, or at least about 5 days, or at least about 6 days, or at least about 6.5 days, or more. In some embodiments, the DVD-Ig ocular half life is greater than the half-life of an antibody or other construct having a smaller size, while retaining a more rapid systemic clearance similar to that of the antibody. In some embodiments, the DVD-Ig binding protein has an ocular half life of at least about 4 (or at least about 4.6) days after intravitreoius administration at 0.25 mg.

In some embodiments, the disclosed binding proteins are DVD-Ig binding proteins and exhibit improved drug-like properties, including one or more of high thermostability (e.g., a T_onset of greater than 50°, 55°, 60°, 61°, 62°, 63°, 64°, or 65° C.), a solubility of at least about 70, 72, 74, 76, 78, or 80 mg/ml, a viscosity at room temperature and at a concentration of 100 mg/ml of about 7.2 centipoise, an effective storage stability in a universal buffer, and/or high freeze-thaw stability. In some embodiments, the DVD-Ig binding protein does not exhibit a significant change in monomer percentage at low concentration after storage at 5° C. or 40° C. for 10, 15, 20, 21, 22, 23, 24, 25, or more days, and/or does not exhibit a significant increase in aggregation at 50-150 mg/ml (or 100+/−10 mg/ml) after 1, 2, 3, 4, 5, or more freeze/thaw cycles.

In certain embodiments, a binding protein exhibiting particularly favorable properties in some or each of the categories listed above is a DVD-Ig binding protein capable of binding VEGF and PDGF, wherein the binding site for VEGF comprises CDRs 1-3 from SEQ ID NO: 35 and CDRs-1-3 from SEQ ID NO: 36, and the binding site for PDGF comprises CDRs 1-3 from SEQ ID NO: 15 and CDRs-1-3 from SEQ ID NO: 16. In an embodiment, the binding site for VEGF comprises SEQ ID NO: 35 and SEQ ID NO: 36, and the binding site for PDGF comprises SEQ ID NO: 15 and SEQ ID NO: 16. In an embodiment, the binding protein is capable of binding VEGF and PDGF, and comprises PR-1610561 (comprising SEQ ID NOs: 131 and 132). In an embodiment, the binding protein comprises a heavy chain constant region on the first polypeptide chain comprising a human IgG1 heavy chain sequence modified by one or more amino acid changes, wherein the changes comprise substitution of leucines at positions 234 and 235 with alanines, and optionally also comprising a substitution of histidine at position 435 with alanine, wherein the amino acid positions are numbered using EU index numbering; and a light chain constant region on the second polypeptide chain comprising a human kappa light chain constant region sequence

In certain embodiments, a binding protein exhibiting particularly favorable properties in some or each of the categories listed above is a DVD-Ig binding protein capable of binding VEGF and PDGF, wherein the binding site for VEGF comprises CDRs 1-3 from SEQ ID NO: 17 and CDRs-1-3 from SEQ ID NO: 18, and the binding site for PDGF comprises CDRs 1-3 from SEQ ID NO: 1 and CDRs-1-3 from SEQ ID NO: 2. In an embodiment, the binding site for VEGF comprises SEQ ID NO: 17 and SEQ ID NO: 18, and the binding site for PDGF comprises SEQ ID NO: 1 and SEQ ID NO: 2. In an embodiment, the binding protein is capable of binding VEGF and PDGF, and comprises PR-1572102 (comprising SEQ ID NOs: 88 and 89) or PR-1572105 (comprising SEQ ID NOs: 94 and 95) or PR1611292 (comprising SEQ ID NOs: 141 and 142). In an embodiment, the binding protein comprises a heavy chain constant region on the first polypeptide chain comprising a human IgG1 heavy chain sequence modified by one or more amino acid changes, wherein the changes comprise substitution of leucines at positions 234 and 235 with alanines, and optionally also comprising a substitution of histidine at position 435 with alanine, wherein the amino acid positions are numbered using EU index numbering; and a light chain constant region on the second polypeptide chain comprising a human kappa light chain constant region sequence.

For instance, in some embodiments, the binding protein disclosed herein (e.g., PR-1610561, PR-1572102, PR-1572105, or PR1611292) may exhibit one or more of the following features: enhanced in vivo efficacy in human VEGF transgenic mice, enhanced potency (as measured, e.g., via BIACORE, ELISA, or co-culture sprouting assay), improved expression (e.g., in HEK293 or CHO cells), and improved drug-like properties (e.g., thermal stability, storage stability, solubility, physicochemical properties, and/or pharmacokinetics) as compared to another binding protein or combination of binding proteins targeting VEGF and PDGF.

Preparation of Binding Proteins

In another aspect, the disclosure provides a method of making a binding protein that binds PDGF, VEGF, and/or either or both cognate receptors. In an embodiment, the method of making a binding protein comprises the steps of a) obtaining a first parent antibody, or antigen binding portion thereof, that binds PDGF, VEGF, or a cognate receptor; b) obtaining a second parent antibody, or antigen binding portion thereof, that binds PDGF, VEGF, or a cognate receptor; c) determining the sequences of the variable domains of the parent antibodies or antigen binding portions thereof; d) preparing construct(s) encoding any of the binding proteins described herein using those variable domain sequences; and e) expressing the polypeptide chains, such that a binding protein that binds PDGF, VEGF, and/or either or both cognate receptors is generated.

In any of the embodiments herein, the VD1 heavy chain variable domain, if present, and light chain variable domain, if present, can be from a first parent antibody or antigen binding portion thereof; the VD2 heavy chain variable domain, if present, and light chain variable domain, if present, can be from a second parent antibody or antigen binding portion thereof. The first and second parent antibodies can be the same or different.

In one embodiment, the first parent antibody or antigen binding portion thereof, binds a first antigen, and the second parent antibody or antigen binding portion thereof, binds a second antigen. In an embodiment, the first and second antigens are the same antigen. In another embodiment, the parent antibodies bind different epitopes on the same antigen. In another embodiment, the first and second antigens are different antigens. In another embodiment, the first parent antibody or antigen binding portion thereof, binds the first antigen with a potency different from the potency with which the second parent antibody or antigen binding portion thereof, binds the second antigen. In yet another embodiment, the first parent antibody or antigen binding portion thereof, binds the first antigen with an affinity different from the affinity with which the second parent antibody or antigen binding portion thereof, binds the second antigen.

In another embodiment, the first parent antibody or antigen binding portion thereof, and the second parent antibody or antigen binding portion thereof, are a human antibody, CDR grafted antibody, humanized antibody, and/or affinity matured antibody. The “parent antibody”, which provides at least one antigen binding specificity of the multivalent and or multispecific binding protein, may be one that is internalized (and/or catabolized) by a cell expressing an antigen to which the antibody binds; and/or may be an agonist, cell death-inducing, and/or apoptosis-inducing antibody, and the multivalent and or multispecific binding protein as described herein may display improvement(s) in one or more of these properties. Moreover, the parent antibody may lack any one or more of these properties, but may acquire one or more of them when constructed as a multivalent binding protein as described herein. For example, different Fc mutants may prevent FcR, FcR-gamma, complement, or C′ binding, or extend half-life.

In various embodiments, an isolated nucleic acid encoding any one of the binding proteins disclosed herein is also provided. Also provided is a composition comprising one or more nucleic acids wherein said one or more nucleic acids encode a nucleic acid encoding any one of the binding proteins disclosed herein. For example, the composition may comprise a nucleic acid that encodes a first polypeptide and a nucleic acid that encodes a second polypeptide, wherein said first and second polypeptide together form a binding protein as described herein. A further embodiment provides a vector (e.g., an expression vector) comprising the isolated nucleic acid disclosed herein. Also provided is a vector (e.g. an expression vector) that comprises one or more nucleic acids that encode a binding protein as described herein. Also provided is a composition comprising one or more vectors that encode a binding protein as described herein. For example, the composition may comprise a vector that encodes a first polypeptide and a vector that encodes a second polypeptide, wherein said first and second polypeptide together form a binding protein as described herein. In some embodiments, the vector is pcDNA; pTT (Durocher et al. (2002) Nucleic Acids Res. 30(2):e9; pTT3 (pTT with additional multiple cloning site; pEFBOS (Mizushima and Nagata (1990) Nucleic Acids Res. 18:17); pBV; pJV; pcDNA3.1 TOPO; pEF6 TOPO; pBOS; pHybE; or pBJ. In an embodiment, the vector is a vector disclosed in U.S. Pat. No. 8,187,836.

In another aspect, a host cell is transformed with the vector disclosed herein. In an embodiment, the host cell is a prokaryotic cell, for example, E. coli. In another embodiment, the host cell is a eukaryotic cell, for example, a protist cell, an animal cell, a plant cell, or a fungal cell. In an embodiment, the host cell is a mammalian cell including, but not limited to, CHO, COS, NSO, SP2, PER.C6, or a fungal cell, such as Saccharomyces cerevisiae, or an insect cell, such as Sf9. In an embodiment, two or more binding proteins, e.g., with different specificities, are produced in a single recombinant host cell. For example, the expression of a mixture of antibodies has been called Oligoclonics™ (Merus B.V., The Netherlands) disclosed in U.S. Pat. Nos. 7,262,028 and 7,429,486.

In various embodiments, a binding proteins disclosed herein can be prepared by culturing any one of the host cells disclosed herein in a culture medium under conditions sufficient to produce the binding protein.

One embodiment provides a composition for the release of a binding protein wherein the composition comprises a crystallized binding protein, an ingredient, and at least one polymeric carrier. In an embodiment, the polymeric carrier is poly (acrylic acid), a poly (cyanoacrylate), a poly (amino acid), a poly (anhydride), a poly (depsipeptide), a poly (ester), poly (lactic acid), poly (lactic-co-glycolic acid) or PLGA, poly (b-hydroxybutyrate), poly (caprolactone), poly (dioxanone), poly (ethylene glycol), poly ((hydroxypropyl) methacrylamide, poly [(organo)phosphazene], a poly (ortho ester), poly (vinyl alcohol), poly (vinylpyrrolidone), a maleic anhydride-alkyl vinyl ether copolymer, a pluronic polyol, albumin, alginate, cellulose, a cellulose derivative, collagen, fibrin, gelatin, hyaluronic acid, an oligosaccharide, a glycaminoglycan, a sulfated polysaccharide, or blends and copolymers thereof. In an embodiment, the ingredient is albumin, sucrose, trehalose, lactitol, gelatin, hydroxypropyl-β-cyclodextrin, methoxypolyethylene glycol, or polyethylene glycol.

The binding proteins provided herein, such as DVD-Ig binding proteins, may be produced by any of a number of techniques known in the art. For example, expression from host cells, wherein expression vector(s) encoding the DVD-Ig heavy and DVD-Ig light chains is (are) transfected into a host cell by standard techniques. Although it is possible to express the DVD-Ig binding proteins provided herein in either prokaryotic or eukaryotic host cells, DVD-Ig binding proteins are preferably expressed in eukaryotic cells, for example, mammalian host cells.

In an exemplary system for recombinant expression of DVD-Ig proteins, a recombinant expression vector encoding both the DVD-Ig heavy chain and the DVD-Ig light chain is introduced into dhfr-CHO cells by calcium phosphate-mediated transfection. Within the recombinant expression vector, the DVD-Ig heavy and light chain sequences are each operatively linked to CMV enhancer/AdMLP promoter regulatory elements to drive high levels of transcription of the genes. The recombinant expression vector also carries a DHFR gene, which allows for selection of CHO cells that have been transfected with the vector using methotrexate selection/amplification. The selected transformant host cells are cultured to allow for expression of the DVD-Ig heavy and light chains and intact DVD-Ig protein is recovered from the culture medium. Standard molecular biology techniques may be used to prepare the recombinant expression vector, transfect the host cells, select for transformants, culture the host cells and recover the DVD-Ig protein from the culture medium. In some embodiments, a method of synthesizing a DVD-Ig binding protein by culturing a host cell provided herein in a suitable culture medium until a DVD-Ig binding protein is synthesized is also provided. The method may further comprise isolating the DVD-Ig protein from the culture medium.

A feature of a DVD-Ig binding protein is that it can be produced and purified in a similar way to a conventional antibody. The design of the full length DVD-Ig binding protein heavy and light chains provided herein leads to assemble primarily to the desired dual-specific multivalent full length binding proteins. In an embodiment, 50%-75% of the binding protein produced by this method is a dual specific tetravalent binding protein (e.g., a DVD-Ig binding protein). In another embodiment, 75%-90% of the binding protein produced by this method is a dual specific tetravalent binding protein. In another embodiment, 90%-95% of the binding protein produced is a dual specific tetravalent binding protein. In some embodiments, at least 50%, at least 75% and at least 90% of the assembled, and expressed dual variable domain immunoglobulin molecules are the desired dual-specific tetravalent protein.

In various embodiments, the disclosure provides methods of expressing a dual variable domain light chain and a dual variable domain heavy chain in a single cell leading to a primary product of a dual-specific tetravalent full length binding protein, where the primary product is more than 50%, such as more than 75% and more than 90%, of all assembled protein, comprising a dual variable domain light chain and a dual variable domain heavy chain.

Therapeutic and Diagnostic Uses

Also disclosed herein, in various embodiments, are methods for diagnosing and treating a mammal (e.g., a human) comprising the step of administering to the mammal, or a sample taken from the mammal, an effective amount of a composition disclosed herein. A binding protein as described herein may be used in a method for therapy or diagnosis.

Given their ability to bind VEGF, PLGF, and/or their cognate receptors, in some embodiments, the binding proteins provided herein can be used to detect one or more of those antigens (e.g., in a biological sample, such as serum or plasma), using a conventional immunoassay, such as an enzyme linked immunosorbent assays (ELISA), a radioimmunoassay (RIA), or tissue immunohistochemistry. The binding protein is directly or indirectly labeled with a detectable substance to facilitate detection of the bound or unbound antibody. Suitable detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin. An example of a luminescent material is luminol and examples of suitable radioactive materials include ³H, ¹⁴C, ³⁵S, ⁹⁰Y, ⁹⁹Tc, ¹¹¹In, ¹²⁵I, ¹³¹I, ¹⁷⁷Lu, ¹⁶⁶Ho, and ¹⁵³Sm.

In some embodiments, a method is disclosed for treating a human subject suffering from a disorder in which the target, or targets, capable of being bound by the binding proteins disclosed herein is/are detrimental, comprising administering to the human subject a binding protein disclosed herein such that the activity of the target, or targets, in the human subject is inhibited and one or more symptoms is alleviated or treatment is achieved is provided. In various embodiments, treatment comprises reducing, improving, or ameliorating one or more symptom of a disorder. Treatment includes but does not necessarily require curing (i.e., completely eliminating) a disorder or a symptom of a disorder.

The binding proteins provided herein can be used to treat humans suffering from diseases such as, for example, those associated with increased angiogenesis and/or inflammation (e.g., ocular inflammation). In an embodiment, the binding proteins provided herein or antigen-binding portions thereof, are used to treat an autoimmune disorder, asthma, ocular inflammation, Crohn's disease, ulcerative colitis, inflammatory bowel disease (IBD), insulin dependent diabetes mellitus, rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus (SLE), multiple sclerosis, sepsis, a neurodegenerative disease, or an oncological disorder. In an embodiment, a binding protein disclosed herein is used to treat an eye disorder (e.g., an angiogenic eye disorder). In an embodiment, the eye disorder is a macular degeneration, such as wet macular degeneration, dry macular degeneration, age related macular degeneration (AMD), exudative AMD, dry eye, glaucoma, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, corneal neovascularization, iris neovascularization, neovascular glaucoma, post-surgical fibrosis in glaucoma, proliferative vitreoretinopathy (PVR), choroidal neovascularization, optic disc neovascularization, retinal neovascularization, vitreal neovascularization, pannus, pterygium, macular edema, diabetic macular edema (DME), vascular retinopathy, retinal degeneration, uveitis, keratoconjunctivitis sicca, blepharitis, keratitis or another inflammatory disease of the eye.

In an embodiment, the binding proteins provided herein are capable of neutralizing the activity of their antigen targets both in vitro and in vivo. Accordingly, such binding proteins can be used to inhibit antigen activity, e.g., in a cell culture containing the antigens, in human subjects or in other mammalian subjects having the antigens with which a binding protein provided herein cross-reacts. In another embodiment, a method for reducing antigen activity in a subject suffering from a disease or disorder in which the antigen activity is detrimental is provided. A binding protein provided herein may be administered to a human subject for therapeutic purposes. In some embodiments, the binding protein (e.g., the DVD-Ig binding protein) is administered to a patient, e.g., a patient suffering from wet AMD, and can have one or more effects selected from regressing mature vasculature (e.g., via VEGF binding), reducing choroidal neovascularization (e.g., via VEGF binding), allowing access to blood vessels by stripping off pericytes (e.g., via PDGF binding), and/or providing anti-fibrotic effects to reduce visual loss from scarring (e.g., via PDGF binding). In some embodiments, the binding protein is multispecific for VEGF and PDGF, and is administered at a reduced number of injections and/or a reduced injection frequency, as compared to a combination antibody therapy.

The term “a disorder in which antigen activity is detrimental” encompasses diseases and other disorders in which the presence of the antigen in a subject suffering from the disorder has been shown to be or is suspected of being either responsible for the pathophysiology of the disorder or a factor that contributes to a worsening of the disorder. Accordingly, a disorder in which antigen activity is detrimental is a disorder in which reduction of antigen activity is expected to alleviate the symptoms and/or progression of the disorder. Such disorders may be evidenced, for example, by an increase in the concentration of the antigen in a biological fluid of a subject suffering from the disorder (e.g., an increase in the concentration of antigen in serum, plasma, synovial fluid, etc., of the subject). Non-limiting examples of disorders that can be treated with the binding proteins provided herein include those disorders discussed below and in the section pertaining to pharmaceutical compositions comprising the binding proteins.

Binding proteins disclosed herein, such as the DVD-Ig binding proteins, can be employed in some embodiments for tissue-specific delivery (target a tissue marker and a disease mediator for enhanced local PK thus higher efficacy and/or lower toxicity), including intracellular delivery (targeting an internalizing receptor and an intracellular molecule), delivering through a biological barrier, such as to the inside of the eye or brain (e.g., targeting transferrin receptor and a CNS disease mediator for crossing the blood-brain barrier). The binding proteins may also serve as carrier proteins to deliver an antigen to a specific location via binding to a non-neutralizing epitope of that antigen and also to increase the half-life of the antigen. Furthermore, the binding protein may be designed to either be physically linked to medical devices implanted into patients or target these medical devices (see Burke et al. (2006) Advanced Drug Deliv. Rev. 58(3): 437-446; Hildebrand et al. (2006) Surface and Coatings Technol. 200(22-23): 6318-6324; Drug/device combinations for local drug therapies and infection prophylaxis, Wu (2006) Biomaterials 27(11):2450-2467; Mediation of the cytokine network in the implantation of orthopedic devices, Marques (2005) Biodegradable Systems in Tissue Engineer. Regen. Med. 377-397).

In an embodiment, diseases that can be treated or diagnosed with the compositions and methods disclosed herein include, but are not limited to, primary and metastatic cancers, including carcinomas of breast, colon, rectum, lung, oropharynx, hypopharynx, esophagus, stomach, pancreas, liver, gallbladder and bile ducts, small intestine, urinary tract (including kidney, bladder and urothelium), female genital tract (including cervix, uterus, and ovaries as well as choriocarcinoma and gestational trophoblastic disease), male genital tract (including prostate, seminal vesicles, testes and germ cell tumors), endocrine glands (including the thyroid, adrenal, and pituitary glands), and skin, as well as hemangiomas, melanomas, sarcomas (including those arising from bone and soft tissues as well as Kaposi's sarcoma), tumors of the brain, nerves, eyes, and meninges (including astrocytomas, gliomas, glioblastomas, retinoblastomas, neuromas, neuroblastomas, Schwannomas, and meningiomas), solid tumors arising from hematopoietic malignancies such as leukemias, and lymphomas (both Hodgkin's and non-Hodgkin's lymphomas).

Another embodiment provides for the use of the binding protein in the treatment of a disease or disorder, wherein the disorder is arthritis, osteoarthritis, juvenile chronic arthritis, septic arthritis, Lyme arthritis, psoriatic arthritis, reactive arthritis, spondyloarthropathy, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, inflammatory bowel disease, insulin dependent diabetes mellitus, thyroiditis, asthma, allergic diseases, psoriasis, dermatitis scleroderma, graft versus host disease, organ transplant rejection, acute or chronic immune disease associated with organ transplantation, sarcoidosis, atherosclerosis, disseminated intravascular coagulation, Kawasaki's disease, Grave's disease, nephrotic syndrome, chronic fatigue syndrome, Wegener's granulomatosis, Henoch-Schoenlein purpurea, microscopic vasculitis of the kidneys, chronic active hepatitis, uveitis, septic shock, toxic shock syndrome, sepsis syndrome, cachexia, infectious diseases, parasitic diseases, acute transverse myelitis, Huntington's chorea, Parkinson's disease, Alzheimer's disease, stroke, primary biliary cirrhosis, hemolytic anemia, malignancies, heart failure, myocardial infarction, Addison's disease, sporadic poly glandular deficiency type I and polyglandular deficiency type II, Schmidt's syndrome, adult (acute) respiratory distress syndrome, alopecia, alopecia areata, seronegative arthopathy, arthropathy, Reiter's disease, psoriatic arthropathy, ulcerative colitic arthropathy, enteropathic synovitis, chlamydia, yersinia and salmonella associated arthropathy, spondyloarthopathy, atheromatous disease/arteriosclerosis, atopic allergy, autoimmune bullous disease, pemphigus vulgaris, pemphigus foliaceus, pemphigoid, linear IgA disease, autoimmune haemolytic anaemia, Coombs positive haemolytic anaemia, acquired pernicious anaemia, juvenile pernicious anaemia, myalgic encephalitis/Royal Free Disease, chronic mucocutaneous candidiasis, giant cell arteritis, primary sclerosing hepatitis, cryptogenic autoimmune hepatitis, Acquired Immunodeficiency Syndrome, Acquired Immunodeficiency Related Diseases, Hepatitis B, Hepatitis C, common varied immunodeficiency (common variable hypogammaglobulinaemia), dilated cardiomyopathy, female infertility, ovarian failure, premature ovarian failure, fibrotic lung disease, cryptogenic fibrosing alveolitis, post-inflammatory interstitial lung disease, interstitial pneumonitis, connective tissue disease associated interstitial lung disease, mixed connective tissue disease associated lung disease, systemic sclerosis associated interstitial lung disease, rheumatoid arthritis associated interstitial lung disease, systemic lupus erythematosus associated lung disease, dermatomyositis/polymyositis associated lung disease, Sjögren's disease associated lung disease, ankylosing spondylitis associated lung disease, vasculitic diffuse lung disease, haemosiderosis associated lung disease, drug-induced interstitial lung disease, fibrosis, radiation fibrosis, bronchiolitis obliterans, chronic eosinophilic pneumonia, lymphocytic infiltrative lung disease, postinfectious interstitial lung disease, gouty arthritis, autoimmune hepatitis, type-1 autoimmune hepatitis (classical autoimmune or lupoid hepatitis), type-2 autoimmune hepatitis (anti-LKM antibody hepatitis), autoimmune mediated hypoglycaemia, type B insulin resistance with acanthosis nigricans, hypoparathyroidism, acute immune disease associated with organ transplantation, chronic immune disease associated with organ transplantation, osteoarthrosis, primary sclerosing cholangitis, psoriasis type 1, psoriasis type 2, idiopathic leucopaenia, autoimmune neutropaenia, renal disease NOS, glomerulonephritides, microscopic vasulitis of the kidneys, lyme disease, discoid lupus erythematosus, male infertility idiopathic or NOS, sperm autoimmunity, multiple sclerosis (all subtypes), sympathetic ophthalmia, pulmonary hypertension secondary to connective tissue disease, Goodpasture's syndrome, pulmonary manifestation of polyarteritis nodosa, acute rheumatic fever, rheumatoid spondylitis, Still's disease, systemic sclerosis, Sjörgren's syndrome, Takayasu's disease/arteritis, autoimmune thrombocytopaenia, idiopathic thrombocytopaenia, autoimmune thyroid disease, hyperthyroidism, goitrous autoimmune hypothyroidism (Hashimoto's disease), atrophic autoimmune hypothyroidism, primary myxoedema, phacogenic uveitis, primary vasculitis, vitiligo acute liver disease, chronic liver diseases, alcoholic cirrhosis, alcohol-induced liver injury, cholestasis, idiosyncratic liver disease, Drug-Induced hepatitis, Non-alcoholic Steatohepatitis, allergy and asthma, group B streptococci (GBS) infection, mental disorders (e.g., depression and schizophrenia), Th2 Type and Th1 Type mediated diseases, acute and chronic pain (different forms of pain), and cancers such as lung, breast, stomach, bladder, colon, pancreas, ovarian, prostate and rectal cancer and hematopoietic malignancies (leukemia and lymphoma) abetalipoproteinemia, Acrocyanosis, acute and chronic parasitic or infectious processes, acute leukemia, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute or chronic bacterial infection, acute pancreatitis, acute renal failure, adenocarcinomas, aerial ectopic beats, AIDS dementia complex, alcohol-induced hepatitis, allergic conjunctivitis, allergic contact dermatitis, allergic rhinitis, allograft rejection, alpha-1-antitrypsin deficiency, amyotrophic lateral sclerosis, anemia, angina pectoris, anterior horn cell degeneration, anti cd3 therapy, antiphospholipid syndrome, anti-receptor hypersensitivity reactions, aordic and peripheral aneuryisms, aortic dissection, arterial hypertension, arteriosclerosis, arteriovenous fistula, ataxia, atrial fibrillation (sustained or paroxysmal), atrial flutter, atrioventricular block, B cell lymphoma, bone graft rejection, bone marrow transplant (BMT) rejection, bundle branch block, Burkitt's lymphoma, burns, cardiac arrhythmias, cardiac stun syndrome, cardiac tumors, cardiomyopathy, cardiopulmonary bypass inflammation response, cartilage transplant rejection, cerebellar cortical degenerations, cerebellar disorders, chaotic or multifocal atrial tachycardia, chemotherapy associated disorders, chronic myelocytic leukemia (CML), chronic alcoholism, chronic inflammatory pathologies, chronic lymphocytic leukemia (CLL), chronic obstructive pulmonary disease (COPD), chronic salicylate intoxication, colorectal carcinoma, congestive heart failure, conjunctivitis, contact dermatitis, cor pulmonale, coronary artery disease, Creutzfeldt-Jakob disease, culture negative sepsis, cystic fibrosis, cytokine therapy associated disorders, Dementia pugilistica, demyelinating diseases, dengue hemorrhagic fever, dermatitis, dermatologic conditions, diabetes, diabetes mellitus, diabetic ateriosclerotic disease, Diffuse Lewy body disease, dilated congestive cardiomyopathy, disorders of the basal ganglia, Down's Syndrome in middle age, drug-induced movement disorders induced by drugs which block CNS dopamine receptors, drug sensitivity, eczema, encephalomyelitis, endocarditis, endocrinopathy, epiglottitis, epstein-barr virus infection, erythromelalgia, extrapyramidal and cerebellar disorders, familial hematophagocytic lymphohistiocytosis, fetal thymus implant rejection, Friedreich's ataxia, functional peripheral arterial disorders, fungal sepsis, gas gangrene, gastric ulcer, graft rejection of any organ or tissue, gram negative sepsis, gram positive sepsis, granulomas due to intracellular organisms, hairy cell leukemia, Hallerrorden-Spatz disease, hashimoto's thyroiditis, hay fever, heart transplant rejection, hemachromatosis, hemodialysis, hemolytic uremic syndrome/thrombolytic thrombocytopenic purpura, hemorrhage, hepatitis A, His bundle arryhthmias, HIV infection/HIV neuropathy, Hodgkin's disease, hyperkinetic movement disorders, hypersensitity reactions, hypersensitivity pneumonitis, hypertension, hypokinetic movement disorders, hypothalamic-pituitary-adrenal axis evaluation, idiopathic Addison's disease, idiopathic pulmonary fibrosis, antibody mediated cytotoxicity, Asthenia, infantile spinal muscular atrophy, inflammation of the aorta, influenza a, ionizing radiation exposure, iridocyclitis/uveitis/optic neuritis, ischemia-reperfusion injury, ischemic stroke, juvenile rheumatoid arthritis, juvenile spinal muscular atrophy, Kaposi's sarcoma, kidney transplant rejection, legionella, leishmaniasis, leprosy, lesions of the corticospinal system, lipedema, liver transplant rejection, lymphederma, malaria, malignamt Lymphoma, malignant histiocytosis, malignant melanoma, meningitis, meningococcemia, metabolic/idiopathic, migraine headache, mitochondrial multi.system disorder, mixed connective tissue disease, monoclonal gammopathy, multiple myeloma, multiple systems degenerations (Mencel Dejerine-Thomas Shy-Drager and Machado-Joseph), myasthenia gravis, mycobacterium avium intracellulare, mycobacterium tuberculosis, myelodyplastic syndrome, myocardial ischemic disorders, nasopharyngeal carcinoma, neonatal chronic lung disease, nephritis, nephrosis, neurodegenerative diseases, neurogenic I muscular atrophies, neutropenic fever, non-hodgkins lymphoma, occlusion of the abdominal aorta and its branches, occlusive arterial disorders, okt3 therapy, orchitis/epidydimitis, orchitis/vasectomy reversal procedures, organomegaly, osteoporosis, pancreas transplant rejection, pancreatic carcinoma, paraneoplastic syndrome/hypercalcemia of malignancy, parathyroid transplant rejection, pelvic inflammatory disease, perennial rhinitis, pericardial disease, peripheral atherlosclerotic disease, peripheral vascular disorders, peritonitis, pernicious anemia, pneumocystis carinii pneumonia, pneumonia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome), post perfusion syndrome, post pump syndrome, post-MI cardiotomy syndrome, preeclampsia, Progressive supranucleo Palsy, primary pulmonary hypertension, radiation therapy, Raynaud's phenomenon and disease, Raynoud's disease, Refsum's disease, regular narrow QRS tachycardia, renovascular hypertension, reperfusion injury, restrictive cardiomyopathy, sarcomas, scleroderma, senile chorea, Senile Dementia of Lewy body type, seronegative arthropathies, shock, sickle cell anemia, skin allograft rejection, skin changes syndrome, small bowel transplant rejection, solid tumors, specific arrythmias, spinal ataxia, spinocerebellar degenerations, streptococcal myositis, structural lesions of the cerebellum, Subacute sclerosing panencephalitis, Syncope, syphilis of the cardiovascular system, systemic anaphalaxis, systemic inflammatory response syndrome, systemic onset juvenile rheumatoid arthritis, T-cell or FAB ALL, Telangiectasia, thromboangitis obliterans, thrombocytopenia, toxicity, transplants, trauma/hemorrhage, type III hypersensitivity reactions, type IV hypersensitivity, unstable angina, uremia, urosepsis, urticaria, valvular heart diseases, varicose veins, vasculitis, venous diseases, venous thrombosis, ventricular fibrillation, viral and fungal infections, vital encephalitis/aseptic meningitis, vital-associated hemaphagocytic syndrome, Wernicke-Korsakoff syndrome, Wilson's disease, xenograft rejection of any organ or tissue, acute coronary syndromes, acute idiopathic polyneuritis, acute inflammatory demyelinating polyradiculoneuropathy, acute ischemia, adult Still's disease, anaphylaxis, anti-phospholipid antibody syndrome, aplastic anemia, atopic eczema, atopic dermatitis, autoimmune dermatitis, autoimmune disorder associated with streptococcus infection, autoimmune enteropathy, autoimmune hearing loss, autoimmune lymphoproliferative syndrome (ALPS), autoimmune myocarditis, autoimmune premature ovarian failure, blepharitis, bronchiectasis, bullous pemphigoid, cardiovascular disease, catastrophic antiphospholipid syndrome, celiac disease, cervical spondylosis, chronic ischemia, cicatricial pemphigoid, clinically isolated syndrome (cis) with risk for multiple sclerosis, childhood onset psychiatric disorder, dacryocystitis, dermatomyositis, diabetic retinopathy, disk herniation, disk prolaps, drug induced immune hemolytic anemia, endometriosis, endophthalmitis, episcleritis, erythema multiforme, erythema multiforme major, gestational pemphigoid, Guillain-Barré syndrome (GBS), hay fever, Hughes syndrome, idiopathic Parkinson's disease, idiopathic interstitial pneumonia, IgE-mediated allergy, immune hemolytic anemia, inclusion body myositis, infectious ocular inflammatory disease, inflammatory demyelinating disease, inflammatory heart disease, inflammatory kidney disease, IPF/UIP, iritis, keratitis, keratoconjunctivitis sicca, Kussmaul disease or Kussmaul-Meier disease, Landry's paralysis, Langerhan's cell histiocytosis, livedo reticularis, macular degeneration, microscopic polyangiitis, morbus bechterev, motor neuron disorders, mucous membrane pemphigoid, multiple organ failure, myelodysplastic syndrome, myocarditis, nerve root disorders, neuropathy, non-A non-B hepatitis, optic neuritis, osteolysis, ovarian cancer, pauciarticular JRA, peripheral artery occlusive disease (PAOD), peripheral vascular disease (PVD), peripheral artery, disease (PAD), phlebitis, polyarteritis nodosa (or periarteritis nodosa), polychondritis, polymyalgia rheumatica, poliosis, polyarticular JRA, polyendocrine deficiency syndrome, polymyositis, post-pump syndrome, primary Parkinsonism, prostate and rectal cancer and hematopoietic malignancies (leukemia and lymphoma), prostatitis, pure red cell aplasia, primary adrenal insufficiency, recurrent neuromyelitis optica, restenosis, rheumatic heart disease, sapho (synovitis, acne, pustulosis, hyperostosis, and osteitis), scleroderma, secondary amyloidosis, shock lung, scleritis, sciatica, secondary adrenal insufficiency, silicone associated connective tissue disease, sneddon-wilkinson dermatosis, spondilitis ankylosans, Stevens-Johnson syndrome (SJS), systemic inflammatory response syndrome, temporal arteritis, toxoplasmic retinitis, toxic epidermal necrolysis, transverse myelitis, TRAPS (tumor necrosis factor receptor, type 1 allergic reaction, type II diabetes, usual interstitial pneumonia (UIP), vernal conjunctivitis, viral retinitis, Vogt-Koyanagi-Harada syndrome (VKH syndrome), wet macular degeneration, wound healing, fibrosis, renal disease, wet macular degeneration, wound healing, age related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, corneal neovascularization, exudative AMD, iris neovascularization, neovascular glaucoma, post-surgical fibrosis in glaucoma, proliferative vitreoretinopathy (PVR), choroidal neovascularization, optic disc neovascularization, retinal neovascularization, vitreal neovascularization, pannus, pterygium, macular edema, diabetic macular edema (DME), vascular retinopathy, retinal degeneration, uveitis, or an inflammatory disease of the eye.

In some embodiments, any one of the binding proteins disclosed herein can be used to treat a disorder listed above. In certain embodiments, the binding protein used to treat any of the disorders discussed herein is one or more of the binding proteins listed in Tables 27-30, 38-42, 46-50, or 55-58. In certain embodiments, the binding protein used to treat any of the disorders discussed herein is one or more of the binding proteins listed in Tables 56-58. In certain embodiments, the binding protein is PR-1572102, PR-1572105, PR-1610561, or PR1611292.

In some embodiments, a binding protein (e.g., PR-1572102, PR-1572105, PR1611292, or PR-1610561) may be used to treat wet AMD that is non-responsive to anti-VEGF monotherapy. For instance, a binding protein targeting VEGF and PDGF (e.g., PR-1572102, PR-1572105, or PR-1610561) may lead to better regression of angiogenesis, thereby providing for a more effective treatment (this does not necessarily mean, however, that such a binding protein would have a reduced administration frequency; whether that is the case is presently unknown). The dual inhibition of both VEGF and PDGF may provide for certain improved treatment outcomes, as compared to anti-VEGF monotherapy.

In another aspect, methods of treating a patient suffering from a disorder are disclosed, comprising the step of administering any one of the binding proteins disclosed herein before, concurrently, or after the administration of a second agent, are provided. In an embodiment, the second agent is an imaging agent, cytotoxic agent, angiogenesis inhibitor, kinase inhibitor, co-stimulation molecule blocker, adhesion molecule blocker, anti-cytokine antibody or functional fragment thereof, methotrexate, cyclosporin, rapamycin, FK506, detectable label or reporter, TNF antagonist, antirheumatic, muscle relaxant, narcotic, non-steroid anti-inflammatory drug (NSAID), analgesic, anesthetic, sedative, local anesthetic, neuromuscular blocker, antimicrobial, antipsoriatic, corticosteriod, anabolic steroid, erythropoietin, immunization, immunoglobulin, immunosuppressive, growth hormone, hormone replacement drug, radiopharmaceutical, antidepressant, antipsychotic, stimulant, asthma medication, beta agonist, inhaled steroid, epinephrine or analog, cytokine, or cytokine antagonist.

Also disclosed, in various embodiments, are anti-idiotype antibodies to the binding proteins disclosed herein. An anti-idiotype antibody includes any protein or peptide-containing molecule that comprises at least a portion of an immunoglobulin molecule such as, but not limited to, at least one complementarily determining region (CDR) of a heavy or light chain or a ligand binding portion thereof, a heavy chain or light chain variable region, a heavy chain or light chain constant region, a framework region, or any portion thereof, that can be incorporated into a binding protein provided herein.

Also disclosed herein, in various embodiments, are methods of determining the presence, amount or concentration of VEGF and/or PDGF, or fragment thereof, in a test sample. In some embodiments, the methods comprise assaying the test sample for the antigen, or fragment thereof, by an immunoassay. The immunoassay (i) employs at least one binding protein and at least one detectable label and (ii) comprises comparing a signal generated by the detectable label as a direct or indirect indication of the presence, amount or concentration of the antigen, or fragment thereof, in the test sample to a signal generated as a direct or indirect indication of the presence, amount or concentration of the antigen, or fragment thereof, in a control or a calibrator. The calibrator is optionally part of a series of calibrators in which each of the calibrators differs from the other calibrators in the series by the concentration of the antigen, or fragment thereof. The method can comprise (i) contacting the test sample with at least one capture agent, which binds to an epitope on the antigen, or fragment thereof, so as to form a capture agent/antigen, or fragment thereof, complex, (ii) contacting the capture agent/antigen, or fragment thereof, complex with at least one detection agent, which comprises a detectable label and binds to an epitope on the antigen, or fragment thereof, that is not bound by the capture agent, to form a capture agent/antigen, or fragment thereof/detection agent complex, and (iii) determining the presence, amount or concentration of the antigen, or fragment thereof, in the test sample based on the signal generated by the detectable label in the capture agent/antigen, or fragment thereof/detection agent complex formed in (ii), wherein at least one capture agent and/or at least one detection agent is the at least one binding protein.

Alternatively, the method may comprise (i) contacting the test sample with at least one capture agent, which binds to an epitope on the antigen, or fragment thereof, so as to form a capture agent/antigen, or fragment thereof, complex, and simultaneously or sequentially, in either order, contacting the test sample with detectably labeled antigen, or fragment thereof, which can compete with any antigen, or fragment thereof, in the test sample for binding to the at least one capture agent, wherein any antigen, or fragment thereof, present in the test sample and the detectably labeled antigen compete with each other to form a capture agent/antigen, or fragment thereof, complex and a capture agent/detectably labeled antigen, or fragment thereof, complex, respectively, and (ii) determining the presence, amount or concentration of the antigen, or fragment thereof, in the test sample based on the signal generated by the detectable label in the capture agent/detectably labeled antigen, or fragment thereof, complex formed in (ii), wherein at least one capture agent is the at least one binding protein and wherein the signal generated by the detectable label in the capture agent/detectably labeled antigen, or fragment thereof, complex is inversely proportional to the amount or concentration of antigen, or fragment thereof, in the test sample.

In some embodiments, the test sample is from a patient, in which case the method can further comprise diagnosing, prognosticating, or assessing the efficacy of therapeutic/prophylactic treatment of the patient. If the method further comprises assessing the efficacy of therapeutic/prophylactic treatment of the patient, the method optionally further comprises modifying the therapeutic/prophylactic treatment of the patient as needed to improve efficacy. The method can be adapted for use in an automated system or a semi-automated system. Accordingly, the methods described herein also can be used to determine whether or not a subject has or is at risk of developing a given disease, disorder or condition. Specifically, such a method can comprise the steps of: (a) determining the concentration or amount in a test sample from a subject of analyte, or fragment thereof, (e.g., using the methods described herein, or methods known in the art); and (b) comparing the concentration or amount of analyte, or fragment thereof, determined in step (a) with a predetermined level, wherein, if the concentration or amount of analyte determined in step (a) is favorable with respect to a predetermined level, then the subject is determined not to have or be at risk for a given disease, disorder or condition. However, if the concentration or amount of analyte determined in step (a) is unfavorable with respect to the predetermined level, then the subject is determined to have or be at risk for a given disease, disorder or condition.

Additionally, in various embodiments, provided herein are methods of monitoring the progression of disease in a subject. In some embodiments, the method can comprise the steps of: (a) determining the concentration or amount in a test sample from a subject of analyte; (b) determining the concentration or amount in a later test sample from the subject of analyte; and (c) comparing the concentration or amount of analyte as determined in step (b) with the concentration or amount of analyte determined in step (a), wherein if the concentration or amount determined in step (b) is unchanged or is unfavorable when compared to the concentration or amount of analyte determined in step (a), then the disease in the subject is determined to have continued, progressed or worsened. By comparison, if the concentration or amount of analyte as determined in step (b) is favorable when compared to the concentration or amount of analyte as determined in step (a), then the disease in the subject is determined to have discontinued, regressed or improved.

Optionally, the method further comprises comparing the concentration or amount of analyte as determined in step (b), for example, with a predetermined level. Further, optionally the method comprises treating the subject with one or more pharmaceutical compositions for a period of time if the comparison shows that the concentration or amount of analyte as determined in step (b), for example, is unfavorably altered with respect to the predetermined level.

Also provided, in various embodiments, are kits for assaying a test sample for VEGF and/or PDGF, or fragment thereof. The kit may comprise at least one component for assaying the test sample for an antigen, or fragment thereof, and instructions for assaying the test sample for an antigen, or fragment thereof, wherein the at least one component includes at least one composition comprising the binding protein disclosed herein, wherein the binding protein is optionally detectably labeled.

Unless otherwise defined herein, scientific and technical terms used herein have the meanings that are commonly understood by those of ordinary skill in the art. In the event of any latent ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition. Unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. The use of “or” means “and/or” unless stated otherwise. The use of the term “including”, as well as other forms, such as “includes” and “included”, is not limiting. Any range disclosed herein is intended to encompass the endpoints of that range unless stated otherwise.

Generally, nomenclatures used in connection with cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those known and commonly used in the art. The methods and techniques provided herein are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

That the disclosure may be more readily understood, select terms are defined below.

The term “antibody” refers to an immunoglobulin (Ig) molecule, which is may comprise four polypeptide chains, two heavy (H) chains and two light (L) chains, or it may comprise a functional fragment, mutant, variant, or derivative thereof, that retains the epitope binding features of an Ig molecule. Such fragment, mutant, variant, or derivative antibody formats are known in the art. In an embodiment of a full-length antibody, each heavy chain is comprised of a heavy chain variable region (VH) and a heavy chain constant region (CH). In the case of an IgG molecule, the CH comprises three domains, CH1, CH2 and CH3. Each light chain is comprised of a light chain variable region (VL) and a light chain constant region (CL). The CL is comprised of a single CL domain. The VH and VL can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs). Generally, each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. CDR regions may be determined by standard methods, e.g., those of Kabat et al. Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2), or subclass.

The term “bispecific antibody” refers to an antibody that binds one antigen (or epitope) on one of its two binding arms (one pair of HC/LC), and binds a different antigen (or epitope) on its second binding arm (a different pair of HC/LC). A bispecific antibody is a type of bispecific binding protein. A bispecific antibody may have two distinct antigen binding arms (in both specificity and CDR sequences), and may be monovalent for each antigen to which it binds. Bispecific antibodies include those generated by quadroma technology (Milstein and Cuello (1983) Nature 305(5934): 537-40), by chemical conjugation of two different monoclonal antibodies (Staerz et al. (1985) Nature 314(6012): 628-31), or by knob-into-hole or similar approaches which introduces mutations in the Fc region (Holliger et al. (1993) Proc. Natl. Acad. Sci. USA 90(14): 6444-6448).

The term “affinity matured” refers to an antibody or binding protein with one or more alterations in one or more CDR or framework (FR) regions thereof, which may result in an improvement in the affinity for an antigen, compared to a parent antibody or binding protein which does not possess those alteration(s). Exemplary affinity matured antibodies or binding protein will have nanomolar or even picomolar affinities for the target antigen. Affinity matured antibodies or binding protein may be produced by procedures known in the art, e.g., Marks et al. (1992) BioTechnology 10:779-783 describes affinity maturation by VH and VL domain shuffling. Random mutagenesis of CDR and/or framework residues is described by Barbas et al. (1994) Proc. Nat. Acad. Sci. USA 91:3809-3813; Schier et al. (1995) Gene 169:147-155; Yelton et al. (1995) J. Immunol. 155:1994-2004; Jackson et al. (1995) J. Immunol. 154(7):3310-9; Hawkins et al. (1992) J. Mol. Biol. 226:889-896 and mutation at selective mutagenesis positions, contact or hypermutation positions with an activity enhancing amino acid residue as described in U.S. Pat. No. 6,914,128.

The term “CDR-grafted” refers to an antibody or binding protein that comprises heavy and light chain variable region sequences in which the sequences of one or more of the CDR regions of VH and/or VL are replaced with CDR sequences of another antibody or binding protein. For example, the two antibodies or binding protein can be from different species, such as antibodies or binding protein having murine heavy and light chain variable regions in which one or more of the murine CDRs has been replaced with human CDR sequences.

The term “humanized” refers to an antibody or binding protein from a non-human species that has been altered to be more “human-like”, i.e., more similar to human germline sequences. One type of humanized antibody or binding protein is a CDR-grafted antibody or binding protein, in which non-human CDR sequences are introduced into human VH and VL sequences to replace the corresponding human CDR sequences. A humanized antibody or binding protein also encompasses a variant, derivative, analog or fragment of an antibody or binding protein that comprises framework region (FR) sequences having substantially (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% identity to) the amino acid sequence of a human antibody and at least one CDR having substantially the amino acid sequence of a non-human antibody. A humanized antibody or binding protein may comprise substantially all of at least one variable domain (Fab, Fab′, F(ab′) 2, FabC, Fv) in which the sequence of all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin (i.e., donor antibody) and the sequence of all or substantially all of the FR regions are those of a human immunoglobulin. The humanized antibody or binding protein also may include the CH1, hinge, CH2, CH3, and/or CH4 regions of the heavy chain. In an embodiment, a humanized antibody or binding protein may also comprise at least a portion of a human immunoglobulin Fc region. In some embodiments, a humanized antibody or binding protein only contains a humanized light chain. In some embodiments, a humanized antibody or binding protein only contains a humanized heavy chain. In some embodiments, a humanized antibody or binding protein only contains a humanized variable domain of a light chain and/or humanized variable domain of a heavy chain. In some embodiments, a humanized antibody or binding protein contains a humanized light chain as well as at least a variable domain of a heavy chain. In some embodiments, a humanized antibody or binding protein contains a humanized heavy chain as well as at least a variable domain of a light chain

The term “anti-idiotypic antibody” refers to an antibody raised against the amino acid sequence of the antigen combining site of another antibody. Anti-idiotypic antibodies may be administered to enhance an immune response against an antigen.

The term “biological activity” refers to any one or more biological properties of a molecule (whether present naturally as found in vivo, or provided or enabled by recombinant means). Biological properties include, but are not limited to, binding a receptor, inducing cell proliferation, inhibiting cell growth, inducing other cytokines, inducing apoptosis, and enzymatic activity.

The term “neutralizing” refers to counteracting the biological activity of an antigen when a binding protein specifically binds to the antigen. In an embodiment, a neutralizing binding protein binds to an antigen (e.g., VEGF and/or PDGF or their receptors) and reduces the antigen's biological activity by at least about 20%, about 40%, about 60%, about 80%, about 85%, about 90%, about 95%, or about 100% (or any percentage in between).

The term “specificity” refers to the ability of a binding protein to selectively bind an antigen.

The term “affinity” refers to the strength of the interaction between a binding protein and an antigen, and is determined by the sequence of the CDRs of the binding protein as well as by the nature of the antigen, such as its size, shape, and/or charge. Binding proteins may be selected for affinities that provide desired therapeutic end-points while minimizing negative side-effects. Affinity may be measured using methods known to one skilled in the art (see, e.g., U.S. Patent Appl. No. 20090311253 and U.S. Pat. No. 7,612,181).

The term “potency” refers to the ability of a binding protein to achieve a desired effect, and is a measurement of its therapeutic efficacy. Potency may be assessed using methods known to one skilled in the art (see, e.g., U.S. Patent Appl. No. 20090311253 and U.S. Pat. No. 7,612,181).

The term “cross-reactivity” refers to the ability of a binding protein to bind a target other than that against which it was raised. Generally, a binding protein will bind its target tissue(s)/antigen(s) with an appropriately high affinity, but will display an appropriately low affinity for non-target normal tissues. Methods of assessing cross-reactivity are known to one skilled in the art (see, e.g., U.S. Patent Appl. No. 20090311253 and U.S. Pat. No. 7,612,181).

The term “biological function” refers the specific in vitro or in vivo actions of a binding protein. Binding proteins may target several classes of antigens and achieve desired therapeutic outcomes through multiple mechanisms of action. Binding proteins may target soluble proteins, cell surface antigens, as well as extracellular protein deposits. Binding proteins may agonize, antagonize, or neutralize the activity of their targets. Binding proteins may assist in the clearance of the targets to which they bind, or may result in cytotoxicity when bound to cells. Portions of two or more antibodies may be incorporated into a multivalent format to achieve distinct functions in a single binding protein molecule. The in vitro assays and in vivo models used to assess biological function are known to one skilled in the art (see, e.g., U.S. Patent Appl. No. 20090311253 and U.S. Pat. No. 7,612,181).

A “stable” binding protein refers to one in which the binding protein retains some level of its physical stability, chemical stability and/or biological activity upon storage. Methods of stabilizing binding proteins and assessing their stability at various temperatures are known to one skilled in the art (see, e.g., U.S. Patent Appl. No. 20090311253 and U.S. Pat. No. 7,612,181).

The term “solubility” refers to the ability of a protein to remain dispersed within an aqueous solution. The solubility of a protein in an aqueous formulation depends upon the proper distribution of hydrophobic and hydrophilic amino acid residues, and therefore, solubility can correlate with the production of correctly folded proteins. A person skilled in the art will be able to detect an increase or decrease in solubility of a binding protein using routine HPLC techniques and methods known to one skilled in the art (see, e.g., U.S. Patent Appl. No. 20090311253 and U.S. Pat. No. 7,612,181).

Binding proteins may be produced using a variety of host cells or may be produced in vitro, and the relative yield per effort determines the “production efficiency.” Factors influencing production efficiency include, but are not limited to, host cell type (prokaryotic or eukaryotic), choice of expression vector, choice of nucleotide sequence, and methods employed. The materials and methods used in binding protein production, as well as the measurement of production efficiency, are known to one skilled in the art (see, e.g., U.S. Patent Appl. No. 20090311253 and U.S. Pat. No. 7,612,181).

The term “immunogenicity” means the ability of a substance to induce an immune response. Administration of a therapeutic binding protein may result in a certain incidence of an immune response. Potential elements that might induce immunogenicity in a multivalent format may be analyzed during selection of the parental antibodies, and steps to reduce such risk can be taken to optimize the parental antibodies prior to incorporating their sequences into a multivalent binding protein format. Methods of reducing the immunogenicity of antibodies and binding proteins are known to one skilled in the art (U.S. Patent Appl. No. 20090311253 and U.S. Pat. No. 7,612,181).

The terms “label” and “detectable label” refer to a moiety attached to a member of a specific binding pair, such as an antibody/binding protein or its analyte to render a reaction (e.g., binding) between the members of the specific binding pair, detectable. The labeled member of the specific binding pair is referred to as “detectably labeled.” Thus, the term “labeled binding protein” refers to a protein with a label incorporated that provides for the identification of the binding protein. In an embodiment, the label is a detectable marker that can produce a signal that is detectable by visual or instrumental means, e.g., incorporation of a radiolabeled amino acid or attachment to a polypeptide of biotinyl moieties that can be detected by marked avidin (e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods). Examples of labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides (e.g., ³H, ¹⁴C, ³⁵S, ⁹⁰Y, ⁹⁹Tc, ¹¹¹In, ¹²⁵I, ¹³¹I, ¹⁷⁷Lu, ¹⁶⁶Ho, or ¹⁵³Sm); chromogens, fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), enzymatic labels (e.g., horseradish peroxidase, luciferase, alkaline phosphatase); chemiluminescent markers; biotinyl groups; predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags); and magnetic agents, such as gadolinium chelates. Representative examples of labels commonly employed for immunoassays include moieties that produce light, e.g., acridinium compounds, and moieties that produce fluorescence, e.g., fluorescein. In this regard, the moiety itself may not be detectably labeled but may become detectable upon reaction with yet another moiety.

The term “conjugate” refers to a binding protein that is chemically linked to a second chemical moiety, such as a therapeutic or cytotoxic agent. The term “agent” includes a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from biological materials. In an embodiment, the therapeutic or cytotoxic agents include, but are not limited to, pertussis toxin, taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. When employed in the context of an immunoassay, the conjugate antibody may be a detectably labeled antibody used as the detection antibody.

The terms “crystal” and “crystallized” refer to a binding protein (e.g., an antibody), or antigen binding portion thereof, that exists in the form of a crystal. Crystals are one form of the solid state of matter, which is distinct from other forms such as the amorphous solid state or the liquid crystalline state. Crystals are composed of regular, repeating, three-dimensional arrays of atoms, ions, molecules (e.g., proteins such as antibodies), or molecular assemblies (e.g., antigen/antibody complexes). These three-dimensional arrays are arranged according to specific mathematical relationships that are well-understood in the field. The fundamental unit, or building block, that is repeated in a crystal is called the asymmetric unit. Repetition of the asymmetric unit in an arrangement that conforms to a given, well-defined crystallographic symmetry provides the “unit cell” of the crystal. Repetition of the unit cell by regular translations in all three dimensions provides the crystal. (See Giege and Ducruix (1999) CRYSTALLIZATION OF NUCLEIC ACIDS AND PROTEINS, A PRACTICAL APPROACH, 2nd ed., pp. 20 1-16, Oxford University Press, NY, N.Y.).

The term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked One type of vector is a “plasmid,” which refers to a circular double stranded DNA loop into which additional DNA segments may be ligated. Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. Other vectors include RNA vectors. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Certain vectors are capable of directing the expression of genes to which they are operatively linked Such vectors are referred to herein as “recombinant expression vectors” (or simply, “expression vectors”). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, “plasmid” and “vector” may be used interchangeably as the plasmid is the most commonly used form of vector. However, other forms of expression vectors are also included, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions. A group of pHybE vectors (e.g., U.S. Pat. No. 8,187,836) may be used for parental antibody and DVD-binding protein cloning. V1, derived from pJP183; pHybE-hCg1,z,non-a V2; and pJP184, may be used for cloning of antibody and DVD heavy chains with a wild type constant region or modified constant region (e.g., a L234, L235, H435A modified IgG1 constant region). V2, derived from pJP191 (with or without modifications to the Kozak site); pHybE-hCk V3, may be used for cloning of antibody and DVD light chains with a kappa constant region. V3, derived from pJP192; pHybE-hCl V2, may be used for cloning of antibody and DVD light chains with a lambda constant region. V4, built with a lambda signal peptide and a kappa constant region, may be used for cloning of DVD light chains with a lambda-kappa hybrid V domain. V5, built with a kappa signal peptide and a lambda constant region, may be used for cloning of DVD light chains with a kappa-lambda hybrid V domain. V7, derived from pJP183; pHybE-hCg1,z,non-a V2, may be used for cloning of antibody and DVD heavy chains with a (234,235 AA) mutant constant region.

The terms “recombinant host cell” or “host cell” refer to a cell into which exogenous, e.g., recombinant, DNA has been introduced. Such terms refer not only to the particular subject cell, but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term “host cell” as used herein. In an embodiment, host cells include prokaryotic and eukaryotic cells. In an embodiment, eukaryotic cells include protist, fungal, plant and animal cells. In another embodiment, host cells include but are not limited to the prokaryotic cell line E. coli; mammalian cell lines CHO, HEK 293, COS, NSO, SP2 and PER.C6; the insect cell line Sf9; and the fungal cell Saccharomyces cerevisiae.

The term “transfection” encompasses a variety of techniques commonly used for the introduction of exogenous nucleic acid (e.g., DNA) into a host cell, e.g., electroporation, calcium-phosphate precipitation, DEAE-dextran transfection and the like.

The term “cytokine” refers to a protein released by one cell population that acts on another cell population as an intercellular mediator. The term “cytokine” includes proteins from natural sources or from recombinant cell culture and biologically active equivalents of the native sequence cytokines.

The term “biological sample” refers to a quantity of a substance from a living thing or formerly living thing Such substances include, but are not limited to, blood, plasma, serum, urine, amniotic fluid, synovial fluid, endothelial cells, leukocytes, monocytes, other cells, organs, tissues, bone marrow, lymph nodes and spleen.

The term “component” refers to an element of a composition. In relation to a diagnostic kit, for example, a component may be a capture antibody, a detection or conjugate antibody, a control, a calibrator, a series of calibrators, a sensitivity panel, a container, a buffer, a diluent, a salt, an enzyme, a co-factor for an enzyme, a detection reagent, a pretreatment reagent/solution, a substrate (e.g., as a solution), a stop solution, and the like that can be included in a kit for assay of a test sample. Thus, a “component” can include a polypeptide or other analyte as above, that is immobilized on a solid support, such as by binding to an anti-analyte (e.g., anti-polypeptide) antibody. Some components can be in solution or lyophilized for reconstitution for use in an assay.

“Control” refers to a composition known to not analyte (“negative control”) or to contain analyte (“positive control”). A positive control can comprise a known concentration of analyte. A “positive control” can be used to establish assay performance characteristics and is a useful indicator of the integrity of reagents (e.g., analytes).

“Predetermined cutoff” and “predetermined level” refer generally to an assay cutoff value that is used to assess diagnostic/prognostic/therapeutic efficacy results by comparing the assay results against the predetermined cutoff/level, where the predetermined cutoff/level already has been linked or associated with various clinical parameters (e.g., severity of disease, progression/nonprogression/improvement, etc.). While the present disclosure may provide exemplary predetermined levels, it is well-known that cutoff values may vary depending on the nature of the immunoassay (e.g., antibodies employed, etc.). It further is well within the ordinary skill of one in the art to adapt the disclosure herein for other immunoassays to obtain immunoassay-specific cutoff values for those other immunoassays based on this disclosure. Whereas the precise value of the predetermined cutoff/level may vary between assays, correlations as described herein (if any) may be generally applicable.

“Pretreatment reagent,” e.g., lysis, precipitation and/or solubilization reagent, as used in a diagnostic assay as described herein refers to one that lyses any cells and/or solubilizes any analyte that is/are present in a test sample. Pretreatment is not necessary for all samples, as described further herein. Among other things, solubilizing the analyte (e.g., polypeptide of interest) may entail release of the analyte from any endogenous binding proteins present in the sample. A pretreatment reagent may be homogeneous (not requiring a separation step) or heterogeneous (requiring a separation step). With use of a heterogeneous pretreatment reagent there is removal of any precipitated analyte binding proteins from the test sample prior to proceeding to the next step of the assay.

“Quality control reagents” in the context of immunoassays and kits described herein, include, but are not limited to, calibrators, controls, and sensitivity panels. A “calibrator” or “standard” typically is used (e.g., one or more, such as a plurality) in order to establish calibration (standard) curves for interpolation of the concentration of an analyte, such as an antibody or an analyte. Alternatively, a single calibrator, which is near a predetermined positive/negative cutoff, can be used. Multiple calibrators (i.e., more than one calibrator or a varying amount of calibrator(s)) can be used in conjunction so as to comprise a “sensitivity panel.”

The term “specific binding partner” refers to a member of a specific binding pair. A specific binding pair comprises two different molecules that specifically bind to each other through chemical or physical means. Therefore, in addition to antigen and antibody specific binding, other specific binding pairs can include biotin and avidin (or streptavidin), carbohydrates and lectins, complementary nucleotide sequences, effector and receptor molecules, cofactors and enzymes, enzyme inhibitors and enzymes, and the like. Furthermore, specific binding pairs can include members that are analogs of the original specific binding members, for example, an analyte-analog. Immunoreactive specific binding members include antigens, antigen fragments, and antibodies, including monoclonal and polyclonal antibodies as well as complexes, fragments, and variants (including fragments of variants) thereof, whether isolated or recombinantly produced.

The term “Fc region” refers to the C-terminal region of an immunoglobulin heavy chain, which may be generated by papain digestion of an intact antibody or binding protein. The Fc region may be a native sequence Fc region or a variant Fc region. The Fc region of an immunoglobulin generally comprises two constant domains, a CH2 domain and a CH3 domain, and optionally comprises a CH4 domain. Replacements of amino acid residues in the Fc portion to alter effector function are known in the art (e.g., U.S. Pat. Nos. 5,648,260 and 5,624,821). The Fc region mediates several important effector functions, e.g., cytokine induction, antibody dependent cell mediated cytotoxicity (ADCC), phagocytosis, complement dependent cytotoxicity (CDC), and half-life/clearance rate of antibody or binding protein and antigen-antibody or antigen-binding protein complexes. In some cases these effector functions are desirable for a therapeutic immunoglobulin but in other cases might be unnecessary or even deleterious, depending on the therapeutic objectives.

The term “antigen-binding portion” of a binding protein refers to one or more fragments of a binding protein that retain the ability to specifically bind to an antigen. The antigen-binding function of a binding protein may be performed by fragments of a full-length binding protein, including bispecific, dual specific, or multi-specific formats; for instance, binding to two or more different antigens. Examples of binding fragments encompassed within the term “antigen-binding portion” of an binding protein include (i) an Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) an F(ab′)₂ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) an Fd fragment consisting of the VH and CH1 domains; (iv) an Fv fragment consisting of the VL and VH domains of a single arm of an antibody or binding protein, (v) a dAb fragment, which comprises a single variable domain; and (vi) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are encoded by separate genes, they may be joined, e.g., using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv). Such single chain antibodies or binding proteins are also intended to be encompassed within the term “antigen-binding portion” of an antibody or binding protein. Other forms of single chain antibodies, such as diabodies are also encompassed. In addition, single chain antibodies or binding protein also include “linear” antibodies or binding protein comprising a pair of tandem Fv segments (VH-CH1-VH-CH1) which, together with complementary light chain polypeptides, form a pair of antigen binding regions.

The term “multivalent binding protein” refers to a binding protein comprising two or more antigen binding sites. In an embodiment, the multivalent binding protein is engineered to have three or more antigen binding sites, and may not be a naturally occurring antibody. The term “multispecific binding protein” refers to a binding protein capable of binding two or more related or unrelated targets. In an embodiment, the dual variable domain (DVD) binding proteins provided herein comprise two or more antigen binding sites and are tetravalent or multivalent binding proteins.

The term “linker” refers to an amino acid residue or a polypeptide comprising two or more amino acid residues joined by peptide bonds that are used to link two polypeptides (e.g., two VH or two VL domains) Such linker polypeptides are well known in the art (see, e.g., Holliger et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak et al. (1994) Structure 2:1121-1123). A number of suitable linkers for use in the binding proteins described herein are set out in Table 55. In some embodiments, the X1 linker on the heavy chain is a GS-H10 linker and the X1 linker on the light chain is a GS-L10(dR) linker. In some embodiments, the X1 linker on the heavy chain is a GS-H10 linker and the X1 linker on the light chain is a GS-L10 linker. In some embodiments, the X1 linker on the heavy chain is an HG-short linker and the X1 linker on the light chain is an LK-long linker.

The terms “Kabat numbering”, “Kabat definitions” and “Kabat labeling” are used interchangeably herein. These terms, which are recognized in the art, refer to a system of numbering amino acid residues which are more variable (i.e., hypervariable) than other amino acid residues in the heavy and light chain variable regions of an antibody or binding protein, or an antigen binding portion thereof (Kabat et al. (1971) Ann. NY Acad. Sci. 190:382-391 and, Kabat et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). For the heavy chain variable region, the hypervariable region ranges from amino acid positions 31 to 35 for CDR1, amino acid positions 50 to 65 for CDR2, and amino acid positions 95 to 102 for CDR3. For the light chain variable region, the hypervariable region ranges from amino acid positions 24 to 34 for CDR1, amino acid positions 50 to 56 for CDR2, and amino acid positions 89 to 97 for CDR3. In some embodiments, the CDR sequences, framework sequences, and or constant region sequences are identified using Kabat numbering.

The term “CDR” refers to a complementarity determining region within an immunoglobulin variable region sequence. There are three CDRs in each of the variable regions of the heavy chain and the light chain, which are designated CDR1, CDR2 and CDR3, for each of the heavy and light chain variable regions. The term “CDR set” refers to a group of three CDRs that occur in a single variable region capable of binding the antigen. The exact boundaries of these CDRs have been defined differently according to different systems. The system described by Kabat (Kabat et al. (1987) and (1991)) not only provides an unambiguous residue numbering system applicable to any variable region of an antibody or binding protein, but also provides precise residue boundaries defining the three CDRs in each heavy or light chain sequence. These CDRs may be referred to as Kabat CDRs. Chothia and coworkers (Chothia and Lesk (1987) J. Mol. Biol. 196:901-917; Chothia et al. (1989) Nature 342:877-883) found that certain sub-portions within Kabat CDRs adopt nearly identical peptide backbone conformations, despite having great diversity at the level of amino acid sequence. These sub-portions were designated as L1, L2 and L3 or H1, H2 and H3 where the “L” and the “H” designates the light chain and the heavy chain regions, respectively. These regions may be referred to as Chothia CDRs, which have boundaries that overlap with Kabat CDRs. Other boundaries defining CDRs overlapping with the Kabat CDRs have been described by Padlan (1995) FASEB J. 9:133-139 and MacCallum (1996) J. Mol. Biol. 262(5):732-45). Still other CDR boundary definitions may not strictly follow one of the herein systems, but will nonetheless overlap with the Kabat CDRs, although they may be shortened or lengthened in light of prediction or experimental findings that particular residues or groups of residues or even entire CDRs do not significantly impact antigen binding. The methods used herein may utilize CDRs defined according to any of these systems, although certain embodiments use Kabat or Chothia defined CDRs.

The term “epitope” refers to a region of an antigen that is specifically bound by a binding protein disclosed herein. In certain embodiments, epitope determinants include chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl, or sulfonyl, and, in certain embodiments, may have specific three dimensional structural characteristics, and/or specific charge characteristics. An antigen or fragment can contain more than one epitope. An epitope may be determined by obtaining an X-ray crystal structure of an antibody:antigen complex and determining which residues on the antigen (e.g., VEGF or PDGF or a receptor) are within a specified distance of residues on the antibody of interest, wherein the specified distance is, 5 Å or less, e.g., 5 Å, 4 Å, 3 Å, 2 Å, 1 Å or less, or any distance in between. In some embodiments, the epitope is defined as a stretch of 8 or more contiguous amino acid residues along the antigen sequence in which at least 50%, 70% or 85% of the residues are within the specified distance of the antibody or binding protein in the X-ray crystal structure.

In certain embodiments, a binding protein specifically binds an antigen when it preferentially recognizes its target antigen in a complex mixture of proteins and/or macromolecules. Binding proteins that bind to the same or similar epitopes will likely cross-compete (one prevents the binding or modulating effect of the other). Cross-competition, however, can occur even without partial or complete epitope overlap, e.g., if epitopes are adjacent in three-dimensional space and/or due to steric hindrance.

The term “pharmacokinetic(s)” refers to the process by which a drug is absorbed, distributed, metabolized, and excreted by an organism. To generate a multivalent binding protein molecule with a desired pharmacokinetic profile, parent monoclonal antibodies with similarly desired pharmacokinetic profiles are selected. The PK profiles of the selected parental monoclonal antibodies can be easily determined in rodents using methods known to one skilled in the art (see, e.g., U.S. Pat. No. 7,612,181).

The term “bioavailability” refers to the degree and rate at which a drug is absorbed into a living system or is made available at the site of physiological activity. Bioavailability can be a function of several of the previously described properties, including stability, solubility, immunogenicity and pharmacokinetics, and can be assessed using methods known to one skilled in the art (see, e.g., U.S. Pat. No. 7,612,181).

The term “surface plasmon resonance” refers to an optical phenomenon that allows for the analysis of real-time biospecific interactions by detection of alterations in protein concentrations within a biosensor matrix, for example using the BIAcore® system (BIAcore International AB, a GE Healthcare company, Uppsala, Sweden and Piscataway, N.J.). For further descriptions, see Jönsson et al. (1993) Ann. Biol. Clin. 51:19-26. The term “K_on” refers to the on rate constant for association of a binding protein (e.g., an antibody or DVD-Ig) to the antigen to form the, e.g., DVD-Ig/antigen complex. The term “K_on” also refers to “association rate constant”, or “ka”, as is used interchangeably herein. This value indicating the binding rate of a binding protein to its target antigen or the rate of complex formation between a binding protein, e.g., an antibody, and antigen also is shown by the equation below:

Antibody (“Ab”)+Antigen (“Ag”)→Ab-Ag

The term “K_off” refers to the off rate constant for dissociation, or “dissociation rate constant”, of a binding protein (e.g., an antibody or DVD-Ig) from the, e.g., DVD-Ig/antigen complex as is known in the art. This value indicates the dissociation rate of a binding protein, e.g., an antibody, from its target antigen or separation of Ab-Ag complex over time into free antibody and antigen as shown by the equation below:

Ab+Ag←Ab-Ag

The terms “K_d” and “equilibrium dissociation constant” may refer to the value obtained in a titration measurement at equilibrium, or by dividing the dissociation rate constant (K_off) by the association rate constant (K_on). The association rate constant, the dissociation rate constant and the equilibrium dissociation constant, are used to represent the binding affinity of a binding protein (e.g., an antibody or DVD-Ig) to an antigen. Methods for determining association and dissociation rate constants are well known in the art. Using fluorescence-based techniques offers high sensitivity and the ability to examine samples in physiological buffers at equilibrium. Other experimental approaches and instruments such as a BIAcore® (biomolecular interaction analysis) assay, can be used (e.g., instrument available from BIAcore International AB, a GE Healthcare company, Uppsala, Sweden). Additionally, a KinExA® (Kinetic Exclusion Assay) assay, available from Sapidyne Instruments (Boise, Id.), can also be used.

The term “variant” refers to a polypeptide that differs from a given polypeptide in amino acid sequence by the addition (e.g., insertion), deletion, or conservative substitution of amino acids, but that retains the biological activity of the given polypeptide (e.g., a variant VEGF antibody can compete with anti-VEGF antibody for binding to VEGF). A conservative substitution of an amino acid, i.e., replacing an amino acid with a different amino acid of similar properties (e.g., hydrophilicity and degree and distribution of charged regions) is recognized in the art as typically involving a minor change. These minor changes can be identified, in part, by considering the hydropathic index of amino acids, as understood in the art (see, e.g., Kyte et al. (1982) J. Mol. Biol. 157: 105-132). The hydropathic index of an amino acid is based on a consideration of its hydrophobicity and charge. It is known in the art that amino acids of similar hydropathic indexes in a protein can be substituted and the protein still retains protein function. In one aspect, amino acids having hydropathic indexes of ±2 are substituted. The hydrophilicity of amino acids also can be used to reveal substitutions that would result in proteins retaining biological function. A consideration of the hydrophilicity of amino acids in the context of a peptide permits calculation of the greatest local average hydrophilicity of that peptide, a useful measure that has been reported to correlate well with antigenicity and immunogenicity (see, e.g., U.S. Pat. No. 4,554,101). Substitution of amino acids having similar hydrophilicity values can result in peptides retaining biological activity, for example immunogenicity, as is understood in the art. In one aspect, substitutions are performed with amino acids having hydrophilicity values within ±2 of each other. Both the hydrophobicity index and the hydrophilicity value of amino acids are influenced by the particular side chain of that amino acid. Consistent with that observation, amino acid substitutions that are compatible with biological function are understood to depend on the relative similarity of the amino acids, and particularly the side chains of those amino acids, as revealed by the hydrophobicity, hydrophilicity, charge, size, and other properties. The term “variant” also includes polypeptide or fragment thereof that has been differentially processed, such as by proteolysis, phosphorylation, or other post-translational modification, yet retains its biological activity or antigen reactivity, e.g., the ability to bind to VEGF. The term “variant” encompasses fragments of a variant unless otherwise defined. A variant may be about 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, or 75% identical to the wild type sequence.

Use of Disclosed Binding Proteins in Treating Various Diseases

The binding protein molecules provided herein are useful as therapeutic molecules to treat various diseases, e.g., wherein the targets that are recognized by the binding proteins are detrimental. Such binding proteins may bind one or more targets involved in a specific disease.

Without limiting the disclosure, further information on certain disease conditions is provided.

1. Age-Related Macular Degeneration (AMD)

In various embodiments, one or more of the binding proteins disclosed herein that are capable of binding to VEGF and PDGF and/or their cognate receptors (e.g., a combination of an anti-VEGF and an anti-PDGF binding protein, or a multispecific binding protein capable of targeting both VEGF and PDGF) can be used to treat AMD. In some embodiments, any of the binding proteins disclosed herein can be used to treat AMD, or a binding protein comprising the CDR and/or variable domain sequences from any of the binding disclosed herein. In certain embodiments, the binding protein used to treat AMD is one or more of the binding proteins listed in Tables 27-30, 38-42, 46-50, or 55-58. In certain embodiments, the binding protein used to treat AMD is one or more of the binding proteins listed in Tables 56-58. In certain embodiments, the binding protein is PR-1572102, PR-1572105, or PR-1610561.

Age-Related Macular Degeneration (AMD) is the leading cause of irreversible vision loss in individuals over the age of 50 in the United States and a major cause of blindness worldwide. Globally more than 160 million people suffer from AMD. AMD is an age-related ocular disease that results in blindness due to damage to the macula; the region of the retina responsible for sharp central vision. It is associated with the degeneration of the macula and in particular the retinal pigmented epithelium (RPE).

The disease occurs in two forms, the dry or non-exudative AMD form and the wet or exudative form. The most common form of macular degeneration, dry AMD (non-neovascular), is an early stage of the disease and may result from aging and thinning of macular tissues, deposition of pigment in the macula, or a combination of both processes. Dry AMD is diagnosed when yellowish spots known as drusen accumulate in and around the macula. Drusen are thought to be deposits or debris from nearby deteriorating tissue. The onset of dry AMD is usually associated with age-related changes in Bruch's membrane, a highly specialized matrix for adhesion of retinal pigment epithelial (RPE) cells. These alterations in Bruch's membrane can result in death of RPE cells in the macula, accumulation of drusen, and damage to photoreceptor cells. Gradual central loss of vision may occur with dry AMD, but the symptoms are typically not nearly as severe as with the wet form of the disease. Dry AMD can slowly progress to late-stage geographic atrophy (GA) resulting in a gradual deterioration of retinal cells that can cause severe vision loss. Dry AMD (both early and late stage) is the most common form of AMD representing more than 85% of all diagnosed cases.

The wet or exudative form of the disease usually results in more severe vision loss. Wet macular degeneration mainly affects central vision, causing “blind spots” in the central line of vision. Approximately 10-15% of dry AMD cases progress to wet AMD. Wet AMD is characterized by new blood vessel growth beneath the retina. Clinically, this is referred to as choroidal neovascularization (CNV). Wet AMD accounts for about 10-15% of all cases of AMD. Progression of dry AMD to wet AMD is marked by the development of neovascularization within Bruch's membrane, as well as in the subretinal space. Wet AMD occurs when abnormal blood vessels behind the retina grow under the macula. These new blood vessels tend to be fragile and often leak blood and fluid. The blood and fluid result in macula inflammation and thickening and disrupts the connection between the photoreceptors and the RPE, leading to vision loss. In wet AMD, neovascularization is stimulated by many angiogenic factors; including vascular endothelial growth factor (VEGF), which appears to be the primary angiogenic factor in patients with wet AMD (Miller et al. (1994) Am. J. Pathol. 145(3):574-584). Additionally, VEGF can act as a powerful endothelial cell mitogen, increasing vascular permeability. The primary goals of current AMD treatment are to block or inhibit choroidal neovascularization (CNV) and macular edema following retinal vein occlusion (RVO), stabilize or improve vision, and to reduce the occurrence of adverse effects.

Anti-VEGF agents may reduce choroidal neovascularization (CNV) and leakage, but do not lead to regression of CNV itself. Emerging evidence indicates the important role of pericytes on the maturation of new blood vessels. Anti-PDGF agents can directly block pericyte recruitment and prevent the maturation and stabilization of choroidal neovascularization. If pericytes can be stripped away from new blood vessels, vascular endothelial cells may become more susceptible to VEGF blockade, ultimately leading to a regression of angiogenesis.

Among other functions, VEGF stimulates endothelial cell proliferation/growth, increases vascular permeability, and promotes leukocyte activity capable of damaging retinal endothelial cells (Leung et al. (1989) Science 246(4935):1306-9). In wet AMD, retinal tissues produce and release angiogenic growth factors such as VEGF that bind to specific receptors located on the endothelial cells of nearby preexisting blood vessels. Activation of endothelial cells can result in the release of enzymes targeting tight junctions. These enzymes act on the basement membrane surrounding all existing blood vessels and lead to the formation of holes in the membrane. The endothelial cells proliferate and migrate out through these holes toward the diseased tissue. Specialized adhesion molecules such as integrins promote formation of new blood vessel sprouts, and matrix metalloproteinases (MMPs) dissolve the tissue in front of the sprouting vessel tip in order to accommodate it. Finally, smooth muscle cells (pericytes) provide structural support to these newly formed blood vessel loops and blood flow begins in these new immature vessels. Thus, VEGF may serve as a rate-limiting step in angiogenesis. VEGF also increases vascular permeability by leukocyte-mediated endothelial cell injury, formation of fenestrations, and the dissolution of tight junctions. This leads to intra-retinal fluid accumulation and a detrimental effect on visual acuity. Moreover, VEGF can also cause the release of inflammatory cytokines that further reinforce the cycle of inflammation and angiogenesis.

In some embodiments, treatments inhibiting VEGF, PDGF, and/or the receptors (in a combination therapy or in one molecule) using the binding proteins disclosed herein may offer improved options for patients with wet AMD, while reducing the number of injections, reducing the safety concerns associated with multiple injections, and reducing cost.

2. Diabetic Retinopathy

Diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness in American adults. It is caused by changes in the blood vessels of the retina. In some people with diabetic retinopathy, blood vessels may swell and leak fluid. In other people, abnormal new blood vessels grow on the surface of the retina. The retina is the light-sensitive tissue at the back of the eye. A healthy retina is necessary for good vision.

Diabetic retinopathy has four stages: (1) Mild Nonproliferative Retinopathy. At this earliest stage, microaneurysms occur. They are small areas of balloon-like swelling in the retina's tiny blood vessels. (2) Moderate Nonproliferative Retinopathy. As the disease progresses, some blood vessels that nourish the retina are blocked. (3) Severe Nonproliferative Retinopathy. Many more blood vessels are blocked, depriving several areas of the retina with their blood supply. These areas of the retina send signals to the body to grow new blood vessels for nourishment. (4) Proliferative Retinopathy. At this advanced stage, the signals sent by the retina for nourishment trigger the growth of new blood vessels. This condition is called proliferative retinopathy. These new blood vessels are abnormal and fragile. They grow along the retina and along the surface of the clear, vitreous gel that fills the inside of the eye. By themselves, these blood vessels do not cause symptoms or vision loss. However, they have thin, fragile walls. If they leak blood, severe vision loss and even blindness can result.

Blood vessels damaged from diabetic retinopathy can cause vision loss in two ways: (1) Fragile, abnormal blood vessels can develop and leak blood into the center of the eye, blurring vision. This is proliferative retinopathy and is the fourth and most advanced stage of the disease. (2) Fluid can leak into the center of the macula, the part of the eye where sharp, straight-ahead vision occurs. The fluid makes the macula swell, blurring vision. This condition is called macular edema. It can occur at any stage of diabetic retinopathy, although it is more likely to occur as the disease progresses. About half of the people with proliferative retinopathy also have macular edema.

In some embodiments, the binding proteins disclosed herein may be used to inhibit VEGF, PDGF, and/or the receptors (in a combination therapy or in one molecule) to treat diabetic retinopathy.

In various embodiments, other diseases may be treated using the binding proteins disclosed herein, including but not limited to other eye disorders, cancers, fibrosis, renal disease, pathologic angiogenesis, wound healing, bone formation, or other diseases associated with aberrant (e.g., elevated) PDGF and/or VEGF expression.

Pharmaceutical Compositions

In various embodiments, pharmaceutical compositions comprising one or more of the binding proteins disclosed herein, either alone or in combination with other prophylactic agents, therapeutic agents, and/or pharmaceutically acceptable carriers, are provided. The pharmaceutical compositions comprising binding proteins provided herein are for use in, but not limited to, diagnosing, detecting, or monitoring a disorder, in preventing, treating, managing, or ameliorating a disorder or one or more symptoms thereof, and/or in research. The formulation of pharmaceutical compositions, either alone or in combination with prophylactic agents, therapeutic agents, and/or pharmaceutically acceptable carriers, are known to one skilled in the art (see, e.g., U.S. Patent Appl. No. 20090311253 and U.S. Pat. No. 7,612,181).

Methods of administering a pharmaceutical composition or a prophylactic or therapeutic agent provided herein include, but are not limited to, parenteral administration (e.g., intradermal, intramuscular, intraperitoneal, intravitreous, intravenous and subcutaneous), epidural administration, intratumoral administration, mucosal administration (e.g., intranasal and oral routes) and pulmonary administration (e.g., aerosolized compounds administered with an inhaler or nebulizer). In an embodiment, the methods of administering a pharmaceutical composition or a prophylactic or therapeutic agent provided herein include topical eye drops, gels, or creams. The formulation of pharmaceutical compositions for specific routes of administration, and the materials and techniques necessary for the various methods of administration are available and known to one skilled in the art (U.S. Patent Appl. No. 20090311253 and U.S. Pat. No. 7,612,181).

Dosage regimens may be adjusted to provide the optimum desired response (e.g., a therapeutic or prophylactic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. The term “dosage unit form” refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms provided herein are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic or prophylactic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals. An exemplary, non-limiting range for a therapeutically or prophylactically effective amount of a binding protein provided herein is 0.1-20 mg/kg, for example, 1-10 mg/kg. It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens may be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.

Combination Therapy

In various embodiments, a binding protein provided herein may also be administered with one or more additional therapeutic agents useful in the treatment of various diseases, the additional agent being selected by the skilled artisan for its intended purpose. For example, the additional agent can be a therapeutic agent art-recognized as being useful to treat the disease or condition being treated by the antibody provided herein, such as AMD. The combination can also include more than one additional agent, e.g., two or three additional agents.

Combination therapy agents include, but are not limited to imaging agents, cytotoxic agents, angiogenesis inhibitors, kinase inhibitors, tyrosine kinase inhibitors, tyrosine kinase receptor inhibitors, co-stimulation molecule blockers, adhesion molecule blockers, anti-cytokine antibodies or functional fragments thereof, methotrexate, cyclosporin, rapamycin, FK506, detectable labels or reporters, TNF antagonists, antirheumatics, muscle relaxants, narcotics, non-steroid anti-inflammatory drugs (NSAIDs), analgesics, anesthetics, local anesthetics, sedatives, a hyaluronidase enzyme, neuromuscular blockers, antimicrobials, antipsoriatics, corticosteriods, anabolic steroids, erythropoietin, immunizations, immunoglobulins, immunosuppressives, growth hormones, hormone replacement drugs, radiopharmaceuticals, antidepressants, antipsychotics, stimulants, asthma medications, beta agonists, inhaled steroids, epinephrine or analogs, cytokines, or cytokine antagonists.

Diagnostics

The disclosure herein also provides, in various embodiments, diagnostic applications including, but not limited to, diagnostic assay methods, diagnostic kits containing one or more binding proteins, and adaptation of the methods and kits for use in automated and/or semi-automated systems. The methods, kits, and adaptations provided may be employed in the detection, monitoring, and/or treatment of a disease or disorder in an individual. This is further elucidated below.

The present disclosure also provides a method for determining the presence, amount or concentration of an analyte, or fragment thereof, in a test sample using at least one binding protein as described herein. Any suitable assay as is known in the art can be used in the method. Examples include, but are not limited to, immunoassays and/or methods employing mass spectrometry.

Immunoassays provided by the present disclosure may include sandwich immunoassays, radioimmunoassay (RIA), enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA), competitive-inhibition immunoassays, fluorescence polarization immunoassay (FPIA), enzyme multiplied immunoassay technique (EMIT), bioluminescence resonance energy transfer (BRET), and homogenous chemiluminescent assays, among others.

A chemiluminescent microparticle immunoassay, in particular one employing the ARCHITECT® automated analyzer (Abbott Laboratories, Abbott Park, Ill.), is an example of an immunoassay.

Methods employing mass spectrometry are provided by the present disclosure and include, but are not limited to MALDI (matrix-assisted laser desorption/ionization) or by SELDI (surface-enhanced laser desorption/ionization).

Methods for collecting, handling, processing, and analyzing biological test samples using immunoassays and mass spectrometry would be well-known to one skilled in the art, are provided for in the practice of the present disclosure (see, e.g., U.S. Pat. No. 7,612,181).

Kits

In various embodiments, a kit for assaying a test sample for the presence, amount or concentration of an analyte, or fragment thereof, in a test sample is also provided. The kit comprises at least one component for assaying the test sample for the analyte, or fragment thereof, and instructions for assaying the test sample for the analyte, or fragment thereof. The at least one component for assaying the test sample for the analyte, or fragment thereof, can include a composition comprising a binding protein, as disclosed herein, and/or an anti-analyte binding protein (or a fragment, a variant, or a fragment of a variant thereof), which is optionally immobilized on a solid phase.

Optionally, the kit may comprise a calibrator or control, which may comprise isolated or purified analyte. The kit can comprise at least one component for assaying the test sample for an analyte by immunoassay and/or mass spectrometry. The kit components, including the analyte, binding protein, and/or anti-analyte binding protein, or fragments thereof, may be optionally labeled using any art-known detectable label. The materials and methods for the creation provided for in the practice of the present disclosure would be known to one skilled in the art (see, e.g., U.S. Pat. No. 7,612,181).

The kit (or components thereof), as well as the method of determining the presence, amount or concentration of an analyte in a test sample by an assay, such as an immunoassay as described herein, can be adapted for use in a variety of automated and semi-automated systems (including those wherein the solid phase comprises a microparticle), as described, for example, in U.S. Pat. Nos. 5,089,424 and 5,006,309, and as commercially marketed, for example, by Abbott Laboratories (Abbott Park, Ill.) as ARCHITECT®.

Other platforms available from Abbott Laboratories include, but are not limited to, AxSYM®, IMx® (see, for example, U.S. Pat. No. 5,294,404, PRISM®, EIA (bead), and Quantum™ II, as well as other platforms. Additionally, the assays, kits and kit components can be employed in other formats, for example, on electrochemical or other hand-held or point-of-care assay systems. The present disclosure is, for example, applicable to the commercial Abbott Point of Care (i-STATED, Abbott Laboratories) electrochemical immunoassay system that performs sandwich immunoassays Immunosensors and their methods of manufacture and operation in single-use test devices are described, for example in, U.S. Pat. Nos. 5,063,081, 7,419,821, 7,682,833, 7,723,099, and 9,035,027; and U.S. Publication No. 20040018577.

Sequences

Table 1 discloses amino acid and nucleotide sequences encoding VEGF-A from different human isoforms and different species. Table 2 discloses amino acid and nucleotide sequences encoding PDGF-BB from different human isoforms and different species. Table 3 discloses human IgG heavy chain and light chain constant domains, including sequences with the indicated amino acid modifications relative to the wild-type sequence. In various embodiments, the constant domains listed in Table 3 can be used with any of the binding proteins disclosed herein. The variable domains of the binding proteins disclosed herein may be attached to constant regions of any immunoglobulin species, isotypes, or mutants. Exemplary modifications in constant domain mutants include those with amino acid mutations intended to increase or reduce constant domain interactions with Fc-gamma receptors, C1q and FcRn, and/or mutations intended to modulate protein stability or valency (full-length and half molecule, heterodimer molecule, etc.). Tables 4 and 5 disclose exemplary heavy and light chain acceptor framework sequences that can be used with any of the CDR sets disclosed herein (i.e., heavy chain acceptor sequences paired with any of the heavy chain CDRs 1-3 disclosed herein, and/or light chain acceptor sequences paired with any of the light chain CDRs 1-3 disclosed herein) to form functional binding sites for PDGF, VEGF, and/or their cognate receptors.

TABLE 1
Amino Acid and Nucleotide Sequences for VEGF-A
	Sequence	Sequence
Kind of Sequence	Identifier	123456789012345678901234567890
Human VEGF-A 165	SEQ ID NO:	APMAEGGGQNHHEVVKFMDVYQRSYCHPIE
Amino Acid Sequence	253	TLVDIFQEYPDEIEYIFKPSCVPLMRCGGC
		CNDEGLECVPTEESNITMQIMRIKPHQGQH
		IGEMSFLQHNKCECRPKKDRARQENPCGPC
		SERRKHLFVQDPQTCKCSCKNTDSRCKARQ
		LELNERTCRCDKPRR
Human VEGF-A 121	SEQ ID NO:	APMAEGGGQNHHEVVKFMDVYQRSYCHPIE
Amino Acid Sequence	254	TLVDIFQEYPDEIEYIFKPSCVPLMRCGGC
		CNDEGLECVPTEESNITMQIMRIKPHQGQH
		IGEMSFLQHNKCECRPKKDRARQEKCDKPR
		R
Human VEGF-A 110	SEQ ID NO:	APMAEGGGQNHHEVVKFMDVYQRSYCHPIE
Amino Acid Sequence	255	TLVDIFQEYPDEIEYIFKPSCVPLMRCGGC
		CNDEGLECVPTEESNITMQIMRIKPHQGQH
		IGEMSFLQHNKCECRCDKPRR
Cynomolgus monkey	SEQ ID NO:	APMAEGGGQNHHEVVKFMDVYQRSYCHPIE
VEGF-A 165 Amino Acid	256	TLVDIFQEYPDEIEYIFKPSCVPLMRCGGC
Sequence		CNDEGLECVPTEESNITMQIMRIKPHQGQH
		IGEMSFLQHNKCECRPKKDRARQENPCGPC
		SERRKHLFVQDPQTCKCSCKNTDSRCKARQ
		LELNERTCRCDKPRR
Mouse VEGF-A 164	SEQ ID NO:	APTTEGEQKSHEVIKFMDVYQRSYCRPIET
Amino Acid Sequence	257	LVDIFQEYPDEIEYIFKPSCVPLMRCAGCC
		NDEALECVPTSESNITMQIMRIKPHQSQHI
		ERMSFLQHSRCECRPKKDRTKPENHCEPCS
		ERRKHLFVQDPQTCKCSCKNTDSRCKARQL
		ELNERTCRCDKPRR
Rat VEGF-A 164 Amino	SEQ ID NO:	APTTEGEQKAHEVVKFMDVYQRSYCRPIET
Acid Sequence	258	LVDIFQEYPDEIEYIFKPSCVPLMRCAGCC
		NDEALECVPTSESNVTMQIMRIKPHQSQHI
		GEMSFLQHSRCECRPKKDRTKPENHCEPCS
		ERRKHLFVQDPQTCKCSCKNTDSRCKARQL
		ELNERTCRCDKPRR
Rabbit VEGF-A Amino	SEQ ID NO:	MNFLLSWVHWSLALLLYLHHAKWSQAAPMA
Acid Sequence	259	EEGDNKPHEVVKFMEVYRRSYCQPIETLVD
		IFQEYPDEIEYIFKPSCVPLVRCGGCCNDE
		SLECVPTEEFNVTMQIMRIKPHQGQHIGEM
		SFLQHNKCECRPKKDRARQENPCGPCSERR
		KHLFVQDPQTCKCSCKNTDSRCKARQLELN
		ERTCRCDKPRR

TABLE 2
Amino Acid and Nucleotide Sequences for PDGF-BB
	Sequence	Sequence
Kind of Sequence	Identifier	123456789012345678901234567890
Human PDGF-BB Amino	SEQ ID NO:	SLGSLTIAEPAMIAECKTRTEVFEISRRLI
Acid Sequence	260	DRTNANFLVWPPCVEVQRCSGCCNNRNVQC
		RPTQVQLRPVQVRKIEIVRKKPIFKKATVT
		LEDHLACKCETVAAARPVT
Human PDGF-BB-RM	SEQ ID NO:	MNRCWALFLSLCCYLRLVSAEGDPIPEELY
(Retention Motif) Amino	261	EMLSDHSIRSFDDLQRLLHGDPGEEDGAEL
Acid Sequence		DLNMTRSHSGGELESLARGRRSLGSLTIAE
		PAMIAECKTRTEVFEISRRLIDRTNANFLV
		WPPCVEVQRCSGCCNNRNVQCRPTQVQLRP
		VQVRKIEIVRKKPIFKKATVTLEDHLACKC
		ETVAAARPVTRSPGGSQEQRAKTPQTRVTI
		RTVRVRRPPKGKHRKFKHTHDKTALKETLG
		A
Cynomolgus monkey	SEQ ID NO:	SLGSLTVAEPAMIAECKTRTEVFEISRRLI
PDGF-BB Amino Acid	262	DRTNANFLVWPPCVEVQRCSGCCNNRNVQC
Sequence		RPTQVQLRPVQVRKIEIVRKKPIFKKATVT
		LEDHLACKCETVAAARPVT
Mouse PDGF-BB Amino	SEQ ID NO:	SLGSLAAAEPAVIAECKTRTEVFQISRNLI
Acid Sequence	263	DRTNANFLVWPPCVEVQRCSGCCNNRNVQC
		RASQVQMRPVQVRKIEIVRKKPIFKKATVT
		LEDHLACKCETIVTPRPVT
Rat PDGF-BB Amino	SEQ ID NO:	SLGSLAAAEPAVIAECKTRTEVFQISRNLI
Acid Sequence	264	DRTNANFLVWPPCVEVQRCSGCCNNRNVQC
		RASQVQMRPVQVRKIEIVRKKPVFKKATVT
		LEDHLACKCETVVTPRPVT
Rabbit PDGF-BBA Amino	SEQ ID NO:	SLGSLAAAEPAVIAECKTRTEVFQISRNLI
Acid Sequence	265	DRTNANFLVWPPCVEVQRCSGCCNNRNVQC
		RASQVQMRPVQVRKIEIVRKKPVFKKATVT
		LEDHLACKCETVVTPRPVT

TABLE 3
Amino Acid Sequences of Human IgG Heavy Chain and
Light Chain Constant Domains
	Sequence	Sequence
Protein	Identifier	123456789012345678901234567890
Ig gamma-1 constant	SEQ ID NO:	ASTKGPSVFFLAPSSKSTSGGTAALGCLVK
region	266	DYFPEPVTVSWNSGALTSGVHTFPAVLQSS
		GLYSLSSVVTVPSSSLGTQTYICNVNHKPS
		NTKVDKKVEPKSCDKTHTCPPCPAPELLGG
		PSVFLFPPKPKDTLMISRTPEVTCVVVDVS
		HEDPEVKFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKCKVSNKA
		LPAPIEKTISKAKGQPREPQVYTLPPSREE
		MTKNQVSLTCLVKGFYPSDIAVEWESNGQP
		ENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
		QQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Ig gamma-1 constant	SEQ ID NO:	ASTKGPSVFFLAPSSKSTSGGTAALGCLVK
region L234A, L235A	267	DYFPEPVTVSWNSGALTSGVHTFPAVLQSS
		GLYSLSSVVTVPSSSLGTQTYICNVNHKPS
		NTKVDKKVEPKSCDKTHTCPPCPAPEAAGG
		PSVFLFPPKPKDTLMISRTPEVTCVVVDVS
		HEDPEVKFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKCKVSNKA
		LPAPIEKTISKAKGQPREPQVYTLPPSREE
		MTKNQVSLTCLVKGFYPSDIAVEWESNGQP
		ENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
		QQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Ig gamma-1 constant	SEQ ID NO:	ASTKGPSVFFLAPSSKSTSGGTAALGCLVK
region L234A, L235A,	268	DYFPEPVTVSWNSGALTSGVHTFPAVLQSS
H435A		GLYSLSSVVTVPSSSLGTQTYICNVNHKPS
		NTKVDKKVEPKSCDKTHTCPPCPAPEAAGG
		PSVFLFPPKPKDTLMISRTPEVTCVVVDVS
		HEDPEVKFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKCKVSNKA
		LPAPIEKTISKAKGQPREPQVYTLPPSREE
		MTKNQVSLTCLVKGFYPSDIAVEWESNGQP
		ENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
		QQGNVFSCSVMHEALHNAYTQKSLSLSPGK
Ig gamma-1 constant	SEQ ID NO:	ASTKGPSVFFLAPSSKSTSGGTAALGCLVK
region L234A, L235A,	269	DYFPEPVTVSWNSGALTSGVHTFPAVLQSS
H435R		GLYSLSSVVTVPSSSLGTQTYICNVNHKPS
		NTKVDKKVEPKSCDKTHTCPPCPAPEAAGG
		PSVFLFPPKPKDTLMISRTPEVTCVVVDVS
		HEDPEVKFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKCKVSNKA
		LPAPIEKTISKAKGQPREPQVYTLPPSREE
		MTKNQVSLTCLVKGFYPSDIAVEWESNGQP
		ENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
		QQGNVFSCSVMHEALHNRYTQKSLSLSPGK
Ig gamma-1 constant	SEQ ID NO:	ASTKGPSVFFLAPSSKSTSGGTAALGCLVK
region C226A, C229A,	270	DYFPEPVTVSWNSGALTSGVHTFPAVLQSS
N297A, F405R (Half		GLYSLSSVVTVPSSSLGTQTYICNVNHKPS
body)		NTKVDKKVEPKSCDKTHTAPPAPAPELLGG
		PSVFLFPPKPKDTLMISRTPEVTCVVVDVS
		HEDPEVKFNWYVDGVEVHNAKTKPREEQYA
		STYRVVSVLTVLHQDWLNGKEYKCKVSNKA
		LPAPIEKTISKAKGQPREPQVYTLPPSREE
		MTKNQVSLTCLVKGFYPSDIAVEWESNGQP
		ENNYKTTPPVLDSDGSFRLYSKLTVDKSRW
		QQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Ig Kappa constant region	SEQ ID NO:	RTVAAPSVFIFPPSDEQLKSGTASVVCLLN
	271	NFYPREAKVQWKVDNALQSGNSQESVTEQD
		SKDSTYSLSSTLTLSKADYEKHKVYACEVT
		HQGLSSPVTKSFNRGEC
Ig Lambda constant region	SEQ ID NO:	GQPKAAPSVTLFPPSSEELQANKATLVCLI
	272	SDFYPGAVTVAWKADSSPVKAGVETTTPSK
		QSNNKYAASSYLSLTPEQWKSHRSYSCQVT
		HEGSTVEKTVAPTECS

TABLE 4
Amino Acid Sequences of Heavy Chain Acceptor Frameworks
	Protein region/
SEQ ID	Closest	Amino Acid Sequence
NO:	Germline Family	12345678901234567890123456789012
273	VH3-7 FR1	EVQLVESGGGLVQPGGSLRLSCAASGFTFS
274	VH3-7 FR2	WVRQAPGKGLEWVA
275	VH3-7 FR3	RFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR
276	JH4 FR4	WGQGTLVTVSS
277	VH3 CONSENUSUS FR1	EVQLVESGGGLVQPGGSLRLSCAASGFTFS
278	VH3 CONSENUSUS FR2	WVRQAPGKGLEWVS
279	VH3 CONSENUSUS FR3	RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR
280	JH4 FR4	WGQGTLVTVSS
281	VH1-46 FR1	QVQLVQSGAEVKKPGASVKVSCKASGYTFT
282	VH1-46 FR2	WVRQAPGQGLEWMG
283	VH1-46 FR3	RVTMTRDTSTSTVYMELSSLRSEDTAVYYCAR
284	JH4 FR4	WGQGTLVTVSS
285	VH3-30 FR1	QVQLVESGGGVVQPGRSLRLSCAASGFTFS
286	VH3-30 FR2	WVRQAPGKGLEWVA
287	VH3-30 FR3	RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR
288	JH3 FR4	WGQGTMVTVSS
289	VH3 CONSENUSUS FR1	EVQLVESGGGLVQPGGSLRLSCAASGFTFS
290	VH3 CONSENUSUS FR2	WVRQAPGKGLEWVS
291	VH3 CONSENUSUS FR3	RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR
292	JH3 FR4	WGQGTMVTVSS
293	VH2-70/JH6 FR1	EVTLRESGPALVKPTQTLTLTCTFSGFSLS
294	VH2-70/JH6 FR2	WIRQPPGKALEWLA
295	VH2-70/JH6 FR3	RLTISKDTSKNQVVLTMTNMDPVDTATYYCAR
296	VH2-70/JH6 FR4	WGQGTTVTVSS
297	VH2-26/JH6 FR1	EVTLKESGPVLVKPTETLTLTCTVSGFSLS
298	VH2-26/JH6 FR2	WIRQPPGKALEWLA
299	VH2-26/JH6 FR3	RLTISKDTSKSQVVLTMTNMDPVDTATYYCAR
300	VH2-26/JH6 FR4	WGQGTTVTVSS
301	VH3-72/JH6 FR1	EVQLVESGGGLVQPGGSLRLSCAASGFTFS
302	VH3-72/JH6 FR2	WVRQAPGKGLEWVG
303	VH3-72/JH6 FR3	RFTISRDDSKNSLYLQMNSLKTEDTAVYYCAR
304	VH3-72/JH6 FR4	WGQGTTVTVSS
305	VH3-21/JH6 FR1	EVQLVESGGGLVKPGGSLRLSCAASGFTFS
306	VH3-21/JH6 FR2	WVRQAPGKGLEWVS
307	VH3-21/JH6 FR3	RFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR
308	VH3-21/JH6 FR4	WGQGTTVTVSS
309	VH1-69/JH6 FR1	EVQLVQSGAEVKKPGSSVKVSCKASGGTFS
310	VH1-69/JH6 FR2	WVRQAPGQGLEWMG
311	VH1-69/JH6 FR3	RVTITADKSTSTAYMELSSLRSEDTAVYYCAR
312	VH1-69/JH6 FR4	WGQGTTVTVSS
313	VH1-18/JH6 FR1	EVQLVQSGAEVKKPGASVKVSCKASGYTFT
314	VH1-18/JH6 FR2	WVRQAPGQGLEWMG
315	VH1-18/JH6 FR3	RVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR
316	VH1-18/JH6 FR4	WGQGTTVTVSS
317	IGHV4-59 FR1	EVQLQESGPGLVKPSETLSLTCTVSGGSIS
318	IGHV4-59 FR2	WIRQPPGKGLEWIG
319	IGHV4-59 FR3	RVTISVDTSKNQFSLKLSSVTAADTAVYYCAR
320	IGHV4-59/JH FR4	WGQGTLVTVSS
321	IGHV3-66 FW1	EVQLVESGGGLVQPGGSLRLSCAVSGGSIS
322	IGHV3-66 FW2	WIRQAPGKGLEWIG
323	IGHV3-66 FW3	RVTISVDTSKNSFYLQMNSLRAEDTAVYYCAR
324	IGHV3-66/JH FW4	WGQGTLVTVSS
325	IGHV4-59 FR1	EVQLQESGPGLVKPGETLSLTCTVSGGSIS
326	IGHV4-59 FR2	WIRQAPGKGLEWIG
327	IGHV4-59 FR3	RVTISVDTSKNQFYLKLSSVRAEDTAVYYCAR
328	IGHV4-59/JH FR4	WGQGTLVTVSS
329	IGHV5-51 FR1	EVQLVQSGTEVKKPGESLKISCKVSGGSIS
330	IGHV5-51 FR2	WIRQMPGKGLEWIG
331	IGHV5-51 FR3	QVTISVDTSFNTFFLQWSSLKASDTAMYYCAR
332	IGHV5-51/JH FR4	WGQGTMVTVSS
333	IGHV2-70 FR1	EVTLRESGPALVKPTQTLTLTCTVSGGSIS
334	IGHV2-70 FR2	WIRQPPGKGLEWIG
335	IGHV2-70 FR3	RVTISVDTSKNQFVLTMTNMDPVDTATYYCAR
336	IGHV2-70/JH FR4	WGQGTTVTVSS
337	IGHV3-15 FR1	EVQLLESGGGLVKSGGSLRLSCAASGFTFR
338	IGHV3-15 FR2	WVRQAPGKGLEWVA
339	IGHV3-15 FR3	RFTISRDNSKNTLYLQLNSLRAEDTAVYYCAK
340	IGHV3-15/JH FR4	WGQGTMVTVSS
341	IGHV3-43 FR1	EVQLVESGGGVVQPGGSLRLSCAASGFTFG
342	IGHV3-43 FR2	WVRQAPGKGLEWVA
343	IGHV3-43 FR3	RFTISRDNSKNTLYLQLNSLRAEDTAVYYCAK
344	IGHV3-43/JH FR4	WGQGTMVTVSS

TABLE 5
Amino Acid Sequences
of Light Chain Acceptor Frameworks
	Protein
	region/
SEQ	Closest
ID	Germline	Sequence
NO:	Family	12345678901234567890123456789012
345	O2 FR1	DIQMTQSPSSLSASVGDRVTITC
346	O2 FR2	WYQQKPGKAPKLLIY
347	O2 FR3	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
348	JK2 FR4	FGQGTKLEIK
349	L2 FR1	EIVMTQSPATLSVSPGERATLSC
350	L2 FR2	WYQQKPGQAPRLLIY
351	L2 FR3	GIPARFSGSGSGTEFTLTISSLQSEDFAVYYC
352	JK2 FR4	FGQGTKLEIK
353	B3/JK4 FR1	DIVMTQSPDSLAVSLGERATINC
354	B3/JK4 FR2	WYQQKPGQPPKLLIY
355	B3/JK4 FR3	GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC
356	B3/JK4 FR4	FGGGTKVEIKR
357	L2/JK4 FR1	EIVMTQSPATLSVSPGERATLSC
358	L2/JK4 FR2	WYQQKPGQAPRLLIY
359	L2/JK4 FR3	GIPARFSGSGSGTEFTLTISSLQSEDFAVYYC
360	L2/JK4 FR4	FGGGTKVEIKR
361	L15/JK4 FR1	DIQMTQSPSSLSASVGDRVTITC
362	L15/JK4 FR2	WYQQKPEKAPKSLIY
363	L15/JK4 FR3	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
364	L15/JK4 FR4	FGGGTKVEIKR
365	L5/JK4 FR1	DIQMTQSPSSVSASVGDRVTITC
366	L5/JK4 FR2	WYQQKPGKAPKLLIY
367	L5/JK4 FR3	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
368	L5/JK4 FR4	FGGGTKVEIKR
369	IGLV3-1 FR1	SYELTQPPSVSVSPGQTASITC
370	IGLV3-1 FR2	WYQQKPGQSPVLVIY
371	IGLV3-1 FR3	GIPERFSGSNSGDTATLTISGTQPMDEADYYC
372	IGLV3-1/JL FR4	FGYGTKVTVL
373	IGLV3-1 FR1	SYELTQPPSVSVSPGQTASITC
374	IGLV3-1 FR2	WYQQKPGQSPVLVIY
375	IGLV3-1 FR3	GIPERFSGSNSGDTATLTISGTQPMDEADYYC
376	IGLV3-1/JL FR4	GGGTKLTVLG
377	IGLV3-1 FR1	YELTQPPSVSVSPGQTASITC
378	IGLV3-1 FR2	WYQQKPGQSPVLVIY
379	IGLV3-1 FR3	GIPERFSGSNSGDTATLTISGTQPMDEADYYC
380	IGLV3-1/JL FR4	GGGTKLTVLG
381	IGLV3-1 FR1	LYVLTQPPSVSVSPGQTASITC
382	IGLV3-1 FR2	WYQQKPGQSPVLVIY
383	IGLV3-1 FR3	GIPERFSGSNSGDTATLTISGTQTMDEADYLC
384	IGLV3-1/JL FR4	FGGGTKVTVLG
385	IGKV6D-21 FR1	EYVLTQSPDFQSVTPKEKVTITC
386	IGKV6D-21 FR2	WYQQKPDQSPKLVIY
387	IGKV6D-21 FR3	GVPSRFSGSNSGDDATLTINSLEAEDAATYYC
388	IGKV6D-21/JK	FGQGTKVEIKR
	FR4
389	IGKV3D-15 FR1	EYVLTQSPATLSVSPGERATLSC
390	IGKV3D-15 FR2	WYQQKPGQSPRLVIY
391	IGKV3D-15 FR3	DIPARFSGSNSGDEATLTISSLQSEDFAVYYC
392	IGKV3D-15/JK	FGQGTRLEIKR
	FR4
393	IGKV4-1 FR1	DYVLTQSPDSLAVSLGERATINC
394	IGKV4-1 FR2	WYQQKPGQSPKLVIY
395	IGKV4-1 FR3	GIPDRFSGSNSGDDATLTISSLQAEDVAVYYC
396	IGKV4-1/JK FR4	FGGGTKVEIKR
397	IGLV3-1 FR1	LPVLTQPPSVSVSPGQTASITC
398	IGLV3-1 FR2	WYQQKPGQSPVLVIY
399	IGLV3-1 FR3	GIPERFSGSNSGNTATLTISGTQTMDEADYLC
400	IGLV3-1/JL FR4	FGGGTKVTVL
401	IGLV3-1 FR1	SYELTQPPSVSVSPGQTASITC
402	IGLV3-1 FR2	WYQQKPGQSPVLVIY
403	IGLV3-1 FR3	GIPERFSGSNSGNTATLTISGTQTMDEADYLC
404	IGLV3-1/JL FR4	FGGGTKLTVL

TABLE A
Select Heavy Chain and Light Chain Variable Domain Sequences
(CDRs in bold)
SEQ		Sequence
ID NO	VD name	12345678901234567890123456789012
1	hBDI-9E8.4 VH	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEW
	(PDGF)	LANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCA
		RIESIGTTYSFDYWGQGTMVTVSS
2	hBDI-9E8.4 VL	EFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLV
	(PDGF)	IYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINID
		IVFGGGTKVEIK
3	hBDI-5H1.9	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTFGMGVGWIRQPPGKALEW
	VH (PDGF)	LANIWWDDDKYYNPSLKNRLTISKDTSKNQAVLTITNMDPVDTATYYCA
		RISTGISSYYVMDAWGQGTTVTVSS
4	hBDI-5H1.9 VL	DFVLTQSPDSLAVSLGERATINCERSSGDIGDTYVSWYQQKPGQPPKNV
	(PDGF)	IYGNDQRPSGVPDRFSGSGSGNSATLTISSLQAEDVAVYFCQSYDSDID
		IVFGGGTKVEIK
5	hBDI-9E8.12	EVQLVESGGGLVQPGGSLRLSCAFSGFSLSTYGMGVGWIRQAPGKGLEW
	VH (PDGF)	LANIWWDDDKYYNPSLKNRLTISKDTSKNQAYLQINSLRAEDTAVYYCA
		RIESIGTTYSFDYWGQGTLVTVSS
6	hBDI-9E8.12	DFQLTQSPSSLSASVGDRVTITCERSSGDIGDSYVSWYQQKPGKAPKNV
	VL (PDGF)	IYADDQRPSGVPSRFSGSGSGNSASLTISSLQPEDFATYYCQSYDINID
		IVFGQGTKVEIK
7	hBDI-9E8.9 VH	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEW
	(PDGF)	LANIWWDDDKYYNPSLKNRLTISKDTSKNQAVLTITNMDPVDTATYYCA
		RIESIGTTYSFDYWGQGTTVTVSS
8	hBDI-9E8.9 VL	DFVLTQSPDSLAVSLGERATINCERSSGDIGDSYVSWYQQKPGQPPKNV
	(PDGF)	IYADDQRPSGVPDRFSGSGSGNSASLTISSLQAEDVAVYFCQSYDINID
		IVFGGGTKVEIK
9	hBDI-9E8.12	EVQLVESGGGLVQPGGSLRLSCAFSGFSLSTYGMGVGWIRQAPGKGLEW
	VH (PDGF)	LANIWWDDDKYYNPSLKNRLTISKDTSKNQAYLQINSLRAEDTAVYYCA
		RIESIGTTYSFDYWGQGTLVTVSS
10	hBDI-9E8.12	DFQLTQSPSSLSASVGDRVTITCERSSGDIGDSYVSWYQQKPGKAPKNV
	VL (PDGF)	IYADDQRPSGVPSRFSGSGSGNSASLTISSLQPEDFATYYCQSYDINID
		IVFGQGTKVEIK
11	hBDI-9E8.4E	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEW
	VH (PDGF)	LANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCA
		RIESIGTTYSFDYWGQGTMVTVSS
12	hBDI-9E8.4E	EFVLTQSPGTLSLSPGERATLSCERSSGDIGESYVSWYQQKPGQAPRLV
	VL (PDGF)	IYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINID
		IVFGGGTKVEIK
13	hBFU-3E2.1	EVQLVQSGAEVKKPGSSVKVSCKASGYTFTESYMYWVKQAPGQGLELIG
	VH (PDGF)	RIDPEDGSTDYVEKFKNKATLTADKSTSTAYMELSSLRSEDTAVYFCAR
		FGARSYFYPMDAWGQGTTVTVSS
14	hBFU-3E2.1 VL	ETVLTQSPATLSLSPGERATLSCRASESVSTLMHWYQQKPGQQPRLLIY
	(PDGF)	GASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPWTF
		GGGTKVEIK
15	CL-33675 VH	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEW
	(PDGF)	LANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCA
		RIESSGPKYSFDYWGQGTMVTVSS
16	CL-33675 VL	EIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQAPRLL
	(PDGF)	IYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYGINID
		VVFGGGTKVEIK
17	hBDB-4G8.3	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMG
	VH (VEGF)	WINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCAR
		TNYYYRSYIFYFDYWGQGTMVTVSS
18	hBDB-4G8.3	DTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIY
	VL (VEGF)	GASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTF
		GQGTKLEIK
19	hBDB-4G8.13	EIQLVQSGTEVKKPGESLKISCKASGYTFTNYGMYWVKQMPGKGLEYMG
	VH (VEGF)	WINTETGKPTYADDFKGRFTFSLDKSFNTAFLQWSSLKASDTAMYFCAR
		TNYYYRSYIFYFDYWGQGTMVTVSS
20	hBDB-4G8.13	ETVLTQSPATLSVSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIY
	VL (VEGF)	GASNLESGVPARFSGSGSGTDFTLTISSLQSEDFAVYFCQQSWNDPFTF
		GQGTRLEIK
21	hBDB-4G8.14	EIQLVQSGGGVVQPGGSLRLSCAASGYTFTNYGMYWVKQAPGKGLEYMG
	VH (VEGF)	WINTETGKPTYADDFKGRFTFSLDTSKSTAYLQLNSLRAEDTAVYFCAR
		TNYYYRSYIFYFDYWGQGTLVTVSS
22	hBDB-4G8.14	DTVLTQSPSTLSASPGERATISCRASESVSTHMHWYQQKPGQAPKLLIY
	VL (VEGF)	GASNLESGVPSRFSGSRSGTDFTLTISSLQPEDFAVYFCQQSWNDPFTF
		GQGTKVEIK
23	hBDB-4G8.15	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMYWVKQAPGKGLEYMG
	VH (VEGF)	WINTETGKPTYADDFKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYFCAR
		TNYYYRSYIFYFDYWGQGTLVTVSS
24	hBDB-4G8.15	DTQLTQSPSSLSASVGDRVTISCRASESVSTHMHWYQQKPGKAPKLLIY
	VL (VEGF)	GASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSWNDPFTF
		GQGTKVEIK
25	hBEW-9A8.12	EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMG
	VH (VEGF)	WINTETGKPIYADDFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR
		VDYDGSFWFAYWGQGTLVTVSS
26	hBEW-9A8.12	DTQLTQSPSSLSASVGDRVTITCRASESVSTVIHWYQQKPGKQPKLLIH
	VL (VEGF)	GASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQHWNDPPTF
		GQGTKLEIK
27	hBDB-4G8.2	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMG
	VH (VEGF)	WINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCAR
		TNYYYRSYIFYFDYWGQGTMVTVSS
28	hBDB-4G8.2	ATQLTQSPSLSASVGDRVTITCRASESVSTHMHWYQQKPGKQPKLLIYG
	VL (VEGF)	ASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSWNDPFTFG
		QGTKLEIK
29	hBDB-4G8.4	EIQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEYMG
	VH (VEGF)	WINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCAR
		TNYYYRSYIFYFDYWGQGTMVTVSS
30	hBDB-4G8.4	AIQLTQSPSSLSASVGDRVTITCRASESVSTHMHWYQQKPGKAPKLLIY
	VL (VEGF)	GASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSWNDPFTF
		GQGTKLEIK
31	hBDB-4G8.5	EIQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEYMG
	VH (VEGF)	WINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCAR
		TNYYYRSYIFYFDYWGQGTMVTVSS
32	hBDB-4G8.5	ATQLTQSPSLSASVGDRVTITCRASESVSTHMHWYQQKPGKQPKLLIYG
	VL (VEGF)	ASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSWNDPFTFG
		QGTKLEIK
33	hBDB-4G8.12	EIQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEYMG
	VH (VEGF)	WINTETGKPTYADDFKGRFTFTLDTSTSTAYMELRSLRSDDTAVYFCAR
		TNYYYRSYIFYFDYWGQGTMVTVSS
34	hBDB-4G8.12	DTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIY
	VL (VEGF)	GASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTF
		GQGTKLEIK
35	hBEW-9E10.1	EIQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVKQAPGQGLEYMG
	VH (VEGF)	WIDTETGRPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCAR
		WSGDTTGIRGPWFAYWGQGTLVTVSS
36	hBEW-9E10.1	DIRMTQSPSSLSASVGDRVTIECLASEDIYSDLAWYQQKPGKSPKLLIY
	VL (VEGF)	NANGLQNGVPSRFSGSGSGTDYSLTISSLQPEDVATYFCQQYNYFPGTF
		GQGTKLEIK
37	hBEW-9E10.6	EVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMG
	VH (VEGF)	WIDTETGRPTYADDFKGRFTFTADKSTSTAYMELSSLRSEDTAVYYCAR
		WSGDTTGIRGPWFAYWGQGTLVTVSS
38	hBEW-9E10.6	DIRMTQSPSSLSASVGDRVTITCLASEDIYSDLAWYQQKPGKSPKLLIY
	VL (VEGF)	NANGLQNGVPSRFSGSGSGTDYTLTISSLQPEDVATYFCQQYNYFPGTF
		GQGTKLEIK
39	hBEW-1B10.1	EVQLVESGGGLVQPGGSLRLSCAASGFSFSKYDMAWFRQAPGKGLEWVA
	VH (VEGF)	SITTSGVGTYYRDSVKGRFTVSRDNAKSTLYLQMNSLRAEDTAVYYCAR
		GYGAMDAWGQGTTVTVSS
40	hBEW-1B10.1	DIQMTQSPSSLSASVGDRVTITCKASQDIDDYLSWYQQKPGKSPKLVIY
	VL (VEGF)	AATRLADGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQSSSTPWTF
		GGGTKVEIK
41	hBEW-1E3.4	EIQLVQSGSELKKPGASVKVSCKASGYPFTNSGMYWVKQAPGQGLEYMG
	VH (VEGF)	WINTEAGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCAR
		WGYISDNSYGWFDYWGQGTLVTVSS
42	hBEW-1E3.4	ATQLTQSPSSLSASVGDRVTISCRASEGVYSYMHWYQQKPGKQPKLLIY
	VL (VEGF)	KASNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCHQNWNDPLTF
		GQGTKLEIK
43	CL-34565 VH	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGLEWMG
	(VEGF)	WIDTETGDPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCAR
		TNYYYRNYMFYFDYWGQGTMVTVSS
44	CL-34565 VL	EIVLTQSPATLSLSPGERATLFCRASQSVSNHMHWYQQKPGQAPRLLIY
	(VEGF)	GASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSWYDPITF
		GQGTKLEIK
211	hBDI-5H1.12	EVQLVESGGGLVQPGGSLRLSCAFSGFSLSTFGMGVGWIRQAPGKGLEW
	VH (PDGF)	LANIWWDDDKYYNPSLKNRLTISKDTSKNQAYLQINSLRAEDTAVYYCA
		RISTGISSYYVMDAWGQGTLVTVSS
212	hBDI-5H1.12	DFQLTQSPSSLSASVGDRVTITCERSSGDIGDTYVSWYQQKPGKAPKNV
	VL (PDGF)	IYGNDQRPSGVPSRFSGSGSGNSATLTISSLQPEDFATYFCQSYDSDID
		IVFGQGTKVEIK

It will be readily apparent to those skilled in the art that other suitable modifications and adaptations of the methods described herein are obvious and may be made using suitable equivalents without departing from the scope of the embodiments disclosed herein. Having now described certain embodiments in detail, the same will be more clearly understood by reference to the following examples, which are included for purposes of illustration only and are not intended to be limiting.

EXAMPLES

Example 1

In Vitro Assays Used to Determine the Functional Activity of Anti-VEGF-A Antibodies, Anti-PDGF-BB Antibodies, Anti-VEGFR Antibodies, Anti-PDGFR-B Antibodies, and DVD-Ig Proteins

Example 1.1

Affinity Determination Using BIACORE® Surface Plasmon Resonance Technology for Antigen Binding

The BIACORE® surface plasmon resonance assay (Biacore, Inc., Piscataway, N.J.) determines the affinity of antibodies with kinetic measurements of on-rate and off-rate constants. Binding of anti-VEGF-A antibodies, anti-PDGF-BB antibodies, anti-VEGFR antibodies, anti-PDGFR-B antibodies, or anti-VEGF-A/anti-PDGF-BB DVD-Ig molecules, to a purified recombinant VEGF-A, PDGF-BB, VEGFR extracellular domain (ECD), PDGFR-B ECD or their Fc fusion proteins was determined by surface plasmon resonance-based measurements with a Biacore® instrument (either a Biacore 2000, Biacore 3000, or Biacore T100; GE Healthcare, Piscataway, N.J.) using running buffer HBS-EPB (10 mM HEPES [pH 7.4], 150 mM NaCl, 3 mM EDTA, 0.1 mg/ml BSA and 0.005% surfactant P20) at 25° C. For example, approximately 9000 RU of goat anti-human Fc specific polyclonal antibody (Thermo Fisher Scientific Inc., Rockford, Ill.) diluted in 10 mM sodium acetate (pH 4.5) is directly immobilized across a CM5 research grade biosensor chip using a standard amine coupling kit according to manufacturer's instructions and procedures at 25 μg/ml. Unreacted moieties on the biosensor surface were blocked with ethanolamine. For kinetic analysis, rate equations derived from the 1:1 Langmuir binding model were fitted simultaneously to multiple antigen injections (using global fit analysis) with the use of Scrubber 2 (BioLogic Software), Biacore Biaevaluation 4.0.1 software or Biacore T100 Evaluation software. Purified antibodies or DVD-Ig molecules were diluted in running buffer for capture across goat anti-human Fc reaction surfaces. Antibodies or DVD-Ig molecules to be captured as a ligand (1 μg/ml) were injected over reaction matrices at a flow rate of 10 μl/minute. During the assay, all measurements were referenced against the capture surface alone (i.e., with no captured antibody or DVD-Ig molecule). The association and dissociation rate constants, K_on (M⁻¹ s⁻¹) and K_off (s⁻¹) were determined under a continuous flow rate of 80 μl/minute. Rate constants were derived by making kinetic binding measurements at different antigen concentrations ranging from 1.23-900 nM, as a 3-fold dilution series, and included buffer-only injections (to be used for double referencing). The equilibrium dissociation constant K_D (M) of the reaction between antibodies and the target antigen was then calculated from the kinetic rate constants by the following formula: K_D=K_off/K_on. Binding was recorded as a function of time and kinetic rate constants were calculated. In this assay, on-rates as fast as 10⁶M⁻¹s⁻¹ and off-rates as slow as 10⁻⁶ s⁻¹ could be measured.

In some experiments, the conditions below were used for affinity determination:

Chip surface: CM5 chip with goat anti human Fc IgG (5000 RU).

Reference: Goat IgG (capture 5000 RU).

Running buffer: HBS-EP, 0.1 mg/ml BSA

DVD-Ig or mAbs were captured at 1 μg/ml, at 70-200 RU.

Recombinant ECD proteins were serially diluted 1:5 at 0.016-50 nM.

Association time was 5 min and dissociation time was observed for 10 and 30 min.

Flow rate was 50 ul/min.

Surface regeneration: two 30s pulses of 10 mM Glycine, pH 1.5, at 50 μl/min.

Example 1.2

Surface Resonance FcγRIIa, FcγRIIb, FcγRIIIa, and FcRn Binding Assay

The binding of VEGF/PDGF DVD-Ig molecules to recombinant FcγRs captured via 6×His-tag (SEQ ID NO: 405) was assessed using a Biacore T200 (GE Healthcare) instrument. A CM5 chip (GE Healthcare, Pittsburgh, Pa.) with mouse anti-6×His antibodies (“6×His” disclosed as SEQ ID NO: 405) that were directly immobilized on the chip via amine coupling according to the GE Healthcare protocol to the density of 10000RU (all flow cells) was used for experiments. Human FcγRs were captured on flow cells 2, 3 and 4. Flow cell 1 was used as a reference surface. HBS-EP+ was used as the running buffer. Anti VEGF/PDGF DVD-Igs were injected over all the flow cells at a flow rate of 50 μL/minute for 1-2 minutes at concentrations of 31.25; 62.5, 125, 250, 500, 1000, 2000 and 4000 nM, followed by 1-3 minutes of dissociation. The chip surfaces were regenerated with an injection of 10 mM glycine pH 1.5 at a flow rate of 100 μL/minute over all four flow cells after each cycle.

For FcRn binding analysis, VEGF/PDGF DVD-Igs were directly immobilized on a CM5 chip by amine coupling according to the manufacturer's (GE Healthcare) protocol to a density of approximately 750 RU. Flow cell 1, where blank immobilization was performed, did not contain DVD-Igs and was used as a reference surface. Human, cynomolgus, mouse, rat and rabbit recombinant FcRns were injected over all the flow cells at a flow rate of 50 μL/minute for 1 minute at a concentrations range of from 2.7 to 6000 nM (three fold serial dilution), followed by a 2 minute dissociation time. The surfaces were regenerated with an injection of 10 mM HCl at 100 μL/minute for 2 seconds followed by an injection of HBS-EP+, pH 7.4, at a flow rate of 50 μL/minute for 30 seconds over all four flow cells. Samples were prepared and run in two running buffer systems, pH 6.0 MES-EP+, and pH 7.4 HBS-EP-EP+. Recombinant human FcγRIIIa V158 and rat and mouse FcRn data were fitted to 1:1 kinetic model. Recombinant human FcγRIIa R131 and FcγRIIa H131, FcγRIIIa F158, and recombinant human, cynomolgus and rabbit FcRn binding data were fitted to a steady state affinity model. Biacore T200 Evaluation Software version 2.0 was used to fit all the data.

Example 1.3

VEGF-A Binding Activity Determined by Capture ELISA

To identify molecules that could bind hVEGF₁₆₅, a direct binding ELISA was performed. 96-well high binding neutravidin plates (Thermo Scientific cat#15507) were coated with 0.25 μg/mL/6.51E-9 M biotinylated recombinant human VEGF₁₆₅ (AP PR-1361002, 50 μL/well in D-PBS), and shaken for 1.5 hours at 25° C. During the coating step, supernatant, antibodies, benchmark compounds or DVD-Ig were diluted in 10% Superblock (Thermo Scientific, cat#37535) and an eight point titration of each sample molecule was performed. Plates were then washed four times with wash buffer (TBS, 0.05% Tween-20). The sample molecule titration was added to the coated plate at 50 μL in duplicate and incubated for one hour at 25° C. with shaking. Following incubation, plates were washed four times with wash buffer. The appropriate anti-species-IgG HRP conjugate was diluted in assay diluent (10% Superblock containing 0.05% surfactamps) and added to plates (50 μL) for forty-five minutes at 25° C. with shaking. Plates were washed four times with wash buffer and developed with the addition of Enhanced K-blue TMB substrate (Neogen, Lexington, Ky. cat#308177). The reaction was stopped with 2N sulfuric acid (VWR, Radnor, Pa. cat#BDH3500-1) and the absorbance was read at 450 nm-570 nm. An increase in optical density indicates the binding of the test molecule to biotinylated recombinant human VEGF₁₆₅. Data was analyzed using Softmax Pro 4.8 software and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.4

VEGF-A Blocking Activity Determined by Inhibition of VEGF-R2 Interaction with Human VEGF₁₆₅

To identify molecules that could block the binding of hVEGF₁₆₅ to the hVEGF-R2 (KDR/Flk-1) receptor, a competition ELISA was performed. 96-well Costar high binding plates (#3369) were coated with 0.5 μg/mL/2.27E-9 M recombinant human VEGF-R2-Fc (R&D Systems cat#357-KD), 50 μL/well in D-PBS), shaken for 2 hours at 25° C. and stored overnight at 4° C. Plates were then washed four times with wash buffer (TBS, 0.05% Tween-20) and blocked with Superblock blocking buffer (Thermo Scientific, cat#37535). During the blocking step, supernatant, antibodies, benchmark compounds or DVD-Ig were diluted in 1% Blocker BSA (Thermo Scientific cat#37525) and an eight point titration of each sample molecule was performed. The biotinylated human VEGF₁₆₅ (AP, PR-1361002) was diluted in 1% Blocker BSA at 35 ng/mL. The sample molecule titration was added to the biotinylated human VEGF₁₆₅ (17.5 ng/mL/4.56E-10 M final concentration) and pre-incubated for 45 minutes at 25° C. with shaking. The pre-incubated sample/hVEGF₁₆₅ complex was added to the coated plate at 50 μL in duplicate and incubated for 30 minutes at 25° C. with shaking. Following incubation, plates were washed four times with wash buffer. Streptavidin-polyHRP-40 (Fitzgerald cal#65r-s104phrp) was diluted in assay diluent (10% Superblock containing 0.05% surfactamps) and added to plates (50 μL) for 45 minutes at 25° C. with shaking. Plates were washed four times with wash buffer and developed with the addition of Enhanced K-blue TMB substrate (Neogen cat#308177). The reaction was stopped with 2N sulfuric acid (VWR, cat# BDH3500-1) and the absorbance was read at 450 nm-570 nm. A decrease in observed optical density indicates the test molecule is blocking the hVEGF₁₆₅ binding to the hVEGF-R2-Fc. Data was analyzed using Softmax Pro 4.8 software and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.5

Mouse VEGF-A Blocking Activity Determined by Inhibition of Mouse VEGF-R2 Interaction with Mouse VEGF₁₆₄

To identify molecules that could block the binding of mVEGF₁₆₄ to the mVEGF-R2, a competition ELISA was performed. 96-well Costar high binding plates (#3369) were coated with 2 μg/mL anti-human IgG-Fc (Thermo-Scientific, cat 31125) shaken for 2 hours at 25° C. and stored overnight at 4° C. Plates were washed four times with wash buffer (TBS, 0.05% Tween-20) and 1 μg/mL/4.55E-9 M recombinant mouse VEGF-R2-Fc (R&D Systems cat#443-KD)(50 μL/well in D-PBS) was added to wells and incubated for 1.5 hour at 25° C. with shaking. Plates were then washed four times with wash buffer (TBS, 0.05% Tween-20) and blocked with Superblock blocking buffer (Thermo Scientific, cat#37535). During the blocking step, hybridoma supernatants were diluted in 1% Blocker BSA (Thermo Scientific cat#37525). The mouse VEGF₁₆₄ (R&D Systems cat#493-MV-005) was diluted in 1% Blocker BSA to 20 ng/mL. The diluted sample was added to the mouse VEGF₁₆₄ (10 ng/mL/5.15E-10 M final concentration) and pre-incubated for 45 minutes at 25° C. with shaking. The pre-incubated sample/mVEGF₁₆₄ complex was added to the coated plate at 50 μL and incubated for 30 minutes at 25° C. with shaking. Following incubation, plates were washed four times with wash buffer. The detection reagent biotinylated goat anti-mVEGF₁₆₄ (R&D Systems cat#BAF-493) was diluted in assay diluent (10% Superblock containing 0.05% surfactamps) and added to plates for 1 hour at 25° C. with shaking. Following incubation, plates were washed four times with wash buffer. Streptavidin-polyHRP-40 (Fitzgerald cat#65r-s104phrp) was diluted in assay diluent and added to plates (50 μK) for 45 minutes at 25° C. with shaking. Plates were washed four times with wash buffer and developed with the addition of Enhanced K-blue TMB substrate (Neogen cat#308177). The reaction was stopped with 2N sulfuric acid (VWR, cat# BDH3500-1) and the absorbance was read at 450 nm-570 nm. A decrease in observed optical density indicates the test molecule is blocking the mVEGF₁₆₄ binding to the mouse VEGF-R2-Fc. Data was analyzed using Softmax Pro 4.8 software and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.6

VEGF-A Blocking Activity Determined by VEGFR2 (Tyr1054) Phosphorylation

To test candidate molecules for the ability to neutralize hVEGF-A activity, a cell based human VEGF-R2 (KDR/Flk-1) phosphorylation assay was performed. Stably transfected VEGFR2-3T3 cells (AP) were trypsinized, washed in D-PBS and resuspended at 3.5E5 cells/mL in growth media assay (DMEM, 2 mM L-glutamine, 100 units/mL penicillin/100 μg/mL streptomycin, 0.1% MEM non-essential amino acids, 1 mM sodium pyruvate, 400 μg/mL geneticin and 10% FBS). Cells were plated at 3.5E4 cells/well in 96-well plates (Costar cat#3599) and incubated for 6 hours at 37° C., 5% CO₂. Growth media was removed and cells were washed with D-PBS. Starvation media was added to wells (DMEM, 2 mM L-glutamine, 100 units/mL penicillin/100 μg/mL streptomycin and 1 mM sodium pyruvate) and cells were incubated for 18 hours at 37° C., 5% CO₂. The following day, the MSD anti-VEGFR2-phospho assay plate (Mesoscale VEGFR2-Tyr1054 phospho-MSD kit cat# K151DJD-2) was blocked with MSD Blocker-A for 1 hour at 25° C. with shaking. During blocking, anti-VEGF-A monoclonal antibodies, benchmark compounds or DVD-Ig were serially diluted in growth media and pre-incubated with recombinant human VEGF₁₆₅ (AP, PR-1350437) (50 ng/ml/1.3E-9 M final concentration), hVEGF₁₁₁ (R&DSystems, cat#5336-VE-10/CF) (50 ng/mL/1.9E-9 M final concentration) or rabbit VEGF₁₆₅ (AbbVie, PR-1563693.0) (50 ng/mL/1.24E-9 M final concentration) for 30 minutes at 25° C. with shaking. Starvation media was removed from wells and pre-incubated sample added to cells in duplicate (100 μL) for 8 minutes at 37° C., 5% CO₂ Immediately following incubation, plates were transferred to ice where media was removed and cells washed with ice-cold D-PBS. Plates were frozen for 10 minutes at −80° C. Ice-cold lysis buffer (CST cat#9803S) containing 1 mM PMSF was added to cells (50 μL) on ice. Plates were centrifuged at 3000 rpm for 15 minutes at 4° C. The MSD plate was washed four times with wash buffer (TBS, 0.05% Tween-20). The cell lysates were transferred to MSD plate (40 μL) and incubated for 1 hour at 25° C. with shaking. Following incubation, the MSD plate was washed four times with wash buffer. The anti-phospho-Tyr1054-IgG-sulfotag reagent was diluted in detection solution (K151DJD-2 components) and 25 μL added to foil covered wells for 1 hour at 25° C. with shaking. Plates were washed four times with wash buffer, 150 μL MSD read buffer (K151DJD-2 component) added to wells and plates read on MSD Sector Imager 6000. A decrease in observed signal indicates the test molecule is neutralizing the hVEGF-A mediated activation. Data was analyzed using Graphpad Prism software and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.7

VEGF-A Blocking Activity Determined by Inhibition of Human VEGF₁₆₅ Stimulated VEGFR2-3T3 Cell Proliferation/Survival

To screen candidate molecules for the ability to neutralize hVEGF₁₆₅ activity, a cell based proliferation assay was performed. Stably transfected VEGFR2-3T3 cells (AP) were trypsinized, washed in D-PBS and resuspended at 8.5E4 cells/mL in assay media (DMEM, 2 mM L-glutamine, 100 units/mL penicillin/100 μg/mL streptomycin, 0.1% MEM non-essential amino acids, 1 mM sodium pyruvate and 0.1% BSA). Cells were plated at 4,250 cells/well (50 μL) on black 96-well plates and incubated for 24 hours at 37° C., 5% CO₂. The following day, anti-VEGF-A monoclonal antibodies, benchmark compounds or DVD-Ig were serially diluted in assay media and pre-incubated with recombinant human VEGF₁₆₅ (AP, PR-1350437) (40 ng/ml/1.04E-9 M final concentration in assay well) for 1 hour at 25° C. with gentle shaking. The pre-incubated samples were then added to the cells (50 μL) in triplicate and plates were incubated at 37° C., 5% C0₂ for 72 hours. Cell survival/proliferation was measured indirectly by assessing ATP levels using an ATPlite kit (Perkin Elmer, Waltham, Mass.) according to the manufacturer's instructions. A decrease in observed signal indicates the test molecule is neutralizing the hVEGF₁₆₅ induced proliferation. Data was analyzed and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.8

VEGF-A Blocking Activity Determined by Inhibition of HumanVEGF₁₁₁ and HumanVEGF₁₂₁ Stimulated VEGFR2-3T3 Cell Proliferation/Survival

To test the ability of candidate molecules to neutralize hVEGF₁₁₁ and hVEGF₁₂₁ activity, a cell based proliferation assay was performed. Stably transfected VEGFR2-3T3 cells (AP) were trypsinized, washed in D-PBS and resuspended at 8.5E4 cells/mL in assay media (DMEM, 2 mM L-glutamine, 100 units/mL penicillin/100 μg/mL streptomycin, 0.1% MEM non-essential amino acids, 1 mM sodium pyruvate and 0.1% BSA). Cells were plated at 4,250 cells/well (50 μL) on black 96-well plates and incubated for 24 hours at 37° C., 5% CO₂. The following day, anti-VEGF-A monoclonal antibodies, benchmark compounds or DVD-Ig were serially diluted in assay media and pre-incubated with either recombinant human VEGF₁₁₁ (R&D Systems, cat#5336-VE) (10 ng/ml/3.85E-10 M final concentration) or human VEGF₁₂₁ (R&D Systems, cat#4644-VS) (10 ng/ml/3.57E-10 M final concentration in assay well) for 1 hour at 25° C. with gentle shaking. The pre-incubated samples were then added to the cells (50 μL) in triplicate and plates were incubated at 37° C., 5% CO₂ for 72 hours. Cell survival/proliferation was measured indirectly by assessing ATP levels using an ATPlite kit (Perkin Elmer, Waltham, Mass.) according to the manufacturer's instructions. A decrease in observed signal indicates the test molecule is neutralizing the hVEGF₁₁₁ or hVEGF₁₂₁ induced proliferation. Data was analyzed and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.9

VEGF-A Blocking Activity Determined by Inhibition of Rabbit VEGF₁₆₅ Stimulated VEGFR2-3T3 Cell Proliferation/Survival

To screen candidates for the ability to neutralize rabbitVEGF₁₆₅, a cell based proliferation assay was performed. Stably transfected VEGFR2-3T3 cells (AP) were trypsinized, washed in D-PBS and resuspended at 8.5E4 cells/mL in assay media (DMEM, 2 mM L-glutamine, 100 units/mL penicillin/100 μg/mL streptomycin, 0.1% MEM non-essential amino acids, 1 mM sodium pyruvate and 0.1% BSA). Cells were plated at 4,250 cells/well (50 μL) on black 96-well plates and incubated for 24 hours at 37° C., 5% CO₂. The following day, anti-VEGF-A monoclonal antibodies, benchmark compounds or DVD-Ig were serially diluted in assay media and pre-incubated with recombinant rabbit VEGF₁₆₅ (AbbVie, PR-1563693.0) (40 ng/ml/9.92E-10M final concentration in assay well) for 1 hour at 25° C. with gentle shaking. The pre-incubated samples were then added to the cells (50 μL) in triplicate and plates were incubated at 37° C., 5% CO₂ for 72 hours. Cell survival/proliferation was measured indirectly by assessing ATP levels using an ATPlite kit (Perkin Elmer, Waltham, Mass.) according to the manufacturer's instructions. A decrease in observed signal indicates the test molecule is neutralizing the rabbitVEGF₁₆₅ induced proliferation. Data was analyzed and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.10

VEGF-A Blocking Activity Determined by Inhibition of Human VEGF₁₆₅ Stimulated Endothelial Cell Proliferation/Survival

To test for the ability to neutralize hVEGF₁₆₅, a cell based proliferation assay was performed. Human microvascular endothelial cells (Lonza, cat#CC-2516) were maintained in EBM-2 (Lonza cat#CC3156) supplemented with EGM-2V singlequots (Lonza cat#3202). The day of the assay, the cells (passage 2-7) were trypsinized, washed in D-PBS and resuspended at 1E5 cells/mL in assay media (M199, 2 mM L-glutamine, 100 units/mL penicillin/100 μg/mL streptomycin, 10 mM HEPES and 10% FBS). Cells were plated at 5,000 cells/well (50 μL) on 96-well gelatin coated plates (BD Biocoat cat#354689) and incubated at 37° C., 5% CO₂. The anti-VEGF-A monoclonal antibodies, benchmark compounds or DVD-Ig were serially diluted in assay media and pre-incubated with recombinant human VEGF₁₆₅ (AP, PR-1350437) (5 ng/ml/1.3E-10 M final concentration in assay well) for 1 hour at 25° C. with gentle shaking. The pre-incubated samples were then added to the cells (50 μL) in triplicate and plates were incubated at 37° C., 5% CO₂ for 72 hours. Cell survival/proliferation was measured indirectly by assessing ATP levels using a CellTiter-Glo Luminescent Cell Viability Assay kit (Promega, Madison, Wis.) according to the manufacturer's instructions. A decrease in observed signal indicates the test molecule is neutralizing the hVEGF₁₆₅ induced proliferation. Data was analyzed and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.11

Generation of Naturally Derived Human VEGF-A and Reactivity to the Anti-VEGF Antibodies or Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Proteins

To identify molecules that could bind naturally derived human VEGF-A, a sandwich ELISA was performed. Native human VEGF-A was obtained from the supernatant of Y-79 cells (ATCC, cat#HTB-18) grown in the presence of dimethyloxalylglycine (Sigma-Aldrich, cat#D3695). The naturally derived material was quantified using the R&D Systems VEGF Duoset kit (cat#DY293B). 96-well Costar high binding plates (#3369) were coated with 13.3E-8 M antibodies, benchmark compounds or DVD-Ig in D-PBS, shaken for 2 hours at 25° C. and stored overnight at 4° C. Plates were blocked with Superblock blocking buffer (Thermo Scientific, cat#37535) followed by four washes with wash buffer (TBS, 0.05% Tween-20). The naturally derived human VEGF-A supernatant was serially diluted in assay diluent (1% Blocker BSA; Pierce, cat#37525) for final test concentrations of 2900 ng/mL-11.88 ng/mL. The dilutions were added to the plates (50 μL) and incubated for 2 hours at 25° C. with shaking. Following incubation, plates were washed four times with wash buffer. Detection antibody from the R&D Systems Duoset kit (Part 840163, cat#DY293B) was diluted in assay diluent and added to plates (50 μL) for 2 hours at 25° C. with shaking. Plates were then washed four times with wash buffer. The streptavidin-HRP from the R&D Systems Duoset kit (Part 890803, cat#DY293B) was diluted in assay diluent and added to plates (50 μL) for 35 minutes at 25° C. with shaking. Plates were washed four times with wash buffer and developed with the addition of Enhanced K-blue TMB substrate (Neogen, cat#308177). The reaction was stopped with 2N sulfuric acid (VWR, cat# BDH3500-1) and the absorbance was read at 450 nm-570 nm. An increase in optical density indicates binding of the test molecule to the naturally derived human VEGF-A. Data was analyzed using Softmax Pro 4.8 software and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.12

PDGF-BB Binding Activity Determined by Capture ELISA

To identify molecules that could bind hPDGF-BB, a direct binding ELISA was performed. 96-well high binding neutravidin plates (Thermo Scientific cat#15507) were coated with 0.5 μg/mL/1.99E-8 M recombinant human PDGF-BB-biotin (CST cat#8912BF; labeled at AbbVie, 50 μL/well in D-PBS), shaken for 2 hours at 25° C. During the coating step, supernatants, benchmark compounds or DVD-Ig were diluted in 10% Superblock (Thermo Scientific, cat#37525) and an eight point titration of each sample molecule was performed. Plates were then washed four times with wash buffer (TBS, 0.05% Tween-20). The sample molecule titration was added to the coated plate at 50 μL in duplicate and incubated for one hour at 25° C. with shaking. Following incubation, plates were washed four times with wash buffer. The appropriate anti-species-IgG HRP conjugate was in assay diluent (10% Superblock containing 0.05% surfactamps) and added to plates (50 μL) for one hour at 25° C. with shaking. Plates were washed four times with wash buffer and developed with the addition of Enhanced K-blue TMB substrate (Neogen, cat#308177). The reaction was stopped with 2N sulfuric acid (VWR, cat# BDH3500-1) and the absorbance was read at 450 nm-570 nm. An increase in optical density indicates binding of the test molecule to biotinylated recombinant human PDGF-BB. Data was analyzed using Softmax Pro 4.8 software and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.13

PDGF-BB Blocking Activity Determined by Inhibition of PDGF-Rβ Interaction with Human PDGF-BB

To identify molecules that could block the binding of hPDGF-BB to the hPDGF-Rβ, a competition ELISA was performed. 96-well Costar high binding plates (#3369) were coated with 0.5 μg/mL/2.98E-9 M recombinant human PDGF-Rβ-Fc (R&D Systems #385-PR, 50 μL/well in D-PBS), shaken for 2 hours at 25° C. and stored overnight at 4° C. Plates were then washed four times with wash buffer (TBS, 0.05% Tween-20) and blocked with Superblock blocking buffer (Thermo Scientific, cat#37535). During the blocking step, supernatants, antibodies, benchmark compounds or DVD-Ig were diluted in assay diluent (10% Superblock containing 0.05% surfactamps) and an eight point titration of each sample molecule was performed. The recombinant human PDGF-BB-biotin (CST cat#8912BF; labeled at AbbVie) was diluted in assay diluent at 20 ng/mL. The sample molecule titration was added to the human PDGF-BB-biotin (10 ng/mL/3.97E-10 M final concentration) and pre-incubated for 45 minutes at 25° C. with shaking. The pre-incubated sample/PDGF-BB complex was added to the coated plate at 50 μL in duplicate and incubated for 35 minutes at 25° C. with shaking. Following incubation, plates were washed four times with wash buffer. Detection reagent Streptavidin-polyHRP-40 (Fitzgerald, cat#65r-s104phrp) was diluted in assay diluent and added to plates (50 μL) for 45 minutes at 25° C. with shaking. Plates were washed four times with wash buffer and developed with the addition of Enhanced K-blue TMB substrate (Neogen, cat#308177). The reaction was stopped with 2N sulfuric acid (VWR, cat# BDH3500-1) and the absorbance was read at 450 nm-570 nm. A decrease in observed optical density indicates the test molecule is blocking the hPDGF-BB binding to the human PDGF-Rβ-Fc. Data was analyzed using Softmax Pro 4.8 software and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.14

PDGF-BB Blocking Activity Determined by PDGFRβ (Tyr751) Phosphorylation

To test candidate molecules for the ability to neutralize hPDGF-BB activity, a cell based PDGF-Rβ phosphorylation assay was performed. Balb-3T3 cells (ATCC cat# CCL-163) were trypsinized, washed in D-PBS and resuspended at 3.5E5 cells/mL in growth media assay (DMEM, 2 mM L-glutamine, 100 units/mL penicillin/100 μg/mL streptomycin, 0.1% MEM non-essential amino acids, 1 mM sodium pyruvate, and 10% FCS). Cells were plated at 3.5E4 cells/well in 96-well plates (Costar cat#3599) and incubated for 20 hours at 37° C., 5% CO₂. Growth media was removed and cells were washed with D-PBS. Starvation media was added to wells (DMEM, 2 mM L-glutamine, 100 units/mL penicillin/100 μg/mL streptomycin and 1 mM sodium pyruvate) and cells were incubated for 18 hours at 37° C., 5% CO₂. The following day, the MSD anti-PDGF-Rβ phospho-assay plate (Mesoscale PDGF-Rβ-Tyr751 phospho-MSD kit cat# K150DVD-2) was blocked with MSD Blocker-A for 1 hour at 25° C. with shaking. During blocking, anti-PDGF-BB supernatants, monoclonal antibodies, benchmark compounds or DVD-Ig were serially diluted in growth media and pre-incubated with recombinant human PDGF-BB (CST, cat#8912BF) (20 ng/ml/7.94E-10 M final concentration) and rat PDGF-BB (R&D Systems,cat#520-BB) (70 ng/ml/1.4E-9 M final concentration) for 30 minutes at 25° C. with shaking. Starvation media was removed from wells and pre-incubated sample added to cells in duplicate (100 μL) for 8 minutes at 37° C., 5% CO₂. Immediately following incubation, plates were transferred to ice where media was removed and cells washed with ice-cold D-PBS. Plates were frozen for 10 minutes at −80° C. On ice, ice-cold lysis buffer (CST cat#9803S) containing 1 mM PMSF was added to cells (50 μL). Plates were centrifuged at 3000 rpm for 15 minutes at 4° C. The MSD plate was washed four times with wash buffer (TBS, 0.05% Tween-20). The cell lysates were transferred to MSD plate (40 μL) and incubated 1 hour at 25° C. with shaking. Following incubation, the MSD plate was washed four times with wash buffer. The anti-phospho-Tyr751-IgG-sulfotag reagent was diluted in detection solution (K150DVD-2 components) and 25 μl added to foil covered wells for 1 hour at 25° C. with shaking. Plates were washed four times with wash buffer, 150 μL MSD read buffer (K150DVD-2 component) added to wells and plates read on MSD Sector Imager 6000. A decrease in observed reporter signal indicates the test molecule is neutralizing the hPDGF-BB mediated activation. Data was analyzed using Graphpad Prism software and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.15

PDGF-BB Blocking Activity Determined by Inhibition of Human PDGF-BB Stimulated NIH-3T3 Cell Proliferation/Survival

To screen candidate molecules for the ability to neutralize hPDGF-BB activity, a cell based proliferation assay was performed. NIH-3T3 cells (ATCC, cat#CRL-1658) were trypsinized, washed in D-PBS and resuspended at 4.5E4 cells/mL in assay media (DMEM, 2 mM L-glutamine, 100 units/mL penicillin/100 μg/mL streptomycin, 0.1% MEM non-essential amino acids, 1 mM sodium pyruvate and 0.1% BSA). Cells were plated at 2,250 cells/well (50 μL) on black 96-well plates and incubated for 5 hours at 37° C., 5% CO₂. During cell incubation, anti-PDGF-BB monoclonal antibodies, benchmark compounds or DVD-Ig were serially diluted in assay media and pre-incubated with recombinant human PDGF-BB (CST, cat#8912BF) (1.67 ng/ml/6.63E-11 M final concentration) for 1 hour at 25° C. with gentle shaking. The pre-incubated samples were then added to the cells (50 μL) in triplicate and plates were incubated at 37° C., 5% CO₂ for 44 hours. Cell survival/proliferation was measured indirectly by assessing ATP levels using a CellTiter-Glo Luminescent Cell Viability Assay kit (Promega, Madison, Wis.) according to the manufacturer's instructions. A decrease in observed signal indicates the test molecule is neutralizing the hPDGF-BB induced proliferation. Data was analyzed and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.16

PDGF-BB Blocking Activity Determined by Inhibition of Cynomolgus PDGF-BB Stimulated NIH-3T3 Cell Proliferation/Survival

To screen candidate molecules for the ability to neutralize cynomolgus PDGF-BB activity, a cell based proliferation assay was performed. NIH-3T3 cells (ATCC, cat#CRL-1658) were trypsinized, washed in D-PBS and resuspended at 4.5E4 cells/mL in assay media (DMEM, 2 mM L-glutamine, 100 units/mL penicillin/100 μg/mL streptomycin, 0.1% MEM non-essential amino acids, 1 mM sodium pyruvate and 0.1% BSA). Cells were plated at 2,250 cells/well (50 μL) on black 96-well plates and incubated for 5 hours at 37° C., 5% CO₂. During cell incubation, anti-PDGF-BB monoclonal antibodies, benchmark compounds or DVD-Ig were serially diluted in assay media and pre-incubated with recombinant cynomolgus PDGF-BB (AP, PR-1575400) (4 ng/ml/1.61E-10 M final concentration in assay well) for 1 hour at 25° C. with gentle shaking. The pre-incubated samples were then added to the cells (50 μL) in triplicate and plates were incubated at 37° C., 5% CO₂ for 44 hours. Cell survival/proliferation was measured indirectly by assessing ATP levels using a CellTiter-Glo Luminescent Cell Viability Assay kit (Promega, Madison, Wis.) according to the manufacturer's instructions. A decrease in observed signal indicates the test molecule is neutralizing the cynoPDGF-BB induced proliferation. Data was analyzed and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.17

PDGF-BB Blocking Activity Determined by Inhibition of Murine PDGF-BB Stimulated NIH-3T3 Cell Proliferation/Survival

To test candidate molecules for the ability to neutralize mouse PDGF-BB activity, a cell based assay was performed. NIH-3T3 cells (ATCC, cat#CRL-1658) were trypsinized, washed in D-PBS and resuspended at 4.5E4 cells/mL in assay media (DMEM, 2 mM L-glutamine, 100 units/mL penicillin/100 μg/mL streptomycin, 0.1% MEM non-essential amino acids, 1 mM sodium pyruvate and 0.1% BSA). Cells were plated at 2,250 cells/well (50 μL) on black 96-well plates and incubated for 5 hours at 37° C., 5% CO₂. During cell incubation, anti-PDGF-BB monoclonal antibodies, benchmark compounds or DVD-Ig were serially diluted in assay media and pre-incubated with recombinant murine PDGF-BB (Abnova, cat#0309-200-58-S) (2 ng/ml/8.13E-11 M final concentration) for 1 hour at 25° C. with gentle shaking. The pre-incubated samples were then added to the cells (50 μL) in triplicate and plates were incubated at 37° C., 5% CO₂ for 44 hours. Cell survival/proliferation was measured indirectly by assessing ATP levels using a CellTiter-Glo Luminescent Cell Viability Assay kit (Promega, Madison, Wis.) according to the manufacturer's instructions. A decrease in observed signal indicates the test molecule is neutralizing the murine PDGF-BB induced proliferation. Data was analyzed and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.18

PDGF-BB Blocking Activity Determined by Inhibition of Rat PDGF-BB Stimulated NIH-3T3 Cell Proliferation/Survival

To test candidate molecules for the ability to neutralize rat PDGF-BB activity, a cell based assay was performed. NIH-3T3 cells (ATCC, cat#CRL-1658) were trypsinized, washed in D-PBS and resuspended at 4.5E4 cells/mL in assay media (DMEM, 2 mM L-glutamine, 100 units/mL penicillin/100 μg/mL streptomycin, 0.1% MEM non-essential amino acids, 1 mM sodium pyruvate and 0.1% BSA). Cells were plated at 2,250 cells/well (50 μL) on black 96-well plates and incubated for 5 hours at 37° C., 5% CO₂. During cell incubation, anti-PDGF-BB monoclonal antibodies, benchmark compounds or DVD-Ig were serially diluted in assay media and pre-incubated with recombinant rat PDGF-BB (R&D Systems,cat#520-BB) (2 ng/ml/8.0E-11 M final concentration) for 1 hour at 25° C. with gentle shaking. The pre-incubated samples were then added to the cells (50 μL) in triplicate and plates were incubated at 37° C., 5% C0₂ for 44 hours. Cell survival/proliferation was measured indirectly by assessing ATP levels using a CellTiter-Glo Luminescent Cell Viability Assay kit (Promega, Madison, Wis.) according to the manufacturer's instructions. A decrease in observed signal indicates the test molecule is neutralizing the rat PDGF-BB induced proliferation. Data was analyzed and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.19

Generation of Naturally Derived Human PDGF-BB and Reactivity to the Anti-PDGF-BB Antibodies or Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Proteins

The native form of human PDGF was purified from platelets by a modified protocol from Antoniades et al. (Antoniades et al. (1979) Proc. Natl. Acad. Sci. USA 76(4): 1809-1813. In the modified protocol, ten units of platelets (Bioreclamation Inc.) were thawed, washed with 12 ml of Platelet Wash Buffer (HBSS—Gibco #14175/0.3% BSA/10 mM EDTA) and centrifuged. The platelets were then suspended in 25 ml of Buffer A (20 mM NaHPO4, pH 7.4, 80 mM NaCl in a 50 ml tube). From here the platelet wash (50 ml tube) and the suspended platelets were worked up in parallel using the same protocol.

Both the suspended platelets and platelets wash tubes were placed into a boiling water bath for 10 minutes, after which the contents of the tubes were cooled on ice. The supernatant was separated from the pellet by centrifugation. The supernatant was placed aside at 4° C. and the pellet was extracted with 30 ml Buffer B (20 mM NaHPO4, pH 7.4, 1M NaCl) by stirring overnight at 4° C. The supernatant was separated from the pellet by centrifugation. The supernatant was placed aside (4° C.) and the pellet was extracted with 30 ml Buffer B by stirring overnight at 4° C. This was repeated two more times. All the supernatants were then dialyzed separately against Buffer A. After removal from dialysis, they were all analyzed for protein content and PDGF-BB (ELISA) (See Table 6).

TABLE 6
Native PDGF Extraction from Human Platelets
			Total
	Volume	PDGF-BB	PDGF-BB	Protein	Total Protein	ng PDGF-BB
Sample	(ml)	(ng/mL)	(ng)	(mg/mL)	(mg)	per mg Protein
Boiled platelet
Supernatant	50	4.52	226.18	0.63	31.50	7.18
Pellet
Extraction 1	35	8.77	306.95	0.31	10.85	28.29
Extraction 2	35	3.79	132.76	0.25	8.58	15.48
Extraction 3	35	1.26	44.03	0.10	3.43	12.83
Extraction 4	37	1.53	56.65	0.19	7.03	8.05
Platelet Wash
Boiled
Supernatant	27	7.49	202.12	0.64	17.28	11.70
Extracted Pellet	37	10.89	402.75	0.90	33.15	12.15
Total	256	5.36	1371.32	0.44	111.82	12.26

TABLE 7
Native PDGF Purification from Human Platelets
					Specific
			Total		Activity
	PDGF-		PDGF-	Total	ng	Endotoxin Levels
Platelet	BB	Volume	BB	Protein	PDGF/mg		EU/mg
Purification	(ng/mL)	(mL)	(ng)	(mg)	Protein	EU/ml	protein	EU/μg PDGF
Eluate 1	214.94	6.74	1449	0.443	3266.49	2.36	35.87	10.98
Flow	1.17	500	585	110.5	5.29
Thru 1

Due to low specific activity (ng PDGF-BB per mg protein), the supernatants were subjected to further purification by CM sepharose. The supernatants were applied (with washing Buffer A) to a 20 ml CM sepharose column (GE Healthcare cat#17-0719-01) and the PDGF was eluted with Buffer B. Subsequently the eluted protein was dialyzed against Buffer A. From here the protein that was eluted and subsequently dialyzed as well as the flow through were all analyzed for protein content and PDGF-BB (ELISA). At this point the specific activity (eluate 1) was high enough to be queried in the assay.

To identify molecules that could bind naturally derived human PDGF-BB, a sandwich ELISA was performed. The native human PDGF-BB was isolated and purified from human platelets (AbbVie, PR-1566692). This material was quantified using the R&D Systems PDGF-BB Duoset kit (cat#DY220). 96-well Costar high binding plates (#3369) were coated with 13.3E-8 M antibodies, benchmark compounds or DVD-Ig in D-PBS, shaken for 2 hours at 25° C. and stored overnight at 4° C. Plates were blocked with Superblock blocking buffer (Thermo Scientific, cat#37535) followed by four washes with wash buffer (TBS, 0.05% Tween-20). The native human PDGF-BB was serially diluted in assay diluent (1% Blocker BSA; Pierce, cat#37525) for final test concentrations of 2000 ng/mL-2.74 ng/mL (5.4E-8 M-7.5E-11 M). The dilutions were added to the plates (50 μL) and incubated for 2 hours at 25° C. with shaking. Following incubation, plates were washed four times with wash buffer. Detection antibody from the R&D Systems Duoset kit (Part 840926, cat#DY220) was diluted in assay diluent and added to plates (50 μL) for 2 hours at 25° C. with shaking. Plates were then washed four times with wash buffer. The streptavidin-HRP from the R&D Systems Duoset kit (Part 890803, cat#DY220) was diluted in assay diluent and added to plates (50 μL) for 35 minutes at 25° C. with shaking. Plates were washed four times with wash buffer and developed with the addition of Enhanced K-blue TMB substrate (Neogen, cat#308177). The reaction was stopped with 2N sulfuric acid (VWR, cat# BDH3500-1) and the absorbance was read at 450 nm-570 nm. An increase in optical density indicates binding of the test molecule to the naturally derived human PDGF-BB. Data was analyzed using Softmax Pro 4.8 software and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.20

hVEGF-A Neutralization Potency of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Proteins when Pre-Incubated with hPDGF-BB

To test candidate molecules for the ability to neutralize hVEGF-A activity in the presence of hPDGF-BB, a cell based VEGF-R2 (KDR/Flk-1) phosphorylation assay was performed. Stably transfected VEGFR2-3T3 cells (AP) were trypsinized, washed in D-PBS and resuspended at 3.5E5 cells/mL in growth media assay (DMEM, 2 mM L-glutamine, 100 units/mL penicillin/100 μg/mL streptomycin, 0.1% MEM non-essential amino acids, 1 mM sodium pyruvate, 400 μg/mL geneticin and 10% FBS). Cells were plated at 3.5E4 cells/well in 96-well plates (Costar cat#3599) and incubated for 6 hours at 37° C., 5% CO₂ Growth media was removed and cells were washed with D-PBS. Starvation media was added to wells (DMEM, 2 mM L-glutamine, 100 units/mL penicillin/100 μg/mL streptomycin and 1 mM sodium pyruvate) and cells were incubated for 18 hours at 37° C., 5% CO₂. The following day, the MSD anti-VEGFR2-phospho assay plate (Mesoscale VEGFR2-Tyr1054 phospho-MSD kit, cat#K151DJD-2) was blocked with MSD Blocker-A for 1 hour at 25° C. with shaking. During blocking, anti-VEGF-A monoclonal antibodies, benchmark compounds or DVD-Ig were serially diluted in growth media and pre-incubated with recombinant human PDGF-BB (CST cat#8912BF) (0.992 μg/ml/3.94E-8 M final concentration) for 30 minutes at 25° C. with shaking. Following the first pre-incubation step, recombinant human VEGF₁₆₅ (AP, PR-1350437) was added to the samples for a final concentration of human VEGF₁₆₅ of 50 ng/ml/1.3E-9 M and of hPDGF-BB of 0.496 μg/ml/1.97E-8 M final concentration for 30 minutes at 25° C. with shaking. Starvation media was removed from wells and pre-incubated sample added to cells in duplicate (100 μL) for 8 minutes at 37° C., 5% CO₂. Immediately following incubation, plates were transferred to ice where media was removed and cells washed with ice-cold D-PBS. Plates were frozen for 10 minutes at −80° C. Ice-cold lysis buffer (CST cat#9803S) containing 1 mM PMSF was added to cells (50 μL) on ice. Plates were centrifuged at 3000 rpm for 15 minutes at 4° C. The MSD plate was washed four times with wash buffer (TBS, 0.05% Tween-20). The cell lysates were transferred to MSD plate (40 μL) and incubated 1 hour at 25° C. with shaking. Following incubation, the MSD plate was washed four times with wash buffer. The anti-phospho-Tyr1054-IgG-sulfotag reagent was diluted in detection solution (K151DJD-2 components) and 25 L added to foil covered wells for 1 hour at 25° C. with shaking. Plates were washed four times with wash buffer, 150 μL MSD read buffer (K151DJD-2 component) added to wells and plates read on MSD Sector Imager 6000. A decrease in observed signal indicates the test molecule is neutralizing the hVEGF₁₆₅ mediated activation in the presence of hPDGF-BB. Data was analyzed using Graphpad Prism software and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.21

PDGF Neutralization Potency of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Proteins when Pre-Incubated with VEGF

To test candidate molecules for the ability to neutralize hPDGF-BB activity in the presence of hVEGF-A, a cell based proliferation assay was performed. NIH-3T3 cells (ATCC, cat#CRL-1658) were trypsinized, washed in D-PBS and resuspended at 4.5E4 cells/mL in assay media (DMEM, 2 mM L-glutamine, 100 units/mL penicillin/100 μg/mL streptomycin, 0.1% MEM non-essential amino acids, 1 mM sodium pyruvate and 0.1% BSA). Cells were plated at 2,250 cells/well (50 μL) on black 96-well plates and incubated for 5 hours at 37° C., 5% CO₂. During cell incubation, anti-PDGF-BB monoclonal antibodies, benchmark compounds or DVD-Ig were serially diluted in assay media containing hVEGF₁₆₅ (4 μg/mL/104.2 nM). The samples were pre-incubated with recombinant human PDGF-BB in assay media (CST, cat#8912BF) (3.34 ng/ml/1.33E-10 M final concentration in well) for 1 hour at 25° C. with gentle shaking. The final concentrations of ligand in assay wells were hVEGF₁₆₅ 2.6E-8 M and hPDGF-BB 6.63E-11 M. The pre-incubated samples were added to the cells (50 μL) in triplicate and plates were incubated at 37° C., 5% C0₂ for 44 hours. Cell survival/proliferation was measured indirectly by assessing ATP levels using a CellTiter-Glo Luminescent Cell Viability Assay kit (Promega, Madison, Wis.) according to the manufacturer's instructions. A decrease in observed signal indicates the test molecule is neutralizing the hPDGF-BB induced proliferation in the presence of hVEGF₁₆₅. Data was analyzed and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.22

Human VEGF-R2 Binding Activity of the Anti-VEGF-R2 Antibodies

To identify molecules which could bind VEGF-R2 (KDR/Flk-1), a direct binding ELISA was performed. 96-well Costar high binding plates (#3369) were coated with 0.5 μg/mL/2.27E-9 M recombinant human VEGF-R2-Fc (R&D Systems cat#357-KD), 50 μL/well in D-PBS), shaken for 2 hours at 25° C. and stored overnight at 4° C. Plates were then washed four times with wash buffer (TBS, 0.05% Tween-20) and blocked with Superblock blocking buffer (Thermo Scientific, cat#37535). During the blocking step, supernatant, antibodies or benchmark compounds were diluted in 1% Blocker BSA (Thermo Scientific cat#37525) and an eight point titration of each sample molecule was performed. The samples were added to wells and incubated for one hour at 25° C. with shaking. Following incubation, plates were washed four times with wash buffer. The appropriate anti-species-IgG HRP conjugate was diluted in assay diluent (10% Superblock containing 0.05% surfactamps) and added to plates (50 μL) for forty-five minutes at 25° C. with shaking. Plates were washed four times with wash buffer and developed with the addition of Enhanced K-blue TMB substrate (Neogen cat#308177). The reaction was stopped with 2N sulfuric acid (VWR, cat# BDH3500-1) and the absorbance was read at 450 nm-570 nm. An increase in observed optical density indicates the test molecule is binding the human VEGF-R2-Fc. Data was analyzed using Softmax Pro 4.8 software and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.23

Human VEGF-R2 Blocking Activity of the Anti-VEGF-R2 Antibodies as Determined by Inhibition of Human VEGF-R2 Interaction with Human VEGF₁₆₅

To identify molecules which could block the binding of VEGF-R2 (KDR/Flk-1) to hVEGF₁₆₅, a competition ELISA was performed. 96-well Costar high binding plates (#3369) were coated with 0.5 μg/mL/2.27E-9 M recombinant human VEGF-R2-Fc (R&D Systems cat#357-KD), 50 μL/well in D-PBS), shaken for 2 hours at 25° C. and stored overnight at 4° C. Plates were then washed four times with wash buffer (TBS, 0.05% Tween-20) and blocked with Superblock blocking buffer (Thermo Scientific, cat#37535). During the blocking step, supernatant, antibodies or benchmark compounds were diluted in 1% Blocker BSA (Thermo Scientific cat#37525) and an eight point titration of each sample molecule was performed. The samples were added to wells and incubated for 30 minutes at 25° C. with shaking. The biotinylated human VEGF₁₆₅ (AP, PR-1361002) was diluted in 1% BSA at 35 ng/mL. This was added to wells (17.5 ng/mL/4.56E-10 M final concentration) and incubation was continued for 30 minutes at 25° C. with shaking. Following incubation, plates were washed four times with wash buffer. Streptavidin-polyHRP-40 (Fitzgerald cat#65r-s104phrp) was diluted in assay diluent (10% Superblock containing 0.05% surfactamps) and added to plates (50 μL) for 45 minutes at 25° C. with shaking. Plates were washed four times with wash buffer and developed with the addition of Enhanced K-blue TMB substrate (Neogen cat#308177). The reaction was stopped with 2N sulfuric acid (VWR, cat# BDH3500-1) and the absorbance was read at 450 nm-570 nm. A decrease in observed optical density indicates the test molecule is blocking the human VEGF-R2-Fc binding to hVEGF₁₆₅. Data was analyzed using Softmax Pro 4.8 software and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.24

VEGF-A Blocking Activity of the Anti-VEGF-R2 Antibodies as Determined by VEGFR2 (Tyr1054) Phosphorylation

To test candidate molecules for the ability to neutralize hVEGF-R2 activity, a cell based VEGF-R2 (KDR/Flk-1) phosphorylation assay was performed. Stably transfected VEGFR2-3T3 cells (AP) were trypsinized, washed in D-PBS and resuspended at 3.5E5 cells/mL in growth media assay (DMEM, 2 mM L-glutamine, 100 units/mL penicillin/100 μg/mL streptomycin, 0.1% MEM non-essential amino acids, 1 mM sodium pyruvate, 400 μg/mL geneticin and 10% FBS). Cells were plated at 3.5E4 cells/well in 96-well plates (Costar cat#3599) and incubated for 6 hours at 37° C., 5% CO₂. Growth media was removed and cells were washed with D-PBS. Starvation media was added to wells (DMEM, 2 mM L-glutamine, 100 units/mL penicillin/100 μg/mL streptomycin and 1 mM sodium pyruvate) and cells were incubated for 18 hours at 37° C., 5% CO₂. The following day, the MSD anti-VEGR2-phospho assay plate (Mesoscale VEGFR2-Tyr1054 phospho-MSD #kit cat K151DJD-2) was blocked with MSD Blocked with MSD Blocker-A for 1 hour at 25° C. with shaking. During blocking, anti-VEGF-R2 supernatant, monoclonal antibodies and benchmark compounds were serially diluted in growth media and pre-incubated with recombinant human VEGFR2-Fc (R&D Systems, cat#357-KD) (500 ng/ml/2.27E-9 M final concentration) for 30 minutes at 25° C. with shaking. Recombinant human VEGF₁₆₅ (AP, PR-1350437) (50 ng/ml/1.3E-9 M final concentration) was added to the wells and incubation was continued for 30 minutes at 25° C. with shaking. Starvation media was removed from wells and pre-incubated sample added to cells in duplicate (100 μL) for 8 minutes at 37° C., 5% CO₂. Immediately following incubation, plates were transferred to ice where media was removed and cells washed with ice-cold D-PBS. Plates were frozen for 10 minutes at −80° C. Ice-cold lysis buffer (CST cat#9803S) containing 1 mM PMSF was added to cells (50 μL) on ice. Plates were centrifuged at 3000 rpm for 15 minutes at 4° C. The MSD plate was washed four times with wash buffer (TBS, 0.05% Tween-20). The cell lysates were transferred to MSD plate (40 μL) and incubated 1 hour at 25° C. with shaking. Following incubation, the MSD plate was washed four times with wash buffer. The anti-phospho-Tyr1054-IgG-sulfotag reagent was diluted in detection solution (K151DJD-2 components) and 25 μL added to foil covered wells for 1 hour at 25° C. with shaking. Plates were washed four times with wash buffer, 150 μL MSD read buffer (K151DJD-2 component) added to wells and plates read on MSD Sector Imager 6000. An increase in observed signal indicates the test molecule is neutralizing the exogeneous hVEGFR2 and allowing for hVEGF₁₆₅ mediated activation. Data was analyzed using Graphpad Prism software and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.25

Mouse VEGF-R2 Blocking Activity of the Anti-VEGF-R2

Antibodies as Determined by Inhibition of Mouse VEGF-R2 Interaction with Mouse VEGF₁₆₄

To identify molecules which could block the binding of mVEGF₁₆₄ to the mVEGF-R2, a competition ELISA was performed. 96-well Costar high binding plates (#3369) were coated with 1 μg/mL/4.55E-9 M recombinant mouse VEGF-R2-Fc (R&D Systems cat#443-KD)(50 μL/well in D-PBS) shaken for 2 hours at 25° C. and stored overnight at 4° C. Plates were washed four times with wash buffer (TBS, 0.05% Tween-20). Plates were then washed four times with wash buffer (TBS, 0.05% Tween-20) and blocked with Superblock blocking buffer (Thermo Scientific, cat#37535). During the blocking step, hybridoma supernatants and rat IgG were diluted in 1% Blocker BSA (Thermo Scientific cat#37525). The sample was added to the plates (50 μL) and incubated for 45 minutes at 25° C. with shaking. The mouse VEGF₁₆₄ (R&D Systems cat#493-MV-005) was diluted in 1% Blocker BSA to 20 ng/mL and added to wells for a final concentration of 10 ng/mL/5.15E-10 M final concentration. Incubation was continued for 30 minutes at 25° C. with shaking. Following incubation, plates were washed four times with wash buffer. The detection reagent biotinylated goat anti-mVEGF₁₆₄ (R&D Systems cat#BAF-493) was diluted in assay diluent (10% Superblock containing 0.05% surfactamps) and added to plates for 1 hour at 25° C. with shaking. Following incubation, plates were washed four times with wash buffer. Streptavidin-polyHRP-40 (Fitzgerald cat#65r-s104phrp) was diluted in assay diluent and added to plates (50 μL) for 45 minutes at 25° C. with shaking. Plates were washed four times with wash buffer and developed with the addition of Enhanced K-blue TMB substrate (Neogen cat#308177). The reaction was stopped with 2N sulfuric acid (VWR, cat# BDH3500-1) and the absorbance was read at 450 nm-570 nm. A decrease in observed optical density indicates the test molecule is blocking the mouse VEGF-R2-Fc binding to the mVEGF₁₆₄. Data was analyzed using Softmax Pro 4.8 software and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.26

PDGF-Rβ Binding Activity of the Anti-PDGF-Rβ Antibodies

To identify molecules which bind hPDGF-Rβ, a direct ELISA was performed. 96-well Costar high binding plates (#3369) were coated with 0.5 μg/mL/2.98E-9 M recombinant human PDGF-Rβ-Fc (R&D Systems #385-PR, 50 μL/well in D-PBS), shaken for 2 hours at 25° C. and stored overnight at 4° C. Plates were then washed four times with wash buffer (TBS, 0.05% Tween-20) and blocked with Superblock blocking buffer (Thermo Scientific, cat#37535). During the blocking step, supernatants, antibodies and benchmark compounds were diluted in assay diluent (10% Superblock containing 0.05% surfactamps) and an eight point titration of each sample molecule was performed. The samples were added to wells and incubated for one hour at 25° C. with shaking. Following incubation, plates were washed four times with wash buffer. The appropriate anti-species-IgG HRP conjugate was diluted in assay diluent (10% Superblock containing 0.05% surfactamps) and added to plates (50 μL) for forty-five minutes at 25° C. with shaking. Plates were washed four times with wash buffer and developed with the addition of Enhanced K-blue TMB substrate (Neogen, cat#308177). The reaction was stopped with 2N sulfuric acid (VWR, cat# BDH3500-1) and the absorbance was read at 450 nm-570 nm. An increase in observed optical density indicates the test molecule is binding the human PDGF-Rβ-Fc. Data was analyzed using Softmax Pro 4.8 software and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.27

PDGF-Rβ Blocking Activity of the Anti-PDGF-Rβ Antibodies as Determined by Inhibition of PDGF-Rβ Interaction with Human PDGF-BB

To identify molecules which could block the binding of hPDGF-Rβ to hPDGF-BB, a competition ELISA was performed. 96-well Costar high binding plates (#3369) were coated with 0.5 μg/mL/2.98E-9 M recombinant human PDGF-Rβ-Fc (R&D Systems #385-PR, 50 μL/well in D-PBS), shaken for 2 hours at 25° C. and stored overnight at 4° C. Plates were then washed four times with wash buffer (TBS, 0.05% Tween-20) and blocked with Superblock blocking buffer (Thermo Scientific, cat#37535). During the blocking step, supernatants, antibodies and benchmark compounds were diluted in assay diluent (10% Superblock containing 0.05% surfactamps) and an eight point titration of each sample molecule was performed. The samples were added to wells and incubated for 30 minutes at 25° C. with shaking. The recombinant human PDGF-BB-biotin (CST cat#8912BF; labeled at ABC) was diluted in assay diluent at 20 ng/mL. This was added to wells (10 ng/mL/3.97E-10 M final concentration) and incubation was continued for 35 minutes at 25° C. with shaking. Following incubation, plates were washed four times with wash buffer. Detection reagent Streptavidin-polyHRP-40 (Fitzgerald, cat#65r-s104phrp) was diluted in assay diluent and added to plates (50 μL) for 45 minutes at 25° C. with shaking. Plates were washed four times with wash buffer and developed with the addition of Enhanced K-blue TMB substrate (Neogen, cat#308177). The reaction was stopped with 2N sulfuric acid (VWR, cat# BDH3500-1) and the absorbance was read at 450 nm-570 nm. A decrease in observed optical density indicates the test molecule is blocking the human PDGF-Rβ-Fc binding to hPDGF-BB. Data was analyzed using Softmax Pro 4.8 software and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.28

PDGF-Rβ Blocking Activity of the Anti-PDGF-Rβ Antibodies as Determined by PDGFRβ (Tyr751) Phosphorylation

To test candidate molecules for the ability to neutralize hPDGF-Rβ activity, a cell based PDGF-Rβ phosphorylation assay was performed. Balb-3T3 cells (ATCC cat# CCL-163) were trypsinized, washed in D-PBS and resuspended at 3.5E5 cells/mL in growth media assay (DMEM, 2 mM L-glutamine, 100 units/mL penicillin/100 μg/mL streptomycin, 0.1% MEM non-essential amino acids, 1 mM sodium pyruvate, and 10% FCS). Cells were plated at 3.5E4 cells/well in 96-well plates (Costar cat#3599) and incubated for 20 hours at 37° C., 5% CO₂. Growth media was removed and cells were washed with D-PBS. Starvation media was added to wells (DMEM, 2 mM L-glutamine, 100 units/mL penicillin/100 μg/mL streptomycin and 1 mM sodium pyruvate) and cells were incubated for 18 hours at 37° C., 5% CO₂. The following day, the MSD anti-PDGFRβ-phospho-assay plate (Mesoscale PDGF-Rβ-Tyr751 phospho-MSD kit cat# K150DVD-2) was blocked with MSD Blocker-A for 1 hour at 25° C. with shaking. During blocking, supernatants, antibodies or benchmark compounds were serially diluted in growth media and pre-incubated with 500 ng/mL/2.98E-9 M hPDGF-Rβ (R&D System, cat 385-PR) for 30 minutes at 25° C. Recombinant human PDGF-BB (CST, cat#8912BF) (20 ng/ml/7.94E-10 nM final concentration) was added to the wells and incubation was continued for 30 minutes at 25° C. with shaking. Starvation media was removed from wells and pre-incubated sample added to cells in duplicate (100 μL) for 8 minutes at 37° C., 5% CO₂. Immediately following incubation, plates were transferred to ice where media was removed and cells washed with ice-cold D-PBS. Plates were frozen for 10 minutes at −80° C. Ice-cold lysis buffer (CST cat#9803S) containing 1 mM PMSF was added to cells (50 μL) on ice. Plates were centrifuged at 3000 rpm for 15 minutes at 4° C. The MSD plate was washed four times with wash buffer (TBS, 0.05% Tween-20). The cell lysates were transferred to MSD plate (40 μL) and incubated 1 hour at 25° C. with shaking. Following incubation, the MSD plate was washed four times with wash buffer. The anti-phospho-Tyr751-IgG-sulfotag reagent was diluted in detection solution (K150DVD—2 components) and 25 μL added to foil covered wells for 1 hour at 25° C. with shaking. Plates were washed four times with wash buffer, 150 μL MSD read buffer (K150DVD-2 components) added to wells and plates read on MSD Sector Imager 6000. An increase in observed signal indicates the test molecule is neutralizing the exogeneous hPDGF-Rβ and allowing for hPDGF-BB mediated activation. Data was analyzed using Graphpad Prism software and IC₅₀ values calculated using a sigmoidal dose response (variable slope) fit in GraphPad Prism 5.

Example 1.29

Reactivity of Anti-PDGF-BB Antibodies and Anti-VEGF-A/anti-PDGF-BB DVD-Ig Molecules to ECM-associated PDGF-BB

Both recombinant cell line HEK293 cells over-expressing PDGFBB-RM and HUVEC naturally expressing ECM-associated PDGF-BB cells were used for staining.

HEK293 Cell Staining:

PDGFB-RM transient transfected HEK 293 cells and parental HEK293 cells were re-suspended at 1E6 cells/mL in PBS and fixed in 4% paraformaldehyde at RT for 10 minutes, washed with PBS and 2E5 cells/tube were incubated in blocking buffer (10% goat serum in PBS) for one hour on ice. Cells were washed with PBS and incubated with primary antibodies or DVD-Ig molecules at 33 nM in antibody dilution buffer (5% goat serum in PBS) for one hour on ice. Cells were washed three times with PBS and incubated with Alexa Fluo 488 conjugated Goat anti-Human IgG (Jackson Immune, code: 109-546-098; lot: 108427) 1:400 dilution in antibody dilution buffer, incubated on ice for 45 minutes, cells were washed three times with PBS and cytospin onto glass slides and mounted with mounting media with DAPI. Pictures were taken by fluorescent microscopy.

HUVEC Staining:

The anti-VEGF/anti-PDGF DVD-Ig was further assessed for its staining on naturally derived ECM-associated PDGF-BB on HUVEC cells. HUVECs (Lonza, cat#: C2519A lot: 181607) were trypsinized, resuspended at 2E4 cells/mL in culture media (Lonza, EGM2 MV Bulletkit: CC-3202). Cells were plated at 10,000 cells/500 μl/well in 8-chamber glass slide and incubated for 16 hours at 37° C., 5% CO₂. After incubation, cells were fixed with 200 μl 4% paraformaldehyde at RT for 10 minutes, washed with PBS and incubated in blocking buffer (10% goat serum in PBS) for one hour on ice. Cells were washed with PBS 3× and incubated with primary antibodies or DVD-Ig molecules at 33 nM in antibody dilution buffer (5% goat serum in PBS) for one hour on ice. Cells were washed three times with PBS and incubated with Alexa Fluo 488 conjugated Goat anti-Human IgG (JacksonImmune, code: 109-546-098; lot: 108427) 1:400 dilution in antibody dilution buffer, incubate on ice for 45 minutes, cells were washed three times with PBS and mounted with mounting media with DAPI. Pictures were taken by fluorescent microscopy.

A. Example 1.30

Inhibition of Sprouting in HUVEC/MSC Co-culture Sprouting Assay by Anti-VEGF-A/anti-PDGF-BB DVD-Ig Molecules

In early therapeutic treatment mode, Cytodex-3 beads (Sigma-Aldrich, cat# C3275) were coated with HUVEC cells (Lonza) overnight, and then embedded (100 beads/well) with human mesenchymal stem cells (Lonza, 20,000 cells/well) in fibrin gel in 24-well tissue culture plates. A 1:1 mixture of fresh EGM-2 complete media (Lonza) and fibroblast (Lonza) conditioned EGM-2 media were added on top of the fibrin gel along with 2 ng/mL of recombinant human HGF. Medium was replaced every 2-3 days till the end of the experiment. After EC sprouts and pericyte covering were formed usually on day 4, anti-VEGF-A (4G8.4), anti-PDGFBB (9E8.) or anti-PDGFBB/VEGF-A DVD-Ig, were added to the culture medium at 10 nM starting. 10 days later cells were fixed in 4% PFA overnight at 4° C. Endothelial cells were stained with anti-PECAM (Abcam, ab32457), followed by fluorescence-conjugated secondary antibody, and pericytes were labeled with anti-aSMA-Cy3 (Sigma, C6198). Cells were then viewed by an inverted fluorescence microscope and 5× images were captured (FIGS. 2 and 3).

Example 2

Analytical Methods and Techniques for Physicochemical Property Characterizations of DVD-Ig Proteins

Example 2.1

Size Exclusion Chromatography Technique

Size exclusion chromatography (SEC) is used to separate proteins based on size. Proteins are carried in an aqueous mobile phase and through a porous stationary phase resin packed in a column. The retention time in the column is a function of the hydrodynamic size of the protein and the size of the pores in the packed resin bed. Smaller molecules can penetrate into smaller pores in the resin and are retained longer than larger molecules. Samples at 1 mg/ml, or diluted with formulation buffer to this concentration, are injected onto the SEC column at a volume of 10 μl. Upon elution from the column, the proteins are detected by UV absorbance. The SEC method uses a TSK gel guard (TOSOH Biosciences, Montgomeryville, Pa., cat. no. 08543) and a TSK gel G3000SWxL (TOSOH Biosciences, Montgomeryville, Pa., cat. no. 08541). The mobile phase was 100 mM Na₂HPO₄, 100 mM Na₂SO₄, pH 6.8. The flow rate is 0.25 ml/minute. The column temperature is room temperature. The autosampler temperature is 2-8° C. The total run time is 55 minutes. The detection is based on UV absorbance at 214 nm wavelength, with band width set at 8 nm, using reference wavelength at 360 nm with band width 100 nm. The resulting chromatogram is analysed for the distribution of different size species (aggregate, monomer, and fragment) by the percentage of the total area of the signal.

Example 2.2

Differential Scanning Calorimetry Technique

The thermal stability of the protein samples was assessed using a differential scanning calorimetry (DSC) instrument. The DSC instrument used was an automated VP-DSC equipment with Capillary Cell (Microcal, GE Healthcare Ltd./Microcal, Buckinghamshire, UK). Unfolding of molecules was studied applying a 1° C./minute scan rate over a 25° C.-95° C. temperature range for samples at 1 mg/mL. Additional measurement parameters applied were a fitting period of 16 seconds, a pre-scan wait time of 10 minutes, and measurements were performed in none-feedback mode. For each measurement, 420 μL of sample or blank buffer was filled into the designated receptacle within the DSC instrument. The thermograms obtained (heat capacity versus temperature) were fitted to a non-two state model to obtain the midpoint temperatures and enthalpies of the different transitions.

Example 2.3

Sample Preparation

The antibodies and DVD-Ig molecules were initially obtained as a solution and diluted below 10 mg/ml with the formulation buffer. Each sample was then inserted into a separate dialysis cartridge (Slide-a-lyzer cassette, 10,000 MWCO, 3-12 mL capacity, Thermo Scientific, USA, Cat. No. 66810) and dialyzed against 2 L of the formulation buffer with continuous stirring via a magnetic stir bar for 18-24 hours. The samples were then retrieved from the cartridge and briefly spun down in a centrifuge and/or passed through 0.45 μm PVDF filters to remove any precipitation or particles. This was followed by up-concentration of the DVD-Ig solutions with centrifuge spin filters (Amicon Ultra 30,000 MWCO Regenerated Cellulose) to reach the desired protein concentration which was confirmed by UV measurements at 280 nm. If the solutions were above the desired concentration, they were diluted to that concentration with the formulation buffer.

Example 2.4

Storage Stability Analysis Method

The antibodies and DVD-Ig molecule solutions prepared according to Example 2.3 were analyzed for their physical stability during storage at 40° C., 25° C., and/or 5° C. Both 25° C. (room temperature) and 5° C. (storage temperature) are typical temperatures at which the samples would be subjected either during preparation and storage for manufacture or as part of the final drug product presentation. Storage at 40° C. is considered an accelerated stability condition which provides an indication of long-term stability prospects. The samples were aliquoted into low volume containers (<0.1 ml), tightly sealed, and placed at the designated temperatures (sometimes in a water bath). The samples were then pulled at periodic intervals and a small portion was removed for analysis by SEC (Example 2.1).

Example 2.5

Freeze-Thaw Analysis Method

The antibody and DVD-Ig molecule solutions prepared according to Example 2.3 were analyzed for their physical stability during freeze/thaw stress. Samples were aliquoted into low volume containers (<1 ml) and tightly sealed. The samples were then placed at −80° C. for at least 6 hours and then thawed at 30° C. in a water bath. This was repeated three more times. After the second and fourth thaws, a small portion of each sample was removed for analysis by SEC (Example 2.1).

DVD-Ig solutions are typically frozen at −80° C. for long term storage as well as shipping to remote manufacturing sites. The samples are then thawed in order to complete the drug product manufacturing process. Stability due to freeze-thawing was assessed at low concentration in order to evaluate greater exposure of protein molecules to the denaturing ice-water interfaces. At higher concentrations, proportionally less protein encounters the ice-water interface, instead interacting with other protein molecules.

Example 2.6

Viscosity Determination Method

The antibody and DVD-Ig molecule solutions prepared according to Example 2.3 were analyzed for their viscosity at room temperature (˜23° C.) with a Malvern Viscosizer 200 instrument. The viscosity serves as an indication of the ease of delivery of the sample through a small diameter needle attached to a syringe, a likely drug product presentation. A higher viscosity requires a greater force for delivery, and vice-versa.

Example 2.7

Intact and Reduced Molecular Weight Determination

The intact molecular weights of the three samples shown in Table 8 were acquired. Each sample was diluted to 1 mg/mL with Milli-Q water. 1.0 μL of the 1 mg/mL sample was injected onto an Agilent 6510 Q-Tof LC/MS system with a C4 MicroTrap column. Table 9 shows the HPLC gradient for intact molecular weight analysis. Buffer A was 0.02% TFA, 0.08% FA in water. Buffer B was 0.02% TFA, 0.08% FA in acetonitrile. The flow rate was 50 μL/minute. The column temperature was set at 60° C. The mass spectrometer was operated at 5 kvolts spray voltage and the scan range was from 600 to 3200 mass to charge ratio. The deglycosylated intact molecular weights of all three samples were measured by Agilent 6510 Q-Tof LC/MS system after the samples were deglycosylated. 100 μL of 1 mg/mL sample was mixed with 5 μL of 10% N-octylglucoside and 2 μL of PNGase F enzyme. The sample was incubated at 37° C. for 18 hours. 1.0 μg of the deglycosylated sample was injected onto an Agilent 6510 Q-Tof LC/MS system with a C4 MicroTrap for deglycosylated intact molecular weight analysis.

The reduced molecular weights of all three samples were obtained. Each sample was diluted to 1 mg/mL with Milli-Q water. 1.0 μL of 1M DTT was added to 100 μL of a 1 mg/mL sample and incubated at 37° C. for 30 minutes. 2.0 μL of the reduced sample was injected onto an Agilent 6510 Q-Tof LC/MS system with a diphenyl column. The HPLC gradient for reduced molecular weight analysis is shown in Table 9. The mass spectrometer was operated at 5 kvolts spray voltage and the scan range was from 600 to 3200 mass to charge ratio.

TABLE 8
VEGF/PDGF DVD-Ig Formulations
			Concentration
Sample ID	Lot	Detailed name	(mg/mL)	Formulation
PR-1572102	Lot 2211502	hu VEGF 4G8.3-GS-hu PDGF	6.5	30 mM histidine,
		9E8.4 (germline) [hu IgG1/k]		8% sucrose pH
		LALA H435A		5.2
PR-1572105	Lot 2211597	hu VEGF 4G8.3-SL-hu PDGF	1.5	30 mM Histidine,
		9E8.4 (germline) [hu IgG1/k]		8% Sucrose pH
		LALA H435A		5.2
PR-1610561	Lot 2213329	hu VEGF 9E10.1-GS-hu PDGF	5	30 mM Histidine,
		33675 [hu IgG1/k] LALA H435A		8% sucrose, pH
				5.2

TABLE 9
PLC Operating Conditions For Intact And Reduced Molecular Weight
Intact/C4		Reduced/Diphenyl
Time (min)	% Buffer B	Time (min)	% Buffer B
0	5	0	5
5	5	5	30
5.5	95	30	40
10	95	32	90
10.5	5	37	90
15	5	39	5
		44	5

Example 2.8

Oligosaccharide Profiles Determined by Fc Molecular Weight Measurement

Samples were partially digested with Lys-C enzyme, reduced and analyzed by LC/MS. Different oligosaccharide species were quantitated based on the peak intensity detected by mass spectrometry and the relative percentage of different oligosaccharide species was reported. Samples were diluted to 1 mg/mL with Milli-Q water. 100 μL of each sample was mixed with 2 μL of 0.005 mg/mL Lys-C enzyme and incubated at 37° C. for 30 minutes. 1 μL of 1 M DTT was added and incubated at 37° C. for 30 minutes for reduction. 2 μL of sample was injected onto an Agilent 6510 Q-Tof LC/MS system with a diphenyl column and a reduced HPLC gradient was used. The column temperature was set at 60° C. The mass spectrometer was operated at 5 kvolts spray voltage and the scan range was from 600 to 3200 mass to charge ratio.

Example 2.9

Charge Heterogeneity by Weak Cation Exchange Chromatography and Imaged Isoelectric Focusing (icIEF)

Charge heterogeneity was studied using a Propac WCX-10 column for weak cation exchange chromatography analysis. Mobile phase A was 20 mM MES, pH 5.5. Mobile phase B was 20 mM MES, 500 mM NaCl, pH 5.5. Each sample was diluted to 1 mg/mL in mobile phase A. 50 μg of each sample was loaded, and the HPLC gradient is shown in Table 10. The flow rate was 1 mL/minute flow rate and the UV detector was monitored at 280 nm.

TABLE 10
Gradient Used For Weak Cation Exchange Chromatography
Time (minutes) Mobile phase B
0              20
5              20
25             40
27             100
32             100
34             20
38             20

Imaged isoelectric focusing was performed on an iCE instrument from ProteinSimple. All three samples were diluted to 1 mg/mL with Milli-Q water before mixing with amphalyte and other components as shown in Table 11. Each sample was vortexed briefly and centrifuged for 5 minutes at 10 k RPM before being transferred to glass inserts for analysis. Each sample was pre-focused at 1500 V for 1 minute and focused at 3000 V for 8 minutes.

TABLE 11
Sample Preparation for icIEF
Component             Volume (μL)
1% Methyl cellulose   70
Pharmalyte 3-10       4
Pharmalyte 5-8        4
Diluted pI 5.1 marker 8
Diluted pI 8.2 marker 8
1 mg/mL test sample   50
Water                 6
8M Urea               50

Example 3

Generation of Rat Anti-VEGF-A, Anti-VEGFRII, Rat-Anti-PDGF-BB, Anti-PDGFR-B Monoclonal Antibodies by DNA Immunization and Rat Hybridoma Technology

Example 3.1

DNA Immunization, Hybridoma Fusion and Screening

Genetic immunization enables the development of antibodies against any protein target directly from a cDNA. A cDNA encoding the soluble human VEGFA-165, soluble human PDGF-BB, human VEGFR-II ECD (extracellular domain) or human PDGFR-BB ECD was cloned into a eukaryotic expression vector (Aldevron GmbH, Freiburg, Germany). Wistar rats were immunized by intradermal application of DNA-coated gold-particles using a hand-held device for particle-bombardment (“gene gun”). Antibody-producing splenocytes or lymph node cells were isolated and fused with fusion partner myeloma cells using polyethylene glycol (PEG) according to standard procedures. To help identify positive antisera and hybridomas, screening is done with the use of either cells transfected with screening vector encoding GPI anchored human VEGF-A165, human PDGF-BB, human VEGFR-II ECD or human PDGFR-BB ECD proteins, soluble recombinant human VEGF-A165 and human PDGF-BB protein or peptides. The tables below are the lists of antibodies generated using the rat DNA immunization approach.

Anti-VEGF-A antibodies derived from rat hybridomas were characterized for binding, function and cross-reactivity in a panel of assays. Supernatants were tested for the ability to bind hVEGF₁₆₅ (Example 1.3) and block binding of hVEGF₁₆₅ to hVEGFR2 in a competition ELISA format (Example 1.4). Select hybridomas were assessed for cross-reactivity by testing for the ability to block human VEGF₁₁₁ and rabbit VEGF₁₆₅ in a Tyr1054 phosphorylation assay (Example 1.6) and blocking of murine VEGF₁₆₄ binding to mVEGFR2 (Example 1.5). Candidate rat IgG was then examined for potency in the hVEGF₁₆₅-induced cell proliferation assay (Example 1.7), reactivity to native hVEGF₁₆₅ (Example 1.11) and binding affinity measurement by Biacore analysis (Example 1.1). The data is summarized in Tables 12 and 13 below.

TABLE 12
A List of Anti-VEGF-A Antibodies Generated Using DNA Immunization and Rat
Hybridoma Technology
							huVEGF-
						Receptor	A165
						Competition	Neutralization
				Phospho-	ELISA	ELISA	Potency in	ELISA	ELISA	Phospho-
		ELISA	ELISA	Tyr1054/	Binding to	huVEGF-	hVEGF-	Mouse	Rat	Tyr1054/
		huVEGF-	huVEGF-	huVEGF-	Naturally	A165/	R2 Over-	VEGF-	VEGF-	Rabbit
Hybridoma		A 165	A121	A111	Derived	huVEGF-	expressing	A164	A164	VEGF-A165
Clones	Isotype	Binding	Binding	Neutralization	huVEGF-A	R2 (nM)	Cells (nM)	Binding	Binding	Neutralization
BEW-	IgG2b/κ	+	NT	+	+	0.18	0.09	−	NT	+
164-
C4
BEW-	IgG2b/κ	+	NT	+	+	0.62	0.39	−	NT	+
1E3-
D6
BEW-	IgG2b/κ	+	NT	+	+	0.156	0.88	−	NT	+
5C3-
E7
BEW-	IgG2b/κ	+	NT	+	+	0.197	<0.1	−	NT	+
6C2-
C8
BEW-	IgG2a/κ	+	NT	+	+	0.342	0.41	−	NT	+
8E6-
E4
BEW-	IgG2a/κ	+	NT	+	+	0.249	0.16	−	NT	+
9A8-
E2
BEW-	IgG2a/κ	+	NT	+	+	0.274	0.17	−	NT	+
9E10-
E7
BEW-	IgG2b/κ	+	NT	+	+	0.42	0.42	−	NT	+
10H2-
B9
BEW-	IgG2a/κ	+	NT	+	+	0.124	<0.1	−	NT	+
9E3--
B9
BEW-	IgG2b/κ	+	NT	+	+	0.207	0.14	−	NT	+
9E7-
B4
BEW-	IgG1/κ	+	NT	+	+	0.584	1.46	−	NT	+
1G1-
C2
BEW-	IgG2b/κ	+	NT	+	+	0.155	<0.1	−	NT	+
9C2-
D6
BEW-	IgG2a/κ	+	NT	+	+	0.127	0.09	−	NT	+
9D2-
E8
BEW-	IgG2a/κ	+	NT	+	+	0.326	2.8	−	NT	+
1B10-
B9-C3
BEW-	IgG2b/κ	+	NT	+	+	0.124	0.96	−	NT	+
3A1-
D10-
G9
BED-	IgG2b/κ	+	NT	+	+	0.13	0.38	−	NT	+
4G10-
C8
BDB-	IgG2b/κ	+	NT	+	+	0.13	0.617	−	NT	+
4G8-
D4
NT = not tested

TABLE 13
Biacore Binding of Rat Anti-VEGF Antibodies
Antibody	kon (M−1 s−1)	koff (M−1)	KD (M)
BDB-4G8-D4	≧1.0E+07	8.1E−06	≦8.1E−13
BDB-4G8-D4	1.4E+07	1.6E−05	1.2E−12
BED-4G10-C8	1.8E+07	1.1E−03	6.0E−11
BEW-1B4-C4	1.8E+07	1.3E−04	7.4E−12
BEW-1B10-B9-C3	4.4E+06	7.2E−05	1.6E−11
BEW-1E3-D6	1.4E+07	1.4E−04	1.0E−11
BEW-1G1-C2	1.6E+07	3.0E−05	1.9E−12
BEW-3A1-D10-G9	1.0E+07	1.4E−03	1.4E−10
BEW-5C3-E7	1.2E+07	4.8E−05	3.9E−12
BEW-6C2-C8	6.9E+06	8.4E−05	1.2E−11
BEW-8E6-E4	6.9E+06	1.2E−04	1.7E−11
BEW-9A8-E2	7.4E+06	7.1E−06	9.6E−13
BEW-9C2-D6	5.5E+06	≦1.0E−06	≦1.8E−13
BEW-9D2-E8	7.0E+06	9.8E−05	1.4E−11
BEW-9E10-E7	1.3E+07	3.9E−05	3.1E−12
BEW-9E3-B9	6.7E+06	9.5E−05	1.4E−11
BEW-9E7-B4	5.9E+06	2.5E−05	4.3E−12
BEW-10H2-B9	2.4E+07	2.7E−04	1.1E−11

Anti-PDGF-BB antibodies derived from rat hybridomas were characterized for binding, function and cross-reactivity in a panel of assays. Supernatants were tested for the ability to bind hPDGF-BB (Example 1.12) and block binding of hPDGF-BB to hPDGF-R in a competition ELISA format (Example 1.13). Select hybridomas were assessed for the ability to block human and rat PDGF-BB in a Tyr751 phosphorylation assay (Example 1.14). Candidate rat IgG was then examined for potency in the human, mouse and cynomolgus PDGF-BB-induced cell proliferation assay (Examples 1.15-1.17), reactivity to native hPDGF-BB (Example 1.19) and binding affinity measurement by Biacore analysis (Example 1.1). The data is summarized in Tables 14 and 15 below.

TABLE 14
A List of Anti-PDGF-BB Antibodies Generated using DNA Immunization and Rat
Hybridoma Technology
			ELISA	Receptor		huPDGF-		mPDGF-	cynoPDGF-
			Binding	Competition		BB	Phospho-	BB	BB
			to	ELISA	Phospho-	Neutralization	Tyr751/	Neutralization	Neutralization
		ELISA	Naturally	huPDGF-	Tyr751/hPDGF-	Potency	ratPDGF-	Potency	Potency
		huPDGF-	Derived	BB/	BB	(nM) in	BB	(nM) in	(nM) in
Hybridoma		BB	huPDGF-	huPDGF	Neutralization	NIH-3T3	Neutralization	NIH-3T3	NIH-3T3
Clones	Isotype	Binding	BB	Rβ (nM)	(nM)	Cells	(nM)	Cells	Cells
BDI-	IgG2b/κ	+	+	1.121	0.629	0.195	0.333	0.026	0.194
9E8-E7
BDI-	IgG2b/κ	+	+	0.528	0.884	0.371	0.319	NT	NT
5H1-F6
BDI-	IgG2b	+	+	>10	>10	>5	>5	NT	NT
7H10-
D8
BDI-	IgG2b/κ	+	NT	>10	1.057	>5	+	NT	NT
1E1-D5
BDI-	IgG2b/λ	+	NT	1.065	0.923	0.741	+	NT	NT
5G2-F9
BDI-	IgG2b/λ	+	NT	3.228	1.618	>5	−	NT	NT
6A3-A9
BDI-	IgG2b	+	NT	>10	>10	>5	−	NT	NT
7F6-D3
BDI-	IgG2b/λ	+	NT	1.035	2.53	>5	−	NT	NT
10E7-
F9
BDI-	IgG2b/λ	+	NT	1.086	3.159	>5	−	NT	NT
8B8-F2
BFF-	IgG2b/κ	+	NT	>50	0.753	>5	NT	NT	NT
5C9-C7-
B5
BFF-	IgG2b/λ	+	NT	>50	1.745	>10	NT	NT	NT
7D7-D3-
E4
BFF-	IgG2b/κ	+	NT	>50	>10	>10	NT	NT	NT
7E9-C3-
B6
BFF-	IgG2b/λ	+	NT	>50	1.896	>10	NT	NT	NT
4G8-B4
BFF-	IgG2b/λ	+	NT	>50	0.739	>10	NT	NT	NT
4E8-E5
BFU-	IgG2b/κ	+	NT	>50	0.642	0.247	NT	NT	NT
3E2-B9-
B8
BFU-	IgG2b/κ	+	NT	7.095	0.736	0.344	NT	NT	NT
11A8-
D6-C3
BFU-	IgG2b	+	NT	2.287	0.639	>10	NT	NT	NT
3H6-D2

TABLE 15
Biacore Binding of Rat Anti-PDGF Antibodies
Antibody	kon (M−1 s−1)	koff (M−1)	KD (M)
BDI-1E1-D5	≧1.0E+07	3.7E−04**	≦3.7E−11**
BDI-5G2-F9	≧1.0E+07	≦1.0E−06	≦1.0E−13
BDI-5H1-F6	≧1.0E+07	≦1.0E−06	≦1.0E−13
BDI-6A3-A9	≧1.0E+07	6.7E−03**	≦6.7E−10**
BDI-7F6-D3	≧1.0E+07	6.0E−03	≦6.0E−10
BDI-7H10-D8	≧1.0E+07	≦1.3E−02**	≦1.3E−09**
BDI-8B8-F2	≧1.0E+07*	≦1.0E−06*	≦1.0E−13*
BDI-9E8-E7	≧1.7E+07	≦1.0E−06	≦5.8E−14
BDI-9E8-E7	≧1.0E+07	≦1.0E−06	≦1.0E−13
BDI-10E7-F9	≧1.0E+07*	1.3E−04*	≦1.3E−11*
BFF-4E8-E5	≧1.0E+07	8.3E−03***	≦8.3E−10***
BFF-4G4-B8	≧1.0E+07	8.3E−03**	≦8.3E−10**
BFF-5C9-C7-B5	≧1.0E+07	5.8E−05	≦5.8E−12
BFF-7D7-D3-E4	≧1.0E+07	2.1E−02**	≦2.1E−09**
BFF-7E9-C3-B6	≧1.0E+07	1.2E−03**	≦1.2E−10**
BFU-3E2-B9-B8	≧1.0E+07	1.5E−06	≦1.5E−13
BFU-3H6-D2	≧1.0E+07	2.7E−04**	≦2.7E−11**
BFU-11A8-D6-C3	2.1E+07	≦1.0E−06	≦4.7E−14
*Low Ag response
**Heterogeneous off-rate
***Low Ag response and Heterogeneous off-rate

Anti-VEGFR2 antibodies derived from rat hybridomas were characterized for binding, function and cross-reactivity in a panel of assays. The subcloned rat antibodies were tested for the ability to bind hVEGFR2 (Example 1.22), block binding of hVEGF-R2 to hVEGF₁₆₅ in a competition ELISA format (Example 1.23), and a hVEGF₁₆₅ Tyr1054 phosphorylation assay (Example 1.24). Candidate molecules were then characterized for species cross-reactivity by testing their ability to block binding of mVEGFR2 to mVEGF₁₆₄ in a competition ELISA format (Example 1.25). The data is summarized in Table 16 below.

TABLE 16
A List of Anti-VEGFR II Antibodies Generated Using
DNA Immunization and Rat Hybridoma Technology
	Potency (nM)
			hVEGF165/	mVEGF164/	Tyr1054
Hybridoma		hVEGFR2-	hVEGFR2-Fc	mVEGFR2-Fc	phospho-
Clones	Isotype	Fc Binding	Competition	Competition	assay
BCU-3D6-C9		+	NT	NT	NT
BCU-6B1-G6	IgG2a/κ	+	4.850	1.350	+
BCU-7A6-C2	IgG2b/κ	+	−	−	+

Anti-PDGF-Rβ antibodies derived from rat hybridomas were characterized for binding and function in a panel of assays. The subcloned rat antibodies were tested for the ability to bind hPDGF-Rβ (Example 1.26). Candidate IgG was also characterized for the ability to block binding of hPDGF-Rβ to hPDGF-BB in a competition ELISA format (Example 1.27) and an hPDGF-BB Tyr751 phosphorylation assay (Example 1.28). The data is summarized in Table 17 below.

TABLE 17
A List of Anti-PDGFR-B Antibodies Generated Using
DNA Immunization and Rat Hybridoma Technology
	Potency (nM)
			hPDGF-BB/	hPDGF-BB/
Hybridoma		hPDGFRβ-	hPDGFRβ-Fc	Tyr751
Clones	Isotype	Fc Binding	Competition	phospho-assay
BDE-3C9-G4	IgG2b/κ	+	0.832	4.696
BDE-4F2-D4	IgG2a/κ	+	0.527	+
BDE-8H6-F7		+	+	−

Example 4

Deduction of Variable Region Protein Sequences of Monoclonal Antibodies by DNA Cloning and Sequencing

Total RNA was extracted from hybridoma cell pellets using RNeasy mini kit (Qiagen, catalog #74104) using the following protocol. 600 μl of buffer RLT were added to disrupt cells by pipetting up and down several times. The cell lysate was homogenized by passing it 10 times through a 20-gauge needle fitted to an RNase-free syringe. One volume of 70% ethanol was added to the homogenized lysate and mixed well by pipetting. Up to 700 μl at a time of the sample were added to an RNeasy spin column and spun for 15 seconds at 10,000 rpm, discarding flow through. 700 μl of buffer RW1 were added to the column and spun for 15 seconds at 10,000 rpm, discarding flow through. 500 μl of buffer RPE were added to wash the column membrane and spun for 15 seconds at 10,000 rpm, discarding flow through. The same step was repeated one more time, but the column was centrifuged for 2 minutes. Sample was then centrifuged for 1 minute at 10,000 rpm to eliminate any carryover of buffer RPE. RNA was eluted with 30 μl of RNase-free water by centrifuging for 1 minute at 10,000 rpm. Subsequently, 2 μg of total RNA were used to synthesize first-strand cDNA using SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen, catalog #11904-018) according to following protocol: 2 tag of RNA+2 μl dNTP+2 μl Oligo (dT)+DEPC-H₂O (to 20 μl) were incubated at 65° C. for 5 minutes, then transferred to ice for at least 1 minute. The sample was then added to the following mixture: 4 μl of 10×RT buffer+8 μl 25 mM MgCl₂+4 μl 0.1 M DTT+2 μl RNase OUT and incubated at 42° C. for 2 minutes. Then, 2 μl of SuperScript II RT were added to the sample and incubated at 42° C. for 50 minutes. Sample was then incubated at 70° C. for 15 minutes and chilled on ice. 2 μl of RNase H were then added and the sample was incubated at 37° C. for 20 minutes. cDNA was then used as template for PCR amplification of variable regions of antibodies. PCR was performed using first-strand cDNA, primers from Mouse Ig-Primer Set (Novagen, catalog #69831-3) and Platinum Super Mix High Fidelity (Invitrogen, catalog #12532-016). To amplify heavy chain variable regions, PCR samples were assembled as follows: 22.5 μl PCR Super Mix+0.25 μl reverse primer MuIgG V_H3′-2+1 μl cDNA+1.25 μl of one the forward primers (VH-A, VH-B) or 0.5 μl of one of the forward primers (VH-C, VH-D, VH-E, VH-F). To amplify light chain variable regions, PCR samples were assembled as follows: 22.5 μl PCR Super Mix+0.25 μl reverse primer MuIgKV_L-3′-1+1 μl cDNA+1.25 μl of one the forward primers (VL-A, VL-B) or 0.5 μl of one of the forward primers (VL-C, VL-D, VL-E, VL-F, VL-G).

For samples with primers VH-A, VH-B, VL-A and VL-B, the following PCR cycles were used (40-45 cycles, steps 2 through 4):

1—Denature 94° C. 2 minutes.2—Denature 94° C. 30 seconds.3—Anneal 50° C. 30 seconds.4—Extend 68° C. 1 minute.5—Final extension 68° C. 5 minutes.6—Cool 4° C. foreverFor samples with primers VH-C through VH-F, and VL-C through VL-G, the following PCR cycles were used (40-45 cycles, steps 2 through 4):1—Denature 94° C. 2 minutes.2—Denature 94° ° C. 30 seconds.3—Anneal 60° C. 30 seconds.4—Extend 68° C. 1 minute.5—Final extension 68° C. 5 minutes.6—Cool 4° C. forever

PCR products were run on a 1.2% agarose gel, and bands migrating at the expected size (400-500 bp) were excised for DNA extraction. DNA was purified using QIAquick Gel Extraction Kit (Qiagen, catalog #28704) according to the following protocol: gel slices were weighed. 3 volumes of buffer QG to 1 volume of gel were added to each gel slice. Samples were incubated at 50° C. for 10 minutes until gel slices were completely dissolved, mixing every 2-3 minutes. One gel volume of isopropanol was then added to each sample and mixed. Samples were then applied to QIAquick column and centrifuged for 1 minute at 13000 rpm. To wash, 750 μl of buffer PE were added to samples and spun for 1 minute at 13000 rpm. Columns were then centrifuged for an additional minute at 13,000 rpm to completely remove residual ethanol DNA was eluted by adding 30 μl of H₂O to each column and by spinning 1 minute at 13,000 rpm. Purified PCR products were then sequenced to identify variable region sequences (see Tables below).

TABLE 18
VH and VL Amino Acid Sequences of Rat
Anti-Human VEGFA Monoclonal Antibodies
SEQ ID		Protein	V Region
NO:	Clone	Region	123456789012345678901234567
406	BDB-4G8-D4 VH		QIQLVQSGPELKKPGESVKISCKASGYTFTNYGMYW
			VKQAPGQGLQYMGWINTETGKPTYADDFKGRFVFFL
			ETSASTAYLQINNLKNEDMATYFCARTNYYYRSYIF
			YFDYWGQGTMVTVSS
407	BDB-4G8-D4	CDR-H1	GYTFTNYGMY
408	BDB-4G8-D4	CDR-H2	WINTETGKPTYADDFKG
409	BDB-4G8-D4	CDR-H3	TNYYYRSYIFYFDY
410	BDB-4G8-D4 VL		DTVLTQSPALAVSPGERVSISCRASESVSTHMHWYQ
			QKPGQQPKLLIYGASNLESGVPARFSGSGSGTDFTL
			TIDPVEADDTATYFCQQSWNDPFTFGAVTKLELK
411	BDB-4G8-D4	CDR-L1	RASESVSTHMH
412	BDB-4G8-D4	CDR-L2	GASNLES
413	BDB-4G8-D4	CDR-L3	QQSWNDPFT
414	BED-4G10-C8 VH		QVQLQQSGTELVKPGSSVKISCKASGYTFTSNYMHW
			IRQQPGNGLEWIGWIYPGDGDTNYNHNFNGKATLTA
			DKSSSTAYMQLSSLTSEDFAVYFCASSTRAIPGWFT
			YWGQGTLVTVSS
415	BED-4G10-C8	CDR-H1	GYTFTSNYMH
416	BED-4G10-C8	CDR-H2	WIYPGDGDTNYNHNFNG
417	BED-4G10-C8	CDR-H3	STRAIPGWFTY
418	BED-4G10-C8 VL		DTVLTQSPALAVSPGERVSISCWASESVSTLMHWYQ
			QKLGQQPKLLIYGASNLESGVPARFRGSGSGTDFTL
			TIDPVEADDTATYFCQQSWSDPYTFGAGTKLELK
419	BED-4G10-C8	CDR-L1	WASESVSTLMH
420	BED-4G10-C8	CDR-L2	GASNLES
421	BED-4G10-C8	CDR-L3	QQSWSDPYT
422	BEW-10H2-B9 VH		QIQLVQSGPELKKPGESVKISCKASGYSFTNFGLYW
			VKQAPGQGLQYMGWIDTETGKPTYADDFRGRFVFFL
			ETSASTAYLQINNLKNEDMATYFCARVYGYPSWYFD
			FWGPGTMVTVSS
423	BEW-10H2-B9	CDR-H1	GYSFTNFGLY
424	BEW-10H2-B9	CDR-H2	WIDTETGKPTYADDFRG
425	BEW-10H2-B9	CDR-H3	VYGYPSWYFDF
426	BEW-10H2-B9 VL		DIQMTQSPASLSTSLEEIVTITCQASQDIDNYLSWY
			QQKPGKSPQLLIHSATSLADGVPSRFSGSRSGTQFS
			LKIHRLQVEDTGIYYCLQHFFPPWTFGGGTKLELK
427	BEW-10H2-B9	CDR-L1	QASQDIDNYLS
428	BEW-10H2-B9	CDR-L2	SATSLAD
429	BEW-10H2-B9	CDR-L3	LQHFFPPWT
430	BEW-1B10-B9-C3 VH		EVQLVESGGGLVQPGRSLKLSCAASGFSFSKYDMAW
			FRQTPTKGLEWVASITTSGVGTYYRDSVKGRFTVSR
			DNAKSTLYLQMDSLRSEDTATYYCARGYGAMDAWGQ
			GTSVTVSS
431	BEW-1B10-B9-C3	CDR-H1	GFSFSKYDMA
432	BEW-1B10-B9-C3	CDR-H2	SITTSGVGTYYRDSVKG
433	BEW-1B10-B9-C3	CDR-H3	GYGAMDA
434	BEW-1B10-B9-C3 VL		DIQMTQSPASLSASLEEIVTITCKASQDIDDYLSWY
			QQKPGKSPQLVIYAATRLADGVPSRFSGSGSGTQYS
			LKISRLQVDDSGIYYCLQSSSTPWTFGGGTNLELK
435	BEW-1B10-B9-C3	CDR-L1	KASQDIDDYLS
436	BEW-1B10-B9-C3	CDR-L2	AATRLAD
437	BEW-1B10-B9-C3	CDR-L3	LQSSSTPWT
438	BEW-1B4-C4 VH		QIQLVQSGPELKKPGESVKISCKASGYSFTNYGMYW
			VKQAPGQGLQYMGWIDTETGKPTYTDDFKGRFVFFL
			ETSASTAYLQINNLKNEDMATYFCARWSGDTAGIRG
			PWFAYWGQGTLVTVSS
439	BEW-1B4-C4	CDR-H1	GYSFTNYGMY
440	BEW-1B4-C4	CDR-H2	WIDTETGKPTYTDDFKG
441	BEW-1B4-C4	CDR-H3	WSGDTAGIRGPWFAY
442	BEW-1B4-C4 VL		DIRMTQSPASLSASLGETVNIECLASEDIYSDLAWY
			QQKPGKSPQLLIYNANDLQKGVPSRFSGSGSGTQYS
			LKINSLQSEDVATYFCQQYNYYPGTFGAGTKLELK
443	BEW-1B4-C4	CDR-L1	LASEDIYSDLA
444	BEW-1B4-C4	CDR-L2	NANDLQK
445	BEW-1B4-C4	CDR-L3	QQYNYYPGT
446	BEW-1C6-D2 VH		QIQLVQSGPELKKPGESVKISCKASGYTFTNYGMYW
			VKQAPGQGLQYMGWINTETGKPTYADDFKGRFVFFL
			ETSASTAYFQINNLKNEDLATYFCARPSDYYDGFWF
			PYWGQGTLVTVSS
447	BEW-1C6-D2	CDR-H1	GYTFTNYGMY
448	BEW-1C6-D2	CDR-H2	WINTETGKPTYADDFKG
449	BEW-1C6-D2	CDR-H3	PSDYYDGFWFPY
450	BEW-1C6-D2 VL		DTALTQSPALAVSPGERVSISCRASEGVNSYMHWYQ
			QSPGQQPKLLIYKASNLASGVPARFSGSGSGTDFTL
			TIDPVEADDTATYFCQQSWYDPLTFGSGTKLEIK
451	BEW-1C6-D2	CDR-L1	RASEGVNSYMH
452	BEW-1C6-D2	CDR-L2	KASNLAS
453	BEW-1C6-D2	CDR-L3	QQSWYDPLT
454	BEW-1E3-D6 VH		QIQLVQSGPELKKPGESVKISCKASGYPFTNSGMYW
			VKQAPGQGLQYMGWINTEAGKPTYADDFKGRFVFFL
			ETSASTAYLQINNLKNEDMATYFCARWGYISDNSYG
			WFDYWGQGTLVTVSS
455	BEW-1E3-D6	CDR-H1	GYPFTNSGMY
456	BEW-1E3-D6	CDR-H2	WINTEAGKPTYADDFKG
457	BEW-1E3-D6	CDR-H3	WGYISDNSYGWFDY
458	BEW-1E3-D6 VL		DTVLTQSPALAVSPGERVSISCRASEGVYSYMHWYQ
			QNPGQQPKLLIYKASNLASGVPARFSGSGSGTDFTL
			TIDPVEADDTATYFCHQNWNDPLTFGSGTKLEIK
459	BEW-1E3-D6	CDR-L1	RASEGVYSYMH
460	BEW-1E3-D6	CDR-L2	KASNLAS
461	BEW-1E3-D6	CDR-L3	HQNWNDPLT
462	BEW-3A1-D10-G9 VH		QVQLEQSGAELVKPGTSVKLSCMASGYTSSSNHMNW
			MKQTTGQGLEWIGIINPGSGGTRYNVKFEGKATLTV
			DKSSSTAFMQLNSLTPEDSAVYYCARAGFPGPFSYY
			AMGAWGQGTSVTVSS
463	BEW-3A1-D10-G9	CDR-H1	GYTSSSNHMN
464	BEW-3A1-D10-G9	CDR-H2	IINPGSGGTRYNVKFEG
465	BEW-3A1-D10-G9	CDR-H3	AGFPGPFSYYAMGA
466	BEW-3A1-D10-G9 VL		DIQMTQSPPVLSASVGDRVTLSCKASQNIHNNLDWY
			QQKHGEAPKLLIFYTNNLQTGIPSRFSGSGSGTDYT
			LTISSLQPEDVATYYCYQYNSGYTFGAGTKLELK
467	BEW-3A1-D10-G9	CDR-L1	KASQNIHNNLD
468	BEW-3A1-D10-G9	CDR-L2	YTNNLQT
469	BEW-3A1-D10-G9	CDR-L3	YQYNSGYT
470	BEW-5C3-E7 VH		QIQLVQSGPELKKPGESVKISCKASGYTFTNYGVYW
			VKQAPGQGLQYMGWINTETGKPTYADDFKGRFVFFL
			ETSTNTAYLQINNLKNEDMATFFCARARQLDWFVYW
			GQGTLVTVSS
471	BEW-5C3-E7	CDR-H1	GYTFTNYGVY
472	BEW-5C3-E7	CDR-H2	WINTETGKPTYADDFKG
473	BEW-5C3-E7	CDR-H3	ARQLDWFVY
474	BEW-5C3-E7 VL		DTVLTQSPALTVSPGERVSISCRARESLTTSLCWFQ
			QKPGQQPKLLIYGASKLESGVPARFSGSGSGTDFTL
			TIDPVEADDTATYFCQQSWYDPPTFGGGTKLELK
475	BEW-5C3-E7	CDR-L1	RARESLTTSLC
476	BEW-5C3-E7	CDR-L2	GASKLES
477	BEW-5C3-E7	CDR-L3	QQSWYDPPT
478	BEW-6C2-C8 VH		EVQLVESGGGLVQPGSSLKLSCAASGFTFSYYGMHW
			IRQAPKKGLEWMALIYYDSSKMYYADSVKGRFTISR
			DNSKNTLYLEMNSLRSEDTAMYYCAAGGTAPVYWGQ
			GVMVTVSS
479	BEW-6C2-C8	CDR-H1	GFTFSYYGMH
480	BEW-6C2-C8	CDR-H2	LIYYDSSKMYYADSVKG
481	BEW-6C2-C8	CDR-H3	GGTAPVY
482	BEW-6C2-C8 VL		NIQLTQSPSLLSASVGDRVTLSCKGSQNIANYLAWY
			QQKLGEAPKLLIYNTDSLQTGIPSRFSGSGSGTDYT
			LTISSLQPEDVATYFCYQSNNGYTFGAGTKLELR
483	BEW-6C2-C8	CDR-L1	KGSQNIANYLA
484	BEW-6C2-C8	CDR-L2	NTDSLQT
485	BEW-6C2-C8	CDR-L3	YQSNNGYT
486	BEW-8E6-E4 VH		QIQLVQSGPELKKPGESVKISCKASGYTFTDYAMHW
			VKQAPGKVLKWMGWINTFTGKPTYIDDFKGRFVFSL
			EASASTANLQISDLKNEDTATYFCARGNYYSGYWYF
			DFWGPGTMVTMSS
487	BEW-8E6-E4	CDR-H1	GYTFTDYAMH
488	BEW-8E6-E4	CDR-H2	WINTFTGKPTYIDDFKG
489	BEW-8E6-E4	CDR-H3	GNYYSGYWYFDF
490	BEW-8E6-E4 VL		DIQMTQSPASLSASLGETISIECRASEDISSNLAWY
			QQKSGKSPQLLIFAANRLQDGVPSRFSGSGSGTQFS
			LKISGMQPEDEGDYFCLQGSKFYTFGAGTKLELK
491	BEW-8E6-E4	CDR-L1	RASEDISSNLA
492	BEW-8E6-E4	CDR-L2	AANRLQD
493	BEW-8E6-E4	CDR-L3	LQGSKFYT
494	BEW-9A8-E2 VH		QIQLVQSGPELKKPGESVKISCKASGYTFTNYGMYW
			VKQAPGQGLQYMGWINTETGKPIYADDFKGRFVFFL
			ETSASTAYLQINNLKNEDMATFFCARVDYDGSFWFA
			YWGQGTLVTVSS
495	BEW-9A8-E2	CDR-H1	GYTFTNYGMY
496	BEW-9A8-E2	CDR-H2	WINTETGKPIYADDFKG
497	BEW-9A8-E2	CDR-H3	VDYDGSFWFAY
498	BEW-9A8-E2 VL		DTVLTQSPALAVSPGERVSISCRASESVSTVIHWYQ
			QKPGQQPKLLIHGASNLESGVPARFSGSGSGTDFTL
			TIDPVEADDTATYFCQQHWNDPPTFGAGTKLEMK
499	BEW-9A8-E2	CDR-L1	RASESVSTVIH
500	BEW-9A8-E2	CDR-L2	GASNLES
501	BEW-9A8-E2	CDR-L3	QQHWNDPPT
502	BEW-9C2-D6 VH		QIQLVQSGPELKKPGESVKVSCKASGYTFTNYGIHW
			VKQAPGQGLQYVGWINTETGRPTYADDFKGRFVFFL
			ETSASTAYLQINNLKNEDMATYFCARPLYYGYAHYF
			DYWGQGVMVTVSS
503	BEW-9C2-D6	CDR-H1	GYTFTNYGIH
504	BEW-9C2-D6	CDR-H2	WINTETGRPTYADDFKG
505	BEW-9C2-D6	CDR-H3	PLYYGYAHYFDY
506	BEW-9C2-D6 VL		DIQMTQSPASLSASLEEIVTITCQASQDIGNWLAWY
			QQKPGKSPQLLIYGATSLADGVPSRFSGSRSGTQYS
			LKISRLQVEDIGIYYCQQASSVTYTFGAGTKLELK
507	BEW-9C2-D6	CDR-L1	QASQDIGNWLA
508	BEW-9C2-D6	CDR-L2	GATSLAD
509	BEW-9C2-D6	CDR-L3	QQASSVTYT
510	BEW-9D2-E8 VH		QIQLVQSGPELKKPGESVKISCKASGYTFTNYGMYW
			VKLAPGQGLQYLGWINTETGKPTYADDFKGRFVFFL
			ETSASTAYLQINNLRNEDMATYFCARPSDYYDGFWF
			AYWGQGTLVTVSS
511	BEW-9D2-E8	CDR-H1	GYTFTNYGMY
512	BEW-9D2-E8	CDR-H2	WINTETGKPTYADDFKG
513	BEW-9D2-E8	CDR-H3	PSDYYDGFWFAY
514	BEW-9D2-E8 VL		DTVLTQSPALTVSPGERVSISCRASEWVNSYMHWYQ
			QNPGQQPKLLIYKASNLASGVPARFSGSGSGTDFTL
			TLDPVEADDTATYFCQQSWNDPLTFGSGTKLEIK
515	BEW-9D2-E8	CDR-L1	RASEWVNSYMH
516	BEW-9D2-E8	CDR-L2	KASNLAS
517	BEW-9D2-E8	CDR-L3	QQSWNDPLT
518	BEW-9E10-E7 VH		QIQLLQSGPELKKPGESVKISCKASGYTFTNYGMYW
			VKQAPGQGLQYMGWIDTETGRPTYADDFKGRFVFFL
			ETSASTAYLQINNLKNEDMATYFCARWSGDTTGIRG
			PWFAYWGQGTLVTVSS
519	BEW-9E10-E7	CDR-H1	GYTFTNYGMY
520	BEW-9E10-E7	CDR-H2	WIDTETGRPTYADDFKG
521	BEW-9E10-E7	CDR-H3	WSGDTTGIRGPWFAY
522	BEW-9E10-E7 VL		DIRMTQSPASLSASLGETVNIECLASEDIYSDLAWY
			QQKPGRSPQLLIYNANGLQNGVPSRFGGSGSGTQYS
			LKINSLQSEDVATYFCQQYNYFPGTFGAGTKLELK
523	BEW-9E10-E7	CDR-L1	LASEDIYSDLA
524	BEW-9E10-E7	CDR-L2	NANGLQN
525	BEW-9E10-E7	CDR-L3	QQYNYFPGT
526	BEW-9E3-B9 VH		QIQLVQSGPELKKPGESVKISCKASGYTFTNYGMYW
			VKQAPGQGLQYMGWINTETGKPTYADDFKGRFVFFL
			ETSASTAFLQINNLKNEDMATYFCARPSDYYDGFWF
			PYWGQGALVTVSS
527	BEW-9E3-B9	CDR-H1	GYTFTNYGMY
528	BEW-9E3-B9	CDR-H2	WINTETGKPTYADDFKG
529	BEW-9E3-B9	CDR-H3	PSDYYDGFWFPY
530	BEW-9E3-B9 VL		DTILTQSPALAVSPGERISISCRASEGVNSYMHWYQ
			QNPGQQPKLLIYKASNLASGVPARFSGSGSGTDFTL
			TIDPVEADDTATYFCQQSWNDPLTFGSGTKLEIK
531	BEW-9E3-B9	CDR-L1	RASEGVNSYMH
532	BEW-9E3-B9	CDR-L2	KASNLAS
533	BEW-9E3-B9	CDR-L3	QQSWNDPLT
534	BEW-9E7-B4 VH		QIQLVQSGPELKKPGESVKISCKASGYTFTNYGMYW
			VKQAPGQGLQYMGWIDTETGKPTYADDFKGRFVFFL
			ETSASTAYLQINNLRNEDMATYFCARWGYTSDYYYG
			WFPDWGQGTLVTVST
535	BEW-9E7-B4	CDR-H1	GYTFTNYGMY
536	BEW-9E7-B4	CDR-H2	WIDTETGKPTYADDFKG
537	BEW-9E7-B4	CDR-H3	WGYTSDYYYGWFPD
538	BEW-9E7-B4 VL		DTVLTQSPALAVSPGERVSISCRASEGVNSYMHWYQ
			QNPGQQPKLLIYKASNLASGVPARFSGSGSGTDFTL
			NIHPVEADDTATYFCQQNWNVPLTFGSGTKLEIK
539	BEW-9E7-B4	CDR-L1	RASEGVNSYMH
540	BEW-9E7-B4	CDR-L2	KASNLAS
541	BEW-9E7-B4	CDR-L3	QQNWNVPLT

TABLE 19
VH and VL Amino Acid Sequences of Rat Anti-Human PDGF-BB Monoclonal
Antibodies
SEQ ID		Protein	V Region
NO:	Clone	Region	12345678901234567890123456
542	BDI-1E1-D5 VH		EVKLQQSGDELVRPGASVKMSCKASGYTFTDYVMHW
			VKQSPGQGLEWIGTIIPLIDTTSYNQKFKGKATLTA
			DKSSNTAYMELSRLTSEDSAVYYCARTSPYYYSSYD
			VMDAWGQGASVTVSS
543	BDI-1E1-D5	CDR-H1	GYTFTDYVMH
544	BDI-1E1-D5	CDR-H2	TIIPLIDTTSYNQKFKG
545	BDI-1E1-D5	CDR-H3	TSPYYYSSYDVMDA
546	BDI-1E1-D5 VL		NIQLTQSPSLLSASVGDRVTLSCKGSQNINNYLAWY
			QQKLGEAPKLLIYKTNNLQTGIPSRFSGCGSGTDYT
			LTISSLHSEDLATYYCYQYDNGYTFGAGTKLELK
547	BDI-1E1-D5	CDR-L1	KGSQNINNYLA
548	BDI-1E1-D5	CDR-L2	KTNNLQT
549	BDI-1E1-D5	CDR-L3	YQYDNGYT
550	BDI-5G2-F9 VH		QVTLKESGPGILQPSQTLSLTCTFSGFSLSTFGMGV
			GWIRQPSGKGLEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSNSQAFLEITNVDTADTATYYCARISTGISSYY
			VMDAWGQGASVTVSS
551	BDI-5G2-F9	CDR-H1	GFSLSTFGMGVG
552	BDI-5G2-F9	CDR-H2	NIWWDDDKYYNPSLKN
553	BDI-5G2-F9	CDR-H3	ISTGISSYYVMDA
554	BDI-5G2-F9 VL		QFTLTQPKSVSGSLRSTITIPCERSSGDIGDTYVSW
			YQQHLGRPPINVIYGNDQRPSEVSDRFSGSIDSSSN
			SASLTITNLQMDDEADYFCQSYDSDIDIVFGGGTKL
			TVL
555	BDI-5G2-F9	CDR-L1	ERSSGDIGDTYVS
556	BDI-5G2-F9	CDR-L2	GNDQRPS
557	BDI-5G2-F9	CDR-L3	QSYDSDIDIV
558	BDI-5H1-F6 VH		QVTLKESGPGILQPSQTLSLTCTFSGFSLSTFGMGV
			GWIRQPSGKGLEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSNSQAFLEITNVDTADTATYYCARISTGISSYY
			VMDAWGQGASVTVSS
559	BDI-5H1-F6	CDR-H1	GFSLSTFGMGVG
560	BDI-5H1-F6	CDR-H2	NIWWDDDKYYNPSLKN
561	BDI-5H1-F6	CDR-H3	ISTGISSYYVMDA
562	BDI-5H1-F6 VL		QFTLTQPKSVSGSLRSTITIPCERSSGDIGDTYVSW
			YQQHLGRPPINVIYGNDQRPSEVSDRFSGSIDSSSN
			SASLTITNLQMDDEADYFCQSYDSDIDIVFGGGTKL
			TVL
563	BDI-5H1-F6	CDR-L1	ERSSGDIGDTYVS
564	BDI-5H1-F6	CDR-L2	GNDQRPS
565	BDI-5H1-F6	CDR-L3	QSYDSDIDIV
566	BDI-6A3-A9 VH		EVQLVESGGGLVQPGRSLKFSCAASGFSFSDSAMAW
			VRQAPKKGLEWVATIIYDGSGTYYRDSVKGRFTISR
			DNAKSTLYLQMDSLRSEDTATYYCARLGFNYGNYGY
			YVMDAWGQGASVTVSS
567	BDI-6A3-A9	CDR-H1	GFSFSDSAMA
568	BDI-6A3-A9	CDR-H2	TIIYDGSGTYYRDSVKG
569	BDI-6A3-A9	CDR-H3	LGFNYGNYGYYVMDA
570	BDI-6A3-A9 VL		QFTLTQPKSVSGSLRNTITIPCERSSGDIGDSYVSW
			YQQHLGRPPINVIFADDQRPSEVSDRFSGSIDSSSN
			SASLTITNLQMDDEADYFCQSYDSNIDINIVFGGGT
			KLTVL
571	BDI-6A3-A9	CDR-L1	ERSSGDIGDSYVS
572	BDI-6A3-A9	CDR-L2	ADDQRPS
573	BDI-6A3-A9	CDR-L3	QSYDSNIDINIV
574	BDI-7H10-D8 VH		EVKLQQSGDELVRPGASVKMSCKASGYTFTDYAMHW
			VKQSPGQGLEWIGTIIPLIDTTSYNQKFKGKATLTA
			DTSSNTAYMELSRLTSEDSAVYYCARDWDNNWGYFD
			YWGQGVMVTVSS
575	BDI-7H10-D8	CDR-H1	GYTFTDYAMH
576	BDI-7H10-D8	CDR-H2	TIIPLIDTTSYNQKFKG
577	BDI-7H10-D8	CDR-H3	DWDNNWGYFDY
578	BDI-7H10-D8 VL		DVVLTQTPVSLSVTLGDQASISCRSSQSLEYSDGYT
			YLEWYLQKPGQSPQLLIYGVSNRFSGVPDRFIGSGS
			GTDFTLKISRVEPEDLGVYYCFQATHDPLTFGSGTK
			LEIK
579	BDI-7H10-D8	CDR-L1	RSSQSLEYSDGYTYLE
580	BDI-7H10-D8	CDR-L2	GVSNRFS
581	BDI-7H10-D8	CDR-L3	FQATHDPLT
582	BDI-9E8-E7 VH		QVTLKESGPGILQPSQTLSLTCTFSGFSLSTYGMGV
			GWIRQPSGKGLEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSNNQAFLKITNVDTADTATYYCARIESIGTTYS
			FDYWGQGVMVTVSS
583	BDI-9E8-E7	CDR-H1	GFSLSTYGMGVG
584	BDI-9E8-E7	CDR-H2	NIWWDDDKYYNPSLKN
585	BDI-9E8-E7	CDR-H3	IESIGTTYSFDY
586	BDI-9E8-E7 VL		QFTLTQPKSVSGSLRSTITIPCERSSGDIGDSYVSW
			YQQHLGRPPINVIYADDQRPSEVSDRFSGSIDSSSN
			SASLTITNLQMDDEADYFCQSYDINIDIVFGGGTKL
			TVL
587	BDI-9E8-E7	CDR-L1	ERSSGDIGDSYVS
588	BDI-9E8-E7	CDR-L2	ADDQRPS
589	BDI-9E8-E7	CDR-L3	QSYDINIDIV
590	BFU-11A8-D6-C3 VH		EVQLQQSGPELQRPGASVKLSCKASGYTFTESYIYW
			VKQRPEQSLELIGRIDPEDGSTDYVEKFKNKATLTA
			DTSSNTAYMQLSSLTSEDTATYFCARFGARSYFYPM
			DAWGQGTSVTVSS
591	BFU-11A8-D6-C3	CDR-H1	GYTFTESYIY
592	BFU-11A8-D6-C3	CDR-H2	RIDPEDGSTDYVEKFKN
593	BFU-11A8-D6-C3	CDR-H3	FGARSYFYPMDA
594	BFU-11A8-D6-C3 VL		DTVLTQSPTLAVSPGERVSIPCRASESVSTLMHWYQ
			QKPGQQPRLLIYGASNLESGVPARFSGSGSGTDFTL
			TIDPVEADDTATYFCQQSWNDPWTFGGGTKLELK
595	BFU-11A8-D6-C3	CDR-L1	RASESVSTLMH
596	BFU-11A8-D6-C3	CDR-L2	GASNLES
597	BFU-11A8-D6-C3	CDR-L3	QQSWNDPWT
598	BFU-3E2-B9-B8 VH		EVQLQQSGPELQRPGASVKLSCKASGYTFTESYMYW
			VKQRPEQSLELIGRIDPEDGSTDYVEKFKNKATLTA
			DTSSNTAYMQLSSLTSEDSATYFCARFGARSYFYPM
			DAWGQGTSVTVSS
599	BFU-3E2-B9-B8	CDR-H1	GYTFTESYMY
600	BFU-3E2-B9-B8	CDR-H2	RIDPEDGSTDYVEKFKN
601	BFU-3E2-B9-B8	CDR-H3	FGARSYFYPMDA
602	BFU-3E2-B9-B8 VL		DTVLTQPPALAVSPGERVSISCRASESVSTLMHWYQ
			QKPGQQPRLLIYGASNLESGVPARFSGSGSGTDFTL
			TIDPVEADDTATYFCQQSWNDPWTFGGGTKLELK
603	BFU-3E2-B9-B8	CDR-L1	RASESVSTLMH
604	BFU-3E2-B9-B8	CDR-L2	GASNLES
605	BFU-3E2-B9-B8	CDR-L3	QQSWNDPWT

TABLE 20
VH and VL Amino Acid Sequences of Rat Anti-Human VEGFR II
Monoclonal Antibodies
SEQ ID		Protein	V Region
NO:	Clone	Region	12345678901234567890123456
606	BCU-3D6-C9 VH		QIQLVQSGPELKKPGESVKISCKASEYTFTDYAIHW
			VKQAPGKGLKWMGWINTYTGKPTYADDFKGRFVFSL
			EASASTANLQISNLKNEDTATYFCARDYGGYGERRD
			YFDYWGQGVMVTVSS
607	BCU-3D6-C9	CDR-H1	EYTFTDYAIH
608	BCU-3D6-C9	CDR-H2	WINTYTGKPTYADDFKG
609	BCU-3D6-C9	CDR-H3	DYGGYGERRDYFDY
610	BCU-3D6-C9 VL		DIQMTQSPASLSASLGETVTIECRVSEDIYNGLAWY
			QQKPGKSPQFLIYNANRLHTGVPSRFSGSGSGTQFS
			LKINSLQSEDVANYFCQQYYDYPLTFGSATKLEIK
611	BCU-3D6-C9	CDR-L1	RVSEDIYNGLA
612	BCU-3D6-C9	CDR-L2	NANRLHT
613	BCU-3D6-C9	CDR-L3	QQYYDYPLT
614	BCU-6B1-G6 VH		QIQLVQSGPELKKPGESVKISCKASGYTFTNYGMYW
			VKQAPGQALQFMGWINTETGQPTYADDFKGRFVFFL
			ETSASTAYLQINNLKNEDMATYFCARLGNNYGIWFA
			YWGQGTLVTVSS
615	BCU-6B1-G6	CDR-H1	GYTFTNYGMY
616	BCU-6B1-G6	CDR-H2	WINTETGQPTYADDFKG
617	BCU-6B1-G6	CDR-H3	LGNNYGIWFAY
618	BCU-6B1-G6 VL		DIQMTQSPASLSASLGETVTIECRASDDLYSTLAWY
			QQKPGDSPQLLIFDANRLAAGVPSRFSGSGSGTQYS
			LKINSLQSEDVASYFCQQYNKFPWTFGGGTKLELK
619	BCU-6B1-G6	CDR-L1	RASDDLYSTLA
620	BCU-6B1-G6	CDR-L2	DANRLAA
621	BCU-6B1-G6	CDR-L3	QQYNKFPWT
622	BCU-7A6-C2 VH		EVQLVESGGGLVQPRGSLKLSCAASGFDFNSYGMSW
			VRQAPGKGLDLVADISSKSYNYATYYADSVKDRFTI
			SRDDSQSMVYLQMDNLKTEDTALYYCTESLELGGAY
			WGQGTLVTVSS
623	BCU-7A6-C2	CDR-H1	GFDFNSYGMS
624	BCU-7A6-C2	CDR-H2	DISSKSYNYATYYADSVKD
625	BCU-7A6-C2	CDR-H3	SLELGGAY
626	BCU-7A6-C2 VL		DIQMTQSPPSLSASLGDEVTITCQASQNINKFIAWY
			QQKPGKAPRLLIRYTSTLKSGTPSRFSGSGSGRDYS
			FSISNVESEDIASYYCLQYDSLPWTFGGGTKLELK
627	BCU-7A6-C2	CDR-L1	QASQNINKFIA
628	BCU-7A6-C2	CDR-L2	YTSTLKS
629	BCU-7A6-C2	CDR-L3	LQYDSLPWT

TABLE 21
VH and VL Amino Acid Sequences of Rat Anti-Human PDGFR-B
Monoclonal Antibodies
SEQ ID		Protein	V Region
NO:	Clone	Region	12345678901234567890123456
630	BDE-3C9-G4 VH		EVQLVESGGGLVQPGRSLKLSCAASGFTFSNYGMA
			WVRQAPTQGLEWVASITNSGGNTYYRDSVKGRFTI
			SRDSAKNTQYLQMDSLRSEDTATYFCARHTPGANY
			FDYWGQGLMVTVSS
631	BDE-3C9-G4	CDR-H1	GFTFSNYGMA
632	BDE-3C9-G4	CDR-H2	SITNSGGNTYYRDSVKG
633	BDE-3C9-G4	CDR-H3	HTPGANYFDY
634	BDE-3C9-G4 VL		DIQMTQSPPSLSASLGEKVTITCQASQSIKNYIAW
			YQLKPGTAPRLLMRYTSTLESGTPSRFSGSGSGRD
			YSFSISNVESEDIASYYCVQYANLYTFGGGTKLEL
			K
635	BDE-3C9-G4	CDR-L1	QASQSIKNYIA
636	BDE-3C9-G4	CDR-L2	YTSTLES
637	BDE-3C9-G4	CDR-L3	VQYANLYT
638	BDE-4F2-D4 VH		QVQLKESGPGLMQPSQTLSLTCTVSGFSLTNYGVS
			WVRQFPGKGLEWIAAISSGGSTYYNSALKSRLSIS
			RDTSRSQVFLKMNSLLTEDTAFYFCTRVYYGSNYF
			DYWGPGVMVTVSS
639	BDE-4F2-D4	CDR-H1	GFSLTNYGVS
640	BDE-4F2-D4	CDR-H2	AISSGGSTYYNSALKS
641	BDE-4F2-D4	CDR-H3	VYYGSNYFDY
642	BDE-4F2-D4 VL		DIVMTQTPSSQAVSAGEKVTMSCKSSQSLLYGGDQ
			KNFLAWYQQKPGQSPKLLIYLASTRESGVPDRFIG
			SGSGTDFTLTISSVQAEDLADYYCQQHYGYPFTFG
			SGTKLEIK
643	BDE-4F2-D4	CDR-L1	KSSQSLLYGGDQKNFLA
644	BDE-4F2-D4	CDR-L2	LASTRES
645	BDE-4F2-D4	CDR-L3	QQHYGYPFT
646	BDE-8H6-F7 VH		EVQLVESGGGLVQPGSSLKLSCLASGFTFSNYNMY
			WIRQAPKKGLEWIALIFYDNNNKYYADSVKGRFTI
			SRDNSKNTLYLEMNSLRSEDTAMYYCLRDSGPFSY
			WGQGTLVTVSS
647	BDE-8H6-F7	CDR-H1	GFTFSNYNMY
648	BDE-8H6-F7	CDR-H2	LIFYDNNNKYYADSVKG
649	BDE-8H6-F7	CDR-H3	DSGPFSY
650	BDE-8H6-F7 VL		DIQMTQSPPSLSASLGDKVTINCQAGQNIKKYIAW
			YQQEPGKVPRLLIRYTSKLESDTPSRFSGSGSGRD
			YSFSISNVESEDIASYYCLQYDNLPWTFGGGTKLE
			LK
651	BDE-8H6-F7	CDR-L1	QAGQNIKKYIA
652	BDE-8H6-F7	CDR-L2	YTSKLES
653	BDE-8H6-F7	CDR-L3	LQYDNLPWT

Example 5

Generation of Chimeric Antibodies

The variable domains of the heavy and light chain of the rat mAbs were cloned in-frame to mutant human IgG1 (L234, 235A) heavy-chain and kappa light-chain constant regions, respectively. The activities of the resulting chimeric antibodies were confirmed in ELISA-based binding and competition assays or Biacore binding assay, and were comparable to their parental rat mAbs.

Chimeric anti-VEGF-A antibodies were characterized for binding, function and cross-reactivity in a panel of assays. Potency for all chimeric molecules was characterized in the hVEGF₁₆₅-induced cell proliferation assay (Example 1.7). Binding affinity of these molecules to hVEGF₁₆₅ was measured by Biacore analysis (Example 1.1). Select chimeric molecules were tested for the ability to block binding of hVEGF₁₆₅ to hVEGF-R2 in a competition ELISA format (Example 1.4) and a hVEGF₁₁₁ Tyr1054 phosphorylation assay (Example 1.6). Candidate molecules were then examined for potency in the HMVEC-d hVEGF₁₆₅-induced proliferation assay (Example 1.10) and species cross-reactivity in the rabVEGF₁₆₅-induced cell proliferation assay (Example 1.9). The data is summarized in Tables 22 and 23 below.

TABLE 22
Characterization of Chimeric Anti-Human VEGF-A Monoclonal Antibodies
		Receptor				huVEGF-
		Competition		huVEGF-A165	rabbitVEGF-A165	A165
		ELISA	Phospho-	Neutralization	Neutralization	Neutralization
	ELISA	huVEGF-	Tyr1054/	Potency in	Potency in	Potency
	huVEGF-	A165/	huVEGF-A111	hVEGFR2	hVEGFR2	in
Chimeric	A165	huVEGFR2	Neuterlization	Overexpressing	Overexpressing	HMVEC-d
Clones	Binding	(nM)	(nM)	Cells (nM)	Cells (nM)	cells (nM)
chBEW-1B4	NT	NT	NT	1.428	NT	NT
chBEW-1B4	NT	NT	NT	1.669	NT	NT
half-body
chBEW-1E3	NT	NT	NT	0.657	NT	NT
chBEW-1E3	NT	NT	NT	3.752	NT	NT
half-body
chBEW-5C3	NT	NT	NT	0.244	NT	NT
chBEW-5C3	NT	NT	NT	2.264	NT	NT
half-body
chBEW-6C2	NT	0.148	0.435	>10	0.58	0.031
chBEW-6C2	NT	NT	NT	>10	NT	NT
half-body
chBEW-8E6	NT	NT	NT	0.499	NT	NT
chBEW-8E6	NT	NT	NT	>10	NT	NT
half-body
chBEW-9A8	NT	0.097	0.260	0.416	0.510	0.026
chBEW-9A82	NT	NT	NT	1.584	NT	NT
half-body
chBEW-9E10	NT	NT	NT	0.448	NT	NT
chBEW-9E10	NT	NT	NT	0.598	NT	NT
half-body
chBEW-10H2	NT	NT	NT	0.912	NT	NT
chBEW-	NT	NT	NT	2.562	NT	NT
10H2-B9 half-
body
chBEW-9C2	NT	NT	NT	2.090	NT	NT
chBEW-9C2	NT	NT	NT	2.740	NT	NT
half-body
chBEW-9D2	NT	NT	NT	1.556	0.740	2.150
chBEW-9D2	NT	NT	NT	>10	NT	NT
half-body
chBEW-1B10	NT	NT	NT	0.377	NT	NT
chBEW-3A1	NT	NT	NT	0.680	NT	NT
chBEW-3A1	NT	NT	NT	>10	NT	NT
half-body
chBDB-4G8	NT	0.157	0.575	0.687	NT	0.195
chBEW-1C6	NT	NT	NT	3.595	NT	NT
half-body
NT—Not tested

TABLE 23
Biacore Binding of Rat and Rat-Human Chimera Anti-VEGF
Antibody	kon (M−1 s−1)	koff (M−1)	KD (M)
chBDB-4G8	1.7E+07	2.4E−05	1.9E−12
chBDB-4G8	1.2E+07	4.7E−05	3.8E−12
chBED-4G10-C8	1.0E+07	5.9E−03	5.9E−10
chBEW-1B4-C4	1.1E+07	1.2E−04	1.1E−11
chBEW-1B10-B9-C3	5.5E+06	5.2E−05	9.4E−12
chBEW-1E3-D6	7.2E+06	8.0E−05	1.1E−11
chBEW-3A1-D10-G9	3.5E+07	8.0E−04	2.3E−11
chBEW-5C3-E7	6.8E+06	8.2E−05	1.2E−11
chBEW-6C2	4.9E+06	4.3E−05	8.8E−12
chBEW-8E6-E4	6.2E+06	1.0E−04	1.6E−11
chBEW-9A8	8.9E+06	≦1.0E−06	≦1.1E−13
chBEW-10H2-B9	2.8E+07	3.5E−04	1.3E−11

Chimeric anti-PDGF-BB antibodies were characterized for binding, function and cross-reactivity in a panel of assays. The chimeric molecules were first tested for the ability to bind hPDGF-BB in a direct binding ELISA (Example 1.12). Binding affinity of these molecules to hPDGF-BB was then measured by Biacore analysis (Example 1.1). Functional characterization of these molecules included testing of the ability to block binding of hPDGF-BB to hPDGF-Rβ in a competition ELISA format (Example 1.13) and an hPDGFRβ Tyr751 phosphorylation assay (Example 1.14). Potency was further characterized in the hPDGF-BB-induced cell proliferation assay (Example 1.15). Candidate molecules were advanced and cross-reactivity was determined for mouse and rat/rabbit PDGF-BB in the cell-based proliferation assay (Examples 1.17-1.18). The data is summarized in Tables 24 and 25 below.

TABLE 24
Characterization of Chimeric Anti-Human PDGF-BB Monoclonal Antibodies
		Receptor	Phospho-	huPDGF-BB	ratPDGF-BB	mPDGF-BB
	ELISA	Competition	Tyr751/hPDGF-	Neutralization	Neutralization	Neutralization
	huPDGF-	ELISA	BB	Potency (nM)	Potency (nM)	Potency (nM)
Chimeric	BB	huPDGF-BB/	Neutralization	in NIH-3T3	in NIH-3T3	in NIH-3T3
Molecule	Binding	huPDGFR	(nM)	Cells	Cells B (nM)	Cells
chBDI-9E8	0.38	0.791	0.388	0.058	0.075	0.08
chBDI-9E8	NT	NT	NT	1.84	NT	NT
half-body
chBDI-5H1	0.12	1.039	1.602	0.275	0.17	NT
chBDI-5H1	NT	NT	NT	>10	NT	NT
half-body
chBDI-7H10	>10	10.1	2.476	>10	NT	NT
chBDI-5G2	NT	1.08	NT	0.181	0.118	NT
chBDI-1E1	NT	0.417	NT	>5	NT	NT
chBDI-1E1	NT	NT	NT	>10	NT	NT
half body
chBDI-8B8	NT	0.179	NT	>10	NT	NT
chBFU-3E2	NT	NT	NT	0.099	NT	NT
chBFU-3E2	NT	NT	NT	2.494	NT	NT
half-body
chBFU-11A8	NT	NT	NT	0.086	NT	NT
chBFU-11A8	NT	NT	NT	>10	NT	NT
half-body
NT—Not tested

TABLE 25
Biacore Binding Of Rat And Rat-Human Chimera Anti-PDGF
Antibody	kon (M−1 s−1)	koff (M−1)	KD (M)
BFU-11A8-D6-C3	2.1E+07	≦1.0E−06	≦4.7E−14
chBDI-5H1	≧1.0E+07	1.5E−04	≦1.5E−11
chBDI-9E8	≧1.0E+07	1.2E−04	≦1.2E−11
chBFU-3E2-B9-B8	≧1.0E+07	1.9E−04	≦1.9E−11
chBFU-11A8-D6-C3	≧1.0E+07	1.5E−04	≦1.5E−11

Chimeric anti-VEGFR2 antibodies were tested for the ability to block binding of VEGFR2 to hVEGF₁₆₅ in a competition ELISA format, as described in Example 1.22. The data is summarized in Table 26.

TABLE 26
Characterization of Chimeric Anti-Human
VEGFR II Monoclonal Antibodies
                   hVEGF165/hVEGFR2-Fc
Chimeric Molecules Competition
chBCU-6B1-G6       0.498
chBCU-7A6-C2       NT

Example 6

Humanization of Rat Monoclonal Antibodies

Below are the humanization designs for the rat monoclonal antibodies, followed by summaries of amino acid sequences and characterization of selected humanized antibodies.

Example 6.1

Humanization of PDGF-BB Antibodies

Example 6.1.1

Humanization Method

Antibody humanization is achieved by grafting CDRs of the rodent antibody onto a “similar” human framework (acceptor) and incorporating minimal number of key framework residues (back-mutation) from the rodent antibody that are selected to maintain the original CDR conformation in order to minimize the immunogenicity while retaining the optimal antigen binding.

Example 6.1.2

Human Germline Sequence Selections for Constructing CDR-Grafted, Humanized PDGF Antibodies

By applying the aforementioned method, the CDR sequences of VH and VL chains of monoclonal antibodies BDI-5H1-F6, BDI-9E8-E7, BDI-7H10-D8, BDI-1E1-D5, BDI-6A3-A9, BFU-3E2 and BFU-11A8 were grafted onto different human heavy and light chain acceptor sequences.

Example 6.1.2.1

BDI-5H1-F6

Based on the alignments with the VH and VL sequences of monoclonal antibody BDI-5H1-F6 of the present invention, the following known human sequences are selected:

1. IGHV2-70*01 and IGHJ6*01 for constructing heavy chain acceptor sequences

2. IGHV2-70*04 and IGHJ6*01 as alternative acceptor sequence for constructing heavy chain

3. IGHV3-66*01 and IGHJ1*01 as alternative acceptor sequence for constructing heavy chain

4. IGLV6-57*01 and IGJL2*01 for constructing light chain acceptor sequences

5. IGKV3-20*01 and IGJK4*01 as alternative acceptor sequences for constructing light chain

6. IGKV4-1*01 and IGJK4*01 as alternative acceptor sequences for constructing light chain

7. IGKV1-39*01 and IGJK1*01 as alternative acceptor sequences for constructing light chain

By grafting the corresponding VH and VL CDRs of BDI-5H1-F6 into said acceptor sequences, the CDR-grafted, humanized, and modified VH and VL sequences were prepared.

Example 6.1.2.2

BDI-9E8-E7

Based on the alignments with the VH and VL sequences of monoclonal antibody BDI-9E8-E7 of the present invention, the following known human sequences are selected:

1. IGHV2-70*01 and IGHJ3*01 for constructing heavy chain acceptor sequences

2. IGHV2-70*04 and IGHJ6*01 as alternative acceptor sequence for constructing heavy chain

3. IGHV3-66*01 and IGHJ1*01 as alternative acceptor sequence for constructing heavy chain

4. IGLV6-57*01 and IGJL2*01 for constructing light chain acceptor sequences

5. IGKV3-20*01 and IGJK4*01 as alternative acceptor for constructing light chain sequences

6. IGKV4-1*01 and IGJK4*01 as alternative acceptor sequences for constructing light chain

7. IGKV1-39*01 and IGJK1*01 as alternative acceptor sequences for constructing light chain

By grafting the corresponding VH and VL CDRs of BDI-9E8-E7 into said acceptor sequences, the CDR-grafted, humanized, and modified VH and VL sequences were prepared.

Example 6.1.2.3

BDI-7H10-D8

Based on the alignments with the VH and VL sequences of monoclonal antibody BDI-7H10-D8 of the present invention, the following known human sequences are selected:

1. IGHV1-69*01 and IGHJ3*01 for constructing heavy chain acceptor sequences

2. IGKV2-29*02 and IGK2*01 for constructing light chain acceptor sequences

By grafting the corresponding VH and VL CDRs of BDI-7H10-D8 into said acceptor sequences, the CDR-grafted, humanized, and modified VH and VL sequences were prepared.

Example 6.1.2.4

BDI-1E1-D5

Based on the alignments with the VH and VL sequences of monoclonal antibody BDI-1E1-D5 of the present invention the following known human sequences are selected:

1. IGHV1-69*06 and IGHJ6*01 for constructing heavy chain acceptor sequences

2. IGKV1D-13*01 and IGKJ2*01 for constructing light chain acceptor sequences

3. IGKV3-11*01 and IGKJ2*01 as alternative acceptor sequence for constructing light chain

By grafting the corresponding VH and VL CDRs of BDI-1E1-D5 into said acceptor sequences, the CDR-grafted, humanized, and modified VH and VL sequences were prepared.

Example 6.1.2.5

BDI-6A3-A9

Based on the alignments with the VH and VL sequences of monoclonal antibody BDI-6A3-A9 of the present invention the following known human sequences are selected:

1. IGHV3-7*01 and IGHJ6*01 for constructing heavy chain acceptor sequences

2. IGHV1-3*01 and IGHJ6*01 as alternative acceptor sequence for constructing heavy chain

3. IGLV6-57*01 and IGJL2*01 for constructing light chain acceptor sequences

By grafting the corresponding VH and VL CDRs of BDI-6A3-A9 into said acceptor sequences, the CDR-grafted, humanized, and modified VH and VL sequences were prepared.

Example 6.1.2.6

BFU-3E2

Based on the alignments with the VH and VL sequences of monoclonal antibody BFU-3E2 of the present invention, the following known human sequences are selected:

1. IGHV1-69*01 and IGHJ6*01 for constructing heavy chain acceptor sequences

2. IGKV3-11*01 and IGKJ4*01 for constructing light chain acceptor sequences

3. IGKV1-13*01 and IGKJ4*01 as alternative acceptor sequence for constructing light chain

By grafting the corresponding VH and VL CDRs of BFU-3E2 into said acceptor sequences, the CDR-grafted, humanized, and modified VH and VL sequences were prepared.

Example 6.1.2.7

BFU-11A8

Based on the alignments with the VH and VL sequences of monoclonal antibody BFU-11A8 of the present invention, the following known human sequences are selected:

1. IGHV1-69*01 and IGHJ6*01 for constructing heavy chain acceptor sequences

2. IGKV3-11*01 and IGKJ4*01 for constructing light chain acceptor sequences

3. IGKV1-5*01 and IGKJ4*01 as alternative acceptor sequence for constructing light chain

By grafting the corresponding VH and VL CDRs of BFU-11A8 into said acceptor sequences, the CDR-grafted, humanized, and modified VH and VL sequences were prepared.

Example 6.1.3

Introducing Potential Framework Back-Mutations in CDR-Grafted Antibodies

To generate humanized antibody with potential framework back-mutations, the mutations were identified and introduced into the CDR-grafted antibody sequences by de novo synthesis of the variable domain, or mutagenic oligonucleotide primers and polymerase chain reactions, or by methods well known in the art. Different combinations of back mutations and other mutations are constructed for each of the CDR-grafts as follows. Residue numbers for these mutations are based on the Kabat numbering system.

BDI-5H1-F6

When IGHV2-70*01 and IGHJ6*01 selected as BDI-5H1-F6 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: Q1→E, A44→G, K75→N, V78→A, M82→I with or without N65→T (CDR change).

When IGHV2-70*04 and IGHJ6*01 selected as BDI-5H1-F6 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: Q→1E, K5→R, K75→N, N76→S, V78→A and M82→I.

When IGHV3-66*01 and IGHJ1*01 selected as BDI-5H1-F6 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: A24→F, V37→I, V48→L, S49→A, F67→L, R71→K, N73→T, T77→Q, L78→A, and M82→I.

When IGLV6-57*01 and IGJL2*01 selected as BDI-5H1-F6 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: N1→Q, S22→P, S43→P, T464→N, G57→E, P59→S, and Y87→F.

When IGKV3-20*01 and IGJK4*01 selected as BDI-5H1-F6 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: I2→F, A43→P, L46→N, L47→V, I58→V, G66→I, G68→S, T69→N, F71→A, Y87→F and with or without two residues insertion D66a, S66b and deletion of T10.

When IGKV4-1*01 and IGJK4*01 selected as BDI-5H1-F6 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: I2→F, M4→L, L46→N, L47→V, T69→N, D70→S, F71→A, Y87→F.

When IGKV1-39*01 and IGJK1*01 selected as BDI-5H1-F6 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: I2→F, M4→L, L46→N, L47→V, T69→N, D70→S, F71→A, and Y87→F.

BDI-9E8-E7

When IGHV2-70*01 and IGHJ6*01 selected as BDI-9E8-E7 heavy chain acceptor sequences, one or more of following residues could be back-mutated as follows: Q1→E, A44→G, V78→A M82→I with or without N65→T (CDR change).

When IGHV2-70*04 and IGHJ6*01 selected as BDI-9E8-E7 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: Q1→E, K5→R, V78→A, and M82→I.

When IGHV3-66*01 and IGHJ1*01 selected as BDI-9E8-E7 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: A24→F, V37→I, V48→L, S49→A, F67→L, R71→K, N73→T, T77→Q, L78→A, and M82→I.

When IGLV6-57*01 and IGJL2*01 selected as BDI-9E8-E7 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: S43→P, T46→N and Y87→F.

When IGKV3-20*01 and IGJK4*01 selected as BDI-9E8-E7 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: I2→F, A43→P, L46→N, L47→V, I58→V, G66→I, T69→N, F71→A, Y87→F and W/WO two residues insertion (D66a, S66b) and deletion of T10.

When IGKV4-1*01 and IGJK4*01 selected as BDI-9E8-E7 light chain acceptor sequences, one or more of the following residues could be back mutated as follows: I2→F, M4→L, L46→N, L47→V, T69→N, D70→S, F71→A, T72→S, and Y87→F.

When IGKV1-39*01 and IGJK1*01 selected as BDI-9E8-E7 light chain acceptor sequences, one or more of the following residues could be back mutated as follows: I2→F, M4→L, L46→N, L47→V, T69→N, D70→S, F71→A, and T72→S.

BDI-7H10-D8

When IGHV1-69*01 and IGHJ3*01 selected as BDI-7H10-D8 heavy chain acceptor sequences, one or more of following residues could be back-mutated as follows: Q1→E, M48→I, V67→A, I69→L, E73→T, S76→N, with or without CDR changes Y27→G and T30→S.

When IGKV2-29*02 and IGKJ2*01 selected as BDI-7H10-D8 light chain acceptor sequences, one or more of following residues could be back-mutated as follows: I2→V and M4→L.

BDI-1E1-D5

When IGHV1-69*06 and IGHJ6*01 selected as BDI-1E1-D5 heavy chain acceptor sequence, one or more of the following residues could be back-mutated as follows: Q1→E M48→I, V67→A, I69→L and S76→N.

When IGKV1D-13*01 and IGKJ2*01 selected as BDI-1E1-D5 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: V58→I and F71→Y.

When IGKV3-11*01 and IGKJ2*01 selected as BDI-1E1-D5 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: F71→Y and V85→T.

BDI-6A3-A9

When IGHV3-7*01 and IGHJ6*01 selected as BDI-6A3-A9 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: S28→T, R60→V, N76→S.

When IGHV1-3*01 and IGHJ6*01 selected as BDI-6A3-A9 heavy chains acceptor sequences, one or more of following residues could be back-mutated as follows: Q1→E, R44→G, M48→V, G49→A, V67→F, T73→N, A78→L and M80→L.

When IGLV6-57*01 and IGJL2*01 selected as BDI-6A3-A9 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: S43→P, T46→N, Y49→F and Y87→F.

BFU-3E2

When IGHV1-69*01 and IGHJ6*01 selected as BFU-3E2 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: R38-->K, G44-->S, W47-->L, M48-->I, R66-->K, V67-->A, 169-->L, S76-->N, Y91-->F.

When IGKV3-11*01 and IGKJ4*01 selected as BFU-3E2 light chain acceptor sequences, one or more of the following could be back-mutated as follows: I2-->T, A43-->Q, 158-->V, Y87-->F.

When IGKV1-13*01 and IGKJ4*01 selected as BFU-3E2 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: I2-->T, T22-->S, A43-->Q, K45-->R, Y87-->F.

BFU-11A8

When IGHV1-69*01 and IGHJ6*01 selected as BFU-11A8 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: R38-->K, W47-->L, M48-->I, R66-->K, V67-->A, 169-->L, S76-->N, and Y91-->F.

When IGKV3-11*01 and IGKJ4*01 selected as BFU-11A8 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: I2-->T, S22-->P, A43-->Q, 158-->V, Y87-->F.

When IGKV1-5*01 and IGKJ4*01 selected as BFU-11A8 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: I2-->T, M4-->L, T22-->P, A43-->Q, Y87-->F.

Example 6.1.4

Generation of Humanized Antibodies to PDGF Containing Framework Back-Mutations in CDR-Grafted Antibodies

The following humanized variable regions of the murine monoclonal PDGF antibodies were cloned into IgG expression vectors for functional characterization.

Example 6.1.4.1

BDI-5H1-F6

TABLE 1.4.1
Sequences of Humanized BDI-5H1-F6 Variable Regions
		Sequence
SEQ ID		12345678901234567890123
NO:	Protein region	4567890
3882	hBDI-5H1-F6VH.1z	QVTLRESGPALVKPTQTLTLTCT
		FSGFSLS
		TFGMGVGWIRQPPGKALEWLANI
		WWDDDKY
		YNPSLKNRLTISKDTSKNQVVLT
		MTNMDPV
		DTATYYCARISTGISSYYVMDAW
		GQGTTVT
		VSS
3883	hBDI-5H1-F6VH.1	EVTLRESGPALVKPTQTLTLTCT
		FSGFSLS
		TFGMGVGWIRQPPGKALEWLANI
		WWDDDKY
		YNPSLKNRLTISKDTSKNQVVLT
		MTNMDPV
		DTATYYCARISTGISSYYVMDAW
		GQGTTVT
		VSS
3884	hBDI-5H1-F6VH.1a	EVTLRESGPALVKPTQTLTLTCT
		FSGFSLS
		TFGMGVGWIRQPPGKGLEWLANI
		WWDDDKY
		YNPSLKNRLTISKDTSNNQAVLT
		ITNMDPV
		DTATYYCARISTGISSYYVMDAW
		GQGTTVT
		VSS
3885	hBDI-5H1-F6VH.1b	EVTLRESGPALVKPTQTLTLTCT
		FSGFSLS
		TFGMGVGWIRQPPGKGLEWLANI
		WWDDDKY
		YNPSLKNRLTISKDTSKNQVVLT
		ITNMDPV
		DTATYYCARISTGISSYYVMDAW
		GQGTTVT
		VSS
3886	hBDI-5H1-F6VH.1c	EVTLRESGPALVKPTQTLTLTCT
		FSGFSLS
		TFGMGVGWIRQPPGKGLEWLANI
		WWDDDKY
		YNPSLKTRLTISKDTSKNQVVLT
		ITNMDPV
		DTATYYCARISTGISSYYVMDAW
		GQGTTVT
		VSS
3887	hBDI-5H1-F6VH.2z	QVTLKESGPALVKPTQTLTLTCT
		FSGFSLS
		TFGMGVGWIRQPPGKALEWLANI
		WWDDDKY
		YNPSLKNRLTISKDTSKNQVVLT
		MTNMDPV
		DTATYYCARISTGISSYYVMDAW
		GQGTTVT
		VSS
3888	hBDI-5H1-F6VH.2	EVTLKESGPALVKPTQTLTLTCT
		FSGFSLS
		TFGMGVGWIRQPPGKALEWLANI
		WWDDDKY
		YNPSLKNRLTISKDTSKNQVVLT
		MTNMDPV
		DTATYYCARISTGISSYYVMDAW
		GQGTTVT
		VSS
3889	hBDI-5H1-F6VH.2a	EVTLKESGPALVKPTQTLTLTCT
		FSGFSLS
		TFGMGVGWIRQPPGKGLEWLANI
		WWDDDKY
		YNPSLKNRLTISKDTSNSQAVLT
		ITNMDPV
		DTATYYCARISTGISSYYVMDAW
		GQGTTVT
		VSS
3890	hBDI-5H1-F6VH.2b	EVTLKESGPALVKPTQTLTLTCT
		FSGFSLS
		TFGMGVGWIRQPPGKALEWLANI
		WWDDDKY
		YNPSLKNRLTISKDTSKNQAVLT
		ITNMDPV
		DTATYYCARISTGISSYYVMDAW
		GQGTTVT
		VSS
3891	hBDI-5H1-F6VH.2c	EVTLRESGPALVKPTQTLTLTCT
		FSGFSLS
		TFGMGVGWIRQPPGKALEWLANI
		WWDDDKY
		YNPSLKNRLTISKDTSKNQAVLT
		ITNMDPV
		DTATYYCARISTGISSYYVMDAW
		GQGTTVT
		VSS
3892	hBDI-5H1-F6VH.v7	EVQLVESGGGLVQPGGSLRLSCA
		FSGFSLS
		TFGMGVGWIRQAPGKGLEWLANI
		WWDDDKY
		YNPSLKNRLTISKDTSKNQAYLQ
		INSLRAE
		DTAVYYCARISTGISSYYVMDAW
		GQGTLVT
		VSS
3893	hBDI-5H1-F6VL.1	NFMLTQPHSVSESPGKTVTISCE
		RSSGDIG
		DTYVSWYQQRPGSSPTTVIYGND
		QRPSGVP
		DRFSGSIDSSSNSASLTISGLKT
		EDEADYY
		CQSYDSDIDIVFGGGTKLTVL
3894	hBDI-5H1-F6VL.1a	NFMLTQPHSVSESPGKTVTISCE
		RSSGDIG
		DTYVSWYQQRPGSPPTNVIYGND
		QRPSGVP
		DRFSGSIDSSSNSASLTISGLKT
		EDEADYF
		CQSYDSDIDIVFGGGTKLTVL
3895	hBDI-5H1-F6VL.1b	QFMLTQPHSVSESPGKTVTIPCE
		RSSGDIG
		DTYVSWYQQRPGSPPTNVIYGND
		QRPSEVS
		DRFSGSIDSSSNSASLTISGLKT
		EDEADYF
		CQSYDSDIDIVFGGGTKLTVL
3896	hBDI-5H1-F6VL.1c	QFMLTQPHSVSESPGKTVTISCE
		RSSGDIG
		DTYVSWYQQRPGSSPTTVIYGND
		QRPSGVP
		DRFSGSIDSSSNSASLTISGLKT
		EDEADYF
		CQSYDSDIDIVFGGGTKLTVL
3897	hBDI-5H1-F6VL.2	EIVLTQSPGTLSLSPGERATLSC
		ERSSGDI
		GDTYVSWYQQKPGQAPRLLIYGN
		DQRPSGI
		PDRFSGSGSGTDFTLTISRLEPE
		DFAVYYC
		QSYDSDIDIVFGGGTKVEIK
3898	hBDI-5H1-F6L.2a	EFVLTQSPGLSLSPGERATLSCE
		RSSGDIG
		DTYVSWYQQKPGQPPRNVIYGND
		QRPSGVP
		DRFSGSIDSSSNDATLTISRLEP
		EDFAVYF
		CQSYDSDIDIVFGGGTKVEIK
3899	hBDI-5H1-F6L.2b	EFVLTQSPGTLSLSPGERATLSC
		ERSSGDI
		GDTYVSWYQQKPGQAPRLVIYGN
		DQRPSGI
		PDRFSGSGSGTDFTLTISRLEPE
		DFAVYYC
		QSYDSDIDIVFGGGTKVEIK
3900	hBDI-5H1-F6L.2c	EFVLTQSPGTLSLSPGERATLSC
		ERSSGDI
		GDTYVSWYQQKPGQPPRNVIYGN
		DQRPSGV
		PDRFSGSGSGTDFTLTISRLEPE
		DFAVYFC
		QSYDSDIDIVFGGGTKVEIK
3901	hBDI-5H1-F6VL.v6	DFVLTQSPDSLAVSLGERATINC
		ERSSGDI
		GDTYVSWYQQKPGQPPKNVIYGN
		DQRPSGV
		PDRFSGSGSGNSATLTISSLQAE
		DVAVYFC
		QSYDSDIDIVFGGGTKVEIK
3902	hBDI-5H1-F6VL.v7	DFQLTQSPSSLSASVGDRVTITC
		ERSSGDI
		GDTYVSWYQQKPGKAPKNVIYGN
		DQRPSGV
		PSRFSGSGSGNSATLTISSLQPE
		DFATYFC
		QSYDSDIDIVFGQGTKVEIK

• • hBDI-5H1-F6VH.1z is a CDR-grafted, humanized BDI-5H1-F6 VH containing IGHV2-70*01 and IGHJ6 framework sequences.
  • hBDI-5H1-F6VH.1 is based on .1z with a Q1E change to prevent pyroglutamate formation.
  • hBDI-5H1-F6VH.1a is a humanized design based on .1 and contains four proposed framework back-mutations (A44G, K75N, V78A and M82I).
  • hBDI-5H1-F6VH.1b is an intermediate design between .1 and .1a and only has two proposed framework back-mutations (A44G and M82I).
  • hBDI-5H1-F6VH.1c is based on .1b with additional one CDR germlining change N65T to improve identity to human germline sequence.
  • hBDI-5H1-F6VH.2z is a CDR-grafted, humanized BDI-5H1-F6 VH containing IGHV2-70*04 and IGHJ6 framework sequences.
  • hBDI-5H1-F6VH.2 is based on .2z with Q1E change to prevent pyroglutamate formation.
  • hBDI-5H1-F6VH.2a (hBDI-5H1-F6VH.1d) is based on .2 and contains four proposed framework back-mutations (K75N, N76S, V78A and M82I).
  • hBDI-5H1-F6VH.2b (hBDI-5H1-F6VH.v2) is an intermediate design between .2 and .2a and only has two proposed framework back-mutations (V78A and M82I).
  • hBDI-5H1-F6VH.2c (hBDI-5H1-F6VH.v6) is based on .2 and contains three proposed framework back-mutations (K5R, V78A, M82I).
  • hBDI-5H1-F6VH.v7 is a humanized BDI-5H1-F6 VH containing IGHV3-66*01 and IGHJ1 framework sequences with ten proposed framework back-mutations (A24F, V37I, V48L, S49A, F67L, R71K, N73T, T77Q, L78A, and M82I).
  • hBDI-5H1-F6VL.1 is a CDR-grafted humanized BDI-5H1-F6 VL containing IGLV6-57*01 and IGJL2*01 framework sequences.
  • hBDI-5H1-F6VL.1a is a humanized design based on .1 with 3 proposed framework back-mutations (S43P, T46N and Y87F).
  • hBDI-5H1-F6VL.1b is a humanized design based on .1 with 7 proposed framework back-mutations (N1Q, S22P, S43P, T46N, G57E, P59S, Y87F).
  • hBDI-5H1-F6VL.1c is an intermediate design between .1 and .1b with 2 back-mutations (N1Q and Y87F).
  • hBDI-5H1-F6VL.2 is a CDR-grafted humanized BDI-5H1-F6 VL containing IGKV3-20*01 and IGJK4*01 framework sequences.
  • hBDI-5H1-F6VL.2a is a humanized design based on .2 with 10 proposed framework back-mutations (I2F, A43P, L46N, L47V, I58V, G66I, G68S, T69N, F71A, Y87F) and one residue deletion (T10) and two residues insertion (D66a and S66b).
  • hBDI-5H1-F6VL.2b is based on .2a only with 2 proposed framework back-mutations (12F, L47V) and without residues deletion (T10) and insertion (D66a, S66b).
  • hBDI-5H1-F6VL.2c is a humanized design on .2 with 6 proposed framework back-mutations

(I2F, A43P, L46N, L47V, I58V, Y87F) and without residues deletion (T10) and insertion (D66a, S66b).

• • hBDI-5H1-F6VL.v6 is a humanized BDI-5H1-F6 VL containing IGKV4-1*01 and IGJK4*01 framework sequences with eight proposed framework back-mutations (I2F, M4L, L46N, L47V, T69N, D70S, F71A, Y87F).
  • hBDI-5H1-F6VL.v7 is a humanized BDI-5H1-F6 VL containing IGKV1-39*01 and

IGJK1*01 framework sequences with eight proposed framework back-mutations (I2F, M4L, L46N, L47V, T69N, D70S, F71A, and Y87F).

Example 6.1.4.2

BDI-9E8-E7

TABLE 1.4.2
Sequences of Humanized BDI-9E8-E7 Variable Regions
SEQ	Protein	Sequence
ID NO:	region	123456789012345678901234567890
3903	hBDI-9E8-	QVTLRESGPALVKPTQTLTLTCTFSGFSLS
	E7VH.1z	TYGMGVGWIRQPPGKALEWLANIWWDDDKY
		YNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTV
		SS
3904	hBDI-9E8-	EVTLRESGPALVKPTQTLTLTCTFSGFSLS
	E7VH.1	TYGMGVGWIRQPPGKALEWLANIWWDDDKY
		YNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTV
		SS
3905	hBDI-9E8-	EVTLRESGPALVKPTQTLTLTCTFSGFSLS
	E7VH.1a	TYGMGVGWIRQPPGKGLEWLANIWWDDDKY
		YNPSLKNRLTISKDTSKNQAVLTITNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTV
		SS
3906	hBDI-9E8-	EVTLRESGPALVKPTQTLTLTCTFSGFSLS
	E7VH.1b	TYGMGVGWIRQPPGKGLEWLANIWWDDDKY
		YNPSLKNRLTISKDTSKNQVVLTITNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTV
		SS
3907	hBDI-9E8-	EVTLRESGPALVKPTQTLTLTCTFSGFSLS
	E7VH.1c	TYGMGVGWIRQPPGKGLEWLANIWWDDDKY
		YNPSLKTRLTISKDTSKNQVVLTITNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTV
		SS
3908	hBDI-9E8-	EVTLRESGPALVKPTQTLTLTCTFSGFSLS
	E7VH.v6	TYGMGVGWIRQPPGKALEWLANIWWDDDKY
		YNPSLKNRLTISKDTSKNQAVLTITNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTTVTV
		SS
3909	hBDI-9E8-	EVQLVESGGGLVQPGGSLRLSCAFSGFSLS
	E7VH.v7	TYGMGVGWIRQAPGKGLEWLANIWWDDDKY
		YNPSLKNRLTISKDTSKNQAYLQINSLRAE
		DTAVYYCARIESIGTTYSFDYWGQGTLVTV
		SS
3910	hBDI-9E8-	NFMLTQPHSVSESPGKTVTISCERSSGDIG
	E7VL.1	DSYVSWYQQRPGSSPTTVIYADDQRPSGVP
		DRFSGSIDSSSNSASLTISGLKTEDEADYY
		CQSYDINIDIVFGGGTKLTVL
3911	hBDI-9E8-	NFMLTQPHSVSESPGKTVTISCERSSGDIG
	E7VL.1a	DSYVSWYQQRPGSPPTNVIYADDQRPSGVP
		DRFSGSIDSSSNSASLTISGLKTEDEADYF
		CQSYDINIDIVFGGGTKLTVL
3912	hBDI-9E8-	EIVLTQSPGTLSLSPGERATLSCERSSGDI
	E7VL.2	GDSYVSWYQQKPGQAPRLLIYADDQRPSGI
		PDRFSGSGSGTDFTLTISRLEPEDFAVYYC
		QSYDINIDIVFGGGTKVEIK
3913	hBDI-9E8-	EFVLTQSPGLSLSPGERATLSCERSSGDIG
	E7VL.2a	DSYVSWYQQKPGQPPRNVIYADDQRPSGVP
		DRFSGSIDSSGNDATLTISRLEPEDFAVYF
		CQSYDINIDIVFGGGTKVEIK
3914	hBDI-9E8-	EFVLTQSPGTLSLSPGERATLSCERSSGDI
	E7VL.2b	GDSYVSWYQQKPGQAPRLVIYADDQRPSGI
		PDRFSGSGSGTDFTLTISRLEPEDFAVYYC
		QSYDINIDIVFGGGTKVEIK
3915	hBDI-9E8-	DFVLTQSPDSLAVSLGERATINCERSSGDI
	E7VL.v6	GDSYVSWYQQKPGQPPKNVIYADDQRPSGV
		PDRFSGSGSGNSASLTISSLQAEDVAVYFC
		QSYDINIDIVFGGGTKVEIK
3916	hBDI-9E8-	DFQLTQSPSSLSASVGDRVTITCERSSGDI
	E7VL.v7	GDSYVSWYQQKPGKAPKNVIYADDQRPSGV
		PSRFSGSGSGNSASLTISSLQPEDFATYYC
		QSYDINIDIVFGQGTKVEIK

• • hBDI-9E8-E7VH.1z is a CDR-grafted, humanized BDI-9E8-E7 VH containing IGHV2-70*01 and IGHJ3*01 framework sequences.
  • hBDI-9E8-E7VH.1 is based on .1z with a Q1E change to prevent pyroglutamate formation.
  • hBDI-9E8-E7VH.1a is a humanized design based on .1 and contains three proposed framework back-mutations (A44G, V78A and M82I).
  • hBDI-9E8-E7VH.1b is an intermediate design between .1 and .1a and only has two proposed framework back-mutations (A44G and M82I).
  • hBDI-9E8-E7VH.1c is based on .1b with additional one CDR germlining change N65T to improve identity to human germline sequence.
  • hBDI-9E8-E7VH.v6 is a humanized BDI-9E8-E7 VH containing IGHV2-70*04 and IGHJ6 framework sequences with four proposed framework back-mutations (Q1E, K5R, V78A, and M82I).
  • hBDI-9E8-E7VH.v7 is a humanized BDI-9E8-E7 VH containing IGHV3-66*01 and IGHJ1 framework sequences with ten proposed framework back-mutations (A24F, V37I, V48L, S49A, F67L, R71K, N73T, T77Q, L78A, and M82I).
  • hBDI-9E8-E7VL.1 is a CDR-grafted humanized BDI-9E8-E7 VL containing IGLV6-57*01 and IGJL2*01 framework sequences.
  • hBDI-9E8-E7VL.1a is a humanized design based on .1 with three proposed framework back-mutations (S43P, T46N and Y87F).
  • hBDI-9E8-E7VL.2 is a CDR-grafted humanized BDI-9E8-E7 VL containing IGKV3-20*01 and IGJK4*01 framework sequences.
  • hBDI-9E8-E7VL.2a is a humanized design based on .2 with 9 proposed framework back-mutations (I2F, A43P, L46N, L47V, I58V, G66I, T69N, F71A, Y87F) and one residue deletion (T10) and two residues insertion (D66a and S66b).
  • hBDI-9E8-E7VL.2b is based on .2a only with 2 proposed framework back-mutations (I2F, L47V) and without residues deletion (T10) and insertion (D66a, S66b).
  • hBDI-9E8-E7VL.v6 is a humanized BDI-9E8-E7 VL containing IGKV4-1*01 and

IGJK4*01 framework sequences with nine proposed framework back-mutations: (I2F, M4L, L46N, L47V, T69N, D70S, F71A, T72S, and Y87F).

• • hBDI-9E8-E7VL.v7 is a humanized BDI-9E8-E7 VL containing IGKV1-39*01 and

IGJK1*01 framework sequences with eight proposed framework back-mutations: I2F, M4L, L46N, L47V, T69N, D70S, F71A, and T72S.

Example 6.1.4.3

BDI-7H10-D8

TABLE 1.4.3
Sequences of Humanized BDI-7H10-D8 Variable
Regions
SEQ ID	Protein	Sequence
NO:	region	123456789012345678901234567890
3917	hBDI-7H10-	QVQLVQSGAEVKKPGSSVKVSCKASGYTFT
	D8VH.1z	DYAMHWVRQAPGQGLEWMGTIIPLIDTTSY
		NQKFKGRVTITADESTSTAYMELSSLRSED
		TAVYYCARDWDNNWGYFDYWGQGTMVTVSS
3918	hBDI-7H10-	EVQLVQSGAEVKKPGSSVKVSCKASGYTFT
	D8VH.1	DYAMHWVRQAPGQGLEWMGTIIPLIDTTSY
		NQKFKGPVTITADESTSTAYMELSSLRSED
		TAVYYCARDWDNNWGYFDYWGQGTMVTVSS
3919	hBDI-7H10-	EVQLVQSGAEVKKPGSSVKVSCKASGYTFT
	D8VH.1a	DYAMHWVRQAPGQGLEWIGTIIPLIDTTSY
		NQKFKGRATLTADTSTNTAYMELSSLRSED
		TAVYYCARDWDNNWGYFDYWGQGTMVTVSS
3920	hBDI-7H10-	EVQLVQSGAEVKKPGSSVKVSCKASGYTFT
	D8VH.1b	DYAMHWVRQAPGQGLEWIGTIIPLIDTTSY
		NQKFKGPVTITADESTSTAYMELSSLRSED
		TAVYYCARDWDNNWGYFDYWGQGTMVTVSS
3921	hBDI-7H10-	EVQLVQSGAEVKKPGSSVKVSCKASGGTFS
	D8VH.1c	DYAMHWVRQAPGQGLEWIGTIIPLIDTTSY
		NQKFKGRVTITADESTSTAYMELSSLRSED
		TAVYYCARDWDNNWGYFDYWGQGTMVTVSS
3922	hBDI-7H10-	DIVMTQTPLSLSVTPGQPASISCRSSQSLE
	D8VL.1	YSDGYTYLEWYLQKPGQSPQLLIYGVSNRF
		SGVPDPFSGSGSGTDFTLKISPVEAEDVGV
		YYCFQATHDPLTFGQGTKLEIK
3923	hBDI-7H10-	DVVLTQTPLSLSVTPGQPASISCRSSQSLE
	D8VL.1a	YSDGYTYLEWYLQKPGQSPQLLIYGVSNRF
		SGVPDPFSGSGSGTDFTLKISPVEAEDVGV
		YYCFQATHDPLTFGQGTKLEIK
3924	hBDI-7H10-	DVVMTQTPLSLSVTPGQPASISCRSSQSLE
	D8VL.1b	YSDGYTYLEWYLQKPGQSPQLLIYGVSNRF
		SGVPDPFSGSGSGTDFTLKISPVEAEDVGV
		YYCFQATHDPLTFGQGTKLEIK

• • hBDI-7H10-D8VH.1z is a CDR-grafted, humanized BDI-7H10-D8 VH containing IGHV1-69*01 and IGHJ3 framework sequences.
  • hBDI-7H10-D8VH.1 is based on .1z with a Q1E change to prevent pyroglutamate formation.
  • hBDI-7H10-D8VH.1a is a humanized design based on .1 and contains five proposed framework back-mutations (M48I, V67A, I69L, E73T and S76N).
  • hBDI-7H10-D8VH.1b is an intermediate design between .1 and .1a and only has one proposed framework back-mutation M48I.
  • hBDI-7H10-D8VH.1c is based on .1b with two additional CDR germlining changes Y27G and T30S.
  • hBDI-7H10-D8VL.1 is a CDR-grafted humanized BDI-7H10-D8 VL containing IGKV2-29*02 and IGKJ2 framework sequences.
  • hBDI-7H10-D8VL.1a is a humanized design based on .1 with 2 proposed framework back-mutations 12V and M4L.
  • hBDI-7H10-D8VL.1b is an intermediate design between .1 and .1a with only one proposed framework back-mutation 12V.

Example 6.1.4.4

BDI-1E1-D5

TABLE 1.4.4
Sequences of Humanized BDI-1E1-D5 Variable Regions
SEQ ID	Protein	Sequence
NO:	region	123456789012345678901234567890
3925	hBDI-1E1-	QVQLVQSGAEVKKPGSSVKVSCKASGYTFT
	D5VH.1z	DYVMHWVRQAPGQGLEWMGTIIPLIDTTSY
		NQKFKGRVTITADKSTSTAYMELSSLRSED
		TAVYYCARTSPYYYSSYDVMDAWGQGTTVT
		VSS
3926	hBDI-1E1-	EVQLVQSGAEVKKPGSSVKVSCKASGYTFT
	D5VH.1	DYVMHWVRQAPGQGLEWMGTIIPLIDTTSY
		NQKFKGRVTITADKSTSTAYMELSSLRSED
		TAVYYCARTSPYYYSSYDVMDAWGQGTTVT
		VSS
3927	hBDI-1E1-	EVQLVQSGAEVKKPGSSVKVSCKASGYTFT
	D5VH.1a	DYVMHWVRQAPGQGLEWIGTIIPLIDTTSY
		NQKFKGRATLTADKSTNTAYMELSSLRSED
		TAVYYCARTSPYYYSSYDVMDAWGQGTTVT
		VSS
3928	hBDI-1E1-	EVQLVQSGAEVKKPGSSVKVSCKASGYTFT
	D5VH.1b	DYVMHWVRQAPGQGLEWIGTIIPLIDTTSY
		NQKFKGRVTITADKSTSTAYMELSSLRSED
		TAVYYCARTSPYYYSSYDVMDAWGQGTTVT
		VSS
3929	hBDI-1E1-	AIQLTQSPSSLSASVGDRVTITCKGSQNIN
	D5VL.1	NYLAWYQQKPGKAPKLLIYKTNNLQTGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYYCYQ
		YDNGYTFGQGTKLEIK
3930	hBDI-	AIQLTQSPSSLSASVGDRVTITCKGSQNIN
	1E1-D5VL.1a	NYLAWYQQKPGKAPKLLIYKTNNLQTGIPS
		RFSGSGSGTDYTLTISSLQPEDFATYYCYQ
		YDNGYTFGQGTKLEIK
3931	hBDI-1E1-	EIVLTQSPATLSLSPGERATLSCKGSQNIN
	D5VL.2	NYLAWYQQKPGQAPRLLIYKTNNLQTGIPA
		RFSGSGSGTDFTLTISSLEPEDFAVYYCYQ
		YDNGYTFGQGTKLEIK
3932	hBDI-	EIVLTQSPATLSLSPGERATLSCKGSQNIN
	1E1-D5VL.2a	NYLAWYQQKPGQAPRLLIYKTNNLQTGIPA
		RFSGSGSGTDYTLTISSLEPEDFATYYCYQ
		YDNGYTFGQGTKLEIK

• • hBDI-1E1-D5VH.1z is a CDR-grafted, humanized BDI-1E1-D5 VH containing IGHV1-69*06 and JH6 framework sequences.
  • hBDI-1E1-D5VH.1 is based on .1z with a Q1E change to prevent pyroglutamate formation.
  • hBDI-1E1-D5VH.1a is a humanized design based on .1 and contains four proposed framework back-mutations (M48I, V67A, I69L and S76N).
  • hBDI-1E1-D5VH.1b is an intermediate design between .1 and .1a and only has one back-mutations M48I. This design eliminates Carter residue back-mutations.
  • hBDI-1E1-D5VL.1 is a CDR-grafted humanized BDI-1E1-D5 VL containing IGKV1D-13*01 and Jk2 framework sequences.
  • hBDI-1E1-D5VL.1a is a humanized design based on .1 with 2 proposed framework back-mutations (V58I and F71Y).
  • hBDI-1E1-D5VL.2 is a CDR-grafted humanized BDI-1E1-D5 VL containing IGKV3-11*01 and Jk2 framework sequences.
  • hBDI-1E1-D5VL.2a is a humanized design based on .2 with 2 proposed framework back-mutations (F71Y and V85T).

Example 6.1.4.5

BDI-6A3-A9

TABLE 1.4.5
Sequences of Humanized BDI-6A3-A9 Variable Regions
SEQ	Protein	Sequence
ID NO:	region	123456789012345678901234567890
3933	BDI-6A3-	EVQLVESGGGLVQPGGSLRLSCAASGFSFS
	A9VH.1	DSAMAWVRQAPGKGLEWVATIIYDGSGTYY
		RDSVKGRFTISRDNAKNSLYLQMNSLRAED
		TAVYYCARLGFNYGNYGYYVMDAWGQGTTV
		TVSS
3934	hBDI-6A3-	EVQLVESGGGLVQPGGSLRLSCAASGFSFS
	A9VH.1a	DSAMAWVRQAPGKGLEWVATIIYDGSGTYY
		RDSVKGRFTISRDNAKSSLYLQMNSLRAED
		TAVYYCARLGFNYGNYGYYVMDAWGQGTTV
		TVSS
3935	hBDI-6A3-	EVQLVESGGGLVQPGGSLRLSCAASGFTFS
	A9VH.1b	DSAMAWVRQAPGKGLEWVATIIYDGSGTYY
		VDSVKGRFTISRDNAKNSLYLQMNSLRAED
		TAVYYCARLGFNYGNYGYYVMDAWGQGTTV
		TVSS
3936	hBDI-6A3-	QVQLVQSGAEVKKPGASVKVSCKASGFSFS
	A9VH.2z	DSAMAWVRQAPGQRLEWMGTIIYDGSGTYY
		RDSVKGRVTITRDTSASTAYMELSSLRSED
		TAVYYCARLGFNYGNYGYYVMDAWGQGTTV
		TVSS
3937	hBDI-6A3-	EVQLVQSGAEVKKPGASVKVSCKASGFSFS
	A9VH.2	DSAMAWVRQAPGQRLEWMGTIIYDGSGTYY
		RDSVKGRVTITRDTSASTAYMELSSLRSED
		TAVYYCARLGFNYGNYGYYVMDAWGQGTTV
		TVSS
3938	hBDI-6A3-	EVQLVQSGAEVKKPGASVKVSCKASGFSFS
	A9VH.2a	DSAMAWVRQAPGQGLEWVATIIYDGSGTYY
		RDSVKGRFTITRDNSASTLYLELSSLRSED
		TAVYYCARLGFNYGNYGYYVMDAWGQGTTV
		TVSS
3939	hBDI-6A3-	EVQLVQSGAEVKKPGASVKVSCKASGFSFS
	A9VH.2b	DSAMAWVRQAPGQGLEWVGTIIYDGSGTYY
		RDSVKGRVTITRDTSASTAYLELSSLRSED
		TAVYYCARLGFNYGNYGYYVMDAWGQGTTV
		TVSS
3940	hBDI-6A3-	NFMLTQPHSVSESPGKTVTISCERSSGDIG
	A9VL.1	DSYVSWYQQRPGSSPTTVIYADDQRPSGVP
		DRFSGSIDSSSNSASLTISGLKTEDEADYY
		CQSYDSNIDINIVFGGGTKLTVL
3941	hBDI-6A3-	NFMLTQPHSVSESPGKTVTISCERSSGDIG
	A9VL.1a	DSYVSWYQQRPGSPPTNVIFADDQRPSGVP
		DRFSGSIDSSSNSASLTISGLKTEDEADYF
		CQSYDSNIDINIVFGGGTKLTVL
3942	hBDI-6A3-	NFMLTQPHSVSESPGKTVTISCERSSGDIG
	A9VL.1b	DSYVSWYQQRPGSSPTTVIFADDQRPSGVP
		DRFSGSIDSSSNSASLTISGLKTEDEADYY
		CQSYDSNIDINIVFGGGTKLTVL

• • hBDI-6A3-A9VH.1 is a CDR-grafted, humanized BDI-6A3-A9 VH containing IGHV3-7*01 and JH6 framework sequences.
  • hBDI-6A3-A9VH.1a is a humanized design based on .1 and contains one proposed framework back-mutation N76S.
  • hBDI-6A3-A9VH.1b is based on .1 with additional two CDR germlining changes S28T and R60V to improve identity to human germline sequence.
  • hBDI-6A3-A9VH.2z is a CDR-grafted, humanized BDI-6A3-A9 VH containing IGHV1-3*01 and JH6 framework sequences.
  • hBDI-6A3-A9VH.2 is based on .2z with a Q1E change to prevent pyroglutamate formation.
  • hBDI-6A3-A9VH.2a is a humanized design based on .2 and contains seven proposed framework back-mutations R44G, M48V, G49A, V67F, T73N, A78L and M80L.
  • hBDI-6A3-A9VH.2b is an intermediate design between .2 and .2a with only three proposed framework back-mutations R44G, M48V and M80L.
  • hBDI-6A3-A9VL.1 is a CDR-grafted humanized BDI-6A3-A9 VL containing IGLV6-57*01 and JL2 framework sequences.
  • hBDI-6A3-A9VL.1a is a humanized design based on .1 with 4 proposed framework back-mutations (S43P, T46N, Y49F and Y87F).
  • hBDI-6A3-A9VL.1b is an intermediate design between .1 and .1a with only 1 proposed framework back-mutation Y49F.

Example 6.1.4.6

BFU-3E2

TABLE 1.4.6
Sequences of Humanized BFU-3E2 Variable Regions
SEQ ID	Protein	Sequence
NO:	region	123456789012345678901234567890
3943	hBFU-3E2VH.1z	QVQLVQSGAEVKKPGSSVKVSCKASGYTFT
		ESYMYWVRQAPGQGLEWMGRIDPEDGSTDY
		VEKFKNRVTITADESTSTAYMELSSLRSED
		TAVYYCARFGARSYFYPMDAWGQGTTVTVS
		S
3944	hBFU-3E2VH.1	EVQLVQSGAEVKKPGSSVKVSCKASGYTFT
		ESYMYWVRQAPGQGLEWMGRIDPEDGSTDY
		VEKFKNRVTITADESTSTAYMELSSLRSED
		TAVYYCARFGARSYFYPMDAWGQGTTVTVS
		S
3945	hBFU-3E2VH.1a	EVQLVQSGAEVKKPGSSVKVSCKASGYTFT
		ESYMYWVKQAPGQGLELIGRIDPEDGSTDY
		VEKFKNRVTITADESTSTAYMELSSLRSED
		TAVYYCARFGARSYFYPMDAWGQGTTVTVS
		S
3946	hBFU-3E2VH.1b	EVQLVQSGAEVKKPGSSVKVSCKASGYTFT
		ESYMYWVRQAPGQGLELIGRIDPEDGSTDY
		VEKFKNRVTLTADESTSTAYMELSSLRSED
		TAVYYCARFGARSYFYPMDAWGQGTTVTVS
		S
3947	hBFU-3E2VH.1c	EVQLVQSGAEVKKPGSSVKVSCKASGYTFT
		ESYMYWVRQAPGQGLELIGRIDPEDGSTDY
		VEKFKNRVTITADESTSTAYMELSSLRSED
		TAVYYCARFGARSYFYPMDAWGQGTTVTVS
		S
3948	hBFU-3E2VH.1d	EVQLVQSGAEVKKPGSSVKVSCKASGYTFT
		ESYMYWVKQAPGQSLELIGRIDPEDGSTDY
		VEKFKNKATLTADESTNTAYMELSSLRSED
		TAVYFCARFGARSYFYPMDAWGQGTTVTVS
		S
3949	hBFU-3E2VL.1	EIVLTQSPATLSLSPGERATLSCRASESVS
		TLMHWYQQKPGQAPRLLIYGASNLESGIPA
		RFSGSGSGTDFTLTISSLEPEDFAVYYCQQ
		SWNDPWTFGGGTKVEIK
3950	hBFU-3E2VL.1a	ETVLTQSPATLSLSPGERATLSCRASESVS
		TLMHWYQQKPGQQPRLLIYGASNLESGVPA
		RFSGSGSGTDFTLTISSLEPEDFAVYFCQQ
		SWNDPWTFGGGTKVEIK
3951	hBFU-3E2VL.1b	ETVLTQSPATLSLSPGERATLSCRASESVS
		TLMHWYQQKPGQAPRLLIYGASNLESGVPA
		RFSGSGSGTDFTLTISSLEPEDFAVYFCQQ
		SWNDPWTFGGGTKVEIK
3952	hBFU-3E2VL.1c	ETVLTQSPATLSLSPGERATLSCRASESVS
		TLMHWYQQKPGQAPRLLIYGASNLESGIPA
		RFSGSGSGTDFTLTISSLEPEDFAVYYCQQ
		SWNDPWTFGGGTKVEIK
3953	hBFU-3E2VL.2	AIQLTQSPSSLSASVGDRVTITCRASESVS
		TLMHWYQQKPGKAPKLLIYGASNLESGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYYCQQ
		SWNDPWTFGGGTKVEIK
3954	hBFU-3E2VL.2a	ATQLTQSPSSLSASVGDRVTISCRASESVS
		TLMHWYQQKPGKQPRLLIYGASNLESGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYFCQQ
		SWNDPWTFGGGTKVEIK
3955	hBFU-3E2VL.2b	ATQLTQSPSSLSASVGDRVTITCRASESVS
		TLMHWYQQKPGKAPRLLIYGASNLESGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYFCQQ
		SWNDPWTFGGGTKVEIK
3956	hBFU-3E2VL.2c	ATQLTQSPSSLSASVGDRVTITCRASESVS
		TLMHWYQQKPGKAPRLLIYGASNLESGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYYCQQ
		SWNDPWTFGGGTKVEIK

• • hBFU-3E2VH.1z is a CDR-grafted, humanized BFU-3E2 VH containing IGHV1-69*01 and IGHJ6*01 framework sequences.
  • hBFU-3E2VH.1 is based on .1z with a Q1E change to prevent pyroglutamate formation.
  • hBFU-3E2VH.1a is a humanized design based on .1 and contains 7 proposed framework back-mutations (R38K, W47L, M48I, R66K, V67A, 169L, Y91F).
  • hBFU-3E2VH.1b is an intermediate design between .1 and .1a and contains 3 proposed framework back-mutations (W47L, M48I, I69L).
  • hBFU-3E2VH.1c is an intermediate design between .1 and .1a and contains 2 proposed framework back-mutations (W47L, M48I.)
  • hBFU-3E2VH.1d is a humanized design based on .1 and contains 9 proposed framework back-mutations (R38K, G44S, W47L, M48I, R66K, V67A, I69L, S76N, Y91F)
  • hBFU-3E2VL.1 is a CDR-grafted, humanized BFU-3E2 VL containing IGKV3-11*01 and

IGKJ4*01 framework sequences.

• • hBFU-3E2VL.1a is a humanized design based on .1 and contains 4 proposed framework back-mutations (I2T, A43Q, I58V, Y87F).
  • hBFU-3E2VL.1b is an intermediate design between .1 and .1a. It contains 3 proposed framework back-mutations (I2T, I58V, Y87F).
  • hBFU-3E2VL.1c is a design based on .1b and contains 1 proposed framework back-mutations: I2T.
  • hBFU-3E2VL.2 is a CDR-grafted, humanized BFU-3E2 VL containing IGKV1-13*01 and

IGKJ4*01 framework sequences.

• • hBFU-3E2VL.2a is a humanized design based on .2 and contains 5 proposed framework back-mutations (I2T, T22S, A43Q, K45R, Y87F).
  • hBFU-3E2VL.2b is an intermediate design between .2 and 2a. It contains 3 proposed framework back-mutations (I2T, K45R, Y87F).
  • hBFU-3E2VL.2c is a design based on .2b and contains 2 proposed framework back-mutations (I2T, K45R).

Example 6.1.4.7

BFU-11A8

TABLE 1.4.7
Sequences of Humanized BFU-11A8 Variable Regions
SEQ
ID	Protein	Sequence
NO:1	region	1234567891234567891234567890
3957	hBFU-11A8VH.1z	QVQLVQSGAEVKKPGSSVKVSCKASGYTFT
		ESYIYWVRQAPGQGLEWMGRIDPEDGSTDY
		VEKFKNRVTITADESTSTAYMELSSLRSED
		TAVYYCARFGARSYFYPMDAWGQGTTVTVS
		S
3958	hBFU-11A8VH.1	EVQLVQSGAEVKKPGSSVKVSCKASGYTFT
		ESYIYWVRQAPGQGLEWMGRIDPEDGSTDY
		VEKFKNRVTITADESTSTAYMELSSLRSED
		TAVYYCARFGARSYFYPMDAWGQGTTVTVS
		S
3959	hBFU-11A8VH.1a	EVQLVQSGAEVKKPGSSVKVSCKASGYTFT
		ESYIYWVKQAPGQGLELIGRIDPEDGSTDY
		VEKFKNKATLTADESTNTAYMELSSLRSED
		TAVYFCARFGARSYFYPMDAWGQGTTVTVS
		S
3960	hBFU-11A8VH.1b	EVQLVQSGAEVKKPGSSVKVSCKASGYTFT
		ESYIYWVRQAPGQGLELIGRIDPEDGSTDY
		VEKFKNRVTLTADESTNTAYMELSSLRSED
		TAVYYCARFGARSYFYPMDAWGQGTTVTVS
		S
3961	hBFU-11A8VH.1c	EVQLVQSGAEVKKPGSSVKVSCKASGYTFT
		ESYIYWVRQAPGQGLELIGRIDPEDGSTDY
		VEKFKNRVTITADESTSTAYMELSSLRSED
		TAVYYCARFGARSYFYPMDAWGQGTTVTVS
		S
3962	hBFU-11A8VL.1	EIVLTQSPATLSLSPGERATLSCRASESVS
		TLMHWYQQKPGQAPRLLIYGASNLESGIPA
		RFSGSGSGTDFTLTISSLEPEDFAVYYCQQ
		SWNDPWTFGGGTKVEIK
3963	hBFU-11A8VL.1a	ETVLTQSPATLSLSPGERATLPCRASESVS
		TLMHWYQQKPGQQPRLLIYGASNLESGVPA
		RFSGSGSGTDFTLTISSLEPEDFAVYFCQQ
		SWNDPWTFGGGTKVEIK
3964	hBFU-11A8VL.1b	ETVLTQSPATLSLSPGERATLSCRASESVS
		TLMHWYQQKPGQAPRLLIYGASNLESGVPA
		RFSGSGSGTDFTLTISSLEPEDFAVYFCQQ
		SWNDPWTFGGGTKVEIK
3965	hBFU-11A8VL.1c	ETVLTQSPATLSLSPGERATLSCRASESVS
		TLMHWYQQKPGQAPRLLIYGASNLESGIPA
		RFSGSGSGTDFTLTISSLEPEDFAVYYCQQ
		SWNDPWTFGGGTKVEIK
3966	hBFU-11A8VL.2	DIQMTQSPSTLSASVGDRVTITCRASESVS
		TLMHWYQQKPGKAPKLLIYGASNLESGVPS
		RFSGSGSGTEFTLTISSLQPDDFATYYCQQ
		SWNDPWTFGGGTKVEIK
3967	hBFU-11A8VL.2a	DTQLTQSPSTLSASVGDRVTIPCRASESVS
		TLMHWYQQKPGKQPKLLIYGASNLESGVPS
		RFSGSGSGTEFTLTISSLQPDDFATYFCQQ
		SWNDPWTFGGGTKVEIK
3968	hBFU-11A8VL.2b	DTQLTQSPSTLSASVGDRVTITCRASESVS
		TLMHWYQQKPGKAPKLLIYGASNLESGVPS
		RFSGSGSGTEFTLTISSLQPDDFATYFCQQ
		SWNDPWTFGGGTKVEIK
3969	hBFU-11A8VL.2c	DTQMTQSPSTLSASVGDRVTITCRASESVS
		TLMHWYQQKPGKAPKLLIYGASNLESGVPS
		RFSGSGSGTEFTLTISSLQPDDFATYYCQQ
		SWNDPWTFGGGTKVEIK

• • hBFU-11A8VH.1z is a CDR-grafted, humanized BFU-11A8 VH containing IGHV1-69*01 and IGHJ6*01 framework sequences.
  • hBFU-11A8VH.1 is based on .1z with a Q1E change to prevent pyroglutamate formation.
  • hBFU-11A8VH.1a is a humanized design based on .1 and contains 8 proposed framework back-mutations: R38K, W47L, M48I, R66K, V67A, 169L, S76N, Y91F.
  • hBFU-11A8VH.1b is an intermediate design between .1 and .1a and contains 4 proposed framework back-mutations: W47L, M48I, I69L, S76N.
  • hBFU-11A8VH.1c is a design based on .1b and contains 2 proposed framework back-mutations: W47L, M48I.
  • hBFU-11A8VL.1 is a CDR-grafted, humanized BFU-11A8 VL containing IGKV3-11*01 and

IGKJ4*01 framework sequences.

• • hBFU-11A8VL.1a is a humanized design based on .1 and contains 5 proposed framework back-mutations: I2T, S22P, A43Q, 158V, Y87F.
  • hBFU-11A8VL.1b is an intermediate design between .1 and .1a. It contains 3 proposed framework back-mutations: I2T, 158V, Y87F.
  • hBFU-11A8VL.1c is a design based on .1b and contains 1 proposed framework back-mutations: I2T.
  • hBFU-11A8VL.2 is a CDR-grafted, humanized BFU-11A8 VL containing IGKV1-5*01 and

IGKJ4*01 framework sequences.

• • hBFU-11A8VL.2a is a humanized design based on .2 and contains 5 proposed framework back-mutations: I2T, M4L, T22P, A43Q, Y87F.
  • hBFU-11A8VL.2b is an intermediate design between .2 and 2a. It contains 3 proposed framework back-mutations: I2T, M4L, Y87F.
  • hBFU-11A8VL.2c is a design based on .2b and contains 1 proposed framework back-mutations: I2T.

Example 6.2

Humanization of VEGF Antibodies

Example 6.2.1

Humanization Method

Antibody humanization is achieved by grafting CDRs of the rodent antibody onto a “similar” human framework (acceptor) and incorporating minimal number of key framework residues (back-mutation) from the rodent antibody that are selected to maintain the original CDR conformation in order to minimize the immunogenicity while retaining the optimal antigen binding.

Example 6.2.2

Human Germline Sequence Selections for Constructing CDR-Grafted, Humanized VEGF Antibodies

By applying the aforementioned method, the CDR sequences of VH and VL chains of monoclonal antibodies BDB-4G8-D4, BEW-9A8-E2, BEW-6C2-C8, BEW-9D2-E8, BEW-9E3-B9, BEW-5C3, BEW-9E10, BEW-1B10, and BEW-1E3 were grafted onto different human heavy and light chain acceptor sequences.

Example 6.2.2.1

BDB-4G8-D4

Based on the alignments with the VH and VL sequences of monoclonal antibody BDB-4G8-D4 of the present invention, the following known human sequences are selected:

1. IGHV7-4-1*02 and IGHJ3*01 for constructing heavy chain acceptor sequences

2. IGHV1-18*01 and IGHJ3*01 as backup acceptor sequences for constructing heavy chain

3. IGHV5-51*01 and IGHJ3*01 as backup acceptor sequences for constructing heavy chain

4. IGHV3-66*01 and IGHJ1*01 as backup acceptor sequences for constructing heavy chain

5. IGKV1D-13*01 and IGKJ2*01 for constructing light chain acceptor sequences

6. IGKV3-11*01 and IGKJ2*01 as alternative acceptor sequences for constructing light chain

7. IGKV3-15*01 and IGKJ5*01 as alternative acceptor sequences for constructing light chain

8. IGKV3-15*01 and IGKJ1*01 as alternative acceptor sequences for constructing light chain

9. IGKV1-39*01 and IGKJ1*01 as alternative acceptor sequences for constructing light chain.

By grafting the corresponding VH and VL CDRs of BDB-4G8-D4 into said acceptor sequences, the CDR-grafted, humanized, and modified VH and VL sequences were prepared.

Example 6.2.2.2

BEW-9A8-E2

Based on the alignments with the VH and VL sequences of monoclonal antibody BEW-9A8-E2 of the present invention the following known human sequences are selected:

1. IGHV7-81*01 and IGHJ1*01 for constructing heavy chain acceptor sequences

2. IGHV1-18*01 and IGHJ1*01 as alternative acceptor sequence for constructing heavy chain

3. IGHV7-4-1*01 and IGHJ1*01 as alternative acceptor sequence for constructing heavy chain

4. IGKV6-21*01 and IGKJ2*01 for constructing light chain acceptor sequences

5. IGKV1-39*01 and IGKJ2*01 as alternative acceptor sequence for constructing light chain

6. IGKV3-11*01 and IGKJ2*01 as alternative acceptor sequence for constructing light chain

7. IGKV1-13*01 and IGKJ2*01 as alternative acceptor sequence for constructing light chain

By grafting the corresponding VH and VL CDRs of BEW-9A8-E2 into said acceptor sequences, the CDR-grafted, humanized, and modified VH and VL sequences were prepared.

Example 6.2.2.3

BEW-6C2-C8

Based on the alignments with the VH and VL sequences of monoclonal antibody BEW-6C2-C8 of the present invention the following known human sequences are selected:

1. IGHV3-7*01 and IGHJ3*01 for constructing heavy chain acceptor sequences

2. IGKV3-11*01 and IGKJ2*01 for constructing light chain acceptor sequences

3. IGKV1-39*01 and IGKJ2*01 as alternative acceptor sequence for constructing light chain

By grafting the corresponding VH and VL CDRs of BEW-6C2-C8 into said acceptor sequences, the CDR-grafted, humanized, and modified VH and VL sequences were prepared.

Example 6.2.2.4

BEW-9D2-E8

Based on the alignments with the VH and VL sequences of monoclonal antibody BEW-9D2-E8 of the present invention the following known human sequences are selected:

1. IGHV7-81*01 and IGHJ4*01 for constructing heavy chain acceptor sequences

2. IGHV1-18*01 and IGHJ4*01 as alternative acceptor sequence for constructing heavy chain

3. IGKV3-11*01 and IGKJ2*01 for constructing light chain acceptor sequences

4. IGKV1-39*01 and IGKJ2*01 as alternative acceptor sequence for constructing light chain

By grafting the corresponding VH and VL CDRs of BEW-9D2-E8 into said acceptor sequences, the CDR-grafted, humanized, and modified VH and VL sequences were prepared.

Example 6.2.2.5

BEW-9E3-B9

Based on the alignments with the VH and VL sequences of monoclonal antibody BEW-9E3-B9 of the present invention the following known human sequences are selected:

1. IGHV7-81*01 and IGHJ4*01 for constructing heavy chain acceptor sequences

2. IGHV1-18*01 and IGHJ4*01 as alternative acceptor sequence for constructing heavy chain

3. IGKV3-11*01 and IGKJ2*01 for constructing light chain acceptor sequences

4. IGKV1-39*01 and IGKJ2*01 as alternative acceptor sequence for constructing light chain

By grafting the corresponding VH and VL CDRs of BEW-9E3-B9 into said acceptor sequences, the CDR-grafted, humanized, and modified VH and VL sequences were prepared.

Example 6.2.2.6

BEW-5C3

Based on the alignments with the VH and VL sequences of monoclonal antibody BEW-5C3 of the present invention, the following known human sequences are selected:

1. IGHV7-4-1*01 and IGHJ1*01 for constructing heavy chain acceptor sequences

2. IGHV1-69*06 and IGHJ1*01 as alternative acceptor for constructing heavy chain

3. IGKV3-11*01 and IGKJ4*01 for constructing light chain acceptor sequences

4. IGKV1-13*01 and IGKJ4*01 as alternative acceptor for constructing light chain

By grafting the corresponding VH and VL CDRs of BEW-5C3 into said acceptor sequences, the CDR-grafted, humanized, and modified VH and VL sequences were prepared.

Example 6.2.2.7

BEW-9E10

Based on the alignments with the VH and VL sequences of monoclonal antibody BEW-9E10 of the present invention, the following known human sequences are selected:

1. IGHV7-4-1*01 and IGHJ1*01 for constructing heavy chain acceptor sequences

2. IGHV1-69*06 and IGHJ1*01 as alternative acceptor for constructing heavy chain

3. IGKV1-27*01 and IGKJ2*01 for constructing light chain acceptor sequences

By grafting the corresponding VH and VL CDRs of BEW-9E10 into said acceptor sequences, the CDR-grafted, humanized, and modified VH and VL sequences were prepared.

Example 6.2.2.8

BEW-1B10

Based on the alignments with the VH and VL sequences of monoclonal antibody BEW-1B10 of the present invention, the following known human sequences are selected:

1. IGHV3-7*01 and IGHJ6*01 for constructing heavy chain acceptor sequences

2. IGKV1-39*01 and IGKJ4*01 for constructing light chain acceptor sequences

By grafting the corresponding VH and VL CDRs of BEW-1B10 into said acceptor sequences, the CDR-grafted, humanized, and modified VH and VL sequences were prepared.

Example 6.2.2.9

BEW-1E3

Based on the alignments with the VH and VL sequences of monoclonal antibody BEW-1E3 of the present invention, the following known human sequences are selected:

1. IGHV7-4-1*01(0-1) and IGHJ1*01 for constructing heavy chain acceptor sequences

2. IGHV1-18*01 and IGHJ1*01 as alternative acceptor for constructing heavy chain

3. IGKV3-11*01 and IGKJ2*01 for constructing light chain acceptor sequences

4. IGKV1-13*01 and IGKJ2*01 as alternative acceptor for constructing light chain

By grafting the corresponding VH and VL CDRs of BEW-1E3 into said acceptor sequences, the CDR-grafted, humanized, and modified VH and VL sequences were prepared.

Example 6.2.3

Introducing Potential Framework Back-Mutations in CDR-Grafted Antibodies

To generate humanized antibody with potential framework back-mutations, the mutations were identified and introduced into the CDR-grafted antibody sequences by de novo synthesis of the variable domain, or mutagenic oligonucleotide primers and polymerase chain reactions, or by methods well known in the art. Different combinations of back mutations and other mutations are constructed for each of the CDR-grafts as follows. Residue numbers for these mutations are based on the Kabat numbering system.

Example 6.2.3.1

BDB-4G8-D4

When IGHV7-4-1*02 and IGHJ3*01 selected as BDB-4G8-D4 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: Q1→, V2→I, W47→Y, and Y91→F.

When IGHV1-18*01 and IGHJ3*01 selected as BDB-4G8-D4 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: Q1→E, V2→I, W47→Y, V67→F, M69→F, T71→L and Y91→F.

When IGHV5-51*01 and IGHJ3*01 selected as BDB-4G8-D4 heavy chain acceptor sequences, one or more following residues could be back-mutated as follows: V2→I, A9→T, G24→A, R38→K, W47→Y, Q66→R, V67→F, I69→F, A71→L, I75→F, S76→N, Y79→F and Y91→F.

When IGHV3-66*01 and IGHJ1*01 selected as BDB-4G8-D4 heavy chain acceptor sequences, one or more following residues could be back-mutated as follows: V2→I, E6→Q, L11→V, R38→K, W47→Y, V48→M, S49→G, I69→F, R71→L, N73→T, N76→S, L78→A, M82→L and Y91→F.

When IGKV1D-13*01 and IGKJ2*01 selected as BDB-4G8-D4 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: I2→T, A43→Q and Y87→F with or without one residue deletion (S10).

When IGKV3-11*01 and IGKJ2*01 selected as BDB-4G8-D4 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: E1→D, I2→T, I58→V, and Y87→F.

When IGKV3-15*01 and IGKJ5*01 or IGKJ5*01 selected as BDB-4G8-D4 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: E1→D, I2→T, M4→L, A9→S, L13→A, L21→I, R45→K, I58→V, A60→S, G66→R, E70→D, E79→Q and Y87→F.

When IGKV1-39*01 and IGKJ1*01 selected as BDB-4G8-D4 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: I2→T, M4→L, T22→S, and Y87→F.

Example 6.2.3.2

BEW-9A8-E2

When IGHV7-81*01 and IGHJ1*01 selected as BEW-9A8-E2 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: Q1→E V2→I, P38→K, W47→Y, M71→L, Y90→F and Y91→F with or without CDR change T28→S.

When IGHV1-18*01 and IGHJ1*01 selected as BEW-9A8-E2 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: Q1→E, V2→I, R38→K, W47→Y, V67→F, M69→F, T71→L, Y90→F and Y91→F.

When IGHV7-4-1*01 and IGHJ1*01 selected as BEW-9A8-E2 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: Q1→E, V2→I, R38→K, W47→Y, Y90→F, Y91→F.

When IGKV6-21*01 and IGKJ2*01 selected as BEW-9A8-E2 light chain accepter sequences, one or more of the following residues could be back-mutated as follows: I2→T, S434Q, K49→H and Y87→F. Additional mutations include the following: F10 deletion.

When IGKV1-39*01 and IGKJ2*01 selected as BEW-9A8-E2 light chain accepter sequences, one or more of the following residues could be back-mutated as follows: I2→T, M4→L, A43→Q, Y49→H and Y87→F. Additional mutations include the following: S10 deletion.

When IGKV3-11*01 and IGKJ2*01 selected as BEW-9A8-E2 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: I2→T, Y49→H, I58→V, V85→T, and Y87→F.

When IGKV1-13*01 and IGKJ2*01 selected as BEW-9A8-E2 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: I2→T, T22→S, Y49→H, Y87→F.

Example 6.2.3.3

BEW-6C2-C8

When IGHV3-7*01 and IGHJ3*01 selected as BEW-6C2-C8 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: V37→I, V48→M and R94→A.

When IGKV3-11*01 and IGKJ2*01 selected as BEW-6C2-C8 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: F71→Y and Y87→F.

When IGKV1-39*01 and IGKJ2*01 selected as BEW-6C2-C8 light chain acceptor sequence, one or more of the following residues could be back-mutated as follows: M4→L, V58→I, F71→Y and Y87→F.

Example 6.2.3.4

BEW-9D2-E8

When IGHV7-81*01 and IGHJ4*01 selected as BEW-9D2-E8 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: Q1→E, V2→I, P38→K, Q39→L, W47→Y, M48→L, M71→L and Y91→F with or without CDR change T28→S.

When IGHV1-18*01 and IGHJ4*01 selected as BEW-9D2-E8 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: Q1→E, V2→I, R38→K, Q39→L, W47→Y, M48→L, V67→F, M69→F, T71→L, M80→L and Y91→F.

When IGKV3-11*01 and IGKJ2*01 selected as BEW-9D2-E8 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: I2→T, A43→Q, I58→V and Y87→F. Additional mutations include the following: T10 deletion.

When IGKV1-39*01 and IGKJ2*01 selected as BEW-9D2-E8 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: I2→T, M4→L, A43→Q and Y87→F. Additional mutations include the following: T10 deletion.

Example 6.2.3.5

BEW-9E3-B9

When IGHV7-81*01 and IGHJ4*01 selected as BEW-9E3-B9 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: Q1E, V2→I, W47→Y, M71→L and Y91→F with or without CDR change T28→S.

When IGHV1-18*01 and IGHJ4*01 selected as BEW-9E3-B9 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: Q1→E, V2→I, W47→Y, V67→F, M69→F, T71→L and Y91→F.

When IGKV3-11*01 and IGKJ2*01 selected as BEW-9E3-B9 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: I2→T, A43→Q, I58→V and Y87→F. Additional mutations include the following: S10 deletion.

When IGKV1-39*01 and IGKJ2*01 selected as BEW-9E3-B9 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: I2→T, M4→L, A43→Q and Y87→F. Additional mutations include the following: S10 deletion.

Example 6.2.3.6

BEW-5C3

When IGHV7-4-1*01 and IGHJ1*01 selected as BEW-5C3 heavy chain accepter sequences, one or more of the following residues could be back-mutated as follows: V2→I, R38→K, W47→Y, Y90→F, Y91→F.

When IGHV1-69*01 and IGHJ1*01 selected as BEW-5C3 heavy chain accepter sequences, one or more of the following residues could be back-mutated as follows: V67→F, I69→F, A71→L. Additional mutations include the following: V2→I, R38→K, W47→Y, T68→V, M80→L, Y90→F, Y91→F.

When IGKV3-11*01 and IGKJ4*01 selected as BEW-5C3 light chain accepter sequences, one or more of the following residues could be back-mutated as follows: E1→D, I2→T, Y36→F, Y87→F. Additional mutations include the following: A43→Q, I58→V, C34→S (CDR change).

When IGKV1-13*01 and IGKJ4*01 selected as BEW-5C3 light chain accepter sequences, one or more of the following residues could be back-mutated as follows: A1→D, I2→T, T22→S, Y36→F, A43→Q, Y87→F with CDR change C34→S.

Example 6.2.3.7

BEW-9E10

When IGHV7-4-1*01 and IGHJ1*01 selected as BEW-9E10 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: V2→I, R38→K, W47→Y, Y91→F.

When IGHV1-69*06 and IGHJ1*01 selected as BEW-9E10 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: V67→F, I69→F. Additional mutations include the following: V2→I, R38→K, W47→Y, Y91→F.

When IGKV1-27*01 and IGKJ2*01 selected as BEW-9E10 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: Q3→R, V43→S, F71→Y, Y87→F. Additional mutations include the following: T22→E, T72→S.

Example 6.2.3.8

BEW-1B10

When IGHV3-7*01 and IGHJ6*01 selected as BEW-1B10 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: V37→F, I69→V. Additional mutations include the following: N76→S, S77→T.

When IGKV1-39*01 and IGKJ4*01 selected as BEW-1B10 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: A43→S, F71→Y. Additional mutations include the following: L47→V.

Example 6.2.3.9

BEW-1E3

When IGHV7-4-1*01 and IGHJ1*01 selected as BEW-1E3 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: V2→I, R38→K, W47→Y, Y91→F.

When IGHV1-18*01 and IGHJ1*01 selected as BEW-1E3 heavy chain acceptor sequences, one or more of the following residues could be back-mutated as follows: V67→F, M69→F, T71→L. Additional mutations include the following: V2→I, R38→K, W47→Y, Y91→F.

When IGKV3-11*01 and IGKJ2*01 selected as BEW-1E3 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: I58→V, Y87→F. Additional mutations include the following: I2→T, A43→Q.

When IGKV1-13*01 and IGKJ2*01 selected as BEW-1E3 light chain acceptor sequences, one or more of the following residues could be back-mutated as follows: Y87→F. Additional mutations include the following: I2→T, T22→S, A43→Q.

Example 6.2.4

Generation of Humanized Antibodies to VEGF Containing Framework Back-Mutations in CDR-Grafted Antibodies

The following humanized variable regions of the murine monoclonal VEGF antibodies were cloned into IgG expression vectors for functional characterization.

Example 6.2.4.1

BDB-4G8-D4

TABLE 2.4.1
Sequences of Humanized BDB-4G8-D4 Variable Regions
SEQ
ID		Sequence
NO:	Protein region	123456789012345678901234567890
654	hBDB-4G8-D4VH.1z	QVQLVQSGSELKKPGASVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEWMGWINTETGKPTY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYIFYFDYWGQGTMVT
		VSS
655	hBDB-4G8-D4VH.1	EVQLVQSGSELKKPGASVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEWMGWINTETGKPTY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYIFYFDYWGQGTMVT
		VSS
656	hBDB-4G8-D4VH.1a	EIQLVQSGSELKKPGASVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEYMGWINTETGKPTY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYFCARTNYYYRSYIFYFDYWGQGTMVT
		VSS
657	hBDB-4G8-D4VH.1b	EVQLVQSGSELKKPGASVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEYMGWINTETGKPTY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYIFYFDYWGQGTMVT
		VSS
658	hBDB-4G8-D4VH.2z	QVQLVQSGAEVKKPGASVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEWMGWINTETGKPTY
		ADDFKGRVTMTTDTSTSTAYMELRSLRSDD
		TAVYYCARTNYYYRSYIFYFDYWGQGTMVT
		VSS
659	hBDB-4G8-D4VH.2	EVQLVQSGAEVKKPGASVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEWMGWINTETGKPTY
		ADDFKGRVTMTTDTSTSTAYMELRSLRSDD
		TAVYYCARTNYYYRSYIFYFDYWGQGTMVT
		VSS
660	hBDB-4G8-D4VH.2a	EIQLVQSGAEVKKPGASVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEYMGWINTETGKPTY
		ADDFKGRFTFTLDTSTSTAYMELRSLRSDD
		TAVYFCARTNYYYRSYIFYFDYWGQGTMVT
		VSS
661	hBDB-4G8-D4VH.2b	EVQLVQSGAEVKKPGASVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEYMGWINTETGKPTY
		ADDFKGRVTMTLDTSTSTAYMELRSLRSDD
		TAVYYCARTNYYYRSYIFYFDYWGQGTMVT
		VSS
662	hBDB-4G8-D4VH.v3	EIQLVQSGTEVKKPGESLKISCKASGYTFT
		NYGMYWVKQMPGKGLEYMCWINTETGKPTY
		ADDFKGRFTFSLDKSFNTAFLQWSSLKASD
		TAMYFCARTNYYYRSYIFYFDYWGQGTMVT
		VSS
663	hBDB-4G8-D4VH.v4	EIQLVQSGGGVVQPGGSLRLSCAASGYTFT
		NYGMYWVKQAPGKGLEYMCWINTETGKPTY
		ADDFKGRFTFSLDTSKSTAYLQLNSLRAED
		TAVYFCARTNYYYRSYIFYFDYWGQGTLVT
		VSS
664	hBDB-4G8-D4VH.v5	EVQLVESGGGLVQPGGSLRLSCAASGYTFT
		NYGMYWVKQAPGKGLEYMGWINTETGKPTY
		ADDFKGRFTFSLDTSKSTAYLQMNSLRAED
		TAVYFCARTNYYYRSYIFYFDYWGQGTLVT
		VSS
665	hBDB-4G8-D4VL.1	AIQLTQSPSSLSASVGDRVTITCRASESVS
		THMHWYQQKPGKAPKLLIYGASNLESGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYYCQQ
		SWNDPFTFGQGTKLEIK
666	hBDB-4G8-D4VL.1a	ATQLTQSPSLSASVGDRVTITCRASESVST
		HMHWYQQKPGKQPKLLIYGASNLESGVPSR
		FSGSGSGTDFTLTISSLQPEDFATYFCQQS
		WNDPFTFGQGTKLEIK
667	hBDB-4G8-D4VL.1b	ATQLTQSPSLSASVGDRVTITCRASESVST
		HMHWYQQKPGKAPKLLIYGASNLESGVPSR
		FSGSGSGTDFTLTISSLQPEDFATYYCQQS
		WNDPFTFGQGTKLEIK
668	hBDB-4G8-D4VL.1c	ATQLTQSPSSLSASVGDRVTITCRASESVS
		THMHWYQQKPGKAPKLLIYGASNLESGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYYCQQ
		SWNDPFTFGQGTKLEIK
669	hBDB-4G8-D4VL.v2	DTVLTQSPATLSLSPGERATLSCRASESVS
		THMHWYQQKPGQAPRLLIYGASNLESGVPA
		RFSGSGSGTDFTLTISSLEPEDFAVYFCQQ
		SWNDPFTFGQGTKLEIK
670	hBDB-4G8-D4VL.v3	ETVLTQSPATLSVSPGERATLSCRASESVS
		THMHWYQQKPGQAPRLLIYGASNLESGVPA
		RFSGSGSGTDFTLTISSLQSEDFAVYFCQQ
		SWNDPFTFGQGTRLEIK
671	hBDB-4G8-D4VL.v4	DTVLTQSPSTLSASPGERATISCRASESVS
		THMHWYQQKPGQAPKLLIYGASNLESGVPS
		RFSGSRSGTDFTLTISSLQPEDFAVYFCQQ
		SWNDPFTFGQGTKVEIK
672	hBDB-4G8-D4VL.v5	DTQLTQSPSSLSASVGDRVTISCRASESVS
		THMHWYQQKPGKAPKLLIYGASNLESGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYFCQQ
		SWNDPFTFGQGTKVEIK

• • hBDB-4G8-D4VH.1z is a CDR-grafted, humanized BDB-4G8-D4 VH containing IGHV7-4-1*02 and IGHJ3*01 framework sequences.
  • hBDB-4G8-D4VH.1 is based on .1z with a Q1E change to prevent pyroglutamate formation.
  • hBDB-4G8-D4VH.1a is a humanized design based on .1 and contains three proposed framework back-mutations (V2I, W47Y and Y91F).
  • hBDB-4G8-D4VH.1b is an intermediate design between .1 and .1a and only has one back-mutations W47Y.
  • hBDB-4G8-D4VH.2z is a CDR-grafted, humanized BDB-4G8-D4 VH containing IGHV1-18*01 and IGHJ3*01 framework sequences.
  • hBDB-4G8-D4VH.2 is based on .2z with a Q1E change to prevent pyroglutamate formation.
  • hBDB-4G8-D4VH.2a is a humanized design based on .2 and contains six proposed framework back-mutations (V2I, W47Y, V67F, M69F, T71L and Y91F).
  • hBDB-4G8-D4VH.2b is an intermediate design between .2 and .2a and only has two proposed framework back-mutations (W47Y and T71L).
  • hBDB-4G8-D4VH.v3 is a humanized BDB-4G8-D4 VH containing IGHV5-51*01 and

IGHJ3*01 framework sequences with thirteen proposed framework back-mutations (V21, A9T, G24A, R38K, W47Y, Q66R, V67F, 169F, A71L, I75F, S76N, Y79F and Y91F).

• • hBDB-4G8-D4VH.v4 is a humanized BDB-4G8-D4 VH containing IGHV3-66*01 and

IGHJ1*01 framework sequences with thirteen proposed framework back-mutations (V21, E6Q, L11V, W47Y, V48M, S49G, 169F, R71L, N73T, N76S, L78A, M82L and Y91F).

• • hBDB-4G8-D4VH.v5 is a humanized BDB-4G8-D4 containing IGHV3-66*01 and IGHJ1*01 framework sequences with ten proposed framework back-mutations (R38K, W47Y, V48M, S49G, 169F, R71L, N73T, N76S, L78A and Y91F).
  • hBDB-4G8-D4VL.1 is a CDR-grafted humanized BDB-4G8-D4 VL containing IGKV1D-13*01 and IGKJ2*01 framework sequences.
  • hBDB-4G8-D4VL.1a is a humanized design based on .1 with 3 proposed framework back-mutations (I2T, A43Q and Y87F) and one residue deletion (S10).
  • hBDB-4G8-D4VL.1b is an intermediate design between .1 and .1a with only one proposed framework back-mutation 12T.
  • hBDB-4G8-D4VL.1c is a humanized design based on .1b with one residue insertion (S10).
  • hBDB-4G8-D4VL.v2 is a humanized BDB-4G8-D4 VL containing IGKV3-11*01 and

IGKJ2*01 framework sequences with four proposed framework back-mutations (E1D, 12T, I58V, and Y87F).

• • hBDB-4G8-D4VL.v3 is a humanized BDB-4G8-D4 VL design containing IGKV3-15*01 and

IGKJ5*01 framework sequences with five proposed framework back-mutations (I2T, M4L, I58V, E70D, and Y87F).

• • hBDB-4G8-D4VL.v4 is a humanized BDB-4G8-D4 VL containing IGKV3-15*01 and

IGKJ1*01 framework sequences with eleven proposed framework back-mutations (E1D, 12T, A9S, L13A, L21I, R45K, I58V, A605, G66R, E79Q, and Y87F).

• • hBDB-4G8-D4VL.v5 is a humanized BDB-4G8-D4 VL containing IGKV1-39*01 and

IGKJ1*01 framework sequences with four proposed framework back-mutations (I2T, M4L, T22S, and Y87F).

Example 6.2.4.2

BEW-9A8-E2

TABLE 2.4.2
Sequences of Humanized BEW-9A8-E2 Variable Regions
SEQ ID	Protein	Sequence
NO:	region	123456789012345678901234567890
673	hBEW-9A8-	QVQLVQSGHEVKQPGASVKVSCKASGYTFT
	E2VH.1z	NYGMYWVPQAPGQGLEWMGWINTETGKPIY
		ADDFKGRFVFSMDTSASTAYLQISSLKAED
		MAMYYCARVDYDGSFWFAYWGQGTLVTVSS
674	hBEW-9A8-	EVQLVQSGHEVKQPGASVKVSCKASGYTFT
	E2VH.1	NYGMYWVPQAPGQGLEWMGWINTETGKPIY
		ADDFKGRFVFSMDTSASTAYLQISSLKAED
		MAMYYCARVDYDGSFWFAYWGQGTLVTVSS
675	hBEW-9A8-	EIQLVQSGHEVKQPGASVKVSCKASGYTFT
	E2VH.1a	NYGMYWVKQAPGQGLEYMGWINTETGKPIY
		ADDFKGRFVFSLDTSASTAYLQISSLKAED
		MAMFFCARVDYDGSFWFAYWGQGTLVTVSS
676	hBEW-9A8-	EVQLVQSGHEVKQPGASVKVSCKASGYTFT
	E2VH.1b	NYGMYWVPQAPGQGLEYMGWINTETGKPIY
		ADDFKGRFVFSLDTSASTAYLQISSLKAED
		MAMFYCARVDYDGSFWFAYWGQGTLVTVSS
677	hBEW-9A8-	EVQLVQSGHEVKQPGASVKVSCKASGYSFT
	E2VH.1c	NYGMYWVPQAPGQGLEYMGWINTETGKPIY
		ADDFKGRFVFSLDTSASTAYLQISSLKAED
		MAMFYCARVDYDGSFWFAYWGQGTLVTVSS
678	hBEW-9A8-	QVQLVQSGAEVKKPGASVKVSCKASGYTFT
	E2VH.2z	NYGMYWVRQAPGQGLEWMGWINTETGKPIY
		ADDFKGRVTMTTDTSTSTAYMELRSLRSDD
		TAVYYCARVDYDGSFWFAYWGQGTLVTVSS
679	hBEW-9A8-	EVQLVQSGAEVKKPGASVKVSCKASGYTFT
	E2VH.2	NYGMYWVRQAPGQGLEWMGWINTETGKPIY
		ADDFKGRVTMTTDTSTSTAYMELRSLRSDD
		TAVYYCARVDYDGSFWFAYWGQGTLVTVSS
680	hBEW-9A8-	EIQLVQSGAEVKKPGASVKVSCKASGYTFT
	E2VH.2a	NYGMYWVKQAPGQGLEYMGWINTETGKPIY
		ADDFKGRFTFTLDTSTSTAYMELRSLRSDD
		TAVFFCARVDYDGSFWFAYWGQGTLVTVSS
681	hBEW-9A8-	EVQLVQSGAEVKKPGASVKVSCKASGYTFT
	E2VH.2b	NYGMYWVRQAPGQGLEYMGWINTETGKPIY
		ADDFKGRVTMTLDTSTSTAYMELRSLRSDD
		TAVFYCARVDYDGSFWFAYWGQGTLVTVSS
682	hBEW-9A8-	EIQLVQSGAEVKKPGASVKVSCKASGYTFT
	E2VH.2c	NYGMYWVKQAPGQGLEYMGWINTETGKPIY
		ADDFKGRFTFTLDTSTSTAYMELRSLRSDD
		TAVYYCARVDYDGSFWFAYWGQGTLVTVSS
683	hBEW-9A8-	EIQLVQSGAEVKKPGASVKVSCKASGYTFT
	E2VH.2d	NYGMYWVRQAPGQGLEWMGWINTETGKPIY
		ADDFKGRFTFTLDTSTSTAYMELRSLRSDD
		TAVYYCARVDYDGSFWFAYWGQGTLVTVSS
684	hBEW-9A8-	QVQLVQSGSELKKPGASVKVSCKASGYTFT
	E2VH.3z	NYGMYWVRQAPGQGLEWMGWINTETGKPIY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARVDYDGSFWFAYWGQGTLVTVSS
685	hBEW-9A8-	EVQLVQSGSELKKPGASVKVSCKASGYTFT
	E2VH.3	NYGMYWVRQAPGQGLEWMGWINTETGKPIY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARVDYDGSFWFAYWGQGTLVTVSS
686	hBEW-9A8-	EIQLVQSGSELKKPGASVKVSCKASGYTFT
	E2VH.3a	NYGMYWVKQAPGQGLEYMGWINTETGKPIY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARVDYDGSFWFAYWGQGTLVTVSS
687	hBEW-9A8-	EIQLVQSGSELKKPGASVKVSCKASGYTFT
	E2VH.3b	NYGMYWVRQAPGQGLEWMGWINTETGKPIY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARVDYDGSFWFAYWGQGTLVTVSS
688	hBEW-9A8-	EIQLVQSGSELKKPGASVKVSCKASGYTFT
	E2VH.3c	NYGMYWVKQAPGQGLEYMGWINTETGKPIY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVFFCARVDYDGSFWFAYWGQGTLVTVSS
689	hBEW-9A8-	EIVLTQSPDFQSVTPKEKVTITCRASESVS
	E2VL.1	TVIHWYQQKPDQSPKLLIKGASNLESGVPS
		RFSGSGSGTDFTLTINSLEAEDAATYYCQQ
		HWNDPPTFGQGTKLEIK
690	hBEW-9A8-	ETVLTQSPDFQSVTPKEKVTITCRASESVS
	E2VL.1a	TVIHWYQQKPDQQPKLLIHGASNLESGVPS
		RFSGSGSGTDFTLTINSLEAEDAATYFCQQ
		HWNDPPTFGQGTKLEIK
691	hBEW-9A8-	ETVLTQSPDFQSVTPKEKVTITCRASESVS
	E2VL.1b	TVIHWYQQKPDQSPKLLIHGASNLESGVPS
		RFSGSGSGTDFTLTINSLEAEDAATYYCQQ
		HWNDPPTFGQGTKLEIK
692	hBEW-9A8-	ETVLTQSPDQSVTPKEKVTITCRASESVST
	E2VL.1c	VIHWYQQKPDQSPKLLIHGASNLESGVPSR
		FSGSGSGTDFTLTINSLEAEDAATYYCQQH
		WNDPPTFGQGTKLEIK
693	hBEW-9A8-	DIQMTQSPSSLSASVGDRVTITCRASESVS
	E2VL.2	TVIHWYQQKPGKAPKLLIYGASNLESGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYYCQQ
		HWNDPPTFGQGTKLEIK
694	hBEW-9A8-	DTQLTQSPSSLSASVGDRVTITCRASESVS
	E2VL.2a	TVIHWYQQKPGKQPKLLIHGASNLESGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYFCQQ
		HWNDPPTFGQGTKLEIK
695	hBEW-9A8-	DTQMTQSPSSLSASVGDRVTITCRASESVS
	E2VL.2b	TVIHWYQQKPGKAPKLLIHGASNLESGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYYCQQ
		HWNDPPTFGQGTKLEIK
696	hBEW-9A8-	DTQMTQSPSLSASVGDRVTITCRASESVST
	E2VL.2c	VIHWYQQKPGKAPKLLIHGASNLESGVPSR
		FSGSGSGTDFTLTISSLQPEDFATYYCQQH
		WNDPPTFGQGTKLEIK
697	hBEW-9A8-	EIVLTQSPATLSLSPGERATLSCRASESVS
	E2VL.3	TVIHWYQQKPGQAPRLLIYGASNLESGIPA
		RFSGSGSGTDFTLTISSLEPEDFAVYYCQQ
		HWNDPPTFGQGTKLEIK
698	hBEW-9A8-	ETVLTQSPATLSLSPGERATLSCRASESVS
	E2VL.3a	TVIHWYQQKPGQAPRLLIHGASNLESGVPA
		RFSGSGSGTDFTLTISSLEPEDFATYFCQQ
		HWNDPPTFGQGTKLEIK
699	hBEW-9A8-	ETVLTQSPATLSLSPGERATLSCRASESVS
	E2VL.3b	TVIHWYQQKPGQAPRLLIYGASNLESGIPA
		RFSGSGSGTDFTLTISSLEPEDFAVYFCQQ
		HWNDPPTFGQGTKLEIK
700	hBEW-9A8-	ETVLTQSPATLSLSPGERATLSCRASESVS
	E2VL.3c	TVIHWYQQKPGQAPRLLIYGASNLESGIPA
		RFSGSGSGTDFTLTISSLEPEDFAVYYCQQ
		HWNDPPTFGQGTKLEIK
701	hBEW-9A8-	AIQLTQSPSSLSASVGDRVTITCRASESVS
	E2VL.4	TVIHWYQQKPGKAPKLLIYGASNLESGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYYCQQ
		HWNDPPTFGQGTKLEIK
702	hBEW-9A8-	ATQLTQSPSSLSASVGDRVTISCRASESVS
	E2VL.4a	TVIHWYQQKPGKAPKLLIHGASNLESGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYFCQQ
		HWNDPPTFGQGTKLEIK
703	hBEW-9A8-	ATQLTQSPSSLSASVGDRVTITCRASESVS
	E2VL.4b	TVIHWYQQKPGKAPKLLIYGASNLESGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYFCQQ
		HWNDPPTFGQGTKLEIK
704	hBEW-9A8-	ATQLTQSPSSLSASVGDRVTITCRASESVS
	E2VL.4c	TVIHWYQQKPGKAPKLLIYGASNLESGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYYCQQ
		HWNDPPTFGQGTKLEIK

• • hBEW-9A8-E2VH.1z is a CDR-grafted, humanized BEW-9A8-E2 VH containing IGHV7-81*01 and IGHJ1*01 framework sequences.
  • hBEW-9A8-E2VH.1 is based on .1z with a Q1E change to prevent pyroglutamate formation.
  • hBEW-9A8-E2VH.1a is a humanized design based on .1 and contains six proposed framework back-mutations (V2I, P38K, W47Y, M71L, Y90F and Y91F).
  • hBEW-9A8-E2VH.1b is an intermediate design between .1 and .1a and only has three proposed framework back-mutations (W47Y, M71L and Y90F).
  • hBEW-9A8-E2VH.1c is based on .1b with additional one CDR germlining change T28S to improve identity to human germline sequence.
  • hBEW-9A8-E2VH.2z is a CDR-grafted, humanized BEW-9A8-E2 VH containing IGHV1-18*01 and IGHJ1*01 framework sequences.
  • hBEW-9A8-E2VH.2 is based on .2z with a Q1E change to prevent pyroglutamate formation.
  • hBEW-9A8-E2VH.2a is a humanized design based on .2 and contains eight proposed framework back-mutations (V2I, R38K, W47Y, V67F, M69F, T71L, Y90F and Y91F).
  • hBEW-9A8-E2VH.2b is an intermediate design between .2 and .2a and contains three back-mutations (W47Y, M71L and Y90F).
  • hBEW-9A8-E2VH.2c (hBEW-9A8VH.4a) is an intermediate design between .2 and .2a and contains six proposed framework back-mutations (V21, R38K, W47Y, V67F, M69F, and T71L).
  • hBEW-9A8-E2VH.2d (hBEW-9A8VH.4b) is an intermediate design between .2 and .2a contains four proposed framework back-mutations (V2I, V67F, M69F, and T71L).
  • hBEW-9A8VH.3z is a CDR-grafted, humanized BEW-9A8 VH containing IGHV7-4-1*01 and IGHJ1*01 framework sequences.
  • hBEW-9A8VH.3 is based on .3z with a Q1E change to prevent pyroglutamate formation.
  • hBEW-9A8VH.3a is a humanized design based on .3 and contains 3 proposed framework back-mutations (V2I, R38K, W47Y).
  • hBEW-9A8VH.3b is an intermediate design between .3 and .3a and contains 1 proposed framework back-mutations: V21.
  • hBEW-9A8VH.3c is a humanized design based on .3 and contains 5 proposed framework back-mutations (V2I, R38K, W47Y, Y90F, Y91F).
  • hBEW-9A8-E2VL.1 is a CDR-grafted humanized BEW-9A8-E2 VL containing IGKV6-21*01 and IGKJ2*01 framework sequences.
  • hBEW-9A8-E2VL.1a is a humanized design based on .1 with four proposed framework back-mutations (I2T, S43Q, K49H and Y87F).
  • hBEW-9A8-E2VL.1b is an intermediate design between .1 and .1a with only two proposed framework back-mutation (I2T and K49H).
  • hBEW-9A8-E2VL.1c is based on .1b with one residue deletion of F10.
  • hBEW-9A8-E2VL.2 is a CDR-grafted humanized BEW-9A8-E2 VL containing IGKV1-39*01 and IGKJ2*01 framework sequences.
  • hBEW-9A8-E2VL.2a is a humanized design based on .2 with five proposed framework back-mutations (I2T, M4L, A43Q, Y49H and Y87F).
  • hBEW-9A8-E2VL.2b is an intermediate design between .1 and .1a with only two proposed framework back-mutation (I2T and Y49H).
  • hBEW-9A8-E2VL.2c is based on .2b with one residue deletion of S10.
  • hBEW-9A8VL.3 is a CDR-grafted, humanized BEW-9A8 VL containing IGKV3-11*01 and IGKJ2*01 framework sequences.
  • hBEW-9A8VL.3a is a humanized design based on .3 and contains 5 proposed framework back-mutations: (I2T, Y49H, I58V, V85T, Y87F).
  • hBEW-9A8VL.3b is an intermediate design between .3 and 3a. It contains 2 proposed framework back-mutations: (I2T, Y87F).
  • hBEW-9A8VL.3c is a design based on .3b and contains 1 proposed framework back-mutations: I2T.
  • hBEW-9A8VL.4 is a CDR-grafted, humanized BEW-9A8 VL containing IGKV1-13*01 and IGKJ2*01 framework sequences.
  • hBEW-9A8VL.4a is a humanized design based on .4 and contains 4 proposed framework back-mutations: I2T, T22S, Y49H, Y87F.
  • hBEW-9A8VL.4b is an intermediate design between .4 and 4a. It contains 2 proposed framework back-mutations: I2T, Y87F.
  • hBEW-9A8VL.4c is a design based on .4b and eliminated Carter residue back-mutations. It contains 1 proposed framework back-mutations: I2T.

Example 6.2.4.3

BEW-6C2-C8

TABLE 2.4.3
Sequences of Humanized BEW-6C2-C8 Variable Regions
SEQ
ID	Protein	Sequence
NO:	region	123456789012345678901234567890
705	hBEW-6C2-C8VH.1	EVQLVESGGGLVQPGGSLRLSCAASGFTFS
		YYGMHWVRQAPGKGLEWVALIYYDSSKMYY
		ADSVKGRFTISRDNAKNSLYLQMNSLRAED
		TAVYYCARGGTAPVYWGQGTMVTVSS
706	hBEW-6C2-	EVQLVESGGGLVQPGGSLRLSCAASGFTFS
	C8VH.1a	YYGMHWIRQAPGKGLEWMALIYYDSSKMYY
		ADSVKGRFTISRDNAKNSLYLQMNSLRAED
		TAVYYCAAGGTAPVYWGQGTMVTVSS
707	hBEW-6C2-	EVQLVESGGGLVQPGGSLRLSCAASGFTFS
	C8VH.1b	YYGMHWVRQAPGKGLEWMALIYYDSSKMYY
		ADSVKGRFTISRDNAKNSLYLQMNSLRAED
		TAVYYCAAGGTAPVYWGQGTMVTVSS
708	hBEW-6C2-C8VL.1	EIVLTQSPATLSLSPGERATLSCKGSQNIA
		NYLAWYQQKPGQAPRLLIYNTDSLQTGIPA
		RFSGSGSGTDFTLTISSLEPEDFAVYYCYQ
		SNNGYTFGQGTKLEIK
709	hBEW-6C2-	EIVLTQSPATLSLSPGERATLSCKGSQNIA
	C8VL.1a	NYLAWYQQKPGQAPRLLIYNTDSLQTGIPA
		RFSGSGSGTDYTLTISSLEPEDFAVYFCYQ
		SNNGYTFGQGTKLEIK
710	hBEW-6C2-C8VL.2	DIQMTQSPSSLSASVGDRVTITCKGSQNIA
		NYLAWYQQKPGKAPKLLIYNTDSLQTGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYYCYQ
		SNNGYTFGQGTKLEIK
711	hBEW-6C2-	DIQLTQSPSSLSASVGDRVTITCKGSQNIA
	C8VL.2a	NYLAWYQQKPGKAPKLLIYNTDSLQTGIPS
		RFSGSGSGTDYTLTISSLQPEDFATYFCYQ
		SNNGYTFGQGTKLEIK

• • hBEW-6C2-C8VH.1 is a CDR-grafted, humanized BEW-6C2-C8 VH containing IGHV3-7*01 and IGHJ3*01 framework sequences.
  • hBEW-6C2-C8VH.1a is a humanized design based on .1 and contains three proposed framework back-mutations V37I, V48M and R94A.
  • hBEW-6C2-C8VH.1b is an intermediate design between .1 and .1a and only has two back-mutations V48M and R94A. This design eliminates Carter residue back-mutations.
  • hBEW-6C2-C8VL.1 is a CDR-grafted humanized BEW-6C2-C8 VL containing IGKV3-11*01 and IGKJ2*01 framework sequences.
  • hBEW-6C2-C8VL.1a is a humanized design based on .1 with 2 proposed framework back-mutations (F71Y and Y87F).
  • hBEW-6C2-C8VL.2 is a CDR-grafted humanized BEW-6C2-C8 VL containing IGKV1-39*01 and IGKJ2*01 framework sequences.
  • hBEW-6C2-C8VL.2a is a humanized design based on .2 with 4 proposed framework back-mutations (M4L, V58I, F71Y and Y87F).

Example 6.2.4.4

BEW-9D2-E8

TABLE 2.4.4
Sequences of Humanized BEW-9D2-E8 Variable Regions
SEQ
ID	Protein	Sequence
NO:	region	123456789012345678901234567890
712	hBEW-9D2-E8VH.1z	QVQLVQSGHEVKQPGASVKVSCKASGYTFT
		NYGMYWVPQAPGQGLEWMGWINTETGKPTY
		ADDFKGRFVFSMDTSASTAYLQISSLKAED
		MAMYYCARPSDYYDGFWFAYWGQGTLVTVS
		S
713	hBEW-9D2-E8VH.1	EVQLVQSGHEVKQPGASVKVSCKASGYTFT
		NYGMYWVPQAPGQGLEWMGWINTETGKPTY
		ADDFKGRFVFSMDTSASTAYLQISSLKAED
		MAMYYCARPSDYYDGFWFAYWGQGTLVTVS
		S
714	hBEW-9D2-E8VH.1a	EIQLVQSGHEVKQPGASVKVSCKASGYTFT
		NYGMYWVKLAPGQGLEYLGWINTETGKPTY
		ADDFKGRFVFSLDTSASTAYLQISSLKAED
		MAMYFCARPSDYYDGFWFAYWGQGTLVTVS
		S
715	hBEW-9D2-E8VH.1b	EVQLVQSGHEVKQPGASVKVSCKASGYTFT
		NYGMYWVKQAPGQGLEYLGWINTETGKPTY
		ADDFKGRFVFSLDTSASTAYLQISSLKAED
		MAMYYCARPSDYYDGFWFAYWGQGTLVTVS
		S
716	hBEW-9D2-E8VH.1c	EVQLVQSGHEVKQPGASVKVSCKASGYSFT
		NYGMYWVKQAPGQGLEYLGWINTETGKPTY
		ADDFKGRFVFSLDTSASTAYLQISSLKAED
		MAMYYCARPSDYYDGFWFAYWGQGTLVTVS
		S
717	hBEW-9D2-E8VH.2z	QVQLVQSGAEVKKPGASVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEWMGWINTETGKPTY
		ADDFKGRVTMTTDTSTSTAYMELRSLRSDD
		TAVYYCARPSDYYDGFWFAYWGQGTLVTVS
		S
718	hBEW-9D2-E8VH.2	EVQLVQSGAEVKKPGASVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEWMGWINTETGKPTY
		ADDFKGRVTMTTDTSTSTAYMELRSLRSDD
		TAVYYCARPSDYYDGFWFAYWGQGTLVTVS
		S
719	hBEW-9D2-E8VH.2a	EIQLVQSGAEVKKPGASVKVSCKASGYTFT
		NYGMYWVKLAPGQGLEYLGWINTETGKPTY
		ADDFKGRFTFTLDTSTSTAYLELRSLRSDD
		TAVYFCARPSDYYDGFWFAYWGQGTLVTVS
		S
720	hBEW-9D2-E8VH.2B	EVQLVQSGAEVKKPGASVKVSCKASGYTFT
		NYGMYWVKQAPGQGLEYLGWINTETGKPTY
		ADDFKGRVTMTLDTSTSTAYLELRSLRSDD
		TAVYYCARPSDYYDGFWFAYWGQGTLVTVS
		S
721	hBEW-9D2-E8VL.1	EIVLTQSPATLSLSPGERATLSCRASEWVN
		SYMHWYQQKPGQAPRLLIYKASNLASGIPA
		RFSGSGSGTDFTLTISSLEPEDFAVYYCQQ
		SWNDPLTFGQGTKLEIK
722	hBEW-9D2-E8VL.1a	ETVLTQSPATLSLSPGERATLSCRASEWVN
		SYMHWYQQKPGQQPRLLIYKASNLASGVPA
		RFSGSGSGTDFTLTISSLEPEDFAVYFCQQ
		SWNDPLTFGQGTKLEIK
723	hBEW-9D2-E8VL.1b	ETVLTQSPATLSLSPGERATLSCRASEWVN
		SYMHWYQQKPGQAPRLLIYKASNLASGIPA
		RFSGSGSGTDFTLTISSLEPEDFAVYYCQQ
		SWNDPLTFGQGTKLEIK
724	hBEW-9D2-E8VL.2	DIQMTQSPSSLSASVGDRVTITCRASEWVN
		SYMHWYQQKPGKAPKLLIYKASNLASGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYYCQQ
		SWNDPLTFGQGTKLEIK
725	hBEW-9D2-E8VL.2a	DTQLTQSPSSLSASVGDRVTITCRASEWVN
		SYMHWYQQKPGKQPKLLIYKASNLASGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYFCQQ
		SWNDPLTFGQGTKLEIK
726	hBEW-9D2-E8VL.2b	DTQMTQSPSSLSASVGDRVTITCRASEWVN
		SYMHWYQQKPGKAPKLLIYKASNLASGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYYCQQ
		SWNDPLTFGQGTKLEIK

• • hBEW-9D2-E8VH.1z is a CDR-grafted, humanized BEW-9D2-E8 VH containing IGHV7-81*01 and IGHJ4*01 framework sequences.
  • hBEW-9D2-E8VH.1 is based on .1z with a Q1E change to prevent pyroglutamate formation.
  • hBEW-9D2-E8VH.1a is a humanized design based on .1 and contains seven proposed framework back-mutations (V2I, P38K, Q39L, W47Y, M48L, M71L and Y91F).
  • hBEW-9D2-E8VH.1b is an intermediate design between .1 and .1a and only has four proposed framework back-mutations (P38K, W47Y, M48L, M71L).
  • BEW-9D2-E8VH.1c is based on .1b with additional one CDR germlining change T28S to improve identity to human germline sequence.
  • hBEW-9D2-E8VH.2z is a CDR-grafted, humanized BEW-9D2-E8 VH containing IGHV1-18*01 and IGHJ4*01 framework sequences.
  • hBEW-9D2-E8VH.2 is based on .2z with a Q1E change to prevent pyroglutamate formation.
  • hBEW-9D2-E8VH.2a is a humanized design based on .2 and contains ten proposed framework back-mutations (V21, R38K, Q39L, W47Y, M48L, V67F, M69F, T71L, M80L and Y91F).
  • hBEW-9D2-E8VH.2b is an intermediate design between .2 and .2a and only has five proposed framework back-mutations (R38K, W47Y, M48L, T71L and M80L).
  • hBEW-9D2-E8VL.1 is a CDR-grafted humanized BEW-9D2-E8 VL containing IGKV3-11*01 and IGKJ2*01 framework sequences.
  • hBEW-9D2-E8VL.1a is a humanized design based on .1 with four proposed framework back-mutations (I2T, A43Q, I58V and Y87F).
  • hBEW-9D2-E8VL.1b is an intermediate design between .1 and .1a with one proposed framework back-mutation 12V.
  • hBEW-9D2-E8VL.2 is a CDR-grafted humanized BEW-9D2-E8 VL containing IGKV1-39*01 and IGKJ2*01 framework sequences.
  • hBEW-9D2-E8VL.2a is a humanized design based on .2 with four proposed framework back-mutations (I2T, M4L, A43Q and Y87F).
  • hBEW-9D2-E8VL.2b is an intermediate design between .2 and .2a with one proposed framework back-mutation 12V.

Example 6.2.4.5

BEW-9E3-B9

TABLE 2.4.5
Sequences of Humanized BEW-9E3-B9 Variable Regions
SEQ
ID	Protein	Sequence
NO:	region	123456789012345678901234567890
727	hBEW-9E3-B9VH.1z	QVQLVQSGHEVKQPGASVKVSCKASGYTFT
		NYGMYWVPQAPGQGLEWMGWINTETGKPTY
		ADDFKGRFVFSMDTSASTAYLQISSLKAED
		MAMYYCARPSDYYDGFWFPYWGQGTLVTVS
		S
728	hBEW-9E3-B9VH.1	EVQLVQSGHEVKQPGASVKVSCKASGYTFT
		NYGMYWVPQAPGQGLEWMGWINTETGKPTY
		ADDFKGRFVFSMDTSASTAYLQISSLKAED
		MAMYYCARPSDYYDGFWFPYWGQGTLVTVS
		S
729	hBEW-9E3-B9VH.1a	EIQLVQSGHEVKQPGASVKVSCKASGYTFT
		NYGMYWVPQAPGQGLEYMGWINTETGKPTY
		ADDFKGRFVFSLDTSASTAYLQISSLKAED
		MAMYFCARPSDYYDGFWFPYWGQGTLVTVS
		S
730	hBEW-9E3-B9VH.1b	EVQLVQSGHEVKQPGASVKVSCKASGYTFT
		NYGMYWVPQAPGQGLEYMGWINTETGKPTY
		ADDFKGPFVFSLDTSASTAYLQISSLKAED
		MAMYYCARPSDYYDGFWFPYWGQGTLVTVS
		S
731	hBEW-9E3-B9VH.1c	EVQLVQSGHEVKQPGASVKVSCKASGYSFT
		NYGMYWVPQAPGQGLEYMGWINTETGKPTY
		ADDFKGRFVFSLDTSASTAYLQISSLKAED
		MAMYYCARPSDYYDGFWFPYWGQGTLVTVS
		S
732	hBEW-9E3-B9VH.2z	QVQLVQSGAEVKKPGASVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEWMGWINTETGKPTY
		ADDFKGPVTMTTDTSTSTAYMELRSLPSDD
		TAVYYCARPSDYYDGFWFPYWGQGTLVTVS
		S
733	hBEW-9E3-B9VH.2	EVQLVQSGAEVKKPGASVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEWMGWINTETGKPTY
		ADDFKGRVTMTTDTSTSTAYMELRSLRSDD
		TAVYYCARPSDYYDGFWFPYWGQGTLVTVS
		S
734	hBEW-9E3-B9VH.2a	EIQLVQSGAEVKKPGASVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEYMGWINTETGKPTY
		ADDFKGRFTFTLDTSTSTAYMELRSLRSDD
		TAVYFCARPSDYYDGFWFPYWGQGTLVTVS
		S
735	hBEW-9E3-B9VH.2b	EVQLVQSGAEVKKPGASVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEYMGWINTETGKPTY
		ADDFKGRVTMTLDTSTSTAYMELRSLRSDD
		TAVYYCARPSDYYDGFWFPYWGQGTLVTVS
		S
736	hBEW-9E3-B9VL.1	EIVLTQSPATLSLSPGERATLSCRASEGVN
		SYMHWYQQKPGQAPRLLIYKASNLASGIPA
		RFSGSGSGTDFTLTISSLEPEDFAVYYCQQ
		SWNDPLTFGQGTKLEIK
737	hBEW-9E3-B9VL.1a	ETVLTQSPATLSLSPGERATLSCRASEGVN
		SYMHWYQQKPGQQPRLLIYKASNLASGVPA
		RFSGSGSGTDFTLTISSLEPEDFAVYFCQQ
		SWNDPLTFGQGTKLEIK
738	hBEW-9E3-B9VL.1b	ETVLTQSPATLSLSPGERATLSCRASEGVN
		SYMHWYQQKPGQAPRLLIYKASNLASGIPA
		RFSGSGSGTDFTLTISSLEPEDFAVYYCQQ
		SWNDPLTFGQGTKLEIK
739	hBEW-9E3-B9VL.2	DIQMTQSPSSLSASVGDRVTITCRASEGVN
		SYMHWYQQKPGKAPKLLIYKASNLASGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYYCQQ
		SWNDPLTFGQGTKLEIK
740	hBEW-9E3-B9VL.2a	DTQLTQSPSSLSASVGDRVTITCRASEGVN
		SYMHWYQQKPGKQPKLLIYKASNLASGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYFCQQ
		SWNDPLTFGQGTKLEIK
741	hBEW-9E3-B9VL.2b	DTQMTQSPSSLSASVGDRVTITCRASEGVN
		SYMHWYQQKPGKAPKLLIYKASNLASGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYYCQQ
		SWNDPLTFGQGTKLEIK

• • hBEW-9E3-B9VH.1z is a CDR-grafted, humanized BEW-9E3-B9 VH containing IGHV7-81*01 and IGHJ4*01 framework sequences.
  • hBEW-9E3-B9VH.1 is based on .1z with a Q1E change to prevent pyroglutamate formation.
  • hBEW-9E3-B9VH.1a is a humanized design based on .1 and contains four proposed framework back-mutations (V2I, W47Y, M71L and Y91F).
  • hBEW-9E3-B9VH.1b is an intermediate design between .1 and .1a and only has two back-mutations (W47Y and M71L).
  • hBEW-9E3-B9VH.1c is based on .1b with additional one CDR germlining change T28S to improve identity to human germline sequence.
  • hBEW-9E3-B9VH.2z is a CDR-grafted, humanized BEW-9E3-B9 VH containing IGHV1-18*01 and IGHJ4*01 framework sequences.
  • hBEW-9E3-B9VH.2 is based on .2z with a Q1E change to prevent pyroglutamate formation.
  • hBEW-9E3-B9VH.2a is a humanized design based on .2 and contains six proposed framework back-mutations (V2I, W47Y, V67F, M69F, T71L and Y91F).
  • hBEW-9E3-B9VH.2b is an intermediate design between .2 and .2a and only has two back-mutations W47Y and T71L.
  • hBEW-9E3-B9VL.1 is a CDR-grafted humanized BEW-9E3-B9 VL containing IGKV3-11*01 and IGKJ2*01 framework sequences.
  • hBEW-9E3-B9VL.1a is a humanized design based on .1 with four proposed framework back-mutations (I2T, A43Q, I58V and Y87F).
  • hBEW-9E3-B9VL.1b is an intermediate design between .1 and .1a with 1 proposed framework back-mutation 12T.
  • hBEW-9E3-B9VL.2 is a CDR-grafted humanized BEW-9E3-B9 VL containing IGKV1-39*01 and IGKJ2*01 framework sequences.
  • hBEW-9E3-B9VL.2a is a humanized design based on .1 with four proposed framework back-mutations (I2T, M4L, A43Q and Y87F).
  • hBEW-9E3-B9VL.2b is an intermediate design between .1 and .1a with 1 proposed framework back-mutation 12T.

Example 6.2.4.6

BEW-5C3

TABLE 2.4.6
Sequences of Humanized BEW-5C3 Variable Regions
SEQ
ID		Sequence
NO:	Protein region	123456789012345678901234567890
742	hBEW-5c3VH.1z	QVQLVQSGSELKKPGASVKVSCKASGYTFT
		NYGVYWVRQAPGQGLEWMGWINTETGKPTY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARARQLDWFVYWGQGTLVTVSS
743	hBEW-5C3VH.1	EVQLVQSGSELKKPGASVKVSCKASGYTFT
		NYGVYWVRQAPGQGLEWMGWINTETGKPTY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARARQLDWFVYWGQGTLVTVSS
744	hBEW-5C3VH.1a	EIQLVQSGSELKKPGASVKVSCKASGYTFT
		NYGVYWVKQAPGQGLEYMGWINTETGKPTY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARARQLDWFVYWGQGTLVTVSS
745	hBEW-5C3VH.1b	EIQLVQSGSELKKPGASVKVSCKASGYTFT
		NYGVYWVKQAPGQGLEYMGWINTETGKPTY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVFFCARARQLDWFVYWGQGTLVTVSS
746	hBEW-5C3VH.2z	QVQLVQSGAEVKKPGSSVKVSCKASGYTFT
		NYGVYWVRQAPGQGLEWMGWINTETGKPTY
		ADDFKGRVTITADKSTSTAYMELSSLRSED
		TAVYYCARARQLDWFVYWGQGTLVTVSS
747	hBEW-5C3VH.2	EVQLVQSGAEVKKPGSSVKVSCKASGYTFT
		NYGVYWVRQAPGQGLEWMGWINTETGKPTY
		ADDFKGRVTITADKSTSTAYMELSSLRSED
		TAVYYCARARQLDWFVYWGQGTLVTVSS
748	hBEW-5C3VH.2a	EIQLVQSGAEVKKPGSSVKVSCKASGYTFT
		NYGVYWVKQAPGQGLEYMGWINTETGKPTY
		ADDFKGRFTFTLDKSTSTAYMELSSLRSED
		TAVYFCARARQLDWFVYWGQGTLVTVSS
749	hBEW-5C3VH.2b	EVQLVQSGAEVKKPGSSVKVSCKASGYTFT
		NYGVYWVRQAPGQGLEWMGWINTETGKPTY
		ADDFKGRFTFTLDKSTSTAYMELSSLRSED
		TAVYYCARARQLDWFVYWGQGTLVTVSS
750	hBEW-5C3VH.2C	EIQLVQSGAEVKKPGSSVKVSCKASGYTFT
		NYGVYWVKQAPGQGLEYMGWINTETGKPTY
		ADDFKGRFVFTLDKSTSTAYLELSSLRSED
		TAVFFCARARQLDWFVYWGQGTLVTVSS
751	hBEW-5C3VL.1	EIVLTQSPATLSLSPGERATLSCRARESLT
		TSLCWYQQKPGQAPRLLIYGASKLESGIPA
		RFSGSGSGTDFTLTISSLEPEDFAVYYCQQ
		SWYDPPTFGGGTKVEIK
752	hBEW-5C3VL.1a	DTVLTQSPATLSLSPGERATLSCRARESLT
		TSLSWFQQKPGQQPRLLIYGASKLESGVPA
		RFSGSGSGTDFTLTISSLEPEDFAVYFCQQ
		SWYDPPTFGGGTKVEIK
753	hBEW-5C3VL.1b	DTVLTQSPATLSLSPGERATLSCRARESLT
		TSLSWFQQKPGQAPRLLIYGASKLESGIPA
		RFSGSGSGTDFTLTISSLEPEDFAVYFCQQ
		SWYDPPTFGGGTKVEIK
754	hBEW-5C3VL.1c	DTVLTQSPATLSLSPGERATLSCRARESLT
		TSLSWYQQKPGQAPRLLIYgasklesGIPA
		RFSGSGSGTDFTLTISSLEPEDFAVYYCQQ
		SWYDPPTFGGGTKVEIK
755	hBEW-5C3VL.2	AIQLTQSPSSLSASVGDRVTITCRARESLT
		TSLSWYQQKPGKAPKLLIYGASKLESGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYYCQQ
		SWYDPPTFGGGTKVEIK
756	hBEW-5C3VL.2a	DTQLTQSPSSLSASVGDRVTISCRARESLT
		TSLSWFQQKPGKQPKLLIYGASKLESGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYFCQQ
		SWYDPPTFGGGTKVEIK
757	hBEW-5C3VL.2b	DTQLTQSPSSLSASVGDRVTITCRARESLT
		TSLSWFQQKPGKAPKLLIYGASKLESGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYFCQQ
		SWYDPPTFGGGTKVEIK
758	hBEW-5C3VL.2c	DTQLTQSPSSLSASVGDRVTITCRARESLT
		TSLSWYQQKPGKAPKLLIYGASKLESGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYYCQQ
		SWYDPPTFGGGTKVEIK

• • hBEW-5C3VH.1z is a CDR-grafted, humanized BEW-5C3 VH containing IGHV7-4-1*01 and IGHJ1*01 framework sequences.
  • hBEW-5C3VH.1 is based on .1z with a Q1E change to prevent pyroglutamate formation.
  • hBEW-5C3VH.1a is a humanized design based on .1 and contains three proposed framework back-mutations (V2I, R38K, W47Y).
  • hBEW-5C3VH.1b is a humanized design based on .1 and contains five proposed framework back-mutations (V2I, R38K, W47Y, Y90F, Y91F).
  • hBEW-5C3VH.2z is a CDR-grafted, humanized BEW-5C3 VH containing IGHV1-69*06 and IGHJ1*01 framework sequences.
  • hBEW-5C3VH.2 is based on .2z with a Q1E change to prevent pyroglutamate formation.
  • hBEW-5C3VH.2a is a humanized design based on .2 and contains seven proposed framework back-mutations (V2I, R38K, W47Y, V67F, I69F, A71L, Y91F).
  • hBEW-5C3VH.2b is an intermediate design between .2 and .2a and contains three proposed framework back-mutations (V67F, I69F, A71L).
  • hBEW-5C3VH.2c is a humanized design based on .2 and contains ten proposed framework back-mutations (V2I, R38K, W47Y, V67F, T68V, I69F, A71L, M80L, Y90F, Y91F).
  • hBEW-5C3VL.1 is a CDR-grafted, humanized BEW-5C3 VL containing IGKV3-11*01 and IGKJ4*01 framework sequences.
  • hBEW-5C3VL.1a is a humanized design based on .1 and contains six proposed framework back-mutations (E1D, I2T, Y36F, A43Q, I58V, Y87F).
  • hBEW-5C3VL.1b is an intermediate design between .1 and .1a. It contains four proposed framework back-mutations (E1D, I2T, Y36F, Y87F).
  • hBEW-5C3VL.1c is a design based on .1b and contains two proposed framework back-mutations (E1D, I2T)
  • hBEW-5C3VL.2 is a CDR-grafted, humanized BEW-5C3 VL containing IGKV1-13*01 and IGKJ4*01 framework sequences.
  • hBEW-5C3VL.2a is a humanized design based on .2 and contains six proposed framework back-mutations (A1D, I2T, T22S, Y36F, A43Q, Y87F).
  • hBEW-5C3VL.2b is an intermediate design between .2 and 2a. It contains four proposed framework back-mutations (A1D, I2T, Y36F, Y87F).
  • hBEW-5C3VL.2c is a design based on .2b and contains two proposed framework back-mutations (A1D, I2T)

Example 6.2.4.7

BEW-9E10

TABLE 2.4.7
Sequences of Humanized BEW-9E10 Variable Regions
SEQ
ID		Sequence
NO:	Protein region	123456789012345678901234567890
759	hBEW-9E10VH.1z	QVQLVQSGSELKKPGASVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEWMGWIDTETGRPTY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARWSGDTTGIRGPWFAYWGQGTLV
		TVSS
760	hBEW-9E10VH.1	EVQLVQSGSELKKPGASVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEWMGWIDTETGRPTY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARWSGDTTGIRGPWFAYWGQGTLV
		TVSS
761	hBEW-9E10VH.1a	EIQLVQSGSELKKPGASVKVSCKASGYTFT
		NYGMYWVKQAPGQGLEYMGWIDTETGRPTY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYFCARWSGDTTGIRGPWFAYWGQGTLV
		TVSS
762	hBEW-9E10VH.2z	QVQLVQSGAEVKKPGSSVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEWMGWIDTETGRPTY
		ADDFKGRVTITADKSTSTAYMELSSLRSED
		TAVYYCARWSGDTTGIRGPWFAYWGQGTLV
		TVSS
763	hBEW-9E10VH.2	EVQLVQSGAEVKKPGSSVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEWMGWIDTETGRPTY
		ADDFKGRVTITADKSTSTAYMELSSLRSED
		TAVYYCARWSGDTTGIRGPWFAYWGQGTLV
		TVSS
764	hBEW-9E10VH.2a	EIQLVQSGAEVKKPGSSVKVSCKASGYTFT
		NYGMYWVKQAPGQGLEYMGWIDTETGRPTY
		ADDFKGRFTFTADKSTSTAYMELSSLRSED
		TAVYFCARWSGDTTGIRGPWFAYWGQGTLV
		TVSS
765	hBEW-9E10VH.2b	EVQLVQSGAEVKKPGSSVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEWMGWIDTETGRPTY
		ADDFKGRFTFTADKSTSTAYMELSSLRSED
		TAVYYCARWSGDTTGIRGPWFAYWGQGTLV
		TVSS
766	hBEW-9E10VL.1	DIQMTQSPSSLSASVGDRVTITCLASEDIY
		SDLAWYQQKPGKVPKLLIYNANGLQNGVPS
		RFSGSGSGTDFTLTISSLQPEDVATYYCQQ
		YNYFPGTFGQGTKLEIK
767	hBEW-9E10VL.1a	DIRMTQSPSSLSASVGDRVTIECLASEDIY
		SDLAWYQQKPGKSPKLLIYNANGLQNGVPS
		RFSGSGSGTDYSLTISSLQPEDVATYFCQQ
		YNYFPGTFGQGTKLEIK
768	hBEW-9E10VL.1b	DIRMTQSPSSLSASVGDRVTITCLASEDIY
		SDLAWYQQKPGKSPKLLIYNANGLQNGVPS
		RFSGSGSGTDYTLTISSLQPEDVATYFCQQ
		YNYFPGTFGQGTKLEIK

• • hBEW-9E10VH.1z is a CDR-grafted, humanized BEW-9E10 VH containing IGHV7-4-1*01 and IGHJ1*01 framework sequences.
  • hBEW-9E10VH.1 is based on .1z with a Q1E change to prevent pyroglutamate formation.
  • hBEW-9E10VH.1a is a humanized design based on .1 and contains four proposed framework back-mutations (V2I, R38K, W47Y, Y91F).
  • hBEW-9E10VH.2z is a CDR-grafted, humanized BEW-9E10 VH containing IGHV1-69*06 and IGHJ1*01 framework sequences.
  • hBEW-9E10VH.2 is based on .2z with a Q1E change to prevent pyroglutamate formation.
  • hBEW-9E10VH.2a is a humanized design based on .2 and contains six proposed framework back-mutations (V2I, R38K, W47Y, V67F, I69F, Y91F).
  • hBEW-9E10VH.2b is an intermediate design between .2 and .2a and contains two proposed framework back-mutations: (V67F, I69F).
  • hBEW-9E10VL.1 is a CDR-grafted, humanized BEW-9E10 VL containing IGKV1-27*01 and IGKJ2*01 framework sequences.
  • hBEW-9E10VL.1a is a humanized design based on .1 and contains six proposed framework back-mutations (Q3R, T22E, V43S, F71Y, T72S, Y87F).
  • hBEW-9E10VL.1b is an intermediate design between .1 and .1a. It contains four proposed framework back-mutations (Q3R, V43S, F71Y, Y87F).

Example 6.2.4.8

BEW-1B10

TABLE 2.4.8
Sequences of Humanized BEW-1B10 Variable Regions
SEQ
ID		Sequence
NO:	Protein region	123456789012345678901234567890
769	hBEW-1B10VH.1	EVQLVESGGGLVQPGGSLRLSCAASGFSFS
		KYDMAWVRQAPGKGLEWVASITTSGVGTYY
		RDSVKGRFTISRDNAKNSLYLQMNSLRAED
		TAVYYCARGYGAMDAWGQGTTVTVSS
770	hBEW-1B10VH.1a	EVQLVESGGGLVQPGGSLRLSCAASGFSFS
		KYDMAWFRQAPGKGLEWVASITTSGVGTYY
		RDSVKGRFTVSRDNAKSTLYLQMNSLRAED
		TAVYYCARGYGAMDAWGQGTTVTVSS
771	hBEW-1B10VH.1b	EVQLVESGGGLVQPGGSLRLSCAASGFSFS
		KYDMAWFRQAPGKGLEWVASITTSGVGTYY
		RDSVKGRFTVSRDNAKNSLYLQMNSLRAED
		TAVYYCARGYGAMDAWGQGTTVTVSS
772	hBEW-1B10VL.1	DIQMTQSPSSLSASVGDRVTITCKASQDID
		DYLSWYQQKPGKAPKLLIYAATRLADGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYYCLQ
		SSSTPWTFGGGTKVEIK
773	hBEW-1B10VL.1a	DIQMTQSPSSLSASVGDRVTITCKASQDID
		DYLSWYQQKPGKSPKLVIYAATRLADGVPS
		RFSGSGSGTDYTLTISSLQPEDFATYYCLQ
		SSSTPWTFGGGTKVEIK
774	hBEW-1B10VL.1b	DIQMTQSPSSLSASVGDRVTITCKASQDID
		DYLSWYQQKPGKSPKLLIYAATRLADGVPS
		RFSGSGSGTDYTLTISSLQPEDFATYYCLQ
		SSSTPWTFGGGTKVEIK

• • hBEW-1B10VH.1 is a CDR-grafted, humanized BEW-1B10 VH containing IGHV3-7*01 and IGHJ6*01 framework sequences.
  • hBEW-1B10VH.1a is a humanized design based on .1 and contains four proposed framework back-mutations (V37F, I69V, N76S, S77T).
  • hBEW-1B10VH.1b is an intermediate design between .1 and .1a and contains two proposed framework back-mutations: (V37F, I69V).
  • hBEW-9E10VH.1z is a CDR-grafted, humanized BEW-9E10 VH containing IGHV7-4-1*01 and IGHJ1*01 framework sequences.
  • hBEW-9E10VH.1 is based on .1z with a Q1E change to prevent pyroglutamate formation.
  • hBEW-1B10VL.1 is a CDR-grafted, humanized BEW-1B10 VL containing IGKV1-39*01 and IGKJ4*01 framework sequences.
  • hBEW-1B10VL.1a is a humanized design based on .1 and contains three proposed framework back-mutations: (A43S, L47V, F71Y).
  • hBEW-1B10VL.1b is an intermediate design between .1 and .1a. It contains two proposed framework back-mutations (A43S, F71Y).

Example 6.2.4.9

BEW-1E3

TABLE 2.4.9
Sequences of Humanized BEW-1E3 Variable Regions
SEQ
ID		Sequence
NO:	Protein region	123456789012345678901234567890
775	hBEW-1E3VH.1z	QVQLVQSGSELKKPGASVKVSCKASGYPFT
		NSGMYWVRQAPGQGLEWMGWINTEAGKPTY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARWGYISDNSYGWFDYWGQGTLVT
		VSS
776	hBEW-1E3VH.1	EVQLVQSGSELKKPGASVKVSCKASGYPFT
		NSGMYWVRQAPGQGLEWMGWINTEAGKPTY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARWGYISDNSYGWFDYWGQGTLVT
		VSS
777	hBEW-1E3VH.1a	EIQLVQSGSELKKPGASVKVSCKASGYPFT
		NSGMYWVKQAPGQGLEYMGWINTEAGKPTY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYFCARWGYISDNSYGWFDYWGQGTLVT
		VSS
778	hBEW-1E3VH.2z	QVQLVQSGAEVKKPGASVKVSCKASGYPFT
		NSGMYWVRQAPGQGLEWMGWINTEAGKPTY
		ADDFKGRVTMTTDTSTSTAYMELRSLRSDD
		TAVYYCARWGYISDNSYGWFDYWGQGTLVT
		VSS
779	hBEW-1E3VH.2	EVQLVQSGAEVKKPGASVKVSCKASGYPFT
		NSGMYWVRQAPGQGLEWMGWINTEAGKPTY
		ADDFKGRVTMTTDTSTSTAYMELRSLRSDD
		TAVYYCARWGYISDNSYGWFDYWGQGTLVT
		VSS
780	hBEW-1E3VH.2a	EIQLVQSGAEVKKPGASVKVSCKASGYPFT
		NSGMYWVKQAPGQGLEYMGWINTEAGKPTY
		ADDFKGRFTFTLDTSTSTAYLEIRSLRSDD
		TAVYFCARWGYISDNSYGWFDYWGQGTLVT
		VSS
781	hBEW-1E3VH.2b	EVQLVQSGAEVKKPGASVKVSCKASGYPFT
		NSGMYWVRQAPGQGLEWMGWINTEAGKPTY
		ADDFKGRFTFTLDTSTSTAYLEIRSLRSDD
		TAVYYCARWGYISDNSYGWFDYWGQGTLVT
		VSS
782	hBEW-1E3VL.1	EIVLTQSPATLSLSPGERATLSCRASEGVY
		SYMHWYQQKPGQAPRLLIYKASNLASGIPA
		RFSGSGSGTDFTLTISSLEPEDFAVYYCHQ
		NWNDPLTFGQGTKLEIK
783	hBEW-1E3VL.1a	ETVLTQSPATLSLSPGERATLSCRASEGVY
		SYMHWYQQKPGQQPRLLIYKASNLASGVPA
		RFSGSGSGTDFTLTISSLEPEDFAVYFCHQ
		NWNDPLTFGQGTKLEIK
784	hBEW-1E3VL.1b	EIVLTQSPATLSLSPGERATLSCRASEGVY
		SYMHWYQQKPGQAPRLLIYKASNLASGVPA
		RFSGSGSGTDFTLTISSLEPEDFAVYFCHQ
		NWNDPLTFGQGTKLEIK
785	hBEW-1E3VL.2	AIQLTQSPSSLSASVGDRVTITCRASEGVY
		SYMHWYQQKPGKAPKLLIYKASNLASGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYYCHQ
		NWNDPLTFGQGTKLEIK
786	hBEW-1E3VL.2a	ATQLTQSPSSLSASVGDRVTISCRASEGVY
		SYMHWYQQKPGKQPKLLIYKASNLASGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYFCHQ
		NWNDPLTFGQGTKLEIK
787	hBEW-1E3VL.2b	AIQLTQSPSSLSASVGDRVTITCRASEGVY
		SYMHWYQQKPGKAPKLLIYKASNLASGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYFCHQ
		NWNDPLTFGQGTKLEIK

• • hBEW-1E3VH.1z is a CDR-grafted, humanized BEW-1E3 VH containing IGHV7-4-1*01 and IGHJ1*01 framework sequences.
  • hBEW-1E3VH.1 is based on .1z with a Q1E change to prevent pyroglutamate formation.
  • hBEW-1E3VH.1a is a humanized design based on .1 and contains four proposed framework back-mutations (V2I, R38K, W47Y, Y91F).
  • hBEW-1E3VH.2z is a CDR-grafted, humanized BEW-1E3 VH containing IGHV1-18*01 and IGHJ1*01 framework sequences.
  • hBEW-1E3VH.2 is based on .2z with a Q1E change to prevent pyroglutamate formation.
  • hBEW-1E3VH.2a is a humanized design based on .2 and contains seven proposed framework back-mutations (V2I, R38K, W47Y, V67F, M69F, T71L, Y91F).
  • hBEW-1E3VH.2b is an intermediate design between .2 and .2a and contains three proposed framework back-mutations (V67F, M69F, T71L).
  • hBEW-1E3VL.1 is a CDR-grafted, humanized BEW-1E3 VL containing IGKV3-11*01 and IGKJ2*01 framework sequences.
  • hBEW-1E3VL.1a is a humanized design based on .1 and contains four proposed framework back-mutations (I2T, A43Q, I58V, Y87F).
  • hBEW-1E3VL.1b is an intermediate design between .1 and .1a. It contains two proposed framework back-mutations (I58V, Y87F).
  • hBEW-1E3VL.2 is a CDR-grafted, humanized BEW-1E3 VL containing IGKV1-13*01 and IGKJ2*01 framework sequences.
  • hBEW-1E3VL.2a is a humanized design based on .2 and contains four proposed framework back-mutations (I2T, T22S, A43Q, Y87F).
  • hBEW-1E3VL.2b is an intermediate design between .2 and 2a. It contains one proposed framework back-mutations Y87F.

Example 6.3

Humanization of VEGFRII Antibodies

Example 6.3.1

Humanization Method

Antibody humanization is achieved by grafting CDRs of the rodent antibody onto a “similar” human framework (acceptor) and incorporating minimal number of key framework residues (back-mutation) from the rodent antibody that are selected to maintain the original CDR conformation in order to minimize the immunogenicity while retaining the optimal antigen binding.

Example 6.3.2

Human Germline Sequence Selections for Constructing CDR-Grafted, Humanized VEGFRII Antibodies

By applying the aforementioned method, the CDR sequences of VH and VL chains of monoclonal antibody BCU-6B1-G6 were grafted onto different human heavy and light chain acceptor sequences.

Example 6.3.2.1

BCU-6B1-G6

Based on the alignments with the VH and VL sequences of monoclonal antibody BCU-6B1-G6 of the present invention, the following known human sequences are selected:

1. IGHV7-4-1*01 and IGHJ1*01 for constructing heavy chain acceptor sequences

2. IGHV1-18*01 and IGHJ1*01 as alternative acceptor for constructing heavy chain

3. IGKV1-27*01 and IGKJ4*01 for constructing light chain acceptor sequences

By grafting the corresponding VH and VL CDRs of BCU-6B1-G6 into said acceptor sequences, the CDR-grafted, humanized, and modified VH and VL sequences were prepared.

Example 6.3.3

Introducing Potential Framework Back-Mutations in CDR-Grafted Antibodies

To generate humanized antibody with potential framework back-mutations, the mutations were identified and introduced into the CDR-grafted antibody sequences by de novo synthesis of the variable domain, or mutagenic oligonucleotide primers and polymerase chain reactions, or by methods well known in the art. Different combinations of back mutations and other mutations are constructed for each of the CDR-grafts as follows. Residue numbers for these mutations are based on the Kabat numbering system.

Example 6.3.3.1

BCU-6B1-G6

When IGHV7-4-1*01 and IGHJ1*01 selected as BCU-6B1-G6 heavy chain acceptor sequence, one or more of the following residues could back-mutated as follows: W47→F. Additional mutations include the following: R38→K, Y91→F.

When IGHV1-18*01 and IGHJ1*01 selected as BCU-6B1-G6 heavy chain acceptor sequence, one or more of the following residues could back-mutated as follows: W47→F, V67→F, M69→F, T71→L. Additional mutations include the following: R38→K, Y91→F.

When IGKV1-27*01 and IGKJ4*01 selected as BCU-6B1-G6 light chain acceptor sequence, one or more of the following residues could back-mutated as follows: V43→S, Y49→F, F71→Y, Y87→F. Additional mutations include the following: T22→E, T72→S.

Example 6.3.4

Generation of Humanized Antibodies to VEGFRII Containing Framework Back-Mutations in CDR-Grafted Antibodies

The following humanized variable regions of the murine monoclonal VEGFRII antibodies were cloned into IgG expression vectors for functional characterization.

Example 6.3.4.1

BCU-6B1-G6

TABLE 3.4.1
Sequences of Humanized BCU-6B1-G6 Variable Regions
SEQ
ID	Protein	Sequence
NO:	region	123456789012345678901234567890
788	hBCU-6B1-G6VH.1z	QVQLVQSGSELKKPGASVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEWMGWINTETGQPTY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARLGNNYGIWFAYWGQGTLVTVSS
789	hBCU-6B1-G6VH.1	EVQLVQSGSELKKPGASVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEWMGWINTETGQPTY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARLGNNYGIWFAYWGQGTLVTVSS
790	hBCU-6B1-G6VH.1a	EVQLVQSGSELKKPGASVKVSCKASGYTFT
		NYGMYWVKQAPGQGLEFMGWINTETGQPTY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYFCARLGNNYGIWFAYWGQGTLVTVSS
791	hBCU-6B1-G6VH.1b	EVQLVQSGSELKKPGASVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEFMGWINTETGQPTY
		ADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARLGNNYGIWFAYWGQGTLVTVSS
792	hBCU-6B1-G6VH.2z	QVQLVQSGAEVKKPGASVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEWMGWINTETGQPTY
		ADDFKGRVTMTTDTSTSTAYMELRSLRSDD
		TAVYYCARLGNNYGIWFAYWGQGTLVTVSS
793	hBCU-6B1-G6VH.2	EVQLVQSGAEVKKPGASVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEWMGWINTETGQPTY
		ADDFKGRVTMTTDTSTSTAYMELRSLRSDD
		TAVYYCARLGNNYGIWFAYWGQGTLVTVSS
794	hBCU-6B1-G6VH.2a	EVQLVQSGAEVKKPGASVKVSCKASGYTFT
		NYGMYWVKQAPGQGLEFMGWINTETGQPTY
		ADDFKGRFTFTLDTSTSTAYMELRSLRSDD
		TAVYFCARLGNNYGIWFAYWGQGTLVTVSS
795	hBCU-6B1-G6VH.2b	EVQLVQSGAEVKKPGASVKVSCKASGYTFT
		NYGMYWVRQAPGQGLEFMGWINTETGQPTY
		ADDFKGRFTFTLDTSTSTAYMELRSLRSDD
		TAVYYCARLGNNYGIWFAYWGQGTLVTVSS
796	hBCU-6B1-	DIQMTQSPSSLSASVGDRVTITCRASDDLY
	G6VL.1	STLAWYQQKPGKVPKLLIYDANRLAAGVPS
		RFSGSGSGTDFTLTISSLQPEDVATYYCQQ
		YNKFPWTFGGGTKVEIK
797	hBCU-6B1-	DIQMTQSPSSLSASVGDRVTIECRASDDLY
	G6VL.1a	STLAWYQQKPGKSPKLLIFDANRLAAGVPS
		RFSGSGSGTDYSLTISSLQPEDVATYFCQQ
		YNKFPWTFGGGTKVEIK
798	hBCU-6B1-	DIQMTQSPSSLSASVGDRVTITCRASDDLY
	G6VL.1b	STLAWYQQKPGKSPKLLIFDANRLAAGVPS
		RFSGSGSGTDYTLTISSLQPEDVATYFCQQ
		YNKFPWTFGGGTKVEIK

• • hBCU-6B1-G6VH.1z is a CDR-grafted, humanized BCU-6B1-G6 VH containing IGHV7-4-1*01 and IGHJ1*01 framework sequences.
  • hBCU-6B1-G6VH.1 is based on .1z with a Q1E change to prevent pyroglutamate formation.
  • hBCU-6B1-G6VH.1a is a humanized design based on .1 and contains 3 proposed framework back-mutations: (R38K, W47F, Y91F).
  • hBCU-6B1-G6VH.1b is an intermediate design between .1 and .1a and contains 1 proposed framework back-mutations: W47F
  • hBCU-6B1-G6VH.2z is a CDR-grafted, humanized BCU-6B1-G6 VH containing IGHV1-18*01 and IGHJ1*01 framework sequences.
  • hBCU-6B1-G6VH.2 is based on .2z with a Q1E change to prevent pyroglutamate formation.
  • hBCU-6B1-G6VH.2a is a humanized design based on .2 and contains six proposed framework back-mutations (R38K, W47F, V67F, M69F, T71L, Y91F).
  • hBCU-6B1-G6VH.2b is an intermediate design between .2 and .2a and contains four proposed framework back-mutations: W47F, V67F, M69F, T71L.
  • hBCU-6B1-G6VL.1 is a CDR-grafted, humanized BCU-6B1-G6 VL containing IGKV1-27*01 and IGKJ4*01 framework sequences.
  • hBCU-6B1-G6VL.1a is a humanized design based on .1 and contains six proposed framework back-mutations (T22E, V43S, Y49F, F71Y, T72S, Y87F).
  • hBCU-6B1-G6VL.1b is an intermediate design between .1 and .1a. It contains four proposed framework back-mutations (V43S, Y49F, F71Y, Y87F).

Example 6.4

Humanization of PDGFRB Antibodies

Example 6.4.1

Humanization Method

Antibody humanization is achieved by grafting CDRs of the rodent antibody onto a “similar” human framework (acceptor) and incorporating minimal number of key framework residues (back-mutation) from the rodent antibody that are selected to maintain the original CDR conformation in order to minimize the immunogenicity while retaining the optimal antigen binding.

Example 6.4.2

Human Germline Sequence Selections for Constructing CDR-Grafted, Humanized PDGFRB Antibodies

By applying the aforementioned method, the CDR sequences of VH and VL chains of monoclonal antibody BDE-3C9-G4 was grafted onto different human heavy and light chain acceptor sequences.

Example 6.4.2.1

BDE-3C9-G4

Based on the alignments with the VH and VL sequences of monoclonal antibody BDE-3C9-G4 of the present invention, the following known human sequences are selected:

1. IGHV3-7*01 and IGHJ3*01 for constructing heavy chain acceptor sequences

2. IGKV1-33*01 and IGKJ4*01 for constructing light chain acceptor sequences

By grafting the corresponding VH and VL CDRs of BDE-3C9-G4 into said acceptor sequences, the CDR-grafted, humanized, and modified VH and VL sequences were prepared.

Example 6.4.3

Introducing Potential Framework Back-Mutations in CDR-Grafted Antibodies

To generate humanized antibody with potential framework back-mutations, the mutations were identified and introduced into the CDR-grafted antibody sequences by de novo synthesis of the variable domain, or mutagenic oligonucleotide primers and polymerase chain reactions, or by methods well known in the art. Different combinations of back mutations and other mutations are constructed for each of the CDR-grafts as follows. Residue numbers for these mutations are based on the Kabat numbering system.

Example 6.4.3.1

BDE-3C9-G4

When IGHV3-7*01 and IGHJ3*01 selected as BDE-3C9-G4 heavy chain acceptor sequence, one or more of the following residues could back-mutated as follows: S77→T, L78→Q, Y91→F.

When IGKV1-33*01 and IGKJ4*01 selected as BDE-3C9-G4 light chain acceptor sequence, one or more of the following residues could back-mutated as follows: Q38→L, K45→R, I48→M, Y49→R, T69→R, F71→Y. Additional mutations include the following: V584T.

Example 6.4.4

Generation of Humanized Antibodies to PDGFRB Containing Framework Back-Mutations in CDR-Grafted Antibodies

The following humanized variable regions of the murine monoclonal PDGFRB antibodies were cloned into IgG expression vectors for functional characterization.

Example 6.4.4.1

BDE-3C9-G4

TABLE 4.4.1
Sequences of Humanized BDE-3C9-G4
Variable Regions
SEQ ID	Protein	Sequence
NO:	region	123456789012345678901234567890
799	hBDE-3C9-	EVQLVESGGGLVQPGGSLRLSCAASGFTFS
	G4VH.1	NYGMAWVRQAPGKGLEWVASITNSGGNTYY
		RDSVKGRFTISRDNAKNSLYLQMNSLRAED
		TAVYYCARHTPGANYFDYWGQGTMVTVSS
800	hBDE-3C9-	EVQLVESGGGLVQPGGSLRLSCAASGFTFS
	G4VH.1a	NYGMAWVRQAPGKGLEWVASITNSGGNTYY
		RDSVKGRFTISRDNAKNTQYLQMNSLRAED
		TAVYFCARHTPGANYFDYWGQGTMVTVSS
801	hBDE-3C9-	DIQMTQSPSSLSASVGDRVTITCQASQSIK
	G4VL.1	NYIAWYQQKPGKAPKLLIYYTSTLESGVPS
		RFSGSGSGTDFTFTISSLQPEDIATYYCVQ
		YANLYTFGGGTKVEIK
802	hBDE-3C9-	DIQMTQSPSSLSASVGDRVTITCQASQSIK
	G4VL.1a	NYIAWYQLKPGKAPRLLMRYTSTLESGTPS
		RFSGSGSGRDYTFTISSLQPEDIATYYCVQ
		YANLYTFGGGTKVEIK
803	hBDE-3C9-	DIQMTQSPSSLSASVGDRVTITCQASQSIK
	G4VL.1b	NYIAWYQQKPGKAPRLLIRYTSTLESGVPS
		RFSGSGSGRDYTFTISSLQPEDIATYYCVQ
		YANLYTFGGGTKVEIK

• • hBDE-3C9-G4VH.1 is a CDR-grafted, humanized BDE-3C9-G4 VH containing IGHV3-7*01 and IGHJ3*01 framework sequences.
  • hBDE-3C9-G4VH.1a is a humanized design based on .1 and contains three proposed framework back-mutations (S77T, L78Q, Y91F).
  • hBDE-3C9-G4VL.1 is a CDR-grafted, humanized BDE-3C9-G4 VL containing IGKV1-33*01 and IGKJ4*01 framework sequences.
  • hBDE-3C9-G4VL.1a is a humanized design based on .1 and contains seven proposed framework back-mutations (Q38L, K45R, 148M, Y49R, V58T, T69R, F71Y).
  • hBDE-3C9-G4VL.1b is an intermediate design between .1 and .1a. It contains four proposed framework back-mutations (K45R, Y49R, T69R, F71Y).

Summary of VH and VL Amino Acid Sequences of Humanized Rat Anti-human VEGF-A and Humanized Rat Anti-human PDGF-BB Monoclonal Antibodies

TABLE 27
VH and VL Amino Acid Sequences of Humanized
Rat Anti-Human VEGF-A Monoclonal Antibodies
(CDRs in bold)
SEQ ID		Protein	V Region
NO:	Clone	Region	123456789012345678901234567890
804	hBDB-4G8.1 VH		EVQLVQSGSELKKPGASVKVSCKASG
			YTFTNYGMYWVRQAPGQGLEWMGWIN
			TETGKPTYADDFKGRFVFSLDTSVST
			AYLQISSLKAEDTAVYYCARTNYYYR
			SYIFYFDYWGQGTMVTVSS
805	hBDB-4G8.1	CDR-H1	GYTFTNYGMY
806	hBDB-4G8.1	CDR-H2	WINTETGKPTYADDFKG
807	hBDB-4G8.1	CDR-H3	TNYYYRSYIFYFDY
808	hBDB-4G8.1 VL		AIQLTQSPSSLSASVGDRVTITCRAS
			ESVSTHMHWYQQKPGKAPKLLIYGAS
			NLESGVPSRFSGSGSGTDFTLTISSL
			QPEDFATYYCQQSWNDPFTFGQGTKL
			EIK
809	hBDB-4G8.1	CDR-L1	RASESVSTHMH
810	hBDB-4G8.1	CDR-L2	GASNLES
811	hBDB-4G8.1	CDR-L3	QQSWNDPFT
812	hBDB-4G8.10 VH		EIQLVQSGAEVKKPGASVKVSCKASG
			YTFTNYGMYWVRQAPGQGLEYMGWIN
			TETGKPTYADDFKGRFTFTLDTSTST
			AYMELRSLRSDDTAVYFCARTNYYYR
			SYIFYFDYWGQGTMVTVSS
813	hBDB-4G8.10	CDR-H1	GYTFTNYGMY
814	hBDB-4G8.10	CDR-H2	WINTETGKPTYADDFKG
815	hBDB-4G8.10	CDR-H3	TNYYYRSYIFYFDY
816	hBDB-4G8.10 VL		AIQLTQSPSSLSASVGDRVTITCRAS
			ESVSTHMHWYQQKPGKAPKLLIYGAS
			NLESGVPSRFSGSGSGTDFTLTISSL
			QPEDFATYYCQQSWNDPFTFGQGTKL
			EIK
817	hBDB-4G8.10	CDR-L1	RASESVSTHMH
818	hBDB-4G8.10	CDR-L2	GASNLES
819	hBDB-4G8.10	CDR-L3	QQSWNDPFT
820	hBDB-4G8.11 VH		EIQLVQSGAEVKKPGASVKVSCKASG
			YTFTNYGMYWVRQAPGQGLEYMGWIN
			TETGKPTYADDFKGRFTFTLDTSTST
			AYMELRSLRSDDTAVYFCARTNYYYR
			SYIFYFDYWGQGTMVTVSS
821	hBDB-4G8.11	CDR-H1	GYTFTNYGMY
822	hBDB-4G8.11	CDR-H2	WINTETGKPTYADDFKG
823	hBDB-4G8.11	CDR-H3	TNYYYRSYIFYFDY
824	hBDB-4G8.11 VL		ATQLTQSPSLSASVGDRVTITCRASE
			SVSTHMHWYQQKPGKQPKLLIYGASN
			LESGVPSRFSGSGSGTDFTLTISSLQ
			PEDFATYFCQQSWNDPFTFGQGTKLE
			IK
825	hBDB-4G8.11	CDR-L1	RASESVSTHMH
826	hBDB-4G8.11	CDR-L2	GASNLES
827	hBDB-4G8.11	CDR-L3	QQSWNDPFT
828	hBDB-4G8.12 VH		EIQLVQSGAEVKKPGASVKVSCKASG
			YTFTNYGMYWVRQAPGQGLEYMGWIN
			TETGKPTYADDFKGRFTFTLDTSTST
			AYMELRSLRSDDTAVYFCARTNYYYR
			SYIFYFDYWGQGTMVTVSS
829	hBDB-4G8.12	CDR-H1	GYTFTNYGMY
830	hBDB-4G8.12	CDR-H2	WINTETGKPTYADDFKG
831	hBDB-4G8.12	CDR-H3	TNYYYRSYIFYFDY
832	hBDB-4G8.12 VL		DTVLTQSPATLSLSPGERATLSCRAS
			ESVSTHMHWYQQKPGQAPRLLIYGAS
			NLESGVPARFSGSGSGTDFTLTISSL
			EPEDFAVYFCQQSWNDPFTFGQGTKL
			EIK
833	hBDB-4G8.12	CDR-L1	RASESVSTHMH
834	hBDB-4G8.12	CDR-L2	GASNLES
835	hBDB-4G8.12	CDR-L3	QQSWNDPFT
836	hBDB-4G8.13 VH		EIQLVQSGTEVKKPGESLKISCKASG
			YTFTNYGMYWVKQMPGKGLEYMGWIN
			TETGKPTYADDFKGRFTFSLDKSFNT
			AFLQWSSLKASDTAMYFCARTNYYYR
			SYIFYFDYWGQGTMVTVSS
837	hBDB-4G8.13	CDR-H1	GYTFTNYGMY
838	hBDB-4G8.13	CDR-H2	WINTETGKPTYADDFKG
839	hBDB-4G8.13	CDR-H3	TNYYYRSYIFYFDY
840	hBDB-4G8.13 VL		ETVLTQSPATLSVSPGERATLSCRAS
			ESVSTHMHWYQQKPGQAPRLLIYGAS
			NLESGVPARFSGSGSGTDFTLTISSL
			QSEDFAVYFCQQSWNDPFTFGQGTRL
			EIK
841	hBDB-4G8.13	CDR-L1	RASESVSTHMH
842	hBDB-4G8.13	CDR-L2	GASNLES
843	hBDB-4G8.13	CDR-L3	QQSWNDPFT
844	hBDB-4G8.14 VH		EIQLVQSGGGVVQPGGSLRLSCAASG
			YTFTNYGMYWVKQAPGKGLEYMGWIN
			TETGKPTYADDFKGRFTFSLDTSKST
			AYLQLNSLRAEDTAVYFCARTNYYYR
			SYIFYFDYWGQGTLVTVSS
845	hBDB-4G8.14	CDR-H1	GYTFTNYGMY
846	hBDB-4G8.14	CDR-H2	WINTETGKPTYADDFKG
847	hBDB-4G8.14	CDR-H3	TNYYYRSYIFYFDY
848	hBDB-4G8.14 VL		DTVLTQSPSTLSASPGERATISCRAS
			ESVSTHMHWYQQKPGQAPKLLIYGAS
			NLESGVPSRFSGSRSGTDFTLTISSL
			QPEDFAVYFCQQSWNDPFTFGQGTKV
			EIK
849	hBDB-4G8.14	CDR-L1	RASESVSTHMH
850	hBDB-4G8.14	CDR-L2	GASNLES
851	hBDB-4G8.14	CDR-L3	QQSWNDPFT
852	hBDB-4G8.15 VH		EVQLVESGGGLVQPGGSLRLSCAASG
			YTFTNYGMYWVKQAPGKGLEYMGWIN
			TETGKPTYADDFKGRFTFSLDTSKST
			AYLQMNSLRAEDTAVYFCARTNYYYR
			SYIFYFDYWGQGTLVTVSS
853	hBDB-4G8.15	CDR-H1	GYTFTNYGMY
854	hBDB-4G8.15	CDR-H2	WINTETGKPTYADDFKG
855	hBDB-4G8.15	CDR-H3	TNYYYRSYIFYFDY
856	hBDB-4G8.15 VL		DTQLTQSPSSLSASVGDRVTISCRAS
			ESVSTHMHWYQQKPGKAPKLLIYGAS
			NLESGVPSRFSGSGSGTDFTLTISSL
			QPEDFATYFCQQSWNDPFTFGQGTKV
			EIK
857	hBDB-4G8.15	CDR-L1	RASESVSTHMH
858	hBDB-4G8.15	CDR-L2	GASNLES
859	hBDB-4G8.15	CDR-L3	QQSWNDPFT
860	hBDB-4G8.2 VH		EVQLVQSGSELKKPGASVKVSCKASG
			YTFTNYGMYWVRQAPGQGLEWMGWIN
			TETGKPTYADDFKGRFVFSLDTSVST
			AYLQISSLKAEDTAVYYCARTNYYYR
			SYIFYFDYWGQGTMVTVSS
861	hBDB-4G8.2	CDR-H1	GYTFTNYGMY
862	hBDB-4G8.2	CDR-H2	WINTETGKPTYADDFKG
863	hBDB-4G8.2	CDR-H3	TNYYYRSYIFYFDY
864	hBDB-4G8.2 VL		ATQLTQSPSLSASVGDRVTITCRASE
			SVSTHMHWYQQKPGKQPKLLIYGASN
			LESGVPSRFSGSGSGTDFTLTISSLQ
			PEDFATYFCQQSWNDPFTFGQGTKLE
			IK
865	hBDB-4G8.2	CDR-L1	RASESVSTHMH
866	hBDB-4G8.2	CDR-L2	GASNLES
867	hBDB-4G8.2	CDR-L3	QQSWNDPFT
868	hBDB-4G8.3 VH		EVQLVQSGSELKKPGASVKVSCKASG
			YTFTNYGMYWVRQAPGQGLEWMGWIN
			TETGKPTYADDFKGRFVFSLDTSVST
			AYLQISSLKAEDTAVYYCARTNYYYR
			SYIFYFDYWGQGTMVTVSS
869	hBDB-4G8.3	CDR-H1	GYTFTNYGMY
870	hBDB-4G8.3	CDR-H2	WINTETGKPTYADDFKG
871	hBDB-4G8.3	CDR-H3	TNYYYRSYIFYFDY
872	hBDB-4G8.3 VL		DTVLTQSPATLSLSPGERATLSCRAS
			ESVSTHMHWYQQKPGQAPRLLIYGAS
			NLESGVPARFSGSGSGTDFTLTISSL
			EPEDFAVYFCQQSWNDPFTFGQGTKL
			EIK
873	hBDB-4G8.3	CDR-L1	RASESVSTHMH
874	hBDB-4G8.3	CDR-L2	GASNLES
875	hBDB-4G8.3	CDR-L3	QQSWNDPFT
876	hBDB-4G8.4 VH		EIQLVQSGSELKKPGASVKVSCKASG
			YTFTNYGMYWVRQAPGQGLEYMGWIN
			TETGKPTYADDFKGRFVFSLDTSVST
			AYLQISSLKAEDTAVYFCARTNYYYR
			SYIFYFDYWGQGTMVTVSS
877	hBDB-4G8.4	CDR-H1	GYTFTNYGMY
878	hBDB-4G8.4	CDR-H2	WINTETGKPTYADDFKG
879	hBDB-4G8.4	CDR-H3	TNYYYRSYIFYFDY
880	hBDB-4G8.4 VL		AIQLTQSPSSLSASVGDRVTITCRAS
			ESVSTHMHWYQQKPGKAPKLLIYGAS
			NLESGVPSRFSGSGSGTDFTLTISSL
			QPEDFATYYCQQSWNDPFTFGQGTKL
			EIK
881	hBDB-4G8.4	CDR-L1	RASESVSTHMH
882	hBDB-4G8.4	CDR-L2	GASNLES
883	hBDB-4G8.4	CDR-L3	QQSWNDPFT
884	hBDB-4G8.5 VH		EIQLVQSGSELKKPGASVKVSCKASG
			YTFTNYGMYWVRQAPGQGLEYMGWIN
			TETGKPTYADDFKGRFVFSLDTSVST
			AYLQISSLKAEDTAVYFCARTNYYYR
			SYIFYFDYWGQGTMVTVSS
885	hBDB-4G8.5	CDR-H1	GYTFTNYGMY
886	hBDB-4G8.5	CDR-H2	WINTETGKPTYADDFKG
887	hBDB-4G8.5	CDR-H3	TNYYYRSYIFYFDY
888	hBDB-4G8.5 VL		ATQLTQSPSLSASVGDRVTITCRASE
			SVSTHMHWYQQKPGKQPKLLIYGASN
			LESGVPSRFSGSGSGTDFTLTISSLQ
			PEDFATYFCQQSWNDPFTFGQGTKLE
			IK
889	hBDB-4G8.5	CDR-L1	RASESVSTHMH
890	hBDB-4G8.5	CDR-L2	GASNLES
891	hBDB-4G8.5	CDR-L3	QQSWNDPFT
892	hBDB-4G8.6 VH		EIQLVQSGSELKKPGASVKVSCKASG
			YTFTNYGMYWVRQAPGQGLEYMGWIN
			TETGKPTYADDFKGRFVFSLDTSVST
			AYLQISSLKAEDTAVYFCARTNYYYR
			SYIFYFDYWGQGTMVTVSS
893	hBDB-4G8.6	CDR-H1	GYTFTNYGMY
894	hBDB-4G8.6	CDR-H2	WINTETGKPTYADDFKG
895	hBDB-4G8.6	CDR-H3	TNYYYRSYIFYFDY
896	hBDB-4G8.6 VL		DTVLTQSPATLSLSPGERATLSCRAS
			ESVSTHMHWYQQKPGQAPRLLIYGAS
			NLESGVPARFSGSGSGTDFTLTISSL
			EPEDFAVYFCQQSWNDPFTFGQGTKL
			EIK
897	hBDB-4G8.6	CDR-L1	RASESVSTHMH
898	hBDB-4G8.6	CDR-L2	GASNLES
899	hBDB-4G8.6	CDR-L3	QQSWNDPFT
900	hBDB-4G8.7 VH		EVQLVQSGAEVKKPGASVKVSCKASG
			YTFTNYGMYWVRQAPGQGLEWMGWIN
			TETGKPTYADDFKGRVTMTTDTSTST
			AYMELRSLRSDDTAVYYCARTNYYYR
			SYIFYFDYWGQGTMVTVSS
901	hBDB-4G8.7	CDR-H1	GYTFTNYGMY
902	hBDB-4G8.7	CDR-H2	WINTETGKPTYADDFKG
903	hBDB-4G8.7	CDR-H3	TNYYYRSYIFYFDY
904	hBDB-4G8.7 VL		AIQLTQSPSSLSASVGDRVTITCRAS
			ESVSTHMHWYQQKPGKAPKLLIYGAS
			NLESGVPSRFSGSGSGTDFTLTISSL
			QPEDFATYYCQQSWNDPFTFGQGTKL
			EIK
905	hBDB-4G8.7	CDR-L1	RASESVSTHMH
906	hBDB-4G8.7	CDR-L2	GASNLES
907	hBDB-4G8.7	CDR-L3	QQSWNDPFT
908	hBDB-4G8.8 VH		EVQLVQSGAEVKKPGASVKVSCKASG
			YTFTNYGMYWVRQAPGQGLEWMGWIN
			TETGKPTYADDFKGRVTMTTDTSTST
			AYMELRSLRSDDTAVYYCARTNYYYR
			SYIFYFDYWGQGTMVTVSS
909	hBDB-4G8.8	CDR-H1	GYTFTNYGMY
910	hBDB-4G8.8	CDR-H2	WINTETGKPTYADDFKG
911	hBDB-4G8.8	CDR-H3	TNYYYRSYIFYFDY
912	hBDB-4G8.8 VL		ATQLTQSPSLSASVGDRVTITCRASE
			SVSTHMHWYQQKPGKQPKLLIYGASN
			LESGVPSRFSGSGSGTDFTLISSLQ
			PEDFATYFCQQSWNDPFTFGQGTKLE
			IK
913	hBDB-4G8.8	CDR-L1	RASESVSTHMH
914	hBDB-4G8.8	CDR-L2	GASNLES
915	hBDB-4G8.8	CDR-L3	QQSWNDPFT
916	hBDB-4G8.9 VH		EVQLVQSGAEVKKPGASVKVSCKASG
			YTFTNYGMYWVRQAPGQGLEWMGWIN
			TETGKPTYADDFKGRVTMTTDTSTST
			AYMELRSLRSDDTAVYYCARTNYYYR
			SYIFYFDYWGQGTMVTVSS
917	hBDB-4G8.9	CDR-H1	GYTFTNYGMY
918	hBDB-4G8.9	CDR-H2	WINTETGKPTYADDFKG
919	hBDB-4G8.9	CDR-H3	TNYYYRSYIFYFDY
920	hBDB-4G8.9 VL		DTVLTQSPATLSLSPGERATLSCRAS
			ESVSTHMHWYQQKPGQAPRLLIYGAS
			NLESGVPARFSGSGSGTDFTLTISSL
			EPEDFAVYFCQQSWNDPFTFGQGTKL
			EIK
921	hBDB-4G8.9	CDR-L1	RASESVSTHMH
922	hBDB-4G8.9	CDR-L2	GASNLES
923	hBDB-4G8.9	CDR-L3	QQSWNDPFT
924	hBEW-1B10.1 VH		EVQLVESGGGLVQPGGSLRLSCAASG
			FSFSKYDMAWFRQAPGKGLEWVASIT
			TSGVGTYYRDSVKGRFTVSRDNAKST
			LYLQMNSLRAEDTAVYYCARGYGAMD
			AWGQGTTVTVSS
925	hBEW-1B10.1	CDR-H1	GFSFSKYDMA
926	hBEW-1B10.1	CDR-H2	SITTSGVGTYYRDSVKG
927	hBEW-1B10.1	CDR-H3	GYGAMDA
928	hBEW-1B10.1 VL		DIQMTQSPSSLSASVGDRVTITCKAS
			QDIDDYLSWYQQKPGKSPKLVIYAAT
			RLADGVPSRFSGSGSGTDYTLTISSL
			QPEDFATYYCLQSSSTPWTFGGGTKV
			EIK
929	hBEW-1B10.1	CDR-L1	KASQDIDDYLS
930	hBEW-1B10.1	CDR-L2	AATRLAD
931	hBEW-1B10.1	CDR-L3	LQSSSTPWT
932	hBEW-1B10.2 VH		EVQLVESGGGLVQPGGSLRLSCAASG
			FSFSKYDMAWFRQAPGKGLEWVASIT
			TSGVGTYYRDSVKGRFTVSRDNAKNS
			LYLQMNSLRAEDTAVYYCARGYGAMD
			AWGQGTTVTVSS
933	hBEW-1B10.2	CDR-H1	GFSFSKYDMA
934	hBEW-1B10.2	CDR-H2	SITTSGVGTYYRDSVKG
935	hBEW-1B10.2	CDR-H3	GYGAMDA
936	hBEW-1B10.2 VL		DIQMTQSPSSLSASVGDRVTITCKAS
			QDIDDYLSWYQQKPGKSPKLVIYAAT
			RLADGVPSRFSGSGSGTDYTLTISSL
			QPEDFATYYCLQSSSTPWTFGGGTKV
			EIK
937	hBEW-1B10.2	CDR-L1	KASQDIDDYLS
938	hBEW-1B10.2	CDR-L2	AATRLAD
939	hBEW-1B10.2	CDR-L3	LQSSSTPWT
940	hBEW-1E3.1 VH		EIQLVQSGSELKKPGASVKVSCKASG
			YPFTNSGMYWVKQAPGQGLEYMGWIN
			TEAGKPTYADDFKGRFVFSLDTSVST
			AYLQISSLKAEDTAVYFCARWGYISD
			NSYGWFDYWGQGTLVTVSS
941	hBEW-1E3.1	CDR-H1	GYPFTNSGMY
942	hBEW-1E3.1	CDR-H2	WINTEAGKPTYADDFKG
943	hBEW-1E3.1	CDR-H3	WGYISDNSYGWFDY
944	hBEW-1E3.1 VL		ETVLTQSPATLSLSPGERATLSCRAS
			EGVYSYMHWYQQKPGQQPRLLIYKAS
			NLASGVPARFSGSGSGTDFTLTISSL
			EPEDFAVYFCHQNWNDPLTFGQGTKL
			EIK
945	hBEW-1E3.1	CDR-L1	RASEGVYSYMH
946	hBEW-1E3.1	CDR-L2	KASNLAS
947	hBEW-1E3.1	CDR-L3	HQNWNDPLT
948	hBEW-1E3.2 VH		EIQLVQSGAEVKKPGASVKVSCKASG
			YPFTNSGMYWVKQAPGQGLEYMGWIN
			TEAGKPTYADDFKGRFTFTLDTSTST
			AYLEIRSLRSDDTAVYFCARWGYISD
			NSYGWFDYWGQGTLVTVSS
949	hBEW-1E3.2	CDR-H1	GYPFTNSGMY
950	hBEW-1E3.2	CDR-H2	WINTEAGKPTYADDFKG
951	hBEW-1E3.2	CDR-H3	WGYISDNSYGWFDY
952	hBEW-1E3.2 VL		ETVLTQSPATLSLSPGERATLSCRAS
			EGVYSYMHWYQQKPGQQPRLLIYKAS
			NLASGVPARFSGSGSGTDFTLTISSL
			EPEDFAVYFCHQNWNDPLTFGQGTKL
			EIK
953	hBEW-1E3.2	CDR-L1	RASEGVYSYMH
954	hBEW-1E3.2	CDR-L2	KASNLAS
955	hBEW-1E3.2	CDR-L3	HQNWNDPLT
956	hBEW-1E3.3 VH		EVQLVQSGAEVKKPGASVKVSCKASG
			YPFTNSGMYWVRQAPGQGLEWMGWIN
			TEAGKPTYADDFKGRFTFTLDTSTST
			AYLEIRSLRSDDTAVYYCARWGYISD
			NSYGWFDYWGQGTLVTVSS
957	hBEW-1E3.3	CDR-H1	GYPFTNSGMY
958	hBEW-1E3.3	CDR-H2	WINTEAGKPTYADDFKG
959	hBEW-1E3.3	CDR-H3	WGYISDNSYGWFDY
960	hBEW-1E3.3 VL		ETVLTQSPATLSLSPGERATLSCRAS
			EGVYSYMHWYQQKPGQQPRLLIYKAS
			NLASGVPARFSGSGSGTDFTLTISSL
			EPEDFAVYFCHQNWNDPLTFGQGTKL
			EIK
961	hBEW-1E3.3	CDR-L1	RASEGVYSYMH
962	hBEW-1E3.3	CDR-L2	KASNLAS
963	hBEW-1E3.3	CDR-L3	HQNWNDPLT
964	hBEW-1E3.4 VH		EIQLVQSGSELKKPGASVKVSCKASG
			YPFTNSGMYWVKQAPGQGLEYMGWIN
			TEAGKPTYADDFKGRFVFSLDTSVST
			AYLQISSLKAEDTAVYFCARWGYISD
			NSYGWFDYWGQGTLVTVSS
965	hBEW-1E3.4	CDR-H1	GYPFTNSGMY
966	hBEW-1E3.4	CDR-H2	WINTEAGKPTYADDFKG
967	hBEW-1E3.4	CDR-H3	WGYISDNSYGWFDY
968	hBEW-1E3.4 VL		ATQLTQSPSSLSASVGDRVTISCRAS
			EGVYSYMHWYQQKPGKQPKLLIYKAS
			NLASGVPSRFSGSGSGTDFTLTISSL
			QPEDFATYFCHQNWNDPLTFGQGTKL
			EIK
969	hBEW-1E3.4	CDR-L1	RASEGVYSYMH
970	hBEW-1E3.4	CDR-L2	KASNLAS
971	hBEW-1E3.4	CDR-L3	HQNWNDPLT
972	hBEW-1E3.5 VH		EIQLVQSGAEVKKPGASVKVSCKASG
			YPFTNSGMYWVKQAPGQGLEYMGWIN
			TEAGKPTYADDFKGRFTFTLDTSTST
			AYLEIRSLRSDDTAVYFCARWGYISD
			NSYGWFDYWGQGTLVTVSS
973	hBEW-1E3.5	CDR-H1	GYPFTNSGMY
974	hBEW-1E3.5	CDR-H2	WINTEAGKPTYADDFKG
975	hBEW-1E3.5	CDR-H3	WGYISDNSYGWFDY
976	hBEW-1E3.5 VL		ATQLTQSPSSLSASVGDRVTISCRAS
			EGVYSYMHWYQQKPGKQPKLLIYKAS
			NLASGVPSRFSGSGSGTDFTLTISSL
			QPEDFATYFCHQNWNDPLTFGQGTKL
			EIK
977	hBEW-1E3.5	CDR-L1	RASEGVYSYMH
978	hBEW-1E3.5	CDR-L2	KASNLAS
979	hBEW-1E3.5	CDR-L3	HQNWNDPLT
980	hBEW-5C3.1 VH		EIQLVQSGSELKKPGASVKVSCKASG
			YTFTNYGVYWVKQAPGQGLEYMGWIN
			TETGKPTYADDFKGRFVFSLDTSVST
			AYLQISSLKAEDTAVYYCARARQLDW
			FVYWGQGTLVTVSS
981	hBEW-5C3.1	CDR-H1	GYTFTNYGVY
982	hBEW-5C3.1	CDR-H2	WINTETGKPTYADDFKG
983	hBEW-5C3.1	CDR-H3	ARQLDWFVY
984	hBEW-5C3.1 VL		DTVLTQSPATLSLSPGERATLSCRAR
			ESLTTSLSWFQQKPGQQPRLLIYGAS
			KLESGVPARFSGSGSGTDFTLTISSL
			EPEDFAVYFCQQSWYDPPTFGGGTKV
			EIK
985	hBEW-5C3.1	CDR-L1	RARESLTTSLS
986	hBEW-5C3.1	CDR-L2	GASKLES
987	hBEW-5C3.1	CDR-L3	QQSWYDPPT
988	hBEW-5C3.2 VH		EIQLVQSGAEVKKPGSSVKVSCKASG
			YTFTNYGVYWVKQAPGQGLEYMGWIN
			TETGKPTYADDFKGRFTFTLDKSTST
			AYMELSSLRSEDTAVYFCARARQLDW
			FVYWGQGTLVTVSS
989	hBEW-5C3.2	CDR-H1	GYTFTNYGVY
990	hBEW-5C3.2	CDR-H2	WINTETGKPTYADDFKG
991	hBEW-5C3.2	CDR-H3	ARQLDWFVY
992	hBEW-5C3.2 VL		DTVLTQSPATLSLSPGERATLSCRAR
			ESLTTSLSWFQQKPGQQPRLLIYGAS
			KLESGVPARFSGSGSGTDFTLTISSL
			EPEDFAVYFCQQSWYDPPTFGGGTKV
			EIK
993	hBEW-5C3.2	CDR-L1	RARESLTTSLS
994	hBEW-5C3.2	CDR-L2	GASKLES
995	hBEW-5C3.2	CDR-L3	QQSWYDPPT
996	hBEW-5C3.3 VH		EVQLVQSGAEVKKPGSSVKVSCKASG
			YTFTNYGVYWVRQAPGQGLEWMGWIN
			TETGKPTYADDFKGRFTFTLDKSTST
			AYMELSSLRSEDTAVYYCARARQLDW
			FVYWGQGTLVTVSS
997	hBEW-5C3.3	CDR-H1	GYTFTNYGVY
998	hBEW-5C3.3	CDR-H2	WINTETGKPTYADDFKG
999	hBEW-5C3.3	CDR-H3	ARQLDWFVY
1000	hBEW-5C3.3 VL		DTVLTQSPATLSLSPGERATLSCRAR
			ESLTTSLSWFQQKPGQQPRLLIYGAS
			KLESGVPARFSGSGSGTDFTLTISSL
			EPEDFAVYFCQQSWYDPPTFGGGTKV
			EIK
1001	hBEW-5C3.3	CDR-L1	RARESLTTSLS
1002	hBEW-5C3.3	CDR-L2	GASKLES
1003	hBEW-5C3.3	CDR-L3	QQSWYDPPT
1004	hBEW-5C3.4 VH		EIQLVQSGSELKKPGASVKVSCKASG
			YTFTNYGVYWVKQAPGQGLEYMGWIN
			TETGKPTYADDFKGRFVFSLDTSVST
			AYLQISSLKAEDTAVYYCARARQLDW
			FVYWGQGTLVTVSS
1005	hBEW-5C3.4	CDR-H1	GYTFTNYGVY
1006	hBEW-5C3.4	CDR-H2	WINTETGKPTYADDFKG
1007	hBEW-5C3.4	CDR-H3	ARQLDWFVY
1008	hBEW-5C3.4 VL		DTQLTQSPSSLSASVGDRVTISCRAR
			ESLTTSLSWFQQKPGKQPKLLIYGAS
			KLESGVPSRFSGSGSGTDFTLTISSL
			QPEDFATYFCQQSWYDPPTFGGGTKV
			EIK
1009	hBEW-5C3.4	CDR-L1	RARESLTTSLS
1010	hBEW-5C3.4	CDR-L2	GASKLES
1011	hBEW-5C3.4	CDR-L3	QQSWYDPPT
1012	hBEW-5C3.5 VH		EIQLVQSGAEVKKPGSSVKVSCKASG
			YTFTNYGVYWVKQAPGQGLEYMGWIN
			TETGKPTYADDFKGRFTFTLDKSTST
			AYMELSSLRSEDTAVYFCARARQLDW
			FVYWGQGTLVTVSS
1013	hBEW-5C3.5	CDR-H1	GYTFTNYGVY
1014	hBEW-5C3.5	CDR-H2	WINTETGKPTYADDFKG
1015	hBEW-5C3.5	CDR-H3	ARQLDWFVY
1016	hBEW-5C3.5 VL		DTQLTQSPSSLSASVGDRVTISCRAR
			ESLTTSLSWFQQKPGKQPKLLIYGAS
			KLESGVPSRFSGSGSGTDFTLTISSL
			QPEDFATYFCQQSWYDPPTFGGGTKV
			EIK
1017	hBEW-5C3.5	CDR-L1	RARESLTTSLS
1018	hBEW-5C3.5	CDR-L2	GASKLES
1019	hBEW-5C3.5	CDR-L3	QQSWYDPPT
1020	hBEW-5C3.6 VH		EVQLVQSGAEVKKPGSSVKVSCKASG
			YTFTNYGVYWVRQAPGQGLEWMGWIN
			TETGKPTYADDFKGRFTFTLDKSTST
			AYMELSSLRSEDTAVYYCARARQLDW
			FVYWGQGTLVTVSS
1021	hBEW-5C3.6	CDR-H1	GYTFTNYGVY
1022	hBEW-5C3.6	CDR-H2	WINTETGKPTYADDFKG
1023	hBEW-5C3.6	CDR-H3	ARQLDWFVY
1024	hBEW-5C3.6 VL		DTQLTQSPSSLSASVGDRVTISCRAR
			ESLTTSLSWFQQKPGKQPKLLIYGAS
			KLESGVPSRFSGSGSGTDFTLTISSL
			QPEDFATYFCQQSWYDPPTFGGGTKV
			EIK
1025	hBEW-5C3.6	CDR-L1	RARESLTTSLS
1026	hBEW-5C3.6	CDR-L2	GASKLES
1027	hBEW-5C3.6	CDR-L3	QQSWYDPPT
1028	hBEW-6C2.1 VH		EVQLVESGGGLVQPGGSLRLSCAASG
			FTFSYYGMHWVRQAPGKGLEWVALIY
			YDSSKMYYADSVKGRFTISRDNAKNS
			LYLQMNSLRAEDTAVYYCARGGTAPV
			YWGQGTMVTVSS
1029	hBEW-6C2.1	CDR-H1	GFTFSYYGMH
1030	hBEW-6C2.1	CDR-H2	LIYYDSSKMYYADSVKG
1031	hBEW-6C2.1	CDR-H3	GGTAPVY
1032	hBEW-6C2.1 VL		EIVLTQSPATLSLSPGERATLSCKGS
			QNIANYLAWYQQKPGQAPRLLIYNTD
			SLQTGIPARFSGSGSGTDFTLTISSL
			EPEDFAVYYCYQSNNGYTFGQGTKLE
			IK
1033	hBEW-6C2.1	CDR-L1	KGSQNIANYLA
1034	hBEW-6C2.1	CDR-L2	NTDSLQT
1035	hBEW-6C2.1	CDR-L3	YQSNNGYT
1036	hBEW-6C2.2 VH		EVQLVESGGGLVQPGGSLRLSCAASG
			FTFSYYGMHWVRQAPGKGLEWVALIY
			YDSSKMYYADSVKGRFTISRDNAKNS
			LYLQMNSLRAEDTAVYYCARGGTAPV
			YWGQGTMVTVSS
1037	hBEW-6C2.2	CDR-H1	GFTFSYYGMH
1038	hBEW-6C2.2	CDR-H2	LIYYDSSKMYYADSVKG
1039	hBEW-6C2.2	CDR-H3	GGTAPVY
1040	hBEW-6C2.2 VL		EIVLTQSPATLSLSPGERATLSCKGS
			QNIANYLAWYQQKPGQAPRLLIYNTD
			SLQTGIPARFSGSGSGTDYTLTISSL
			EPEDFAVYFCYQSNNGYTFGQGTKLE
			IK
1041	hBEW-6C2.2	CDR-L1	KGSQNIANYLA
1042	hBEW-6C2.2	CDR-L2	NTDSLQT
1043	hBEW-6C2.2	CDR-L3	YQSNNGYT
1044	hBEW-6C2.3 VH		EVQLVESGGGLVQPGGSLRLSCAASG
			FTFSYYGMHWVRQAPGKGLEWVALIY
			YDSSKMYYADSVKGRFTISRDNAKNS
			LYLQMNSLRAEDTAVYYCARGGTAPV
			YWGQGTMVTVSS
1045	hBEW-6C2.3	CDR-H1	GFTFSYYGMH
1046	hBEW-6C2.3	CDR-H2	LIYYDSSKMYYADSVKG
1047	hBEW-6C2.3	CDR-H3	GGTAPVY
1048	hBEW-6C2.3 VL		DIQMTQSPSSLSASVGDRVTITCKGS
			QNIANYLAWYQQKPGKAPKLLIYNTD
			SLQTGVPSRFSGSGSGTDFTLTISSL
			QPEDFATYYCYQSNNGYTFGQGTKLE
			IK
1049	hBEW-6C2.3	CDR-L1	KGSQNIANYLA
1050	hBEW-6C2.3	CDR-L2	NTDSLQT
1051	hBEW-6C2.3	CDR-L3	YQSNNGYT
1052	hBEW-6C2.4 VH		EVQLVESGGGLVQPGGSLRLSCAASG
			FTFSYYGMHWVRQAPGKGLEWVALIY
			YDSSKMYYADSVKGRFTISRDNAKNS
			LYLQMNSLRAEDTAVYYCARGGTAPV
			YWGQGTMVTVSS
1053	hBEW-6C2.4	CDR-H1	GFTFSYYGMH
1054	hBEW-6C2.4	CDR-H2	LIYYDSSKMYYADSVKG
1055	hBEW-6C2.4	CDR-H3	GGTAPVY
1056	hBEW-6C2.4 VL		DIQLTQSPSSLSASVGDRVTITCKGS
			QNIANYLAWYQQKPGKAPKLLIYNTD
			SLQTGIPSRFSGSGSGTDYTLTISSL
			QPEDFATYFCYQSNNGYTFGQGTKLE
			IK
1057	hBEW-6C2.4	CDR-L1	KGSQNIANYLA
1058	hBEW-6C2.4	CDR-L2	NTDSLQT
1059	hBEW-6C2.4	CDR-L3	YQSNNGYT
1060	hBEW-6C2.5 VH		EVQLVESGGGLVQPGGSLRLSCAASG
			FTFSYYGMHWIRQAPGKGLEWMALIY
			YDSSKMYYADSVKGRFTISRDNAKNS
			LYLQMNSLRAEDTAVYYCAAGGTAPV
			YWGQGTMVTVSS
1061	hBEW-6C2.5	CDR-H1	GFTFSYYGMH
1062	hBEW-6C2.5	CDR-H2	LIYYDSSKMYYADSVKG
1063	hBEW-6C2.5	CDR-H3	GGTAPVY
1064	hBEW-6C2.5 VL		EIVLTQSPATLSLSPGERATLSCKGS
			QNIANYLAWYQQKPGQAPRLLIYNTD
			SLQTGIPARFSGSGSGTDFTLTISSL
			EPEDFAVYYCYQSNNGYTFGQGTKLE
			IK
1065	hBEW-6C2.5	CDR-L1	KGSQNIANYLA
1066	hBEW-6C2.5	CDR-L2	NTDSLQT
1067	hBEW-6C2.5	CDR-L3	YQSNNGYT
1068	hBEW-6C2.6 VH		EVQLVESGGGLVQPGGSLRLSCAASG
			FTFSYYGMHWIRQAPGKGLEWMALIY
			YDSSKMYYADSVKGRFTISRDNAKNS
			LYLQMNSLRAEDTAVYYCAAGGTAPV
			YWGQGTMVTVSS
1069	hBEW-6C2.6	CDR-H1	GFTFSYYGMH
1070	hBEW-6C2.6	CDR-H2	LIYYDSSKMYYADSVKG
1071	hBEW-6C2.6	CDR-H3	GGTAPVY
1072	hBEW-6C2.6 VL		EIVLTQSPATLSLSPGERATLSCKGS
			QNIANYLAWYQQKPGQAPRLLIYNTD
			SLQTGIPARFSGSGSGTDYTLTISSL
			EPEDFAVYFCYQSNNGYTFGQGTKLE
			IK
1073	hBEW-6C2.6	CDR-L1	KGSQNIANYLA
1074	hBEW-6C2.6	CDR-L2	NTDSLQT
1075	hBEW-6C2.6	CDR-L3	YQSNNGYT
1076	hBEW-6C2.7 VH		EVQLVESGGGLVQPGGSLRLSCAASG
			FTFSYYGMHWIRQAPGKGLEWMALIY
			YDSSKMYYADSVKGRFTISRDNAKNS
			LYLQMNSLRAEDTAVYYCAAGGTAPV
			YWGQGTMVTVSS
1077	hBEW-6C2.7	CDR-H1	GFTFSYYGMH
1078	hBEW-6C2.7	CDR-H2	LIYYDSSKMYYADSVKG
1079	hBEW-6C2.7	CDR-H3	GGTAPVY
1080	hBEW-6C2.7 VL		DIQMTQSPSSLSASVGDRVTITCKGS
			QNIANYLAWYQQKPGKAPKLLIYNTD
			SLQTGVPSRFSGSGSGTDFTLTISSL
			QPEDFATYYCYQSNNGYTFGQGTKLE
			IK
1081	hBEW-6C2.7	CDR-L1	KGSQNIANYLA
1082	hBEW-6C2.7	CDR-L2	NTDSLQT
1083	hBEW-6C2.7	CDR-L3	YQSNNGYT
1084	hBEW-6C2.8 VH		EVQLVESGGGLVQPGGSLRLSCAASG
			FTFSYYGMHWIRQAPGKGLEWMALIY
			YDSSKMYYADSVKGRFTISRDNAKNS
			LYLQMNSLRAEDTAVYYCAAGGTAPV
			YWGQGTMVTVSS
1085	hBEW-6C2.8	CDR-H1	GFTFSYYGMH
1086	hBEW-6C2.8	CDR-H2	LIYYDSSKMYYADSVKG
1087	hBEW-6C2.8	CDR-H3	GGTAPVY
1088	hBEW-6C2.8 VL		DIQLTQSPSSLSASVGDRVTITCKGS
			QNIANYLAWYQQKPGKAPKLLIYNTD
			SLQTGIPSRFSGSGSGTDYTLTISSL
			QPEDFATYFCYQSNNGYTFGQGTKLE
			IK
1089	hBEW-6C2.8	CDR-L1	KGSQNIANYLA
1090	hBEW-6C2.8	CDR-L2	NTDSLQT
1091	hBEW-6C2.8	CDR-L3	YQSNNGYT
1092	hBEW-9A8.1 VH		EVQLVQSGHEVKQPGASVKVSCKASG
			YTFTNYGMYWVPQAPGQGLEWMGWIN
			TETGKPIYADDFKGRFVFSMDTSAST
			AYLQISSLKAEDMAMYYCARVDYDGS
			FWFAYWGQGTLVTVSS
1093	hBEW-9A8.1	CDR-H1	GYTFTNYGMY
1094	hBEW-9A8.1	CDR-H2	WINTETGKPIYADDFKG
1095	hBEW-9A8.1	CDR-H3	VDYDGSFWFAY
1096	hBEW-9A8.1 VL		EIVLTQSPDFQSVTPKEKVTITCRAS
			ESVSTVIHWYQQKPDQSPKLLIKPGAS
			NLESGVPSRFSGSGSGTDFTLTINSL
			EAEDAATYYCQQHWNDPPTFGQGTKL
			EIK
1097	hBEW-9A8.1	CDR-L1	RASESVSTVIH
1098	hBEW-9A8.1	CDR-L2	GASNLES
1099	hBEW-9A8.1	CDR-L3	QQHWNDPPT
1100	hBEW-9A8.10 VH		EVQLVQSGAEVKKPGASVKVSCKASG
			YTFTNYGMYWVRQAPGQGLEWMGWIN
			TETGKPIYADDFKGRVTMTTDTSTST
			AYMELRSLRSDDTAVYYCARVDYDGS
			FWFAYWGQGTLVTVSS
1101	hBEW-9A8.10	CDR-H1	GYTFTNYGMY
1102	hBEW-9A8.10	CDR-H2	WINTETGKPIYADDFKG
1103	hBEW-9A8.10	CDR-H3	VDYDGSFWFAY
1104	hBEW-9A8.10 VL		ETVLTQSPDFQSVTPKEKVTITCRAS
			ESVSTVIHWYQQKPDQQPKLLIHGAS
			NLESGVPSRFSGSGSGTDFTLTINSL
			EAEDAATYFCQQHWNDPPTFGQGTKL
			EIK
1105	hBEW-9A8.10	CDR-L1	RASESVSTVIH
1106	hBEW-9A8.10	CDR-L2	GASNLES
1107	hBEW-9A8.10	CDR-L3	QQHWNDPPT
1108	hBEW-9A8.11 VH		EVQLVQSGAEVKKPGASVKVSCKASG
			YTFTNYGMYWVRQAPGQGLEWMGWIN
			TETGKPIYADDFKGRVTMTTDTSTST
			AYMELRSLRSDDTAVYYCARVDYDGS
			FWFAYWGQGTLVTVSS
1109	hBEW-9A8.11	CDR-H1	GYTFTNYGMY
1110	hBEW-9A8.11	CDR-H2	WINTETGKPIYADDFKG
1111	hBEW-9A8.11	CDR-H3	VDYDGSFWFAY
1112	hBEW-9A8.11 VL		DIQMTQSPSSLSASVGDRVTITCRAS
			ESVSTVIHWYQQKPGKAPKLLIYGAS
			NLESGVPSRFSGSGSGTDFTLTISSL
			QPEDFATYYCQQHWNDPPTFGQGTKL
			EIK
1113	hBEW-9A8.11	CDR-L1	RASESVSTVIH
1114	hBEW-9A8.11	CDR-L2	GASNLES
1115	hBEW-9A8.11	CDR-L3	QQHWNDPPT
1116	hBEW-9A8.12 VH		EVQLVQSGAEVKKPGASVKVSCKASG
			YTFTNYGMYWVRQAPGQGLEWMGWIN
			TETGKPIYADDFKGRVTMTTDTSTST
			AYMELRSLRSDDTAVYYCARVDYDGS
			FWFAYWGQGTLVTVSS
1117	hBEW-9A8.12	CDR-H1	GYTFTNYGMY
1118	hBEW-9A8.12	CDR-H2	WINTETGKPIYADDFKG
1119	hBEW-9A8.12	CDR-H3	VDYDGSFWFAY
1120	hBEW-9A8.12 VL		DTQLTQSPSSLSASVGDRVTITCRAS
			ESVSTVIHWYQQKPGKQPKLLIHGAS
			NLESGVPSRFSGSGSGTDFTLTISSL
			QPEDFATYFCQQHWNDPPTFGQGTKL
			EIK
1121	hBEW-9A8.12	CDR-L1	RASESVSTVIH
1122	hBEW-9A8.12	CDR-L2	GASNLES
1123	hBEW-9A8.12	CDR-L3	QQHWNDPPT
1124	hBEW-9A8.13 VH		EIQLVQSGAEVKKPGASVKVSCKASG
			YTFTNYGMYWVKQAPGQGLEYMGWIN
			TETGKPIYADDFKGRFTFTLDTSTST
			AYMELRSLRSDDTAVFFCARVDYDGS
			FWFAYWGQGTLVTVSS
1125	hBEW-9A8.13	CDR-H1	GYTFTNYGMY
1126	hBEW-9A8.13	CDR-H2	WINTETGKPIYADDFKG
1127	hBEW-9A8.13	CDR-H3	VDYDGSFWFAY
1128	hBEW-9A8.13 VL		EIVLTQSPDFQSVTPKEKVTITCRAS
			ESVSTVIHWYQQKPDQSPKLLIKGAS
			NLESGVPSRFSGSGSGTDFTLTINSL
			EAEDAATYYCQQHWNDPPTFGQGTKL
			EIK
1129	hBEW-9A8.13	CDR-L1	RASESVSTVIH
1130	hBEW-9A8.13	CDR-L2	GASNLES
1131	hBEW-9A8.13	CDR-L3	QQHWNDPPT
1132	hBEW-9A8.14 VH		EIQLVQSGAEVKKPGASVKVSCKASG
			YTFTNYGMYWVKQAPGQGLEYMGWIN
			TETGKPIYADDFKGRFTFTLDTSTST
			AYMELRSLRSDDTAVFFCARVDYDGS
			FWFAYWGQGTLVTVSS
1133	hBEW-9A8.14	CDR-H1	GYTFTNYGMY
1134	hBEW-9A8.14	CDR-H2	WINTETGKPIYADDFKG
1135	hBEW-9A8.14	CDR-H3	VDYDGSFWFAY
1136	hBEW-9A8.14 VL		ETVLTQSPDFQSVTPKEKVTITCRAS
			ESVSTVIHWYQQKPDQQPKLLIHGAS
			NLESGVPSRFSGSGSGTDFTLTINSL
			EAEDAATYFCQQHWNDPPTFGQGTKL
			EIK
1137	hBEW-9A8.14	CDR-L1	RASESVSTVIH
1138	hBEW-9A8.14	CDR-L2	GASNLES
1139	hBEW-9A8.14	CDR-L3	QQHWNDPPT
1140	hBEW-9A8.15 VH		EIQLVQSGAEVKKPGASVKVSCKASG
			YTFTNYGMYWVKQAPGQGLEYMGWIN
			TETGKPIYADDFKGRFTFTLDTSTST
			AYMELRSLRSDDTAVFFCARVDYDGS
			FWFAYWGQGTLVTVSS
1141	hBEW-9A8.15	CDR-H1	GYTFTNYGMY
1142	hBEW-9A8.15	CDR-H2	WINTETGKPIYADDFKG
1143	hBEW-9A8.15	CDR-H3	VDYDGSFWFAY
1144	hBEW-9A8.15 VL		DIQMTQSPSSLSASVGDRVTITCRAS
			ESVSTVIHWYQQKPGKAPKLLIYGAS
			NLESGVPSRFSGSGSGTDFTLTISSL
			QPEDFATYYCQQHWNDPPTFGQGTKL
			EIK
1145	hBEW-9A8.15	CDR-L1	RASESVSTVIH
1146	hBEW-9A8.15	CDR-L2	GASNLES
1147	hBEW-9A8.15	CDR-L3	QQHWNDPPT
1148	hBEW-9A8.16 VH		EIQLVQSGAEVKKPGASVKVSCKASG
			YTFTNYGMYWVKQAPGQGLEYMGWIN
			TETGKPIYADDFKGRFTFTLDTSTST
			AYMELRSLRSDDTAVFFCARVDYDGS
			FWFAYWGQGTLVTVSS
1149	hBEW-9A8.16	CDR-H1	GYTFTNYGMY
1150	hBEW-9A8.16	CDR-H2	WINTETGKPIYADDFKG
1151	hBEW-9A8.16	CDR-H3	VDYDGSFWFAY
1152	hBEW-9A8.16 VL		DTQLTQSPSSLSASVGDRVTITCRAS
			ESVSTVIHWYQQKPGKQPKLLIHGAS
			NLESGVPSRFSGSGSGTDFTLTISSL
			QPEDFATYFCQQHWNDPPTFGQGTKL
			EIK
1153	hBEW-9A8.16	CDR-L1	RASESVSTVIH
1154	hBEW-9A8.16	CDR-L2	GASNLES
1155	hBEW-9A8.16	CDR-L3	QQHWNDPPT
1156	hBEW-9A8.17 VH		EIQLVQSGSELKKPGASVKVSCKASG
			YTFTNYGMYWVKQAPGQGLEYMGWIN
			TETGKPIYADDFKGRFVFSLDTSVST
			AYLQISSLKAEDTAVYYCARVDYDGS
			FWFAYWGQGTLVTVSS
1157	hBEW-9A8.17	CDR-H1	GYTFTNYGMY
1158	hBEW-9A8.17	CDR-H2	WINTETGKPIYADDFKG
1159	hBEW-9A8.17	CDR-H3	VDYDGSFWFAY
1160	hBEW-9A8.17 VL		ETVLTQSPATLSLSPGERATLSGRAS
			ESVSTVIHWYQQKPGQQPRLLIHGAS
			NLESGVPARFSGSGSGTDFTLTISSL
			EPEDFAVYFCQQHWNDPPTFGQGTKL
			EIK
1161	hBEW-9A8.17	CDR-L1	RASESVSTVIH
1162	hBEW-9A8.17	CDR-L2	GASNLES
1163	hBEW-9A8.17	CDR-L3	QQHWNDPPT
1164	hBEW-9A8.2 VH		EVQLVQSGHEVKQPGASVKVSCKASG
			YTFTNYGMYWVPQAPGQGLEWMGWIN
			TETGKPIYADDFKGRFVFSMDTSAST
			AYLQISSLKAEDMAMYYCARVDYDGS
			FWFAYWGQGTLVTVSS
1165	hBEW-9A8.2	CDR-H1	GYTFTNYGMY
1166	hBEW-9A8.2	CDR-H2	WINTETGKPIYADDFKG
1167	hBEW-9A8.2	CDR-H3	VDYDGSFWFAY
1168	hBEW-9A8.2 VL		ETVLTQSPDFQSVTPKEKVTITGRAS
			ESVSTVIHWYQQKPDQQPKLLIHGAS
			NLESGVPSRFSGSGSGTDFTLTINSL
			EAEDAATYFCQQHWNDPPTFGQGTKL
			EIK
1169	hBEW-9A8.2	CDR-L1	RASESVSTVIH
1170	hBEW-9A8.2	CDR-L2	GASNLES
1171	hBEW-9A8.2	CDR-L3	QQHWNDPPT
1172	hBEW-9A8.20 VH		EIQLVQSGAEVKKPGASVKVSCKASG
			YTFTNYGMYWVKQAPGQGLEYMGWIN
			TETGKPIYADDFKGRFTFTLDTSTST
			AYMELRSLRSDDTAVYYCARVDYDGS
			FWFAYWGQGTLVTVSS
1173	hBEW-9A8.20	CDR-H1	GYTFTNYGMY
1174	hBEW-9A8.20	CDR-H2	WINTETGKPIYADDFKG
1175	hBEW-9A8.20	CDR-H3	VDYDGSFWFAY
1176	hBEW-9A8.20 VL		ETVLTQSPATLSLSPGERATLSCRAS
			ESVSTVIHWYQQKPGQQPRLLIHGAS
			NLESGVPARFSGSGSGTDFTLTISSL
			EPEDFAVYFCQQHWNDPPTFGQGTKL
			EIK
1177	hBEW-9A8.20	CDR-L1	RASESVSTVIH
1178	hBEW-9A8.20	CDR-L2	GASNLES
1179	hBEW-9A8.20	CDR-L3	QQHWNDPPT
1180	hBEW-9A8.21 VH		EIQLVQSGAEVKKPGASVKVSCKASG
			YTFTNYGMYWVRQAPGQGLEWMGWIN
			TETGKPIYADDFKGRFTFTLDTSTST
			AYMELRSLRSDDTAVYYCARVDYDGS
			FWFAYWGQGTLVTVSS
1181	hBEW-9A8.21	CDR-H1	GYTFTNYGMY
1182	hBEW-9A8.21	CDR-H2	WINTETGKPIYADDFKG
1183	hBEW-9A8.21	CDR-H3	VDYDGSFWFAY
1184	hBEW-9A8.21 VL		ETVLTQSPATLSLSPGERATLSCRAS
			ESVSTVIHWYQQKPGQQPRLLIHGAS
			NLESGVPARFSGSGSGTDFTLTISSL
			EPEDFAVYFCQQHWNDPPTFGQGTKL
			EIK
1185	hBEW-9A8.21	CDR-L1	RASESVSTVIH
1186	hBEW-9A8.21	CDR-L2	GASNLES
1187	hBEW-9A8.21	CDR-L3	QQHWNDPPT
1188	hBEW-9A8.3 VH		EVQLVQSGHEVKQPGASVKVSCKASG
			YTFTNYGMYWVPQAPGQGLEWMGWIN
			TETGKPIYADDFKGRFVFSMDTSAST
			AYLQISSLKAEDMAMYYCARVDYDGS
			FWFAYWGQGTLVTVSS
1189	hBEW-9A8.3	CDR-H1	GYTFTNYGMY
1190	hBEW-9A8.3	CDR-H2	WINTETGKPIYADDFKG
1191	hBEW-9A8.3	CDR-H3	VDYDGSFWFAY
1192	hBEW-9A8.3 VL		DIQMTQSPSSLSASVGDRVTITCRAS
			ESVSTVIHWYQQKPGKAPKLLIYGAS
			NLESGVPSRFSGSGSGTDFTLTISSL
			QPEDFATYYCQQHWNDPPTFGQGTKL
			EIK
1193	hBEW-9A8.3	CDR-L1	RASESVSTVIH
1194	hBEW-9A8.3	CDR-L2	GASNLES
1195	hBEW-9A8.3	CDR-L3	QQHWNDPPT
1196	hBEW-9A8.4 VH		EVQLVQSGHEVKQPGASVKVSCKASG
			YTFTNYGMYWVPQAPGQGLEWMGWIN
			TETGKPIYADDFKGRFVFSMDTSAST
			AYLQISSLKAEDMAMYYCARVDYDGS
			FWFAYWGQGTLVTVSS
1197	hBEW-9A8.4	CDR-H1	GYTFTNYGMY
1198	hBEW-9A8.4	CDR-H2	WINTETGKPIYADDFKG
1199	hBEW-9A8.4	CDR-H3	VDYDGSFWFAY
1200	hBEW-9A8.4 VL		DTQLTQSPSSLSASVGDRVTITCRAS
			ESVSTVIHWYQQKPGKQPKLLIHGAS
			NLESGVPSRFSGSGSGTDFTLTISSL
			QPEDFATYFCQQHWNDPPTFGQGTKL
			EIK
1201	hBEW-9A8.4	CDR-L1	RASESVSTVIH
1202	hBEW-9A8.4	CDR-L2	GASNLES
1203	hBEW-9A8.4	CDR-L3	QQHWNDPPT
1204	hBEW-9A8.5 VH		EIQLVQSGHEVKQPGASVKVSCKASG
			YTFTNYGMYWVKQAPGQGLEYMGWIN
			TETGKPIYADDFKGRFVFSLDTSAST
			AYLQISSLKAEDMAMFFCARVDYDGS
			FWFAYWGQGTLVTVSS
1205	hBEW-9A8.5	CDR-H1	GYTFTNYGMY
1206	hBEW-9A8.5	CDR-H2	WINTETGKPIYADDFKG
1207	hBEW-9A8.5	CDR-H3	VDYDGSFWFAY
1208	hBEW-9A8.5 VL		EIVLTQSPDFQSVTPKEKVTITCRAS
			ESVSTVIHWYQQKPDQSPKLLIKGAS
			NLESGVPSRFSGSGSGTDFTLTINSL
			EAEDAATYYCQQHWNDPPTFGQGTKL
			EIK
1209	hBEW-9A8.5	CDR-L1	RASESVSTVIH
1210	hBEW-9A8.5	CDR-L2	GASNLES
1211	hBEW-9A8.5	CDR-L3	QQHWNDPPT
1212	hBEW-9A8.6 VH		EIQLVQSGHEVKQPGASVKVSCKASG
			YTFTNYGMYWVKQAPGQGLEYMGWIN
			TETGKPIYADDFKGRFVFSLDTSAST
			AYLQISSLKAEDMAMFFCARVDYDGS
			FWFAYWGQGTLVTVSS
1213	hBEW-9A8.6	CDR-H1	GYTFTNYGMY
1214	hBEW-9A8.6	CDR-H2	WINTETGKPIYADDFKG
1215	hBEW-9A8.6	CDR-H3	VDYDGSFWFAY
1216	hBEW-9A8.6 VL		ETVLTQSPDFQSVTPKEKVTITCRAS
			ESVSTVIHWYQQKPDQQPKLLIHGAS
			NLESGVPSRFSGSGSGTDFTLTINSL
			EAEDAATYFCQQHWNDPPTFGQGTKL
			EIK
1217	hBEW-9A8.6	CDR-L1	RASESVSTVIH
1218	hBEW-9A8.6	CDR-L2	GASNLES
1219	hBEW-9A8.6	CDR-L3	QQHWNDPPT
1220	hBEW-9A8.7 VH		EIQLVQSGHEVKQPGASVKVSCKASG
			YTFTNYGMYWVKQAPGQGLEYMGWIN
			TETGKPIYADDFKGRFVFSLDTSAST
			AYLQISSLKAEDMAMFFCARVDYDGS
			FWFAYWGQGTLVTVSS
1221	hBEW-9A8.7	CDR-H1	GYTFTNYGMY
1222	hBEW-9A8.7	CDR-H2	WINTETGKPIYADDFKG
1223	hBEW-9A8.7	CDR-H3	VDYDGSFWFAY
1224	hBEW-9A8.7 VL		DIQMTQSPSSLSASVGDRVTITCRAS
			ESVSTVIHWYQQKPGKAPKLLIYGAS
			NLESGVPSRFSGSGSGTDFTLTISSL
			QPEDFATYYCQQHWNDPPTFGQGTKL
			EIK
1225	hBEW-9A8.7	CDR-L1	RASESVSTVIH
1226	hBEW-9A8.7	CDR-L2	GASNLES
1227	hBEW-9A8.7	CDR-L3	QQHWNDPPT
1228	hBEW-9A8.8 VH		EIQLVQSGHEVKQPGASVKVSCKASG
			YTFTNYGMYWVKQAPGQGLEYMGWIN
			TETGKPIYADDFKGRFVFSLDTSAST
			AYLQISSLKAEDMAMFFCARVDYDGS
			FWFAYWGQGTLVTVSS
1229	hBEW-9A8.8	CDR-H1	GYTFTNYGMY
1230	hBEW-9A8.8	CDR-H2	WINTETGKPIYADDFKG
1231	hBEW-9A8.8	CDR-H3	VDYDGSFWFAY
1232	hBEW-9A8.8 VL		DTQLTQSPSSLSASVGDRVTITCRAS
			ESVSTVIHWYQQKPGKQPKLLIHGAS
			NLESGVPSRFSGSGSGTDFTLTISSL
			QPEDFATYFCQQHWNDPPTFGQGTKL
			EIK
1233	hBEW-9A8.8	CDR-L1	RASESVSTVIH
1234	hBEW-9A8.8	CDR-L2	GASNLES
1235	hBEW-9A8.8	CDR-L3	QQHWNDPPT
1236	hBEW-9A8.9 VH		EVQLVQSGAEVKKPGASVKVSCKASG
			YTFTNYGMYWVRQAPGQGLEWMGWIN
			TETGKPIYADDFKGRVTMTTDTSTST
			AYMELRSLRSDDTAVYYCARVDYDGS
			FWFAYWGQGTLVTVSS
1237	hBEW-9A8.9	CDR-H1	GYTFTNYGMY
1238	hBEW-9A8.9	CDR-H2	WINTETGKPIYADDFKG
1239	hBEW-9A8.9	CDR-H3	VDYDGSFWFAY
1240	hBEW-9A8.9 VL		EIVLTQSPDFQSVTPKEKVTITCRAS
			ESVSTVIHWYQQKPDQSPKLLIKGAS
			NLESGVPSRFSGSGSGTDFTLTINSL
			EAEDAATYYCQQHWNDPPTFGQGTKL
			EIK
1241	hBEW-9A8.9	CDR-L1	RASESVSTVIH
1242	hBEW-9A8.9	CDR-L2	GASNLES
1243	hBEW-9A8.9	CDR-L3	QQHWNDPPT
1244	hBEW-9E10.1 VH		EIQLVQSGSELKKPGASVKVSCKASG
			YTFTNYGMYWVKQAPGQGLEYMGWID
			TETGRPTYADDFKGRFVFSLDTSVST
			AYLQISSLKAEDTAVYFCARWSGDTT
			GIRGPWFAYWGQGTLVTVSS
1245	hBEW-9E10.1	CDR-H1	GYTFTNYGMY
1246	hBEW-9E10.1	CDR-H2	WIDTETGRPTYADDFKG
1247	hBEW-9E10.1	CDR-H3	WSGDTTGIRGPWFAY
1248	hBEW-9E10.1 VL		DIRMTQSPSSLSASVGDRVTIECLAS
			EDIYSDLAWYQQKPGKSPKLLIYNAN
			GLQNGVPSRFSGSGSGTDYSLTISSL
			QPEDVATYFCQQYNYFPGTFGQGTKL
			EIK
1249	hBEW-9E10.1	CDR-L1	LASEDIYSDLA
1250	hBEW-9E10.1	CDR-L2	NANGLQN
1251	hBEW-9E10.1	CDR-L3	QQYNYFPGT
1252	hBEW-9E10.2 VH		EIQLVQSGAEVKKPGSSVKVSCKASG
			YTFTNYGMYWVKQAPGQGLEYMGWID
			TETGRPTYADDFKGRFTFTADKSTST
			AYMELSSLRSEDTAVYFCARWSGDTT
			GIRGPWFAYWGQGTLVTVSS
1253	hBEW-9E10.2	CDR-H1	GYTFTNYGMY
1254	hBEW-9E10.2	CDR-H2	WIDTETGRPTYADDFKG
1255	hBEW-9E10.2	CDR-H3	WSGDTTGIRGPWFAY
1256	hBEW-9E10.2 VL		DIRMTQSPSSLSASVGDRVTIECLAS
			EDIYSDLAWYQQKPGKSPKLLIYNAN
			GLQNGVPSRFSGSGSGTDYSLTISSL
			QPEDVATYFCQQYNYFPGTFGQGTKL
			EIK
1257	hBEW-9E10.2	CDR-L1	LASEDIYSDLA
1258	hBEW-9E10.2	CDR-L2	NANGLQN
1259	hBEW-9E10.2	CDR-L3	QQYNYFPGT
1260	hBEW-9E10.3 VH		EVQLVQSGAEVKKPGSSVKVSCKASG
			YTFTNYGMYWVRQAPGQGLEWMGWID
			TETGRPTYADDFKGRFTFTADKSTST
			AYMELSSLRSEDTAVYYCARWSGDTT
			GIRGPWFAYWGQGTLVTVSS
1261	hBEW-9E10.3	CDR-H1	GYTFTNYGMY
1262	hBEW-9E10.3	CDR-H2	WIDTETGRPTYADDFKG
1263	hBEW-9E10.3	CDR-H3	WSGDTTGIRGPWFAY
1264	hBEW-9E10.3 VL		DIRMTQSPSSLSASVGDRVTIECLAS
			EDIYSDLAWYQQKPGKSPKLLTYNAN
			GLQNGVPSRFSGSGSGTDYSLTISSL
			QPEDVATYFCQQYNYFPGTFGQGTKL
			EIK
1265	hBEW-9E10.3	CDR-L1	LASEDIYSDLA
1266	hBEW-9E10.3	CDR-L2	NANGLQN
1267	hBEW-9E10.3	CDR-L3	QQYNYFPGT
1268	hBEW-9E10.4 VH		EIQLVQSGSELKKPGASVKVSCKASG
			YTFTNYGMYWVKQAPGQGLEYMGWID
			TETGRPTYADDFKGRFVFSLDTSVST
			AYLQISSLKAEDTAVYFCARWSGDTT
			GIRGPWFAYWGQGTLVTVSS
1269	hBEW-9E10.4	CDR-H1	GYTFTNYGMY
1270	hBEW-9E10.4	CDR-H2	WIDTETGRPTYADDFKG
1271	hBEW-9E10.4	CDR-H3	WSGDTTGIRGPWFAY
1272	hBEW-9E10.4 VL		DIRMTQSPSSLSASVGDRVTITCLAS
			EDIYSDLAWYQQKPGKSPKLLTYNAN
			GLQNGVPSRFSGSGSGTDYTLTISSL
			QPEDVATYFCQQYNYFPGTFGQGTKL
			EIK
1273	hBEW-9E10.4	CDR-L1	LASEDIYSDLA
1274	hBEW-9E10.4	CDR-L2	NANGLQN
1275	hBEW-9E10.4	CDR-L3	QQYNYFPGT
1276	hBEW-9E10.5 VH		EIQLVQSGAEVKKPGSSVKVSCKASG
			YTFTNYGMYWVKQAPGQGLEYMGWID
			TETGRPTYADDFKGRFTFTADKSTST
			AYMELSSLRSEDTAVYFCARWSGDTT
			GIRGPWFAYWGQGTLVTVSS
1277	hBEW-9E10.5	CDR-H1	GYTFTNYGMY
1278	hBEW-9E10.5	CDR-H2	WIDTETGRPTYADDFKG
1279	hBEW-9E10.5	CDR-H3	WSGDTTGIRGPWFAY
1280	hBEW-9E10.5 VL		DIRMTQSPSSLSASVGDRVTITCLAS
			EDIYSDLAWYQQKPGKSPKLLTYNAN
			GLQNGVPSRFSGSGSGTDYTLTISSL
			QPEDVATYFCQQYNYFPGTFGQGTKL
			EIK
1281	hBEW-9E10.5	CDR-L1	LASEDIYSDLA
1282	hBEW-9E10.5	CDR-L2	NANGLQN
1283	hBEW-9E10.5	CDR-L3	QQYNYFPGT
1284	hBEW-9E10.6 VH		EVQLVQSGAEVKKPGSSVKVSCKASG
			YTFTNYGMYWVRQAPGQGLEWMGWID
			TETGRPTYADDFKGRFTFTADKSTST
			AYMELSSLRSEDTAVYYCARWSGDTT
			GIRGPWFAYWGQGTLVTVSS
1285	hBEW-9E10.6	CDR-H1	GYTFTNYGMY
1286	hBEW-9E10.6	CDR-H2	WIDTETGRPTYADDFKG
1287	hBEW-9E10.6	CDR-H3	WSGDTTGIRGPWFAY
1288	hBEW-9E10.6 VL		DIRMTQSPSSLSASVGDRVTITCLAS
			EDIYSDLAWYQQKPGKSPKLLIYNAN
			GLQNGVPSRFSGSGSGTDYTLTISSL
			QPEDVATYFCQQYNYFPGTFGQGTKL
			EIK
1289	hBEW-9E10.6	CDR-L1	LASEDIYSDLA
1290	hBEW-9E10.6	CDR-L2	NANGLQN
1291	hBEW-9E10.6	CDR-L3	QQYNYFPGT
1292	AB014 VH		EVQLVESGGGLVQPGGSLR
			LSCAASGYTFTNYGMNWVR
			QAPGKGLEWVGWINTYTGE
			PTYAADFKRRFTFSLDTSK
			STAYLQMNSLRAEDTAVYY
			CAKYPHYYGSSHWYFDVWG
			QGTLVTVSS
1293	AB014	CDR-H1	GYTFTNYGMN
1294	AB014	CDR-H2	WINTYTGEPTYAADFKR
1295	AB014	CDR-H3	YPHYYGSSHWYFDV
1296	AB014 VL		DIQMTQSPSSLSASVGDRV
			TITCSASQDISNYLNWYQQ
			KPGKAPKVLIYFTSSLHSG
			VPSRFSGSGSGTDFTLTIS
			SLQPEDFATYYCQQYSTVP
			WTFGQGTKVEIK
1297	AB014	CDR-L1	SASQDISNYLN
1298	AB014	CDR-L2	FTSSLHS
1299	AB014	CDR-L3	QQYSTVPWT

TABLE 28
VH and VL Amino Acid Sequences of Humanized Versions of
Rat Anti-Human PDGF-BB Monoclonal Antibodies (CDRs in bold)
SEQ ID		Protein	V Region
NO:	Clone	Region	123456789012345678901234567890
1300	hBDI-1E1.1 VH		EVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYVMHW
			VRQAPGQGLEWMGTIIPLIDTTSYNQKFKGRVTITA
			DKSTSTAYMELSSLRSEDTAVYYCARTSPYYYSSYD
			VMDAWGQGTTVTVSS
1301	hBDI-1E1.1	CDR-H1	GYTFTDYVMH
1302	hBDI-1E1.1	CDR-H2	TIIPLIDTTSYNQKFKG
1303	hBDI-1E1.1	CDR-H3	TSPYYYSSYDVMDA
1304	hBDI-1E1.1 VL		AIQLTQSPSSLSASVGDRVTITCKGSQNINNYLAWY
			QQKPGKAPKLLIYKTNNLQTGVPSRFSGSGSGTDFT
			LTISSLQPEDFATYYCYQYDNGYTFGQGTKLEIK
1305	hBDI-1E1.1	CDR-L1	KGSQNINNYLA
1306	hBDI-1E1.1	CDR-L2	KTNNLQT
1307	hBDI-1E1.1	CDR-L3	YQYDNGYT
1308	hBDI-1E1.10 VH		EVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYVMHW
			VRQAPGQGLEWIGTIIPLIDTTSYNQKFKGRVTITA
			DKSTSTAYMELSSLRSEDTAVYYCARTSPYYYSSYD
			VMDAWGQGTTVTVSS
1309	hBDI-1E1.10	CDR-H1	GYTFTDYVMH
1310	hBDI-1E1.10	CDR-H2	TIIPLIDTTSYNQKFKG
1311	hBDI-1E1.10	CDR-H3	TSPYYYSSYDVMDA
1312	hBDI-1E1.10 VL		AIQLTQSPSSLSASVGDRVTITCKGSQNINNYLAWY
			QQKPGKAPKLLIYKTNNLQTGIPSRFSGSGSGTDYT
			LTISSLQPEDFATYYCYQYDNGYTFGQGTKLEIK
1313	hBDI-1E1.10	CDR-L1	KGSQNINNYLA
1314	hBDI-1E1.10	CDR-L2	KTNNLQT
1315	hBDI-1E1.10	CDR-L3	YQYDNGYT
1316	hBDI-1E1.11 VH		EVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYVMHW
			VRQAPGQGLEWIGTIIPLIDTTSYNQKFKGRVTITA
			DKSTSTAYMELSSLRSEDTAVYYCARTSPYYYSSYD
			VMDAWGQGTTVTVSS
1317	hBDI-1E1.11	CDR-H1	GYTFTDYVMH
1318	hBDI-1E1.11	CDR-H2	TIIPLIDTTSYNQKFKG
1319	hBDI-1E1.11	CDR-H3	TSPYYYSSYDVMDA
1320	hBDI-1E1.11 VL		EIVLTQSPATLSLSPGERATLSCKGSQNINNYLAWY
			QQKPGQAPRLLIYKTNNLQTGIPARFSGSGSGTDFT
			LTISSLEPEDFAVYYCYQYDNGYTFGQGTKLEIK
1321	hBDI-1E1.11	CDR-L1	KGSQNINNYLA
1322	hBDI-1E1.11	CDR-L2	KTNNLQT
1323	hBDI-1E1.11	CDR-L3	YQYDNGYT
1324	hBDI-1E1.12 VH		EVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYVMHW
			VRQAPGQGLEWIGTIIPLIDTTSYNQKFKGRVTITA
			DKSTSTAYMELSSLRSEDTAVYYCARTSPYYYSSYD
			VMDAWGQGTTVTVSS
1325	hBDI-1E1.12	CDR-H1	GYTFTDYVMH
1326	hBDI-1E1.12	CDR-H2	TIIPLIDTTSYNQKFKG
1327	hBDI-1E1.12	CDR-H3	TSPYYYSSYDVMDA
1328	hBDI-1E1.12 VL		EIVLTQSPATLSLSPGERATLSCKGSQNINNYLAWY
			QQKPGQAPRLLIYKTNNLQTGIPARFSGSGSGTDYT
			LTISSLEPEDFATYYCYQYDNGYTFGQGTKLEIK
1329	hBDI-1E1.12	CDR-L1	KGSQNINNYLA
1330	hBDI-1E1.12	CDR-L2	KTNNLQT
1331	hBDI-1E1.12	CDR-L3	YQYDNGYT
1332	hBDI-1E1.2 VH		EVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYVMHW
			VRQAPGQGLEWMGTIIPLIDTTSYNQKFKGRVTITA
			DKSTSTAYMELSSLRSEDTAVYYCARTSPYYYSSYD
			VMDAWGQGTTVTVSS
1333	hBDI-1E1.2	CDR-H1	GYTFTDYVMH
1334	hBDI-1E1.2	CDR-H2	TIIPLIDTTSYNQKFKG
1335	hBDI-1E1.2	CDR-H3	TSPYYYSSYDVMDA
1336	hBDI-1E1.2 VL		AIQLTQSPSSLSASVGDRVTITCKGSQNINNYLAWY
			QQKPGKAPKLLIYKTNNLQTGIPSRFSGSGSGTDYT
			LTISSLQPEDFATYYCYQYDNGYTFGQGTKLEIK
1337	hBDI-1E1.2	CDR-L1	KGSQNINNYLA
1338	hBDI-1E1.2	CDR-L2	KTNNLQT
1339	hBDI-1E1.2	CDR-L3	YQYDNGYT
1340	hBDI-1E1.3 VH		EVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYVMHW
			VRQAPGQGLEWMGTIIPLIDTTSYNQKFKGRVTITA
			DKSTSTAYMELSSLRSEDTAVYYCARTSPYYYSSYD
			VMDAWGQGTTVTVSS
1341	hBDI-1E1.3	CDR-H1	GYTFTDYVMH
1342	hBDI-1E1.3	CDR-H2	TIIPLIDTTSYNQKFKG
1343	hBDI-1E1.3	CDR-H3	TSPYYYSSYDVMDA
1344	hBDI-1E1.3 VL		EIVLTQSPATLSLSPGERATLSCKGSQNINNYLAWY
			QQKPGQAPRLLIYKTNNLQTGIPARFSGSGSGTDFT
			LTISSLEPEDFAVYYCYQYDNGYTFGQGTKLEIK
1345	hBDI-1E1.3	CDR-L1	KGSQNINNYLA
1346	hBDI-1E1.3	CDR-L2	KTNNLQT
1347	hBDI-1E1.3	CDR-L3	YQYDNGYT
1348	hBDI-1E1.4 VH		EVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYVMHW
			VRQAPGQGLEWMGTIIPLIDTTSYNQKFKGRVTITA
			DKSTSTAYMELSSLRSEDTAVYYCARTSPYYYSSYD
			VMDAWGQGTTVTVSS
1349	hBDI-1E1.4	CDR-H1	GYTFTDYVMH
1350	hBDI-1E1.4	CDR-H2	TIIPLIDTTSYNQKFKG
1351	hBDI-1E1.4	CDR-H3	TSPYYYSSYDVMDA
1352	hBDI-1E1.4 VL		EIVLTQSPATLSLSPGERATLSCKGSQNINNYLAWY
			QQKPGQAPRLLIYKTNNLQTGIPARFSGSGSGTDYT
			LTISSLEPEDFATYYCYQYDNGYTFGQGTKLEIK
1353	hBDI-1E1.4	CDR-L1	KGSQNINNYLA
1354	hBDI-1E1.4	CDR-L2	KTNNLQT
1355	hBDI-1E1.4	CDR-L3	YQYDNGYT
1356	hBDI-1E1.5 VH		EVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYVMHW
			VRQAPGQGLEWIGTIIPLIDTTSYNQKFKGRATLTA
			DKSTNTAYMELSSLRSEDTAVYYCARTSPYYYSSYD
			VMDAWGQGTTVTVSS
1357	hBDI-1E1.5	CDR-H1	GYTFTDYVMH
1358	hBDI-1E1.5	CDR-H2	TIIPLIDTTSYNQKFKG
1359	hBDI-1E1.5	CDR-H3	TSPYYYSSYDVMDA
1360	hBDI-1E1.5 VL		AIQLTQSPSSLSASVGDRVTITCKGSQNINNYLAWY
			QQKPGKAPKLLIYKTNNLQTGVPSRFSGSGSGTDFT
			LTISSLQPEDFATYYCYQYDNGYTFGQGTKLEIK
1361	hBDI-1E1.5	CDR-L1	KGSQNINNYLA
1362	hBDI-1E1.5	CDR-L2	KTNNLQT
1363	hBDI-1E1.5	CDR-L3	YQYDNGYT
1364	hBDI-1E1.6 VH		EVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYVMHW
			VRQAPGQGLEWIGTIIPLIDTTSYNQKFKGRATLTA
			DKSTNTAYMELSSLRSEDTAVYYCARTSPYYYSSYD
			VMDAWGQGTTVTVSS
1365	hBDI-1E1.6	CDR-H1	GYTFTDYVMH
1366	hBDI-1E1.6	CDR-H2	TIIPLIDTTSYNQKFKG
1367	hBDI-1E1.6	CDR-H3	TSPYYYSSYDVMDA
1368	hBDI-1E1.6 VL		AIQLTQSPSSLSASVGDRVTITCKGSQNINNYLAWY
			QQKPGKAPKLLIYKTNNLQTGIPSRFSGSGSGTDYT
			LTISSLQPEDFATYYCYQYDNGYTFGQGTKLEIK
1369	hBDI-1E1.6	CDR-L1	KGSQNINNYLA
1370	hBDI-1E1.6	CDR-L2	KTNNLQT
1371	hBDI-1E1.6	CDR-L3	YQYDNGYT
1372	hBDI-1E1.7 VH		EVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYVMHW
			VRQAPGQGLEWIGTIIPLIDTTSYNQKFKGRATLTA
			DKSTNTAYMELSSLRSEDTAVYYCARTSPYYYSSYD
			VMDAWGQGTTVTVSS
1373	hBDI-1E1.7	CDR-H1	GYTFTDYVMH
1374	hBDI-1E1.7	CDR-H2	TIIPLIDTTSYNQKFKG
1375	hBDI-1E1.7	CDR-H3	TSPYYYSSYDVMDA
1376	hBDI-1E1.7 VL		EIVLTQSPATLSLSPGERATLSCKGSQNINNYLAWY
			QQKPGQAPRLLIYKTNNLQTGIPARFSGSGSGTDFT
			LTISSLEPEDFAVYYCYQYDNGYTFGQGTKLEIK
1377	hBDI-1E1.7	CDR-L1	KGSQNINNYLA
1378	hBDI-1E1.7	CDR-L2	KTNNLQT
1379	hBDI-1E1.7	CDR-L3	YQYDNGYT
1380	hBDI-1E1.8 VH		EVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYVMHW
			VRQAPGQGLEWIGTIIPLIDTTSYNQKFKGRATLTA
			DKSTNTAYMELSSLRSEDTAVYYCARTSPYYYSSYD
			VMDAWGQGTTVTVSS
1381	hBDI-1E1.8	CDR-H1	GYTFTDYVMH
1382	hBDI-1E1.8	CDR-H2	TIIPLIDTTSYNQKFKG
1383	hBDI-1E1.8	CDR-H3	TSPYYYSSYDVMDA
1384	hBDI-1E1.8 VL		EIVLTQSPATLSLSPGERATLSCKGSQNINNYLAWY
			QQKPGQAPRLLIYKTNNLQTGIPARFSGSGSGTDYT
			LTISSLEPEDFATYYCYQYDNGYTFGQGTKLEIK
1385	hBDI-1E1.8	CDR-L1	KGSQNINNYLA
1386	hBDI-1E1.8	CDR-L2	KTNNLQT
1387	hBDI-1E1.8	CDR-L3	YQYDNGYT
1388	hBDI-1E1.9 VH		EVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYVMHW
			VRQAPGQGLEWIGTIIPLIDTTSYNQKFKGRVTITA
			DKSTSTAYMELSSLRSEDTAVYYCARTSPYYYSSYD
			VMDAWGQGTTVTVSS
1389	hBDI-1E1.9	CDR-H1	GYTFTDYVMH
1390	hBDI-1E1.9	CDR-H2	TIIPLIDTTSYNQKFKG
1391	hBDI-1E1.9	CDR-H3	TSPYYYSSYDVMDA
1392	hBDI-1E1.9 VL		AIQLTQSPSSLSASVGDRVTITCKGSQNINNYLAWY
			QQKPGKAPKLLIYKTNNLQTGVPSRFSGSGSGTDFT
			LTISSLQPEDFATYYCYQYDNGYTFGQGTKLEIK
1393	hBDI-1E1.9	CDR-L1	KGSQNINNYLA
1394	hBDI-1E1.9	CDR-L2	KTNNLQT
1395	hBDI-1E1.9	CDR-L3	YQYDNGYT
1396	hBDI-5H1.1 VH		EVTLRESGPALVKPTQTLTLTCTFSGFSLSTFGMGV
			GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQVVLTMTNMDPVDTATYYCARISTGISSYY
			VMDAWGQGTTVTVSS
1397	hBDI-5H1.1	CDR-H1	GFSLSTFGMGVG
1398	hBDI-5H1.1	CDR-H2	NIWWDDDKYYNPSLKN
1399	hBDI-5H1.1	CDR-H3	ISTGISSYYVMDA
1400	hBDI-5H1.1 VL		NFMLTQPHSVSESPGKTVTISCERSSGDIGDTYVSW
			YQQRPGSSPTTVIYGNDQRPSGVPDRFSGSIDSSSN
			SASLTISGLKTEDEADYYCQSYDSDIDIVFGGGTKL
			TVL
1401	hBDI-5H1.1	CDR-L1	ERSSGDIGDTYVS
1402	hBDI-5H1.1	CDR-L2	GNDQRPS
1403	hBDI-5H1.1	CDR-L3	QSYDSDIDIV
1404	hBDI-5H1.10 VH		EVTLRESGPALVKPTQTLTLTCTFSGFSLSTFGMGV
			GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQAVLTITNMDPVDTATYYCARISTGISSYY
			VMDAWGQGTTVTVSS
1405	hBDI-5H1.10	CDR-H1	GFSLSTFGMGVG
1406	hBDI-5H1.10	CDR-H2	NIWWDDDKYYNPSLKN
1407	hBDI-5H1.10	CDR-H3	ISTGISSYYVMDA
1408	hBDI-5H1.10 VL		DFQLTQSPSSLSASVGDRVTITCERSSGDIGDTYVS
			WYQQKPGKAPKNVIYGNDQRPSGVPSRFSGSGSGNS
			ATLTISSLQPEDFATYFCQSYDSDIDIVFGQGTKVE
			IK
1409	hBDI-5H1.10	CDR-L1	ERSSGDIGDTYVS
1410	hBDI-5H1.10	CDR-L2	GNDQRPS
1411	hBDI-5H1.10	CDR-L3	QSYDSDIDIV
1412	hBDI-5H1.11 VH		EVQLVESGGGLVQPGGSLRLSCAFSGFSLSTFGMGV
			GWIRQAPGKGLEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQAYLQINSLRAEDTAVYYCARISTGISSYY
			VMDAWGQGTLVTVSS
1413	hBDI-5H1.11	CDR-H1	GFSLSTFGMGVG
1414	hBDI-5H1.11	CDR-H2	NIWWDDDKYYNPSLKN
1415	hBDI-5H1.11	CDR-H3	ISTGISSYYVMDA
1416	hBDI-5H1.11 VL		DFVLTQSPDSLAVSLGERATINCERSSGDIGDTYVS
			WYQQKPGQPPKNVIYGNDQRPSGVPDRFSGSGSGNS
			ATLTISSLQAEDVAVYFCQSYDSDIDIVFGGGTKVE
			IK
1417	hBDI-5H1.11	CDR-L1	ERSSGDIGDTYVS
1418	hBDI-5H1.11	CDR-L2	GNDQRPS
1419	hBDI-5H1.11	CDR-L3	QSYDSDIDIV
1420	hBDI-5H1.12 VH		EVQLVESGGGLVQPGGSLRLSCAFSGFSLSTFGMGV
			GWIRQAPGKGLEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQAYLQINSLRAEDTAVYYCARISTGISSYY
			VMDAWGQGTLVTVSS
1421	hBDI-5H1.12	CDR-H1	GFSLSTFGMGVG
1422	hBDI-5H1.12	CDR-H2	NIWWDDDKYYNPSLKN
1423	hBDI-5H1.12	CDR-H3	ISTGISSYYVMDA
1424	hBDI-5H1.12 VL		DFQLTQSPSSLSASVGDRVTITCERSSGDIGDTYVS
			WYQQKPGKAPKNVIYGNDQRPSGVPSRFSGSGSGNS
			ATLTISSLQPEDFATYFCQSYDSDIDIVFGQGTKVE
			IK
1425	hBDI-5H1.12	CDR-L1	ERSSGDIGDTYVS
1426	hBDI-5H1.12	CDR-L2	GNDQRPS
1427	hBDI-5H1.12	CDR-L3	QSYDSDIDIV
1428	hBDI-5H1.13 VH		EVTLKESGPALVKPTQTLTLTCTFSGFSLSTFGMGV
			GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQAVLTITNMDPVDTATYYCARISTGISSYY
			VMDAWGQGTTVTVSS
1429	hBDI-5H1.13	CDR-H1	GFSLSTFGMGVG
1430	hBDI-5H1.13	CDR-H2	NIWWDDDKYYNPSLKN
1431	hBDI-5H1.13	CDR-H3	ISTGISSYYVMDA
1432	hBDI-5H1.13 VL		DFQLTQSPSSLSASVGDRVTITCERSSGDIGDTYVS
			WYQQKPGKAPKNVIYGNDQRPSGVPSRFSGSGSGNS
			ATLTISSLQPEDFATYFCQSYDSDIDIVFGQGTKVE
			IK
1433	hBDI-5H1.13	CDR-L1	ERSSGDIGDTYVS
1434	hBDI-5H1.13	CDR-L2	GNDQRPS
1435	hBDI-5H1.13	CDR-L3	QSYDSDIDIV
1436	hBDI-5H1.16 VH		EVTLKESGPALVKPTQTLTLTCTFSGFSLSTFGMGV
			GWIRQPPGKGLEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSNSQAVLTITNMDPVDTATYYCARISTGISSYY
			VMDAWGQGTTVTVSS
1437	hBDI-5H1.16	CDR-H1	GFSLSTFGMGVG
1438	hBDI-5H1.16	CDR-H2	NIWWDDDKYYNPSLKN
1439	hBDI-5H1.16	CDR-H3	ISTGISSYYVMDA
1440	hBDI-5H1.16 VL		EFVLTQSPGTLSLSPGERATLSCERSSGDIGDTYVS
			WYQQKPGQPPRNVIYGNDQRPSGVPDRFSGSGSGTD
			FTLTISRLEPEDFAVYFCQSYDSDIDIVFGGGTKVE
			IK
1441	hBDI-5H1.16	CDR-L1	ERSSGDIGDTYVS
1442	hBDI-5H1.16	CDR-L2	GNDQRPS
1443	hBDI-5H1.16	CDR-L3	QSYDSDIDIV
1444	hBDI-5H1.17 VH		EVTLKESGPALVKPTQTLTLTCTFSGFSLSTFGMGV
			GWIRQPPGKGLEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSNSQAVLTITNMDPVDTATYYCARISTGISSYY
			VMDAWGQGTTVTVSS
1445	hBDI-5H1.17	CDR-H1	GFSLSTFGMGVG
1446	hBDI-5H1.17	CDR-H2	NIWWDDDKYYNPSLKN
1447	hBDI-5H1.17	CDR-H3	ISTGISSYYVMDA
1448	hBDI-5H1.17 VL		EFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVS
			WYQQKPGQAPRLVIYADDQRPSGIPDRFSGSGSGTD
			FTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVE
			IK
1449	hBDI-5H1.17	CDR-L1	ERSSGDIGDSYVS
1450	hBDI-5H1.17	CDR-L2	ADDQRPS
1451	hBDI-5H1.17	CDR-L3	QSYDINIDIV
1452	hBDI-5H1.2 VH		EVTLRESGPALVKPTQTLTLTCTFSGFSLSTFGMGV
			GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQVVLTMTNMDPVDTATYYCARISTGISSYY
			VMDAWGQGTTVTVSS
1453	hBDI-5H1.2	CDR-H1	GFSLSTFGMGVG
1454	hBDI-5H1.2	CDR-H2	NIWWDDDKYYNPSLKN
1455	hBDI-5H1.2	CDR-H3	ISTGISSYYVMDA
1456	hBDI-5H1.2 VL		NFMLTQPHSVSESPGKTVTISCERSSGDIGDTYVSW
			YQQRPGSPPTNVIYGNDQRPSGVPDRFSGSIDSSSN
			SASLTISGLKTEDEADYFCQSYDSDIDIVFGGGTKL
			TVL
1457	hBDI-5H1.2	CDR-L1	ERSSGDIGDTYVS
1458	hBDI-5H1.2	CDR-L2	GNDQRPS
1459	hBDI-5H1.2	CDR-L3	QSYDSDIDIV
1460	hBDI-5H1.3 VH		EVTLRESGPALVKPTQTLTLTCTFSGFSLSTFGMGV
			GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQVVLTMTNMDPVDTATYYCARISTGISSYY
			VMDAWGQGTTVTVSS
1461	hBDI-5H1.3	CDR-H1	GFSLSTFGMGVG
1462	hBDI-5H1.3	CDR-H2	NIWWDDDKYYNPSLKN
1463	hBDI-5H1.3	CDR-H3	ISTGISSYYVMDA
1464	hBDI-5H1.3 VL		EIVLTQSPGTLSLSPGERATLSCERSSGDIGDTYVS
			WYQQKPGQAPRLLIYGNDQRPSGIPDRFSGSGSGTD
			FTLTISRLEPEDFAVYYCQSYDSDIDIVFGGGTKVE
			IK
1465	hBDI-5H1.3	CDR-L1	ERSSGDIGDTYVS
1466	hBDI-5H1.3	CDR-L2	GNDQRPS
1467	hBDI-5H1.3	CDR-L3	QSYDSDIDIV
1468	hBDI-5H1.4 VH		EVTLRESGPALVKPTQTLTLTCTFSGFSLSTFGMGV
			GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQVVLTMTNMDPVDTATYYCARISTGISSYY
			VMDAWGQGTTVTVSS
1469	hBDI-5H1.4	CDR-H1	GFSLSTFGMGVG
1470	hBDI-5H1.4	CDR-H2	NIWWDDDKYYNPSLKN
1471	hBDI-5H1.4	CDR-H3	ISTGISSYYVMDA
1472	hBDI-5H1.4 VL		EFVLTQSPGTLSLSPGERATLSCERSSGDIGDTYVS
			WYQQKPGQAPRLVIYGNDQRPSGIPDRFSGSGSGTD
			FTLTISRLEPEDFAVYYCQSYDSDIDIVFGGGTKVE
			IK
1473	hBDI-5H1.4	CDR-L1	ERSSGDIGDTYVS
1474	hBDI-5H1.4	CDR-L2	GNDQRPS
1475	hBDI-5H1.4	CDR-L3	QSYDSDIDIV
1476	hBDI-5H1.5 VH		EVTLKESGPALVKPTQTLTLTCTFSGFSLSTFGMGV
			GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQAVLTITNMDPVDTATYYCARISTGISSYY
			VMDAWGQGTTVTVSS
1477	hBDI-5H1.5	CDR-H1	GFSLSTFGMGVG
1478	hBDI-5H1.5	CDR-H2	NIWWDDDKYYNPSLKN
1479	hBDI-5H1.5	CDR-H3	ISTGISSYYVMDA
1480	hBDI-5H1.5 VL		NFMLTQPHSVSESPGKTVTISCERSSGDIGDTYVSW
			YQQRPGSSPTTVIYGNDQRPSGVPDRFSGSIDSSSN
			SASLTISGLKTEDEADYYCQSYDSDIDIVFGGGTKL
			TVL
1481	hBDI-5H1.5	CDR-L1	ERSSGDIGDTYVS
1482	hBDI-5H1.5	CDR-L2	GNDQRPS
1483	hBDI-5H1.5	CDR-L3	QSYDSDIDIV
1484	hBDI-5H1.6 VH		EVTLKESGPALVKPTQTLTLTCTFSGFSLSTFGMGV
			GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQAVLTITNMDPVDTATYYCARISTGISSYY
			VMDAWGQGTTVTVSS
1485	hBDI-5H1.6	CDR-H1	GFSLSTFGMGVG
1486	hBDI-5H1.6	CDR-H2	NIWWDDDKYYNPSLKN
1487	hBDI-5H1.6	CDR-H3	ISTGISSYYVMDA
1488	hBDI-5H1.6 VL		NFMLTQPHSVSESPGKTVTISCERSSGDIGDTYVSW
			YQQRPGSPPTNVIYGNDQRPSGVPDRFSGSIDSSSN
			SASLTISGLKTEDEADYFCQSYDSDIDIVFGGGTKL
			TVL
1489	hBDI-5H1.6	CDR-L1	ERSSGDIGDTYVS
1490	hBDI-5H1.6	CDR-L2	GNDQRPS
1491	hBDI-5H1.6	CDR-L3	QSYDSDIDIV
1492	hBDI-5H1.7 VH		EVTLKESGPALVKPTQTLTLTCTFSGFSLSTFGMGV
			GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQAVLTITNMDPVDTATYYCARISTGISSYY
			VMDAWGQGTTVTVSS
1493	hBDI-5H1.7	CDR-H1	GFSLSTFGMGVG
1494	hBDI-5H1.7	CDR-H2	NIWWDDDKYYNPSLKN
1495	hBDI-5H1.7	CDR-H3	ISTGISSYYVMDA
1496	hBDI-5H1.7 VL		EIVLTQSPGTLSLSPGERATLSCERSSGDIGDTYVS
			WYQQKPGQAPRLLIYGNDQRPSGIPDRFSGSGSGTD
			FTLTISRLEPEDFAVYYCQSYDSDIDIVFGGGTKVE
			IK
1497	hBDI-5H1.7	CDR-L1	ERSSGDIGDTYVS
1498	hBDI-5H1.7	CDR-L2	GNDQRPS
1499	hBDI-5H1.7	CDR-L3	QSYDSDIDIV
1500	hBDI-5H1.8 VH		EVTLKESGPALVKPTQTLTLTCTFSGFSLSTFGMGV
			GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQAVLTITNMDPVDTATYYCARISTGISSYY
			VMDAWGQGTTVTVSS
1501	hBDI-5H1.8	CDR-H1	GFSLSTFGMGVG
1502	hBDI-5H1.8	CDR-H2	NIWWDDDKYYNPSLKN
1503	hBDI-5H1.8	CDR-H3	ISTGISSYYVMDA
1504	hBDI-5H1.8 VL		EFVLTQSPGTLSLSPGERATLSCERSSGDIGDTYVS
			WYQQKPGQAPRLVIYGNDQRPSGIPDRFSGSGSGTD
			FTLTISRLEPEDFAVYYCQSYDSDIDIVFGGGTKVE
			IK
1505	hBDI-5H1.8	CDR-L1	ERSSGDIGDTYVS
1506	hBDI-5H1.8	CDR-L2	GNDQRPS
1507	hBDI-5H1.8	CDR-L3	QSYDSDIDIV
1508	hBDI-5H1.9 VH		EVTLRESGPALVKPTQTLTLTCTFSGFSLSTFGMGV
			GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQAVLTITNMDPVDTATYYCARISTGISSYY
			VMDAWGQGTTVTVSS
1509	hBDI-5H1.9	CDR-H1	GFSLSTFGMGVG
1510	hBDI-5H1.9	CDR-H2	NIWWDDDKYYNPSLKN
1511	hBDI-5H1.9	CDR-H3	ISTGISSYYVMDA
1512	hBDI-5H1.9 VL		DFVLTQSPDSLAVSLGERATINCERSSGDIGDTYVS
			WYQQKPGQPPKNVIYGNDQRPSGVPDRFSGSGSGNS
			ATLTISSLQAEDVAVYFCQSYDSDIDIVFGGGTKVE
			IK
1513	hBDI-5H1.9	CDR-L1	ERSSGDIGDTYVS
1514	hBDI-5H1.9	CDR-L2	GNDQRPS
1515	hBDI-5H1.9	CDR-L3	QSYDSDIDIV
1516	hBDI-9E8.1 VH		EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGV
			GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQVVLTMTNMDPVDTATYYCARIESIGTTYS
			FDYWGQGTMVTVSS
1517	hBDI-9E8.1	CDR-H1	GFSLSTYGMGVG
1518	hBDI-9E8.1	CDR-H2	NIWWDDDKYYNPSLKN
1519	hBDI-9E8.1	CDR-H3	IESIGTTYSFDY
1520	hBDI-9E8.1 VL		NFMLTQPHSVSESPGKTVTISCERSSGDIGDSYVSW
			YQQRPGSSPTTVIYADDQRPSGVPDRFSGSIDSSSN
			SASLTISGLKTEDEADYYCQSYDINIDIVFGGGTKL
			TVL
1521	hBDI-9E8.1	CDR-L1	ERSSGDIGDSYVS
1522	hBDI-9E8.1	CDR-L2	ADDQRPS
1523	hBDI-9E8.1	CDR-L3	QSYDINIDIV
1524	hBDI-9E8.10 VH		EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGV
			GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQAVLTITNMDPVDTATYYCARIESIGTTYS
			FDYWGQGTTVTVSS
1525	hBDI-9E8.10	CDR-H1	GFSLSTYGMGVG
1526	hBDI-9E8.10	CDR-H2	NIWWDDDKYYNPSLKN
1527	hBDI-9E8.10	CDR-H3	IESIGTTYSFDY
1528	hBDI-9E8.10 VL		DFQLTQSPSSLSASVGDRVTITCERSSGDIGDSYVS
			WYQQKPGKAPKNVIYADDQRPSGVPSRFSGSGSGNS
			ASLTISSLQPEDFATYYCQSYDINIDIVFGQGTKVE
			IK
1529	hBDI-9E8.10	CDR-L1	ERSSGDIGDSYVS
1530	hBDI-9E8.10	CDR-L2	ADDQRPS
1531	hBDI-9E8.10	CDR-L3	QSYDINIDIV
1532	hBDI-9E8.11 VH		EVQLVESGGGLVQPGGSLRLSCAFSGFSLSTYGMGV
			GWIRQAPGKGLEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQAYLQINSLRAEDTAVYYCARIESIGTTYS
			FDYWGQGTLVTVSS
1533	hBDI-9E8.11	CDR-H1	GFSLSTYGMGVG
1534	hBDI-9E8.11	CDR-H2	NIWWDDDKYYNPSLKN
1535	hBDI-9E8.11	CDR-H3	IESIGTTYSFDY
1536	hBDI-9E8.11 VL		DFVLTQSPDSLAVSLGERATINCERSSGDIGDSYVS
			WYQQKPGQPPKNVIYADDQRPSGVPDRFSGSGSGNS
			ASLTISSLQAEDVAVYFCQSYDINIDIVFGGGTKVE
			IK
1537	hBDI-9E8.11	CDR-L1	ERSSGDIGDSYVS
1538	hBDI-9E8.11	CDR-L2	ADDQRPS
1539	hBDI-9E8.11	CDR-L3	QSYDINIDIV
1540	hBDI-9E8.12 VH		EVQLVESGGGLVQPGGSLRLSCAFSGFSLSTYGMGV
			GWIRQAPGKGLEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQAYLQINSLRAEDTAVYYCARIESIGTTYS
			FDYWGQGTLVTVSS
1541	hBDI-9E8.12	CDR-H1	GFSLSTYGMGVG
1542	hBDI-9E8.12	CDR-H2	NIWWDDDKYYNPSLKN
1543	hBDI-9E8.12	CDR-H3	IESIGTTYSFDY
1544	hBDI-9E8.12 VL		DFQLTQSPSSLSASVGDRVTITCERSSGDIGDSYVS
			WYQQKPGKAPKNVIYADDQRPSGVPSRFSGSGSGNS
			ASLTISSLQPEDFATYYCQSYDINIDIVFGQGTKVE
			IK
1545	hBDI-9E8.12	CDR-L1	ERSSGDIGDSYVS
1546	hBDI-9E8.12	CDR-L2	ADDQRPS
1547	hBDI-9E8.12	CDR-L3	QSYDINIDIV
1548	hBDI-9E8.13 VH		EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGV
			GWIRQPPGKGLEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQAVLTITNMDPVDTATYYCARIESIGTTYS
			FDYWGQGTMVTVSS
1549	hBDI-9E8.13	CDR-H1	GFSLSTYGMGVG
1550	hBDI-9E8.13	CDR-H2	NIWWDDDKYYNPSLKN
1551	hBDI-9E8.13	CDR-H3	IESIGTTYSFDY
1552	hBDI-9E8.13 VL		DFQLTQSPSSLSASVGDRVTITCERSSGDIGDSYVS
			WYQQKPGKAPKNVIYADDQRPSGVPSRFSGSGSGNS
			ASLTISSLQPEDFATYYCQSYDINIDIVFGQGTKVE
			IK
1553	hBDI-9E8.13	CDR-L1	ERSSGDIGDSYVS
1554	hBDI-9E8.13	CDR-L2	ADDQRPS
1555	hBDI-9E8.13	CDR-L3	QSYDINIDIV
1556	hBDI-9E8.2 VH		EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGV
			GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQVVLTMTNMDPVDTATYYCARIESIGTTYS
			FDYWGQGTMVTVSS
1557	hBDI-9E8.2	CDR-H1	GFSLSTYGMGVG
1558	hBDI-9E8.2	CDR-H2	NIWWDDDKYYNPSLKN
1559	hBDI-9E8.2	CDR-H3	IESIGTTYSFDY
1560	hBDI-9E8.2 VL		NFMLTQPHSVSESPGKTVTISCERSSGDIGDSYVSW
			YQQRPGSPPTNVIYADDQRPSGVPDRFSGSIDSSSN
			SASLTISGLKTEDEADYFCQSYDINIDIVFGGGTKL
			TVL
1561	hBDI-9E8.2	CDR-L1	ERSSGDIGDSYVS
1562	hBDI-9E8.2	CDR-L2	ADDQRPS
1563	hBDI-9E8.2	CDR-L3	QSYDINIDIV
1564	hBDI-9E8.3 VH		EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGV
			GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQVVLTMTNMDPVDTATYYCARIESIGTTYS
			FDYWGQGTMVTVSS
1565	hBDI-9E8.3	CDR-H1	GFSLSTYGMGVG
1566	hBDI-9E8.3	CDR-H2	NIWWDDDKYYNPSLKN
1567	hBDI-9E8.3	CDR-H3	IESIGTTYSFDY
1568	hBDI-9E8.3 VL		EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVS
			WYQQKPGQAPRLLIYADDQRPSGIPDRFSGSGSGTD
			FTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVE
			IK
1569	hBDI-9E8.3	CDR-L1	ERSSGDIGDSYVS
1570	hBDI-9E8.3	CDR-L2	ADDQRPS
1571	hBDI-9E8.3	CDR-L3	QSYDINIDIV
1572	hBDI-9E8.4 VH		EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGV
			GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQVVLTMTNMDPVDTATYYCARIESIGTTYS
			FDYWGQGTMVTVSS
1573	hBDI-9E8.4	CDR-H1	GFSLSTYGMGVG
1574	hBDI-9E8.4	CDR-H2	NIWWDDDKYYNPSLKN
1575	hBDI-9E8.4	CDR-H3	IESIGTTYSFDY
1576	hBDI-9E8.4 VL		EFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVS
			WYQQKPGQAPRLVIYADDQRPSGIPDRFSGSGSGTD
			FTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVE
			IK
1577	hBDI-9E8.4	CDR-L1	ERSSGDIGDSYVS
1578	hBDI-9E8.4	CDR-L2	ADDQRPS
1579	hBDI-9E8.4	CDR-L3	QSYDINIDIV
1580	hBDI-9E8.5 VH		EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGV
			GWIRQPPGKGLEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQAVLTITNMDPVDTATYYCARIESIGTTYS
			FDYWGQGTMVTVSS
1581	hBDI-9E8.5	CDR-H1	GFSLSTYGMGVG
1582	hBDI-9E8.5	CDR-H2	NIWWDDDKYYNPSLKN
1583	hBDI-9E8.5	CDR-H3	IESIGTTYSFDY
1584	hBDI-9E8.5 VL		NFMLTQPHSVSESPGKTVTISCERSSGDIGDSYVSW
			YQQRPGSSPTTVIYADDQRPSGVPDRFSGSIDSSSN
			SASLTISGLKTEDEADYYCQSYDINIDIVFGGGTKL
			TVL
1585	hBDI-9E8.5	CDR-L1	ERSSGDIGDSYVS
1586	hBDI-9E8.5	CDR-L2	ADDQRPS
1587	hBDI-9E8.5	CDR-L3	QSYDINIDIV
1588	hBDI-9E8.6 VH		EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGV
			GWIRQPPGKGLEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQAVLTITNMDPVDTATYYCARIESIGTTYS
			FDYWGQGTMVTVSS
1589	hBDI-9E8.6	CDR-H1	GFSLSTYGMGVG
1590	hBDI-9E8.6	CDR-H2	NIWWDDDKYYNPSLKN
1591	hBDI-9E8.6	CDR-H3	IESIGTTYSFDY
1592	hBDI-9E8.6 VL		NFMLTQPHSVSESPGKTVTISCERSSGDIGDSYVSW
			YQQRPGSPPTNVIYADDQRPSGVPDRFSGSIDSSSN
			SASLTISGLKTEDEADYFCQSYDINIDIVFGGGTKL
			TVL
1593	hBDI-9E8.6	CDR-L1	ERSSGDIGDSYVS
1594	hBDI-9E8.6	CDR-L2	ADDQRPS
1595	hBDI-9E8.6	CDR-L3	QSYDINIDIV
1596	hBDI-9E8.7 VH		EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGV
			GWIRQPPGKGLEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQAVLTITNMDPVDTATYYCARIESIGTTYS
			FDYWGQGTMVTVSS
1597	hBDI-9E8.7	CDR-H1	GFSLSTYGMGVG
1598	hBDI-9E8.7	CDR-H2	NIWWDDDKYYNPSLKN
1599	hBDI-9E8.7	CDR-H3	IESIGTTYSFDY
1600	hBDI-9E8.7 VL		EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVS
			WYQQKPGQAPRLLIYADDQRPSGIPDRFSGSGSGTD
			FTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVE
			IK
1601	hBDI-9E8.7	CDR-L1	ERSSGDIGDSYVS
1602	hBDI-9E8.7	CDR-L2	ADDQRPS
1603	hBDI-9E8.7	CDR-L3	QSYDINIDIV
1604	hBDI-9E8.8 VH		EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGV
			GWIRQPPGKGLEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQAVLTITNMDPVDTATYYCARIESIGTTYS
			FDYWGQGTMVTVSS
1605	hBDI-9E8.8	CDR-H1	GFSLSTYGMGVG
1606	hBDI-9E8.8	CDR-H2	NIWWDDDKYYNPSLKN
1607	hBDI-9E8.8	CDR-H3	IESIGTTYSFDY
1608	hBDI-9E8.8 VL		EFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVS
			WYQQKPGQAPRLVIYADDQRPSGIPDRFSGSGSGTD
			FTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVE
			IK
1609	hBDI-9E8.8	CDR-L1	ERSSGDIGDSYVS
1610	hBDI-9E8.8	CDR-L2	ADDQRPS
1611	hBDI-9E8.8	CDR-L3	QSYDINIDIV
1612	hBDI-9E8.9 VH		EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGV
			GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQAVLTITNMDPVDTATYYCARIESIGTTYS
			FDYWGQGTTVTVSS
1613	hBDI-9E8.9	CDR-H1	GFSLSTYGMGVG
1614	hBDI-9E8.9	CDR-H2	NIWWDDDKYYNPSLKN
1615	hBDI-9E8.9	CDR-H3	IESIGTTYSFDY
1616	hBDI-9E8.9 VL		DFVLTQSPDSLAVSLGERATINCERSSGDIGDSYVS
			WYQQKPGQPPKNVIYADDQRPSGVPDRFSGSGSGNS
			ASLTISSLQAEDVAVYFCQSYDINIDIVFGGGTKVE
			IK
1617	hBDI-9E8.9	CDR-L1	ERSSGDIGDSYVS
1618	hBDI-9E8.9	CDR-L2	ADDQRPS
1619	hBDI-9E8.9	CDR-L3	QSYDINIDIV
1620	hBDI-9E8.4E VH		EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGV
			GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTIS
			KDTSKNQVVLTMTNMDPVDTATYYCARIESIGTTYS
			FDYWGQGTMVTVSS
1621	hBDI-9E8.4E	CDR-H1	GFSLSTYGMGVG
1622	hBDI-9E8.4E	CDR-H2	NIWWDDDKYYNPSLKN
1623	hBDI-9E8.4E	CDR-H3	IESIGTTYSFDY
1624	hBDI-9E8.4E VL		EFVLTQSPGTLSLSPGERATLSCERSSGDIGESYVS
			WYQQKPGQAPRLVIYADDQRPSGIPDRFSGSGSGTD
			FTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVE
			IK
1625	hBDI-9E8.4E	CDR-L1	ERSSGDIGESYVS
1626	hBDI-9E8.4E	CDR-L2	ADDQRPS
1627	hBDI-9E8.4E	CDR-L3	QSYDINIDIV
1628	hBFU-3E2.1 VH		EVQLVQSGAEVKKPGSSVKVSCKASGYTFTESYMYW
			VKQAPGQGLELIGRIDPEDGSTDYVEKFKNKATLTA
			DKSTSTAYMELSSLRSEDTAVYFCARFGARSYFYPM
			DAWGQGTTVTVSS
1629	hBFU-3E2.1	CDR-H1	GYTFTESYMY
1630	hBFU-3E2.1	CDR-H2	RIDPEDGSTDYVEKFKN
1631	hBFU-3E2.1	CDR-H3	FGARSYFYPMDA
1632	hBFU-3E2.1 VL		ETVLTQSPATLSLSPGERATLSCRASESVSTLMHWY
			QQKPGQQPRLLIYGASNLESGVPARFSGSGSGTDFT
			LTISSLEPEDFAVYFCQQSWNDPWTFGGGTKVEIK
1633	hBFU-3E2.1	CDR-L1	RASESVSTLMH
1634	hBFU-3E2.1	CDR-L2	GASNLES
1635	hBFU-3E2.1	CDR-L3	QQSWNDPWT
1636	hBFU-3E2.2 VH		EVQLVQSGAEVKKPGSSVKVSCKASGYTFTESYMYW
			VRQAPGQGLELIGRIDPEDGSTDYVEKFKNRVTLTA
			DKSTSTAYMELSSLRSEDTAVYYCARFGARSYFYPM
			DAWGQGTTVTVSS
1637	hBFU-3E2.2	CDR-H1	GYTFTESYMY
1638	hBFU-3E2.2	CDR-H2	RIDPEDGSTDYVEKFKN
1639	hBFU-3E2.2	CDR-H3	FGARSYFYPMDA
1640	hBFU-3E2.2 VL		ETVLTQSPATLSLSPGERATLSCRASESVSTLMHWY
			QQKPGQQPRLLIYGASNLESGVPARFSGSGSGTDFT
			LTISSLEPEDFAVYFCQQSWNDPWTFGGGTKVEIK
1641	hBFU-3E2.2	CDR-L1	RASESVSTLMH
1642	hBFU-3E2.2	CDR-L2	GASNLES
1643	hBFU-3E2.2	CDR-L3	QQSWNDPWT
1644	hBFU-3E2.3 VH		EVQLVQSGAEVKKPGSSVKVSCKASGYTFTESYMYW
			VKQAPGQGLELIGRIDPEDGSTDYVEKFKNKATLTA
			DKSTSTAYMELSSLRSEDTAVYFCARFGARSYFYPM
			DAWGQGTTVTVSS
1645	hBFU-3E2.3	CDR-H1	GYTFTESYMY
1646	hBFU-3E2.3	CDR-H2	RIDPEDGSTDYVEKFKN
1647	hBFU-3E2.3	CDR-H3	FGARSYFYPMDA
1648	hBFU-3E2.3 VL		ATQLTQSPSSLSASVGDRVTISCRASESVSTLMHWY
			QQKPGKQPRLLIYGASNLESGVPSRFSGSGSGTDFT
			LTISSLQPEDFATYFCQQSWNDPWTFGGGTKVEIK
1649	hBFU-3E2.3	CDR-L1	RASESVSTLMH
1650	hBFU-3E2.3	CDR-L2	GASNLES
1651	hBFU-3E2.3	CDR-L3	QQSWNDPWT
1652	hBFU-3E2.4 VH		EVQLVQSGAEVKKPGSSVKVSCKASGYTFTESYMYW
			VRQAPGQGLELIGRIDPEDGSTDYVEKFKNRVTLTA
			DKSTSTAYMELSSLRSEDTAVYYCARFGARSYFYPM
			DAWGQGTTVTVSS
1653	hBFU-3E2.4	CDR-H1	GYTFTESYMY
1654	hBFU-3E2.4	CDR-H2	RIDPEDGSTDYVEKFKN
1655	hBFU-3E2.4	CDR-H3	FGARSYFYPMDA
1656	hBFU-3E2.4 VL		ATQLTQSPSSLSASVGDRVTISCRASESVSTLMHWY
			QQKPGKQPRLLIYGASNLESGVPSRFSGSGSGTDFT
			LTISSLQPEDFATYFCQQSWNDPWTFGGGTKVEIK
1657	hBFU-3E2.4	CDR-L1	RASESVSTLMH
1658	hBFU-3E2.4	CDR-L2	GASNLES
1659	hBFU-3E2.4	CDR-L3	QQSWNDPWT

TABLE 29
VH and VL Amino Acid Sequences of Humanized Versions of
Rat Anti-Human VEGFR II Monoclonal Antibodies (CDRs in bold)
SEQ ID		Protein	V Region
NO:	Clone	Region	12345678901234567890123456
1660	hBCU-6B1.1 VH		EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMY
			WVKQAPGQGLEFMGWINTETGQPTYADDFKGRFVF
			SLDTSVSTAYLQISSLKAEDTAVYFCARLGNNYGI
			WFAYWGQGTLVTVSS
1661	hBCU-6B1.1	CDR-H1	GYTFTNYGMY
1662	hBCU-6B1.1	CDR-H2	WINTETGQPTYADDFKG
1663	hBCU-6B1.1	CDR-H3	LGNNYGIWFAY
1664	hBCU-6B1.1 VL		DIQMTQSPSSLSASVGDRVTIECRASDDLYSTLAW
			YQQKPGKSPKLLIFDANRLAAGVPSRFSGSGSGTD
			YSLTISSLQPEDVATYFCQQYNKFPWTFGGGTKVE
			IK
1665	hBCU-6B1.1	CDR-L1	RASDDLYSTLA
1666	hBCU-6B1.1	CDR-L2	DANRLAA
1667	hBCU-6B1.1	CDR-L3	QQYNKFPWT
1668	hBCU-6B1.2 VH		EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMY
			WVKQAPGQGLEFMGWINTETGQPTYADDFKGRFTF
			TLDTSTSTAYMELRSLRSDDTAVYFCARLGNNYGI
			WFAYWGQGTLVTVSS
1669	hBCU-6B1.2	CDR-H1	GYTFTNYGMY
1670	hBCU-6B1.2	CDR-H2	WINTETGQPTYADDFKG
1671	hBCU-6B1.2	CDR-H3	LGNNYGIWFAY
1672	hBCU-6B1.2 VL		DIQMTQSPSSLSASVGDRVTIECRASDDLYSTLAW
			YQQKPGKSPKLLIFDANRLAAGVPSRFSGSGSGTD
			YSLTISSLQPEDVATYFCQQYNKFPWTFGGGTKVE
			IK
1673	hBCU-6B1.2	CDR-L1	RASDDLYSTLA
1674	hBCU-6B1.2	CDR-L2	DANRLAA
1675	hBCU-6B1.2	CDR-L3	QQYNKFPWT
1676	hBCU-6B1.3 VH		EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMY
			WVRQAPGQGLEFMGWINTETGQPTYADDFKGRFTF
			TLDTSTSTAYMELRSLRSDDTAVYYCARLGNNYGI
			WFAYWGQGTLVTVSS
1677	hBCU-6B1.3	CDR-H1	GYTFTNYGMY
1678	hBCU-6B1.3	CDR-H2	WINTETGQPTYADDFKG
1679	hBCU-6B1.3	CDR-H3	LGNNYGIWFAY
1680	hBCU-6B1.3 VL		DIQMTQSPSSLSASVGDRVTIECRASDDLYSTLAW
			YQQKPGKSPKLLIFDANRLAAGVPSRFSGSGSGTD
			YSLTISSLQPEDVATYFCQQYNKFPWTFGGGTKVE
			IK
1681	hBCU-6B1.3	CDR-L1	RASDDLYSTLA
1682	hBCU-6B1.3	CDR-L2	DANRLAA
1683	hBCU-6B1.3	CDR-L3	QQYNKFPWT
1684	hBCU-6B1.4 VH		EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMY
			WVRQAPGQGLEFMGWINTETGQPTYADDFKGRFTF
			TLDTSTSTAYMELRSLRSDDTAVYYCARLGNNYGI
			WFAYWGQGTLVTVSS
1685	hBCU-6B1.4	CDR-H1	GYTFTNYGMY
1686	hBCU-6B1.4	CDR-H2	WINTETGQPTYADDFKG
1687	hBCU-6B1.4	CDR-H3	LGNNYGIWFAY
1688	hBCU-6B1.4 VL		DIQMTQSPSSLSASVGDRVTITCRASDDLYSTLAW
			YQQKPGKSPKLLIFDANRLAAGVPSRFSGSGSGTD
			YTLTISSLQPEDVATYFCQQYNKFPWTFGGGTKVE
			IK
1689	hBCU-6B1.4	CDR-L1	RASDDLYSTLA
1690	hBCU-6B1.4	CDR-L2	DANRLAA
1691	hBCU-6B1.4	CDR-L3	QQYNKFPWT

TABLE 30
VH and VL Amino Acid Sequences of Humanized Versions of
Rat Anti-Human PDGFR b Monoclonal Antibodies (CDRs in bold)
SEQ ID		Protein	V Region
NO:	Clone	Region	123456789012345678901234567890
1692	hBDE-3C9.1 VH		EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMA
			WVRQAPGKGLEWVASITNSGGNTYYRDSVKGRFTI
			SRDNAKNTQYLQMNSLRAEDTAVYFCARHTPGANY
			FDYWGQGTMVTVSS
1693	hBDE-3C9.1	CDR-H1	GFTFSNYGMA
1694	hBDE-3C9.1	CDR-H2	SITNSGGNTYYRDSVKG
1695	hBDE-3C9.1	CDR-H3	HTPGANYFDY
1696	hBDE-3C9.1 VL		DIQMTQSPSSLSASVGDRVTITCQASQSIKNYIAW
			YQLKPGKAPRLLMRYTSTLESGTPSRFSGSGSGRD
			YTFTISSLQPEDIATYYCVQYANLYTFGGGTKVEI
			K
1697	hBDE-3C9.1	CDR-L1	QASQSIKNYIA
1698	hBDE-3C9.1	CDR-L2	YTSTLES
1699	hBDE-3C9.1	CDR-L3	VQYANLYT
1700	hBDE-3C9.2 VH		EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMA
			WVRQAPGKGLEWVASITNSGGNTYYRDSVKGRFTI
			SRDNAKNSLYLQMNSLRAEDTAVYYCARHTPGANY
			FDYWGQGTMVTVSS
1701	hBDE-3C9.2	CDR-H1	GFTFSNYGMA
1702	hBDE-3C9.2	CDR-H2	SITNSGGNTYYRDSVKG
1703	hBDE-3C9.2	CDR-H3	HTPGANYFDY
1704	hBDE-3C9.2 VL		DIQMTQSPSSLSASVGDRVTITCQASQSIKNYIAW
			YQQKPGKAPRLLIRYTSTLESGVPSRFSGSGSGRD
			YTFTISSLQPEDIATYYCVQYANLYTFGGGTKVEI
			K
1705	hBDE-3C9.2	CDR-L1	QASQSIKNYIA
1706	hBDE-3C9.2	CDR-L2	YTSTLES
1707	hBDE-3C9.2	CDR-L3	VQYANLYT

Generation of Humanized Antibodies

All variants were cloned into pHybE vectors and were transiently transfected into 50 mls of HEK 2936e suspension cell cultures in a ratio of 60% to 40% light to heavy chain construct. 1 mg/ml PEI was used to transfect the cells. Cell supernatants were harvested after six days in shaking flasks, spun down to pellet cells, and filtered through 0.22 μm filters to separate IgG from culture contaminates. All were batch purified by adding 1 supernatant volume of protein A IgG binding buffer (Thermo Scientific 21001) and 1 ml of rProteinA sepharose fast flow beads (GE Healthcare, 17-1279-04). Supernatants, with beads and buffer added, were rocked overnight at 4° C., and the day after beads were collected by gravity over poly prep chromatography columns (Bio Rad, 731-1550). Once supernatants had passed through the columns the beads were washed with 10 column volumes of binding buffer, and IgG was eluted with Immunopure IgG elution buffer (Pierce, 185 1520) and collected in 1 ml aliquots. Fractions containing IgG were pooled and dialyzed in 15 mM Histidine pH 6 overnight at 4° C.

Purified variants were further characterized for their affinities for recombinant human target proteins by binding ELISA, by Biacore, and by cell-based potency assays.

TABLE 31
Summary of Protein Expression and Purification for
Humanized Anti-Human VEGF-A And Humanized
Anti-Human PDGF-BB Monoclonal Antibodies
		Octet Titer	~Yield	SEC
	Name	(mg/L)1	(mg/L)2	(% monomer)3
	hBDB-4G8.1	19.9	19.7	100.0
	hBDB-4G8.2	105.3	95.8	100.0
	hBDB-4G8.3	34.8	31.9	100.0
	hBDB-4G8.4	45.8	34.2	100.0
	hBDB-4G8.5	24.7	27.4	100.0
	hBDB-4G8.6	28.6	34.2	100.0
	hBDB-4G8.7	75.8	63.4	100.0
	hBDB-4G8.8	145.9	101.4	100.0
	hBDB-4G8.9	38.8	39.0	100.0
	hBDB-4G8.10	40.7	32.9	89.1
	hBDB-4G8.11	47.9	38.0	87.2
	hBDB-4G8.12	37.5	38.3	100.0
	hBDB-4G8.13	44.8	35.1	100.0
	hBDB-4G8.14	73.0	47.0	100.0
	hBDB-4G8.15	161.2	94.9	100.0
	hBDI-5H1.1	49.8	38.7	100.0
	hBDI-5H1.2	63.4	62.0	100.0
	hBDI-5H1.3	94.2	86.5	99.1
	hBDI-5H1.4	109.0	123.1	99.2
	hBDI-5H1.5	23.0	27.7	100.0
	hBDI-5H1.6	41.2	46.0	100.0
	hBDI-5H1.7	9.6	9.6	88.1
	hBDI-5H1.8	36.0	41.5	100.0
	hBDI-5H1.9	56.0	60.2	85.6
	hBDI-5H1.10	34.2	31.1	85.2
	hBDI-5H1.11	41.0	34.4	96.3
	hBDI-5H1.12	37.7	30.2	100.0
	hBDI-9E8.1	90.0	72.4	100.0
	hBDI-9E8.2	89.9	89.1	99.3
	hBDI-9E8.3	28.8	24.4	97.1
	hBDI-9E8.4	52.8	54.8	98.2
	hBDI-9E8.5	78.0	57.7	100.0
	hBDI-9E8.6	60.6	61.4	100.0
	hBDI-9E8.7	30.4	27.9	88.1
	hBDI-9E8.8	37.1	38.0	98.4
	hBDI-9E8.9	50.3	44.9	94.6
	hBDI-9E8.10	93.0	56.2	94.7
	hBDI-9E8.11	78.4	52.7	99.1
	hBDI-9E8.12	92.3	68.5	100.0
	hBDI-5H1.13	13.6	10.5	88.1
	hBDI-9E8.13	53.5	66.9	100.0
	hBDI-1E1.1	133.5	ND	ND
	hBDI-1E1.2	115.6	ND	ND
	hBDI-1E1.3	83.4	ND	ND
	hBDI-1E1.4	137.6	ND	ND
	hBDI-1E1.5	97.4	ND	ND
	hBDI-1E1.6	70.6	ND	ND
	hBDI-1E1.7	91.9	ND	ND
	hBDI-1E1.8	71.2	ND	ND
	hBDI-1E1.9	94.3	ND	ND
	hBDI-1E1.10	72.7	ND	ND
	hBDI-1E1.11	57.4	ND	ND
	hBDI-1E1.12	151.6	ND	ND
	hBEW-9A8.1	0.2	ND	ND
	hBEW-9A8.2	0.2	ND	ND
	hBEW-9A8.3	0.2	ND	ND
	hBEW-9A8.4	0.2	ND	ND
	hBEW-9A8.5	0.5	ND	ND
	hBEW-9A8.6	0.2	ND	ND
	hBEW-9A8.7	0.3	ND	ND
	hBEW-9A8.8	3.5	ND	ND
	hBEW-9A8.9	15.3	18.6	ND
	hBEW-9A8.10	5.2	ND	ND
	hBEW-9A8.11	30.6	18.9	ND
	hBEW-9A8.12	38.3	28.4	ND
	hBEW-9A8.13	0.4	ND	ND
	hBEW-9A8.14	0.3	ND	ND
	hBEW-9A8.15	0.3	ND	ND
	hBEW-9A8.16	3.2	ND	ND
	hBEW-6C2.1	5.4	ND	ND
	hBEW-6C2.2	1.5	ND	ND
	hBEW-6C2.3	14.8	7.8	ND
	hBEW-6C2.4	79.6	29.5	ND
	hBEW-6C2.5	4.7	ND	ND
	hBEW-6C2.6	3.9	ND	ND
	hBEW-6C2.7	140.8	39.7	ND
	hBEW-6C2.8	75.3	24.8	ND
	hBDI-5H1.16	ND	23.9	93.4
	hBDI-5H1.17	ND	21.0	92.1
	hBFU-3E2.1	ND	40.2	88.1
	hBFU-3E2.2	ND	34.6	93.6
	hBFU-3E2.3	ND	33.6	84.2
	hBFU-3E2.4	ND	38.4	94.7
	hBEW-9A8.17	ND	20.0	98.7
	hBEW-9A8.20	ND	17.6	86.6
	hBEW-9A8.21	ND	13.3	97.5
	hBEW-5C3.1	ND	20.8	85.0
	hBEW-5C3.2	ND	17.7	74.6
	hBEW-5C3.3	ND	6.9	93.7
	hBEW-5C3.4	ND	32.0	88.7
	hBEW-5C3.5	ND	30.6	85.1
	hBEW-5C3.6	ND	19.4	75.4
	hBEW-9E10.1	ND	42.7	98.0
	hBEW-9E10.2	ND	46.1	98.0
	hBEW-9E10.3	ND	45.9	97.6
	hBEW-9E10.4	ND	47.1	98.0
	hBEW-9E10.5	ND	56.2	97.9
	hBEW-9E10.6	ND	52.9	97.6
	hBEW-1B10.1	ND	34.1	97.8
	hBEW-1B10.2	ND	45.3	98.1
	hBEW-1E3.1	ND	29.6	95.5
	hBEW-1E3.2	ND	20.9	98.3
	hBEW-1E3.3	ND	22.0	98.5
	hBEW-1E3.4	ND	48.0	98.1
	hBEW-1E3.5	ND	23.8	98.5
	hBEW-1E3.6	ND	17.0	98.7
	ND = Not Determined
	1Octet titer is the amout of IgG in the unpurified supernatant as determined by protein A binding compared to a standard curve using an Octet instrument.
	2Yield is determined by the total amount of purified protein in mg divided by the total cell culture volume in liters.
	3SEC % monomer is determined using HPLC size exclusion chromatography.

Humanized anti-VEGF antibodies were tested for their binding to human VEGF-A according to the method described in Example 1.1. The on-rate, off-rate and binding kinetics are summarized in Table 32 below.

TABLE 32
Biacore Binding of Humanized Anti-VEGF Antibodies
	Antibody	kon (M−1 s−1)	koff (M−1)	KD (M)
	hBDB-4G8.1	1.8E+07	1.0E−04	5.8E−12
	hBDB-4G8.2	1.7E+07	6.2E−05	3.6E−12
	hBDB-4G8.3	1.0E+07	4.8E−05	4.8E−12
	hBDB-4G8.4	2.7E+07	1.5E−04	5.5E−12
	hBDB-4G8.5	2.5E+07	4.0E−05	1.6E−12
	hBDB-4G8.6	2.6E+07	3.7E−05	1.4E−12
	hBDB-4G8.7	3.7E+07	1.3E−03	3.4E−11
	hBDB-4G8.8	1.8E+07	8.6E−04	4.7E−11
	hBDB-4G8.9	1.4E+07	8.8E−04	6.2E−11
	hBDB-4G8.10	2.7E+07	2.2E−04	8.1E−12
	hBDB-4G8.11	2.6E+07	3.4E−05	1.3E−12
	hBDB-4G8.12	2.6E+07	3.2E−05	1.2E−12
	hBDB-4G8.13	2.2E+07	1.7E−04	7.6E−12
	hBDB-4G8.14	1.5E+07	5.6E−05	3.7E−12
	hBDB-4G8.15	2.0E+07	8.7E−05	4.4E−12
	hBEW-9A8.9	1.0E+07	8.2E−03	8.2E−10
	hBEW-9A8.11	1.5E+07	1.1E−03	7.4E−11
	hBEW-9A8.12	9.6E+06	1.4E−04	1.5E−11
	hBEW-9A8.17	7.9E+06	1.4E−05	1.7E−12
	hBEW-9A8.20	7.6E+06	1.2E−05	1.6E−12
	hBEW-9A8.21	5.8E+06	3.9E−05	6.7E−12
	hBEW-5C3.1	1.1E+07	6.9E−05	6.0E−12
	hBEW-5C3.4	9.9E+06	8.5E−05	8.6E−12
	hBEW-5C3.5	1.2E+07	9.7E−05	8.5E−12
	hBEW-9E10.1	1.2E+07	2.5E−05	2.1E−12
	hBEW-9E10.2	1.6E+07	1.9E−04	1.2E−11
	hBEW-9E10.3	1.3E+07	4.2E−05	3.2E−12
	hBEW-9E10.4	1.2E+07	2.5E−05	2.1E−12
	hBEW-9E10.5	1.6E+07	2.3E−04	1.5E−11
	hBEW-9E10.6	1.5E+07	4.0E−05	2.6E−12
	hBEW-1B10.1	7.6E+06	1.4E−04	1.8E−11
	hBEW-1B10.2	7.5E+06	1.5E−04	2.0E−11
	hBEW-1E3.1	1.1E+07	8.5E−05	7.7E−12
	hBEW-1E3.2	1.1E+07	1.0E−04	9.2E−12
	hBEW-1E3.4	9.8E+06	9.6E−05	9.7E−12
	hBEW-1E3.5	1.0E+07	1.0E−04	1.0E−11

Humanized anti-VEGF-A antibodies were tested for potency against hVEGF₁₆₅-induced cell proliferation in one of two cellular assay formats. The HMVEC-d bioassay utilizes cells which natively express VEGFR2 (Example 1.10). The VEGFR2-3T3 cells are stably transfected with VEGFR2 (Example 1.7). The data is summarized in Table 33 below.

TABLE 33
Summary of Characterization of Humanized
Anti-Human VEGF-A Monoclonal Antibodies.
	hVEGF165 IC50 (nM)
			VEGFR2-
	Humanized Molecules	HMVEC-d	3T3
	hBDB-4G8.1	NT	0.847
	hBDB-4G8.2	NT	0.603
	hBDB-4G8.3	NT	0.665
	hBDB-4G8.3 half-body	NT	>10
	hBDB-4G8.4	NT	0.918
	hBDB-4G8.5	NT	0.620
	hBDB-4G8.6	NT	0.488
	hBDB-4G8.7	NT	>10
	hBDB-4G8.8	NT	>10
	hBDB-4G8.9	NT	>10
	hBDB-4G8.10	NT	>10
	hBDB-4G8.11	NT	0.385
	hBDB-4G8.12	NT	0.563
	hBDB-4G8.13	NT	0.791
	hBDB-4G8.14	NT	0.499
	hBDB-4G8.15	NT	0.963
	hBEW-1B10.1	0.168	NT
	hBEW-1B10.2	0.222	NT
	hBEW-1E3.1	0.138	NT
	hBEW-1E3.4	0.212	NT
	hBEW-1E3.2	0.161	NT
	hBEW-1E3.3	0.205	NT
	hBEW-1E3.5	0.184	NT
	hBEW-1E3.6	0.26	NT
	hBEW-5C3.1	0.071	NT
	hBEW-5C3.2	0.162	NT
	hBEW-5C3.3	>2	NT
	hBEW-5C3.4	0.098	NT
	hBEW-5C3.5	0.123	NT
	hBEW-5C3.6	>2	NT
	hBEW-9A8.9	NT	>10
	hBEW-9A8.11	NT	>10
	hBEW-9A8.12	NT	0.598
	hBEW-9A8.17	0.059	NT
	hBEW-9A8.20	0.064	NT
	hBEW-9A8.21	0.09	NT
	hBEW-9E10.1	0.064	NT
	hBEW-9E10.2	0.181	NT
	hBEW-9E10.3	0.062	NT
	hBEW-9E10.4	0.071	NT
	hBEW-9E10.5	0.229	NT
	hBEW-9E10.6	0.068	NT
	NT = Not tested

Humanized anti-PDGF-BB antibodies were tested for their binding to human PDGF-BB according to the method described in Example 1.1. The on-rate, off-rate and binding kinetics are summarized in Table 34 below.

TABLE 34
Biacore Binding of Humanized Anti-PDGF Antibodies
	Antibody	kon (M−1 s−1)	koff (M−1)	KD (M)
	hBDI-9E8.1	≧1.0E+07	5.6E−03	≦5.6E−10
	hBDI-9E8.2	≧1.0E+07	5.1E−03	≦5.1E−10
	hBDI-9E8.3	≧1.0E+07	6.5E−04	≦6.5E−11
	hBDI-9E8.4	>1.0E+07	2.1E−04	≦2.1E−11
	hBDI-9E8.5	≧1.0E+07	2.1E−03	≦2.1E−10
	hBDI-9E8.6	≧1.0E+07	2.1E−03	≦2.1E−10
	hBDI-9E8.7	≧1.0E+07	4.5E−04	≦4.5E−11
	hBDI-9E8.8	≧1.0E+07	1.7E−04	≦1.7E−11*
	hBDI-9E8.9	≧1.0E+07	1.5E−03	≦1.5E−10
	hBDI-9E8.10	≧1.0E+07	1.8E−03	≦1.8E−10
	hBDI-9E8.11	≧1.0E+07	7.4E−04	≦7.4E−11
	hBDI-9E8.12	≧1.0E+07	2.1E−03	≦2.1E−10
	hBDI-9E8.13	≧1.0E+07	1.0E−03*	≦1.0E−10*
	hBDI-5H1.1	≧1.0E+07	4.1E−03	≦4.1E−10
	hBDI-5H1.2	≧1.0E+07	1.9E−03	≦1.9E−10
	hBDI-5H1.3	≧1.0E+07	4.5E−03	≦4.5E−10
	hBDI-5H1.4	≧1.0E+07	1.4E−02	≦1.4E−09
	hBDI-5H1.5	≧1.0E+07	1.7E−03	≦1.7E−10
	hBDI-5H1.6	≧1.0E+07	8.2E−04	≦8.2E−11
	hBDI-5H1.7	≧1.0E+07	2.9E−02*	≦2.9E−09*
	hBDI-5H1.8	≧1.0E+07	7.2E−01*	≦7.2E−08*
	hBDI-5H1.9	≧1.0E+07	3.1E−03	≦3.1E−10
	hBDI-5H1.10	≧1.0E+07	2.3E−03	≦2.3E−10
	hBDI-5H1.11	≧1.0E+07	3.7E−03	≦3.7E−10
	hBDI-5H1.12	≧1.0E+07	2.3E−03	≦2.3E−10
	hBDI-5H1.13	≧1.0E+07	4.9E−03*	≦4.9E−10*
	*Heterogeneous off-rate

Humanized anti-PDGF-BB antibodies were tested for potency against hPDGF-BB in functional assays. The ability to neutralize hPDGF-BB-induced cell proliferation was assessed (Example 1.15) as well as the ability to block binding of hPDGF-BB to hPDGF-Rβ in a competition ELISA format (Example 1.13). The data is summarized in Table 35 below.

TABLE 35
Summary of Characterization of Humanized
Anti-Human PDGF-BB Monoclonal Antibodies
			hPDGF-
			BB/hPDGFRβ
		hPDGF-BB	Competition
	Humanized Molecules	IC50 (nM)	IC50 (nM)
	hBDI-9E8.1	>5	+
	hBDI-9E8.2	>5	+
	hBDI-9E8.3	1.583	+
	hBDI-9E8.4	0.061	4.301
	hBDI-9E8.4 half body	>5	NT
	hBDI-9E8.5	>5	+
	hBDI-9E8.6	>5	+
	hBDI-9E8.7	0.350	+
	hBDI-9E8.8	0.105	+
	hBDI-9E8.9	0.574	+
	hBDI-9E8.10	0.562	+
	hBDI-9E8.11	0.309	1.730
	hBDI-9E8.12	0.525	+
	hBDI-5H1.1	<10	+
	hBDI-5H1.2	<10	+
	hBDI-5H1.3	<10	−
	hBDI-5H1.4	<10	−
	hBDI-5H1.9	<10	+
	hBDI-5H1.10	<10	−
	hBDI-5H1.11	<10	−
	hBDI-5H1.12	<10	−
	hBDI-5H1.5	<10	+
	hBDI-5H1.6	<10	+
	hBDI-5H1.7	<10	−
	hBDI-5H1.8	<10	−
	hBDI-5H1.13	<10	+
	hBDI-5H1.16	<10	NT
	hBDI-5H1.17	<10	NT
	hBFU-3E2.1	0.183	NT
	hBFU-3E2.2	0.659	NT
	hBFU-3E2.3	0.335	NT
	hBFU-3E2.4	0.571	NT
	NT—Not tested

Humanized anti-VEGFR2 antibodies were tested for potency against hVEGFR2 in functional assay formats. The antibodies were characterized for the ability to block VEGFR2 binding to hVEGF₁₆₅ in a competition ELISA format (Example 1.22). The antibodies were also tested for the ability to bind exogeneous hVEGFR2 and allow signaling in response to hVEGF₁₆₅ (Example 1.23). The data is summarized in Table 36 below.

TABLE 36
Summary of Characterization of Humanized
Anti-Human VEGFR II Monoclonal Antibodies.
	Potency (nM)
		hVEGF165/	hVEGF165/
	Humanized	hVEGFR2-Fc	Tyr1054
	Molecules	Competition	phospho-assay
	hBCU-6B1.1	0.474	NT
	hBCU-6B1.2	0.340	NT
	hBCU-6B1.3	0.319	NT
	hBCU-6B1.4	0.335	NT
	NT—Not tested

Humanized anti-PDGF-Rβ antibodies were characterized for activity in functional assays. Antibodies were assessed for the ability to bind hPDGF-Rβ (Example 1.26) and block binding of hPDGF-Rβ to hPDGF-BB in a competition ELISA format (Example 1.27). They were also tested for the ability to bind exogenoeous hPDGF-Rβ and allow signaling in response to hPDGF-BB (Example 1.28). The data is summarized in Table 37 below.

TABLE 37
Summary of Characterization of Humanized
Anti-Human PDGFR-B Monoclonal Antibodies
	Potency (nM)
		hPDGF-BB/	hPDGF-BB
	hPDGFRβ-Fc	hPDGFRβ-Fc	Tyr751
Humanized Molecules	Binding	Competition	phospho-assay
hBDE-3C9.1	NT	0.217	1.053
hBDE-3C9.2	NT	0.260	0.882
NT—Not tested

Example 7

Affinity Maturation of Anti-Human VEGF-A Antibody 4G8

Library Designs And Strategy

Two different hBDB-4G8.3 parental sequences were made: One with “DT” and another with “EI” at the beginning of VL. Both parentals were tested as scFv, and the “EI” was chosen as the template for the libraries. Two libraries were made by dope primers: HC and LC. After library selection and diversity reduction, libraries were combined into one recombined library (rHC+LC). Final selected clones from each of 3 libraries were converted to IgG.

HC Library

• • Doping (X) 11 residues at 76080808: 30, 31, 33, 53, 56, 58, 95, 96, 100, 100a and 100c
  • Co-evolve (1): D61Q/D62G/K64T. Library will contain DDFKG (SEQ ID NO: 1708) or QGFTG (SEQ ID NO: 1709)

A 10⁹ library will be able to sample mutants carrying up to 4 doped residues at least 4 times. On average, library members will have 5 doped residues.

LC Library

• • Doping (X) 10 residues at 76080808: 30, 31, 32, 50, 53, 91-94 and 96
  • Germline toggle (Z): E27Q, V58I and F87Y
  • Co-evolve (1): M33L/H34A. Library will contain HMHW (SEQ ID NO: 1710) or YLAW (SEQ ID NO: 1711)

A 10⁹ library will be able to sample mutants carrying up to 4 doped residues at least 4 times. On average, library members will have 5 doped residues.

Recombined Library

H1+H2 library is recombined with H3 library into a HC library. HC library is combined with LC library for a total recombined library rHC+LC.

Codons Specified for Residues To Be Doped

For instance, if a proline is to be doped, the doping oligo will have C_(5-85-5-5)C_(5-85-5-5)S codon regardless of the original codon in the antibody sequence. These codons are selected based on the following criteria: Increase non-synonymous mutation; increase coverage of more amino acids when mutated; and uses high frequency codons and avoid SSS and WWW codons

Doping Order is A-C-G-T

A(70-10-10-10)	C(10-70-10-10)	G(10-10-70-10)	T(10-10-10-70)
Alanine (A):
GCN	G(10-10-70-10) C(10-70-10-10) S
Threonine (T):
ACN	A(70-10-10-10) C(10-70-10-10) S
Proline (P):
CCN	C(10-70-10-10) C(10-70-10-10) S
Serine (S):
TCN	T(10-10-10-70) C(10-70-10-10) S
AGY	A(70-10-10-10) G(10-10-70-10) C(10-70-10-10)
Valine (V):
GTN	G(10-10-70-10) T(10-10-10-70) S
Glycine (G):
GGN	G(10-10-70-10) G(10-10-70-10) S
Leucine (L):
CTN	C(10-70-10-10) T(10-10-10-70) S
TTR	T(10-10-10-70) T(10-10-10-70) G(10-10-70-10)
Arginine (R):
CGN	C(10-70-10-10) G(10-10-70-10) S
AGR	A(70-10-10-10) G(10-10-70-10) G(10-10-70-10)
Methionine (M):
ATG	A(70-10-10-10) T(10-10-10-70) G(10-10-70-10)
Tryptophan (W):
TGG	T(10-10-10-70) G(10-10-70-10) G(10-10-70-10)
Pheylalanine (F):
TTY	T(10-10-10-70) T(10-10-10-70) C(10-70-10-10)
Isoleucine (I):
50% ATY	A(70-10-10-10) T(10-10-10-70) C(10-70-10-10)
50% ATA	A(70-10-10-10) T(10-10-10-70) A(70-10-10-10)
Tyrosine (Y):
TAY	T(10-10-10-70) A(70-10-10-10) C
Histidine (H):
CAY	C(10-70-10-10) A(70-10-10-10) C(10-70-10-10)
Glutamine (Q):
CAR	C(10-70-10-10) A(70-10-10-10) G(10-10-70-10)
Asparagine (N):
AAY	A(70-10-10-10) A(70-10-10-10) C(10-70-10-10)
Lysine (K):
AAR	A(70-10-10-10) A(70-10-10-10) G(10-10-70-10)
Aspartic Acid (D):
GAY	G(10-10-70-10) A(70-10-10-10) C(10-70-10-10)
Glutamic acid (E):
GAR	G(10-10-70-10) A(70-10-10-10) G(10-10-70-10)
Cysteine (C):
TGY	NNS

List of Amino Acid Sequences of Affinity Matured H4g8.3 VH Variants.

Table 38 provides a list of amino acid sequences of unique, functional VH regions of affinity matured humanized anti-VEGF antibodies derived from hBDB-4G8.3. Amino acid residues of individual CDRs of each VH sequence are indicated in bold.

TABLE 38
List of Amino Acid Sequences of
Affinity Matured H4g8.3 VH Variants
Clone	SEQ ID NO:	VH
CL-27663	1712	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYRMYWVRQAPGQGL
		EWMGWINTETGXPAYADDFKRRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTKYYYSSYIFYFDYWGQGTMVTVSS
CL-27664	1713	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYSMYWVRQAPGQGL
		EWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTKYYYRFYLFYFDYWGQGTMVTVSS
CL-27665	1714	EVQLVQSGSELKKPGASVKVSCKASGYTFTYYGMYWVRQAPGQGL
		EWMGWINTKTGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYGSYIFYFDYWGQGTMVTVSS
CL-27666	1715	EVQLVQSGSELKKPGASVKVSCKASGYTFINYRMYWVRQAPGQGL
		EWMGWINTETGKPVYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYSSYKFYFDYWGQGTMVTVSS
CL-27667	1716	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYAMYWVRQAPGQGL
		EWMGWINTETGKPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTIYYYXKYIFYFDYWGQGTMVTVSS
CL-27668	1717	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARPTYYYWIYIFYFDYWGQGTMVTVSS
CL-27669	1718	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYCMYWVRQAPGQGL
		EWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARRNYYYXCYIFYFDYWGQGTMVTVSS
CL-27670	1719	EVQLVQSGSELKKPGASVKVSCKASGYTFTTYDMYWVRQAPGQGL
		EWMGWINTVTGSPAYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTTYYYCSYTFYFDYWGQGTMVTVSS
CL-27671	1720	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTGTGXPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARXNYYYXSYXFYFDYWGQGTMVTVSS
CL-27672	1721	EVQLVQSGSELKKPGASVKVSCKASGYTFSKYGMYWVRQAPGQGL
		EWMGWINTYTGKPLYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYMGYRFYFDYWGQGTMVTVSS
CL-27673	1722	EVQLVQSGSELKKPGASVKVSCKASGYTFTPYGMYWVRQAPGQGL
		EWMGWINTETGVPSYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARSNYYYRSYRFYFDYWGQGTMVTVSS
CL-27674	1723	EVQLVQSGSELKKPGASVKVSCKASGYTFINYVMYWVRQAPGQGL
		EWMGWINTATGXPSYAQGFTGRFVFSFDTSVSTTYLQISSLKAED
		TAVYYCARTTYYYRRYIFYFDYWGQGTMVTVSS
CL-27675	1724	EVQLVQSGSELKKPGASVKVSCKASGYTFTKYDMYWVRQAPGQGL
		EWMGWINTATGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTLYYYRRYIFYFDYWGQGTMVTVSS
CL-27676	1725	EVQLVQSGSELKKPGASVKVSCKASGYTFIKYGMYWVRQAPGQGL
		EWMGWINTETGRPAYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARIRYYYGSYIFYFDYWGQGTMVTVSS
CL-27677	1726	EVQLVQSGSELKKPGASVKVSCKASGYTFKNYEMYWVRQAPGQGL
		EWMGWINTETGKPRYADDFKGRFVFSLDTSVNTAYLQISSLKAED
		TAVYYCARTNYYYRSYVFYFDYWGQGTMVTVSS
CL-27678	1727	EVQLVQSGSELKKPGASVKVSCKASGYTFPLYSMYWVRQAPGQGL
		EWMGWINTHTGNPSYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYTFYFDYWGQGTMVTVSS
CL-27679	1728	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTATGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARMNYYYRSYIFYFDYWGQGTMVTVSS
CL-27680	1729	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYCMYWVRQAPGQGL
		EWMGWINTETGKPLYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARRNYYYGGYIFYFDYWGQGTMVTVSS
CL-27681	1730	EVQLVQSGSELKKPGASVKVSCKASGYTFTXYGMYWVRQAPGQGL
		EWMGWINTQTGPPPYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTYYYYRWYIFYFDYWGQGTMVTVSS
CL-27682	1731	EVQLVQSGSELKKPGASVKVSCKASGYTFTIYEMYWVRQAPGQGL
		EWMGWINTETGTPPYAXDFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARXXYYYXSYIFYFDYWGQGTMVTVSS
CL-27683	1732	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYVMYWVRQAPGQGL
		EWMGWINTDTGNPAYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTTYYYRVYMFYFDYWGQGTMVTVSS
CL-27685	1733	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYCMYWVRQAPGQGL
		EWMGWINTATGNPSYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYASYIFYFDYWGQGTMVTVSS
CL-27686	1734	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYAMYWVRQAPGQGL
		EWMGWINTPTGMPNYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTSYYYSSYLFYFDYWGQGTMVTVSS
CL-27687	1735	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTDTGTPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTEYYYRSYIFYFDYWGQGTMVTVSS
CL-27688	1736	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYEMYWVRQAPGQGL
		EWMGWINTATGKPSYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTIYYYVRYIFYFDYWGQGTMVTVSS
CL-27689	1737	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGTPSYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTVYYYRSYLFYFDYWGQGTMVTVSS
CL-27690	1738	EVQLVQSGSELKKPGASVKVSCKASGYTFATYGMYWVGQAPGQGL
		EWMGWINTETGMPAYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARIRYYYGRYLFYFDYWGQGTMVTVSS
CL-27691	1739	EVQLVQSGSELKKPGASVKVSCKASGYTFSIYYMYWVRQAPGQGL
		EWMGWINTGTGTPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTSYYYRSYLFYFDYWGQGTMVTVSS
CL-27692	1740	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYAMYWVRQAPGQGL
		EWMGWINTQTGKPRYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARPQYYYTSYIFYFDYWGQGTMVTVSS
CL-27694	1741	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTXTGXPTYAXDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARXXYYYRSYXFYFDYWGQGTMVTVSS
CL-27695	1742	EVQLVQSGSELKKPGASVKVSCKASGYTFTYYNMYWVRQAPGQGL
		EWMGWINTATGSPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARSTYYYRSYIFYFDYWGQGTMVTVSS
CL-27696	1743	EVQLVQSGSELKKPGASVKVSCKASGYTFTKYGMYWVRQAPGQGL
		EWMGWINTQTGKPRYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYWSYIFYFDYWGQGTMVTVSS
CL-27697	1744	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYPMYWVRQAPGQGL
		EWMGWINTETGXPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARXXYYYXRYIFYFDYWGQGTMVTVSS
CL-27699	1745	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYDMYWVRQAPGQGL
		EWMGWINTATGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYRSYLFYFDYWGQGTMVTVSS
CL-27700	1746	EVQLVQSGSELKKPGASVKVSCKASGYTFAHYGMYWVRQAPGQGL
		EWMGWINTETGNPDYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRCYIFYFDYWGQGTMVTVSS
CL-27701	1747	EVQLVQSGSELKKPGASVKVSCKASGYTFTIYGMYWVRQAPGQGL
		EWMGWINTETGKPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRCYMFYFDYWGQGTMVTVSS
CL-27702	1748	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTVTGAPIYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYWGYRFYFDYWGQGTMVTVSS
CL-27703	1749	EVQLVQSGSELKKPGASVKVSCKASGYTFRSYVMYWVRQAPGQGL
		EWMGWINTDTGTPSYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARPYYYYRRYIFYFDYWGQGTMVTVSS
CL-27704	1750	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYCMYWVRQAPGQGL
		EWMGWINTKTGNPAYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARXIYYYRRYVLYFDYWGQGTMVTVSS
CL-27705	1751	EVQLVQSGSELKKPGASVKVSCKASGYTFANYSMYWVRQAPGQGL
		EWMGWINTETGKPKYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRRYSFYFDYWGQGTMVTVSS
CL-27706	1752	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYCMYWVRQAPGQGL
		EWMGWINTTTGKPNYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARSNYYYRRYLFYFDYWGQGTMVTVSS
CL-27708	1753	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTMTGKPNYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTDYYYRSYDFYFDYWGQGTMVTVSS
CL-27709	1754	EVQLVQSGSELKKPGASVKVSCKASGYTFPKYAMYWVRQAPGQGL
		EWMGWINTETGXPRYAHDFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRGYIFYFDYWGQGTMVTVSS
CL-27710	1755	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYVMYWVRQAPGQGL
		EWMGWINTETGTPMYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARRDYYYRRYVFYFDYWGQGTMVTVSS
CL-27711	1756	EVQLVQSGSELKKPGASVKVSCKASGYTFTKYDMYWVRQVPGQGL
		EWMGWVNTDTGKPPYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARSKYYYWTYVFYFDYWGQGTMVTVSS
CL-27712	1757	EVQLVQSGSELKKPGASVKVSCKASGYTFTYYDMYWVRQAPGQGL
		EWMGWINTXTGKPIYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTIYYYGRYSFYFDYWGQGTMVTVSS
CL-27713	1758	EVQLVQSGSELKKPGASVKVSCKASGYTFPFYVMYWVRQAPGQGL
		EWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRRYIFYFDYWGQGTMVTVSS
CL-27714	1759	EVQLVQSGSELKKPGASVKVSCKASGYTFTTYSMYWVRQAPGQGL
		EWMGWINTKTGKPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTIYYYMCYVFYFDYWGQGTMVTVSS
CL-27715	1760	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGNPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARKHYYYGSYLFYFDYWGQGTMVTVSS
CL-27716	1761	EVQLVQSGSELKKPGASVKVSCKASGYTFPDYDMYWVRQAPGQGL
		EWMGWINTETGMPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRGYIFYFDYWGQGTMVTVSS
CL-27717	1762	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTDTGKPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTYYYYKKYIFYFDYWGQGTMVTVSS
CL-27718	1763	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTGTGRPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTQYYYRRYIFYFDYWGQGTMVTVSS
CL-27719	1764	EVQLVQSGSELKKPGASVKVSCKASGYTFPNYGMYWVRQAPGQGL
		EWMGWINTKTGKPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARKNYYYKSYVFYFDYWGQGTMVTVSS
CL-27721	1765	EVQLVQSVSELKKPGASVKVSCKASGYTFTKYTMYWVRQAPGQGL
		EWMGWINTETGNPMYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRIYIFYFDYWGQGTMVTVSS
CL-27722	1766	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTATGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARSSYYYRNYIFYFDYWGQGTMVTVSS
CL-27723	1767	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTVTGKPDYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARQKYYYRSYFFYFDYWGQGTMVTVSS
CL-27725	1768	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYDMYWVRQAPGQGL
		EWMGWINTDTGKPAYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARPSYYYVXYIFYFDYWGQGTMVTVSS
CL-27726	1769	EVQLVQSGSELKKPGASVKVSCKASGYTFTLYXMYWVRQAPGQGL
		EWMGWINTATGKPTYAHDFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTXYYYRSYIFYFDYWGQGTMVTVSS
CL-27727	1770	EVQLVQSGSELKKPGASVKVSCKASGYTFTKYGMYWVRQAPGQGL
		EWMGWINTHTGNPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRCYIFYFDYWGQGTMVTVSS
CL-27728	1771	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGKPEYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARPNYYYRSYFFYFDYWGQGTMVTVSS
CL-27729	1772	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWINTETGRPGYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARLWYYYWMYIFYFDYWGQGTMVTVSS
CL-27730	1773	EVQLVQSGSELKKPGASVKVSCKASGYTFTYYGMYWVRQAPGQGL
		EWMGWINTETGTPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARVYYYYGSYSFYFDYWGQGTMVTVSS
CL-27731	1774	EVQLVQSGSELKKPGASVKVSCKASGYTFVNYAMYWVRQAPGQGL
		EWMGWINTXTGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARKTYYYRGYIFYFDYWGQGTMVTVSS
CL-27733	1775	EVQLVQSGSELKKPGASVKVSCKASGYTFTHYYMYWVRQAPGQGL
		EWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARSKYYYRSYTFYFDYWGQGTMVTVSS
CL-27734	1776	EVQLVQSGSELKKPGASVKVSCKASGYTFLHYGMYWVRQAPGQGL
		EWMGWINTETGWPRYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTSYYYVSYIFYFDYWGQGTMVTVSS
CL-27735	1777	EVQLVQSGSELKKPGASVKVSCKASGYTFTIYGMYWVRQAPGQGL
		EWMGWINTATGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTXYYYRSYVFYFDYWGQGTMVTVSS
CL-27736	1778	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGNPIYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARAHYYYRTYXFYFDYWGQGTMVTVSS
CL-27737	1779	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGNPIYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARAHYYYRTYNFYFDYWGQGTMVTVSS
CL-27738	1780	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYWMYWVRQAPGQGL
		EWMGWINTETGRPRYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARVYYYYRCYSFYFDYWGQGTMVTVSS
CL-27739	1781	EVQLVQSGSELKKPGASVKVSCKASGYTFTHYWMYWVRQAPGQGL
		EWMGWINTETGTPSYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTTYYYRSYIFYFDYWGQGTMVTVSS
CL-27741	1782	EVQLVQSGSELKKPGASVKVSCKASGYTFTKYGMYWVRQAPGQGL
		EWMGWINTNTGKPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARAYYYYWSYIFYFDYWGQGTMVTVSS
CL-27742	1783	EVQLVQSGSELKKPGASVKVSCKASGYTFTSYVMYWVRQAPGQGL
		EWMGWINTKTGMPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTTYYYMSYIFYFDYWGQGTMVTVSS
CL-27744	1784	EVQLVQSGSELKKPGASVKVSCKASGYTFTQYGMYWVRQAPGQGL
		EWMGWINTETGKPKYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYWSYKFYFDYWGQGTMVTVSS
CL-27747	1785	EVQLVQSGSELKKPGASVKVSCKASGYTFSTYMMYWVRQAPGQGL
		EWMGWINTETGXPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARSNYYYRSYIFYFDYWGQGTMVTVSS
CL-27750	1786	EVQLVQSGSELKKPGASVKVSCKASGYTFMNYVMYWVRQAPGQGL
		EWMGWINTKTGMPRYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYMRYIFYFDYWGQGTMVTVSS
CL-27751	1787	EVQLVQSGSELKKPGASVKVSCKASGYTFTTYGMYWVRQAPGQGL
		EWMGWINTQTGEPPYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTGYYYWNYLFYFDYWGQGTMVTVSS
CL-27752	1788	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYRMYWVRQAPGQGL
		EWMGWINTETGKPPYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYMSYIFYFDYWGQGTMVTVSS
CL-27753	1789	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGSPRYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYVSYIFYFDYWGQGTMVTVSS
CL-27755	1790	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGXPTYAHDFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARXNYYYXXYIFYFDYWGQGTMVTVSS
CL-27756	1791	EVQLVQSGSELKKPGASVKVSCKASGYTFTIYGMYWVRQAPGQGL
		EWMGWINTDTGRPIYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARIIYYYCSYIFYFDYWGQGTMVTVSS
CL-27757	1792	EVQLVQSGSELKKPGASVKVSCKASGYTFNNYGMYWVRQAPGQGL
		EWMGWINTETGKPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYIFYFDYWGQGTMVTVSS
CL-27758	1793	EVQLVQSGSELKKPGASVKVSCKASGYTFSLYAMYWVRQAPGQGL
		EWMGWINTETGKPTYADDFKGQFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYNFYFDYWGQGTMVTVSS
CL-27760	1794	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYIFYFDYWGQGTMVTVSS
CL-27824	1795	EVQLVQSGSELNXPGASLKVSCKASGYTFXNYGXYWVRQAPGQGL
		EWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYIFYFDYWGQGTMVTVSS
CL-27833	1796	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGIYWVRQAPGQGL
		EWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYIFYFDYWGQGTMVTVSS
CL-29884	1797	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRLYMFYFDYWGQGTMVTVSS
CL-29885	1798	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYQSYMFYFDYWGQGTMVTVSS
CL-29887	1799	EVQLVQSGSELKKPGASVKVSCKASGYTFPNYGMYWVRQAPGQGL
		EWMGWINTETGEPSYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-29888	1800	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWINTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYRTYMFYFDYWGQGTMVTVSS
CL-29889	1801	EVQLVQSGSELKKPGASVKVSCKASGYTFADYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARSNYYYRTYMFYFDYWGQGTMVTVSS
CL-29890	1802	EVQLVQSGSELKKPGASVKVSCKASGYTFTTYGMYWVRQAPGQGL
		EWMGWINTETGXPTYAXDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARRXYYYXSYXFYFDYWGQGTMVTVSS
CL-29891	1803	EVQLVQSGSELKKPGASVKVSCKASGYTFPNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-29892	1804	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWINTETGQPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-29893	1805	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARVNYYYRNYMFYFDYWGQGTMVTVSS
CL-29895	1806	EVQLVQSGSELKKPGASVKVSCKASGYTFSDYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARVNYYYMSYMFYFDYWGQGTMVTVSS
CL-29896	1807	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWINTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRMYMFYFDYWGQGTMVTVSS
CL-29897	1808	EVQLVQSGSELKKPGASVKVSCKASGYTFLNYGMYWVRQAPGQGL
		EWMGWINTETGKPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTKYYYWRYIFYFDYWGQGTMVTVSS
CL-29898	1809	EVQLVQSGSELKKPGASVKVSCKASGYTFNDYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-29899	1810	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARINYYYRSYMFYFDYWGQGTMVTVSS
CL-29901	1811	EVQLVQSGSELKKPGASVKVSCKASGYTFMNYGMYWVRQAPGQGL
		EWMGWIDTETGXXXYAHDFTGRFVFSLDTSVSTAYLEISSLKAED
		TAVYYCARXNYYYXXYMFYFDYWGQGTMVTVSS
CL-29902	1812	EVQLVQSGSELKKPGASVKVSCKASGYTFTSYGMYWVRQAPGQGL
		EWMGWINTETGQPMYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARRIYYYRCYLFYFDYWGQGTMVTVSS
CL-29904	1813	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTDTGMPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYRSYMFYFDYWGQGTMVTVSS
CL-29906	1814	EVQLVQSGSELKKPGASVKVSCKASGYTFNNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRNYMFYFDYWGQGTMVTVSS
CL-29907	1815	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWINTETGEPSYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARSNYYYRSYMFYFDYWGQGTMVTVSS
CL-29908	1816	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYKSYMFYFDYWGQGTMVTVSS
CL-29909	1817	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYRSYMFYFDYWGQGTMVTVSS
CL-29910	1818	EVQLVQSGSELKKPGASVKVSCKASGYTFNYYGMYWVRQAPGQRL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYESYMFYFDYWGQGTMVTVSS
CL-29912	1819	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWINTDTGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-29913	1820	EVQLVQSGSELKKPGASVKVSCKASGYTFTKYRMYWVRQAPGQGL
		EWMGWINTVTGKPKYADDFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARFKYYYGSYFFYFDYWGQGTMVTVSS
CL-29914	1821	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGQPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-29915	1822	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRNYMFYFDYWGQGTMVTVSS
CL-29916	1823	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWINTETGDPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-29917	1824	EVQLVQSGSELKKPGASVKVSCKASGYTFNNYGMYWVRQAPGQGL
		EWMGWIDTETGQPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPRYMFYFDYWGQGTMVTVSS
CL-29918	1825	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWINTDTGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYASYMFYFDYWGQGTMVTVSS
CL-29919	1826	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYQSYMFYFDYWGQGTMVTVSS
CL-29921	1827	EVQLVQSGSELKKPGASVKVSCKASGYTFSHYGMYWVRQAPGQGL
		EWMGWINTETGSPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-29922	1828	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTDTGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-29924	1829	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWINTETGNPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-29925	1830	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYAXGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-29926	1831	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARSNYYYTSYMFYFDYWGQGTMVTVSS
CL-29927	1832	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWINTETGQPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRMYMFYFDYWGQGTMVTVSS
CL-29928	1833	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGEPYYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPKYMFYFDYWGQGTMVTVSS
CL-29929	1834	EVQLVQSGSELKKPGASVKVSCKASGYTFTHYWMYWVRQAPGQGL
		EWMGWINTETGKPAYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYIYYLFYFDYWGQGTMVTVSS
CL-29931	1835	EVQLVQSGSELKKPGASVKVSCKASGYTFPNYGMYWVRQAPGQGL
		EWMGWINTGTGKPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRNYMFYFDYWGQGTMVTVSS
CL-29932	1836	EVQLVQSGSELKKPGASVKVSCKASGYTFTPYGMYWVRQAPGQGL
		EWMGWINTDTGXPPYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYTCYIFYFDYWGQGTMVTVSS
CL-29934	1837	EVQLVQSGSELKKPGASVKVSCKASGYTFTHYGMYWVRQAPGQGL
		EWMGWINTETGXPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPRYMFYFDYWGQGTMVTVSS
CL-29935	1838	EVQLVQSGSELKKPGASVKVSCKASGYTFPDYGMYWVRQAPGQGL
		EWMGWIDTETGMPXYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRNYMFYFDYWGQGTMVTVSS
CL-29936	1839	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-29937	1840	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGDPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARXNYYYRXYMFYFDYWGQGTMVTVSS
CL-29938	1841	EVQLVQSGSELKKPGASVKVSCKASGYTFNKYDMYWVRQAPGQGL
		EWMGWINTKTGKPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTAYYYRNYKSTLITGGQGTMVTVSS
CL-29939	1842	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYKGYMFYFDYWGQGTMVTVSS
CL-29940	1843	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGTPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTYYYYRTYIFYFDYWGQGTMVTVSS
CL-29941	1844	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRGYMFYFDYWGQGTMVTVSS
CL-29942	1845	EVQLVQSGSELKKPGASVKVSCKASGYNFTKYEMYWVRQAPGQGL
		EWMGWINTETGNPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTKYYYRSYVFYFDYWGQGTMVTVSS
CL-29943	1846	EVQLVQSGSELKKPGASVKVSCKASGYTFPNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYLSYMFYFDYWGQGTMVTVSS
CL-29946	1847	EVQLVQSGSELKKPGASVKVSCKASGYTFTHYGMYWVRQAPGQGL
		EWMGWINTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-29947	1848	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWINTDTGDPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYRTYMFYFDYWGQGTMVTVSS
CL-29948	1849	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGTPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-29949	1850	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGDPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARVNYYYRSYMFYFDYWGQGTMVTVSS
CL-29950	1851	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTQTGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARSNYYYRLYMFYFDYWGQGTMVTVSS
CL-29951	1852	EVQLVQSGSELKKPGASVKVSCKASGYTFPDYGMYWVRQAPGQGL
		EWMGWIDTETGQPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARADYYYPTYMFYFDYWGQGTMVTVSS
CL-29952	1853	EVQLVQSGSELKKPGASVKVSCKASGYTFTHYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPTYMFYFDYWGQGTMVTVSS
CL-29955	1854	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARSNYYYRSYMFYFDYWGQGTMVTVSS
CL-29957	1855	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTVTGQPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTHYYYRTYLFYFDYWGQGTMVTVSS
CL-29958	1856	EVQLVQSGSELKKPGASVKVSCKASGYTFPNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-29959	1857	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRGYMFYFDYWGQGTMVTVSS
CL-29960	1858	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYSMYWVRQAPGQGL
		EWMGWINTXTGKPIYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTKYYYRTYRFYFDYWGQGTMVTVSS
CL-29961	1859	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWIDTETGTPVYADDFKGRFVFSLDTSVNTAYLQISSLKAED
		TAVYYCARTNYYYKSYMFYFDYWGQGTMVTVSS
CL-29962	1860	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARSNYYYSSYMFYFDYWGQGTMVTVSS
CL-29963	1861	EVQLVQSGSELKKPGASVKVSCKASGYTFSEYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-29966	1862	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARVNYYYRWYMFYFDYWGQGTMVTVSS
CL-29967	1863	EVQLVQSGSELKKPGASVKVSCKASGYTFPNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-29968	1864	EVQLVQSGSELKKPGASVKVSCKAYGYTFTDYGMYWVRQAPGQGL
		EWMGWINTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYEKYMFYFDYWGQGTMVTVSS
CL-29969	1865	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARSNYYYRGYMFYFDYWGQGTMVTVSS
CL-29970	1866	EVQLVQSGSELKKPGASVKVSCKASGYTFMTYVMYWVRQAPGQGL
		EWMGWINTETGKPSYAHDFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARMXYYYXIYMFYFDYWGQGTMVTVSS
CL-29971	1867	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-29972	1868	EVQLVQSGSELKKPGASVKVSCNASGXTFTNYGMYWVRQAPGQGL
		EWMGWINTETGKPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARINYYYRSYIFYFDYWGQGTMVTVSS
CL-29973	1869	EVQLVQSGSELKKPGASVKVSCKASGYTFNDYGMYWVRQAPGQGL
		EWMGWINTETGEPTYAXXFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYEGYMFYFDYWGQGTMVTVSS
CL-29974	1870	EVQLVQSGSELKKPGASVKVSCKASGYTFSDYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-29975	1871	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYKSYMFYFDYWGQGTMVTVSS
CL-29976	1872	EVQLVQSGSELRKPGASVKVSCKASGYTFNNYGMYWVRQAPGQGL
		EWMGWIDTETGRPWYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYQGYMFYFDYWGQGTMVTVSS
CL-29980	1873	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMHWVRQAPGQGL
		EWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYIFYFDYWGQGTMVTVSS
CL-30036	1874	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSHIFYFDYWGQGTMVTVSS
CL-30060	1875	EVQLVQSGSELKKPGASVRVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYIFYFDYWGQGTMVTVSS
CL-30075	1876	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTXTGKPTYAXGFTGRFVFSLDTSVSTAYLQIXXLXAXD
		TAVYYCARXKYYYXSYIFYFDYWGQGTMVTVSS
CL-30076	1877	EVQLVQSGSELKKPGASVKVSCKASGYTFYNYCMYWVRQAPGQGL
		EWMGWINTETGIPKYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARINYYYKRYIFYFDYWGQGTMVTVSS
CL-30077	1878	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYYMYWVRQAPGQGL
		EWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTXYYYXRYXFYFDYWGQGTMVTVSS
CL-30078	1879	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYIFYFDYWGQGTMVTVFS
CL-30079	1880	EVQLVQSGSELKKPGASVKVSCKASGYTFIHYGMYWVRQAPGQGL
		EWMGWINTETGRPTYADDFKGRFVFSLDTSVSTAYLQISSLKXED
		TAVYYCARTVYYYPRYTFYFDYWGQGTMVTVSS
CL-30082	1881	EVQLVQSGSELKKPGASVKVSCKASGYTFMNYGMYWVRQAPGQGL
		EWMGWINTETGKPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPGYIFYFDYWGQGTMVTVSS
CL-30083	1882	EVQLVQSGSELKKPGASVKVSCKASGYTFTLYGMYWVRQAPGQGL
		EWMGWINTDTGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYXSYIFYFDYWGQGTMVTVSS
CL-30084	1883	EVQLVQSGSELKKPGASVKVSCKASGYTFNKYGMYWVRQAPGQGL
		EWMGWINTETGKPSYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARAKYYYRSYIFYFDYWGQGTMVTVSS
CL-30086	1884	EVQLVQSGSELKKPGASVKVSCKASGYTFLNYGMYWVRQAPGQGL
		EWMGWINTETGRPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRIYRFYFDYWGQGTMVTVSS
CL-30087	1885	EVQLVQSGSELKKPGASVKVSCKASGYTFYNYGMYWVRQAPGQGL
		EWMGWINTATGKPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARXKYYYXSXXFYFDYWGQGTMVTVSS
CL-30091	1886	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYDMYWVRQAPGQGL
		EWMGWINTVTGLPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTIYYYKSYIFYFDYWGQGTMVTVSS
CL-30092	1887	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWINTGTGIPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTSYYYRNYLFYFDYWGQGTMVTVSS
CL-30093	1888	EVQLVQSGSELKKPGASVKVSCKASGYTFTKYGMYWVRQAPGQGL
		EWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTTYYYRRYIFYFDYWGQGTMVTVSS
CL-30096	1889	EVQLVQSGSELKKPGASVKVSCKASGYTFTTYAMYWVRQAPGQGL
		EWMGWINTETGKPRYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYRSYIFYFDYWGQGTMVTVSS
CL-30097	1890	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQIXXLKTED
		TAVYYCARSNYYYRGYIFYFDYWGQGTMVTVSS
CL-30103	1891	EVQLVQSGSELKKPGASVKVSCKASGYTFAIYRMYWVRQAPGQGL
		EWMGWINTDTGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARSKYYYGFYMFYFDYWGQGTMVTVSS
CL-30107	1892	EVQLVQSGSELKKPGASVKVSCKASGYTFMNYGMYWVRQAPGQGL
		EWMGWINTETGRPVYAQGFTGRFVFSLDTSVSTAYLQISSLKAXD
		TAVYYCARTNYYYLRYVFYFDYWGQGTMVTVSS
CL-30108	1893	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTGTGMPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARNKYYYRSYMFYFDYWGQGTMVTVSS
CL-30110	1894	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYDMYWVRQAPGQGL
		EWMGWINTETGKPPYADGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYIFYFDYWGQGTMVTVSS
CL-30113	1895	EVQLVQSGSELKKPGASVKVSCKASGYTFTSYGMYWVRQAPGQGL
		EWMGWINTETGIPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARWDYYYTSYKFYFDYWGQGTMVTVSS
CL-30114	1896	EVQLVQSGSELKKPGASVKVSCKASGYTFTIYGMYWVRQAPGQGL
		EWMGWINTVTGNPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTEYYYMNYIFYFDYWGQGTMVTVSS
CL-30116	1897	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYDMYWVRQAPGQGL
		EWMGWINTGTGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYSRYDFYFDYWGQGTMVTVSS
CL-30119	1898	EVQLVQSGSELKKPGASVKVSCKASGYTFTKYGMYWVRQAPGQGL
		EWMGWINTQTGKPAYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARAIYYYRIYIFYFDYWGQGTMVTVSS
CL-30124	1899	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYAMYWVRQAPGQGL
		EWMGWINTQTGEPSYAQGFTGXFVFSLDTSASTEYLXISILXDXD
		TAVYYCARXTYYYXNYIFYFDYWGXGTMVTVSS
CL-30127	1900	EVQLVQSGSELKKPGASVKVSCKASGYTFTTYGMYWVRQAPGQGL
		EWMGWINTETGRPTYADDFNGWFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRIYIFYFDYWGQGTMVTVSS
CL-30128	1901	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYIFYFDYWGQGTMVTVSS
CL-30129	1902	EVQLVQSGSELKKPGASVKVSCKASGYTFNNYGMYWVRQAPGQGL
		EWMGWINTGTGKPTYAQGFTGRFVFSLDTSVSTAYLQIXSLKAED
		TAVYYCARPIYYYIRYIFYFDYWGQGTMVTVSS
CL-30130	1903	EVQLVQSGSELKKPGASVKVSCKASGYTFADYPMYWVRQAPGQGL
		EWMGWINTXTGQPLYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTSYYYRSYIFYFDYWGQGTMVTVSS
CL-30135	1904	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAXD
		TAVYYCARTNYYYRSYIFYFDYWGQGTMVTVSS
CL-30136	1905	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYSMYWVRQAPGQGL
		EWMGWINTETGKPRYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTSYYYRSYIFYFDYWGQGTMVTVSS
CL-30138	1906	EVQLVQSGSELKKPGASVKVSCKASGYTFTTYWMYWVRQAPGQGL
		EWMGWINTETGEPRYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTEYYYKSYNFYFDYWGQGTMVTVSS
CL-30140	1907	EVQLVQSGSELKKPGASVKVSCKASGYTFTAYGMYWVRQAPGQGL
		EWMGWINTETGMPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTKYYYRSYMFYFDYWGQGTMVTVSS
CL-30141	1908	EVQLVQSGSELKKPGASVKVSCKASGYTFHNYGMYWVRQAPGQGL
		EWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTSYYYRSYFFYFDYWGQGTMVTVSS
CL-30142	1909	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYVMYWVRQAPGQGL
		EWMGWINTETGNPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARLIYYYXTYIFYFDYWGQGTMVTVSS
CL-30145	1910	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYAMYWVRQAPGQGL
		EWMGWINTETGKPPYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTLYYYRTYIFYFDYWGQGTMVTVSS
CL-30147	1911	EVQLVQSGSELKKPGASVKVSCKASGYTFTHYGMYWVRQAPGQGL
		EWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRRYIFYFDYWGQGTMVTVXS
CL-30148	1912	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWINTETGQPSYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRCYIFYFDYWGQGTMVTVSS
CL-30151	1913	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGKPNYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARPNYYYRSYIFYFDYWGQGTMVTVSS
CL-30154	1914	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYAMYWVRQAPGQGL
		EWMGWINTETGNPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYGIYLFYFDYWGQGTMVTVSS
CL-30156	1915	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYDMYWVRQAPGQGL
		EWMGWINTVTGRPAYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARITYYYRMYRFYFDYWGQGTMVTVSS
CL-30159	1916	EVQLVQSGSELKKPGASVKVSCKASGYTFIDYLMYWVRQAPGQGL
		EWMGWINTVTGKPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTHYYYRSYAFYFDYWGQGTMVTVSS
CL-30161	1917	EVQLVQSGSELKKPGASVKVSCKASGYTFAKYEMYWVRQAPGQGL
		EWMGWINTETGNPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRDYTFYFDYWGQGTMVTVSS
CL-30162	1918	EVQLVQSGSELKKPGASVKVSCKASGYTFTTYRMYWVRQAPGQGL
		EWMGWINTVTGRPSYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARNIYYYRSYIFYFDYWGQGTMVTVSS
CL-30164	1919	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYIFYFDYWGQGTMVTVSS
CL-30165	1920	EVQLVQSGSELKKPGASVKVSCKASGYTFRNYVMYWVRQAPGQGL
		EWMGWINTQTGEPSYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYGIYIFYFDYWGQGTMVTVSS
CL-30166	1921	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLQAED
		TAVYYCARTNYYYRSYIFYFDYWGQGTMVTVSS
CL-30168	1922	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWINTETGMPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARSNYYYRGYIFYFDYWGQGTMVTVSS
CL-30169	1923	EVQLVQSGSELKKPGASVKVSCKASGYTFLGYSMYWVRQAPGQGL
		EWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARKFYYYESYIFYFDYWGQGTMVTVSS
CL-30170	1924	EVQLVQSGSELKKPGASVKVSCKASGYTFTYYCMYWVRQAPGQGL
		EWMGWINTHTGKPMYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARKKYYYRSYIFYFDYWGQGTMVTVSS
CL-30593	1925	EVQLVQSGSELKKPGASVKVSCKASGYTFSDYGMYWVRQAPGQGL
		EWMGWIDTETGDPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYMSYMFYFDYWGQGTMVTVSS
CL-30594	1926	EVQLVQSGSELKKPGASVKVSCKASGYTFMNYGMYWVRQAPGQGL
		EWMGWINTETGKPMYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTIYYYPRYIFYFDYWGQGTMVTVSS
CL-30595	1927	EVQLVQSGSELKKPGASVKVSCKASGYTFAMYKMYWVRQAPGQGL
		EWMGWINTQTGGPSYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTKYYYWRYVFYFDYWGQGTMVTVSS
CL-30597	1928	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWINTETGQPMYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-30599	1929	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGNPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARSNYYYSSYMFYFDYWGQGTMVTVSS
CL-30600	1930	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTATGQPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYMYYLFYFDYWGQGTMVTVSS
CL-30602	1931	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYRLYMFYFDYWGQGTMVTVSS
CL-30604	1932	EVQLVQSGSELKKPGASVKVSCKASGYTFPNYGMYWVRQAPGQGL
		EWMGWINTWTGKPTYAXDFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-30605	1933	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYRTYMFYFDYWGQGTMVTVSS
CL-30606	1934	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYRMYWVRQAPGQGL
		EWMGWINTETGKPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYSSYMFYFDYWGQGTMVTVSS
CL-30608	1935	EVQLVQSGSELKKPGASVKVSCKASGYTFTTYDMYWVRQAPGQGL
		EWMGWINTVTGXPTYAXXFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARSXYYYRSYIFYFDYWGQGTMVTVSS
CL-30609	1936	EVQLVQSGSELKKPGASVKVSCKASGYTFNNYGMYWVRQAPGQGL
		EWMGWINTETGKPRYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTDYYYRRYTFYFDYWGQGTMVTVSS
CL-30611	1937	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWINTYTGIPSYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARVNYYYSTYIFYFDYWGQGTMVTVSS
CL-30613	1938	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGIYWVRQAPGQGL
		EWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARSNYYYRGYMFYFDYWGQGTMVTVSS
CL-30614	1939	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARSNYYYRSYMFYFDYWGQGTMVTVSS
CL-30615	1940	EVQLVQSGSELKKPGASVKVSCKASGYTFNNYGMYWVRQAPGQGL
		EWMGWINTDTGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARVNYYYRSYMFYFDYWGQGTMVTVSS
CL-30616	1941	EVQLVQSGSELKKPGASVKVSCKASGYTFTTYGMYWVRQAPGQGL
		EWMGWINTLTGAPMYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYSSYIFYFDYWGQGTMVTVSS
CL-30617	1942	EVQLVQSGSELKKPGASVKVSCKASGYTFKNYSMYWVRQAPGQGL
		EWMGWINTDTGMPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRFYIFYFDYWGQGTMVTVSS
CL-30618	1943	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARVNYYYRSYMFYFDYWGQGTMVTVSS
CL-30619	1944	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYRSYMFYFDYWGQGTMVTVSS
CL-30620	1945	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRGYMFYFDYWGQGTMVTVSS
CL-30623	1946	EVQLVQSGSELKKPGASVKVSCKASGYTFANYGMYWVRQAPGQGL
		EWMGWINTETGQPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYQSYMFYFDYWGQGTMVTVSS
CL-30624	1947	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTDTGTPAYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYTRYNFYFDYWGQGTMVTVSS
CL-30626	1948	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWINTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-30628	1949	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYRSYMFYFDYWGQGTMVTVSS
CL-30629	1950	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYDMYWVRQAPGQGL
		EWMGWINTETGNPTYAXXFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARXNYYYSSYIFYFDYWGQGTMVTVSS
CL-30630	1951	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARSNYYYRTYMFYFDYWGQGTMVTVSS
CL-30631	1952	EVQLVQSGSELKKPGASVKVSCKASGYTFNNYGMYWVRQAPGQGL
		EWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-30632	1953	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-30634	1954	EVQLVQSGSELKKPGASVKVSCKASGYTFTYYGMYWVRQAPGQGL
		EWMGWINTETGKPSYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTIYYYTTYIFYFDYWGQGTMVTVSS
CL-30635	1955	EVQLVQSGSELKKPGASVKVSCKASGYTFPNYGMYWVRQAPGQGL
		EWMGWIDTETGEPIYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARINYYYPNYMFYFDYWGQGTMVTVSS
CL-30636	1956	EVQLVQSGSELKKPGASVKVSCKTSGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRGYMFYFDYWGQGTMVTVSS
CL-30637	1957	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-30638	1958	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWIDTETGNPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYRSYMFYFDYWGQGTMVTVSS
CL-30639	1959	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGTPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-30640	1960	EVQLVQSGSELKKPGASVKVSCKASGYTFSSYGMYWVRQAPGQGL
		EWMGWIDTETGEPKYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-30642	1961	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARYNYYYRIYLFYFDYWGQGTMVTVSS
CL-30643	1962	EVQLVQSGSELKKPGASVKVSCKASGYTFPYYSMYWVRQAPGQGL
		EWMGWINTDTGTPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTTYYYWSYIFYFDYWGQGTMVTVSS
CL-30644	1963	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGDPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-30645	1964	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTXTGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTSYYYRCYIFYFDYWGQGTMVTVSS
CL-30647	1965	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWINTETGQPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-30649	1966	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWIDTDTGKPTYAXDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYTGYMFYFDYWGQGTMVTVSS
CL-30651	1967	EVQLVQSGSELEKPGASVKVSCKASGYTFPNYGMYWVRQAPGQGL
		EWMGWIDTDTGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYRSYMFYFDYWGQGTMVTVSS
CL-30653	1968	EVQLVQSGSELKKPGASVKVSCKASGYTFNNYGMYWVRQAPGQGL
		EWMGWIDTETGDPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYLSYMFYFDYWGQGTMVTVSS
CL-30654	1969	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYIFYFDYWGQGTMVTVSS
CL-30655	1970	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGEPSYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-30657	1971	EVQLVQSGSELKKPGASVKVSCKASGYTFANYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYKSYMFYFDYWGQGTMVTVSS
CL-30658	1972	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWINTDTGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-30659	1973	EVQLVQSGSELKKPGASVKVSCKASGYTFPYYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYRMYMFYFDYWGQGTMVTVSS
CL-30660	1974	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGDPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRGYMFYFDYWGQGTMVTVSS
CL-30662	1975	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGSPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARIIYYYLSYLFYFDYWGQGTMVTVSS
CL-30663	1976	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWINTETGDPTYAQGFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-30664	1977	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYSGYMFYFDYWGQGTMVTVSS
CL-30665	1978	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWINTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRYYMFYFDYWGQGTMVTVSS
CL-30666	1979	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-30669	1980	EVQLVQSGSELKKPGASVKVSCKASGYTFTKYAMYWVRQAPGQGL
		EWMGWINTYTGVPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARGHYYYMMYIFYFDYWGQGTMVTVSS
CL-30670	1981	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWIDTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARYKYYYRSYKFYFDYWGQGTMVTVSS
CL-30671	1982	EVQLVQSGSELKKPGASVKVSCKASGYTFPDYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRGYMFYFDYWGQGTMVTVSS
CL-30674	1983	EVQLVQSGSELKKPGASVKVSCKASGYTFSHYGMYWVRQAPGQGL
		EWMGWINTETGDPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-30675	1984	EVQLVQSGSELKKPGASVKVSCKASGYTFPNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-30676	1985	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGYPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYRTYMFYFDYWGQGTMVTVSS
CL-30677	1986	EVQLVQSGSELKKPGASVKVSCKASGYTFNNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRTYMFYFDYWGQGTMVTVSS
CL-30678	1987	EVQLVQSGSELKKPGASVKVSCKASGYTFSHYGMYWVRQAPGQGL
		EWMGWINTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYRSYMFYFDYWGQGTMVTVSS
CL-30679	1988	EVQLVQSGSELKKPGASVKVSCKASGYTFTSYRMYWVRQAPGQGL
		EWMRWINTETGWPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTSYYYRNYMFYFDYWGQGTMVTVSS
CL-30682	1989	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWINTETGNPMYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-30684	1990	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRNYMFYFDYWGQGTMVTVSS
CL-30685	1991	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCVRTNYYYRTYMFYFDYWGQGTMVTVSS
CL-32447	1992	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWXRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-32466	1993	EVQLVQSGSELKKPGASVKVSCKASGYTFHDYGMYWVRQAPGQGL
		EWMGWIDTETGTPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYSSYMFYFDYWGQGTMVTVSS
CL-32470	1994	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGXPTYAXXFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-32507	1995	EVQLVQSGSELKKPGASVKVSCKASGYTFNDYGMYWVRQAPGQGL
		EWMGWIDTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYSSYMFYFDYWGQGTMVTVSS
CL-34445	1996	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-34457	1997	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYAHDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARXNYYYRSYMFYFDYWGQGTMVTVSS
CL-34458	1998	EVQLVQSGSELKKPGAPVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-34465	1999	EVQLVQSGSELKKPGASVKVSCKASGYTFPDYGMYWVRQAPGQGL
		EWMGWIDTETGQPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRTYMFYFDYWGQGTMVTVSS
CL-34466	2000	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGEPIYAQGFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYNSYMFYFDYWGQGTMVTVSS
CL-34468	2001	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGEPRYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-34478	2002	EVQLVQSGSELKKPGASVKVSCKASGYTFPHYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYSSYMFYFDYWGQGTMVTVSS
CL-34480	2003	EVQLVQSGSELKKPGASVKVSCKASGYTFEDYGMYWVRQAPGQGL
		EWMGWINTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRNYMFYFDYWGQGTMVTVSS
CL-34482	2004	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRTYMFYFDYWGQGTMVTVSS
CL-34488	2005	EVQLVQSGSELKKPGASVKVSCKASGYTFDDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-34490	2006	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGTPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-34493	2007	EVQLVQSGSELKKPGASVKVSCKASGYTFGDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARVNYYYRNYMFYFDYWGQGTMVTVSS
CL-34495	2008	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGQPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYKSYMFYFDYWGQGTMVTVSS
CL-34496	2009	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRGYMFYFDYWGQGTMVTVSS
CL-34499	2010	EVQLVQSGSELKKPGASVKVSCKASGYTFSDYGMYWVRQAPGQGL
		EWMGWIDTETGDPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-34502	2011	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-34503	2012	EVQLVQSGSELKKPGASVKVSCKASGYTFSDYGMYWVRQAPGQGL
		EWMGWIDTETGTPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYKSYMFYFDYWGQGTMVTVSS
CL-34505	2013	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGQPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-34510	2014	EVQLVQSGSELKKPGASVKVSCKASGYTFSHYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYMSYMFYFDYWGQGTMVTVSS
CL-34512	2015	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTDTGTPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPKYMFYFDYWGQGTMVTVSS
CL-34527	2016	EVQLVQSGSELKKPGASVKVSCKASGYTFANYGMYWVRQAPGQGL
		EWMGWIDTETGTPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-34528	2017	EVHLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWIDTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-34529	2018	EVQLVQSGSELNKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGEPSYADDFKGRFVFSLDTXVSTAYXQISSLKAED
		XAVYXCARTNYYYSSYMFYFDYWGQGTXVTVSS
CL-34534	2019	EVQLVQSGSELKKPGASVKVSCKASGYTFNDYGMYWVRQAPGQGL
		EWMGWIDTETGNPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYRSYMFYFDYWGQGTMVTVSS
CL-34539	2020	EVQLVPSGSHFNNPGASXKVSCSASGYTFSDYGMYWVRQAPGQGL
		EWMGWIDTETGDPTYADDFKGXFVFSLDTSVXXAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-34548	2021	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGDPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-34562	2022	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGKPTYADDFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRTYMFYFDYWGQGTMVTVSS
CL-34568	2023	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGQPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-34577	2024	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGTPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYESYMFYFDYWGQGTMVTVSS
CL-34582	2025	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-34586	2026	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYAXXFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-34590	2027	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-34592	2028	EVQLVQSGSELKKPGASVKVSCKASGYTFNDYGMYWVRQAPGQGL
		EWMGWIDTETGTPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYSSYMFYFDYWGQGTMVTVSS
CL-34595	2029	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRTYMFYFDYWGQGTMVTVSS
CL-34596	2030	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRNYMFYFDYWGQGTMVTVSS
CL-34597	2031	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-34599	2032	EVQLVQSGSELKKPGASVKVSCKASGYTFSDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-34600	2033	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISNLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-34617	2034	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPRYMFYFDYWGQGTMVTVSS
CL-40631	2035	EVQLVQSGSELKKPGASVKVSCXASGYTFSDYGMYWVRQAPGQGL
		EWMGWIDTETGDPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYRSYMFYFDYWGQGTMVTVSS
CL-40642	2036	RVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-40646	2037	EVQLVQSGSELKKPGASVKVSCEASGYTFSDYGMYWVRQAPGQGL
		EWMGWIDTETGDPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYRSYMFYFDYWGQGTMVTVSS
CL-40665	2038	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTSLQ
CL-40668	2039	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKVED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-40671	2040	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGTPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYSSYMFYFDYWGQGTMVTVSS
CL-40687	2041	ASAAVQSGSELKKPGASVKVSCKASGYTFENYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYSSYMFYFDYWGQGTMVTVSS
CL-40688	2042	EVQLVQSGSELKKPGASVKVSCKASGYTFENYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYSSYMFYFDYWGQGTMVTVSS
CL-40694	2043	EVQLVQSGSELKKPGASVKVSCKASGYTFENYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLGTSVSTAYLQISSLKAED
		TAVYYCARTNYYYSSYMFYFDYWGQGTMVTVSS
CL-40708	2044	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYSSYMFYFDYWGQGTMVTVSS
CL-40716	2045	EVQLVQSGSELKKPGASVKVSCKASGYTFSDYGMYWVRQAPGQGL
		EWMGWIDTETGDPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARANYYYRSYMFYFDYWGQGTMVTVSS
CL-40717	2046	EVQLVQSGSELKKPGASVKVSCKASGYTFDDYGMYWVRQAPGQGL
		EWMGWIDTETGTPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYSSYMFYFDYWGQGTMVTVSS
CL-40721	2047	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-40722	2048	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-40723	2049	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-40736	2050	EVQLVQSGSELKKPGASVKVSCKASGYTFTHYGMYXVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-40740	2051	EVQLVQSGSELKKPGASVKVSCKASGYTFSDYGMYWVRQAPGQGL
		EWMGWIDTETGDPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-40741	2052	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGP
		EWMGWIDTETGNPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-40742	2053	EVQLVQSGSELKKPGASVKVSCKASGYTFTHYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEN
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-40745	2054	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-40746	2055	EVQLVQSGSXLKXPGXSXKVSCXVSGYTFQNYGMYCVRPAPGQWL
		XWMGWIDXXTGEPTYAYDFKGWFLFSLHTSVSMSSLQNXSLKXDD
		TAVYYCAKTNYYYNSYMFYFDYWGQGTXXTVSS
CL-40747	2056	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGQPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRNYMFYFDYWGQGTMVTVSS
CL-40753	2057	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGDPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRNYMFYFDYWGQGTMVTVSS
CL-40758	2058	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAED
		TAVHYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-40760	2059	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYSSYMFYFDYWGQGTMVTVSS
CL-40763	2060	EVQLVQSGSELKKPGASVKVSCKASGYTFTHYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-40764	2061	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGNPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-40765	2062	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGQPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-40766	2063	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEG
		TAVYYCARTNYYYSSYMFCFDYWGQGTMVTVSS
CL-40768	2064	EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYSSYMFYFDYWGQGAMVTVSS
CL-40770	2065	EVQLVQSGSELKKPGASVKVSCKASGYTFTHYGMYWVRRAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-40774	2066	EVQLVQSGSELKKPGASVKVSCKASGYTFSDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKVED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-40779	2067	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-40780	2068	EVQLVQSGSELEKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRGYMFYFDYWGQGTMVTSLQ
CL-40788	2069	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDAETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRGYMFYFDYWGQGTMVTVSS
CL-40790	2070	EGHLGQSGSELKNPGASVKVSCXASGYTFXNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYAXDFKGRFVFSLGTSVSTAYLQIXSLRAED
		TAVYYCEXTNYYYSRYMFYFXYWGQGTMVTVSS
CL-40791	2071	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGXIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYKSYMFYFDYWGQGTMVTVSS
CL-40793	2072	EVQLVQSGSELKKPGASVKVSCKASGYTFSDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVFS
CL-40795	2073	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRGYMLYFDYWGQGTMVTVSS
CL-40796	2074	EVQLVQSGSELKKPGASVKVSCKASGYTFPNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYKSYMFYFDYWGQGTMVTVSS
CL-40800	2075	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRRAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRGYMFYFDYWGQGTMVTVSS
CL-40801	2076	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRLVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYKSYMFYFDYWGQGTMVTVSS
CL-40805	2077	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYSSYMFYFDYWGQGTMVTVSS
CL-40806	2078	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRGYMFYFDYWGQGTMVTVSS
CL-40811	2079	EVQLVQSGSELKKPGASVKVSCKASGYTFPNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS
CL-40812	2080	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYXSYMFYFDYWGQGTMVTVSS
CL-40815	2081	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYKSYMFYFDYWGQGTMVTVSS
CL-40816	2082	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGQFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSYMFYFDYWGQGTMVTVSS
CL-40817	2083	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYPSHMFYFDYWGQGTMVTVSS
CL-40819	2084	EVQLVQSGSELKKPGASVKVSCKASGYTFSDYGMYWVRQAPGQGL
		EWMGWIDTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAED
		TAVYYCARTNYYYRSYMFYFDYWGQGTMVTVSS

List of Amino Acid Sequences of Affinity Matured h4G8.3 VL Variants

Table 39 provides a list of amino acid sequences of unique, functional VL regions of affinity matured humanized VEGF antibodies derived from hBDB-4G8.3. Amino acid residues of individual CDRs of each VL sequence are indicated in bold.

TABLE 39
List of Amino Acid Sequences of Affinity Matured
H4g8.3 VL Variants
Clone	SEQ ID NO:	VL
CL-27686	2085	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGXA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNDPFTFGQGTKLEIK
CL-27698	2086	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSRSGTDFTLTISSLEPEDFAVY
		FCQQSWNDPFTFGQGTKLEIK
CL-27717	2087	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNDPFTFGQGAKLEIK
CL-27741	2088	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNDPFTFGLGTKLEIK
CL-27758	2089	EIVLTQFPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNDPFTFGQGTKLEIK
CL-27762	2090	EIVLTQSPATLSLSPGERATLSCRASQSVTPHMHWYQQKPGQA
		PRLLIYGASTLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSCNDPFTFGQGTKLEIK
CL-27763	2091	EIVLTQSPATLSLSPGERATLSGRASESVDKYMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSRNDPLTFGQGTKLEIK
CL-27764	2092	EIVLTQSPATLSLSPGERATLSCRASQSVKTDMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSRNEPFTFGQGTKLEIK
CL-27765	2093	EIVLTQSPATLSLSPGERATLSCRASQSVSTHLAWYQQKPGQA
		PRLLIYRASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQNWNDPLTFGQGTKLEIK
CL-27766	2094	EIVLTQSPATLSLSPGERATLSCRASQSVRTHMHWYQQKPGQA
		PRLLIYGASALESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQGCNXPFTFGQGTKLEIK
CL-27767	2095	EIVLTQSPATLSLSPGERATLSCRASQSVRTHMHWYQQKPGQA
		PRLLIYEASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSCNDPFTFGQGTKLEIK
CL-27768	2096	EIVLTQSPATLSLSPGERATLSCRASQSVSTDMHWYQQKPGQA
		PRLLIYGASKLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNDPFTFGQGTKLEIK
CL-27770	2097	EIVLTQSPATLSLSPGERATLSCRASQSVSPHMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTSNEPFTFGQGTKLEIK
CL-27771	2098	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASDLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSXIDPVTFGQGTKLEIK
CL-27772	2099	EIVLTQSPATPSLSPGERATLSCRASESVNAHMHWYQQKPGQA
		PRLLIYDASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWSDPFTFGQGTKLEIK
CL-27773	2100	EIVLTQSPATLSLSPGERATLSCRASESVRTQLAWYQQKPGQA
		PRLLIYSASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSRTEPFTFGQGTKLEIK
CL-27774	2101	EIVLTQSPATLSLSPGERATLSCRASQSVSTPMHWYQQKPGQA
		PRLLIYSASNLESGIPARFSDSGSGTDFTLTISSLEPEDFAVY
		YCQQFWDDPYTFGQGTKLEIK
CL-27775	2102	EIVLTQSPATLSLSPGERATLSCRASESVITHLAWYQQKPGQA
		PRLLIYSASILESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQCCIDPFTFGQGTKLEIK
CL-27776	2103	EIVLTQSPATLSLSPGERATLSCRASQSVRSQLAWYQQKPGQA
		PRLLIYVASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSXNDPFTFGQGTKLEIK
CL-27779	2104	EIVLTQSPATLSLSPGERATLSCRASESVRTHMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWIDPFTFGQGTKLEIK
CL-27780	2105	EIVLTQSPATLSLSPGERATLSCRASESVSIHLAWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPFTFGQGTKLEIK
CL-27781	2106	EIVLTQSPATLSLSPGERATLSCRASQSVSTPMHWYQQKPGQA
		PRLLIYGASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNEPYTFGQGTKLEIK
CL-27782	2107	EIVLTQSPATLSLSPGERATLSCRASESVSAHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWIYPFTFGQGTKLEIK
CL-27783	2108	EIVLTQSPATLSLSPGERATLSCRASQSVRTHMHWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGIDFTLTISSLEPEDFAVY
		YCQQSXRYPFTFGQGTKLEIK
CL-27784	2109	EIVLTQSPATLSLSPGERATLSCRASQSVRTHMHWYQQKPGQA
		PRLLIYRASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQRSNEPFTFGQGTKLEIK
CL-27785	2110	EIVLTQSPATLSLSPGERATLSCRASQSVRSHMHWYQQKPGQA
		PRLLIYGASGLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQRWNEPSTFGQGTKLEIK
CL-27786	2111	EIVLTQSPATLSLSPGERATLSCRASQSVRFHMHWYQQKPGQA
		PRLLIYGASPLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSRRHPFTFGQGTKLEIK
CL-27787	2112	EIVLTQSPATLSLSPGERATLSCRASQSVSIQMHWYQQKPGQA
		PRLLIYGASKLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQQWNVPFTFGQGTKLEIK
CL-27788	2113	EIVLTQSPATLSLSPGERATLSCRASQSVSTPMHWYQQKPGQA
		PRLLIYRASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQGGNDPYTFGQGTKLEIK
CL-27790	2114	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYWASDLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQCWNGPLTFGQGTKLEIK
CL-27791	2115	EIVLTQSPATLSLSPGERATFSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGCGTDFTLTISSLEPEDFAVY
		XCQQSGNDPFTFGQGTKLEIK
CL-27792	2116	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYRASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQGGNVPCTFGQGTKLEIK
CL-27794	2117	EIVLTQSPATLSLSPGERATLSCRASESVSWHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQIRADPFTFGQGTKLEIK
CL-27795	2118	EIVLTQSPATLSLSPGERATLSCRASESVCAHMHWYQQKPGQA
		PRLLIYWASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSGLDPVTFGQGTKLEIK
CL-27796	2119	EIVLTQSPATLSLSPGERATLSCRASESVSTQMHWYQQKPGQA
		PRLLIYGASILESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSGNNPFTFGQGTKLEIK
CL-27797	2120	EIVLTQSPATLSLSPGERATLSCRASQSVSTLMHWYQQKPGQA
		PRLLIYRASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQGWNKPFTFGQGTKLEIK
CL-27798	2121	EIVLTQSPATLSLSPGERATLSCRASQSVTTHLAWYQQKPGQA
		PRLLIYWASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSSKNPFTFGQGTKLEIK
CL-27799	2122	EIVLTQSPATLSLSPGERATLSCRASESVSXHMHWYQQKPGQA
		PRLLIYWASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNDPPTFGQGTKLEIK
CL-27800	2123	EIVLTQSPATLSLSPGERATLSCRASQSVSSHLAWYQQKPGQA
		PRLLIYGASKLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSSRDPFTFGQGTKLEIK
CL-27801	2124	EIVLTQSPATLSLSPGERATLSCRASQSVTTNMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQRWNDPFTFGQGTKLEIK
CL-27802	2125	EIVLTQSPATLSLSPGERATLSCRASQSVSTHLAWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQKSNXPFTFGQGTKLEIK
CL-27803	2126	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYRASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWKDPYTFGQGTKLEIK
CL-27805	2127	EIVLTQSPATLSLSPGERATLSCRASQSVSAHLAWYQQKPGQA
		PRLLIYEASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNVPFTFGQGTKLEIK
CL-27806	2128	EIVLTQSPATLSLSPGERATLSCRASESVLILMHWYQQKPGQA
		PRLLIYEASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSSNDPFTFGQGTKLEIK
CL-27807	2129	EIVLTQSPATLSLSPGERATLSCRASQSVSSLMHWYQQKPGQA
		PRLLIYGASCLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQYXNDPYTFGQGTKLEIK
CL-27809	2130	EIVLTQSPATLSLSPGERATLSCRASQSVITHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQRWKFPFTFGQGTKLEIK
CL-27810	2131	EIVLTQSPATLSLSPGERATLSCRASESVSTQLAWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQNWNNPLTFGQGTKLEIK
CL-27811	2132	EIVLTQSPATLSLSPGERATLSCRASQSVSRDMHWYQQKPGQA
		PRLLIYGASYLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQRWKEPFTFGQGTKLEIK
CL-27812	2133	EIVLTQSPATLSLSPGERATLSCRASQSVTTLMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQGCNDPLTFGQGTKLEIK
CL-27813	2134	EIVLTQSPATLSLSPGERATLSCRASESVVTHMHWYQQKPGQA
		PRLLIYRASGLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWQHPFTFGQGTKLEIK
CL-27814	2135	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSGNDPCTFGQGTKLEIK
CL-27815	2136	EIVLTQSPATLSLSPGERATLSCRASQSVNSYLAWYQQKPGQA
		PRLLIYWASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQAWNDPSTFGQGTKLEIK
CL-27816	2137	EIVLTQSPATLSLSPGERATLSCRASQSVSNPMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNDPFTFGQGTKLEIK
CL-27818	2138	EIVLTQSPATLSLSPGERATLSCRASQSVSTLMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQGLTDPFTFGQGTKLEIK
CL-27819	2139	EIVLTQSPATLSLSPGERATLSCRASESVSPPLAWYQQKPGQA
		PRLLIYGASHLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSENDPLTFGQGTKLEIK
CL-27820	2140	EIVLTQSPATLSLSPGERATLSCRASESVNTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWNHPFTFGQGTKLEIK
CL-27821	2141	EIVLTQSPATLSLSPGERATLSCRASESVSYPMHWYQQKPGQA
		PRLLIYGASRLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQRWSDPFTFGQGTKLEIK
CL-27822	2142	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYIASFLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSXFEPSTFGQGTKLEIK
CL-27823	2143	EIVLTQSPATLSLSPGERATLSCRASESVSTQMHWYQQKPGQA
		PRLLIYGASYLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWKDPFTFGQGTKLEIK
CL-27824	2144	EIVLTQSPATLSLSPGERATLSCRASQSVSTKMHWYQQKPGQA
		PRLLIYRASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWIDPFTFGQGTKLEIK
CL-27826	2145	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYRASYLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWKDPFTFGQGTKLEIK
CL-27827	2146	EIVLTQSPATLSLSPGERATLSCRASQSVMTHLAWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNEPFTFGQGTKLEIK
CL-27828	2147	EIVLTQSPATLSLSPGERATLSCRASQSVXTHLAWYQQKPGQA
		PRLLIYGASKLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWQDPITFGQGTKLEIK
CL-27833	2148	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYAASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		XXQQSWNDPFTFGQGTKLEIK
CL-27838	2149	EIVLTQSPATLSLSPGERATLSCRASQSVSSLMHWYQQKPGQA
		PRLLIYVASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNYPFTFGQGTKLEIK
CL-27840	2150	EIVLTQSPATLSLSPGERATLSCRASQSVITPLAWYQQKPGQA
		PRLLIYGASRLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQIWNDPFTFGQGTKLEIK
CL-27841	2151	EIVLTQSPATLSLSPGERATLSCRASQSVSPLLAWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQRWNEPFTFGQGTKLEIK
CL-27842	2152	EIVLTQSPATLSLSPGERATLSCRASQSVNPHLAWYQQKPGQA
		PRLLIYWASSLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQNWNDPFTFGQGTKLEIK
CL-27843	2153	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASRLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQGWNYPFTFGQGTKLEIK
CL-27844	2154	EIVLTQSPATLSLSPGERATLSCRASQSVSTRMHWYQQKPGQA
		PRLLIYGASYLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTRYDPFTFGQGTKLEIK
CL-27845	2155	EIVLTQSPATLSLSPGERATLSCRASESVSSHMHWYQQKPGQA
		PRLLIYGASRLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPFTFGQGTKLEIK
CL-27846	2156	EIVLTQSPATLSLSPGERATLSCRASQSVTTHMHWYQQKPGQA
		PRLLIYAASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNHPFTFGQGTKLEIK
CL-27847	2157	EIVLTQSPATLSLSPGERATLSCRASQSVKTQLAWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQRCNGPFTFGQGTKLEIK
CL-27848	2158	EIVLTQSPATLSLSPGERATLSCRASQSVSTQLAWYQQKPGQA
		PRLLIYGASHLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTGNDPFTFGQGTKLEIK
CL-27849	2159	EIVLTQSPATLSLSPGERATLSCRASESVSPLMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWKDPFTFGQGTKLEIK
CL-27850	2160	EIVLTQSPATLSLSPGERATLSCRASESVSAHMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQWWNNPFTFGQGTKLEIK
CL-27851	2161	EIVLTQSPATLSLSPGERATLSCRASQSVNTHMHWYQQKPGQA
		PRLLIYRASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNEPLTFGQGTKLEIK
CL-29979	2162	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWQDPLTFGQGTKLEIK
CL-29980	2163	EIVLTQSPATLSLSPGERATLSCRASQSVNTNMHWYQQKPGQA
		PRLLIYGASILESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWNVPFTFGQGTKLEIK
CL-29981	2164	EIVLTQSPATLSLSPGERATLSCRASESVSTAMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWNVPITFGQGTKLEIK
CL-29982	2165	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASMLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-29983	2166	EIVLTQSPATLSLSPGERATLSCRASESVNDHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNNPITFGQGTKLEIK
CL-29984	2167	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNDPLTFGQGTKLEIK
CL-29985	2168	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWDDPITFGQGTKLEIK
CL-29986	2169	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSFLDPITFGQGTKLEIK
CL-29987	2170	EIVLTQSPATLSLSPGERATLSCRASESVSTNMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQGWSDPLTFGQGTKLEIK
CL-29988	2171	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWIDPLTFGQGTKLEIK
CL-29989	2172	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASHLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWIDPITFGQGTKLEIK
CL-29990	2173	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGCGTDFTLTISSLEPEDFAVY
		FCQQSWHDPLTFGQGTKLEIK
CL-29991	2174	EIVLTQSPATLSLSPGERATLSCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWDDPITFGQGTKLEIK
CL-29992	2175	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASELESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWNDPITFGQGTKLEIK
CL-29993	2176	EIVLTQSPATLSLSPGERATLSCRASESVNTLMHWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWNEPITFGQGTKLEIK
CL-29994	2177	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWSDPLTFGQGTKLEIK
CL-29995	2178	EIVLTQSPATLSLSPGERATLSCRASQSVSKHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNNPITFGQGTKLEIK
CL-29996	2179	EIVLTQSPATLSLSPGERATLSCRASQSVDTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWHDPITFGQGTKLEIK
CL-29997	2180	EIVLTQSPATLSLSPGERATLSCRASESVSNHMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWTDPLTFGQGTKLEIK
CL-29998	2181	EIVLTQSPATLSLSPGERATLSCRASQSVSSHMHWYQQKPGQA
		PRLLIYGASHLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNDPLTFGQGTKLEIK
CL-29999	2182	EIVLTQSPATLSLSPGERATLSCRASESVSTNMHWYQQKPGQA
		PRLLIYAASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNEPFTFGQGTKLEIK
CL-30000	2183	EIVLTQSPATLSLSPGERATLSCRASQSVDTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWGDPLTFGQGTKLEIK
CL-30001	2184	EIVLTQSPATLSLSPGERATLSCRASESVSNNLAWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWNDPITFGQGTKLEIK
CL-30002	2185	EIVLTQSPATLSLSPGERATLSCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPITFGQGTKLEIK
CL-30003	2186	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNEPWTFGQGTKLEIK
CL-30004	2187	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASKLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWIDPLTFGQGTKLEIK
CL-30005	2188	EIVLTQSPATLSLSPGERATLSCRASQSVGNNMHWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30006	2189	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFGGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWTDPLTFGQGTKLEIK
CL-30007	2190	EIVLTQSPATLSLSPGERATLSCRASESVYTXLAWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQILNDPFTFGQGTKLEIK
CL-30009	2191	EIVLTQSPATLSLSPGERATLSCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30010	2192	EIVLTQSPATLSLSPGERATLSCRASQSVGTNMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNDPITFGQGTKLEIK
CL-30011	2193	EIVLTQSPATLSLSPGERATLSCRASESVATHMHWYQQKPGQA
		PRLLIYGASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30012	2194	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30013	2195	EIVLTQSPATLSLSPGERATLSCRASESVMNHLAWYQQKPGQA
		PRLLIYGASYLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWSDPLTFGQGTKLEIK
CL-30014	2196	EIVLTQSPATLSLSPGERATLSCRASQSVGTSMHWYQQKPGQA
		PRLLIYAASELESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPFTFGQGTKLEIK
CL-30015	2197	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNDPLTFGQGTKLEIK
CL-30017	2198	EIVLTQSPATLSLSPGERATLSCRASESVSNNMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWSDPFTFGQGTKLEIK
CL-30018	2199	EIVLTQSPATLSLSPGERATLSCRASQSVSSHMHWYQQKPGQA
		PRLLIYGASKLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSFSDPITFGQGTKLEIK
CL-30019	2200	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWSDPLTFGQGTKLEIK
CL-30020	2201	EIVLTQSPATLSLSPGERATLSCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30021	2202	EIVLTQSPATLSLSPGERATLSCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNPPITFGQGTKLEIK
CL-30022	2203	EIVLTQSPATLSLSPGERATLSCRASESVSNHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNEPFTFGQGTKLEIK
CL-30023	2204	EIVLTQSPATLSLSPGERATLSCRASQSVGTNMHWYQQKPGQA
		PRLLIYGASILESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWNEPITFGQGTKLEIK
CL-30024	2205	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPVTFGQGTKLEIK
CL-30025	2206	EIVLTQSPATLSLSPGERATLSCRASESVGTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWNDPLTFGQGTKLEIK
CL-30026	2207	EIVLTQSPATLSLSPGERATLSCRASQSVSSHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-30027	2208	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-30028	2209	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWSDPLTFGQGTKLEIK
CL-30029	2210	EIVLTQSPATLSLSPGERATLSCRASESVSTHMNWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNVPYTFGQGTKLEIK
CL-30030	2211	EIVLTQSPATLSLSPGERATLSCRASESVTSNMHWYQQKPGQA
		PRLLIYAASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWQNPITFGQGTKLEIK
CL-30031	2212	EIVLTQSPATLSLSPGERATLSCRASESVSDHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWTDPLTFGQGTKLEIK
CL-30032	2213	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30033	2214	EIVLTQSPATLSLSPGERATLSCRASESVSNYMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWTDPLTFGQGTKLEIK
CL-30034	2215	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASILESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWNDPITFGQGTKLEIK
CL-30035	2216	EIVLTQSPATLSLSPGERATLSCRASQSVGTAMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWDAPFTFGQGTKLEIK
CL-30036	2217	EIVLTQSPATLSLSPGERATLSCRASQSVRSHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWTPPITFGQGTKLEIK
CL-30037	2218	EIVLTQSPATLSLSPGERATLSCRASESVSTSMNWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWKDPITFGQGTKLEIK
CL-30038	2219	EIVLTQSPATLSLSPGERATLSCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNVPWTFGQGTKLEIK
CL-30039	2220	EIVLTQSPATLSLSPGERATLSCRASESVSNSMHWYQQKPGQA
		PRLLIYGASTLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWTDPLTFGQGTKLEIK
CL-30040	2221	EIVLTQSPATLSLSPGERATLSCRASESVGTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWNDPSTFGQGTKLEIK
CL-30041	2222	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30042	2223	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASTLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWSDPLTFGQGTKLEIK
CL-30043	2224	EIVLTQSPATLSLSPGERATLSCRASESVDSNMHWYQQKPGQA
		PRLLIYRASILESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWGDPITFGQGTKLEIK
CL-30044	2225	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30045	2226	EIVLTQSPATLSLSPGERATLSCRASESVSNHMHWYQQKPGQA
		PRLLIYGASYLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30046	2227	EIVLTQSPATLSLSPGERATLSCRASESVSDHMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWTDPLTFGQGTKLEIK
CL-30047	2228	EIVLTQSPATLSLSPGERATLSCRASESVGTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30048	2229	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWSDPLTFGQGTKLEIK
CL-30049	2230	EIVLTQSPATLSLSPGERATLSCRASESVNTHLAWYQQKPGQA
		PRLLIYGASMLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWSLPYTFGQGTKLEIK
CL-30050	2231	EIVLTQSPATLSLSPGERATLSCRASQSVSSHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30053	2232	EIVLTQSPATLSLSPGERATLSCRASESVSTHMNWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNDPFTFGQGTKLEIK
CL-30054	2233	EIVLTQSPATLSLSPGERATLSCRASESVGTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNEPYTFGQGTKLEIK
CL-30055	2234	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWGDPITFGQGTKLEIK
CL-30056	2235	EIVLTQSPATLSLSPGERATLSCRASQSVSTNMHWYQQKPGQA
		PRLLIYAASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWNEPITFGQGTKLEIK
CL-30057	2236	EIVLTQSPATLSLSPGERATLSCRASESVGKHMHWYQQKPGQA
		PRLLIYGASKLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWNDPITFGQGTKLEIK
CL-30058	2237	EIVLTQSPATLSLSPGERATLSCRASESVSNHMHWYQQKPGQA
		PRLLIYGASFLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWTNPITFGQGTKLEIK
CL-30059	2238	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWDDPLTFGQGTKLEIK
CL-30060	2239	EIVLTQSPATLSLSPGERATLSCRASESVGTHMHWYQQKPGQA
		PRLLIYGASYLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWTDPITFGQGTKLEIK
CL-30061	2240	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASHLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWIDPITFGQGTKLEIK
CL-30062	2241	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASKLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPITFGQGTKLEIK
CL-30063	2242	EIVLTQSPATLSLSPGERATLSCRASESVCTRMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPYTFGQGTKLEIK
CL-30064	2243	EIVLTQSPATLSLSPGERATLSCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTFDDPLTFGQGTKLEIK
CL-30066	2244	EIVLTQSPATLSLSPGERATLSCRASQSVGDSLAWYQQKPGQA
		PRLLIYAASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWNVPITFGQGTKLEIK
CL-30067	2245	EIVLTQSPATLSLSPGERATLSCRASESVANHLAWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPITFGQGTKLEIK
CL-30068	2246	EIVLTQSPATLSLSPGERATLSCRASESVSTHMNWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQGWYDPLTFGQGTKLEIK
CL-30069	2247	EIVLTQSPATLSLSPGERATLSCRASESVSSHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPITFGQGTKLEIK
CL-30070	2248	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNVPFTFGQGTKLEIK
CL-30071	2249	EIVLTQSPATLSLSPGERATLSCRASESVNKHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWIDPFTFGQGTKLEIK
CL-30072	2250	EIVLTQSPATLSLSPGERATLSCRASQSVGNHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNMPITFGQGTKLEIK
CL-30073	2251	EIVLTQSPATLSLSPGERATLSCRASESVGEHMHWYQQKPGQA
		PRLLIYAASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-30074	2252	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWDVPLTFGQGTKLEIK
CL-30078	2253	ENVLTQSPATLSLSPGERATLSCRASESVITHMNWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPFTFGQGTKLEIK
CL-30090	2254	EIVLTQSPATLSLSPGERATLSCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-30095	2255	EIVLTQSPATLSLSPGERATLSCRASESVSNHMHWYQQKPGQA
		PRLLIYGASELESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWSDPLTFGQGTKLEIK
CL-30098	2256	EIVLTQSPATLSLSPGERATLSCRASQSVDTHMHWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWIDPITFGQGTKLEIK
CL-30099	2257	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWIDPLTFGQGTKLEIK
CL-30103	2258	EIVLTQSPATPSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNDPFTFGQGTKLEIK
CL-30104	2259	EIVLTQSPATLSLSPGERATLSCRASESVSSHMHWYQQKPGQA
		PRLLIYGASILESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWNDPITFGQGTKLEIK
CL-30106	2260	EIVLTQSPATLSLSPGERATLSCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30109	2261	EIVLTQSPATLSLSPGERATLSCRASQSVITHMNWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWNDPITFGQGTKLEIK
CL-30115	2262	EIVLTQSPATLSLSPGERATLSCRASESVQTHMNWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPFTFGQGTKLEIK
CL-30120	2263	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYAASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-30121	2264	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNDPLTFGQGTKLEIK
CL-30123	2265	EIVLTQSPATLSLSPGERATLSCRASESVITHMNWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWDNPITFGQGTKLEIK
CL-30126	2266	EIVLTQSPATLSLSPGERATLSCRASQSVHKHMNWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQGWDDPLTFGQGTKLEIK
CL-30128	2267	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30131	2268	EIVLTQSPATLSLSPGERATLSCRASESVLTHMNWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWYEPWTFGQGTKLEIK
CL-30132	2269	EIVLTQSPATLSLSPGERATLSCRASESVDTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPITFGQGTKLEIK
CL-30133	2270	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWSDPITFGQGTKLEIK
CL-30134	2271	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMNWYQQKPGQA
		PRLLIYGASFLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWSDPITFGQGTKLEIK
CL-30135	2272	EIVLTQSPATLSLSPGERATLSCRASQSVGTPMHWYQQKPGQA
		PRLLIYGASTLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-30137	2273	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASYLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPITFGQGTKLEIK
CL-30143	2274	EIVLTQSPATLSLSPGERATLSCRASESVDTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPITFGQGTKLEIK
CL-30144	2275	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASMLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWTDPITFGQGTKLEIK
CL-30147	2276	EIVLTQSPATLSLXPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLEYGVPARFSGSGCGTDFTLTISSIEHEDFAVY
		FCQQSWNDPFTFGQGTKLEIK
CL-30150	2277	EIVLTQSPATLSLSPGERATLSCRASQSVANHLAWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWTDPITFGQGTKLEIK
CL-30152	2278	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASMLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNNPITFGQGTKLEIK
CL-30155	2279	EIVLTQSPATLSLSPGERATLSCRASQSVSNHMHWYQQKPGQA
		PRLLIYAASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWDDPLTFGQGTKLEIK
CL-30158	2280	EIVLTQSPATLSLSPGERVTLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPITFGQGTKLEIK
CL-30160	2281	EIVLTQSPATLSLSPGERATLSCRASQSVSNHMHWYQQKPGQA
		PRLLIYAASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30163	2282	EIVLTQSPATLSLSPGERATLSCRASQSVSSHMHWYQQKPGQA
		PRLLIYAASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-30164	2283	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWMDPITFGQGTKLEIK
CL-30166	2284	EIVLTQSPATLSLSPGERATLSCRASESVSTNMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWSEPWTFGQGTKLEIK
CL-30167	2285	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWSDPLTFGQGTKLEIK
CL-30593	2286	EIVLTQSPATLSLSPGERATLSCRASQSVDTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-30594	2287	EIVLTQSPATLSLSPGERATLSCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNEPFTFGQGTKLEIK
CL-30595	2288	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPITFGQGTKLEIK
CL-30597	2289	EIVLTQSPATLSLSPGERATLSCRASESVSNHMHWYQQKPGQA
		PRLLIYGASTLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30598	2290	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASVLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWDDPLTFGQGTKLEIK
CL-30600	2291	EIVLTQSPATLSLSPGERATLSCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWLDPITFGQGTKLEIK
CL-30601	2292	EIVLTQSPATLSLSPGERATLSCRASQSVNTHLAWYQQKPGQA
		PRLLIYAASHLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWTDPLTFGQGTKLEIK
CL-30602	2293	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWSDPLTFGQGTKLEIK
CL-30604	2294	EIVLTQSPATLSLSPGERATLSCRASQSVSNPMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNXPFTFGQGTKLEIK
CL-30606	2295	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWDDPFTFGQGTKLEIK
CL-30608	2296	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWSDPLTFGQGTKLEIK
CL-30609	2297	EIVLTQSPATLSLSPGERATLSCRASESVNSNMHWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIK
CL-30610	2298	EIVLTQSPATLSLSPGERATLSCRASQSVRNHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWDDPLTFGQGTKLEIK
CL-30611	2299	EIVLTQSPATLSLSPGERATLSCRASESVSNHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWDDPLTFGQGTKLEIK
CL-30613	2300	EIVLTQSPATLSLSPGERATLSCRASQSVNTAMHWYQQKPGQA
		PRLLIYGASSLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30614	2301	EIVLTQSPATLSLSPGERATLSCRASESVGSHMHWYQQKPGQA
		PRLLIYGASHLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNLPLTFGQGTKLEIK
CL-30615	2302	EIVLTQSPATLSLSPGERATLSCRASESVSNHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPITFGQGTKLEIK
CL-30616	2303	EIVLTQSPATLSLSPGERATLSCRASQSVITHMNWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWGDPWTFGQGTKLEIK
CL-30617	2304	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWIDPLTFGQGTKLEIK
CL-30618	2305	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASMLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWDDPLTFGQGTKLEIK
CL-30619	2306	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYAASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPITFGQGTKLEIK
CL-30620	2307	EIVLTQSPATLSLSPGERATLSCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPITFGQGTKLEIK
CL-30624	2308	EIVLTQSPATPSLSPGERATLSCRASESVGSCMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWYDPLTFGQGTKLEIK
CL-30626	2309	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNDPLTFGQGTKLEIK
CL-30627	2310	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30628	2311	EIVLTQSPATLSLSPGERATLSCRASESVSRHMHWYQQKPGQA
		PRLLIYGASHLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNNPLTFGQGTKLEIK
CL-30629	2312	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPATFGQGTKLEIK
CL-30630	2313	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30631	2314	EIVLTQSPATLSLSPGERATLSCRASQSVGRHMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWTDPLTFGQGTKLEIK
CL-30632	2315	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWSDPITFGQGTKLEIK
CL-30634	2316	EIVLTQSPATLSLSPGERATLSCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30635	2317	EIVLTQSPATLSLSPGERATLSCRASESVSSNMNWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSFYDPITFGQGTKLEIK
CL-30636	2318	EIVLTQSPATLSLSPGERATLSCRASESVSSHMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWSDPLTFGQGTKLEIK
CL-30637	2319	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASHLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWHDPLTFGQGTKLEIK
CL-30638	2320	EIVLTQSPATLSLSPGERATLSCRASESVSNHMHWYQQKPGQA
		PRLLIYAASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWIDPITFGQGTKLEIK
CL-30639	2321	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWTDPLTFGQGTKLEIK
CL-30640	2322	EIVLTQSPATLSLSPGERATLSCRASESVRSHLAWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSIEPEDFAVY
		FCQQSWNAPFTFGQGTKLEIK
CL-30641	2323	EIVLTQSPATLSLSPGERATLSCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWSDPLTFGQGTKLEIK
CL-30642	2324	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASILESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWDDPITFGQGTKLEIK
CL-30643	2325	EIVLTQSPATLSLSPGERATLSCRASESVSNHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNEPLTFGQGTKLEIK
CL-30644	2326	EIVLTQSPATLSLSPGERATLSCRASESVSTHMPWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30645	2327	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWSDPLTFGQGTKLEIK
CL-30647	2328	EIVLTQSPATLSLSPGERATLSCRASQSVSTAMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWFDPLTFGQGTKLEIK
CL-30648	2329	EIVLTQSPATLSLSPGERATLSCRASESVSNHMHWYQQKPGQA
		PRLLIYGASILESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWSDPITFGQGTKLEIK
CL-30649	2330	EIVLTQSPATLSLSPGERATLSCRASESVNSDMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-30650	2331	EIVLTQSPATLSLSPGERATLSCRASESVSNHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNVPITFGQGTKLEIK
CL-30651	2332	EIVLTQSPATLSLSPGERATLSCRASESVSTNLAWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWNDPITFGQGTKLEIK
CL-30653	2333	EIVLTQSPATLSLSPGERATLSCRASESVSNHMHWYQQKPGQA
		PRLLIYAASHLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWTDPITFGQGTKLEIK
CL-30654	2334	EIVLTQSPATLSLSPGERATLSCRASESVSTHMNWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWTDPITFGQGTKLEIK
CL-30655	2335	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWDVPFTFGQGTKLEIK
CL-30657	2336	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWSDPITFGQGTKLEIK
CL-30658	2337	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQCRNDPFTFGQGTKLEIK
CL-30659	2338	EIVLTQSPATLSLSPGERATLSCRASESVSKHMNWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWTDPLTFGQGTKLEIK
CL-30660	2339	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASRLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30662	2340	EIVLTQSPATLSLSPGERATLSCRASESVGTHMHWYQQKPGQA
		PRLLIYGASHLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWDDPLTFGQGTKLEIK
CL-30663	2341	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNEPYTFGQGTKLEIK
CL-30664	2342	EIVLTQSPATLSLSPGERATLSCRASESVGMHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30665	2343	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMNWYQQKPGQA
		PRLLIYAASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSFNNPLTFGQGTKLEIK
CL-30666	2344	EIVLTQSPATLSLSPGERATLSCRASQSVNTHLHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWFDPLTFGQGTKLEIK
CL-30667	2345	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNDPLTFGQGTKLEIK
CL-30669	2346	EIVLTQSPATLSLSPGERATLSCRASESVSNHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIK
CL-30670	2347	EIVLTQSPATLSLSPGERATLSCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWLDPLTFGQGTKLEIK
CL-30671	2348	EIVLTQSPATLSLSPGERATLSCRASESVSNHMHWYQQKPGQA
		PRLLIYGASILESGVLARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30672	2349	EIVLTQSPATLSLSPGERATLSCRASESVSSHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWNYPITFGQGTKLEIK
CL-30673	2350	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPITFGQGTKLEIK
CL-30674	2351	EIVLTQSPATLSLSPGERATLSCRASESVGNHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWIDPLTFGQGTKLEIK
CL-30675	2352	EIVLTQSPATLSLSPGERATLSCRASESVSNHMHWYQQKPGQA
		PRLLIYAASKLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWVEPFTFGQGTKLEIK
CL-30676	2353	EIVLTQSPATLSLSPGERATLSCRASQSVETHMHWYQQKPGQA
		PRLLIYGASHLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWRDPLTFGQGTKLEIK
CL-30677	2354	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMNWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWDDPLTFGQGTKLEIK
CL-30678	2355	EIVLTQSPATLSLSPGERATLSCRASQSVGSSMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNDPLTFGQGTKLEIK
CL-30679	2356	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30681	2357	EIVLTQSPATLSLSPGERATLSCRASQSVTNHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWHDPLTFGQGTKLEIK
CL-30682	2358	EIVLTQSPATLSLSPGERATLSCRASESVSSHLAWYQQKPGQA
		PRLLIYGASTLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWGDPFTFGQGTKLEIK
CL-30683	2359	EIVLTQSPATLSLSPGERATLSCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWSDPLTFGQGTKLEIK
CL-30684	2360	EIVLTQSPATLSLSPGERATLSCRASESVHDHMHWYQQKPGQA
		PRLLIYAASHLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPLTFGQGTKLEIK
CL-30685	2361	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWADPLTFGQGTKLEIK
CL-34444	2362	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASILESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34445	2363	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASHLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPFTFGQGTKLEIK
CL-34446	2364	EIVLTQSPATLSLSPGERATLSCRASESVSNHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSFYDPLTFGQGTKLEIK
CL-34447	2365	EIVLTQSPATLSLSPGERATLSCRASESVGTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34448	2366	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASMLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWMDPITFGQGTKLEIK
CL-34450	2367	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWMDPLTFGQGTKLEIK
CL-34451	2368	EIVLTQSPATLSLSPGERATLSCRASESVSNHMHWYQQKPGQA
		PRLLIYGASILESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34452	2369	EIVLTQSPATLSLSPGERATLSCRASESVGTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWHDPLTFGQGTKLEIK
CL-34453	2370	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSFTNPLTFGQGTKLEIK
CL-34454	2371	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34457	2372	EIVLTQSPATLSLSPGERATLSCRASXSVNTHMHWYQQKPGQA
		PRLLIYGASXLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQXWYDPITFGQGTKLEIK
CL-34458	2373	EIVLTQSPATLSLSPGERATLSCRASESVRTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34459	2374	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-34460	2375	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASHLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34461	2376	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34462	2377	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASVLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34464	2378	EIVLTQSPATLSLSPGERATLSCRASQSVSRHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPITFGQGTKLEIK
CL-34465	2379	EIVLTQSPATLSLSPGERATLSCRASQSVSSHMHWYQQKPGQA
		PRLLIYGASILESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWDDPITFGQGTKLEIK
CL-34467	2380	EIVLTQSPATLSLSPGERATLSCRASESVSTSMHWYQQKPGQA
		PRLLIYGASQLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNVPFTFGQGTKLEIK
CL-34468	2381	EIVLTQSPATLSLSPGERATLSCRASESVGTHMHWYQQKPGQA
		PRLLIYGASRLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWTVPLTFGQGTKLEIK
CL-34472	2382	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASHLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-34473	2383	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASVLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIK
CL-34474	2384	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASTLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIK
CL-34478	2385	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWYDPLTFGQGTKLEIK
CL-34479	2386	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASTLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-34480	2387	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34481	2388	EIVLTQSPATLSLSPGERATLSCRASQSVNNHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34482	2389	EIVLTQSPATLSLSPGERATLSCRASQSVGEHMHWYQQKPGQA
		PRLLIYGASHLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPITFGQGTKLEIK
CL-34485	2390	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASHLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-34487	2391	EIVLTQSPATLSLSPGERATLSCRASQSVSTNMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWYDPITFGQGTKLEIK
CL-34488	2392	EIVLTQSPATLSLSPGERATLSCRASESVGTHMHWYQQKPGQA
		PRLLIYGASTLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34490	2393	EIVLTQSPATLSLSPGERATLSCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIK
CL-34494	2394	EIVLTQSPATLSLSPGERATLSCRASQSVGSHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPITFGQGTKLEIK
CL-34496	2395	EIVLTQSPATLSLSPGERATLSCRASQSVGNHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIK
CL-34498	2396	EIVLTQSPATLSLSPGERATLSCRASESVGTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-34499	2397	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPITFGQGTKLEIK
CL-34500	2398	EIVLTQSPATLSLSPGERATLSCRASESVGTHMHWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPITFGQGTKLEIK
CL-34502	2399	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34504	2400	EIVLTQSPATLSLSPGERATLSCRASESVSRHMNWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWYDPITFGQGTNLEIK
CL-34505	2401	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASYLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPITFGQGTKLEIK
CL-34506	2402	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPITFGQGTKLEIK
CL-34508	2403	EIVLTQSPATLSLSPGERATLSCRASESVDTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34509	2404	EIVLTQSPATLSLSPGERATLSCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPITFGQGTKLEIK
CL-34511	2405	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34512	2406	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34514	2407	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASILESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34515	2408	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWYDPITFGQGTKLEIK
CL-34517	2409	EIVLTQSPATLSLSPGERATLSCRASESVGTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34520	2410	EIVLTQSPATLSLSPGERATLSCRASESVGTHMHWYQQKPGQA
		PRLLIYGASILESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIK
CL-34521	2411	EIVLTQSPATLSLSPGERATLSCRASESVDRHMHWYQQKPGQA
		PRLLIYGASHLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-34523	2412	EIVLTQSPATLSLSPGERATLSCRASQSVTNHMHWYQQKPGQA
		PRLLIYGASVLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34524	2413	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPITFGQGTKLEIK
CL-34525	2414	EIVLTQSPATLSLSPGERATLSCRASESVSNHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPITFGQGTKLEIK
CL-34526	2415	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-34529	2416	EIVLTQSPATLYLXPGERATLSCRASQSVSTHMHWYQQKPGQA
		ARLVMYGASNLEFGVPARFSGSGSGTEFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34533	2417	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPITFGQGTKLEIK
CL-34534	2418	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34536	2419	EIVLTQSPATLSLSPGERATLSCRASQSVGAHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-34539	2420	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWSDPLTFGQGTKLEIK
CL-34541	2421	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASILESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPITFGQGTKLEIK
CL-34548	2422	EIVLTQSPATLSLSPGERATLSCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASHLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34556	2423	EIVLTQSPATLSLSPGERATLSCRASESVSXHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34558	2424	EIVLTQSPATLSLSPGERATLSCRASESVSTAMHWYQQKPGQA
		PRLLIYAASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34561	2425	EIVLTQSPATLSLSPGERATLSCRASESVGTHMHWYQQKPGQA
		PRLLIYGASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPITFGQGTKLEIK
CL-34562	2426	EIVLTQSPATLSLSPGERATLSCRASQSVGSHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-34563	2427	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIK
CL-34566	2428	EIVLTQSPATLSLSPGERATLSCRASQSVGTNMHWYQQKPGQA
		PRLLIYGASVLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWYDPITFGQGTKLEIK
CL-34568	2429	EIVLTQSPATLSLSPGERATLSCRASESVGKHMHWYQQKPGQA
		PRLLIYGASHLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWMDPLTFGQGTKLEIK
CL-34573	2430	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASFLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34574	2431	EIVLTQSPATLSLSPGERATLSCRASESVGTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWGDPLTFGQGTKLEIK
CL-34577	2432	EIVLTQSPATLSLSPGERATLSCRASESVSKHMHWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34580	2433	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASMLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWDDPLTFGQGTKLEIK
CL-34582	2434	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34585	2435	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIK
CL-34586	2436	EIVLTQSPATLSLSPGERATLSCRASQSVXXHMHWYQQKPGQA
		PRLLIYGASTLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWTDPXTFGQGTKLEIK
CL-34587	2437	EIVLTQSPATLSLSPGERATLSCRASESVSTHLHWYQQKPGQA
		PRLLIYGASILESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34590	2438	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34591	2439	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPITFGQGTKLEIK
CL-34592	2440	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPITFGQGTKLEIK
CL-34593	2441	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASMLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34594	2442	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPITFGQGTKLEIK
CL-34598	2443	EIVLTQSPATLSLSPGERATLSCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWIEPYTFGQGTKLEIK
CL-34599	2444	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPITFGQGTKLEIK
CL-34600	2445	EIVLTQSPATLSLSPGERATLSCRASESVNTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWNDPFTFGQGTKLEIK
CL-34601	2446	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASILESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIK
CL-34602	2447	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPGTFGQGTKLEIK
CL-34604	2448	EIVLTQSPATLSLSPGERATLSCRASQSVNNHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-34610	2449	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-34612	2450	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMQWYQQKPGQA
		PRLLIYGASILESGIPARFSGSGSGTDFTLTISSLEHEDFAVY
		XCQQSWYDPLTFGQGTKLEIK
CL-34613	2451	EIVLTQSPATLSLSPGERATLSCRASESVGRHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWYDPITFGQGTKLEIK
CL-34614	2452	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIK
CL-34617	2453	EIVLTQSPATLSLSPGERATLSCRASESVDSSMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-34618	2454	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPITFGQGTKLEIK
CL-40245	2455	EIVLTQSPATLSLSPGERAALSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-40250	2456	EIVLTQSPATLSLSPGERATLSYRASQSVGTHMHWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-40251	2457	EIVLTQSPGTLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-40253	2458	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGADFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-40255	2459	EIVLTQSPGTLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-40258	2460	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASHPESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-40266	2461	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPMTFGQGTKLEIK
CL-40271	2462	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLGSN
CL-40272	2463	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLRSN
CL-40283	2464	EIVLTQSPGTLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPMTFGQGTKLEIK
CL-40284	2465	EIVLTQSPATLSLSPGERAILSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLAFGQGTKLEIK
CL-40286	2466	EIVLPQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLEPGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNDPFTFGQGTKLEIK
CL-40287	2467	EIVLTQSPGTLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNDPFTFGQGTKLEIK
CL-40288	2468	EIVLTQSPGTLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-40299	2469	RNCVTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-40302	2470	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWCDPLTFGQGTKLEIK
CL-40303	2471	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLPIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-40317	2472	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLGPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-40324	2473	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-40327	2474	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPMTFGQGTKLEIK
CL-40328	2475	EIVLTQSPGTLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-40331	2476	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQRTKLEIK
CL-40332	2477	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPMAFGQGTKLEIK
CL-40335	2478	RNCVDKSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASHLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-40336	2479	EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-40337	2480	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQRSWYDPLTFGQGTKLEIK
CL-40338	2481	EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWNDPFTFGQGTKLEIK
CL-40339	2482	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-40341	2483	EIVLTQSPATLSLSPGERATLFCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFVVY
		YCQQSWYDPITFGQGTKLEIK
CL-40342	2484	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTCYDPLTFGQGTKLEIK
CL-40350	2485	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGADFTLTISSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIK
CL-40356	2486	EIVLTQSPATLSLSPGERATLSCRASESVGKHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWYDPITFGQGTKLEIK
CL-40357	2487	EIVLTQSPATLSLSPGERATLFCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-40364	2488	EIVLTQSPGTLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSFYDPLTFGQGTKLEIK
CL-40367	2489	EIVLTQSPGTLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWYDPLTFGQGTKLEIK
CL-40370	2490	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFILTISSLEPEDFAVY
		YCQQSFYDPLTFGQGTKLEIK
CL-40373	2491	EIVLTQSPGTLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIK
CL-40381	2492	EIVLTQSPGTLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAIY
		FCQQTWYDPLTFGQGTKLEIK
CL-40382	2493	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGIDFTLTISSLEPEDFAVY
		FCQQTWYDPLTFGQGTKLEIK
CL-40390	2494	EIVLTQSPATLSLSPGERATLSCRASGSVGKHMHWYQQKPGQA
		PRLLIYAASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-40394	2495	EIVLTQSPGTLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEEFAVY
		FCQQTWYDPLTFGQGTKLEIK
CL-40399	2496	EIVLTQSPATLSLSPGERATLSCRASQSVSKHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDSTLTISSLEPEDFAVY
		FCQQTWYDPITFGQGTKLEIK
CL-40408	2497	EIVLTQSPATLSLPPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSFYDPLTFGQGTKLEIK
CL-40414	2498	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFGGSGSGTDFTLTISSLEPEDFAVY
		YCQQSFYDPLTFGQGTKLEIK
CL-40426	2499	EIVSTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTIGSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIK
CL-40440	2500	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTNLEIK
CL-40441	2501	EIVLTQSPATLSLSPGERATFSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-40443	2502	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAAY
		FCQQTWYDPLTFGQGTKLEIK
CL-40445	2503	EIVLTQSPSTLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWYDPLTFGQGTKLEIK
CL-40447	2504	EIVLTQSPATLSLSPGERATLSCRASQSVNNHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIX
CL-40453	2505	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWCQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWYDPLTFGQGTKLEIK
CL-40463	2506	EIVLTQSPGTLSLSPGERATLSCRASQSVNNHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIK
CL-40466	2507	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIK
CL-40470	2508	EIVLTQSPGTLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIK
CL-40472	2509	EIVLTQSPATLSLSPGERATLSCRASQSVNNHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-40476	2510	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLRSN
CL-40479	2511	EIVLTQSPATLSLSPGERATLSCRASQSVATHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLRSN
CL-40480	2512	EIVLTQSPGTLSLSPGERATLSCRASQSVSTHMHWYQQEPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-40484	2513	EIVLTQSPGTLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-40485	2514	RNLLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWYDPLTFGQGTKLEIK
CL-40489	2515	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWYDPLTFGQGTKLVIK
CL-40494	2516	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGADFTLTISSLEPEDFAVY
		FCQQTWYDPLTFGQGTKLEIK
CL-40498	2517	EIVLTQSPATLSLSPGERATLSCRASQSVNNHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSRYDPLTFGQGTKLEIK
CL-40503	2518	EIVLTQSPGTLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWYDPLTFGQGTKLEIK
CL-40505	2519	EIVLTQSPGTLSLSPGERATLSCRASQSVATHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-40511	2520	AIVLTQSPATLSLSPGERATLSCRASQSVATHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-40526	2521	EIVLTQSPAALSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWYDPLTFGQGTKLEIK
CL-40531	2522	EIVLTQSPATLSLSPGERATLSCRASQSVNNHMHWYQQKPGQA
		PRLLIYGASIPESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIK
CL-41836	2523	AIVLTQSPGTLSLSPGERATLSCRASQSVATHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-41845	2524	EIVLTQSPATLSLSPGERATLSCRASQSVNNHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIK
CL-41849	2525	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASKLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-41850	2526	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIK
CL-41852	2527	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-41854	2528	EIVLTQSPATLSLSPGERATLSCRASQSVATHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-41855	2529	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWYDPLTFGQGTKLEIK
CL-41885	2530	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTITSLEPEDFAVY
		FCXQTWYDPLTFGQGTKLEIK
CL-41886	2531	EIVLTQSPATLSLSPGERATLFCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPITFGQGTKLRSN
CL-41888	2532	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-41920	2533	EIVLTQSPGTLSLSPGERASLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSFYDPLTFGRGTKLEIK
CL-41923	2534	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIN
CL-41928	2535	EIVLTQSPATLSLSPGERATLSCRTSESVGKHMHWYQQKPGQA
		PRLLIYAASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-41938	2536	EIVLTQSPATLSLSPGERATLSCRASESVGKHMHWYQQKPGQA
		PRLLIYAASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPLTFGQGTKLEIK
CL-41940	2537	EIVLTQSPATLSLSPGERATLFCRASQSVSNHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSWYDPITFGQGTKLEIK
CL-41941	2538	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASILESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWYDPLTFGQGTKLEIK
CL-41947	2539	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSFYDPLTFGQGTKLEIQ
CL-41949	2540	EIVLTQSPATLSLSPGERATLSCRASQSVSKHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQTWYDPITFGQGTKLEIK
CL-41950	2541	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQTWYDPLTFGQGTKLEIK
CL-41951	2542	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		YCQQSFYDPLTFGQGTKLEIK
CL-41952	2543	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQA
		PRLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVY
		FCQQSWYDPLTFGQGTKLEIK

TABLE 40
Amino Acid Residues Found In Each Position of the Heavy
Chain Variable Region During The Affinity Maturation Of
Humanized Anti-Human VEGF Antibody Hbdb-4G8.3
hBDB-4G8|Heavy Chain Variable Region
SEQ ID NO: Sequence
2544       1         2         3         4         5         6
           123456789012345678901234567890123456789012345678901234567890
           EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWINTETGKPTY
           R          S       S S                    Y  N I
           N      QK D                    L  D M
           DY K                    V  T K
           ET C                    W  P A
           NM V                    A  W N
           AG E                    Q  Y P
           GA L                    H  V L
           HI W                    G  S V
           KL P                    K  M W
           ME Y                    N  A D
           LP M                    M  I Y
           RQ N                    T  G G
           IF T                    P  R E
           Y                          L
           V
           7         8         9        10        11        12
           123456789012345678901234567890123456789012345678901234567890
           ADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYIFYFDYWGQGTMVT
           Y  N             T        D           H    N L
           H                         T          YI   ST N
           GT   NK T
           ID   EM V
           S    MY A
           KF   LC R
           NL   TI F
           PE   WF D
           LV   QL
           WY   GD S
           MA   IW
           FG   AX
           RW   CV
           QQ   V
           R
           123
           VSS
           SFQ
           L

TABLE 41
Amino Acid Residues Found In Each Position of the Light
Chain Variable Region During The Affinity Maturation Of
Humanized Anti-Human VEGF Antibody Hbdb-4G8.3
hBDB-4G8|Light Chain Variable Region
SEQ ID NO: Sequence
2545       1         2         3         4         5         6
           123456789012345678901234567890123456789012345678901234567890
           EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGASNLESGVPA
           A         NSA A               W  H  Y
           DRD P               V  Y
           C                 I  M
           TAP                 E  T
           RER                 S  F
           HDY                 D  V
           EM                     R
           IPL                    Q
           LYQ                    A
           QIK                    S
           CW                     E
           MF                     G
           Y                      C
           K                      D
           V                      P
           7         8         9        10
           12345678901234567890123456789012345678901234567
           RFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIK
           CCIN M        G
           GLTY G
           IGDA Y
           W GL
           REM  A
           NSSM W
           A HP S
           Y AG V
           K RH C
           Q VF P
           F LK
           F
           K
           Q

TABLE 42
Variable Region Sequences of hBDB-4G8.3 Affinity
Matured Clones Converted To IgG
SEQ ID		Protein	V Region
NO:	Clone	Region	123456789012345678901234567890
2546	CL-32416 VH		EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYW
			VRQAPGQGLEWMGWIDTETGEPTYADDFKGRFVFSL
			DTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYMF
			YFDYWGQGTMVTVSS
2547	CL-32416	CDR-H1	GYTFTDYGMY
2548	CL-32416	CDR-H2	WIDTETGEPTYADDFKG
2549	CL-32416	CDR-H3	TNYYYRSYMFYFDY
2550	CL-32416 VL		EIVLTQSPATLSLSPGERATLSCRASESVSTHMHWY
			QQKPGQAPRLLIYGASNLESGVPARFSGSGSGTDFT
			LTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIK
2551	CL-32416	CDR-L1	RASESVSTHMH
2552	CL-32416	CDR-L2	GASNLES
2553	CL-32416	CDR-L3	QQSWNDPFT
2554	CL-34449 VH		EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYW
			VRQAPGQGLEWMGWIDTETGEPTYADDFKGRFVFSL
			DTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYMF
			YFDYWGQGTMVTVSS
2555	CL-34449	CDR-H1	GYTFTDYGMY
2556	CL-34449	CDR-H2	WIDTETGEPTYADDFKG
2557	CL-34449	CDR-H3	TNYYYRSYMFYFDY
2558	CL-34449 VL		EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWY
			QQKPGQAPRLLIYGASHLESGIPARFSGSGSGTDFT
			LTISSLEPEDFAVYYCQQTWYDPLTFGQGTKLEIK
2559	CL-34449	CDR-L1	RASQSVGTHMH
2560	CL-34449	CDR-L2	GASHLES
2561	CL-34449	CDR-L3	QQTWYDPLT
2562	CL-34455 VH		EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYW
			VRQAPGQGLEWMGWIDTETGEPTYAQGFTGRFVFSL
			DTSVSTAYLQISSLKAEDTAVYYCARTNYYYPSYMF
			YFDYWGQGTMVTVSS
2563	CL-34455	CDR-H1	GYTFTNYGMY
2564	CL-34455	CDR-H2	WIDTETGEPTYAQGFTG
2565	CL-34455	CDR-H3	TNYYYPSYMFYFDY
2566	CL-34455 VL		EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWY
			QQKPGQAPRLLIYGASKLESGVPARFSGSGSGTDFT
			LTISSLEPEDFAVYYCQQSWYDPLTFGQGTKLEIK
2567	CL-34455	CDR-L1	RASQSVGTHMH
2568	CL-34455	CDR-L2	GASKLES
2569	CL-34455	CDR-L3	QQSWYDPLT
2570	CL-34463 VH		EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYW
			VRQAPGQGLEWMGWIDTETGNPTYADDFKGRFVFSL
			DTSVSTAYLQISSLKAEDTAVYYCARTNYYYPSYMF
			YFDYWGQGTMVTVSS
2571	CL-34463	CDR-H1	GYTFTDYGMY
2572	CL-34463	CDR-H2	WIDTETGNPTYADDFKG
2573	CL-34463	CDR-H3	TNYYYPSYMFYFDY
2574	CL-34463 VL		EIVLTQSPATLSLSPGERATLSCRASQSVSKHMHWY
			QQKPGQAPRLLIYGASNLESGIPARFSGSGSGTDFT
			LTISSLEPEDFAVYFCQQTWYDPITFGQGTKLEIK
2575	CL-34463	CDR-L1	RASQSVSKHMH
2576	CL-34463	CDR-L2	GASNLES
2577	CL-34463	CDR-L3	QQTWYDPIT
2578	CL-34469 VH		EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYW
			VRQAPGQGLEWMGWIDTETGEPTYADDFKGRFVFSL
			DTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYMF
			YFDYWGQGTMVTVSS
2579	CL-34469	CDR-H1	GYTFTNYGMY
2580	CL-34469	CDR-H2	WIDTETGEPTYADDFKG
2581	CL-34469	CDR-H3	TNYYYRSYMFYFDY
2582	CL-34469 VL		EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWY
			QQKPGQAPRLLIYGASNLESGVPARFSGSGSGTDFT
			LTISSLEPEDFAVYYCQQSWYDPLTFGQGTKLEIK
2583	CL-34469	CDR-L1	RASQSVSTHMH
2584	CL-34469	CDR-L2	GASNLES
2585	CL-34469	CDR-L3	QQSWYDPLT
2586	CL-34475 VH		EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYW
			VRQAPGQGLEWMGWIDTETGEPTYADDFKGRFVFSL
			DTSVSTAYLQISSLKAEDTAVYYCARTNYYYSSYMF
			YFDYWGQGTMVTVSS
2587	CL-34475	CDR-H1	GYTFTDYGMY
2588	CL-34475	CDR-H2	WIDTETGEPTYADDFKG
2589	CL-34475	CDR-H3	TNYYYSSYMFYFDY
2590	CL-34475 VL		EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWY
			QQKPGQAPRLLIYGASNLESGIPARFSGSGSGTDFT
			LTISSLEPEDFAVYYCQQSWYDPLTFGQGTKLEIK
2591	CL-34475	CDR-L1	RASQSVSTHMH
2592	CL-34475	CDR-L2	GASNLES
2593	CL-34475	CDR-L3	QQSWYDPLT
2594	CL-34483 VH		EVQLVQSGSELKKPGASVKVSCKASGYTFPNYGMYW
			VRQAPGQGLEWMGWIDTETGEPTYADDFKGRFVFSL
			DTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYMF
			YFDYWGQGTMVTVSS
2595	CL-34483	CDR-H1	GYTFPNYGMY
2596	CL-34483	CDR-H2	WIDTETGEPTYADDFKG
2597	CL-34483	CDR-H3	TNYYYRSYMFYFDY
2598	CL-34483 VL		EIVLTQSPATLSLSPGERATLSCRASQSVATHMHWY
			QQKPGQAPRLLIYGASNLESGVPARFSGSGSGTDFT
			LTISSLEPEDFAVYYCQQSWYDPLTFGQGTKLEIK
2599	CL-34483	CDR-L1	RASQSVATHMH
2600	CL-34483	CDR-L2	GASNLES
2601	CL-34483	CDR-L3	QQSWYDPLT
2602	CL-34489 VH		EVQLVQSGSELKKPGASVKVSCKASGYTFSNYGMYW
			VRQAPGQGLEWMGWIDTETGEPTYADDFKGRFVFSL
			DTSVSTAYLQISSLKAEDTAVYYCARTNYYYSSYMF
			YFDYWGQGTMVTVSS
2603	CL-34489	CDR-H1	GYTFSNYGMY
2604	CL-34489	CDR-H2	WIDTETGEPTYADDFKG
2605	CL-34489	CDR-H3	TNYYYSSYMFYFDY
2606	CL-34489 VL		EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWY
			QQKPGQAPRLLIYGASNLESGIPARFSGSGSGTDFT
			LTISSLEPEDFAVYFCQQSWYDPLTFGQGTKLEIK
2607	CL-34489	CDR-L1	RASQSVSTHMH
2608	CL-34489	CDR-L2	GASNLES
2609	CL-34489	CDR-L3	QQSWYDPLT
2610	CL-34501 VH		EVQLVQSGSELKKPGASVKVSCKASGYTFSDYGMYW
			VRQAPGQGLEWMGWIDTETGDPTYADDFKGRFVFSL
			DTSVSTAYLQISSLKAEDTAVYYCARTNYYYPSYMF
			YFDYWGQGTMVTVSS
2611	CL-34501	CDR-H1	GYTFSDYGMY
2612	CL-34501	CDR-H2	WIDTETGDPTYADDFKG
2613	CL-34501	CDR-H3	TNYYYPSYMFYFDY
2614	CL-34501 VL		EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWY
			QQKPGQAPRLLIYGASILESGVPARFSGSGSGTDFT
			LTISSLEPEDFAVYFCQQTWYDPLTFGQGTKLEIK
2615	CL-34501	CDR-L1	RASQSVSTHMH
2616	CL-34501	CDR-L2	GASILES
2617	CL-34501	CDR-L3	QQTWYDPLT
2618	CL-34513 VH		EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYW
			VRQAPGQGLEWMGWIDTETGEPTYADDFKGRFVFSL
			DTSVSTAYLQISSLKAEDTAVYYCARTNYYYRGYMF
			YFDYWGQGTMVTVSS
2619	CL-34513	CDR-H1	GYTFTDYGMY
2620	CL-34513	CDR-H2	WIDTETGEPTYADDFKG
2621	CL-34513	CDR-H3	TNYYYRGYMFYFDY
2622	CL-34513 VL		EIVLTQSPATLSLSPGERATLSCRASQSVNNHMHWY
			QQKPGQAPRLLIYGASILESGVPARFSGSGSGTDFT
			LTISSLEPEDFAVYFCQQSWYDPLTFGQGTKLEIK
2623	CL-34513	CDR-L1	RASQSVNNHMH
2624	CL-34513	CDR-L2	GASILES
2625	CL-34513	CDR-L3	QQSWYDPLT
2626	CL-34518 VH		EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYW
			VRQAPGQGLEWMGWIDTETGEPTYADDFKGRFVFSL
			DTSVSTAYLQISSLKAEDTAVYYCARTNYYYKSYMF
			YFDYWGQGTMVTVSS
2627	CL-34518	CDR-H1	GYTFTNYGMY
2628	CL-34518	CDR-H2	WIDTETGEPTYADDFKG
2629	CL-34518	CDR-H3	TNYYYKSYMFYFDY
2630	CL-34518 VL		EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWY
			QQKPGQAPRLLIYGASKLESGVPARFSGSGSGTDFT
			LTISSLEPEDFAVYYCQQSWYDPLTFGQGTKLEIK
2631	CL-34518	CDR-L1	RASQSVSTHMH
2632	CL-34518	CDR-L2	GASKLES
2633	CL-34518	CDR-L3	QQSWYDPLT
2634	CL-34522 VH		EVQLVQSGSELKKPGASVKVSCKASGYTFENYGMYW
			VRQAPGQGLEWMGWIDTETGEPTYADDFKGRFVFSL
			DTSVSTAYLQISSLKAEDTAVYYCARTNYYYSSYMF
			YFDYWGQGTMVTVSS
2635	CL-34522	CDR-H1	GYTFENYGMY
2636	CL-34522	CDR-H2	WIDTETGEPTYADDFKG
2637	CL-34522	CDR-H3	TNYYYSSYMFYFDY
2638	CL-34522 VL		EIVLTQSPATLSLSPGERATLSCRASQSVGTHMHWY
			QQKPGQAPRLLIYGASKLESGVPARFSGSGSGTDFT
			LTISSLEPEDFAVYYCQQSWYDPLTFGQGTKLEIK
2639	CL-34522	CDR-L1	RASQSVGTHMH
2640	CL-34522	CDR-L2	GASKLES
2641	CL-34522	CDR-L3	QQSWYDPLT
2642	CL-34537 VH		EVQLVQSGSELKKPGASVKVSCKASGYTFSDYGMYW
			VRQAPGQGLEWMGWIDTETGDPTYADDFKGRFVFSL
			DTSVSTAYLQISSLKAEDTAVYYCARANYYYRSYMF
			YFDYWGQGTMVTVSS
2643	CL-34537	CDR-H1	GYTFSDYGMY
2644	CL-34537	CDR-H2	WIDTETGDPTYADDFKG
2645	CL-34537	CDR-H3	ANYYYRSYMFYFDY
2646	CL-34537 VL		EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWY
			QQKPGQAPRLLIYGASNLESGIPARFSGSGSGTDFT
			LTISSLEPEDFAVYFCQQSWYDPMTFGQGTKLEIK
2647	CL-34537	CDR-L1	RASQSVSTHMH
2648	CL-34537	CDR-L2	GASNLES
2649	CL-34537	CDR-L3	QQSWYDPMT
2650	CL-34538 VH		EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYW
			VRQAPGQGLEWMGWIDTETGEPTYADDFKGRFVFSL
			DTSVSTAYLQISSLKAEDTAVYYCARTNYYYPSYMF
			YFDYWGQGTMVTVSS
2651	CL-34538	CDR-H1	GYTFTDYGMY
2652	CL-34538	CDR-H2	WIDTETGEPTYADDFKG
2653	CL-34538	CDR-H3	TNYYYPSYMFYFDY
2654	CL-34538 VL		EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWY
			QQKPGQAPRLLIYGASNLESGVPARFSGSGSGTDFT
			LTISSLEPEDFAVYFCQQTWYDPLTFGQGTKLEIK
2655	CL-34538	CDR-L1	RASQSVSTHMH
2656	CL-34538	CDR-L2	GASNLES
2657	CL-34538	CDR-L3	QQTWYDPLT
2658	CL-34540 VH		EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYW
			VRQAPGQGLEWMGWIDTETGQPTYADDFKGRFVFSL
			DTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYMF
			YFDYWGQGTMVTVSS
2659	CL-34540	CDR-H1	GYTFTDYGMY
2660	CL-34540	CDR-H2	WIDTETGQPTYADDFKG
2661	CL-34540	CDR-H3	TNYYYRSYMFYFDY
2662	CL-34540 VL		EIVLTQSPATLSLSPGERATLSCRASESVGKHMHWY
			QQKPGQAPRLLIYAASNLESGVPARFSGSGSGTDFT
			LTISSLEPEDFAVYYCQQSWYDPLTFGQGTKLEIK
2663	CL-34540	CDR-L1	RASESVGKHMH
2664	CL-34540	CDR-L2	AASNLES
2665	CL-34540	CDR-L3	QQSWYDPLT
2666	CL-34565 VH		EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYW
			VRQAPGQGLEWMGWIDTETGDPTYADDFKGRFVFSL
			DTSVSTAYLQISSLKAEDTAVYYCARTNYYYRNYMF
			YFDYWGQGTMVTVSS
2667	CL-34565	CDR-H1	GYTFTDYGMY
2668	CL-34565	CDR-H2	WIDTETGDPTYADDFKG
2669	CL-34565	CDR-H3	TNYYYRNYMFYFDY
2670	CL-34565 VL		EIVLTQSPATLSLSPGERATLFCRASQSVSNHMHWY
			QQKPGQAPRLLIYGASILESGVPARFSGSGSGTDFT
			LTISSLEPEDFAVYYCQQSWYDPITFGQGTKLEIK
2671	CL-34565	CDR-L1	RASQSVSNHMH
2672	CL-34565	CDR-L2	GASILES
2673	CL-34565	CDR-L3	QQSWYDPIT
2674	CL-34570 VH		EVQLVQSGSELKKPGASVKVSCKASGYTFDDYGMYW
			VRQAPGQGLEWMGWIDTETGTPTYADDFKGRFVFSL
			DTSVSTAYLQISSLKAEDTAVYYCARTNYYYSSYMF
			YFDYWGQGTMVTVSS
2675	CL-34570	CDR-H1	GYTFDDYGMY
2676	CL-34570	CDR-H2	WIDTETGTPTYADDFKG
2677	CL-34570	CDR-H3	TNYYYSSYMFYFDY
2678	CL-34570 VL		EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWY
			QQKPGQAPRLLIYGASNLESGIPARFSGSGSGTDFT
			LTISSLEPEDFAVYYCQQSWYDPLTFGQGTKLEIK
2679	CL-34570	CDR-L1	RASQSVSTHMH
2680	CL-34570	CDR-L2	GASNLES
2681	CL-34570	CDR-L3	QQSWYDPLT
2682	CL-34603 VH		EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYW
			VRQAPGQGLEWMGWIDTETGEPTYAQGFTGRFVFSL
			DTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYMF
			YFDYWGQGTMVTVSS
2683	CL-34603	CDR-H1	GYTFTDYGMY
2684	CL-34603	CDR-H2	WIDTETGEPTYAQGFTG
2685	CL-34603	CDR-H3	TNYYYRSYMFYFDY
2686	CL-34603 VL		EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWY
			QQKPGQAPRLLIYGASNLESGVPARFSGSGSGTDFT
			LTISSLEPEDFAVYYCQQTWYDPLTFGQGTKLEIK
2687	CL-34603	CDR-L1	RASQSVSTHMH
2688	CL-34603	CDR-L2	GASNLES
2689	CL-34603	CDR-L3	QQTWYDPLT
2690	CL-34605 VH		EVQLVQSGSELKKPGASVKVSCKASGYTFTHYGMYW
			VRQAPGQGLEWMGWIDTETGEPTYADDFKGRFVFSL
			DTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYMF
			YFDYWGQGTMVTVSS
2691	CL-34605	CDR-H1	GYTFTHYGMY
2692	CL-34605	CDR-H2	WIDTETGEPTYADDFKG
2693	CL-34605	CDR-H3	TNYYYRSYMFYFDY
2694	CL-34605 VL		EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWY
			QQKPGQAPRLLIYGASNLESGIPARFSGSGSGTDFT
			LTISSLEPEDFAVYYCQQSFYDPLTFGQGTKLEIK
2695	CL-34605	CDR-L1	RASQSVSTHMH
2696	CL-34605	CDR-L2	GASNLES
2697	CL-34605	CDR-L3	QQSFYDPLT
2698	CL-34633 VH		EVQLVQSGSELKKPGASVKVSCKASGYTFSDYGMYW
			VRQAPGQGLEWMGWIDTETGEPTYADDFKGRFVFSL
			DTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYMF
			YFDYWGQGTMVTVSS
2699	CL-34633	CDR-H1	GYTFSDYGMY
2700	CL-34633	CDR-H2	WIDTETGEPTYADDFKG
2701	CL-34633	CDR-H3	TNYYYRSYMFYFDY
2702	CL-34633 VL		EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWY
			QQKPGQAPRLLIYGASNLESGVPARFSGSGSGTDFT
			LTISSLEPEDFAVYFCQQSWYDPLTFGQGTKLEIK
2703	CL-34633	CDR-L1	RASQSVSTHMH
2704	CL-34633	CDR-L2	GASNLES
2705	CL-34633	CDR-L3	QQSWYDPLT

TABLE 43
Summary of Protein Expression and Purification Affinity
Matured Humanized Anti-Human VEGF-A Antibodies
		Yield	SEC (%
	Name	(mg/L)1	monomer)2
	CL-32416-IgG	28.5	100.0
	CL-34449-IgG	16.1	100.0
	CL-34455-IgG	34.1	100.0
	CL-34469-IgG	21.3	100.0
	CL-34475-IgG	33.6	100.0
	CL-34522-IgG	18.4	100.0
	CL-34538-IgG	40.8	100.0
	CL-34540-IgG	80.0	100.0
	CL-34565-IgG	133.6	100.0
	CL-34570-IgG	28.3	100.0
	CL-34633-IgG	49.9	100.0
	1Yield is determined by the total amount of purified protein in mg divided by the total cell culture volume in liters.
	2SEC % monomer is determined using HPLC size exclusion chromatography.

TABLE 44
Biacore Binding of Affinity Matured Humanized
Anti-VEGF Antibodies
	Antibody	kon (M−1 s−1)	koff (M−1)	KD (M)
	CL-28815-IgG	9.2E+06	1.1E−04	1.2E−11
	(El version of
	parent mAb)
	CL-32416-IgG	2.0E+07	1.1E−05	5.4E−13
	CL-34449-IgG	1.1E+07	9.1E−06	8.5E−13
	CL-34455-IgG	2.2E+07	1.0E−05	4.6E−13
	CL-34469-IgG	1.5E+07	9.5E−06	6.2E−13
	CL-34475-IgG	2.7E+07	1.4E−05	5.2E−13
	CL-34522-IgG	2.0E+07	1.0E−05	5.3E−13
	CL-34538-IgG	3.3E+07	8.1E−06	2.4E−13
	CL-34540-IgG	8.4E+06	7.1E−06	8.5E−13
	CL-34565-IgG	2.0E+07	7.8E−06	4.0E−13
	CL-34570-IgG	1.9E+07	5.5E−06	2.9E−13
	CL-34633-IgG	1.7E+07	4.1E−06	2.4E−13

Affinity matured humanized anti-VEGF antibodies were characterized for hVEGF₁₆₅ binding and potency. Binding affinity of these molecules to hVEGF₁₆₅ was determined by Biacore analysis (Example 1.1). Potency was evaluated in both cell-based and ELISA formats. The ability to block binding of hVEGF₁₆₅ to hVEGFR2 was evaluated in a competition ELISA (Example 1.4) Inhibition of hVEGF₁₆₅-induced cell proliferation was assessed using HMVEC-d cells (Example 1.10). The data is summarized in Table 45 below.

TABLE 45
Summary of Characterization of Affinity Matured Humanized
Anti-Human VEGF-A Antibodies
	hVEGF165 IC50 (nM)
Affinity Matured	VEGFR2	Potency	Potency
Humanized IgG	Competition	HMVEC-d	VEGFR2-3T3
CL-32416-IgG	<0.1	0.117	NT
CL-34449-IgG	<0.1	0.077	NT
CL-34455-IgG	<0.1	0.105	NT
CL-34469-IgG	<0.1	0.094	NT
CL-34475-IgG	<0.1	0.106	NT
CL-34522-IgG	<0.1	0.116	NT
CL-34540-IgG	<0.1	0.139	NT
CL-34633-IgG	<0.1	0.138	NT
CL-34538-IgG	<0.1	0.127	NT
CL-34570-IgG	<0.1	0.11	NT
CL-34565-IgG	<0.1	0.126	NT

Example 8

Affinity Maturation of Anti-Human PDGF-BB Antibody hBDI-9E8

The PDGF-β antibody hBDI-9E8.4 was obtained from rat hybridomas generated at Aldevron and was humanized at AbbVie Bioresearch Center (100 Research Drive, Worcester, Mass. 01605). The human germlines for this clone are VH2-70 and IGKV3-20. To improve the affinity of hBDI-9E8.4, hypermutated CDR residues were identified from other human antibody sequences in the IgBLAST database that also shared high identity to germlines VHVH2-70 and IGKV3-20. The corresponding h9E8.4 CDR residues were then subjected to limited mutagenesis by PCR with primers having low degeneracy at these positions to create three antibody libraries in the scFv format suitable for surface display. To improve the affinity of hBDI-9E8.4 to PDGFβ we generated three antibody libraries in scFv format suitable for surface display. In the first library, residues 30, 32, 34, 35, and 35b in the VH CDR1 and residues 50, 52, 54, 56, 57, 58, 60, 61 and 65 (Kabat numbering) in the VH CDR2 were subjected to limited mutagenesis by primers. In the second library residues 95-100a, 100c and 102 (Kabat numbering) in the VH CDR3 were subjected to limited mutagenesis by primers. In the third library residues 24, 25, 27b, and 29-32 in the VL CDR1, residues 47, 50, 51, 53, 55, and 56 in the VL CDR2 and residues 90, 93-95a, 96 and 97 (Kabat numbering) in the VL CDR3 were subjected to limited mutagenesis by primers.

These hBDI-9E8.4 libraries were displayed to be selected against a low concentration of biotinylated PDGFβ by magnetic then fluorescence activated cell sorting. Selections for improved on-rate, off-rate, or both were carried out and antibody protein sequences of affinity-modulated hBDI-9E8.4 clones.

Table 46 provides a list of amino acid sequences of VH regions of affinity matured humanized PDGF antibodies derived from hBDI-9E8.4. Amino acid residues of individual CDRs of each VH sequence are indicated in bold.

TABLE 46
List of amino Acid Sequences Of Affinity Matured
hBDI-9E8.4 VH Variants
Clone	SEQ ID NO:	VH
CL-22556	2706	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGVGVGWIRQPPGK
		ALEWLANIWWVDEIFYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22557	2707	EVTLRESGPALVKPTQTLTLTCTFSGFSLWTSGMGVVWIRQPPGK
		ALEWLALIDWADVKSYNPSLKNRLTISEDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22558	2708	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGVSVGWIRQPPGK
		ALEWLALIDWYDDMYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22559	2709	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGVRVVWIRQPPGK
		ALEWLANIWWDDYLDYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22560	2710	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMSVGWIRQPPGK
		ALEWLALIDWADDTYYNPSLNNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22561	2711	EVTLRESGPALVKPTQTLTLTCTFSGFSLATYGMSVAWIRQPPGK
		ALEWLALIDWYDDEYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22562	2712	EVTLRESGPALVKPTQTLTLTCTFSGFSLXTYGVGVGWIRQPPGK
		ALEWLANIWWVDDKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22563	2713	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGK
		ALEWLALIDWADDKYYNPSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22564	2714	EVTLRESGPALVKPTQTLTLTCTFSGFSLCTSGVRVRWIRQPPGK
		ALEWLALIDWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22565	2715	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGK
		ALEWLANIWWDDNXYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22567	2716	EVTLRESGPALVKPTQTLTLTCTFSGFSLATSGVSVGWIRQPPGK
		ALEWLALIDWEDDKGYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22569	2717	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMRVGWIRQPPGK
		ALEWLALIDWDDHKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22570	2718	EVTLRESGPALVKPTQTLTLTCTFSGFSLCTSGVGVGWIRQPPGK
		ALEWLALIDWDDDNYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22571	2719	EVTLRESGPALVKPTQTLTLTCTFSGFSLFTYGMGVGWIRQPPGK
		ALEWLALIDWVDDKFYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22572	2720	EVTLRESGPALVKPTQTLTLTCTFSGFSLCTSGVGVGWIRQPPGK
		ALEWLANIWWDDDRYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22573	2721	EVTLRESGPALVKPTQTLTLTCTFSGFSLCTSGMSVGWIRQPPGK
		ALEWLALICWDDDRYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22575	2722	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMRVGWIRQPPGK
		ALEWLALIDWGDDMSYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22576	2723	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPGK
		ALEWLALIDWEDDKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22578	2724	EVTLRESGPALVKPTQTLTLTCTFSGFSLLTYGVGVCWIRQPPGK
		ALEGWLNIWWADGKCYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22581	2725	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGVRVSWIRQPPGK
		ALEWLALIDWDDEECYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22582	2726	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVSWIRQPPGK
		ALEWLALIDWVDDMGYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22583	2727	EVTLRESGPALVKPTQTLTLTCTFSGFSLXTYGMGVGWIRQPPGK
		ALEWLALIDWADYRSYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22584	2728	EVTLRESGPALVKPTQTLTLTCTFSGFSLATYGVGVGWIRQPPGK
		ALEWLALIDWEDAVNYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22585	2729	EVTLRESGPALVKPTQTLTLTCTFSGFSLCTYGMGVCWIRQPPGK
		ALEWLALIGWDDENYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22586	2730	EVTLRESGPALVKPTQTLTLTCTFSGFSLTTYGVRVGWIRQPPGK
		ALEWLALIDWDDDKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22587	2731	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMSVCWIRQPPGK
		ALEWLANIWWDDGCCYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22588	2732	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMRVGWIRQPPGK
		ALEWLALIDWCDDKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22589	2733	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGK
		ALEWLALIDWDDHXHYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22591	2734	EVTLRESGPALVKPTQTLTLTCTFSGFSLWTSGVGVGWIRQPPGK
		ALEWLALIDWEDNKDYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22593	2735	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGVRVGWIRQPPGK
		ALEWLALIDWVDDMYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22595	2736	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVEWIRQPPGK
		ALEWLALIDWDDDKDYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22596	2737	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPGK
		ALEWLALIDWCDNRYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22597	2738	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMRVGWIRQPPGK
		ALEWLALIDWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22598	2739	EVTLRESGPALVKPTQTLTLTCTFSGFSLRTYGVSVGWIRQPPGK
		ALEWLALIDWYDGKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22599	2740	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVDWIRQPPGK
		ALEWLALIDWEDDKSYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22600	2741	EVTLRESGPALVKPTQTLTLTCTFSGFSLWTYGVSVRWIRQPPGK
		ALEWLALIDWDDVKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22601	2742	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGK
		ALEWLALIDWDDDKFYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22602	2743	EVTLRESGPALVKPTQTLTLTCTFSGFSLPTYGVRVGWIRQPPGK
		ALEWLANIWWVDNKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22603	2744	EVTLRESGPALVKPTQTLTLTCTFSGFSLXTSGVRVGWIRQPPGK
		ALEWLALIDWDDYQYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22604	2745	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGVSVGWIRQPPGK
		ALEWLANIWWYDLKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22605	2746	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGVGVGWIRQPPGK
		ALEWLALIDWDDDKCYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22606	2747	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGVSVGWIRQPPGK
		ALEWLANIWWDDEKAYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22607	2748	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGVGVSWIRQPPGK
		ALEWLALIDWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22608	2749	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLALIDWDDDKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22609	2750	EVTLRESGPALVKPTQTLTLTCTFSGFSLPTSGVSVGWIRQPPGK
		ALEWLANIWWADSKFYSTSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22610	2751	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGVSVDWIRQPPGK
		ALEWLALIDWGDQTNYNPSLKNRLTISKDTSKNQVVXTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22611	2752	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGVGVEWIRQPPGK
		ALEWLALIDWYDDKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22612	2753	EVTLRESGPALVKPTQTLTLTCTFSGFSLPTSGVGVGWIRQPPGK
		ALEWLALIDWEDHMDYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22614	2754	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMRVGWIRQPPGK
		ALEWLALIDWXDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22615	2755	EVTLRESGPALVKPTQTLTLTCTFSGFSLTTSGVGVGWIRQPPGK
		ALEWLALIDWYDERFYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22617	2756	EVTLRESGPALVKPTQTLTLTXTFSGFSLSTYGMRVGWIRQPPGK
		ALEWLANIWWADNXSYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22618	2757	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMSVGWIRQPPGK
		ALEWLALIDWADDNYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22619	2758	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGVSVGWIRQPPGK
		ALEWLALIDWEDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22620	2759	EVTLRESGPALVKPTQTLTLTCTFSGFSLWTSGMGVGWIRQPPGK
		ALEWLALIDWDDEKAYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22621	2760	EVTLRESGPALVKPTQTLTLTCTFSGFSLWTSGMRVGWIRQPPGK
		ALEWLANIWWDDDKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22622	2761	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGVSVGWIRQPPGK
		ALEWLALIDWHDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22624	2762	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMSVGWIRQPPGK
		ALEWLALIDWNDNKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22625	2763	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGK
		ALEWLALIDWDDDKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22626	2764	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGVRVCWIRQPPGK
		ALEWLALIDWDDDKSYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22627	2765	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGVSVTWIRQPPGK
		ALEWLALIDWNDDNHYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22628	2766	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGVSVVWIRQPPGK
		ALEWLANIWWDDEKCYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22629	2767	EVTLRESGPALVKPTQTLTLTCTFTGFSLYTSGMGVGWIRQPPGK
		ALEWLALIDWDDDKNYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22630	2768	EVTLRESGPALVKPTQTLTLTCTFSGFSLFTYGVGVDWIRQPPGK
		ALEWLANIWWPDDNYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22631	2769	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGK
		ALEWLALIDWDDDXCYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22633	2770	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGVSVGWIRQPPGK
		ALEWLALIDWDDEKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22634	2771	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGK
		ALEWLALIDWIDDEDYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22635	2772	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGVSVRWIRQPPGK
		ALEWLANIWWDDNKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22636	2773	EVTLRESGPALVKPTQTLTLTCTFSGFSLCTSGMGVGWIRQPPGK
		ALEWLANIWWDDDNYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22637	2774	EVTLRESGPALVKPTQTLTLTCTFSGFSLLTYGMGVGWIRQPPGK
		ALEWLANIWWHDDKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22638	2775	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGVSVAWIRQPPGK
		ALEWLANIWWDDDKYYSTSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22639	2776	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGVRVGWIRQPPGK
		ALEWLALIDWEDYLCYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22640	2777	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGK
		ALEWLALIDWDDDYYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22641	2778	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22642	2779	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPGK
		ALEWLANIWWVDDNYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22643	2780	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVYWIRQPPGK
		ALEWLALIDWDDDNYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22644	2781	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGVSVGWIRQPPGK
		ALEWLALIDWDDGKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22645	2782	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGVRVVWIRQPPGK
		ALEWLALIDWNDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22646	2783	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGVSVVWIRQPPGK
		ALEWLANIWWHDDKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22648	2784	EVTLRESGPALVKPTQTLTLTCTFSGFSLMTSGMSVCWIRQPPGK
		ALEWLANIWWYDHKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22649	2785	EVTLRESGPALVKPTQTLTLTCTFSGFSLRTYGVSVGWIRQPPGK
		ALEWLANIWWDDAKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22650	2786	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGVRVAWIRQPPGK
		ALEWLANIWWDDVKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22651	2787	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIAASYSFDYWGQGTMVTVSS
CL-22652	2788	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARFEYLGAMYXFDYWGQGTMVTVSS
CL-22653	2789	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARXDSFRKPYSFDYWGQGTMVTVSS
CL-22654	2790	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIXSIGSTYWFDYWGQGTMVTVSS
CL-22655	2791	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARLVSIVTKYSFDYWGQGTMVTVSS
CL-22656	2792	XVTLXESGPALXKPTXTLTLTCTFSGFXLSTXGMGVGWIRQPPRK
		ALXWLANXWWDDDKYYNPSLXNRLXISKDTSKNQVVLTMTNMDPV
		DTAXYYCARXXXXXMXYSFDYWGQGTMVTXSX
CL-22658	2793	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARLEPIPMTYSFDYWGQGTMVTVSS
CL-22659	2794	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIEWSAITYSFDYWGQGTMVTVSS
CL-22660	2795	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIECTXNRYXFDYWGQGTMVTVSS
CL-22661	2796	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIECNSTTYSFDYWGQGTMVTVSS
CL-22664	2797	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARLASLCATYYFDYWGQGTMVTVSS
CL-22665	2798	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIGWRLRMYSFDYWGQGTMVTVSS
CL-22666	2799	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIVSIGGTYSFDYWGQGTMVTVSS
CL-22668	2800	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARVESIGTTYYFDYWGQGTMVTVSS
CL-22669	2801	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARYAPIGTTYWFDYWGQGTMVTVSS
CL-22670	2802	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESTRTTYLFDYWGQGTMVTVSS
CL-22671	2803	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESTGTAYSFDYWGQGTMVTVSS
CL-22672	2804	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIASVGTSYSFDYWGQGTMVTVSS
CL-22673	2805	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCAREESTCPTYYFDYWGQGTMVTVSS
CL-22675	2806	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARTESIDRAYSFDYWGQGTMVTVSS
CL-22677	2807	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIGSTGISYSFDYWGQGTMVTVSS
CL-22678	2808	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARRESIGTTYSFDYWGQGTMVTVSS
CL-22679	2809	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARKVTIETAYYFDYWGQGTMVTVSS
CL-22680	2810	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATXYCARFASIGTTYSFDYWGQGTMVTVSS
CL-22681	2811	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARMKSIATTYSFDYWGQGTMVTVSS
CL-22682	2812	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESRRATYSFDYWGQGTMVTVSS
CL-22683	2813	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIGXIGSAYTFDYWGQGTMVTVSS
CL-22685	2814	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARTGSGVTTYSFDYWGQGTMVTVSS
CL-22688	2815	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIGSIESAYSFDYWGQGTMVTVSS
CL-22689	2816	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARVYSKGTTYSFDYWGQGTMVTVSS
CL-22691	2817	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARFEALGLSYSFDYWGQGTMVTVSS
CL-22692	2818	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATXYCARRGTIRTTYSFDYWGQGTMVTVSS
CL-22694	2819	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIYWIGPTYCFDYWGQGTMVTVSS
CL-22695	2820	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESMRTTYSFDYWGQGTMVTVSS
CL-22696	2821	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIRSIVTTYSFDYWGQGTMVTVSS
CL-22698	2822	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARTQSSAMTYSFDYWGQGTMVTVSS
CL-22702	2823	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARNESMGTSYSFDYWGQGTMVTVSS
CL-22703	2824	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIEFVRAIYSFDYWGQGTMVTVSS
CL-22704	2825	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARFESLGETYSFDYWGQGTMVTVSS
CL-22705	2826	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIEAIGNQYSFDYWGQGTMVTVSS
CL-22706	2827	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARKDSMVTTYLFDYWGQGTMVTVSS
CL-22707	2828	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARVEWQGSTYSFDYWGQGTMVTVSS
CL-22708	2829	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYMFDYWGQGTMVTVSS
CL-22709	2830	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARCASVSTTYCFDYWGQGTMVTVSS
CL-22710	2831	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARILSIGNTYSFDYWGQGTMVTVSS
CL-22711	2832	EVTLRESGPALVKPTQTLTLTCTFFGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWCDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESNGNTYSFDYWGQGTMVTVSS
CL-22712	2833	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARRDSTGTPYSFDYWGQGTMVTVSS
CL-22713	2834	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARVESIVTTYYFDYWGQGTMVTVSS
CL-22714	2835	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARLEKFGRTYPFDYWGQGTMVTVSS
CL-22715	2836	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARFKSNRPSYSFDYWGQGTMVTVSS
CL-22716	2837	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSXKNRLXISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLDTTYXFDXXGQGXMXTVSS
CL-22717	2838	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIXATGMLYSFDYWGQGTMVTVSS
CL-22718	2839	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIETTYXFDYWGQGTMVTVSS
CL-22719	2840	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIEXMAPMYSFDYWGQGTMVTVSS
CL-22720	2841	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARVRPLVTIYSFDYWGQGTMVTVSS
CL-22721	2842	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIDSVWTTYSFDYWGQGTMVTVSS
CL-22722	2843	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARVEEIGNTYNFDYWGQGTMVTVSS
CL-22723	2844	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARRGLFRIRYSFDYWGQGTMVTVSS
CL-22724	2845	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRXTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22725	2846	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIEVIGTAYSFDYWGQGTMVTVSS
CL-22726	2847	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARLDVIGMLYAFDYWGQGTMVTVSS
CL-22728	2848	EVTLRESGPALVKPTKTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIMSIGSSYXFDYWGQGTMVTVSS
CL-22729	2849	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIDWIGTTYSFDYWGQGTMVTVSS
CL-22730	2850	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARNSSIGSTYSFDYWGQGTMVTVSS
CL-22731	2851	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESPGTWYSFDYWGQGTMVTVSS
CL-22732	2852	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIEWIGITYCFDYWGQGTMVTVSS
CL-22733	2853	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIEXLGTTYSFDYWGQGTMVTVSS
CL-22734	2854	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARKELTCSTYSFDYWGQGTMVTVSS
CL-22736	2855	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIEXIRMRYSFDYWGQGTMVTVSS
CL-22737	2856	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARKAAIATLYLFDYWGQGTMVTVSS
CL-22738	2857	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARRRPIVTTYSFDYWGQGTMVTVSS
CL-22740	2858	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTVYSFDYWGQGTMVTVSS
CL-22741	2859	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIASIGSMYSFDYWGQGTMVTVSS
CL-22742	2860	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESRATTYSFDYWGQGTMVTVSS
CL-22743	2861	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARNVWLGTTYSFDYWGQGTMVTVSS
CL-22744	2862	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIMSIGTAYSFDYWGQGTMVTVSS
CL-22745	2863	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIKWIWTTYSFDYWGQGTMVTVSS
CL-22746	2864	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIEXRGSTYIFDYWGQGTMVTVSS
CL-22759	2865	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCXRIESIGTTYSFDYWGQGTMVTVSS
CL-22763	2866	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNXDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-22806	2867	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYXFXYWGQGTMVTVSS
CL-22812	2868	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATXYCARIESIGTTYSFDYXGQGTMVTVSS
CL-22819	2869	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCAXIESIGTTYSFDYWGQGTMVTVSS
CL-22833	2870	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYXCARIESIGTTYSXDYWGQGTXVTVSS
CL-25629	2871	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRKPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25633	2872	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNVDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25645	2873	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ELEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25649	2874	EVTLRESGPALVKPTQTLTLTCTFSGFSLATSGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25656	2875	EVTLRESGPALVKPTQTLTLTCTFSGFRLSTYGMGVGWIRKPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25657	2876	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTANYYCARIASIPTMYAFDYWGQGTMVTVSS
CL-25676	2877	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWMANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25679	2878	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDHDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25684	2879	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25696	2880	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGVGVGWIRQPPGK
		ALEWLANIWWDDDKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25697	2881	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRKPPGK
		ALEWLANIWWDDDKYYNPSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25699	2882	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPGK
		ALEWLANIWWDDDRYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25700	2883	EVTLRESGPALVKPTQTLTLTCTFSGFSLMTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25702	2884	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNTSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25710	2885	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLENIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25738	2886	EVTLKKSGPALVKPXQTLTLTCTFSGFSLSTYGMGVGWIRXPPGK
		GLEWLANIWWDDDKYYNPSLKNRLTIXKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25739	2887	EVTLKESGPALVKPTXTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25745	2888	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSX
CL-25749	2889	EVTLRESGPALVKPTXTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25755	2890	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARMKSIGSTYSFDYWGQGTMVTVSS
CL-25763	2891	EVTLKESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25765	2892	EVTLRESGPALVKPTXTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGXMVTVSS
CL-25769	2893	EVTLKESGPALVKPTXTLTLTCTFSGFSLSTYGMGVGWIRHPPGK
		ALEWLANIWWNNDNYYNPSLKNRLTINKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25773	2894	EVTLKESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEGLANIWWDDDKYYNPSLKNRLTINKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25789	2895	EVTLRESGPALVKPTHTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25791	2896	EVTLKESGPALVKPTQTLTLTCTFSGFRLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25797	2897	EVTLXESGPALVKPTXTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-25815	2898	EVTLKESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTINKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-28144	2899	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESGWTTYSFDYWGQGTMVTVSS
CL-28145	2900	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIWTSYSFDYWGQGTMVTVSS
CL-28146	2901	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIVSSWTIYSFDYWGQGTMVTVSS
CL-28147	2902	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIYSSGTVYSFDYWGQGTMVTVSS
CL-28148	2903	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLGISYSFDYWGQGTMVTVSS
CL-28149	2904	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESTGTSYSFDYWGQGTMVTVSS
CL-28151	2905	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLGPSYSFDYWGQGTMVTVSS
CL-28152	2906	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGSSYSFDYWGQGTMVTVSS
CL-28155	2907	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIVSIGWSYSFDYWGQGTMVTVSS
CL-28156	2908	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIYSDWTIYSFDYWGQGTMVTVSS
CL-28157	2909	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSWITYSFDYWGQGTMVTVSS
CL-28160	2910	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESEWTTYNFDYWGQGTMVTVSS
CL-28161	2911	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSPTTYSFDYWGQGTMVTVSS
CL-28162	2912	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGISYSFDYWGQGTMVTVSS
CL-28163	2913	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSATIYSFDYWGQGTMVTVSS
CL-28164	2914	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESTGTTYSFDYWGQGTMVTVSS
CL-28167	2915	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTSYSFDYWGQGTMVTVSS
CL-28169	2916	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIVSTWTTYSFDYWGQGTMVTVSS
CL-28170	2917	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLGTSYNFDYWGQGTMVTVSS
CL-28173	2918	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESTWWTYSFDYWGQGTMVTVSS
CL-28175	2919	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSGWSYAFDYWGQGTMVTVSS
CL-28177	2920	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGYSYSFDYWGQGTMVTVSS
CL-28180	2921	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWMANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIETLGISYSFDYWGQGTMVTVSS
CL-28181	2922	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESMWSSYSFDYWGQGTMVTVSS
CL-28182	2923	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIETIGTSYSFDYWGQGTMVTVSS
CL-28186	2924	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIVSDVTTYSFDYWGQGTMVTVSS
CL-28187	2925	EVTLRESGPALVKPTKTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESFGTSYSFDYWGQGTMVTVSS
CL-28189	2926	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIKSIGWTYSFDYWGQGTMVTVSS
CL-28190	2927	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESNFWSYSFDYWGQGTMVTVSS
CL-28195	2928	EVTLRESGPALVKPTHTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIMSLETRYDFYYWGQGTMVTVSS
CL-28196	2929	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESVETSYNFDYWGQGTMVTVSS
CL-28198	2930	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESFWTTYSFDYWGQGTMVTVSS
CL-28204	2931	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESMGTSYSFDYWGQGTMVTVSS
CL-28205	2932	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIWSSYSFDYWGQGTMVTVSS
CL-28208	2933	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGFSYSFDYWGQGTMVTVSS
CL-28212	2934	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESVGPSYSFDYWGQGTMVTVSS
CL-28213	2935	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLGWTYSFDYWGQGTMVTVSS
CL-28215	2936	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESDWTTYSFDYWGQGTMVTVSS
CL-28219	2937	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGPSYSFDYWGQGTMVTVSS
CL-28233	2938	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLVTSYDFDYWGQGTMVTVSS
CL-28235	2939	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESVGTSYNFDYWGQGTMVTVSS
CL-29595	2940	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESTEASYSFDYWGQGTMVTVSS
CL-29596	2941	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESNGASYSFDYWGQGTMVTVSS
CL-29597	2942	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSVTTYSFDYWGQGTMVTVSS
CL-29598	2943	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDNYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARXESXWTSYSFDYWGQGTMVTVSS
CL-29600	2944	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGASYSFDYWGQGTMVTVSS
CL-29601	2945	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESTGRSYGFDYWGQGTMVTVSS
CL-29607	2946	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIETLGTSYSFDYWGQGTMVTVSS
CL-29608	2947	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLGTTYSFDYWGQGTMVTVSS
CL-29611	2948	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIPTAYSFDYWGQGTMVTVSS
CL-29612	2949	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLGTTYSFDYWGQGTMVTVSS
CL-29613	2950	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARLESIATTYSFDYWGQGTMVTVSS
CL-29614	2951	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGPSYSFDYWGHGTMVTVSS
CL-29617	2952	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSYTSYSFDYWGQGTMVTVSS
CL-29618	2953	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESTWTSYSFDYWGQGTMVTVSS
CL-29620	2954	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSVTNYQFDYWGQGTMVTVSS
CL-29621	2955	EVTLRESGPALVKPTQTLTLICTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTSYSFDYWGQGTMVTVSS
CL-29625	2956	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLGPAYSFDYWGQGTMVTVSS
CL-29627	2957	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSNNQVVLTMTNMDPV
		DTATYYCARIESFGSSYSFDYWGQGTMVTVSS
CL-29629	2958	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSETTYTFDYWGQGTMVTVSS
CL-29630	2959	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIWTTYSFDYWGQGTMVTVSS
CL-29631	2960	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNLLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESFGTSYSFDYWGQGTMVTVSS
CL-29632	2961	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIASXGTSYSFDYWGQGTMVTVSS
CL-29634	2962	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDEKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTSYSFDYWGQGTMVTVSS
CL-29635	2963	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSPTSYSFDYWGQGTMVTVSS
CL-29636	2964	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGWSYAFDYWGQGTMVTVSS
CL-29637	2965	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGWTYSFDYWGQGTMVTVSS
CL-29638	2966	EVTLRESGPALVKPTQTLTLTCTFSGFSLATSGVSVLWIRQPPGK
		ALEWLANIWWDDGXYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESFGTSYSFDYWGQGTMVTVSS
CL-29639	2967	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLWTTYSFDYWGQGTMVTVSS
CL-29643	2968	EVTLRESGPALVKPTQTLTLTCTFSGFSLDTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSGYTYSFDYWGQGTMVTVSS
CL-29644	2969	EVTLRESGPALVKPTQTLTLTCTFSGFSLTTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSGSSYSFDYWGQGTMVTVSS
CL-29645	2970	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARVASSWVEYSFDYWGQGTMVTVSS
CL-29647	2971	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESFGTSYSFDYWGQGTMVTVSS
CL-29648	2972	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSGTTYSFDYWGQGTMVTVSS
CL-29649	2973	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRKPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESMGISYSFDYWGQGTMVTVSS
CL-29651	2974	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGIAYSFDYWGQGTMVTVSS
CL-29654	2975	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIXWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIVTTYSFDYWGQGTMVTVSS
CL-29658	2976	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESGWTIYSFDYWGQGTMVTVSS
CL-29662	2977	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLGPTYSFDYWGQGTMVTVSS
CL-29663	2978	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESVGTSYSFDYWGQGTMVTVSS
CL-29665	2979	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPGK
		ALEWLANIWWDDDQYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSWTTYSFDYWGQGTMVTVSS
CL-29667	2980	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESFGPSYSFDYWGQGTMVTVSS
CL-29668	2981	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSGTSYSFDYWGQGTMVTVSS
CL-29673	2982	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARXXSIVTTYSFDYWGQGTMVTVSS
CL-29674	2983	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTSYSFDYWGQGTMVTVSS
CL-29676	2984	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGLIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESVGTSYSFDYWGQGTMVTVSS
CL-29678	2985	EVTLKESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIGSSGTTYSFDYWGQGTMVTVSS
CL-29679	2986	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNTSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIDSFGAIYSFDYWGQGTMVTVSS
CL-29680	2987	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ELEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		ETATYYCARIESIGTAYNFDYWGQGTMVTVSS
CL-29683	2988	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLGTSYSFDYWGQGTMFTVSS
CL-29688	2989	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLGTSYSFDYWGQGTMVTVSS
CL-29689	2990	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIEAKGTTYSFDYWGQGTMVTVSS
CL-29699	2991	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESRGTSYSFDYWGQGTMVTVSS
CL-29706	2992	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESMGPTYSFDYWGQGTMVTVSS
CL-29707	2993	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIETSYSFDYWGQGTMVTVSS
CL-29709	2994	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYRARIESLGTTYSFDYWGQGTMVTVSS
CL-29711	2995	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRHPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESMGTSYSFDYWGQGTMVTVSS
CL-29713	2996	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESMGTTYSFDYWGQGTMVTVSS
CL-29714	2997	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCALIESSGTTYSFDYWGQGTMVTVSS
CL-29720	2998	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESKGVSYSFDYWGQGTMVTVSS
CL-29721	2999	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIPTTYSFDYWGQGTMVTVSS
CL-29727	3000	EVTLRESXPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ELEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLGTTYSFDYWGQGTMVTVSS
CL-29728	3001	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLGITYSFDYWGQGTMVTVSS
CL-29730	3002	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESMGRSYSFDYWGQGTMVTVSS
CL-29731	3003	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIATSYSFDYWGQGTMVTVSS
CL-29732	3004	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYNFDYWGQGTMVTVSS
CL-29735	3005	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESMGPMYSFDYWGQGTMVTVSS
CL-29736	3006	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTAYSFDYWGQGTMVTVSS
CL-29738	3007	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARMESSWTTYSFDYWGQGTMVTVSS
CL-29739	3008	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESTGATYSFDYWGQGTMVTVSS
CL-29740	3009	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESMGPKYSFDYWGQGTMVTVSS
CL-29742	3010	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESMGMSYSFDYWGQGTMVTVSS
CL-29744	3011	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGLSYSFDYWGQGTMVTVSS
CL-29745	3012	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYRARIESLGMSYSFDYWGQGTMVTVSS
CL-29746	3013	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARLXSTGTNYSFDYWGQGTMVTVSS
CL-29748	3014	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSDTIYSFDYWGQGTMVTVSS
CL-29749	3015	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVDWIRQPPGK
		ALEWLALIDWDDDIHYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-29751	3016	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESVGTTYSFDYWGQGTMVTVSS
CL-29753	3017	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWYDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESTGTTYSFDYWGQGTMVTVSS
CL-29756	3018	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARNESFGRMYXFDYWGQGTMVTVSS
CL-29757	3019	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARXESIGTTYSFDYWGQGTMVTVSS
CL-29758	3020	EVTLRESGPSLVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESFGTTYSFDYWGQGTMVTVSS
CL-29759	3021	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIETLGTAYSFDYWGQGTMVTVSS
CL-29761	3022	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESFGSSYSFDYWGQGTMVTVSS
CL-29763	3023	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESGPTTYSFDYWGQGTMVTVSS
CL-29765	3024	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTMYSFDYWGQGTMVTVSS
CL-29771	3025	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESTXTTYSXDYWGQGTMVTVSS
CL-29772	3026	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGITYSFDYWGQGTMVTVSS
CL-29773	3027	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESMETTYSFDYWGQGTMVTVSS
CL-29776	3028	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESNAITYSFDYWGQGTMVTVSS
CL-29777	3029	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSETTYMFDYWGQGTMVTVSS
CL-29780	3030	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLTNIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESMGTSYSFDYWGQGTMVTVSS
CL-29786	3031	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIYSIGTSYSFDYWGQGTMVTVSS
CL-33292	3032	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSPWTYSFDYWGQGTMVTVSS
CL-33332	3033	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESRPDTYSFDYWGQGTMVTVSS
CL-33361	3034	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIQSSASNYEFDYWGQGTMVTVSS
CL-33368	3035	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIQSGWTNXEFDYWGQGTMVTVSS
CL-33583	3036	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIQSIWTRYDFDYWGQGTMVTVSS
CL-33588	3037	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIQSFATNYEFDYWGQGTMVTVSS
CL-33591	3038	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESVPWSYSFDYWGQGTMVTVSS
CL-33592	3039	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESTPFSYSFDYWGQGTMVTVSS
CL-33599	3040	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSWTSYDFDYWGQGTMVTVSS
CL-33601	3041	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIQSSSTNYEFDYWGQGTMVTVSS
CL-33612	3042	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIQSSWRRYEFDYWGQGTMVTVSS
CL-33616	3043	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIKTSATNYDFDYWGQGTMVTVSS
CL-33618	3044	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSAFSYNFDYWGQGTMVTVSS
CL-33626	3045	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVFLTMTNMDPV
		DTATYYCARIVSSLTEYNFDYWGQGTMVTVSS
CL-33627	3046	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESRVDSYSFDYWGQGTMVTVSS
CL-33628	3047	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESTWTSYDFDYWGQGTMVTVSS
CL-33654	3048	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESVAWRYDFDYWGQGTMVTVSS
CL-33657	3049	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLPTSYNFDYWGQGTMVTVSS
CL-33663	3050	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSPFTYSFDYWGQGTMVTVSS
CL-33665	3051	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESDYTKYDFDYWGQGTMVTVSS
CL-33667	3052	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLPTRYDFDYWGQGTMVTVSS
CL-33674	3053	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWMANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIPTSYSFDYWGQGTMVTVSS
CL-33679	3054	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESKPTSYSFDYWGQGTMVTVSS
CL-33680	3055	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSWTTYSFDYWGQGTMVTVSS
CL-33687	3056	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTSYSFDYWGQGTMVTVSS
CL-33688	3057	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTFKNQVVLTMTNMDPV
		DTATYYCARIESIPTSYSFDYWGQGTMVTVSS
CL-33690	3058	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDETYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESDFTSYMFDYWGQGTMVTVSS
CL-33693	3059	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESNWWSYSFDYWGQGTMVTVSS
CL-33696	3060	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSFTTYSFDYWGQGTMVTVSS
CL-33698	3061	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESXGXSYSFDYWGQGTMVTVSS
CL-33705	3062	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESRLDTYSFDYWGQGTMVTVSS
CL-33707	3063	EVTLRESGPALVKPTQTLTLTCTFSGFSLDTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTSYSFDYWGQGTMVTVSS
CL-33709	3064	EVTLRESGPALVKPTQTLTLTCTFSGFSLATSGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIPWSYSFDYWGQGTMVTVSS
CL-33711	3065	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESTGYSYSFDYWGQGTMVTVSS
CL-33712	3066	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRKPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSWTSYSFDYWGQGTMVTVSS
CL-33722	3067	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSFFSYSFDYWGQGTMVTVSS
CL-33725	3068	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDEYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLGTSYSFDYWGQGTMVTVSS
CL-33734	3069	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLPGSYDFDYWGQGTMVTVSS
CL-33735	3070	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ELEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESNPLTYSFDYWGQGTMVTVSS
CL-33741	3071	EVTLRESGPALVKPTKTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGISYSFDYWGQGTMVTVSS
CL-33743	3072	EVTLRESGPALVKPTQTLTLTCTFSGFSLATYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLPTSYSFDYWGQGTMVTVSS
CL-33745	3073	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSPFAYSFDYWGQGTMVTVSS
CL-33746	3074	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSWFTYAFDYWGQGTMVTVSS
CL-33747	3075	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIETIXPKYSFDYWGQGTMVTVSS
CL-33754	3076	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSWTTYAFDYWGQGTMVTVSS
CL-33755	3077	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSEWTYSFDYWGQGTMVTVSS
CL-33756	3078	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIQSSWTTYEFDYWGQGTMVTVSS
CL-33760	3079	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIETLGSSYSFDYWGQGTMVTVSS
CL-33766	3080	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRKPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSFTSYSFDYWGQGTMVTVSS
CL-33770	3081	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESGGISYSFDYWGQGTMVTVSS
CL-33773	3082	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLPTTYSFDYWGQGTMVTVSS
CL-33777	3083	EVTLRESGPALVKPTQTLTLTCTFSGFSLYTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESVGTSYSFDYWGQGTMVTVSS
CL-33781	3084	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSWYSYNFDYWGQGTMVTVSS
CL-33782	3085	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSWRSYCFDYWGQGTMVTVSS
CL-33784	3086	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSPMSYSFDYWGQGTMVTVSS
CL-33789	3087	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLPTSYCFDYWGQGTMVTVSS
CL-33791	3088	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSWWTYSFDYWGQGTMVTVSS
CL-33794	3089	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESRPTSYCFDYWGQGTMVTVSS
CL-33795	3090	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESVPTSYSFDYWGQGTMVTVSS
CL-33798	3091	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIQSDGPMYSFDYWGQGTMVTVSS
CL-33802	3092	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESTGASYSFDYWGQGTMVTVSS
CL-33813	3093	EVTLRESGPALVKPTQTLTLTCTFSGFSLYTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLPTSYSFDYWGQGTMVTVSS
CL-33814	3094	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDTV
		DTATYYCARIESTPWSYSFDYWGQGTMVTVSS
CL-33816	3095	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSWTSYAFDYWGQGTMVTVSS
CL-33823	3096	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ELEWLANIWWDDDKYYNPSLNNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSGPKYSFDYWGQGTMVTVSS
CL-33833	3097	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGWSYSFDYWGQGTMVTVSS
CL-33840	3098	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSAWTYSFDYWGQGTMVTVSS
CL-33842	3099	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESYGPKYSFDYWGQGTMVTVSS
CL-33844	3100	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKTRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIETSWWKYSFDYWGQGTMVTVSS
CL-33847	3101	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNLSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSPTSYSFDYWGQGTMVTVSS
CL-33849	3102	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIVSSYFTYSFDYWGQGTMVTVSS
CL-33858	3103	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDEEYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGISYSFDYWGQGTMVTVSS
CL-33861	3104	EVTLRESGPALVKPTQTLTLTCTFSGFSLYTSGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSWTTYSFDYWGQGTMVTVSS
CL-33862	3105	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIPTRYDFDYWGQGTMVTVSS
CL-41180	3106	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNRVVLTMTNMDPV
		DTATYYCARIVSDWTTYSFDYWGQGTMVTVSS
CL-41185	3107	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTDMDPV
		DTATYYCARIESSWTTYSFDYWGQGTMVTVSS
CL-41193	3108	RXHWRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIETFGPKYSFDYWGQGTMVTVSS
CL-41204	3109	RGNTEESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTTTYYCARIESLPTSYSFDYWGQGTMVTVSS
CL-41213	3110	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLXTNYSFDYWGQGTMVTVSS
CL-41224	3111	EVTLREGGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESHWWSYAFDYWGQGTMVTVSS
CL-41229	3112	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSFTSYSFDYWGQGTMVTEXC
CL-41232	3113	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESHWWSYAFDYWGQGTMVTVSS
CL-41233	3114	RXHXGESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSWTTYSFDYWGQGTMVTVSS
CL-41246	3115	EVTLRESGPALAKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESHWWSYAFDYWGQGTMVTVSS
CL-41252	3116	EVTLRESGPALVKPTQTLTLTCAFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSWTTYSFDYWGQGTMVTVSS
CL-41255	3117	EVTLRESGPALVEPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESNPWKYSFDYWGQGTMVTVSS
CL-41257	3118	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESNWRTYSFDYWGQGTMVTVSS
CL-41260	3119	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSFTSYSFDYWGQGTMVTVSS
CL-41261	3120	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESHWWSYAFDYWGQGTMVTVSI
CL-41262	3121	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIVSDWTTYSFDYWGQGTMVTVSS
CL-41268	3122	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLGWSYSFDYWGQGTMVTVSS
CL-41269	3123	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLPTSYSFDYWGQGTMVTVSS
CL-41270	3124	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSWTTYSFDYWGQGTMVTVSS
CL-41272	3125	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESNPWKYSFDYWGQGTMVTVSS
CL-41273	3126	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIETFGPKYSFDYWGQGTMVTVSS
CL-41276	3127	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGIGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESMGPKYAFDYWGQGTMVTVSS
CL-41283	3128	EVTLRESGPALVKPTQTLTLTRTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIPTSYSFDYWGQGTMVTVSS
CL-41325	3129	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRKPPGK
		ALEWLANIWWDGDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSGPKYSFDYWGQGTMVTVSS
CL-41342	3130	EVTLRESGPALVKPTQTLTLACTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESVWTKYYFDXGGQGTMVTVSS
CL-41348	3131	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYEMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTPKNQVVLTMTNMDPV
		DTATYYCARIESVWTRYDFDYWGQGTMVKXVV
CL-41353	3132	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESLGTSYSFDYWGQGTMVTVSS
CL-41358	3133	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGPKYSFDYWGQGTMVTVSS
CL-41361	3134	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESVWTRYDFDYWGQGTMVTVSS
CL-41362	3135	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIETMGPKYSFDYWGQGTMVTVSS
CL-41365	3136	RGNTRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALKWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGPKYSFDYWGQGTMVTVSS
CL-41366	3137	EVTLRESGPAQVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIPTSYSFDYWGQGTMVTVSS
CL-41367	3138	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRKPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSGPKYSFDYWGQGTMVTVSS
CL-41368	3139	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGPKYSFDXGGQGTMVTVSS
CL-41369	3140	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIPTSYSFDYWGQGTMVTVSS
CL-41376	3141	EVKLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIQTIGTNYSFDYWGQGTMVTVSS
CL-41377	3142	EGQLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSWTSYSFDYWGQGTMVTVSS
CL-41381	3143	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSWTSYSFDYWGQSTMVTVSS
CL-41385	3144	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSWTSYSFDYWGQGTIVTVSS
CL-41399	3145	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKSRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSWTSYSFDYWGQGTMVTVSS
CL-41405	3146	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTAAYYCARIETIGPKYSFDYWGQGTMVTVSS
CL-41411	3147	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIQSGWTNYEFDYWGQGTMVTVVV
CL-41420	3148	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIQSMWTRYDFDYWGQGTMVTVSS
CL-41425	3149	RXHXRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSGPKYSFDYWGQGTMVTVSS
CL-41427	3150	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DAATYYCARIQSGWTNYEFDYWGQGTMVTVSS
CL-41436	3151	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSWTSYSFDYWSQGTMVTVSS
CL-41439	3152	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIETIGPKYSFDYWGQGTMVTVSS
CL-41443	3153	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSGPKYSFDYWGQGTMVTVSS
CL-41446	3154	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSWTSYSFDYWGQGTMVTVSS
CL-41447	3155	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQAVLTMTNMDPV
		DTATYYCARIQSGWTNYEFDYWGQGTMVTVSS
CL-41448	3156	RGNTEKSGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSWTSYSFDYWGQGTMVTVSS
CL-41449	3157	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIQSGWTNYEFDYWGQGTMVTVSS
CL-41452	3158	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMEXVVR
CL-41459	3159	EVTLRESGPALVKPTQTLTLTCTFSGFILSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-41463	3160	EVTLRESGPALVKSTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS
CL-41465	3161	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSS

Table 47 provides a list of amino acid sequences of VL regions of affinity matured humanized PDGF antibodies derived from hBDI-9E8.4. Amino acid residues of individual CDRs of each VL sequence are indicated in bold.

TABLE 47
List of Amino Acid Sequences Of Affinity
Matured hBDI-9E8.4 VL Variants
Clone	SEQ ID NO:	VL
CL-22656	3162	EIVLTQSXGTLSLSPGXRXTLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-22715	3163	EIVLXQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-22747	3164	EIVLTQSPGTLSLSPGERATLSCERSSGSIWYSYVSWYQQKPGQ
		APRLVIYADDQRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINKDLTFGGGTKVEIK
CL-22748	3165	EIVLTQSPGTLSLSPGERATLSCERSSGSIGYSYVSWYQQKPGQ
		APRLVIYAADQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGIIIDITFGGGTKVEIK
CL-22749	3166	EIVLTQSPGTLSLSPGERATLSCERSSGSIEHAYVSWYQQKPGQ
		APRLLIYGADHRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDFNNTITFGGGTKVEIK
CL-22750	3167	EIVLTQSPGTLSLSPGERATLSCERSSGDIGHCYVSWYQQKPGQ
		APRLVIYAADHRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGKNIDGTFGGGTKVEIK
CL-22752	3168	EIVLTQSPGTLSLSPGERATLSCRASSGDIGDFCVSWYQQKPGQ
		APRLLIYVDDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGRRLDITFGGGTKVEIK
CL-22753	3169	EIVLTQSPGTLSLSPGERATLSCERSSGDIVLPYVSWYQQKPGQ
		APRLVIYAADWRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYDITIDTVFGGGTKVEIK
CL-22754	3170	EIVLTQSPGTLSLSPGERATLSCRASSGSIGYECVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDRQIVFGGGTKVEIK
CL-22755	3171	EIVLTQSPGTLSLSPGERATLSCRASSGSIVGSYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGVHIDITFGGGTKVEIK
CL-22756	3172	EIVLTQSPGTLSLSPGERATLSCERSSGDIGHSDVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIGQVFGGGTKVEIK
CL-22758	3173	EIVLTQSPGTLSLSPGERATLSCRASSGSIGHPYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGCHIYNVFGGGTKVEIK
CL-22759	3174	EIVLTQSPGTLSLSPGERATLSCERSSGSICDTYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIYIHIVFGGGTKVEIK
CL-22760	3175	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYSCVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGIDIVIVFGGGTKVEIK
CL-22761	3176	EIVLTQSPGTLSLSPGERATLSCERSSGSIGYSDVSWYQQKPGQ
		APRLLIYADDKRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDKYIVFGGGTKVEIK
CL-22763	3177	EIVLTQSPGTLSLSPGERATLSCERSSGDIWHFYVSWYQQKPGQ
		APRLVIYAADHRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGTNIEIVFGGGTKVEIK
CL-22764	3178	EIVLTQSPGTLSLSPGERATLSCERSSGDIGXADVSWYQQKPGQ
		APRLVIYVDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGEYIDRTFGGGTKVEIK
CL-22765	3179	EIVLTQSPGTLSLSPGERATLSCRASSGSIGGSYVSWYQQKPGQ
		APRLLIYADDHRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGINIGTVFGGGTKVEIK
CL-22766	3180	EIVLTQSPGTLSLSPGERATLSCERSSGDIECDFVSWYQQKPGQ
		APRLVIYADDHRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGINNDITFGGGTKVEIK
CL-22767	3181	EIVLTQSPGTLSLSPGERATLSCERSSGDIGCSYVSWYQQKPGQ
		APRLVIYGDDQRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINKEITFGGGTKVEIK
CL-22768	3182	EIVLTQSPGTLSLSPGERATLSCERSSGSIGHSRVSWYQQKPGQ
		APRLVIYVDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDNNIATVFGGGTKVEIK
CL-22769	3183	EIVLTQSPGTLSLSPGERATLSCERSSGSINHCHVSWYQQKPGQ
		APRLVIYAADXRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIILDITFGGGTKVEIK
CL-22770	3184	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDHRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYDFDIDITFGGGTKVEIK
CL-22771	3185	EIVLTQSPGTLSLSPGERATLSCRASSGSIRYTYVSWYQQKPGQ
		APRLVIYAADEPPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINRNIVFGGGTKVEIK
CL-22772	3186	EIVLTQSPGTLSLSPGERATLSCERSSGDIGCTYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGISTVLVFGGGTKVEIK
CL-22773	3187	EIVLTQSPGTLSLSPGERATLSCERSSGDIRYCYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDVDIVFGGGTKVEIK
CL-22774	3188	EIVLTQSPGTLSLSPGERATLSCRASSGSISQSYVSWYQQKPGQ
		APRLVIYADDLRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGINIDITFGGGTKVEIK
CL-22775	3189	EIVLTQSPGTLSLSPGERATLSCERSSGSIFYGCVSWYQQKPGQ
		APRLLIYADDQRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYDINIVITFGGGTKVEIK
CL-22776	3190	EIVLTQSPGTLSLSPGERATLSCRASSGSIWYSYVSWYQQKPGQ
		APRLVIYAADQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINKYAVFGGGTKVEIK
CL-22777	3191	EIVLTQSPGTLSLSPGERATLSCRASSGDISYSYVSWYQQKPGQ
		APRLVIYVDDERASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYDIYKDLTFGGGTKVEIK
CL-22778	3192	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDXRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYDSNIDIVFGGGTKVEIK
CL-22779	3193	EIVLTQSPGTLSLSPGERATLSCERSSGSICYXYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYDVNLEHTFGGGTKVEIK
CL-22780	3194	EIVLTQSPGTLSLSPGERATLSCRASSGDIRHCYVSWYQQKPGQ
		APRLLIYPDDLRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-22781	3195	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYVDDHRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGTSLDNTFGGGTKVEIK
CL-22782	3196	EIVLTQSPGTLSLSPGERATLSCERSSGDIGHSYVSWYQQKPGQ
		APRLVIYAADHRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGVNIYITFGGGTKVEIK
CL-22783	3197	EIVLTQSPGTLSLSPGERATLSCRASSGSIRYSYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYDINKVIVFGGGTKVEIK
CL-22784	3198	EIVLTQSPGTLSLSPGERATLSCERSSGDIGKPTSPWYQQKPGQ
		APRLVIYSADERPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGVNRDIVFGGGTKVEIK
CL-22785	3199	EIVLTQSPGTLSLSPGERATLSCERSSGSIGPCYVSWYQQKPGQ
		APRLVIYADDHRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYDINLVITFGGGTKVEIK
CL-22786	3200	EIVLTQSPGTLSLSPGERATLSCERSSGSIHYSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGISIDITFGGGTKVEIK
CL-22787	3201	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDPYVSWYQQKPGQ
		APRLVIYAADPRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYDISIYIVFGGGTKVEIK
CL-22788	3202	EIVLTQSPGTLSLSPGERATLSCERSSGDIKHCCVSWYQQKPGQ
		APRLVIYLDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYDISIDITFGGGTKVEIK
CL-22789	3203	EIVLTQSPGTLSLSPGERATLSCRASSGSIVQSYVSWYQQKPGQ
		APRLLIYSDDPRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGLYRDITFGGGTKVEIK
CL-22790	3204	EIVLTQSPGTLSLSPGERATLSCRASSGSISYSYVSWYQQKPGQ
		APRLLIYADDXRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQHYDIHINITFGGGTKVEIK
CL-22791	3205	EIVLTQSPGTLSLSPGERATLSCRASSGDIGYAHVSWYQQKPGQ
		APRLLIYGDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGKNSEITFGGGTKVEIK
CL-22792	3206	EIVLTQSPGTLSLSPGERATLSCRASSGSIGHSYVSWYQQKPGQ
		APRLLIYDDDPRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGINVDIVFGGGTKVEIK
CL-22794	3207	EIVLTQSPGTLSLSPGERATLSCRASSGSIGHSCVSWYQQKPGQ
		APRLVIYSADERASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYDLNTLFVFGGGTKVEIK
CL-22795	3208	EIVLTQSPGTLSLSPGERATLSCRASSGDIGHXYVSWYQQKPGQ
		APRLVIYAADHRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGISIAVVFGGGTKVEIK
CL-22796	3209	EIVLTQSPGTLSLSPGERATLSCERSSGSIGLSYVSWYQQKPGQ
		APRLVIYAADQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYDRHLDATFGGGTKVEIK
CL-22797	3210	EIVLTQSPGTLSLSPGERATLSCERSSGDIGCSYVSWYQQKPGQ
		APRLLIYGADHRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGIDIDITFGGGTKVEIK
CL-22798	3211	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDASVSWYQQKPGQ
		APRLLIYAADQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDITIGVVFGGGTKVEIK
CL-22799	3212	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYCFVSWYQQKPGQ
		APRLVIYAADLRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIKIGITFGGGTKVEIK
CL-22800	3213	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYWDVSWYQQKPGQ
		APRLLIYADDERASGIPDRFSGSGSGTDFTLTISRLEPEDFSVY
		YCQSYGINKDFVFGGGTKVEIK
CL-22801	3214	EIVLTQSPGTLSLSPGERATLSCRASSGDIGHTYVSWYQQKPGQ
		APRLVIYTDDLRASGIPDRFSGSGSGTDFTLTISRLDPEDFAVY
		YCQQYDLNIDIVFGGGTKVEIK
CL-22802	3215	EIVLTQSPGTLSLSPGERATLSCERSSGSIGXSHVSWYQQKPGQ
		APRLLIYVDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIKKGXTFGGGTKVEIK
CL-22803	3216	EIVLTQSPGTLSLSPGERATLSCRASSGDIGHSFVSWYQQKPGQ
		APRLVIYADDHRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGVNIDITFGGGTKVEIK
CL-22804	3217	EIVLTQSPGTLSLSPGERATLSCRASSGSIFQSDVSWYQQKPGQ
		APRLVIYADDHRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGKNIYIVFGGGTKVEIK
CL-22805	3218	EIVLTQSPGTLSLSPGERATLSCRASSGDIGYSAVSWYQQKPGQ
		APRLVXYVDDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIKLDFVFGGGTKVEIK
CL-22806	3219	EIVLTQSPGTLSLSPGERATLSCRASSGSIVYSSVSWYQQKPGQ
		APRLVIYVXDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYDIHIDITFGGGTKVEIK
CL-22807	3220	EIVLTQSPGTLSLSPGERATLSCRASSGSIRDFYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGINLDNTFGGGTKVEIK
CL-22808	3221	EIVLTQSPGTLSLSPGERATLSCERSSGDISDSHVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDITFGGGTKVEIK
CL-22811	3222	EIVLTQSPGTLSLSPGERATLSCERSSGSIALSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINLDIVFGGGTKVEIK
CL-22812	3223	EIVLTQSPGTLSLSPGERATLSCERSSGDMRYSDVSWYQQKPGQ
		APRMVIYAVDQRASGIPDRLSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYDVGMVLTFGGGTKVEIK
CL-22813	3224	EIVLTQSPGTLSLSPGERATLSCRASSGDIGHFYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGISIDLTFGGGTKVEIK
CL-22815	3225	EIVLTQSPGTLSLSPGERATLSCERSSGDIDHSYVSWYQQKPGQ
		APRLVIYADDPRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGLNIDLTFGGGTKVEIK
CL-22816	3226	EIVLTQSPGTLSLSPGERATLSCERSSGSIRHSCVSWYQQKPGQ
		APRLVIYADDHRASGIPDRFSDSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-22818	3227	EIVLTQSPGTLSLSPGERATLSCRASSGDIWHSYVSWYQQKPGQ
		APRLVIYTDDHRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGCDKDITFGGGTKVEIK
CL-22819	3228	EIVLTQSPGTLSLSPGERATLSCRASSGSIGDFYVSWYQQKPGQ
		APRLVIYADDQRPTGIPDRLSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGIHIEIVFGGGTKVEIK
CL-22820	3229	EIVLTQSPGTLSLSPGERATLSCRASSGDIGHSAVSWYQQKPGQ
		APRLLIYADDPRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGKNKELVFGGGTKVEIK
CL-22821	3230	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGINSYLVFGGGTKVEIK
CL-22822	3231	EIVLTQSPGTLSLSPGERATLSCRASSGDIGPSYVSWYQQKPGQ
		APRLLIYPDDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYDINKELVFGGGTKVEIK
CL-22823	3232	EIVLTQSPGTLSLSPGERATLSCERSSGDIWYSYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGKNVDIVFGGGTKVEIK
CL-22824	3233	EIVLTQSPGTLSLSPGERATLSCRASSGSILDTYVSWYQQKPGQ
		APRLVIYADDSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYDVNVDIVFGGGTKVEIK
CL-22825	3234	EIVLTQSPGTLSLSPGERATLSCRASSGSISQSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDXTIGIVFGGGTKVEIK
CL-22826	3235	EIVLTQSPGTLSLSPGERATLSCERSSGSIGFSYVSWYQQKPGQ
		APRLVIYEDDPRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGANIEIVFGGGTKVEIK
CL-22827	3236	EIVLTQSPGTLSLSPGERATLSCRASSGYISHEYVSWYQQKPGQ
		APRLVIYAADQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGIHIHVTFGGGTKVEIK
CL-22828	3237	EIVLTQSPGTLSLSPGERATLSCRASSGDIGHSYVSWYQQKPGQ
		APRLVIYEDDQRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGGNIGIVFGGGTKVEIK
CL-22829	3238	EIVLTQSPGTLSLSPGERATLSCRASSGSIDASYVSWYQQKPGQ
		APRLLIYTDDRRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGIILDIVFGGGTKVEIK
CL-22830	3239	EIVLTQSPGTLSLSPGERATLSCRASSGSIGYSYVSWYQQKPGQ
		APRLLIYADDHRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGVIIYITFGGGTKVEIK
CL-22832	3240	EIVLTQSPGTLSLSPGERATLSCRASSGDIFYSYVSWYQQKPGQ
		APRLVIYADDXRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-22833	3241	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYLYVSWYQQKPGQ
		APXLVIYPDDXRASGIPDRFSGSGSGXDFTLTISRLEPEDXAVY
		YCQQYDKTIDIVFGGGTKVEIK
CL-22834	3242	EIVLTQSPGTLSLSPGERATLSCRASSGDICESCVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINKDIVFGGGTKVEIK
CL-22835	3243	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYSNVSWYQQKPGQ
		APRLLIYEDDKRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGXLVPIVFGGGTKVEIK
CL-22836	3244	EIVLTQSPGTLSLSPGERATLSCERSSGDIGHSYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYGIKVDSTFGGGTKVEIK
CL-22837	3245	EIVLTQSPGTLSLSPGERATLSCERSSGSIQSLHVSWYQQKPGQ
		APRLLIYADDXRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGRHIGLVFGGGTKVEIK
CL-22838	3246	EIVLTQSPGTLSLSPGERATLSCERSSGSIGYCYVSWYQQKPGQ
		APRLVIYADDHRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYDLCIYITFGGGTKVEIK
CL-22839	3247	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSHVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIAITFGGGTKVEIK
CL-22840	3248	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYTYVSWYQQKPGQ
		APRLLIYPDDKRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIIRPTTFGGGTKVEIK
CL-22841	3249	EIVLTQSPGTLSLSPGERATLSCERSSGDIAHSYVSWYQQKPGQ
		APRLVIYAADYRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYDSHNNIVFGGGTKVEIK
CL-22842	3250	EIVLTQSPGTLSLSPGERATLSCRASSGSIRGLRVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGLNFDIVFGGGTKVEIK
CL-25631	3251	EIVLTQSPGTLSLSPGERATLSCRASSGSITYYYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINTDIVFGGGTKVEIK
CL-25634	3252	EFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-25648	3253	EIVLTQSPGTLSLSPGEXATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYVDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-25655	3254	EIVLTQSPGTLSLSPGERXTLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-25666	3255	EIVLTQXPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-25690	3256	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYSDDQRPGGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-25721	3257	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGYGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-25724	3258	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLLIYVDDWRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDIDVVFGGGTKVEIK
CL-25725	3259	EIVLTQSPGTLSLSPGERATLSCERSSGDIDYSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDIVFGGGTKVEIK
CL-25726	3260	EIVLTQSPGTLSLSPGERATLSCRASSGSIGYSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINTDVVFGGGTKVEIK
CL-25727	3261	EIVLTQSPGTLSLSPGERATLSCERSSGDIWYSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIYIDVTFGGGTKVEIK
CL-25728	3262	EIVLTQSPGTLSLSPGERATLSCERSSGSIGYSYVSWYQQKPGQ
		APRLVIYSDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDIVFGGGTKVEIK
CL-25729	3263	EIVLTQSPGTLSLSPGERATLSCERSSGDIAGYYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDITFGGGTKVEIK
CL-25730	3264	EIVLTQSPGTLSLSPGERATLSCERSSGDIGESYVSWYQQKPGQ
		APRLVIYADDLRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIVIDIXFGGGTKVEIK
CL-25731	3265	EIVLTQSPGTLSLSPGERATLSCRASSGSIVYSYVSWYQQKPGQ
		APRLVIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIYIDITFGGGTKVEIK
CL-25732	3266	EIVLTQSPGTLSLSPGERATLSCRASSGDIVYSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDIDVTFGGGTKVEIK
CL-25733	3267	EIVLTQSPGTLSLSPGERATLSCRASSGDIWDAYVSWYQQKPGQ
		APRLLIYADDHRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDITFGGGTKVEIK
CL-25734	3268	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYAYVSWYQQKPGQ
		APRLVIYADDYRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDVDIVFGGGTKVEIK
CL-25735	3269	EIVLTQSPGTLSLSPGERATLSCRASSGDILDSYVSWYQQKPGQ
		APRLVIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDTIIDITFGGGTKVEIK
CL-25736	3270	EIVLTQSPGTLSLSPGERATLSCERSSGDIDDYYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIYIDVTFGGGTKVEIK
CL-25737	3271	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDFYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDVTIDVTFGGGTKVEIK
CL-25738	3272	EIVLTQSPGTLSLSPGERATLSCERSSGDIGLSYVSWYQQKPGQ
		APRLVIYSDDLRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDVDIDVTFGGGTKVEIK
CL-25739	3273	EIVLTQSPGTLSLSPGERATLSCERSSGDIFYTYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLDIDITFGGGTKVEIK
CL-25740	3274	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLLIYADDQRAIGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIYVDVVFGGGTKVEIK
CL-25741	3275	EIVLTQSPGTLSLSPGERATLSCRASSGDIEGSYVSWYQQKPGQ
		APRLVIYSDDLRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDIVFGGGTKVEIK
CL-25742	3276	EIVLTQSPGTLSLSPGERATLSCRASSGDISCSYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINTDIVFGGGTKVEIK
CL-25743	3277	EIVLTQSPGTLSLSPGERATLSCRASSGSIGSYYVSWYQQKPGQ
		APRLVIYSDDQRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIYIDVVFGGGTKVEIK
CL-25745	3278	EIVLTQSPGTLSLSPGERATLSCRASSGDIWYSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIEIDVTFGGGTKVEIK
CL-25747	3279	EIVLTQSPGTLSLSPGERATLSCRASSGDIGYSYVSWYQQKPGQ
		APRLLIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIISDITFGGGTKVEIK
CL-25748	3280	EIVLTQSPGTLSLSPGERATLSCRASSGSIDYAYVSWYQQKPGQ
		APRLVIYADDQRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGITIDVVFGGGTKVEIK
CL-25749	3281	EIVLTQSPGTLSLSPGERATLSCRASSGSIYFAYVSWYQQKPGQ
		APRLVIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGITIDVVFGGGTKVEIK
CL-25751	3282	EIVLTQSPGTLSLSPGERATLSCRASSGSIWYSYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINVDIVFGGGTKVEIK
CL-25752	3283	EIVLTQSPGTLSLSPGERATLSCRASSGDIAHSYVSWYQQKPGQ
		APRLVIYTDDARASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIVDIVFGGGTKVEIK
CL-25754	3284	EIVLTQSPGTLSLSPGERATLSCERSSGDICQYYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLNIDVTFGGGTKVEIK
CL-25756	3285	EIVLTQSPGTLSLSPGERATLSCERSSGSIGDSYVSWYQQKPGQ
		APRLLIYNDDDRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLTIDVTFGGGTKVEIK
CL-25758	3286	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYSYVSWYQQKPGQ
		APRLVIYADDQRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDIVFGGGTKVEIK
CL-25759	3287	EIVLTQSPGTLSLSPGERATLSCERSSGDIGHSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDVDIVFGGGTKVEIK
CL-25760	3288	EIVLTQSPGTLSLSPGERATLSCERSSGSIWDMYVSWYQQKPGQ
		APRLVIYADDQRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIEIDITFGGGTKVEIK
CL-25761	3289	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYGDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDITFGGGTKVEIK
CL-25763	3290	EIVLTQSPGTLSLSPGERATLSCERSSGDIWESYVSWYQQKPGQ
		APRLVIYADDERATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDIVFGGGTKVEIK
CL-25765	3291	EIVLTQSPGTLSLSPGERATLSCRASSGDIAYSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-25767	3292	EIVLTQSPGTLSLSPGERATLSCRASSGSIFGAYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIITDIVFGGGTKVEIK
CL-25769	3293	EIVLTQSPGTLSLSPGERATLSCRASSGSIADSLVSWYQQKPGQ
		APRLVIYTDDWRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-25770	3294	EIVLTQSPGTLSLSPGERATLSCERSSGSIGDSYVSWYQQKPGQ
		APRLLIYTDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDITIDIVFGGGTKVEIK
CL-25771	3295	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDYYVSWYQQKPGQ
		APRLVIYSDDQRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLDIDITFGGGTKVEIK
CL-25772	3296	EIVLTQSPGTLSLSPGERATLSCERSSGSIVHSYVSWYQQKPGQ
		APRLVXYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIXVDIVFGGGTKVEIK
CL-25773	3297	EIVLTQSPGTLSLSPGERATLSCRASSGDIWYSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGITVDIVFGGGTKVEIK
CL-25775	3298	EIVLTQSPGTLSLSPGERATLSCERSSGDIFYSYVSWYQQKPGQ
		APRLVIYADDERASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIEIDIVFGGGTKVEIK
CL-25776	3299	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDVDIVFGGGTKVEIK
CL-25778	3300	EIVLTQSPGTLSLSPGERATLSCERSSGDIGLSYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLIIDIVFGGGTKVEIK
CL-25779	3301	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYSYVSWYQQKPGQ
		APRLVIYSDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDIVFGGGTKVEIK
CL-25780	3302	EIVLTQSPGTLSLSPGERATLSCRASSGDIGYSYVSWYQQKPGQ
		APRLVIYADDERASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIEIDITFGGGTKVEIK
CL-25782	3303	EIVLTQSPGTLSLSPGERATLSCRASSGDIGYSYVSWYQQKPGQ
		APRLLIYFDDYRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIEIDIVFGGGTKVEIK
CL-25783	3304	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYYYVSWYQQKPGQ
		APRLVIYADDERATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIYIDVVFGGGTKVEIK
CL-25784	3305	EIVLTQSPGTLSLSPGERATLSCRASSGDISDSYVSWYQQKPGQ
		APRLVIYTDDHRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDIVFGGGTKVEIK
CL-25785	3306	EIVLTQSPGTLSLSPGERATLSCERSSGSIGDSYVSWYQQKPGQ
		APRLVIYVDDWRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDVDIVFGGGTKVEIK
CL-25786	3307	EIVLTQSPGTLSLSPGERATLSCERSSGDIGHSYVSWYQQKPGQ
		APRLVIYSDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDIVFGGGTKVEIK
CL-25787	3308	EIVLTQSPGTLSLSPGERATLSCERSSGDIWYSYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYDIIDDIVFGGGTKVEIK
CL-25788	3309	EIVLTQSPGTLSLSPGERATLSCRASSGDIGYSYVSWYQQKPGQ
		APRLLIYADDFRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIITDITFGGGTKVEIK
CL-25789	3310	EIVLTQSPGTLSLSPGERATLSCERSSGDIYYSYVSWYQQKPGQ
		APRLVIYSDDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDVTFGGGTKVEIK
CL-25790	3311	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYSYVSWYQQKPGL
		APRLLIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGTYVDIVFGGGTKVEIK
CL-25791	3312	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDTYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRXSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDXVFGGGTKVEIK
CL-25792	3313	EIVLTQSPGTLSLSPGERATLSCERSSGSIWQYYVSWYQQKPGQ
		APRLVIYSDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-25793	3314	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDWRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIYIDIVFGGGTKVEIK
CL-25794	3315	EIVLTQSPGTLSLSPGERATLSCERSSGDIGHSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDTIIDIVFGGGTKVEIK
CL-25795	3316	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDYYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDVVFGGGTKVEIK
CL-25796	3317	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDTIIDIVFGGGTKVEIK
CL-25797	3318	EIVLTQSPGTLSLSPGERATLSCERSSGDIWQYYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLNIDITFGGGTKVEIK
CL-25798	3319	EIVLTQSPGTLSLSPGERATLSCRASSGDIGESYVSWYQQKPGQ
		APRLVIYSDDSRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDIVFGGGTKVEIK
CL-25799	3320	EIVLTQSPGTLSLSPGERATLSCRASSGDIGYSYVSWYQQKPGQ
		APRLVIYADDLRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIIIDIVFGGGTKVEIK
CL-25800	3321	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDYYVSWYQQKPGQ
		APRLVIYWDDYRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDVILDITFGGGTKVEIK
CL-25801	3322	EIVLTQSPGTLSLSPGERATLSCERSSGDISYTYVSWYQQKPGQ
		APRLVIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIITDIVFGGGTKVEIK
CL-25802	3323	EIVLTQSPGTLSLSPGERATLSCERSSGDIGESYVSWYQQKPGQ
		APRLVIYTDDWRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGSNIDVVFGGGTKVEIK
CL-25803	3324	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDYYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGILTDITFGGGTKVEIK
CL-25804	3325	EIVLTQSPGTLSLSPGERATLSCRASSGSIAHSYVSWYQQKPGQ
		APRLVIYSDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIVDIVFGGGTKVEIK
CL-25805	3326	EIVLTQSPGTLSLSPGERATLSCRASSGSIVYSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIITDIVFGGGTKVEIK
CL-25806	3327	EIVLTQSPGTLSLSPGERATLSCERSSGDISYSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDITFGGGTKVEIK
CL-25807	3328	EIVLTQSPGTLSLSPGERATLSCRASSGSIGDTYVSWYQQKPGQ
		APRLLIYADDWRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIEIDIVFGGGTKVEIK
CL-25808	3329	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDTYVSWYQQKPGQ
		APRLVIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDIVFGGGTKVEIK
CL-25809	3330	EIVLTQSPGTLSLSPGERATLSCERSSGSIGETYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGTIIDIVFGGGTKVEIK
CL-25810	3331	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDTYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDIVFGGGTKVEIK
CL-25812	3332	EIVLTQSPGTLSLSPGERATLSCERSSGDIWYSYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDIVFGGGTKVEIK
CL-25813	3333	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLLIYADDYRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIIVDITFGGGTKVEIK
CL-25814	3334	EIVLTQSPGTLSLSPGERATLSCERSSGDIGQSYVSWYQQKPGQ
		APRLVIYSDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDIVFGGGTKVEIK
CL-25815	3335	EIVLTQSPGTLSLSPGERATLSCRESSGDILYTYVSWYQQKPGQ
		APRLVIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIEIDITFGGGTKVEIK
CL-25816	3336	EIVLTQSPGTLSLSPGERATLSCRASSGDIGHSYVSWYQQKPGQ
		APRLVIYADDQRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIIIDVTFGGGTKVEIK
CL-25818	3337	EIVLTQSPGTLSLSPGERATLSCRASSGDISDSYVSWYQQKPGQ
		APRLLIYSDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIIIDIVFGGGTKVEIK
CL-25819	3338	EIVLTQSPGTLSLSPGERATLSCRASSGSIGHSYVSWYQQKPGQ
		APRLVIYGDDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDVDIDVVFGGGTKVEIK
CL-28175	3339	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYVDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-28178	3340	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVCGGGTKVEIK
CL-28195	3341	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPGRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-28212	3342	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDFYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-28215	3343	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDYYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTINRMEPEDFAVY
		YCQSYDINMDIVFGGGTKVEIK
CL-28233	3344	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYGDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-29595	3345	EIVLTQSPGTLSLSPGERATLSCRASSGSISYSYVSWYQQKPGQ
		APRLVIYADDLRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-29596	3346	EIVLTQSPGTLSLSPGERATLSCERSSGDIWYSYVSWYQQKPGQ
		APRLLIYADDQRASGIPYRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINVDTVFGGGTKVEIK
CL-29597	3347	EIVLTQSPGTLSLSPGERATLSCERSSGSIGDAYVSWYQQKPGQ
		APRLVIYSDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIIVDVVFGGGTKVEIK
CL-29598	3348	EIVLTQSPGTLSLSPGERATLSCRASSGSIGDSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIAIDIVFGGGTKVEIK
CL-29599	3349	EIVLTQSPGTLSLSPGERATLSCRASSGSIEYSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIIVDIVFGGGTKVEIK
CL-29600	3350	EIVLTQSPGTLSLSPGERATLSCRASSGSIEGAYVSWYQQKPGQ
		APRLVIYSDDERATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIITDIVFGGGTKVEIK
CL-29601	3351	EIVLTQSPGTLSLSPGERATLSCERSSGSIGGTYVSWYQQKPGQ
		APRLVIYADDLRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIEIDITFGGGTKVEIK
CL-29602	3352	EIVLTQSPGTLSLSPGERATLSCERSSGDIGSCYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDVVFGGGTKVEIK
CL-29603	3353	EIVLTQSPGTLSLSPGERATLSCRASSGDIGYTYVSWYQQKPGQ
		APRLVIYADDVRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDVDIVFGGGTKVEIK
CL-29604	3354	EIVLTQSPGTLSLSPGERATLSCERSSGSIWGYYVSWYQQKPGQ
		APRLVIYADDHRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDITFGGGTKVEIK
CL-29605	3355	EIVLTQSPGTLSLSPGERATLSCERSSGDIGEAYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDITFGGGTKVEIK
CL-29606	3356	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYSYVSWYQQKPGQ
		APRLLIYSDDNRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGTIIDITFGGGTKVEIK
CL-29607	3357	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDITIDIVFGGGTKVEIK
CL-29608	3358	EIVLTQSPGTLSLSPGERATLSCERSSGDIWYSYVSWYQQKPGQ
		APRLLIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLIIDVVFGGGTKVEIK
CL-29609	3359	EIVLTQSPGTLSLSPGERATLSCERSSGDIWHSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDITFGGGTKVEIK
CL-29610	3360	EIVLTQSPGTLSLSPGERATLSCRASSGDIGDSYVSWYQQKPGQ
		APRLVIYADDDRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDVDVTFGGGTKVEIK
CL-29611	3361	EIVLTQSPGTLSLSPGERATLSCRASSGDIAHSYVSWYQQKPGQ
		APRLLIYVDDLRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDITIDIVFGGGTKVEIK
CL-29612	3362	EIVLTQSPGTLSLSPGERATLSCERSSGDIYSYYVSWYQQKPGQ
		APRLLIYSDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLNIDVVFGGGTKVEIK
CL-29613	3363	EIVLTQSPGTLSLSPGERATLSCRASSGDISESYVSWYQQKPGQ
		APRLLIYTDDLRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDTDIVFGGGTKVEIK
CL-29614	3364	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSLVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGVIVDIVFGGGTKVEIK
CL-29615	3365	EIVLTQSPGTLSLSPGERATLSCRASSGDIYESYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDVTIDIVFGGGTKVEIK
CL-29617	3366	EIVLTQSPGTLSLSPGERATLSCERSSGDIGFAYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDIDIVFGGGTKVEIK
CL-29618	3367	EIVLTQSPGTLSLSPGERAPLSCERSSGSIWDSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDVDIDIVFGGGTKVEIK
CL-29620	3368	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDSYVSWYQQKPGQ
		APRLVIYSDDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIIIDITFGGGTKVEIK
CL-29621	3369	EIVLTQSPGTLSLSPGERATLSCRASSGSIGYSYVSWYQQKPGQ
		APRLVIYADDRRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIRDIVFGGGTKVEIK
CL-29622	3370	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIIVDIVFGGGTKVEIK
CL-29623	3371	EIVLTQSPGTLSLSPGERATLSCRASSGSIWYSYVSWYQQKPGQ
		APRLVIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVTFGGGTKVEIK
CL-29624	3372	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDSYVSWYQQKPGQ
		APRLVIYSDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIIIDIVFGGGTKVEIK
CL-29625	3373	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYFYVSWYQQKPGQ
		APRLVIYVDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-29626	3374	EIVLTQSPGTLSLSPGERATLSCRASSGSIGDTYVSWYQQKPGQ
		APRLLIYSDDHRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-29627	3375	EIVLTQSPGTLSLSPGERATLSCRASSGDIWYSFVSWYQQKPGQ
		APRLLIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIISDIVFGGGTKVEIK
CL-29628	3376	EIVLTQSPGTLSLSPGERATLSCERSSGSIGETYVSWYQQKPGQ
		APRLVIYADDLRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIIVDIVFGGGTKVEIK
CL-29629	3377	EIVLTQSPGTLSLSPGERATLSCRASSGDIGDCFVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-29630	3378	EIVLTQSPGTLSLSPGERATLSCRASSGDIRHSFVSWYQQKPGQ
		APRLVIYWDDYRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDVTFGGGTKVEIK
CL-29631	3379	EIVLTQSPGTLSLSPGERATLSCERSSGSIDECYVSWYQQKPGQ
		APRLVIYADDDRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDVVFGGGTKVEIK
CL-29632	3380	EIVLTQSPGTLSLSPGERATLSCERSSGDIGESYVSWYQQKPGQ
		APRLVIYTDDRRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGSNIDVVFGGGTKVEIK
CL-29634	3381	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQQYDIDTDIVFGGGTKVEIK
CL-29635	3382	EIVLTQSPGTLSLSPGERATLSCERSSGDIGHSYVSWYQQKPGQ
		APRLVIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDITFGGGTKVEIK
CL-29636	3383	EIVLTQSPGTLSLSPGERATLSCRASSGDICHSYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIVDIVFGGGTKVEIK
CL-29637	3384	EIVLTQSPGTLSLSPGERATLSCERSSGSINESYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDIDIVFGGGTKVEIK
CL-29638	3385	EIVLTQSPGTLSLSPGERATLSCERSSGSIWYSYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDVTFGGGTKVEIK
CL-29639	3386	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDTYVSWYQQKPGQ
		APRLLIYADDERASRIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDIDVVFGGGTKVEIK
CL-29640	3387	EIVLTQSPGTLSLSPGERATLSCRASSGDIWYSYVSWYQQKPGQ
		APRLVIYADDQRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDITFGGGTKVEIK
CL-29641	3388	EIVLTQSPGTLSLSPGERATLSCERSSGDIWQSYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIVIDITFGGGTKVEIK
CL-29642	3389	EIVLTQSPGTLSLSPGERATLSCERSSGDIWYSYVSWYQQKPGQ
		APRLLIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDIVFGGGTKVEIK
CL-29643	3390	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDYYVSWYQQKPGQ
		APRLVIYSDDQRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLIIDITFGGGTKVEIK
CL-29644	3391	EIVLTQSPGTLSLSPGERATLSCRASSGDIGYTYVSWYQQKPGQ
		APRLVIYSDDHRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIIVDIVFGGGTKVEIK
CL-29645	3392	EIVLTQSPGTLSLSPGERATLSCERSSGDISGAYVSWYQQKPGQ
		APRLVIYGDDERASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDVTFGGGTKVEIK
CL-29646	3393	EIVLTQSPGTLSLSPGERATLSCRASSGDIGRSYVSWYQQKPGQ
		APRLVIYADDLRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDVNTDIVFGGGTKVEIK
CL-29647	3394	EIVLTQSPGTLSLSPGERATLSCERSSGSIWHTYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIIIDITFGGGTKVEIK
CL-29648	3395	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYAYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIILDVTFGGGTKVEIK
CL-29649	3396	EIVLTQSPGTLSLSPGERATLSCRASSGDIEHSYVSWYQQKPGQ
		APRLLIYVDDQRPTGIPDRFSGSGSGTDFTLTISRLXPEDFAVY
		YCQSYGIREDIVFGGGTKVEIK
CL-29650	3397	EIVLTQSPGTLSLSPGERATLSCERSSGSIGFSYVSWYQQKPGQ
		APRLVIYADDLRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGTYVDVVFGGGTKVEIK
CL-29651	3398	EIVLTQSPGTLSLSPGERATLSCRASSGDIWYSYVSWYQQKPGQ
		APRLVIYSDDERPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGVDVDVVFGGGTKVEIK
CL-29652	3399	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDIVFGGGTKVEIK
CL-29653	3400	EIVLTQSPGTLSLSPGERATLSCRASSGDIEHSYVSWYQQKPGQ
		APRLLIYADDYRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDPDITFGGGTKVEIK
CL-29654	3401	EIVLTQSPGTLSLSPGERATLSCRASSGDISHSYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDITFGGGTKVEIK
CL-29655	3402	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDAYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIFIDIVFGGGTKVEIK
CL-29656	3403	EIVLTQSPGTLSLSPGERATLSCERSSGDIGEYYVSWYQQKPGQ
		APRLVIYADDRRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDVTFGGGTKVEIK
CL-29657	3404	EIVLTQSPGTLSLSPGERATLSCERSSGSIDYAYVSWYQQKPGQ
		APRLVIYSDDYRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDITFGGGTKVEIK
CL-29658	3405	EIVLTQSPGTLSLSPGERATLSCRASSGDIWYSYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIVIDIVFGGGTKVEIK
CL-29659	3406	EIVLTQSPGTLSLSPGERATLSCERSSGSIGYSYVSWYQQKPGQ
		APRLVMYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDVIIDVVFGGGTKVEIK
CL-29660	3407	EIVLTQSPGTLSLSPGERATLSCRASSGDIGYSYVSWYQQKPGQ
		APRLVIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDVTFGGGTKVEIK
CL-29661	3408	EIVLTQSPGTLSLSPGERATLSCRASSGSIWHSYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCKSYGINIDVTFGGGTKVEIK
CL-29662	3409	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYSYVSWYQQKPGQ
		APRLVIYSDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDVVFGGGTKVEIK
CL-29663	3410	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDTYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDIDITFGGGTKVEIK
CL-29664	3411	EIVLTQSPGTLSLSPGERATLSCRASSGDIRHSYVSWYQQKPGQ
		APRLVIYADDDRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINTDIVFGGGTKVEIK
CL-29665	3412	EIVLTQSPGTLSLSPGERATLSCRASSGDIGGSYVSWYQQKPGQ
		APRLVIYTDDWRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-29666	3413	EIVLTQSPGTLSLSPGERATLSCRASSGDISYSYVSWYQQKPGQ
		APRLLIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIIIDVVFGGGTKVEIK
CL-29667	3414	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDMYVSWYQQKPGQ
		APRLVIYSDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDIVFGGGTKVEIK
CL-29668	3415	EIVLTQSPGTLSLSPGERATLSCERSSGDIDYTYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLTLDITFGGGTKVEIK
CL-29669	3416	EIVLTQSPGTLSLSPGERATLSCERSSSSIWHSYVSWYQQKPGQ
		APRLVIYADDYRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDVVFGGGTKVEIK
CL-29670	3417	EIVLTQSPGTLSLSPGERATLSCRASSGSIDYSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIYIDVVFGGGTKVEIK
CL-29671	3418	EIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGQYIDVVFGGGTKVEIK
CL-29672	3419	EIVLTQSPGTLSLSPGERATLSCRASSGDIDESYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIIIDIVFGGGTKVEIK
CL-29673	3420	EIVLTQSPGTLSLSPGERATLSCRASSGDIXYSYVSWYQQKPGQ
		APRLVIYSDDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDSIIDVTFGGGTKVEIK
CL-29674	3421	EIVLTQSPGTLSLSPGERATLSCRASSGDIWYSYVSWYQQKPGQ
		APRLLIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINVDIVFGGGTKVEIK
CL-29675	3422	EIVLTQSPGTLSLSPGERATLSCERSSGSIMYAYVSWYQQKPGQ
		APRLVIYADDQRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLIIDVTFGGGTKVEIK
CL-29676	3423	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDTYVSWYQQKPGQ
		APRLVIYADDARATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLDIDITFGGGTKVEIK
CL-29677	3424	EIVLTQSPGTLSLSPGERATLSCERSSGDIWHSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDISIDVTFGGGTKVEIK
CL-29678	3425	EIVLTQSPGTLSLSPGERATLSCERSSGSIGETYVSWYQQKPGQ
		APRLLIYSDDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDIDIVFGGGTKVEIK
CL-29679	3426	EIVLTQSPGTLSLSPGERATLSCRASSGSIGDSYVSWYQQKPGQ
		APRLLIYSDDDRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGISIDVTFGGGTKVEIK
CL-29681	3427	EIVLTQSPGTLSLSPGERATLSCRASSGDIGHSYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDITFGGGTKVEIK
CL-29682	3428	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDTYVSWYQQKPGQ
		APRLVIYSDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIIIDIVFGGGTKVEIK
CL-29683	3429	EIVLTQSPGTLSLSPGERATLSCERSSGDIYSYYVSWYQQKPGQ
		APRLLIYSDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVTFGGGTKVEIK
CL-29684	3430	EIVLTQSPGTLSLSPGERATLSCERSSGSIWHSYVSWYQQKPGQ
		APRLVIYSDDQQASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDIVFGGGTKVEIK
CL-29685	3431	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYSYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIVIDIVFGGGTKVEIK
CL-29686	3432	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDTYVSWYQQKPGQ
		APRLVIYADDQRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLTIDIVFGGGTKVEIK
CL-29687	3433	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDICIDVTFGGGTKVEIK
CL-29688	3434	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLLIYSDDHRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIIIDIVFGGGTKVEIK
CL-29689	3435	EIVLTQSPGTLSLSPGERATLSCERSSGSIGGYYVSWYQQKPGQ
		APRLLIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIIIDIVFGGGTKVEIK
CL-29690	3436	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYSYVSWYQQKPGQ
		APRLVIYGADLRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDIDIVFGGGTKVEIK
CL-29722	3437	EIVLTQSPGTLSLSPGERATLSCERSXGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-29732	3438	EIVLTQSPGTLSLSPGERATLSCERSSVDIGDSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-29741	3439	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIHADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-29746	3440	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPVQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-29756	3441	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		ATRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-29759	3442	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYAYDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-29765	3443	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYSDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-29771	3444	EXXLTQSPGTLSLSPGERATXSCERSSGDXGDSYVSWYQQKPGQ
		APRLVIYXDDQRPSGIPDRFSGSGSGTDFTLTISGLEPEDFAVY
		YCQSXDINMDIVFGGGTKVEIK
CL-29780	3445	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGVGTKVEIK
CL-29781	3446	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFVVY
		YCQSYDINIDIVFGGGTKVEIK
CL-33580	3447	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYXDDQRPSGIPDRFSGSGSGGDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-33673	3448	EIVLTQSPGTLSLSPGERATLSCERSSGDIWEYYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLEVDIVFGGGTKVEIK
CL-33674	3449	EIVLTQSPGTLSLSPGERATLSCERSSGSIWDTYVSWYQQKPGQ
		APRLVIYSDDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINVDIVFGGGTKVEIK
CL-33676	3450	EIVLTQSPGTLSLSPGERATLSCERSSGDIWGYYVSWYQQKPGQ
		APRLLIYADDLRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDVVFGGGTKVEIK
CL-33677	3451	EIVLTQSPGTLSLSPGERATLSCERSSGSIYYTYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDVDVVFGGGTKVEIK
CL-33678	3452	EIVLTQSPGTLSLSPGERATLSCERSSGDIWGYYVSWYQQKPGQ
		APRLLIYADDLRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDIDITFGGGTKVEIK
CL-33679	3453	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDTYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGLNVDVVFGGGTKVEIK
CL-33680	3454	EIVLTQSPGTLSLSPGERATLSCERSSGDIYETYVSWYQQKPGQ
		APRLVIYSDDHRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDVVFGGGTKVEIK
CL-33681	3455	EIVLTQSPGTLSLSPGERATLSCERSSGSIWYSYVSWYQQKPGQ
		APRLLIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIITDVTFGGGTKVEIK
CL-33684	3456	EIVLTQSPGTLSLSPGERATLSCERSSGDIWGYYVSWYQQKPGQ
		APRLLIYADDLRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDVVFGGGTEVEIK
CL-33685	3457	EIVLTQSPGTLSLSPGERATLSCERSSGDIYYTYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-33687	3458	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDYYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLDIDVVFGGGTKVEIK
CL-33688	3459	EIVLTQSPGTLSLSPGERATLSCERSSGSIWQSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDIVFGGGTKVEIK
CL-33690	3460	EIVLTQSPGTLSLSPGERATLSCKRSSGSIYDTYVSWYQQKPGQ
		APRLVIYSDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDVDSDIVFGGGTKVEIK
CL-33691	3461	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDYYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDIDVTFGGGTKVEIK
CL-33692	3462	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDYYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLDIDVTFGGGTKVEIK
CL-33693	3463	EIVLTQSPGTLSLSPGERATLSCERSSGSIYESYVSWYQQKPGQ
		APRLLIYSDDQRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDIDVVFGGGTKVEIK
CL-33694	3464	EIVLTQSPGTLSLSPGERATLSCERSSGSIYHTYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLDIDVTFGGGTKVEIK
CL-33695	3465	EIVLTQSPGTLSLSPGERATLSCERSSGSIYDTYVSWYQQKPGQ
		APRLVIYSDDQRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLDIDIVFGGGTKVEIK
CL-33697	3466	EIVLTQSPGTLSLSPGERATLSCERSSGDIWQTYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDVDIVFGGGTKVEIK
CL-33698	3467	EIVLTQSPGTLSLSPGERATLSCERSSGDIWXYYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLFIDVTFGGGTKVEIK
CL-33700	3468	EIVLTQSPGTLSLSPGERATLSCERSSGDIWHYYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLEIDVTFGGGTKVEIK
CL-33704	3469	EIVLTQSPGTLSLSPGERATLSCERSSGDIWSYYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLTVDVVFGGGTKVEIK
CL-33707	3470	EIVLTQSPGTLSLSPGERATLSCERSSGDIWSYYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLDIDVTFGGGTKVEIK
CL-33708	3471	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDYYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDVTFGGGTKVEIK
CL-33709	3472	EIVLTQSPGTLSLSPGERATLSCERSSGDIWQTYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDVTFGGGTKVEIK
CL-33710	3473	EIVLTQSPGTLSLSPGERATLSCERSSGDIWEYYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLDIDVVFGGGTKVEIK
CL-33712	3474	EIVLTQSPGTLSLSPGERATLSCRASSGSIYYSYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDVVFGGGTKVEIK
CL-33713	3475	EIVLTQSPGTLSLSPGERATLSCERYSGDIWYTYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDVDVVFGGGTKVEIK
CL-33716	3476	EIVLTQSPGTLSLSPGERATLSCERSSGDIWEYYVSWYQQKPGQ
		APRLVIYADDLRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLDIDVTFGGGTKVEIK
CL-33718	3477	EIVLTQSPGTLSLSPGERATLSCERSSGDIWEYYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLNIDVVFGGGTKVEIK
CL-33719	3478	EIVLTQSPGTLSLSPGERATLSCERSSGDIWEYYVSWYQQKPGQ
		APRLVIYADDLRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLDIDVTFGGGTKVEIK
CL-33720	3479	EIVLTQSPGTLSLSPGERATLSCERSSGDIWEYYVSWYQQKPGQ
		APRLVIYTDDLRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIETDIVFGGGTKVEIK
CL-33721	3480	EIVLTQSPGTLSLSPGERATLSCERSSGDIWYSYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDVDVTFGGGTKVEIK
CL-33722	3481	EIVLTQSPGTLSLSPGERATLSCERSSGDIWYSYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIYIDVVFGGGTKVEIK
CL-33723	3482	EIVLTQSPGTLSLSPGERATLSCERSSGDIWEYYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDVCIDVVFGGGTKVEIK
CL-33725	3483	EIVLTQSPGTLSLSPGERATLSCERSSGDIWEYYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLDIDVVFGGGTKVEIK
CL-33726	3484	EIVLTQSPGTLSLSPGERATLSCERSSGSIWYSYVSWYQQKPGQ
		APRLVIYSDDLRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDVVFGGGTKVEIK
CL-33727	3485	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYWDDYRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDVDIVFGGGTKVEIK
CL-33729	3486	EIVLTQSPGTLSLSPGERATLSCERSSGDIWSYYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLDIDITFGGGTKVEIK
CL-33730	3487	EIVLTQSPGTLSLSPGERATLSCERSSGDIWSYYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLNIDTVFGGGTKVEIK
CL-33732	3488	EIVLTQSPGTLSLSPGERATLSCERSSCDIWQYYVSWYQQKPGQ
		APRLLIYADDQRATGIPDRFSGSGSGTDFTLIISRLEPEDFAVY
		YCQSYDLDIDVVFGGGTKVEIK
CL-33733	3489	EIVLTQSPGTLSLSPGERATLSCERSSGDIWEYYVSWYQQKPGQ
		APRLVIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIITDVVFGGGTKVEIK
CL-33734	3490	EIVLTQSPGTLSLSPGERATLSCERSSGDIWHTYVSWYQQKPGQ
		APRLVIYADDQRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDVNIDVVFGGGTKVEIK
CL-33740	3491	EIVLTQSPGTLSLSPGERATLSCERSSGSIWSTYVSWYQQKPGQ
		APRLLIYSDDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDVVIDIVFGGGTKVEIK
CL-33741	3492	EIVLTQSPGTLSLSPGERATLSCERSSGDIWEYYVSWYQQKPGQ
		APRLLIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLIIDIVFGGGTKVEIK
CL-33742	3493	EIVLTQSPGTLSLSPGERATLSCERSSGDIWHYYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLDIDVTFGGGTKVEIK
CL-33743	3494	EIVLTQSPGTLSLSPGERATLSCERSSGSIWGYYVSWYQQKPGQ
		APRLVIYADDHRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDETIDIVFGGGTKVEIK
CL-33745	3495	EIVLTQSPGTLSLSPGERATLSCERSSGDIYYTYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDITFGGGTKVEIK
CL-33746	3496	EIVLTQSPGTLSLSPGERATLSCERSSGDIWQSYVSWYQQKPGQ
		APRLVIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDVDIVFGGGTKVEIK
CL-33747	3497	EIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQ
		APRLVIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-33755	3498	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYSDDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGTNIDVVFGGGTKVEIK
CL-33756	3499	EIVLTQSPGTLSLSPGERATLSCERSSGDIWESYVSWYQQKPGQ
		APRLVIYADDQRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIIDDIVFGGGTKVEIK
CL-33757	3500	EIVLTQSPGTLSLSPGERATLSCERSSGDIWETYVSWYQQKPGQ
		APRLVIYSDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDVTFGGGTKVEIK
CL-33758	3501	EIVLTQSPGTLSLSPGERATLSCERSSGDIWQTYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDVVFGGGTKVEIK
CL-33760	3502	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGLNIDVVFGGGTKVEIK
CL-33761	3503	EIVLTQSPGTLSLSPGERATLSCERSSGDIWSYYVSWYQQKPGQ
		APRLLIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDICIDVTFGGGTKVEIK
CL-33763	3504	EIVLTQSPGTLSLSPGERATLSCERSSGDIWEYYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDIVFGGGTKVEIK
CL-33766	3505	EIVLTQSPGTLSLSPGERATLSCERSSGDIYDAYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDVDVVFGGGTKVEIK
CL-33768	3506	EIVLTQSPGTLSLSPGERATLSCERSSGSIWDTYVSWYQQKPGQ
		APRLVIYSDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDVVFGGGTKVEIK
CL-33771	3507	EIVLTQSPGTLSLSPGERATLSCERSSGSIWQYYVSWYQQKPGQ
		APRLLIYADDKRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDEDIDITFGGGTKVEIK
CL-33773	3508	EIVLTQSPGTLSLSPGERATLSCERSSGDIWSYYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLNIDVTFGGGTKVEIK
CL-33774	3509	EIVLTQSPGTLSLSPGERATLSCERSSGDIWSYYVSWYQQKPGQ
		APRLLIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLYIDIVFGGGTKVEIK
CL-33775	3510	EIVLTQSPGTLSLSPGERATLSCERSSGDIWQTYVSWYQQKPGQ
		APRLVIYADDMRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLNIDVTFGGGTKVEIK
CL-33776	3511	EIVLTQSPGTLSLSPGERATLSCERSSGDIGYSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIIIDIVFGGGTKVEIK
CL-33777	3512	EIVLTQSPGTLSLSPGERATLSCERSSGDIYETYVSWYQQKPGQ
		APRLLIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDVVFGGGTKVEIK
CL-33778	3513	EIVLTQSPGTLSLSPGERATLSCERSSGDIWEYYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGLITDVTFGGGTKVEIK
CL-33779	3514	EIVLTQSPGTLSLSPGERATLSCERSSGSIWETYVSWYQQKPGQ
		APRLVIYADDRRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDIDVVFGGGTKVEIK
CL-33781	3515	EIVLTQSPGTLSLSPGERATLSCERSSGDIWEYYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDTDIVFGGGTKVEIK
CL-33782	3516	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDTYVSWYQQKPGQ
		APRLVIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-33785	3517	EIVLTQSPGTLSLSPGERATLSCERSSGSIWQTYVSWYQQKPGQ
		APRLVIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIVIDVVFGGGTKVEIK
CL-33787	3518	EIVLTQSPGTLSLSPGERATLSCERSSGDIWQYYVSWYQQKPGQ
		APRLVIYADDHRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLDIDVTFGGGTKVEIK
CL-33790	3519	EIVLTQSPGTLSLSPGERATLSCERSSGDIWHTYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDVDIDITFGGGTKVEIK
CL-33791	3520	EIVLTQSPGTLSLSPGERATLSCERSSGDIWQAYVSWYQQKPGQ
		APRLVIYSDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIEDITFGGGTKVEIK
CL-33792	3521	EIVLTQSPGTLSLSPGERATLSCERSSGDIYETYVSWYQQKPGQ
		APRLVIYSDDHRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIITDIVFGGGTKVEIK
CL-33794	3522	EIVLTQSPGTLSLSPGERATLSCERSSGSIWDYYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLITDIVFGGGTKVEIK
CL-33795	3523	EIVLTQSPGTLSLSPGERATLSCERSSGDIWQTYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-33796	3524	EIVLTQSPGTLSLSPGERATLSCERSSGDIWEYYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLIRDIVFGGGTKVEIK
CL-33799	3525	EIVLTQSPGTLSLSPGERATLSCERSSGSIYETYVSWYQQKPGQ
		APRLLIYADDWRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDITVDVVFGGGTKVEIK
CL-33801	3526	EIVLTQSPGTLSLSPGERATLSCERSSGDIWESYVSWYQQKPGQ
		APRLVIYSDDQRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIIDDIVFGGGTKVEIK
CL-33802	3527	EIVLTQSPGTLSLSPGERATLSCERSSGDIWEYYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLDIDITFGGGTKVEIK
CL-33813	3528	EIVLTQSPGTLSLSPGERATLSCERSSGDIWQTYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDIDVVFGGGTKVEIK
CL-33814	3529	EIVLTQSPGTLSLSPGERATLSCRASSGSIWYSYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-33815	3530	EIVLTQSPGTLSLSPGERATLSCERSSGDIYETYVSWYQQKPGQ
		APRLVIYSDDHRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDVDVVFGGGTKVEIK
CL-33816	3531	EIVLTQSPGTLSLSPGERATLSCERSSGDIYETYVSWYQQKPGQ
		APRLVIYSDDHRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINVDVVFGGGTKVEIK
CL-33817	3532	EIVLTQSPGTLSLSPGERATLSCRASSGDISDKYVSWYQQKPGQ
		APRLVIYADDYRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLCIDVTFGGGTKVEIK
CL-33819	3533	EIVLTQSPGTLSLSPGERATLSCRASSGDISDKYVSWYQQKPGQ
		APRLLIYADDWRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDVDVVFGGGTKVEIK
CL-33825	3534	EIVLTQSPGTLSLSPGERATLSCERSSGSIWQYYVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLDIDVTFGGGTKVEIK
CL-33826	3535	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDYYVSWYQQKPGQ
		APRLVIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLEIDVVFGGGTKVEIK
CL-33828	3536	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDTYVSWYQQKPGQ
		APRLLIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDITVDVVFGGGTKVEIK
CL-33829	3537	EIVLTQSPGTLSLSPGERATLSCERSSGSIWYSYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDVTFGGGTKVEIK
CL-33832	3538	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDYYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLIIDVTFGGGTKVEIK
CL-33833	3539	EIVLTQSPGTLSLSPGERATLSCERSSGDIWETYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDVDIVFGGGTKVEIK
CL-33834	3540	EIVLTQSPGTLSLSPGERATLSCERSSGSIWYSYVSWYQQKPGQ
		APRLVIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDSDIVFGGGTKVEIK
CL-33836	3541	EIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINVDIVFGGGTKVEIK
CL-33837	3542	EIVLTQSPGTLSLSPGERATLSCERSSGDIYQTYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDIDVVFGGGTKVEIK
CL-33839	3543	EIVLTQSPGTLSLSPGERATLSCERSSGSIWETYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGVDIDVVFGGGTKVEIK
CL-33840	3544	EIVLTQSPGTLSLSPGERATLSCERSSGDIYETYVSWYQQKPGQ
		APRLVIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDVVFGGGTKVEIK
CL-33841	3545	EIVLTQSPGTLSLSPGERATLSCERSSGSIWQYYVSWYQQKPGQ
		APRLVIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLFIDVTFGGGTKVEIK
CL-33844	3546	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDTYVSWYQQKPGQ
		APRLLIYSDDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIYVDIVFGGGTKVEIK
CL-33847	3547	EIVLTQSPGTLSLSPGERATLSCERSSGSIYYTYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIEIDITFGGGTKVEIK
CL-33848	3548	EIVLTQSPGTLSLSPGERATLSCERSSGDIYETYVSWYQQKPGQ
		APRLVIYSDDHRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDTDIVFGGGTKVEIK
CL-33849	3549	EIVLTQSPGTLSLSPGERATLSCERSSGDIWYSYVSWYQQKPGQ
		APRLVIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-33854	3550	EIVLTQSPGTLSLSPGERATLSCERSSGDIWHTYVSWYQQKPGQ
		APRLLIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINVDVVFGGGTKVEIK
CL-33857	3551	EIVLTQSPGTLSLSPGERATLSCERSSGDIWESYVSWYQQKPGQ
		APRLLIYSDDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-33858	3552	EIVLTQSPGTLSLSPGERATLSCERSSGDIGHTYVSWYQQKPGQ
		APRLVIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIISDVVFGGGTKVEIK
CL-33862	3553	EIVLTQSPGTLSLSPGERATLSCERSSGSIWGTYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDVTFGGGTKVEIK
CL-41468	3554	EIVLTQSPGTLSLPPGERATLSCKRSSGSIYDTYVSWYQQKPGQ
		APRLVIYSDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLTIDITFGGGTKVEIK
CL-41469	3555	EIVLTQSPGTLSLSPGERATLSCERSSGSIWHSYVSWYQQKPGQ
		APRLLIYSDDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIYIDVVFGGGTRSKLS
CL-41472	3556	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDTYVSWYQQKPGQ
		APRLLIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLTIDITFGGGTKVEIK
CL-41477	3557	EIVLTQSPGTLSLSPGERATPSCRASSGSIWYSFVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-41479	3558	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDYYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQPYDLFIDVTFGGGTKVEIK
CL-41480	3559	EIVLTQSPGTLSLSPGERATLSCERSSGDIWQSYVSWYQQKPGQ
		APRLVIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAGY
		YCQSYGINIDVVFGGGTKVEIK
CL-41486	3560	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDYYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLFIDVTFGGGTKVEIK
CL-41505	3561	EIVLTQSPGTLSLSPGERATLSCERSSGSIWHSYVSWYQQKPGQ
		APRLLIYSDDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIETDIVFGGGTKVEIK
CL-41509	3562	EIVLTQSPGTWSLSPGERATLSCERSSGSNYDTYVSWYQQKPGQ
		APRLLIYADDLRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIETDIVFGGGTKVEIK
CL-41528	3563	EIVLTQSPGTLSLSPGERATLSCERSSGSIWHSYVSWYQQKPGQ
		APRLLIYSDDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIYIDVVFGGDTKVEIK
CL-41529	3564	EIVLTQSPGTLSLSSGERATLSCERSSGSNYDTYVSWYQQKPGQ
		APRLLIYADDLRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIETDIVFGGGTKVEIK
CL-41532	3565	EIVLTQSPGTLSLSPGERATLSCRASSGSTWYSFVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-41535	3566	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDYYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLTIDITFGGGTKVEIK
CL-41536	3567	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDYYVSWYQQKPGQ
		APRLVIYSDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLFIDXTFGGGTKVEIK
CL-41539	3568	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDTYVSWYQQKPGQ
		APRLLIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEGFAVY
		YCQSYDIIIDIVFGGGTKVEIK
CL-41543	3569	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDTYVSWYQQKPGQ
		ASRLLIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDIVFGGGTKVEIK
CL-41547	3570	EIVLTQSPGTLSLSPGERATLSCERSSGSIWHSYVSWYQQKPGQ
		APRLLIYSDDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIYIDVVFGGGTNVEIK
CL-41550	3571	EIVLTQSPGTLSLSPGERATLSCKRSSGSIYDTYVSWYQQKPGQ
		APRLVIYSDDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLTIDITFGGGTKVEIK
CL-41554	3572	EIVLTQSPGTLSLSPGERATLSCERSSGDIWQSYVSWYQQKPGQ
		APRLVIYSDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-41556	3573	EIVLTQSPGTLSLSPGERATLSCERSSGSIWHSYVSWYQQKPGQ
		APRLLIYSDDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIYIDVVFGGGTKVEIK
CL-41557	3574	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDTYVSWYQQKPGQ
		APRLLIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIIIDIVFGGGTKVEIK
CL-41560	3575	EIFLTQSPGTLSLSPGKKATLSGKRSSGSIYNTYFSGYQQKPGQ
		APKRVIYSDDRRPSGIPDRFSGSGXGTDFTLTISXLEPKDFAVY
		YCQSYDLTINLXFGGGTKVXIX
CL-41561	3576	EIVLTQSPGTLSLSPGERATLSCERSSGSNYDTYVSWYQQKPGQ
		APRLLIYADDLRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIETDIVFGGGTKVEIK
CL-41562	3577	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		SPRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-41569	3578	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRPRGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-41577	3579	EIVLTQSPGTLSLSPGERATLSCERSSGSIWQSYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDVVFGGGTKVEIS
CL-41581	3580	EIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSRYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-41591	3581	EIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGIDIDVVFGGGTKVEIK
CL-41599	3582	KSSLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-41600	3583	EIVLTQSLGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-41615	3584	EIVLTQSPGTLSLSPGERATLSCERSSGDIWQMYVSWYQQKPGQ
		APRLVIYGDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDITFGGGTKVEIK
CL-41616	3585	EIVLTQSPGTLSLPPGERATLSCERSSGDIWQTYVSWYQQKPGQ
		APRLVIYGDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDITFGGGHKGRNX
CL-41639	3586	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDYYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDSAVY
		YCQSYDLFIDVTFGGGTKVEIK
CL-41642	3587	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDYYVSWYQRKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-41645	3588	EIVLTQSPGTLSLSPGERATLSCERSSGDIWQTYVSWYQQKPGQ
		APRLVIYGDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDITFGGGTKVEIK
CL-41646	3589	EIVLTQSPGTLSLSPGERATLSCERSSGSIWQSYVSWYQQKPGQ
		APRLVIYADDQRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDIDIDVVFGGGTKVEIK
CL-41649	3590	EIVLTQSPGTLSLSPGERATLSCERSSGDIWDYYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDLFIDVTFGGGTKVEIK
CL-41654	3591	EIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVH
		YCQSYGINIDVVFGGGTKVEIK
CL-41655	3592	EIVLTQSPGTLSLSPGERATLSCERSSGDIWQTYVSWYQQKPGQ
		APRLVIYGDDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-41668	3593	EIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVC
		YCQSYGINIDVVFGGGTKVEIK
CL-41673	3594	EIVLTQSPGTLSLSPGERAPLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIX
CL-41685	3595	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTINRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-41705	3596	EIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQ
		APRLLIYADDQRASGIPDRLSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-41707	3597	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADGQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-41710	3598	EIVLTQSPSTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-41713	3599	EIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIN
CL-41714	3600	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVELS
CL-41720	3601	EIVLTQIPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-41725	3602	EIVLTQSPGTLSLSPGERATLSCERSSGSNYDTYVSWYQQKPGQ
		APRLLIYADDLRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-41727	3603	EIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YRQSYGINIDVVFGGGTKVEIK
CL-41729	3604	EIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQ
		APRLLIYADDQRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYGINIDVVFGGGTKVEIK
CL-41732	3605	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRPIGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-41735	3606	EIVLTQSPGTLSLSPVERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-41737	3607	EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVY
		YCQSYDINIDIVFGGGTKVEIK
CL-41738	3608	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQAP
		RLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYC
		QQSWYDPLTFGQGTKLEIK
CL-41739	3609	EIVLTQSPATLSLSPGERAALSCRASQSVSTHMHWYQQKPGQAP
		RLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYC
		QQSWYDPLTFGQGTKLEIK
CL-41740	3610	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQAP
		RLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYC
		QQSRYDPLTFGQGTKLEIK
CL-41742	3611	EIVLTQSPGTLSLSPGERATLSCRASQSVSTHMHWYQQKPGQAP
		RLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYC
		QQSWYDPLTFGQGTKLEIK
CL-41751	3612	AKLCXPVPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQAP
		RLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYC
		QQSWYDPLTFGQGTKLEIK
CL-41752	3613	EIVLTQSPATLSLSPGERATLSCRASQSVSTHMHWYQQKPGQAP
		RLLIYGASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYC
		QQSWYDPLTFGQGTKLRSN

TABLE 48
Amino Acid Residues Found In Each Position Of The Heavy
Chain Variable Region During The Affinity Maturation
Of Anti-PDGF-BB Antibody hBDI-9E8.4
hBDI-9E8.4-2I|CL-22843 Heavy Chain Variable Region
SEQ ID NO: Sequence
3614       1         2         3         4         5         6
           123456789012345678901234567890123456789012345678901234567890
           EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWDDDKY
           I Y SEVSIDL             L DCYGEEH
           R A    R L                C NNGTC
           D      A                G HHVID
           T      C                  V AQN
           M      V                  E HVS
           R      Y                  I YNA
           L      R                  P NRF
           C      T                  A QYG
           F      E                  C SL
           W      S                  G LM
           P                            C
           7         8         9        10        11        12
           12345678901234567890123456789012345678901234567890123456789012
           YNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIESIGTTYSFDYWGQGTMVTVSS
           SL  NS                                 LYQTGWPN E Y
           T   T                                NVASPWS D
           LKYMFRK Y
           MYWVCIR A
           VLPLYFM C
           RDLFAAA N
           KGVNEME M
           FAEDLYI W
           CMKHVSV T
           TRFYSLL Q
           ESCTDGW G
           RRDP I
           Q KQ L
           K V  P
           E N
           P E

TABLE 49
Amino Acid Residues Found In Each Position Of The Light Chain
Variable Region During The Affinity Maturation
Of Anti-PDGF Antibody hBDI-9E8.4
hBDI-9E8.4-2I|CL-22843 Light Chain Variable Region
SEQ ID NO: Sequence
3615       1         2         3         4         5         6
           123456789012345678901234567890123456789012345678901234567890
           EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRPSGI
           F                     RAY CSNWYTFFPR  R         MHGYGLQAIR
           KE  VYTYQYLS G              SA RP T
           S MSNMR                 WV H  R
           MHKH                 T  W  G
           HGAN                 L  Y
           DECC                 V  M
           RSFA                 F  K
           EKLD                 N  D
           NFES                 P  A
           CRWT                 E  E
           ALD                  D  N
           LCP                     V
           VAG                     S
           FP                      F
           T                       P
           Q
           K
           7         8         9         10         11
           12345678901234567890123456789012345678901234567890
           PDRFSGSGSGTDFTLTISRLEFEDFAVYYCQSYDINIDIVFGGGTKVEIK
           RKP GLFTNVT
           Q  VDSPL
           H  EEVAG
           TTDYT
           SIRGS
           QYEHN
           RCMEF
           NVLVA
           KSPLH
           GRFQR
           AANTQ
           CLK
           FG
           H
           K

TABLE 50
Variable Region Sequences of h9E8.4 Affinity
Matured Clones Converted to IgG
		Protein	V Region
SEQ ID NO:	Clone	Region	123456789012345678901234567890
3616	CL-33578 VH		EVTLRESGPALVKPTQTLTLTCTFSG
			FSLSTYGMGVGWIRQPPGKALEWLAN
			IWWDDDKYYNPSLKNRLTISKDTSKN
			QVVLTMTNMDPVDTATYYCARIQSGW
			TNYEFDYWGQGTMVTVSS
3617	CL-33578	CDR-H1	GFSLSTYGMGVG
3618	CL-33578	CDR-H2	NIWWDDDKYYNPSLKN
3619	CL-33578	CDR-H3	IQSGWTNYEFDY
3620	CL-33578 VL		EIVLTQSPGTLSLSPGERATLSCERS
			SGDIGDSYVSWYQQKPGQAPRLVIYA
			DDQRPSGIPDRFSGSGSGTDFTLTIS
			RLEPEDFAVYYCQSYDINIDIVFGGG
			TKVEIK
3621	CL-33578	CDR-L1	ERSSGDIGDSYVS
3622	CL-33578	CDR-L2	ADDQRPS
3623	CL-33578	CDR-L3	QSYDINIDIV
3624	CL-33587 VH		EVTLRESGPALVKPTQTLTLTCTFSG
			FSLSTYGMGVGWIRQPPGKALEWLAN
			IWWDDDKYYNPSLKNRLTISKDTSKN
			QVVLTMTNMDPVDTATYYCARIQSMW
			TRYDFDYWGQGTMVTVSS
3625	CL-33587	CDR-H1	GFSLSTYGMGVG
3626	CL-33587	CDR-H2	NIWWDDDKYYNPSLKN
3627	CL-33587	CDR-H3	IQSMWTRYDFDY
3628	CL-33587 VL		EIVLTQSPGTLSLSPGERATLSCERS
			SGDIGDSYVSWYQQKPGQAPRLVIYA
			DDQRPSGIPDRFSGSGSGTDFTLTIS
			RLEPEDFAVYYCQSYDINIDIVFGGG
			TKVEIK
3629	CL-33587	CDR-L1	ERSSGDIGDSYVS
3630	CL-33587	CDR-L2	ADDQRPS
3631	CL-33587	CDR-L3	QSYDINIDIV
3632	CL-33675 VH		EVTLRESGPALVKPTQTLTLTCTFSG
			FSLSTYGMGVGWIRQPPGKALEWLAN
			IWWDDDKYYNPSLKNRLTISKDTSKN
			QVVLTMTNMDPVDTATYYCARIESSG
			PKYSFDYWGQGTMVTVSS
3633	CL-33675	CDR-H1	GFSLSTYGMGVG
3634	CL-33675	CDR-H2	NIWWDDDKYYNPSLKN
3635	CL-33675	CDR-H3	IESSGPKYSFDY
3636	CL-33675 VL		EIVLTQSPGTLSLSPGERATLSCRAS
			SGSIWYSFVSWYQQKPGQAPRLLIYA
			DDQRASGIPDRFSGSGSGTDFTLTIS
			RLEPEDFAVYYCQSYGINIDVVFGGG
			TKVEIK
3637	CL-33675	CDR-L1	RASSGSIWYSFVS
3638	CL-33675	CDR-L2	ADDQRAS
3639	CL-33675	CDR-L3	QSYGINIDVV
3640	CL-33682 VH		EVTLRESGPALVKPTQTLTLTCTFSG
			FSLSTYGMGVGWIRQPPGKALEWLAN
			IWWDDDKYYNPSLKNRLTIKDTSKN
			QVVLTMTNMDPVDTATYYCARIESSW
			TSYSFDYWGQGTMVTVSS
3641	CL-33682	CDR-H1	GFSLSTYGMGVG
3642	CL-33682	CDR-H2	NIWWDDDKYYNPSLKN
3643	CL-33682	CDR-H3	IESSWTSYSFDY
3644	CL-33682 VL		EIVLTQSPGTLSLSPGERATLSCERS
			SGSNYDTYVSWYQQKPGQAPRLLIYA
			DDLRASGIPDRFSGSGSGTDFTLTIS
			RLEPEDFAVYYCQSYGINIDVVFGGG
			TKVEIK
3645	CL-33682	CDR-L1	ERSSGSNYDTYVS
3646	CL-33682	CDR-L2	ADDLRAS
3647	CL-33682	CDR-L3	QSYGINIDVV
3648	CL-33683 VH		EVTLRESGPALVKPTQTLTLTCTFSG
			FSLSTYGMGVGWIRQPPGKALEWLAN
			IWWDDDKYYNPSLKNRLTISKDTSKN
			QVVLTMTNMDPVDTATYYCARIETIG
			PKYSFDYWGQGTMVTVSS
3649	CL-33683	CDR-H1	GFSLSTYGMGVG
3650	CL-33683	CDR-H2	NIWWDDDKYYNPSLKN
3651	CL-33683	CDR-H3	IETIGPKYSFDY
3652	CL-33683 VL		EIVLTQSPGTLSLSPGERATLSCRAS
			SGSIWYSFVSWYQQKPGQAPRLLIYA
			DDQRASGIPDRFSGSGSGTDFTLTIS
			RLEPEDFAVYYCQSYGINIDVVFGGG
			TKVEIK
3653	CL-33683	CDR-L1	RASSGSIWYSFVS
3654	CL-33683	CDR-L2	ADDQRAS
3655	CL-33683	CDR-L3	QSYGINIDVV
3656	CL-33699 VH		EVTLRESGPALVKPTQTLTLTCTFSG
			FSLSTYGMGIGWIRQPPGKALEWLAN
			IWWDDDKYYNPSLKNRLTISKDTSKN
			QVVLTMTNMDPVDTATYYCARIESMG
			PKYAFDYWGQGTMVTVSS
3657	CL-33699	CDR-H1	GFSLSTYGMGIG
3658	CL-33699	CDR-H2	NIWWDDDKYYNPSLKN
3659	CL-33699	CDR-H3	IESMGPKYAFDY
3660	CL-33699 VL		EIVLTQSPGTLSLSPGERATLSCRAS
			SGSIWYSFVSWYQQKPGQAPRLLIYA
			DDQRASGIPDRFSGSGSGTDFTLTIS
			RLEPEDFAVYYCQSYGINIDVVFGGG
			TKVEIK
3661	CL-33699	CDR-L1	RASSGSIWYSFVS
3662	CL-33699	CDR-L2	ADDQRAS
3663	CL-33699	CDR-L3	QSYGINIDVV
3664	CL-33701 VH		EVTLRESGPALVKPTQTLTLTCTFSG
			FSLSTYGMGVGWIRQPPGKALEWLAN
			IWWDDDKYYNPSLKNRLTISKDTSKN
			QVVLTMTNMDPVDTATYYCARIESLG
			TSYSFDYWGQGTMVTVSS
3665	CL-33701	CDR-H1	GFSLSTYGMGVG
3666	CL-33701	CDR-H2	NIWWDDDKYYNPSLKN
3667	CL-33701	CDR-H3	IESLGTSYSFDY
3668	CL-33701 VL		EIVLTQSPGTLSLSPGERATLSCERS
			SGDIWDYYVSWYQQKPGQAPRLVIYA
			DDQRPSGIPDRFSGSGSGTDFTLTIS
			RLEPEDFAVYYCQSYDLFIDVTFGGG
			TKVEIK
3669	CL-33701	CDR-L1	ERSSGDIWDYYVS
3670	CL-33701	CDR-L2	ADDQRPS
3671	CL-33701	CDR-L3	QSYDLFIDVT
3672	CL-33706 VH		EVTLRESGPALVKPTQTLTLTCTFSG
			FSLSTYGMGVGWIRQPPGKALEWLAN
			IWWDDDKYYNPSLKNRLTISKDTSKN
			QVVLTMTNMDPVDTATYYCARIETMG
			PKYSFDYWGQGTMVTVSS
3673	CL-33706	CDR-H1	GFSLSTYGMGVG
3674	CL-33706	CDR-H2	NIWWDDDKYYNPSLKN
3675	CL-33706	CDR-H3	IETMGPKYSFDY
3676	CL-33706 VL		EIVLTQSPGTLSLSPGERATLSCRAS
			SGSIWYSFVSWYQQKPGQAPRLLIYA
			DDQRASGIPDRFSGSGSGTDFTLTIS
			RLEPEDFAVYYCQSYGINIDVVFGGG
			TKVEIK
3677	CL-33706	CDR-L1	RASSGSIWYSFVS
3678	CL-33706	CDR-L2	ADDQRAS
3679	CL-33706	CDR-L3	QSYGINIDVV
3680	CL-33731 VH		EVTLRESGPALVKPTQTLTLTCTFSG
			FSLSTYGMGVGWIRQPPGKALEWLAN
			IWWDDDKYYNPSLKNRLTISKDTSKN
			QVVLTMTNMDPVDTATYYCARIESIP
			TSYSFDYWGQGTMVTVSS
3681	CL-33731	CDR-H1	GFSLSTYGMGVG
3682	CL-33731	CDR-H2	NIWWDDDKYYNPSLKN
3683	CL-33731	CDR-H3	IESIPTSYSFDY
3684	CL-33731 VL		EIVLTQSPGTLSLSPGERATLSCERS
			SGSIWQSYVSWYQQKPGQAPRLVIYA
			DDQRATGIPDRFSGSGSGTDFTLTIS
			RLEPEDFAVYYCQSYDIDIDVVFGGG
			TKVEIK
3685	CL-33731	CDR-L1	ERSSGSIWQSYVS
3686	CL-33731	CDR-L2	ADDQRAT
3687	CL-33731	CDR-L3	QSYDIDIDVV
3688	CL-33737 VH		EVTLRESGPALVKPTQTLTLTCTFSG
			FSLSTYGMGVGWIRKPPGKALEWLAN
			IWWDDDKYYNPSLKNRLTISKDTSKN
			QVVLTMTNMDPVDTATYYCARIESSG
			PKYSFDYWGQGTMVTVSS
3689	CL-33737	CDR-H1	GFSLSTYGMGVG
3690	CL-33737	CDR-H2	NIWWDDDKYYNPSLKN
3691	CL-33737	CDR-H3	IESSGPKYSFDY
3692	CL-33737 VL		EIVLTQSPGTLSLSPGERATLSCRAS
			SGSIWYSFVSWYQQKPGQAPRLLIYA
			DDQRASGIPDRFSGSGSGTDFTLTIS
			RLEPEDFAVYYCQSYGINIDVVFGGG
			TKVEIK
3693	CL-33737	CDR-L1	RASSGSIWYSFVS
3694	CL-33737	CDR-L2	ADDQRAS
3695	CL-33737	CDR-L3	QSYGINIDVV
3696	CL-33759 VH		EVTLRESGPALVKPTQTLTLTCTFSG
			FSLSTYGMGVGWIRQPPGKALEWLAN
			IWWDDDKYYNPSLKNRLTISKDTSKN
			QVVLTMTNMDPVDTATYYCARIESVW
			TRYDFDYWGQGTMVTVSS
3697	CL-33759	CDR-H1	GFSLSTYGMGVG
3698	CL-33759	CDR-H2	NIWWDDDKYYNPSLKN
3699	CL-33759	CDR-H3	IESVWTRYDFDY
3700	CL-33759 VL		EIVLTQSPGTLSLSPGERATLSCERS
			SGDIWQTYVSWYQQKPGQAPRLVIYG
			DDQRASGIPDRFSGSGSGTDFTLTIS
			RLEPEDFAVYYCQSYDIDIDITFGGG
			TKVEIK
3701	CL-33759	CDR-L1	ERSSGDIWQTYVS
3702	CL-33759	CDR-L2	GDDQRAS
3703	CL-33759	CDR-L3	QSYDIDIDIT
3704	CL-33767 VH		EVTLRESGPALVKPTQTLTLTCTFSG
			FSLSTYGMGVGWIRQPPGKALEWLAN
			IWWDDDKYYNPSLKNRLTISKDTSKN
			QVVLTMTNMDPVDTATYYCARIESIG
			PKYSFDYWGQGTMVTVSS
3705	CL-33767	CDR-H1	GFSLSTYGMGVG
3706	CL-33767	CDR-H2	NIWWDDDKYYNPSLKN
3707	CL-33767	CDR-H3	IESIGPKYSFDY
3708	CL-33767 VL		EIVLTQSPGTLSLSPGERATLSCRAS
			SGSIWYSFVSWYQQKPGQAPRLLIYA
			DDQRASGIPDRFSGSGSGTDFTLTIS
			RLEPEDFAVYYCQSYGINIDVVFGGG
			TKVEIK
3709	CL-33767	CDR-L1	RASSGSIWYSFVS
3710	CL-33767	CDR-L2	ADDQRAS
3711	CL-33767	CDR-L3	QSYGINIDVV
3712	CL-33769 VH		EVTLRESGPALVKPTQTLTLTCTFSG
			FSLSTYGMGVGWIRQPPGKALEWLAN
			IWWDDDKYYNPSLKNRLTISKDTSKN
			QVVLTMTNMDPVDTATYYCARIESIG
			PKYSFDYWGQGTMVTVSS
3713	CL-33769	CDR-H1	GFSLSTYGMGVG
3714	CL-33769	CDR-H2	NIWWDDDKYYNPSLKN
3715	CL-33769	CDR-H3	IESIGPKYSFDY
3716	CL-33769 VL		EIVLTQSPGTLSLSPGERATLSCRAS
			SGSIWYSFVSWYQQKPGQAPRLLIYA
			DDQRASGIPDRFSGSGSGTDFTLTIS
			RLEPEDFAVYYCQSYGINIDVVFGGG
			TKVEIK
3717	CL-33769	CDR-L1	RASSGSIWYSFVS
3718	CL-33769	CDR-L2	ADDQRAS
3719	CL-33769	CDR-L3	QSYGINIDVV
3720	CL-33797 VH		EVTLRESGPALVKPTQTLTLTCTFSG
			FSLSTYGMGVGWIRQPPGKALEWLAN
			IWWDDDKYYNPSLKNRLTISKDTSKN
			QVVLTMTNMDPVDTATYYCARIESLG
			WSYSFDYWGQGTMVTVSS
3721	CL-33797	CDR-H1	GFSLSTYGMGVG
3722	CL-33797	CDR-H2	NIWWDDDKYYNPSLKN
3723	CL-33797	CDR-H3	IESLGWSYSFDY
3724	CL-33797 VL		EIVLTQSPGTLSLSPGERATLSCERS
			SGDIWDYYVSWYQQKPGQAPRLVIYA
			DDQRPSGIPDRFSGSGSGTDFTLTIS
			RLEPEDFAVYYCQSYDLFIDVTFGGG
			TKVEIK
3725	CL-33797	CDR-L1	ERSSGDIWDYYVS
3726	CL-33797	CDR-L2	ADDQRPS
3727	CL-33797	CDR-L3	QSYDLFIDVT
3728	CL-33803 VH		EVTLRESGPALVKPTQTLTLTCTFSG
			FSLSTYGMGVGWIRQPPGKALEWLAN
			IWWDDDKYYNPSLKNRLTISKDTSKN
			QVVLTMTNMDPVDTATYYCARIESLP
			TSYSFDYWGQGTMVTVSS
3729	CL-33803	CDR-H1	GFSLSTYGMGVG
3730	CL-33803	CDR-H2	NIWWDDDKYYNPSLKN
3731	CL-33803	CDR-H3	IESLPTSYSFDY
3732	CL-33803 VL		EIVLTQSPGTLSLSPGERATLSCERS
			SGDIWDTYVSWYQQKPGQAPRLLIYA
			DDQRPSGIPDRFSGSGSGTDFTLTIS
			RLEPEDFAVYYCQSYDIIIDIVFGGG
			TKVEIK
3733	CL-33803	CDR-L1	ERSSGDIWDTYVS
3734	CL-33803	CDR-L2	ADDQRPS
3735	CL-33803	CDR-L3	QSYDIIIDIV
3736	CL-33805 VH		EVTLRESGPALVKPTQTLTLTCTFSG
			FSLSTYGMGVGWIRQPPGKALEWLAN
			IWWDDDKYYNPSLKNRLTISKDTSKN
			QVVLTMTNMDPVDTATYYCARIESHW
			WSYAFDYWGQGTMVTVSS
3737	CL-33805	CDR-H1	GFSLSTYGMGVG
3738	CL-33805	CDR-H2	NIWWDDDKYYNPSLKN
3739	CL-33805	CDR-H3	IESHWWSYAFDY
3740	CL-33805 VL		EIVLTQSPGTLSLSPGERATLSCERS
			SGSNYDTYVSWYQQKPGQAPRLLIYA
			DDLRASGIPDRFSGSGSGTDFTLTIS
			RLEPEDFAVYYCQSYGIETDIVFGGG
			TKVEIK
3741	CL-33805	CDR-L1	ERSSGSNYDTYVS
3742	CL-33805	CDR-L2	ADDLRAS
3743	CL-33805	CDR-L3	QSYGIETDIV
3744	CL-33811 VH		EVTLRESGPALVKPTQTLTLTCTFSG
			FSLSTYGMGVGWIRQPPGKALEWLAN
			IWWDDDKYYNPSLKNRLTISKDTSKN
			QVVLTMTNMDPVDTATYYCARIESSW
			TTYSFDYWGQGTMVTVSS
3745	CL-33811	CDR-H1	GFSLSTYGMGVG
3746	CL-33811	CDR-H2	NIWWDDDKYYNPSLKN
3747	CL-33811	CDR-H3	IESSWTTYSFDY
3748	CL-33811 VL		EIVLTQSPGTLSLSPGERATLSCERS
			SGSIWHSYVSWYQQKPGQAPRLLIYS
			DDQRATGIPDRFSGSGSGTDFTLTIS
			RLEPEDFAVYYCQSYGIYIDVVFGGG
			TKVEIK
3749	CL-33811	CDR-L1	ERSSGSIWHSYVS
3750	CL-33811	CDR-L2	SDDQRAT
3751	CL-33811	CDR-L3	QSYGIYIDVV
3752	CL-33812 VH		EVTLRESGPALVKPTQTLTLTCTFSG
			FSLSTYGMGVGWIRQPPGKALEWLAN
			IWWDDDKYYNPSLKNRLTISKDTSKN
			QVVLTMTNMDPVDTATYYCARIESNP
			WKYSFDYWGQGTMVTVSS
3753	CL-33812	CDR-H1	GFSLSTYGMGVG
3754	CL-33812	CDR-H2	NIWWDDDKYYNPSLKN
3755	CL-33812	CDR-H3	IESNPWKYSFDY
3756	CL-33812 VL		EIVLTQSPGTLSLSPGERATLSCERS
			SGDIWQSYVSWYQQKPGQAPRLVIYS
			DDQRASGIPDRFSGSGSGTDFTLTIS
			RLEPEDFAVYYCQSYGINIDVVFGGG
			TKVEIK
3757	CL-33812	CDR-L1	ERSSGDIWQSYVS
3758	CL-33812	CDR-L2	SDDQRAS
3759	CL-33812	CDR-L3	QSYGINIDVV
3760	CL-33820 VH		EVTLRESGPALVKPTQTLTLTCTFSG
			FSLSTYGMGVGWIRQPPGKALEWLAN
			IWWDDDKYYNPSLKNRLTISKDTSKN
			QVVLTMTNMDPVDTATYYCARIESSF
			TSYSFDYWGQGTMVTVSS
3761	CL-33820	CDR-H1	GFSLSTYGMGVG
3762	CL-33820	CDR-H2	NIWWDDDKYYNPSLKN
3763	CL-33820	CDR-H3	IESSFTSYSFDY
3764	CL-33820 VL		EIVLTQSPGTLSLSPGERATLSCKRS
			SGSIYDTYVSWYQQKPGQAPRLVIYS
			DDQRPSGIPDRFSGSGSGTDFTLTIS
			RLEPEDFAVYYCQSYDLTIDITFGGG
			TKVEIK
3765	CL-33820	CDR-L1	KRSSGSIYDTYVS
3766	CL-33820	CDR-L2	SDDQRPS
3767	CL-33820	CDR-L3	QSYDLTIDIT
3768	CL-33845 VH		EVTLRESGPALVKPTQTLTLTCTFSG
			FSLSTYGMGVGWIRQPPGKALEWLAN
			IWWDDDKYYNPSLKNRLTISKDTSKN
			QVVLTMTNMDPVDTATYYCARIVSDW
			TTYSFDYWGQGTMVTVSS
3769	CL-33845	CDR-H1	GFSLSTYGMGVG
3770	CL-33845	CDR-H2	NIWWDDDKYYNPSLKN
3771	CL-33845	CDR-H3	IVSDWTTYSFDY
3772	CL-33845 VL		EIVLTQSPGTLSLSPGERATLSCRAS
			SGSIWYSFVSWYQQKPGQAPRLLIYA
			DDQRASGIPDRFSGSGSGTDFTLTIS
			RLEPEDFAVYYCQSYGINIDVVFGGG
			TKVEIK
3773	CL-33845	CDR-L1	RASSGSIWYSFVS
3774	CL-33845	CDR-L2	ADDQRAS
3775	CL-33845	CDR-L3	QSYGINIDVV
3776	CL-33855 VH		EVTLRESGPALVKPTQTLTLTCTFSG
			FSLSTYGMGVGWIRQPPGKALEWLAN
			IWWDDDKYYNPSLKNRLTISKDTSKN
			QVVLTMTNMDPVDTATYYCARIETFG
			PKYSFDYWGQGTMVTVSS
3777	CL-33855	CDR-H1	GFSLSTYGMGVG
3778	CL-33855	CDR-H2	NIWWDDDKYYNPSLKN
3779	CL-33855	CDR-H3	IETFGPKYSFDY
3780	CL-33855 VL		EIVLTQSPGTLSLSPGERATLSCRAS
			SGSIWYSFVSWYQQKPGQAPRLLIYA
			DDQRASGIPDRFSGSGSGTDFTLTIS
			RLEPEDFAVYYCQSYGINIDVVFGGG
			TKVEIK
3781	CL-33855	CDR-L1	RASSGSIWYSFVS
3782	CL-33855	CDR-L2	ADDQRAS
3783	CL-33855	CDR-L3	QSYGINIDVV

TABLE 51
Summary of Protein Expression And Purification Of
Affinity Matured Humanized Anti-Human PDGF-BB
Antibodies
		Octet Titer	~Yield	SEC (%
	Name	(mg/L)1	(mg/L)2	monomer)3
	CL-33578-IgG	176.5	98.9	91.3
	CL-33587-IgG	155.7	109.1	94.2
	CL-33675-IgG	275.2	57.7	96.9
	CL-33682-IgG	203.6	80.7	94.6
	CL-33683-IgG	136.7	24.5	48.1
	CL-33701-IgG	114.9	79.2	97.9
	CL-33706-IgG	169.8	25.8	100.0
	CL-33731-IgG	137.0	73.6	95.8
	CL-33803-IgG	98.0	50.5	96.7
	CL-33805-IgG	227.5	66.5	97.9
	CL-33811-IgG	190.2	31.7	99.0
	CL-33812-IgG	171.0	76.4	96.7
	CL-33820-IgG	135.3	75.0	95.7
	CL-33855-IgG	50.9	13.8	94.3
	CL-33699-IgG	ND	10.5	81.7
	CL-33737-IgG	ND	5.0	88.0
	CL-33759-IgG	ND	18.5	100.0
	CL-33767-IgG	ND	16.5	50.9
	CL-33845-IgG	ND	0.8	60.6
	ND = Not Determined
	1Octet titer is the amount of IgG in the unpurified supernatant as determined by protein A binding compared to a standard curve using an Octet instrument.
	2Yield is determined by the total amount of purified protein in mg divided by the total cell culture volume in liters.
	3SEC % monomer is determined using HPLC size exclusion chromatography.

TABLE 52
Biacore Binding of Affinity-Matured Humanized
Anti-PDGF Antibodies
	Antibody	kon (M−1 s−1)	koff (M−1)	KD (M)
	CL-33578	≧9.0E+07	2.70E−05	≦3.0E−13
	CL-33587	≧9.0E+07	2.00E−05	≦2.2E−13
	CL-33675	3.60E+07	2.20E−05	6.10E−13
	CL-33682	≧9.0E+07	2.20E−05	≦2.4E−13
	CL-33683	1.90E+07	8.20E−06	4.40E−13
	CL-33701	7.30E+07	1.80E−05	2.40E−13
	CL-33706	1.80E+07	1.20E−05	6.90E−13
	CL-33731	8.10E+07	1.60E−05	2.00E−13
	CL-33803	≧9.0E+07	1.40E−05	≦1.6E−13
	CL-33805	6.80E+07	1.50E−05	2.10E−13
	CL-33811	2.70E+07	1.20E−05	4.50E−13
	CL-33812	6.30E+07	1.90E−05	3.00E−13
	CL-33820	≧9.8E+07	1.60E−05	≦1.6E−13
	CL-33855	2.00E+07	≦1.0E−06	≦5.0E−14
	*Heterogeneous off-rate

Affinity matured humanized anti-PDGF-BB antibodies were characterized for PDGF-BB binding and potency. Human PDGF-BB binding affinity was determined by Biacore analysis (Example 1.1). Potency was evaluated in both cell-based and ELISA formats. The ability to block binding of hPDGF-BB to hPDGF-Rβ was tested in a competition ELISA format (Example 1.13) Inhibition of human and cynomolgus PDGF-BB-induced cell proliferation was assessed using NIH-3T3 cells (Examples 1.15 and 1.16). The data is summarized in Table 53 below.

TABLE 53
Summary of Characterization of Affinity Matured Humanized
Anti-Human PDGF-BB Antibodies
	PDGF-BB IC50 Potency (nM)
	hPDGF-BB	cynoPDGF-BB	hPDGF-BB/
Affinity Matured	NIH-3T3	NIH-3T3	hPDGFR□
Humanized IgG	Proliferation	Proliferation	Competition
CL-33578-Ig	0.033	0.023	0.049
CL-33587-Ig	0.046	0.029	<0.1
CL-33675-Ig	0.04	0.024	0.054
CL-33682-Ig	0.03	0.019	0.069
CL-33683-Ig	0.029	0.028	0.126
CL-33699-Ig	0.033	0.016	0.072
CL-33706-Ig	0.035	0.019	0.081
CL-33731Ig	0.036	0.023	0.068
CL-33759-Ig	0.293	0.18	1.267
CL-33811-Ig	0.032	0.012	0.1
CL-33812-Ig	0.033	0.028	0.043
CL-33820-Ig	0.017	0.013	0.066
CL-33855-Ig	0.037	0.019	0.162
CL-33701-Ig	0.056	0.012	0.059
CL-33737-Ig	0.03	0.024	0.092
CL-33803-Ig	0.024	0.018	0.044
C-L33767-Ig	0.09	0.042	0.114
CL-33845-Ig	0.171	0.073	0.409
CL-33805-Ig	0.039	0.018	0.063

Example 9

Methods of Selecting Preferred Humanized Antibodies as DVD-Ig Building Blocks

Example 9.1

A Technique for Assessing the Stability of Regions of the Parental Antibodies Intended for DVD-Ig Protein Incorporation

The technique of differential scanning calorimetry (DSC) can be used to determine the thermal stabilities of the different domains of an antibody (e.g. CH2, CH3, CH1-CL, and VH-VL). The temperature of the highest peak in a DSC thermogram (plotted as heat capacity versus temperature) of an antibody has been shown to correspond to the midpoint of the unfolding transition or process of that antibody's VH-VL region due to increasing temperature. This may be interpreted as a measure of VH-VL thermal stability. VH-VL regions with high thermal stability in the antibody format will also likely have high thermal stability when incorporated into the DVD-Ig format as one of the binding domains. Therefore, antibodies can be screened to determine those with VH-VL regions of high thermal stability. Those regions can then be incorporated into the DVD-Ig format to increase the probability of generating a more stable DVD-Ig molecule.

Example 9.2

Determination of the Thermal Stability of the VH-VL Regions of Anti-VEGF mAbs and Anti-PDGF mAbs by Differential Scanning Calorimetry

A total of 73 mAbs (45 anti-VEGF and 28 anti-PDGF) were selected and analyzed by DSC (Example 2.2) and the thermal stabilities of their VH-VL regions were quantitated by determining the temperature of the highest peak in the DSC thermograms as detailed in Example 9.1 (Table 54).

TABLE 54
Thermal Stability of Anti-VEGF and Anti-PDGF Antibodies
		Temperature of highest peak in
Name	Target Antigen	DSC thermogram (° C.)
hBDB-4G8.1	VEGF	71.97
hBDB-4G8.2	VEGF	69.13
hBDB-4G8.3	VEGF	65.65
hBDB-4G8.4	VEGF	75.27
hBDB-4G8.5	VEGF	73.07
hBDB-4G8.6	VEGF	68.68
hBDB-4G8.7	VEGF	76.27
hBDB-4G8.8	VEGF	73.16
hBDB-4G8.9	VEGF	68.95
hBDB-4G8.10	VEGF	73.44
hBDB-4G8.11	VEGF	69.77
hBDB-4G8.12	VEGF	67.48
hBDB-4G8.13	VEGF	67.12
hBDB-4G8.14	VEGF	63.4
hBDB-4G8.15	VEGF	69.41
h4G8.3 EI	VEGF	68.31
h4G8 CL-32416	VEGF	68.95
h4G8 CL-34449	VEGF	72.7
h4G8 CL-34455	VEGF	70.69
h4G8 CL-34469	VEGF	70.23
h4G8 CL-34475	VEGF	70.69
h4G8 CL-34522	VEGF	67.49
h4G8 CL-34540	VEGF	69.87
h4G8 CL-34633	VEGF	69.22
h4G8 CL-34538	VEGF	71.15
h4G8 CL-34570	VEGF	66.84
h4G8 CL-34565	VEGF	71.15
hBEW-9A8.17	VEGF	64.56
hBEW-9A8.21	VEGF	54.25
hBEW-5C3.4	VEGF	66.94
hBEW-9E10.1	VEGF	71.88
hBEW-9E10.3	VEGF	71.24
hBEW-9E10.4	VEGF	71.77
hBEW-9E10.6	VEGF	71.24
hBEW-9A8.20	VEGF	61.85
hBEW-5C3.1	VEGF	63.15
hBEW-5C3.5	VEGF	64.83
hBEW-9E10.2	VEGF	71.37
hBEW-9E10.5	VEGF	71.24
hBEW-1B10.1	VEGF	87.95
hBEW-1B10.2	VEGF	86.38
hBEW-1E3.1	VEGF	62.74
hBEW-1E3.2	VEGF	66.29
hBEW-1E3.4	VEGF	66.11
hBEW-1E3.5	VEGF	68.83
hBDI-9E8.1	PDGF	77.6
hBDI-9E8.2	PDGF	76.28
hBDI-9E8.3	PDGF	87.4
hBDI-9E8.4	PDGF	84.2
hBDI-9E8.5	PDGF	77.69
hBDI-9E8.6	PDGF	75.91
hBDI-9E8.7	PDGF	87.4
hBDI-9E8.8	PDGF	84.29
hBDI-9E8.9	PDGF	82.09
hBDI-9E8.10	PDGF	83.37
hBDI-9E8.11	PDGF	80.9
hBDI-9E8.12	PDGF	82.64
hBDI-9E8.13	PDGF	85.39
CL-33578-IgG	PDGF	75.03
CL-33587-IgG	PDGF	76.37
CL-33675-IgG	PDGF	87.4
CL-33682-IgG	PDGF	78.52
CL-33683-IgG	PDGF	82.55
CL-33701-IgG	PDGF	73.62
CL-33706-IgG	PDGF	86.85
CL-33731-IgG	PDGF	77.33
CL-33803-IgG	PDGF	74.26
CL-33805-IgG	PDGF	80.35
CL-33811-IgG	PDGF	79.71
CL-33812-IgG	PDGF	78.15
CL-33820-IgG	PDGF	78.88
CL-33855-IgG	PDGF	82.18
hBFU-3E2.1	PDGF	68.31

Example 10

Generation of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules

The variable domain sequences from humanized anti-human VEGF-A and anti-human PDGF-BB mAbs were used to design the VH and VL domains of anti-human VEGF-A/anti-human PDGF-BB DVD-Ig molecules. In some cases, variable regions were synthesized using two-step PCR. Primers were designed with homologous flanking regions to the cloning vector and the linker region between each DVD variable pair. In some cases, variable regions were generated using gene synthesis. Bacterial transformations were performed to identify positive clones and constructs were harvested and purified for use in mammalian transfection using standard protocols known in the art.

The variable domains of the heavy and light chain were cloned in-frame into mutant human IgG1 (L234, 235A) heavy-chain or mutant human IgG1 (L234, 235A, H435A) heavy-chain, and kappa light-chain constant regions, respectively, into pHybE vectors to generate anti-human VEGF-A/anti-human PDGF-BB DVD-Ig molecules.

TABLE 55
Amino Acid Sequences of DVD-Ig Linkers
Seq ID
No	Name	Sequence
3784	HG-short	ASTKGP
3785	HG-long	ASTKGPSVFPLAP
3786	GS-H10	GGGGSGGGGS
3787	LK-short	RTVAAP
3788	LK-long	RTVAAPSVFIFPP
3789	GS-L10	RGGSGGGGSG
3790	GS-L10(dR)	GGSGGGGSGG
3791	GS-L11	RGGSGGGGSGG
3792		AKTTPKLEEGEFSEAR
3793		AKTTPKLEEGEFSEARV
3794		AKTTPKLGG
3795		SAKTTPKLGG
3796		SAKTTP
3797		RADAAP
3798		RADAAPTVS
3799		RADAAAAGGPGS
3800		RADAAAA(G4S)4
3801		SAKTTPKLEEGEFSEARV
3802		ADAAP
3803		ADAAPTVSIFPP
3804		TVAAP
3805		TVAAPSVFIFPP
3806		QPKAAP
3807		QPKAAPSVTLFPP
3808		AKTTPP
3809		AKTTPPSVTPLAP
3810		AKTTAP
3811		AKTTAPSVYPLAP
3812		ASTKGP
3813		ASTKGPSVFPLAP
3814		GGGGSGGGGSGGGGS
3815		GENKVEYAPALMALS
3816		GPAKELTPLKEAKVS
3817		GHEAAAVMQVQYPAS
3818		TVAAPSVFIFPPTVAAPSVFIFPP
3819		ASTKGPSVFPLAPASTKGPSVFPLAP
3820		GGGGSGGGGS
3821		GGSGGGGSG
		G/S based sequences
		(e.g., G4S (SEQ ID NO: 3822)
		and G4S repeats (“G4S”
		disclosed as SEQ ID NO: 3822))

TABLE 56
Heavy (H) and Light Chain (L) Composition of Anti-VEGF-A/Anti-PDGF-BB DVD-
Ig Molecules (first and second polypeptide chains are listed in alternating rows of the table)
						SEQ ID NO
						VD1-X1-
SEQ ID		DVD-Ig Variable Domain	Outer Variable		Inner Variable	VD2
NO	Corporate ID	Name	Domain Name	Linker	Domain Name	Formula
	NA	AB014-GS-9E8.4a	AB014 VH	GS-H10	hBDI-9E8.4 VH
			AB014 VL	GS-L10	hBDI-9E8.4 VL
	NA	9E8.4-GS-AB014a	hBDI-9E8.4 VH	GS-H10	AB014 VH
			hBDI-9E8.4 VL	GS-L10	AB014 VL
	NA	AB014-SS-9E8.4a	AB014 VH	HG-short	hBDI-9E8.4 VH
			AB014 VL	LK-short	hBDI-9E8.4 VL
	NA	9E8.4-SS-AB014a	hBDI-9E8.4 VH	HG-short	AB014 VH
			hBDI-9E8.4 VL	LK-short	AB014 VL
	NA	AB014-SL-9E8.4a	AB014 VH	HG-short	hBDI-9E8.4 VH
			AB014 VL	LK-long	hBDI-9E8.4 VL
	NA	9E8.4-SL-AB014a	hBDI-9E8.4 VH	HG-short	AB014 VH
			hBDI-9E8.4 VL	LK-long	AB014 VL
	NA	AB014-LS-9E8.4a	AB014 VH	HG-long	hBDI-9E8.4 VH
			AB014 VL	LK-short	hBDI-9E8.4 VL
	NA	9E8.4-LS-AB014a	hBDI-9E8.4 VH	HG-long	AB014 VH
			hBDI-9E8.4 VL	LK-short	AB014 VL
	PR-1563988	9E8.4-GS-4G8.3a	hBDI-9E8.4 VH	GS-H10	hBDB-4G8.3 VH
			hBDI-9E8.4 VL	GS-L10	hBDB-4G8.3 VL
	PR-1563990	9E8.4-SS-4G8.3a	hBDI-9E8.4 VH	HG-short	hBDB-4G8.3 VH
			hBDI-9E8.4 VL	LK-short	hBDB-4G8.3 VL
	PR-1563998	9E8.4-SL-4G8.3a	hBDI-9E8.4 VH	HG-short	hBDB-4G8.3 VH
			hBDI-9E8.4 VL	LK-long	hBDB-4G8.3 VL
	PR-1564009	9E8.4-LS-4G8.3a	hBDI-9E8.4 VH	HG-long	hBDB-4G8.3 VH
			hBDI-9E8.4 VL	LK-short	hBDB-4G8.3 VL
	PR-1564010	4G8.3-GS-9E8.4a	hBDB-4G8.3 VH	GS-H10	hBDI-9E8.4 VH
			hBDB-4G8.3 VL	GS-H10	hBDI-9E8.4 VL
	PR-1564011	4G8.3-SS-9E8.4a	hBDB-4G8.3 VH	HG-short	hBDI-9E8.4 VH
			hBDB-4G8.3 VL	LK-short	hBDI-9E8.4 VL
	PR-1564012	4G8.3-SL-9E8.4a	hBDB-4G8.3 VH	HG-short	hBDI-9E8.4 VH
			hBDB-4G8.3 VL	LK-long	hBDI-9E8.4 VL
	PR-1564013	4G8.3-LS-9E8.4a	hBDB-4G8.3 VH	HG-long	hBDI-9E8.4 VH
			hBDB-4G8.3 VL	LK-short	hBDI-9E8.4 VL
	PR-1569574	9E8.4-GS-4G8.3	hBDI-9E8.4 VH	GS-H10	hBDB-4G8.3 VH
			hBDI-9E8.4 VL	GS-L10	hBDB-4G8.3 VL
	PR-1569579	9E8.4-SL-4G8.3	hBDI-9E8.4 VH	HG-short	hBDB-4G8.3 VH
			hBDI-9E8.4 VL	LK-long	hBDB-4G8.3 VL
	PR-1575573	9E8.4-LS-4G8.3	hBDI-9E8.4 VH	HG-long	hBDB-4G8.3 VH
			hBDI-9E8.4 VL	LK-short	hBDB-4G8.3 VL
	PR-1572102	4G8.3-GS-9E8.4 (g)	hBDB-4G8.3 VH	GS-H10	hBDI-9E8.4 VH
			hBDB-4G8.3 VL	GS-L10	hBDI-9E8.4 VL
	PR-1572103	4G8.3-GS(11)-9E8.4 (g)	hBDB-4G8.3 VH	GS-H10	hBDI-9E8.4 VH
			hBDB-4G8.3 VL	GS-L11	hBDI-9E8.4 VL
	PR-1572104	4G8.3-GS(noR)-9E8.4 (g)	hBDB-4G8.3 VH	GS-H10	hBDI-9E8.4 VH
			hBDB-4G8.3 VL	GS-	hBDI-9E8.4 VL
				L10 (dR)
	PR-1572105	4G8.3-SL-9E8.4 (g)	hBDB-4G8.3 VH	HG-short	hBDI-9E8.4 VH
			hBDB-4G8.3 VL	LK-long	hBDI-9E8.4 VL
	PR-1572106	4G8.3-LS-9E8.4 (g)	hBDB-4G8.3 VH	HG-long	hBDI-9E8.4 VH
			hBDB-4G8.3 VL	LK-short	hBDI-9E8.4 VL
	PR-1575832	4G8.3-GS-9E8.4E	hBDB-4G8.3 VH	GS-H10	hBDI-9E8.4E VH
			hBDB-4G8.3 VL	GS-L10	hBDI-9E8.4E VL
	PR-1575834	4G8.3-SL-9E8.4E	hBDB-4G8.3 VH	HG-short	hBDI-9E8.4E VH
			hBDB-4G8.3 VL	LK-long	hBDI-9E8.4E VL
	PR-1575835	4G8.3-LS-9E8.4E	hBDB-4G8.3 VH	HG-long	hBDI-9E8.4E VH
			hBDB-4G8.3 VL	LK-short	hBDI-9E8.4E VL
	PR-1577165	9A8.12-GS-9E8.4E	hBEW-9A8.12	GS-H10	hBDI-9E8.4E VH
			VH
			hBEW-9A8.12 VL	GS-L10	hBDI-9E8.4E VL
	PR-1577166	9A8.12-SL-9E8.4E	hBEW-9A8.12	HG-short	hBDI-9E8.4E VH
			VH
			hBEW-9A8.12 VL	LK-long	hBDI-9E8.4E VL
	PR-1577547	9A8.12-LS-9E8.4E	hBEW-9A8.12	HG-long	hBDI-9E8.4E VH
			VH
			hBEW-9A8.12 VL	LK-short	hBDI-9E8.4E VL
	PR-1578137	9E8.4E-GS-9A8.12	hBDI-9E8.4E VH	GS-H10	hBEW-9A8.12 VH
			hBDI-9E8.4E VL	GS-L10	hBEW-9A8.12 VL
	PR-1577548	9E8.4E-SL-9A8.12	hBDI-9E8.4E VH	HG-short	hBEW-9A8.12 VH
			hBDI-9E8.4E VL	LK-long	hBEW-9A8.12 VL
	PR-1577550	9E8.4E-LS-9A8.12	hBDI-9E8.4E VH	HG-long	hBEW-9A8.12 VH
			hBDI-9E8.4E VL	LK-short	hBEW-9A8.12 VL
	PR-1598261	4G8.2-GS-9E8.4	hBDB-4G8.2 VH	GS-H10	hBDI-9E8.4 VH
			hBDB-4G8.2 VL	GS-L10	hBDI-9E8.4 VL
	PR-1598262	4G8.4-GS-9E8.4	hBDB-4G8.4 VH	GS-H10	hBDI-9E8.4 VH
			hBDB-4G8.4 VL	GS-L10	hBDI-9E8.4 VL
	PR-1598263	4G8.5-GS-9E8.4	hBDB-4G8.5 VH	GS-H10	hBDI-9E8.4 VH
			hBDB-4G8.5 VL	GS-L10	hBDI-9E8.4 VL
	PR-1598264	4G8.12-GS-9E8.4	hBDB-4G8.12 VH	GS-H10	hBDI-9E8.4 VH
			hBDB-4G8.12 VL	GS-L10	hBDI-9E8.4 VL
	PR-1598265	4G8.13-GS-9E8.4	hBDB-4G8.13 VH	GS-H10	hBDI-9E8.4 VH
			hBDB-4G8.13 VL	GS-L10	hBDI-9E8.4 VL
	PR-1598266	4G8.14-GS-9E8.4	hBDB-4G8.14 VH	GS-H10	hBDI-9E8.4 VH
			hBDB-4G8.14 VL	GS-L10	hBDI-9E8.4 VL
	PR-1613183	CL-34565_GS_CL-33675	CL-34565 VH	GS-H10	CL-33675 VH
			CL-34565 VL	GS-	CL-33675 VL
				L10 (dR)
	PR-1613184	CL-34565_GS_9E8.4	CL-34565 VH	GS-H10	hBDI-9E8.4 VH
			CL-34565 VL	GS-	hBDI-9E8.4 VL
				L10 (dR)
	PR-1613185	CL-34565_GS_3E2.1	CL-34565 VH	GS-H10	hBFU-3E2.1 VH
			CL-34565 VL	GS-	hBFU-3E2.1 VL
				L10 (dR)
	PR-1611291	4G8.5_GS_CL-33675	hBDB-4G8.5 VH	GS-H10	CL-33675 VH
			hBDB-4G8.5 VL	GS-	CL-33675 VL
				L10 (dR)
	PR-1612489	4G8.5_GS_9E8.4	hBDB-4G8.5 VH	GS-H10	hBDI-9E8.4 VH
			hBDB-4G8.5 VL	GS-	hBDI-9E8.4 VL
				L10 (dR)
	PR-1610560	4G8.5_GS_3E2.1	hBDB-4G8.5 VH	GS-H10	hBFU-3E2.1 VH
			hBDB-4G8.5 VL	GS-	hBFU-3E2.1 VL
				L10 (dR)
	PR-1610561	9E10.1_GS_CL-33675	hBEW-9E10.1 VH	GS-H10	CL-33675 VH
			hBEW-9E10.1 VL	GS-	CL-33675 VL
				L10 (dR)
	PR-1612491	9E10.1_GS_9E8.4	hBEW-9E10.1 VH	GS-H10	hBDI-9E8.4 VH
			hBEW-9E10.1 VL	GS-	hBDI-9E8.4 VL
				L10 (dR)
	PR-1610562	9E10.1_GS_3E2.1	hBEW-9E10.1 VH	GS-H10	hBFU-3E2.1 VH
			hBEW-9E10.1 VL	GS-	hBFU-3E2.1 VL
				L10 (dR)
	PR-1612492	9E10.6_GS_CL-33675	hBEW-9E10.6 VH	GS-H10	CL-33675 VH
			hBEW-9E10.6 VL	GS-	CL-33675 VL
				L10 (dR)
	PR-1612493	9E10.6_GS_9E8.4	hBEW-9E10.6 VH	GS-H10	hBDI-9E8.4 VH
			hBEW-9E10.6 VL	GS-	hBDI-9E8.4 VL
				L10 (dR)
	PR-1610563	9E10.6_GS_3E2.1	hBEW-9E10.6 VH	GS-H10	hBFU-3E2.1 VH
			hBEW-9E10.6 VL	GS-	hBFU-3E2.1 VL
				L10 (dR)
	PR-1611292	1B10.1_GS_CL-33675	hBEW-1B10.1 VH	GS-H10	CL-33675 VH
			hBEW-1B10.1 VL	GS-	CL-33675 VL
				L10 (dR)
	PR-1612494	1B10.1_GS_9E8.4	hBEW-1B10.1 VH	GS-H10	hBDI-9E8.4 VH
			hBEW-1B10.1 VL	GS-	hBDI-9E8.4 VL
				L10 (dR)
	PR-1610564	1B10.1_GS_3E2.1	hBEW-1B10.1 VH	GS-H10	hBFU-3E2.1 VH
			hBEW-1B10.1 VL	GS-	hBFU-3E2.1 VL
				L10 (dR)
	PR-1611293	1E3.4_GS_CL-33675	hBEW-1E3.4 VH	GS-H10	CL-33675 VH
			hBEW-1E3.4 VL	GS-	CL-33675 VL
				L10 (dR)
	PR-1611294	1E3.4_GS_9E8.4	hBEW-1E3.4 VH	GS-H10	hBDI-9E8.4 VH
			hBEW-1E3.4 VL	GS-	hBDI-9E8.4 VL
				L10 (dR)
	PR-1612495	1E3.4_GS_3E2.1	hBEW-1E3.4 VH	GS-H10	hBFU-3E2.1 VH
			hBEW-1E3.4 VL	GS-	hBFU-3E2.1 VL
				L10 (dR)
	PR-1613186	CL-33675_GS_CL-34565	CL-33675 VH	GS-H10	CL-34565 VH
			CL-33675 VL	GS-	CL-34565 VL
				L10 (dR)
	PR-1612496	CL-33675_GS_4G8.5	CL-33675 VH	GS-H10	hBDB-4G8.5 VH
			CL-33675 VL	GS-	hBDB-4G8.5 VL
				L10 (dR)
	PR-1611295	CL-33675_GS_9E10.1	CL-33675 VH	GS-H10	hBEW-9E10.1 VH
			CL-33675 VL	GS-	hBEW-9E10.1 VL
				L10 (dR)
	PR-1611296	CL-33675_GS_9E10.6	CL-33675 VH	GS-H10	hBEW-9E10.6 VH
			CL-33675 VL	GS-	hBEW-9E10.6 VL
				L10 (dR)
	PR-1612498	CL-33675_GS_1B10.1	CL-33675 VH	GS-H10	hBEW-1B10.1 VH
			CL-33675 VL	GS-	hBEW-1B10.1
				L10 (dR)	VL
	PR-1611297	CL-33675_GS_1E3.4	CL-33675 VH	GS-H10	hBEW-1E3.4
					VH
			CL-33675 VL	GS-	hBEW-1E3.4 VL
				L10 (dR)
	PR-1613187	9E8.4_GS_CL-34565	hBDI-9E8.4 VH	GS-H10	CL-34565 VH
			hBDI-9E8.4 VL	GS-	CL-34565 VL
				L10 (dR)
	PR-1613188	9E8.4_GS_4G8.5	hBDI-9E8.4 VH	GS-H10	hBDB-4G8.5 VH
			hBDI-9E8.4 VL	GS-	hBDB-4G8.5 VL
				L10 (dR)
	PR-1611298	9E8.4_GS_9E10.1	hBDI-9E8.4 VH	GS-H10	hBEW-9E10.1
					VH
				GS-	hBEW-9E10.1H
				L10 (dR)	VL
	PR-1611299	9E8.4_GS_9E10.6	hBDI-9E8.4 VH	GS-H10	hBEW-9E10.6
					VH
			hBDI-9E8.4 VL	GS-	hBEW-9E10.6
				L10 (dR)	VL
	PR-1611300	9E8.4_GS_1B10.1	hBDI-9E8.4 VH	GS-H10	hBEW-1B10.1 VH
			hBDI-9E8.4 VL	GS-	hBEW-1B10.1
				L10 (dR)	VL
	PR-1611301	9E8.4_GS_1E3.4	hBDI-9E8.4 VH	GS-H10	hBEW-1E3.4
					VH
			hBDI-9E8.4 VL	GS-	hBEW-1E3.4 VL
				L10 (dR)
	PR-1613189	3E2.1_GS_CL-34565	hBFU-3E2.1 VH	GS-H10	CL-34565 VH
			hBFU-3E2.1 VL	GS-	CL-34565 VL
				L10 (dR)
	PR-1612499	3E2.1_GS_4G8.5	hBFU-3E2.1 VH	GS-H10	hBDB-4G8.5 VH
			hBFU-3E2.1 VL	GS-	hBDB-4G8.5 VL
				L10 (dR)
	PR-1612500	3E2.1_GS_9E10.1	hBFU-3E2.1 VH	GS-H10	hBEW-9E10.1
					VH
			hBFU-3E2.1 VL	GS-	hBEW-9E10.1
				L10 (dR)	VL
	PR-1612501	3E2.1_GS_9E10.6	hBFU-3E2.1 VH	GS-H10	hBEW-9E10.6
					VH
			hBFU-3E2.1 VL	GS-	hBEW-9E10.6
				L10 (dR)	VL
	PR-1612502	3E2.1_GS_1B10.1	hBFU-3E2.1 VH	GS-H10	hBEW-1B10.1 VH
			hBFU-3E2.1 VL	GS-	hBEW-1B10.1
				L10 (dR)	VL
	PR-1613190	3E2.1_GS_1E3.4	hBFU-3E2.1 VH	GS-H10	hBEW-1E3.4
					VH
			hBFU-3E2.1 VL	GS-	hBEW-1E3.4 VL
				L10 (dR)
	PR-1629646	9E10.1_SL_CL-33675	hBEW-9E10.1 VH	HG-short	CL-33675 VH
			hBEW-9E10.1 VL	LK-long	CL-33675 VL
	PR-1629647	1B10.1_SL_CL-33675	hBEW-1B10.1 VH	HG-short	CL-33675 VH
			hBEW-1B10.1 VL	LK-long	CL-33675 VL
	PR-1629648	9E10.1_LS_CL-33675	hBEW-9E10.1 VH	HG-long	CL-33675 VH
			hBEW-9E10.1 VL	LK-short	CL-33675 VL
	PR-1629649	1B10.1_LS_CL-33675	hBEW-1B10.1 VH	HG-long	CL-33675 VH
			hBEW-1B10.1 VL	LK-short	CL-33675 VL
	PR-1564883	DVD3896a	hBDI-5H1.9 VH	HG-short	hBDB-4G8.13
					VH
			hBDI-5H1.9 VL	LK-long	hBDB-4G8.13
					VL
	PR-1564893	DVD3897a	hBDI-5H1.9 VH	HG-short	hBDB-4G8.14
					VH
			hBDI-5H1.9 VL	LK-long	hBDB-4G8.14
					VL
	PR-1564896	DVD3898a	hBDI-5H1.9 VH	HG-short	hBDB-4G8.15
					VH
			hBDI-5H1.9 VL	LK-long	hBDB-4G8.15
					VL
	PR-1564898	DVD3899a	hBDI-9E8.12 VH	HG-short	hBDB-4G8.14
					VH
			hBDI-9E8.12 VL	LK-long	hBDB-4G8.14
					VL
	PR-1564899	DVD3900a	hBDI-9E8.12 VH	HG-short	hBDB-4G8.15
					VH
			hBDI-9E8.12 VL	LK-long	hBDB-4G8.15
					VL
	PR-1565023	DVD3901a	hBDI-9E8.9 VH	HG-short	hBDB-4G8.13
					VH
			hBDI-9E8.9 VL	LK-long	hBDB-4G8.13
					VL
	PR-1565029	DVD3902a	hBDI-9E8.9 VH	HG-short	hBDB-4G8.14
					VH
			hBDI-9E8.9 VL	LK-long	hBDB-4G8.14
					VL
	PR-1565030	DVD3903a	hBDI-9E8.9 VH	HG-short	hBDB-4G8.15
					VH
			hBDI-9E8.9 VL	LK-long	hBDB-4G8.15
					VL
	PR-1565031	DVD3904a	hBDI-5H1.13 VH	HG-short	hBDB-4G8.14
					VH
			hBDI-5H1.13 VL	LK-long	hBDB-4G8.14
					VL
	PR-1565032	DVD3905a	hBDI-9E8.12 VH	HG-short	hBDB-4G8.15
					VH
			hBDI-9E8.12 VL	LK-long	hBDB-4G8.15
					VL
	PR-1565035	DVD3906a	hBDI-5H1.13 VH	HG-short	hBDB-4G8.15
					VH
			hBDI-5H1.13 VL	LK-long	hBDB-4G8.15
					VL
	PR-1565033	DVD3907a	hBDI-9E8.13 VH	HG-short	hBDB-4G8.15
					VH
			hBDI-9E8.13 VL	LK-long	hBDB-4G8.15
					VL
aThese DVDs were made with Ig gamma-1 constant region L234A, L235A, all other DVDs made with Ig gamma-1 constant region L234A, L235A, and H435A.

TABLE 57
Heavy (H) and Light Chain (L) Amino Acid Composition of
Some Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules
(Linker sequence in italics; CDR sequences in bold;
HC = heavy chain and LC = light chain)
Sequence	DVD-Ig Variable	Sequence
Identifier	Domain (Corporate ID)	12345678901234567890123456789012
SEQ ID NO: 3823	4G8.3-GS-9E8.4 HC	EVQLVQSGSELKKPGASVKVSCKASGYTFTNY
	(PR-1569574)	GMYWVRQAPGQGLEWMGWINTETGKPTYADDF
		KGRFVFSLDTSVSTAYLQISSLKAEDTAVYYC
		ARTNYYYRSYIFYFDYWGQGTMVTVSSGGGGS
		GGGGSEVTLRESGPALVKPTQTLTLTCTFSGF
		SLSTYGMGVGWIRQPPGKALEWLANIWWDDDK
		YYNPSLKNRLTISKDTSKNQVVLTMTNMDPVD
		TATYYCARIESIGTTYSFDYWGQGTMVTVSSA
		STKGPSVFPLAPSSKSTSGGTAALGCLVKDYF
		PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL
		SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKK
		VEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPK
		PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
		VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
		QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCLVKGFYP
		SDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
		YSKLTVDKSRWQQGNVFSCSVMHEALHNAYTQ
		KSLSLSPGK
SEQ ID NO: 3824	4G8.3-GS-9E8.4 LC	DTVLTQSPATLSLSPGERATLSCRASESVSTH
	(PR-1569574)	MHWYQQKPGQAPRLLIYGASNLESGVPARFSG
		SGSGTDFTLTISSLEPEDFAVYFCQQSWNDPF
		TFGQGTKLEIKRGGSGGGGSGEFVLTQSPGTL
		SLSPGERATLSCERSSGDIGDSYVSWYQQKPG
		QAPRLVIYADDQRPSGIPDRFSGSGSGTDFTL
		TISRLEPEDFAVYYCQSYDINIDIVFGGGTKV
		EIKGTVAAPSVFIFPPSDEQLKSGTASVVCLL
		NNFYPREAKVQWKVDNALQSGNSQESVTEQDS
		KDSTYSLSSTLTLSKADYEKHKVYACEVTHQG
		LSSPVTKSFNRGEC
SEQ ID NO: 3825	4G8.3-SL-9E8.4 HC	EVQLVQSGSELKKPGASVKVSCKASGYTFTNY
	(PR-1569579)	GMYWVRQAPGQGLEWMGWINTETGKPTYADDF
		KGRFVFSLDTSVSTAYLQISSLKAEDTAVYYC
		ARTNYYYRSYIFYFDYWGQGTMVTVSSASTKG
		PEVTLRESGPALVKPTQTLTLTCTFSGFSLST
		YGMGVGWIRQPPGKALEWLANIWWDDDKYYNP
		SLKNRLTISKDTSKNQVVLTMTNMDPVDTATY
		YCARIESIGTTYSFDYWGQGTMVTVSSASTKG
		PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV
		TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV
		TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPK
		SCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDT
		LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
		EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL
		NGKEYKCKVSNKALPAPIEKTISKAKGQPREP
		QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA
		VEWESNGQPENNYKTTPPVLDSDGSFFLYSKL
		TVDKSRWQQGNVFSCSVMHEALHNAYTQKSLS
		LSPGK
SEQ ID NO: 3826	4G8.3-SL-9E8.4 LC	DTVLTQSPATLSLSPGERATLSCRASESVSTH
	(PR-1569579)	MHWYQQKPGQAPRLLIYGASNLESGVPARFSG
		SGSGTDFTLTISSLEPEDFAVYFCQQSWNDPF
		TFGQGTKLEIKRTVAAPSVFIFPPEFVLTQSP
		GTLSLSPGERATLSCERSSGDIGDSYVSWYQQ
		KPGQAPRLVIYADDQRPSGIPDRFSGSGSGTD
		FTLTISRLEPEDFAVYYCQSYDINIDIVFGGG
		TKVEIKGTVAAPSVFIFPPSDEQLKSGTASVV
		CLLNNFYPREAKVQWKVDNALQSGNSQESVTE
		QDSKDSTYSLSSTLTLSKADYEKHKVYACEVT
		HQGLSSPVTKSFNRGEC
SEQ ID NO: 3827	4G8.3-LS-9E8.4 HC	EVQLVQSGSELKKPGASVKVSCKASGYTFTNY
	(PR-1575573)	GMYWVRQAPGQGLEWMGWINTETGKPTYADDF
		KGRFVFSLDTSVSTAYLQISSLKAEDTAVYYC
		ARTNYYYRSYIFYFDYWGQGTMVTVSSASTKG
		PSVFPLAPEVTLRESGPALVKPTQTLTLTCTF
		SGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
		DDKYYNPSLKNRLTISKDTSKNQVVLTMTNMD
		PVDTATYYCARIESIGTTYSFDYWGQGTMVTV
		SSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
		DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL
		YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV
		DKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLF
		PPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF
		NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT
		VLHQDWLNGKEYKCKVSNKALPAPIEKTISKA
		KGQPREPQVYTLPPSREEMTKNQVSLTCLVKG
		FYPSDIAVEWESNGQPENNYKTTPPVLDSDGS
		FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNA
		YTQKSLSLSPGK
SEQ ID NO: 3828	4G8.3-LS-9E8.4 LC	DTVLTQSPATLSLSPGERATLSCRASESVSTH
	(PR-1575573)	MHWYQQKPGQAPRLLIYGASNLESGVPARFSG
		SGSGTDFTLTISSLEPEDFAVYFCQQSWNDPF
		TFGQGTKLEIKRTVAAPEFVLTQSPGTLSLSP
		GERATLSCERSSGDIGDSYVSWYQQKPGQAPR
		LVIYADDQRPSGIPDRFSGSGSGTDFTLTISR
		LEPEDFAVYYCQSYDINIDIVFGGGTKVEIKG
		TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFY
		PREAKVQWKVDNALQSGNSQESVTEQDSKDST
		YSLSSTLTLSKADYEKHKVYACEVTHQGLSSP
		VTKSFNRGEC
SEQ ID NO: 3829	4G8.3-GS-9E8.4 (g)	EVQLVQSGSELKKPGASVKVSCKASGYTFTNY
	HC (PR-1572102)	GMYWVRQAPGQGLEWMGWINTETGKPTYADDF
		KGRFVFSLDTSVSTAYLQISSLKAEDTAVYYC
		ARTNYYYRSYIFYFDYWGQGTMVTVSSGGGGS
		GGGGSEVTLRESGPALVKPTQTLTLTCTFSGF
		SLSTYGMGVGWIRQPPGKALEWLANIWWDDDK
		YYNPSLKNRLTISKDTSKNQVVLTMTNMDPVD
		TATYYCARIESIGTTYSFDYWGQGTMVTVSSA
		STKGPSVFPLAPSSKSTSGGTAALGCLVKDYF
		PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL
		SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKK
		VEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPK
		PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
		VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
		QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCLVKGFYP
		SDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
		YSKLTVDKSRWQQGNVFSCSVMHEALHNAYTQ
		KSLSLSPGK
SEQ ID NO: 3830	4G8.3-GS-9E8.4 (g) LC	DTVLTQSPATLSLSPGERATLSCRASESVSTH
	(PR-1572102)	MHWYQQKPGQAPRLLIYGASNLESGVPARFSG
		SGSGTDFTLTISSLEPEDFAVYFCQQSWNDPF
		TFGQGTKLEIKRGGSGGGGSGEFVLTQSPGTL
		SLSPGERATLSCERSSGDIGDSYVSWYQQKPG
		QAPRLVIYADDQRPSGIPDRFSGSGSGTDFTL
		TISRLEPEDFAVYYCQSYDINIDIVFGGGTKV
		EIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL
		NNFYPREAKVQWKVDNALQSGNSQESVTEQDS
		KDSTYSLSSTLTLSKADYEKHKVYACEVTHQG
		LSSPVTKSFNRGEC
SEQ ID NO: 3831	4G8.3-SL-9E8.4 (g) HC	EVQLVQSGSELKKPGASVKVSCKASGYTFTNY
	(PR-1572105)	GMYWVRQAPGQGLEWMGWINTETGKPTYADDF
		KGRFVFSLDTSVSTAYLQISSLKAEDTAVYYC
		ARTNYYYRSYIFYFDYWGQGTMVTVSSASTKG
		PEVTLRESGPALVKPTQTLTLTCTFSGFSLST
		YGMGVGWIRQPPGKALEWLANIWWDDDKYYNP
		SLKNRLTISKDTSKNQVVLTMTNMDPVDTATY
		YCARIESIGTTYSFDYWGQGTMVTVSSASTKG
		PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV
		TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV
		TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPK
		SCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDT
		LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
		EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL
		NGKEYKCKVSNKALPAPIEKTISKAKGQPREP
		QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA
		VEWESNGQPENNYKTTPPVLDSDGSFFLYSKL
		TVDKSRWQQGNVFSCSVMHEALHNAYTQKSLS
		LSPGK
SEQ ID NO: 3832	4G8.3-SL-9E8.4 (g) LC	DTVLTQSPATLSLSPGERATLSCRASESVSTH
	(PR-1572105)	MHWYQQKPGQAPRLLIYGASNLESGVPARFSG
		SGSGTDFTLTISSLEPEDFAVYFCQQSWNDPF
		TFGQGTKLEIKRTVAAPSVFIFPPEFVLTQSP
		GTLSLSPGERATLSCERSSGDIGDSYVSWYQQ
		KPGQAPRLVIYADDQRPSGIPDRFSGSGSGTD
		FTLTISRLEPEDFAVYYCQSYDINIDIVFGGG
		TKVEIKrTVAAPSVFIFPPSDEQLKSGTASVV
		CLLNNFYPREAKVQWKVDNALQSGNSQESVTE
		QDSKDSTYSLSSTLTLSKADYEKHKVYACEVT
		HQGLSSPVTKSFNRGEC
SEQ ID NO: 3833	9E10.1_GS_CL-33675	EIQLVQSGSELKKPGASVKVSCKASGYTFTNY
	HC (PR-1610561)	GMYWVKQAPGQGLEYMGWIDTETGRPTYADDF
		KGRFVFSLDTSVSTAYLQISSLKAEDTAVYFC
		ARWSGDTTGIRGPWFAYWGQGTLVTVSSGGGG
		SGGGGSEVTLRESGPALVKPTQTLTLTCTFSG
		FSLSTYGMGVGWIRQPPGKALEWLANIWWDDD
		KYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSGPKYSFDYWGQGTMVTVSS
		ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY
		FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
		LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK
		KVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPP
		KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
		YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL
		HQDWLNGKEYKCKVSNKALPAPIEKTISKAKG
		QPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
		PSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
		LYSKLTVDKSRWQQGNVFSCSVMHEALHNAYT
		QKSLSLSPGK
SEQ ID NO: 3834	9E10.1_GS_CL-33675	DIRMTQSPSSLSASVGDRVTIECLASEDIYSD
	LC (PR-1610561)	LAWYQQKPGKSPKLLIYNANGLQNGVPSRFSG
		SGSGTDYSLTISSLQPEDVATYFCQQYNYFPG
		TFGQGTKLEIKGGSGGGGSGGEIVLTQSPGTL
		SLSPGERATLSCRASSGSIWYSFVSWYQQKPG
		QAPRLLIYADDQRASGIPDRFSGSGSGTDFTL
		TISRLEPEDFAVYYCQSYGINIDVVFGGGTKV
		EIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL
		NNFYPREAKVQWKVDNALQSGNSQESVTEQDS
		KDSTYSLSSTLTLSKADYEKHKVYACEVTHQG
		LSSPVTKSFNRGEC
SEQ ID NO: 3835	1B10.1_GS_CL-33675	EVQLVESGGGLVQPGGSLRLSCAASGFSFSKY
	HC (PR-1611292)	DMAWFRQAPGKGLEWVASITTSGVGTYYRDSV
		KGRFTVSRDNAKSTLYLQMNSLRAEDTAVYYC
		ARGYGAMDAWGQGTTVTVSSGGGGSGGGGSEV
		TLRESGPALVKPTQTLTLTCTFSGFSLSTYGM
		GVGWIRQPPGKALEWLANIWWDDDKYYNPSLK
		NRLTISKDTSKNQVVLTMTNMDPVDTATYYCA
		RIESSGPKYSFDYWGQ
		GTMVTVSSASTKGPSVFPLAPSSKSTSGGTAA
		LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
		LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK
		PSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGG
		PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
		VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE
		KTISKAKGQPREPQVY
		TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEW
		ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD
		KSRWQQGNVFSCSVMHEALHNAYTQKSLSLSP
		GK
SEQ ID NO: 3836	1B10.1_GS_CL-33675	DIQMTQSPSSLSASVGDRVTITCKASQDIDDY
	LC (PR-1611292)	LSWYQQKPGKSPKLVIYAATRLADGVPSRFSG
		SGSGTDYTLTISSLQPEDFATYYCLQSSSTPW
		TFGGGTKVEIKGGSGGGGSGGEIVLTQSPGTL
		SLSPGERATLSCRASSGSIWYSFVSWYQQKPG
		QAPRLLIYADDQRASGIPDRFSGSGSGTDFTL
		TISRLEPEDFAVYYCQSYGINIDVVFGGGTKV
		EIKRTVAAPSVFIFPP
		SDEQLKSGTASVVCLLNNFYPREAKVQWKVDN
		ALQSGNSQESVTEQDSKDSTYSLSSTLTLSKA
		DYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Example 11

Generation of CO-DVD-Ig Molecules

Cross-over DVD-Ig binding proteins are constructed as shown below. Each of VD1, VD2, VD3 and VD4 could be the VH or VL from a mAb. In cross-over DVD-Ig, VD1 and VD4 form one antigen binding domain. VD2 and VD3 form another binding domain.

TABLE 58
Heavy Chain and Light Chain Amino Acid Sequences of Anti-Human
VEGF-A/Anti-Human PDGF-BB Cross-over DVD-Ig Molecules
(Linker sequence in italics; CDR sequences in bold)
Seq ID	Name (Corporate	Sequence
No	ID)	1234567890123456789012345678901234567890
3844	CODV001 HC	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQA
	(PR-1565040)	PGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAY
		LQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVT
		VSSGEVTLKESGPALVKPTQTLTLTCTFSGFSLSTFGMGV
		GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTS
		KNQAVLTITNMDPVDTATYYCARISTGISSYYVMDAWGQG
		TTVTVSSGGASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
		YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV
		PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPP
		CPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV
		LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV
		YTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
		NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM
		HEALHNHYTQKSLSLSPGK
3845	CODV001 LC	DFQLTQSPSSLSASVGDRVTITCERSSGDIGDTYVSWYQQ
	(PR-1565040)	KPGKAPKNVIYGNDQRPSGVPSRFSGSGSGNSATLTISSL
		QPEDFATYFCQSYDSDIDIVFGQGTKVEIKGGGSGGGDIQ
		MTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKA
		PKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDF
		ATYYCQQYSTVPWTFGQGTKVEIKGGGSGRTVAAPSVFIF
		PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
		SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
		QGLSSPVTKSFNRGEC
3837	CODV002 HC	EVTLKESGPALVKPTQTLTLTCTFSGFSLSTFGMGVGWIR
	(PR-1565042)	QPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQA
		VLTITNMDPVDTATYYCARISTGISSYYVMDAWGQGTTVT
		VSSGEVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNW
		VRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSK
		STAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQG
		TLVTVSSGGASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
		YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV
		PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPP
		CPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV
		LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV
		YTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
		NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM
		HEALHNHYTQKSLSLSPGK
3838	CODV002 LC	DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKP
	(PR-1565042)	GKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQP
		EDFATYYCQQYSTVPWTFGQGTKVEIKGGGSGGGDFQLTQ
		SPSSLSASVGDRVTITCERSSGDIGDTYVSWYQQKPGKAP
		KNVIYGNDQRPSGVPSRFSGSGSGNSATLTISSLQPEDFA
		TYFCQSYDSDIDIVFGQGTKVEIKGGGSGRTVAAPSVFIF
		PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
		SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
		QGLSSPVTKSFNRGEC
213	CODV003 HC	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQA
	(PR-1565044)	PGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAY
		LQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVT
		VSSGEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGV
		GWIRQPPGKGLEWLANIWWDDDKYYNPSLKNRLTISKDTS
		KNQAVLTITNMDPVDTATYYCARIESIGTTYSFDYWGQGT
		MVTVSSGGASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY
		FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
		SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC
		PAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL
		HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
		TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
		NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH
		EALHNHYTQKSLSLSPGK
214	CODV003 LC	DFQLTQSPSSLSASVGDRVTITCERSSGDIGDSYVSWYQQ
	(PR-1565044)	KPGKAPKNVIYADDQRPSGVPSRFSGSGSGNSASLTISSL
		QPEDFATYFCQSYDINIDIVFGQGTKVEIKGGGSGGGDIQ
		MTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKA
		PKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDF
		ATYYCQQYSTVPWTFGQGTKVEIKGGGSGRTVAAPSVFIF
		PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
		SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
		QGLSSPVTKSFNRGEC
215	CODV004 HC	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIR
	(PR-1565051)	QPPGKGLEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQA
		VLTITNMDPVDTATYYCARIESIGTTYSFDYWGQGTMVTV
		SSGEVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWV
		RQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKS
		TAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGT
		LVTVSSGGASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY
		FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
		SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC
		PAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL
		HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
		TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
		NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH
		EALHNHYTQKSLSLSPGK
216	CODV004 LC	DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKP
	(PR-1565051)	GKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQP
		EDFATYYCQQYSTVPWTFGQGTKVEIKGGGSGGGDFQLTQ
		SPSSLSASVGDRVTITCERSSGDIGDSYVSWYQQKPGKAP
		KNVIYADDQRPSGVPSRFSGSGSGNSASLTISSLQPEDFA
		TYFCQSYDINIDIVFGQGTKVEIKGGGSGRTVAAPSVFIF
		PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
		SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
		QGLSSPVTKSFNRGEC
217	CODV005 HC	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMYWVKQA
	(PR-1565083)	PGKGLEYMGWINTETGKPTYADDFKGRFTFSLDTSKSTAY
		LQMNSLRAEDTAVYFCARTNYYYRSYIFYFDYWGQGTLVT
		VSSGEVTLKESGPALVKPTQTLTLTCTFSGFSLSTFGMGV
		GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTS
		KNQAVLTITNMDPVDTATYYCARISTGISSYYVMDAWGQG
		TTVTVSSGGASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
		YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV
		PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPP
		CPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV
		LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV
		YTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
		NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM
		HEALHNHYTQKSLSLSPGK
218	CODV005 LC	DFQLTQSPSSLSASVGDRVTITCERSSGDIGDTYVSWYQQ
	(PR-1565083)	KPGKAPKNVIYGNDQRPSGVPSRFSGSGSGNSATLTISSL
		QPEDFATYFCQSYDSDIDIVFGQGTKVEIKGGGSGGGDTQ
		LTQSPSSLSASVGDRVTISCRASESVSTHMHWYQQKPGKA
		PKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDF
		ATYFCQQSWNDPFTFGQGTKVEIKGGGSGRTVAAPSVFIF
		PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
		SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
		QGLSSPVTKSFNRGEC
219	CODV006 HC	EVTLKESGPALVKPTQTLTLTCTFSGFSLSTFGMGVGWIR
	(PR-1565084)	QPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQA
		VLTITNMDPVDTATYYCARISTGISSYYVMDAWGQGTTVT
		VSSGEVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMYW
		VKQAPGKGLEYMGWINTETGKPTYADDFKGRFTFSLDTSK
		STAYLQMNSLRAEDTAVYFCARTNYYYRSYIFYFDYWGQG
		TLVTVSSGGASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
		YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV
		PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPP
		CPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV
		LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV
		YTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
		NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM
		HEALHNHYTQKSLSLSPGK
220	CODV006 LC	DTQLTQSPSSLSASVGDRVTISCRASESVSTHMHWYQQKP
	(PR-1565084)	GKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQP
		EDFATYFCQQSWNDPFTFGQGTKVEIKGGGSGGGDFQLTQ
		SPSSLSASVGDRVTITCERSSGDIGDTYVSWYQQKPGKAP
		KNVIYGNDQRPSGVPSRFSGSGSGNSATLTISSLQPEDFA
		TYFCQSYDSDIDIVFGQGTKVEIKGGGSGRTVAAPSVFIF
		PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
		SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
		QGLSSPVTKSFNRGEC
221	CODV007 HC	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMYWVKQA
	(PR-1565085)	PGKGLEYMGWINTETGKPTYADDFKGRFTFSLDTSKSTAY
		LQMNSLRAEDTAVYFCARTNYYYRSYIFYFDYWGQGTLVT
		VSSGEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGV
		GWIRQPPGKGLEWLANIWWDDDKYYNPSLKNRLTISKDTS
		KNQAVLTITNMDPVDTATYYCARIESIGTTYSFDYWGQGT
		MVTVSSGGASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY
		FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
		SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC
		PAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL
		HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
		TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
		NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH
		EALHNHYTQKSLSLSPGK
222	CODV007 LC	DFQLTQSPSSLSASVGDRVTITCERSSGDIGDSYVSWYQQ
	(PR-1565085)	KPGKAPKNVIYADDQRPSGVPSRFSGSGSGNSASLTISSL
		QPEDFATYFCQSYDINIDIVFGQGTKVEIKGGGSGGGDTQ
		LTQSPSSLSASVGDRVTISCRASESVSTHMHWYQQKPGKA
		PKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDF
		ATYFCQQSWNDPFTFGQGTKVEIKGGGSGRTVAAPSVFIF
		PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
		SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
		QGLSSPVTKSFNRGEC
223	CODV008 HC	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIR
	(PR-1565086)	QPPGKGLEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQA
		VLTITNMDPVDTATYYCARIESIGTTYSFDYWGQGTMVTV
		SSGEVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMYWV
		KQAPGKGLEYMGWINTETGKPTYADDFKGRFTFSLDTSKS
		TAYLQMNSLRAEDTAVYFCARTNYYYRSYIFYFDYWGQGT
		LVTVSSGGASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY
		FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
		SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC
		PAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL
		HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
		TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
		NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH
		EALHNHYTQKSLSLSPGK
224	CODV008 LC	DTQLTQSPSSLSASVGDRVTISCRASESVSTHMHWYQQKP
	(PR-1565086)	GKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQP
		EDFATYFCQQSWNDPFTFGQGTKVEIKGGGSGGGDFQLTQ
		SPSSLSASVGDRVTITCERSSGDIGDSYVSWYQQKPGKAP
		KNVIYADDQRPSGVPSRFSGSGSGNSASLTISSLQPEDFA
		TYFCQSYDINIDIVFGQGTKVEIKGGGSGRTVAAPSVFIF
		PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
		SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
		QGLSSPVTKSFNRGEC
225	CODV009 HC	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQA
	(PR-1571821)	PGQGLEWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAY
		LQISSLKAEDTAVYYCARTNYYYRSYIFYFDYWGQGTMVT
		VSSGEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGV
		GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTS
		KNQVVLTMTNMDPVDTATYYCARIESIGTTYSFDYWGQGT
		MVTVSSGGASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY
		FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
		SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC
		PAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL
		HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
		TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
		NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH
		EALHNAYTQKSLSLSPGK
226	CODV009 LC	EFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQ
	(PR-1571821)	KPGQAPRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRL
		EPEDFAVYYCQSYDINIDIVFGGGTKVEIKGGGSGGGDTV
		LTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDF
		AVYFCQQSWNDPFTFGQGTKLEIKGGGSGRTVAAPSVFIF
		PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
		SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
		QGLSSPVTKSFNRGEC
227	CODV010 HC	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIR
	(PR-1571823)	QPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQV
		VLTMTNMDPVDTATYYCARIESIGTTYSFDYWGQGTMVTV
		SSGEVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWV
		RQAPGQGLEWMGWINTETGKPTYADDFKGRFVFSLDTSVS
		TAYLQISSLKAEDTAVYYCARTNYYYRSYIFYFDYWGQGT
		MVTVSSGGASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY
		FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
		SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC
		PAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL
		HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
		TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
		NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH
		EALHNAYTQKSLSLSPGK
228	CODV010 LC	DTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKP
	(PR-1571823)	GQAPRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEP
		EDFAVYFCQQSWNDPFTFGQGTKLEIKGGGSGGGEFVLTQ
		SPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAP
		RLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFA
		VYYCQSYDINIDIVFGGGTKVEIKGGGSGRTVAAPSVFIF
		PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
		SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
		QGLSSPVTKSFNRGEC
229	CODV011 HC	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQA
	(PR-1575521)	PGQGLEWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAY
		LQISSLKAEDTAVYYCARTNYYYRSYIFYFDYWGQGTMVT
		VSSGGGGSGGGGSEFVLTQSPGTLSLSPGERATLSCERSS
		GDIGDSYVSWYQQKPGQAPRLVIYADDQRPSGIPDRFSGS
		GSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKV
		EIKGGGSGASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY
		FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
		SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC
		PAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL
		HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
		TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
		NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH
		EALHNAYTQKSLSLSPGK
230	CODV011 LC	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIR
	(PR-1575521)	QPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQV
		VLTMTNMDPVDTATYYCARIESIGTTYSFDYWGQGTMVTV
		SSGGGGSGGGGSDTVLTQSPATLSLSPGERATLSCRASES
		VSTHMHWYQQKPGQAPRLLIYGASNLESGVPARFSGSGSG
		TDFTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKG
		GGSGRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPRE
		AKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSK
		ADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
231	CODV012 HC	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQA
	(PR-1571824)	PGQGLEWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAY
		LQISSLKAEDTAVYYCARTNYYYRSYIFYFDYWGQGTMVT
		VSSGGGGSGGGEFVLTQSPGTLSLSPGERATLSCERSSGD
		IGDSYVSWYQQKPGQAPRLVIYADDQRPSGIPDRFSGSGS
		GTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEI
		KGGGSGASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
		EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS
		SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPA
		PEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP
		EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ
		DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL
		PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
		KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA
		LHNAYTQKSLSLSPGK
232	CODV012 LC	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIR
	(PR-1571824)	QPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQV
		VLTMTNMDPVDTATYYCARIESIGTTYSFDYWGQGTMVTV
		SSGGGGSGGGDTVLTQSPATLSLSPGERATLSCRASESVS
		THMHWYQQKPGQAPRLLIYGASNLESGVPARFSGSGSGTD
		FTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKGGG
		SGRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK
		VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKAD
		YEKHKVYACEVTHQGLSSPVTKSFNRGEC
233	CODV013 HC	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQA
	(PR-1571825)	PGQGLEWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAY
		LQISSLKAEDTAVYYCARTNYYYRSYIFYFDYWGQGTMVT
		VSSGGGGSGGGEFVLTQSPGTLSLSPGERATLSCERSSGD
		IGDSYVSWYQQKPGQAPRLVIYADDQRPSGIPDRFSGSGS
		GTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEI
		KGGSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
		VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
		GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE
		AAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV
		KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW
		LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPP
		SREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
		NAYTQKSLSLSPGK
234	CODV013 LC	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIR
	(PR-1571825)	QPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQV
		VLTMTNMDPVDTATYYCARIESIGTTYSFDYWGQGTMVTV
		SSGGGGSGGGDTVLTQSPATLSLSPGERATLSCRASESVS
		THMHWYQQKPGQAPRLLIYGASNLESGVPARFSGSGSGTD
		FTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKGGG
		SGRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK
		VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKAD
		YEKHKVYACEVTHQGLSSPVTKSFNRGEC
235	CODV014 HC	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQA
	(PR-1571826)	PGQGLEWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAY
		LQISSLKAEDTAVYYCARTNYYYRSYIFYFDYWGQGTMVT
		VSSGGGGSEFVLTQSPGTLSLSPGERATLSCERSSGDIGD
		SYVSWYQQKPGQAPRLVIYADDQRPSGIPDRFSGSGSGTD
		FTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKGG
		SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV
		SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
		TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG
		GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN
		WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRE
		EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
		VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNAY
		TQKSLSLSPGK
236	CODV014 LC	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIR
	(PR-1571826)	QPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQV
		VLTMTNMDPVDTATYYCARIESIGTTYSFDYWGQGTMVTV
		SSGGGGSGGGDTVLTQSPATLSLSPGERATLSCRASESVS
		THMHWYQQKPGQAPRLLIYGASNLESGVPARFSGSGSGTD
		FTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKGGG
		SGRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK
		VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKAD
		YEKHKVYACEVTHQGLSSPVTKSFNRGEC
237	CODV015 HC	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQA
	(PR-1571827)	PGQGLEWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAY
		LQISSLKAEDTAVYYCARTNYYYRSYIFYFDYWGQGTMVT
		VSSGGGGSGGGEFVLTQSPGTLSLSPGERATLSCERSSGD
		IGDSYVSWYQQKPGQAPRLVIYADDQRPSGIPDRFSGSGS
		GTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEI
		KGGGSGASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
		EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS
		SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPA
		PEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP
		EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ
		DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL
		PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
		KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA
		LHNAYTQKSLSLSPGK
238	CODV015 LC	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIR
	(PR-1571827)	QPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQV
		VLTMTNMDPVDTATYYCARIESIGTTYSFDYWGQGTMVTV
		SSGGGGSGGGDTVLTQSPATLSLSPGERATLSCRASESVS
		THMHWYQQKPGQAPRLLIYGASNLESGVPARFSGSGSGTD
		FTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKGGS
		RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
		WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYE
		KHKVYACEVTHQGLSSPVTKSFNRGEC
239	CODV016 HC	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQA
	(PR-1571828)	PGQGLEWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAY
		LQISSLKAEDTAVYYCARTNYYYRSYIFYFDYWGQGTMVT
		VSSGGGGSGGGEFVLTQSPGTLSLSPGERATLSCERSSGD
		IGDSYVSWYQQKPGQAPRLVIYADDQRPSGIPDRFSGSGS
		GTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEI
		KGGGSGASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
		EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS
		SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPA
		PEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP
		EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ
		DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL
		PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
		KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA
		LHNAYTQKSLSLSPGK
240	CODV016 LC	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIR
	(PR-1571828)	QPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQV
		VLTMTNMDPVDTATYYCARIESIGTTYSFDYWGQGTMVTV
		SSGGGGSDTVLTQSPATLSLSPGERATLSCRASESVSTHM
		HWYQQKPGQAPRLLIYGASNLESGVPARFSGSGSGTDFTL
		TISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKGGSRTV
		AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKV
		DNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK
		VYACEVTHQGLSSPVTKSFNRGEC
241	CODV017 HC	DTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKP
	(PR-1571830)	GQAPRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEP
		EDFAVYFCQQSWNDPFTFGQGTKLEIKGGGSGGGEFVLTQ
		SPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAP
		RLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPEDFA
		VYYCQSYDINIDIVFGGGTKVEIKGGGSGASTKGPSVFPL
		APSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH
		TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN
		TKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPK
		DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK
		TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL
		PAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS
		KLTVDKSRWQQGNVFSCSVMHEALHNAYTQKSLSLSPGK
242	CODV017 LC	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIR
	(PR-1571830)	QPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQV
		VLTMTNMDPVDTATYYCARIESIGTTYSFDYWGQGTMVTV
		SSGEVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWV
		RQAPGQGLEWMGWINTETGKPTYADDFKGRFVFSLDTSVS
		TAYLQISSLKAEDTAVYYCARTNYYYRSYIFYFDYWGQGT
		MVTVSSGGRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNF
		YPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTL
		TLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
243	CODV018 HC	EFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQ
	(PR-1571831)	KPGQAPRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRL
		EPEDFAVYYCQSYDINIDIVFGGGTKVEIKGGGSGGGDTV
		LTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQA
		PRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEPEDF
		AVYFCQQSWNDPFTFGQGTKLEIKGGGSGASTKGPSVFPL
		APSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH
		TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN
		TKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPK
		DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK
		TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL
		PAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS
		KLTVDKSRWQQGNVFSCSVMHEALHNAYTQKSLSLSPGK
244	CODV018 LC	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQA
	(PR-1571831)	PGQGLEWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAY
		LQISSLKAEDTAVYYCARTNYYYRSYIFYFDYWGQGTMVT
		VSSGEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGV
		GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTS
		KNQVVLTMTNMDPVDTATYYCARIESIGTTYSFDYWGQGT
		MVTVSSGGRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNF
		YPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTL
		TLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
245	CODV019 HC	DTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKP
	(PR-1571832)	GQAPRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEP
		EDFAVYFCQQSWNDPFTFGQGTKLEIKGGGSGGGGEVTLR
		ESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMT
		NMDPVDTATYYCARIESIGTTYSFDYWGQGTMVTVSSLGG
		CGGGSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE
		PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
		LGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAP
		EAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE
		VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP
		PSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK
		TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
		HNAYTQKSLSLSPGK
246	CODV019 LC	EFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQ
	(PR-1571832)	KPGQAPRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRL
		EPEDFAVYYCQSYDINIDIVFGGGTKVEIKGGGSGGGGEV
		QLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPG
		QGLEWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQ
		ISSLKAEDTAVYYCARTNYYYRSYIFYFDYWGQGTMVTVS
		SLGGCGGGSRTVAAPSVFIFPPSDEQLKSGTASVVCLLNN
		FYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSST
		LTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
247	CODV020 HC	EFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQ
	(PR-1571836)	KPGQAPRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRL
		EPEDFAVYYCQSYDINIDIVFGGGTKVEIKGGGSGGGGEV
		QLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPG
		QGLEWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQ
		ISSLKAEDTAVYYCARTNYYYRSYIFYFDYWGQGTMVTVS
		SLGGCGGGSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
		YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV
		PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPP
		CPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV
		LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV
		YTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
		NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM
		HEALHNAYTQKSLSLSPGK
248	CODV020 LC	DTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKP
	(PR-1571836)	GQAPRLLIYGASNLESGVPARFSGSGSGTDFTLTISSLEP
		EDFAVYFCQQSWNDPFTFGQGTKLEIKGGGSGGGGEVTLR
		ESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGK
		ALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMT
		NMDPVDTATYYCARIESIGTTYSFDYWGQGTMVTVSSLGG
		CGGGSRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPR
		EAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLS
		KADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
249	CODV021 HC	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQA
	(PR-1577053)	PGQGLEWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAY
		LQISSLKAEDTAVYYCARTNYYYRSYIFYFDYWGQGTMVT
		VSSGGGGSGGGEFVLTQSPGTLSLSPGERATLSCERSSGD
		IGESYVSWYQQKPGQAPRLVIYADDQRPSGIPDRFSGSGS
		GTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEI
		KGGGSGASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
		EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS
		SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPA
		PEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP
		EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ
		DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL
		PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
		KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA
		LHNAYTQKSLSLSPGK
250	CODV021 LC	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIR
	(PR-1577053)	QPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQV
		VLTMTNMDPVDTATYYCARIESIGTTYSFDYWGQGTMVTV
		SSGGGGSGGGDTVLTQSPATLSLSPGERATLSCRASESVS
		THMHWYQQKPGQAPRLLIYGASNLESGVPARFSGSGSGTD
		FTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKGGS
		RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
		WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYE
		KHKVYACEVTHQGLSSPVTKSFNRGEC
251	CODV022 HC	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQA
	(PR-1577056)	PGQGLEWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAY
		LQISSLKAEDTAVYYCARTNYYYRSYIFYFDYWGQGTMVT
		VSSGGGGSGGGEFVLTQSPGTLSLSPGERATLSCERSSGD
		IGESYVSWYQQKPGQAPRLVIYADDQRPSGIPDRFSGSGS
		GTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEI
		KGGGSGASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
		EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS
		SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPA
		PEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP
		EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ
		DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL
		PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
		KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA
		LHNAYTQKSLSLSPGK
252	CODV022 LC	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIR
	(PR-1577056)	QPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQV
		VLTMTNMDPVDTATYYCARIESIGTTYSFDYWGQGTMVTV
		SSGGGGSDTVLTQSPATLSLSPGERATLSCRASESVSTHM
		HWYQQKPGQAPRLLIYGASNLESGVPARFSGSGSGTDFTL
		TISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKGGSRTV
		AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKV
		DNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK
		VYACEVTHQGLSSPVTKSFNRGEC

Example 12

Generation of scFv-IgG Fusion Proteins

All Ig-scFv molecules used the same anti-VEGF-A mAb AB014 as the IgG molecule. A single chain Fv (scFv) anti-PDGF-BB antibody was fused to the C-terminus of AB014 heavy chain using various length of GS linker using standard molecular cloning techniques. Four different heavy chains and one common light chain were made, as shown in the table below. Each heavy chain and the common light chain were co-transfected into HEK293 cells and the resulting Ig-scFv fusion proteins were purified using rProtein-A chromatography.

TABLE 59
Heavy Chain and Light Chain Amino Acid Sequences of Anti-human
VEGF-A/anti-human PDGF-BB Ig-scFv Molecules
(Linker sequence in italics; CDR sequences in bold)
Seq ID	Name	Sequence
No	(Corporate ID)	1234567890123456789012345678901234567890
3839	AB014-GS6-9E8.4	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQA
	VH-VK HC	PGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAY
	(PR-1599234)	LQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVT
		VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV
		TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG
		TQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEA
		AGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK
		FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL
		NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
		REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT
		PPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN
		AYTQKSLSLSPGKGGSGGGEVTLRESGPALVKPTQTLTLT
		CTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWDDDKYY
		NPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIE
		SIGTTYSFDYWGQGTMVTVSSGGGGSGGGGSGGGGSEIVL
		TQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQ
		APRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRLEPED
		FAVYYCQSYDINIDIVFGGGTKVEIK
3940	AB014-GS10-9E8.4	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQA
	VH-VK HC	PGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAY
	(PR-1599236)	LQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVT
		VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV
		TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG
		TQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEA
		AGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK
		FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL
		NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
		REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT
		PPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN
		AYTQKSLSLSPGKGGSGGGGSGGEVTLRESGPALVKPTQT
		LTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWDD
		DKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYC
		ARIESIGTTYSFDYWGQGTMVTVSSGGGGSGGGGSGGGGS
		EIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQ
		KPGQAPRLVIYADDQRPSGIPDRFSGSGSGTDFTLTISRL
		EPEDFAVYYCQSYDINIDIVFGGGTKVEIK
3841	AB014-GS15-9E8.4	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQA
	VH-VK HC	PGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAY
	(PR-1599239)	LQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVT
		VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV
		TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG
		TQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEA
		AGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK
		FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL
		NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
		REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT
		PPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN
		AYTQKSLSLSPGKGGSGGGGSGGGGSGGEVTLRESGPALV
		KPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLAN
		IWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDT
		ATYYCARIESIGTTYSFDYWGQGTMVTVSSGGGGSGGGGS
		GGGGSEIVLTQSPGTLSLSPGERATLSCERSSGDIGDSYV
		SWYQQKPGQAPRLVIYADDQRPSGIPDRFSGSGSGTDFTL
		TISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIK
3842	AB014-GS10-9E8.4	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQA
	VK-VH HC	PGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAY
	(PR-1599240)	LQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVT
		VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV
		TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG
		TQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEA
		AGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK
		FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL
		NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
		REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT
		PPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN
		AYTQKSLSLSPGKGGSGGGGSGGEIVLTQSPGTLSLSPGE
		RATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRP
		SGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINI
		DIVFGGGTKVEIKGGGGSGGGGSGGGGSEVTLRESGPALV
		KPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLAN
		IWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDT
		ATYYCARIESIGTTYSFDYWGQGTMVTVSS
3843	AB014 LC	DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKP
		GKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQP
		EDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPP
		SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
		ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQG
		LSSPVTKSFNRGEC

All HC use the exact same LC (last sequence in Table 59). The naming of the HC follows the following convention: VH name—Linker length (between Fc and scFv)—scFv name with orientation of scFv.

Example 13

In Vitro Characterization of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules and Other Bispecific Molecules

Example 13.1

Expression and Purification of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules and CO-DVD-Ig Molecules

All variants were transiently transfected into 200-500 mls of HEK 293 6e suspension cell cultures in a ratio of 60% to 40% light to heavy chain construct. 1 mg/ml PEI was used to transfect the cells. Alternatively variants were transiently transfected into 500 mls of Expi293 suspension cell cultures using the ExpiFectamine kit (LifeTechnologies A14524). Supernatants were harvested after six days in shaking flasks, spun down to pellet cells, and filtered through 0.22 μm filters to separate IgG from culture contaminates. All was purified via gravity flow using 1-2 ml of rProteinA sepharose fast flow beads (GE Healthcare, 17-1279-04) over poly prep chromatography columns (Bio Rad, 731-1550). Once supernatants had passed through the columns the beads were washed with 10 column volumes of binding buffer, and IgG was eluted with Immunopure IgG elution buffer (Pierce, 185 1520) and collected in 1 ml aliquots. Fractions containing DVD-Ig were pooled and dialyzed in PBS or 15 mM Histidine pH 6 overnight at 4° C.

TABLE 60
Expression Level and SEC Profile of Anti-VEGF-A/Anti-
PDGF-BB DVD-Ig, CO-DVD-Ig and IgG-scFv Fusion Proteins
		Octet
		Titer	Yield	SEC (%
Name	Corporate ID	(mg/L)	(mg/L)	monomer)
AB014-GS-9E8.4	NA	4.2	ND	ND
9E8.4-GS-AB014	NA	1.2	ND	ND
AB014-SS-9E8.4	NA	3.5	0.4	ND
9E8.4-SS-AB014	NA	3.5	0.6	ND
AB014-SL-9E8.4	NA	2.0	ND	ND
9E8.4-SL-AB014	NA	2.8	0.1	ND
AB014-LS-9E8.4	NA	3.3	ND	ND
9E8.4-LS-AB014	NA	3.6	ND	ND
9E8.4-GS-4G8.3	PR-1563988	6.5	2.8	94.5
9E8.4-SS-4G8.3	PR-1563990	5.9	4.5	92.1
9E8.4-SL-4G8.3	PR-1563998	3.4	2.0	94.0
9E8.4-LS-4G8.3	PR-1564009	10.7	8.0	93.3
4G8.3-GS-9E8.4	PR-1564010	3.6	2.1	98.4
4G8.3-SS-9E8.4	PR-1564011	5.7	3.1	99.4
4G8.3-SL-9E8.4	PR-1564012	2.6	0.7	99.4
4G8.3-LS-9E8.4	PR-1564013	6.7	3.1	99.2
DVD3896	PR-1564883	ND	2.8	100.0
DVD3897	PR-1564893	ND	2.7	79.1
DVD3898	PR-1564896	ND	22.0	93.0
DVD3899	PR-1564898	ND	14.7	87.4
DVD3900	PR-1564899	ND	12.1	72.4
DVD3901	PR-1565023	ND	1.3	99.1
DVD3902	PR-1565029	ND	3.2	98.3
DVD3903	PR-1565030	ND	2.9	98.0
DVD3904	PR-1565031	ND	13.8	97.8
DVD3905	PR-1565032	ND	15.1	92.5
DVD3906	PR-1565035	ND	28.2	85.5
DVD3907	PR-1565033	ND	0.5	ND
CODV001	PR-1565040	ND	88.4	87.6
CODV002	PR-1565042	ND	46.5	97.0
CODV003	PR-1565044	ND	37.3	77.3
CODV004	PR-1565051	ND	75.8	77.4
CODV005	PR-1565083	ND	104.5	86.9
CODV006	PR-1565084	ND	83.9	96.4
CODV007	PR-1565085	ND	43.9	77.4
CODV008	PR-1565086	ND	44.5	75.5
CODV009	PR-1571821	2.0	1.2	86.6
CODV010	PR-1571823	4.5	3.6	94.8
CODV011	PR-1575521	3.7	2.0	100.0
CODV012	PR-1571824	2.0	0.7	98.9
CODV013	PR-1571825	0.7	0.4	90.6
CODV014	PR-1571826	4.5	0.5	89.6
CODV015	PR-1571827	0.7	0.9	91.7
CODV016	PR-1571828	2.6	1.4	93.6
CODV017	PR-1571830	4.2	2.6	99.8
CODV018	PR-1571831	2.6	1.5	88.8
CODV019	PR-1571832	0.4	0.2	87.1
CODV020	PR-1571836	2.1	0.3	58.1
4G8.3-GS-9E8.4	PR-1569574	4.4	4.3	ND
4G8.3-SL-9E8.4	PR-1569579	0.7	0.5	ND
4G8.3-LS-9E8.4	PR-1575573	3.8	2.7	ND
4G8.3-GS-9E8.4 (g)	PR-1572102	2.5	0.4	98.8
4G8.3-GS(11)-9E8.4 (g)	PR-1572103	5.3	1.4	100.0
4G8.3-GS(noR)-9E8.4 (g)	PR-1572104	4.1	0.7	99.5
4G8.3-SL-9E8.4 (g)	PR-1572105	1.4	0.3	98.6
4G8.3-LS-9E8.4 (g)	PR-1572106	4.0	0.8	100.0
4G8.3-GS-9E8.4E	PR-1575832	9.8	8.1	99.2
4G8.3-SL-9E8.4E	PR-1575834	4.5	2.6	99.0
4G8.3-LS-9E8.4E	PR-1575835	16.0	9.7	99.6
CODV021	PR-1577053	2.6	0.3	92.8
CODV022	PR-1577056	2.0	0.2	93.2
9A8.12-GS-9E8.4E	PR-1577165	3.3	2.4	82.99
9A8.12-SL-9E8.4E	PR-1577166	1.1	0.2	51.54
9A8.12-LS-9E8.4E	PR-1577547	10.6	1.1	97.35
9E8.4E-GS-9A8.12	PR-1578137	12.0	3.8	97.3
9E8.4E-SL-9A8.12	PR-1577548	5.0	1.7	97.51
9E8.4E-LS-9A8.12	PR-1577550	2.5	2.5	96.96
AB014-GS6-9E8.4 VH-VK	PR-1599234	70.0	25.6	33.8
AB014-GS10-9E8.4 VH-	PR-1599236	70.0	24.3	34.7
VK
AB014-GS15-9E8.4 VH-	PR-1599239	70.0	29.3	39.3
VK
AB014-GS10-9E8.4 VK-	PR-1599240	47.0	21.4	33.2
VH
4G8.2-GS-9E8.4	PR-1598261	29.4	10.3	98.31
4G8.4-GS-9E8.4	PR-1598262	61.0	20.4	87.65
4G8.5-GS-9E8.4	PR-1598263	31.3	11.5	98.5
4G8.12-GS-9E8.4	PR-1598264	44.0	15.1	93.12
4G8.13-GS-9E8.4	PR-1598265	6.3	2.6	83.58
4G8.14-GS-9E8.4	PR-1598266	19.3	9.9	96.52
CL-34565_GS_CL-33675	PR-1613183	101.4	27.7	88.2
CL-34565_GS_9E8.4	PR-1613184	49.3	31.3	95.9
CL-34565_GS_3E2.1	PR-1613185	109.8	82.5	96.3
4G8.5_GS_CL-33675	PR-1611291	91.1	10.4	96.9
4G8.5_GS_9E8.4	PR-1612489	39.0	23.0	97.0
4G8.5_GS_3E2.1	PR-1610560	127.0	13.9	100.0
9E10.1_GS_CL-33675	PR-1610561	136.0	19.2	92.9
9E10.1_GS_9E8.4	PR-1612491	86.0	50.1	95.0
9E10.1_GS_3E2.1	PR-1610562	44.0	10.2	96.0
9E10.6_GS_CL-33675	PR-1612492	152.0	65.7	89.0
9E10.6_GS_9E8.4	PR-1612493	96.0	50.1	93.0
9E10.6_GS_3E2.1	PR-1610563	122.0	18.0	95.0
1B10.1_GS_CL-33675	PR-1611292	233.0	22.7	75.4
1B10.1_GS_9E8.4	PR-1612494	123.0	52.1	77.0
1B10.1_GS_3E2.1	PR-1610564	142.0	23.3	93.7
1E3.4_GS_CL-33675	PR-1611293	54.0	9.3	83.7
1E3.4_GS_9E8.4	PR-1611294	67.5	11.6	72.1
1E3.4_GS_3E2.1	PR-1612495	101.0	29.6	97.0
CL-33675_GS_CL-34565	PR-1613186	73.5	17.7	87.6
CL-33675_GS_4G8.5	PR-1612496	36.0	8.6	94.0
CL-33675_GS_9E10.1	PR-1611295	148.5	2.3	95.9
CL-33675_GS_9E10.6	PR-1611296	185.3	4.9	95.8
CL-33675_GS_1B10.1	PR-1612498	19.0	7.0	65.0
CL-33675_GS_1E3.4	PR-1611297	72.8	3.5	95.9
9E8.4_GS_CL-34565	PR-1613187	67.5	53.6	79.0
9E8.4_GS_4G8.5	PR-1613188	95.2	73.6	81.7
9E8.4_GS_9E10.1	PR-1611298	237.5	21.5	73.3
9E8.4_GS_9E10.6	PR-1611299	179.0	19.1	71.9
9E8.4_GS_1B10.1	PR-1611300	93.7	12.9	71.7
9E8.4_GS_1E3.4	PR-1611301	87.9	12.2	66.4
3E2.1_GS_CL-34565	PR-1613189	76.1	65.7	93.3
3E2.1_GS_4G8.5	PR-1612499	98.0	46.9	95.0
3E2.1_GS_9E10.1	PR-1612500	126.0	59.2	85.0
3E2.1_GS_9E10.6	PR-1612501	141.0	61.0	86.5
3E2.1_GS_1B10.1	PR-1612502	141.0	61.0	97.0
3E2.1_GS_1E3.4	PR-1613190	107.8	79.9	96.5
9E10.1_SL_CL-33675	PR-1629646	7.6	1.0	98.7
1B10.1_SL_CL-33675	PR-1629647	157.0	111.7	63.3
9E10.1_LS_CL-33675	PR-1629648	64.4	36.4	92.9
1B10.1_LS_CL-33675	PR-1629649	218.4	157.7	65.4

Example 13.2

Binding Affinity of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules and CO-DVD-Ig Molecules

The binding affinity of anti-VEGF-A/anti-PDGF-BB DVD-Ig molecules and CO-DVD-Ig molecules to VEGF-A and PDGF-BB were measured by Biacore using the method described in Example 1.1 and the data is summarized in Tables 61 and 62 below.

TABLE 61
Biacore Binding of Anti-VEGF/anti-PDGF DVD-Ig Molecules
	VEGF	PDGF
		kon	koff	KD	kon	koff	KD
DVD Name	Corporate ID	(M−1 s−1)	(M−1)	(M)	(M−1 s−1)	(M−1)	(M)
9E8.4-GS-4G8.3	PR-1563988	2.2E+05	6.3E−05	2.9E−10	1.0E+07	2.0E−04	2.0E−11
9E8.4-SS-4G8.3	PR-1563990	1.6E+05	1.2E−04	7.8E−10	1.0E+07	2.0E−04	2.0E−11
9E8.4-SL-4G8.3	PR-1563998	7.0E+05	8.0E−05	1.2E−10	1.0E+07	1.9E−04	1.9E−11
9E8.4-LS-4G8.3	PR-1564009	2.7E+05	5.5E−05	2.0E−10	1.0E+07	2.0E−04	2.0E−11
4G8.3-GS-9E8.4	PR-1564010	3.3E+06	5.7E−05	1.7E−11	1.0E+07	1.4E−04	1.3E−11
4G8.3-SS-9E8.4	PR-1564011	3.1E+06	4.1E−05	1.3E−11	7.5E+06	1.5E−04	1.9E−11
4G8.3-SL-9E8.4	PR-1564012	3.1E+06	4.1E−05	1.3E−11	1.4E+07	1.4E−04	9.9E−12
4G8.3-LS-9E8.4	PR-1564013	3.1E+06	3.9E−05	1.2E−11	1.7E+07	1.4E−04	8.6E−12
DVD3904	PR-1565031	6.1E+05	1.1E−04	1.9E−10	1.0E+07	9.0E−04	9.0E−11
DVD3905	PR-1565032	1.1E+06	1.0E−04	9.4E−11	1.0E+07	1.8E−03	1.8E−10
DVD3906	PR-1565035	9.2E+05	9.3E−05	1.0E−10	1.0E+07	7.2E−03	7.2E−10
4G8.3-GS(9)-9E8.4 (g)	PR-1572102	6.0E+06	7.6E−05	1.3E−11	1.3E+07	1.7E−04	1.3E−11
4G8.3-GS(11)-9E8.4	PR-1572103	6.3E+06	7.5E−05	1.2E−11	1.4E+07	1.7E−04	1.3E−11
(g)
4G8.3-GS(noR)-9E8.4	PR-1572104	6.1E+06	6.9E−05	1.1E−11	1.5E+07	1.4E−04	8.9E−12
(g)
4G8.3-SL-9E8.4 (g)	PR-1572105	5.6E+06	6.1E−05	1.1E−11	1.3E+07	1.7E−04	1.3E−11
4G8.3-LS-9E8.4 (g)	PR-1572106	6.3E+06	5.1E−05	8.1E−12	1.8E+07	2.0E−04	1.1E−11
4G8.3-GS-9E8.4E	PR-1575832	6.1E+06	8.0E−05	1.3E−11	1.3E+07	2.7E−04	2.0E−11
4G8.3-SL-9E8.4E	PR-1575834	6.2E+06	6.3E−05	1.0E−11	1.7E+07	2.5E−04	1.5E−11
4G8.3-LS-9E8.4E	PR-1575835	5.8E+06	5.9E−05	1.0E−11	2.0E+07	2.8E−04	1.4E−11
9A8.12-GS-9E8.4E	PR-1577165	7.7E+05	1.4E−04	1.8E−10	3.3E+07	2.6E−04	8.1E−12
9A8.12-SL-9E8.4E	PR-1577166	2.5E+05	1.2E−04	4.7E−10	2.7E+07	2.3E−04	8.3E−12
9A8.12-LS-9E8.4E	PR-1577547	2.7E+05	9.3E−05	3.5E−10	3.6E+07	2.3E−04	6.5E−12
9E8.4E-SL-9A8.12	PR-1577548	2.2E+06	3.4E−04	1.6E−10	5.0E+07	3.2E−04	6.4E−12
9E8.4E-LS-9A8.12	PR-1577550	6.4E+05	1.5E−04	2.3E−10	5.0E+07	2.5E−04	5.0E−12
9E8.4E-GS-9A8.12	PR-1578137	4.7E+05	1.8E−04	3.8E−10	5.0E+07	4.4E−04	8.8E−12
CL-34565_GS_CL-	PR-1613183	1.2E+07	2.0E−05	1.7E−12	6.0E+07	1.1E−05	1.9E−13
33675
CL-34565_GS_9E8.4	PR-1613184	1.5E+07	1.6E−05	1.1E−12	3.5E+07	1.9E−04	5.4E−12
CL-34565_GS_3E2.1	PR-1613185	1.2E+07	1.7E−05	1.4E−12	4.5E+07	5.2E−04	1.2E−11
4G8.5_GS_CL-33675	PR-1611291	4.7E+06	3.1E−05	6.6E−12	1.6E+07	1.2E−05	7.4E−13
4G8.5_GS_9E8.4	PR-1612489	5.4E+06	4.6E−05	8.5E−12	5.8E+06	1.6E−04	2.8E−11
4G8.5_GS_3E2.1	PR-1610560	4.8E+06	4.2E−05	8.7E−12	4.1E+07	5.5E−04	1.3E−11
9E10.1_GS_CL-33675	PR-1610561	9.7E+06	1.7E−05	1.8E−12	2.0E+07	9.1E−06	4.5E−13
9E10.1_GS_9E8.4	PR-1612491	1.1E+07	2.5E−05	2.2E−12	6.8E+06	1.7E−04	2.5E−11
9E10.1_GS_3E2.1	PR-1610562	9.3E+06	2.3E−05	2.4E−12	4.1E+07	8.5E−04	2.1E−11
9E10.6_GS_CL-33675	PR-1612492	1.1E+07	2.2E−05	2.0E−12	2.4E+07	2.8E−05	1.2E−12
9E10.6_GS_3E2.1	PR-1610563	8.6E+06	2.5E−05	3.0E−12	5.8E+06	2.1E−04	3.6E−11
1B10.1_GS_CL-33675	PR-1611292	2.1E+06	1.3E−04	6.2E−11	2.2E+07	1.2E−05	5.4E−13
1E3.4_GS_3E2.1	PR-1612495	5.3E+06	5.2E−05	9.8E−12	4.5E+07	5.1E−04	1.2E−11
CL-33675_GS_4G8.5	PR-1612496	2.3E+05	4.0E−05	1.8E−10	3.8E+07	9.0E−06	2.3E−13
3E2.1_GS_4G8.5	PR-1612499	2.4E+05	3.9E−05	1.7E−10	≧9.0E+07	3.4E−04	≦3.8E−12
3E2.1_GS_9E10.1	PR-1612500	6.3E+05	1.2E−05	1.9E−11	≧9.0E+07	3.9E−04	≦4.3E−12
3E2.1_GS_9E10.6	PR-1612501	5.7E+05	2.3E−05	4.1E−11	≧9.0E+07	4.5E−04	≦5.3E−12
3E2.1_GS_1B10.1	PR-1612502	3.5E+05	1.2E−04	3.2E−10	8.4E+07	1.5E−04	1.8E−12
3E2.1_GS_1E3.4	PR-1613190	3.6E+05	9.2E−05	2.6E−10	≧9.0E+07	4.8E−04	≦5.3E−12

TABLE 62
Biacore Binding of Anti-VEGF/anti-PDGF CO-DVD-Ig Molecules
	VEGF	PDGF
CO-DVD-Ig		kon	koff	KD	kon	koff	KD
Name	Corporate ID	(M−1 s−1)	(M−1)	(M)	(M−1 s−1)	(M−1)	(M)
CODV003	PR-1565044	no binding	2.3E+07	2.5E−04	1.1E−11
CODV004	PR-1565051	no binding	1.0E+07	8.7E−04	8.7E−11
CODV005	PR-1565083			3.5E−08	1.2E+07	1.3E−04	1.1E−11
CODV006	PR-1565084	no binding	2.2E+07	2.1E−04	9.7E−12
CODV007	PR-1565085			2.2E−08	2.9E+07	2.2E−04	7.3E−12
CODV008	PR-1565086	no binding	1.7E+07	1.3E−04	7.4E−12
CODV009	PR-1571821			2.6E−08	3.5E+07	2.0E−04	5.6E−12
CODV010	PR-1571823	5.7E+04	3.7E−04	6.6E−09	4.1E+07	1.6E−04	4.0E−12
CODV011	PR-1575521	1.1E+06	4.0E−05	3.8E−11	3.8E+07	6.9E−05	1.8E−12
CODV012	PR-1571824	2.7E+06	7.6E−05	2.8E−11	7.0E+07	1.0E−04	1.5E−12
CODV014	PR-1571826	2.2E+06	7.7E−05	3.6E−11	5.5E+07	1.3E−04	2.4E−12
CODV015	PR-1571827	2.7E+06	6.5E−05	2.4E−11	7.0E+07	9.1E−05	1.3E−12
CODV016	PR-1571828	2.9E+06	5.9E−05	2.0E−11	4.6E+07	1.1E−04	2.5E−12
CODV017	PR-1571830	—	—	5.7E−08	3.0E+07	2.0E−04	6.5E−12
CODV018	PR-1571831	—	—	3.1E−08	3.5E+07	1.9E−04	5.3E−12
CODV019	PR-1571832	2.9E+06	1.4E−04	5.0E−11	3.9E+07	1.7E−04	4.4E−12
CODV020	PR-1571836	3.1E+06	1.0E−04	3.3E−11	4.6E+07	1.6E−04	3.5E−12
CODV021	PR-1577053	3.8E+06	6.8E−05	1.8E−11	6.1E+07	1.2E−04	1.9E−12
CODV022	PR-1577056	4.5E+06	5.6E−05	1.3E−11	3.2E+07	1.3E−04	4.2E−12

Example 13.2.1

Binding of Anti-VEGF/anti-PDGF DVD-Ig Molecule (PR-1610561) to Various VEGF-A Isoforms and VEGF-A and PDGF-BB of Different Species

Binding of anti-VEGF/anti-PDGF DVD-Ig molecule (PR-1610561) and their parental monoclonal antibodies to various VEGF-A isoforms and VEGF-A and PDGF-BB of different species were measured by Biacore using the method described in Example 1.1 and the data is summarized in Table 63 below. Tables 63A-B summarize the high affinity for VEGF-A₁₆₅ (65 pM), VEGF-A₁₂₁(230 pM), VEGF-A₁₁₁ (290 pM), isoforms and the high affinity for soluble PDGF-BB (5 pM), observed for PR-1610561. The data shows that PR-1610561binds to both soluble and extracellular-matrix (ECM) bound forms of PDGF-BB.

TABLE 63
Binding of Anti-VEGF/Anti-PDGF DVD-Ig Molecule (PR-1610561) and Parental mAbs to VEGF-A Isoforms and PDGF
	human VEGF 165	human PDGF-B
	PR-1350437, 1925483	PR-1373790, 1926007
				Ka	Kd	KD	Ka	Kd	KD
No		PR-	lot	(M−1s−1)	(s−1)	(M)	(M−1s−1)	(s−1)	(M)
1	9E10.1-GS-33675	PR-1610561	2213329	5.2E+05	3.4E−05	6.5E−11	≧1.0E+07	5.2E−05	≦5.2E−12
2	AB014 (Avastin)	PR-1545939	2129911	5.5E+05	4.1E−05	7.6E−11
3	AB642 (9E10.1)	PR-1594047	2169800	1.6E+07	2.8E−05	1.8E−12
4	CL-33675	PR-1593725	2178826				≧1.0E+07	5.8E−06	≦5.8E−13
	human VEGF 121
	PR-1515941, 2069355
				Ka	Kd	KD
No		PR-	lot	(M−1s−1)	(s−1)	(M)
1	9E10.1-GS-33675	PR-1610561	2213329	1.8E+05	4.1E−05	2.3E−10
2	AB014 (Avastin)	PR-1545939	2129911	1.8E+05	5.1E−05	2.8E−10
3	AB642 (9E10.1)	PR-1594047	2169800	3.2E+06	6.8E−05	2.1E−11
4	CL-33675	PR-1593725	2178826
	human VEGF 111
	PR-1520687, 2074657
				Ka	Kd	KD
No		PR-	lot	(M−1s−1)	(s−1)	(M)
1	9E10.1-GS-33675	PR-1610561	2213329	1.5E+05	4.3E−05	2.9E−10
2	AB014 (Avastin)	PR-1545939	2129911	1.4E+05	5.3E−05	3.8E−10
3	AB642 (9E10.1)	PR-1594047	2169800	1.8E+06	1.0E−04	5.8E−11
4	CL-33675	PR-1593725	2178826
	cyno PDGF-B
	PR-1575400, 2154322
				cyno VEGF has similar	Ka	Kd	KD
No		PR-	lot	sequence as human	(M−1s−1)	(s−1)	(M)
1	9E10.1-GS-33675	PR-1610561	2213329		≧1.0E+07	8.1E−06	≦8.1E−13
2	AB014 (Avastin)	PR-1545939	2129911
3	AB642 (9E10.1)	PR-1594047	2169800
4	CL-33675	PR-1593725	2178826		≧1.0E+07	1.3E−05	≦1.3E−12
	mouse VEGF	mouse PDGF-B
	PR-1578904, 2150241	PR-1577160, 2147923
				Ka	Kd	KD	Ka	Kd	KD
No		PR-	lot	(M−1s−1)	(s−1)	(M)	(M−1s−1)	(s−1)	(M)
1	9E10.1-GS-33675	PR-1610561	2213329			potentially	≧1.0E+07	5.2E−05	≦5.2E−12
						very weak binding
2	AB014 (Avastin)	PR-1545939	2129911			no binding
3	AB642 (9E10.1)	PR-1594047	2169800			potentially
						very weak binding
4	CL-33675	PR-1593725	2178826				≧1.0E+07	5.8E−06	≦5.8E−13
	rat VEGF	rat PDGF-B
	PR-1645045, 2235296	PR-1645048, 2235300
				Ka	Kd	KD	Ka	Kd	KD
No		PR-	lot	(M−1s−1)	(s−1)	(M)	(M−1s−1)	(s−1)	(M)
1	9E10.1-GS-33675	PR-1610561	2213329			potentially	≧1.0E+07	5.2E−05	≦5.2E−12
						very weak binding
2	AB014 (Avastin)	PR-1545939	2129911			no binding
3	AB642 (9E10.1)	PR-1594047	2169800			potentially
						very weak binding
4	CL-33675	PR-1593725	2178826				≧1.0E+07	5.8E−06	≦5.8E−13
	rabbit VEGF
	PR-1563693, 2130027
				Ka	Kd	KD	rabbit PDGF-B has similar
No		PR-	lot	(M−1s−1)	(s−1)	(M)	sequence as rat
1	9E10.1-GS-33675	PR-1610561	2213329	9.6E+05	4.0E−05	4.1E−11
2	AB014 (Avastin)	PR-1545939	2129911	9.4E+05	4.4E−05	4.7E−11
3	AB642 (9E10.1)	PR-1594047	2169800	1.6E+07	2.8E−05	1.8E−12
4	CL-33675	PR-1593725	2178826

TABLE 63A
Affinity of PR-1610561 to Various Isoforms of Human VEGF-A
	Human VEGF-A
	Isoforms
	A165	A121	A111
	Affinity KD (pM)	65	230	290

TABLE 63B
Affinity of PR-1610561 to Human PDGF-BB
	Human PDGF-BB Forms	Soluble	ECM-associated
	Affinity KD (pM)	5	n/t
	Cell Staining	n/t	+

Example 13.3

Neutralization Potencies of Anti-VEGF-A/anti-PDGF-BB DVD-Ig Molecules and CO-DVD-Ig Molecules

The DVD-Ig molecules and CO-DVD-Ig molecules were evaluated for their potencies to block VEGF₁₆₅/VEGFR2 interaction (Example 1.4) and neutralize VEGF₁₆₅ activity in HMVEC-d or VEGFR2-3T3 proliferation assays (Examples 1.10 and 1.7). The molecules were also characterized for the ability to block PDGF-BB/PDGF-Rβ interaction (Example 1.13) and inhibition of PDGF-BB induced proliferation of NIH-3T3 cells (Example 1.15). The data is summarized in Table 64 below. PR-1610561 exhibited neutralization activity against human VEGF-A (IC₅₀ of 145 pM) and human PDGF-BB (IC₅₀ of 34 pM), as summarized in Table 64A.

TABLE 64
Human VEGF-A and Human PDGF-BB Neutralization Potency of
Anti-VEGF-A/anti-PDGF-BB DVD-Ig and CO-DVD-Ig Proteins
	Potency IC50 (nM)
					hVEGFR2	hPDGF β
			VEGFR2-		Competition	Competition
		HMVEC-d	3T3	NIH-3T3	ELISA	ELISA
DVD-Ig	Corporate ID	hVEGF165	hVEGF165	hPDGF-BB	IC50 nM	IC50 nM
9E8.4-GS-4G8.3	PR-1563988	2.643	>5	0.076	NT	NT
9E8.4-SS-4G8.3	PR-1563990	NT	>5	0.094	NT	NT
9E8.4-SL-4G8.3	PR-1563998	NT	>5	0.091	NT	NT
9E8.4-LS-4G8.3	PR-1564009	NT	>5	0.104	NT	NT
4G8.3-GS-9E8.4	PR-1564010	0.096	NT	NT	0.126	NT
4G8.3-GS-9E8.4E	PR-1575832	NT	2.953	>5	NT	NT
4G8.3-SS-9E8.4	PR-1564011	NT	0.747	5.511	NT	NT
4G8.3-SL-9E8.4	PR-1564012	NT	NT	0.365	0.086	NT
4G8.3-SL-9E8.4E	PR-1575834	NT	3.090	0.572	NT	NT
4G8.3-LS-9E8.4	PR-1564013	0.060	NT	0.152	0.092	NT
CODV009	PR-1571821	NT	>5	>5	NT	NT
CODV010	PR-1571823	NT	>5	2.139	NT	NT
CODV011	PR-1575521	NT	2.553	0.043	NT	NT
CODV012	PR-1571824	NT	1.424	0.182	NT	NT
CODV013	PR-1571825	NT	0.785	0.11	NT	NT
CODV014	PR-1571826	NT	3.768	0.469	NT	NT
CODV015	PR-1571827	0.104	0.407	0.075	NT	NT
CODV021	PR-1577053	NT	>5	0.056	NT	NT
CODV016	PR-1571828	0.115	0.503	0.096	NT	NT
CODV022	PR-1577056	NT	1.462	0.059	NT	NT
CODV017	PR-1571830	NT	>5	>5	NT	NT
CODV018	PR-1571831	NT	>5	>5	NT	NT
DVD3904	PR-1565031	NT	>5	>5	NT	NT
DVD3905	PR-1565032	NT	>5	>5	NT	NT
DVD3906	PR-1565035	NT	>5	>5	NT	NT
CODV003	PR-1565044	NT	>5	>5	NT	NT
CODV004	PR-1565051	NT	>5	>5	NT	NT
CODV005	PR-1565083	NT	>5	>5	NT	NT
CODV006	PR-1565084	NT	>5	>5	NT	NT
CODV007	PR-1565085	NT	>5	>5	NT	NT
CODV008	PR-1565086	NT	>5	>5	NT	NT
4G8.3-GS(9)-9E8.4 (g)	PR-1572102	0.417	0.986	.528	0.157	>5
4G8.3-GS(11)-9E8.4 (g)	PR-1572103	NT	0.318	0.298	NT	NT
4G8.3-GS(noR)-9E8.4 (g)	PR-1572104	NT	0.217	0.095	NT	NT
4G8.3-SL-9E8.4 (g)	PR-1572105	0.347	1.603	0.290	0.111	>5
4G8.3-LS-9E8.4 (g)	PR-1572106	NT	0.203	0.109	NT	NT
4G8.3-LS-9E8.4E	PR-1575835	NT	2.852	0.176	NT	NT
9A8.12-GS-9E8.4E	PR-1577165	NT	2.992	0.204	NT	NT
9A8.12-SL-9E8.4E	PR-1577166	NT	5.536	0.148	NT	NT
9A8.12-LS-9E8.4E	PR-1577547	NT	4.13	0.133	NT	NT
9E8.4E−SL-9A8.12	PR-1577548	NT	>5	0.147	NT	NT
9E8.4E−LS-9A8.12	PR-1577550	NT	>5	0.066	NT	NT
9E8.4E−GS-9A8.12	PR-1578137	NT	>5	0.327	NT	NT
hVEGF 4G8.3-GS-hPDGF	PR-1569574	0.341	1.02	0.630	0.137	>5
9E8.4 [hu IgG1/k]
mut(234, 235) H435A
hVEGF 4G8.3-SL-hPDGF	PR-1569579	0.36	1.178	0.427	0.133	>5
9E8.4 [hu IgG1/k]
mut(234, 235) H435A
hVEGF 4G8.3-LS-hPDGF	PR-1575573	NT	NT	NT	0.131	>5
9E8.4 [hu IgG1/k]
mut(234, 235) H435A
AB014-GS6-9E8.4	PR-1599234	0.124	NT	0.222	NT	NT
VH-VK
AB014-GS10-9E8.4	PR-1599236	0.095	NT	0.063	NT	NT
VH-VK
AB014-GS15-9E8.4	PR-1599239	0.13	NT	0.066	NT	NT
VH-VK
AB014-GS10-9E8.4	PR-1599240	0.086	NT	0.074	NT	NT
VK-VH
4G8.2-GS10-9E8.4	PR-1598261	0.221	NT	>5	NT	NT
4G8.4-GS10-9E8.4	PR-1598262	0.281	NT	1.327	NT	NT
4G8.5-GS10-9E8.4	PR-1598263	0.079	NT	>5	NT	NT
4G8.12-GS10-9E8.4	PR-1598264	0.079	NT	0.227	NT	NT
4G8.13-GS10-9E8.4	PR-1598265	0.907	NT	0.255	NT	NT
4G8.14-GS10-9E8.4	PR-1598266	0.113	NT	0.459	NT	NT
4G8.5_GS_CL-33675	PR-1611291	0.076	NT	0.05	NT	NT
4G8.5_GS_3E2.1	PR-1610562	0.072	NT	1.398	NT	NT
9E10.1_GS_CL-33675	PR-1610561	0.145	0.433	0.034	0.045	0.09
9E10.1_GS_3E2.1	PR-1610562	0.054	NT	5.724	NT	NT
9E10.6_GS_3E2.1	PR-1610563	0.06	NT	1.317	NT	NT
1B10.1_GS_CL-33675	PR-1611292	0.05	NT	0.037	NT	NT
1B10.1_GS_3E2.1	PR-1610564	0.084	NT	1.545	NT	NT
1E3.4_GS_CL-33675	PR-1611293	0.067	NT	0.037	NT	NT
1E3.4_GS_9E8.4	PR-1611294	0.092	NT	0.329	NT	NT
CL-33675_GS_9E10.1	PR-1611295	0.064	NT	0.031	NT	NT
CL-33675_GS_9E10.6	PR-1611296	0.082	NT	0.037	NT	NT
CL-33675_GS_1E3.4	PR-1611297	0.372	NT	0.039	NT	NT
9E8.4_GS_9E10.1	PR-1611298	0.073	NT	0.317	NT	NT
9E8.4_GS_9E10.6	PR-1611299	0.132	NT	0.213	NT	NT
9E8.4_GS_1B10.1	PR-1611300	0.391	NT	0.109	NT	NT
9E8.4_GS_1E3.4	PR-1611301	0.897	NT	0.131	NT	NT
4G8.5_GS_9E8.4	PR-1612489	0.069	NT	4.829	NT	NT
9E10.1_GS_9E8.4	PR-1612491	0.059	NT	1.913	NT	NT
9E10.6_GS_CL-33675	PR-1612492	0.05	NT	0.037	NT	NT
9E10.6_GS_9E8.4	PR-1612493	0.049	NT	1.14	NT	NT
1B10.1_GS_9E8.4	PR-1612494	0.127	NT	0.678	NT	NT
1E3.4_GS_3E2.1	PR-1612495	0.043	NT	6.253	NT	NT
CL-33675_GS_4G8.5	PR-1612496	0.219	NT	0.035	NT	NT
CL-33675_GS_1B10.1	PR-1612498	0.265	NT	0.11	NT	NT
3E2.1_GS_4G8.5	PR-1612499	0.743	NT	0.38	NT	NT
3E2.1_GS_9E10.1	PR-1612500	0.133	NT	0.394	NT	NT
3E2.1_GS_9E10.6	PR-1612501	0.188	NT	0.377	NT	NT
3E2.1_GS_1B10.1	PR-1612502	1.78	NT	0.187	NT	NT
CL-34565_GS_CL-33675	PR-1613183	0.059	NT	0.052	NT	NT
CL-34565_GS_9E8.4	PR-1613184	0.065	NT	0.323	NT	NT
CL-34565_GS_3E2.1	PR-1613185	0.053	NT	6.005	NT	NT
CL-33675_GS_CL-34565	PR-1613186	0.05	NT	0.043	NT	NT
9E8.4_GS_CL-34565	PR-1613187	0.058	NT	0.134	NT	NT
9E8.4_GS_4G8.5	PR-1613188	0.354	NT	0.108	NT	NT
3E2.1_GS_CL-34565	PR-1613189	0.063	NT	1.157	NT	NT
3E2.1_GS_1E3.4	PR-1613190	0.709	NT	0.896	NT	NT
NT—Not tested

TABLE 64A
Neutralization Activities in Cellular Assays
	Protein	Human VEGF-A	Human PDGF-BB
	Potency IC50 (pM)	145	34

Selected DVD-Ig molecules were further characterized for the ability to neutralize human VEGF₁₁₁ and human VEGF₁₂₁, isoforms of human VEGF-A. The molecules were tested for inhibition of VEGF₁₁₁ and human VEGF₁₂₁ induced proliferation of VEGFR2-3T3 cells (Example 1.8). Neutralization of non-human VEGF-A species was also evaluated. Molecules were tested for inhibition of rabbit VEGF₁₆₅ induced proliferation of VEGFR2-3T3 cells (Example 1.9). The data is summarized in Table 65 below. As noted, the amino acid sequence of cynomolgus monkey VEGF-A is identical to human VEGF-A. Parental antibodies had previously been examined for mouse VEGF₁₆₄ cross-reactivity in a competition ELISA and no blocking was observed (Example 1.5).

TABLE 65
Neutralization of Different VEGF-A Isoforms by Anti-VEGF-A/
Anti-PDGF-BB DVD-Ig Molecules
	Potency IC50 (nM)
		human	human	rabbit
DVD-Ig and Controls	Corporate ID	VEGF111	VEGF121	VEGF165
4G8.3-GS(9)-9E8.4	PR-1572102	0.771	0.182	0.869
(g)
4G8.3-SL-9E8.4 (g)	PR-1572105	0.654	0.139	1.194
4G8.3-LS-9E8.4 (g)	PR-1572106	0.431	0.148	0.601
4G8.3-LS-9E8.4E	PR-1575835	NT	NT	1.534
hVEGF 4G8.3-GS-	PR-1569574	0.674	0.124	0.841
hPDGF 9E8.4
[hu IgG1/k]
mut(234, 235) H435A
hVEGF 4G8.3-SL-	PR-1569579	0.576	0.154	1.213
hPDGF 9E8.4
[hu IgG1/k]
mut(234, 235) H435A
9E10.1_GS_CL-	PR-1610561	0.213	0.097	0.520
33675
NT—Not tested

Selected DVD-Ig molecules were further evaluated for their potencies to neutralize PDGF-BB of different species using the assay described in Examples 1.15-1.18. The data is summarized in Table 66 below. As noted, the amino acid sequence of rabbit PDGF-BB is identical to rat PDGF-BB.

TABLE 66
Neutralization of Different PDGF-BB Species by Anti-VEGF-
A/Anti-PDGF-BB DVD-Ig Molecules
	Potency IC50 (nM)
DVD-Ig and	Corporate	cynoPDGF-	mPDGF-	ratPDGF-
Controls	ID	BB	BB	BB
4G8.3-GS-9E8.4	PR-1564010	NT	0.440	1.359
4G8.3-SL-9E8.4	PR-1564012	NT	0.290	0.650
4G8.3-SL-9E8.4E	PR-1575834	NT	0.772	NT
4G8.3-LS-9E8.4	PR-1564013	NT	0.110	0.210
4G8.3-GS(9)-9E8.4	PR-1572102	0.139	0.174	2.202
(g)
4G8.3-SL-9E8.4 (g)	PR-1572105	0.142	0.096	1.296
4G8.3-LS-9E8.4 (g)	PR-1572106	0.094	0.14	NT
hVEGF 4G8.3-GS-	PR-1569574	0.139	0.134	1.514
hPDGF 9E8.4
[hu IgG1/k]
mut(234, 235)
H435A
hVEGF 4G8.3-SL-	PR-1569579	0.144	0.150	0.994
hPDGF 9E8.4
[hu IgG1/k]
mut(234, 235)
H435A
9E10.1_GS_CL-	PR-1610561	0.035	0.032	0.038
33675
NT—Not tested

Selected DVD-Ig molecules were evaluated for their ability to neutralize in the presence of a second ligand. To evaluate hPDGF-BB potency, the DVD-Ig molecules were pre-incubated with an excess of human VEGF₁₆₅ prior to testing in the NIH-3T3 proliferation assay (Example 1.21). To evaluate hVEGF₁₆₅ potency, the DVD-Ig molecules were pre-incubated with an excess of human hPDGF-BB prior to testing in the VEGFR2-3T3 (KDR/Flk-1) phosphorylation assay (Example 1.20). The data is summarized in Table 67 below.

TABLE 67
Simultaneous binding to VEGF and PDGF
	Co-incubation Potency
	IC50 (nM)
DVD-Ig	Corporate ID	hPDGF-BB	hVEGF165
9E8.4-GS-4G8.3	PR-1563988	NT	NT
9E8.4-SS-4G8.3	PR-1563990	NT	NT
9E8.4-SL-4G8.3	PR-1563998	NT	NT
9E8.4-LS-4G8.3	PR-1563009	NT	NT
4G8.3-GS-9E8.4	PR-1564010	NT	NT
4G8.3-SS-9E8.4	PR-1564011	NT	NT
4G8.3-SL-9E8.4	PR-1564012	NT	NT
4G8.3-LS-9E8.4	PR-1564013	NT	NT
4G8.3-GS(9)-9E8.4 (g)	PR-1572102	0.051	0.701
4G8.3-SL-9E8.4 (g)	PR-1572105	0.047	0.773
hVEGF 4G8.3-GS-	PR-1569574	0.032	0.594
hPDGF 9E8.4 [hu
IgG1/k] mut(234, 235)
H435A
hVEGF 4G8.3-SL-	PR-1569579	0.038	0.789
hPDGF 9E8.4 [hu
IgG1/k] mut(234, 235)
H435A
9E10.1_GS_CL-33675	PR-1610561	0.04	0.464
NT—Not tested

Selected DVD-Ig molecules were further evaluated for their ability to bind naturally derived human VEGF₁₆₅ (Example 1.11) and naturally derived human PDGF-BB (Example 1.19). The data is summarized in Table 68 below.

TABLE 68
Binding of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules to
hVEGF165 and hPDGF-BB by ELISA
	Binding
		Platelet derived	Y-79 derived
DVD-Ig	Corporate ID	hPDGF-BB	hVEGF165
4G8.3-GS(9)-9E8.4 (g)	PR-1572102	Yes	NT
4G8.3-SL-9E8.4 (g)	PR-1572105	Yes	NT
hVEGF 4G8.3-GS-	PR-1569574	Yes	NT
hPDGF 9E8.4 [hu
IgG1/k] mut(234, 235)
H435A
hVEGF 4G8.3-SL-	PR-1569579	Yes	NT
hPDGF 9E8.4 [hu
IgG1/k] mut(234, 235)
H435A
9E10.1_GS_CL-33675	PR-1610561	Yes	Yes
NT—Not tested

Example 13.4

Species Cross-Reactivity of an Anti-VEGF/Anti-PDGF DVD-Ig Molecule (PR-1610561)

PR-1610561 was further evaluated for its ability to cross-react with cynomolgus monkey, mouse, rat, and rabbit using cell-based proliferation assays (Examples 1.6, 1.17, 1.18, and 1.25). The data is summarized in Table 69 below.

TABLE 69
Species Cross-Reactivity of Anti-VEGF/anti-
PDGF DVD-Ig Molecule (PR-1610561)
	VEGF	PDGF
Protein	cyno	mo	rat	rab	cyno	mo	rat	rab
Affinity	65	—	—	41	0.8	0.3	3	3
KD (pM)

Example 13.5

Reactivity of Anti-PDGF-BB Antibodies and Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules to ECM-Associated PDGF-BB

As described in Example 1.27, first recombinant cell line HEK293 cells over-expressing PDGFBB-RM and then HUVEC naturally expressing ECM-associated PDGF-BB cells were used for staining:

HEK293 Cell Staining: PDGFB-RM transient transfected HEK 293 cells and parental HEK293 cells were re-suspended at 1E6 cells/mL in PBS and fixed in 4% paraformaldehyde at RT for 10 minutes, washed with PBS and 2E5 cells/tube were incubated in blocking buffer (10% goat serum in PBS) for one hour on ice. Cells were washed with PBS and incubated with primary antibody or DVD at 33 nM in antibody dilution buffer (5% goat serum in PBS) for one hour on ice. Cells were washed three times with PBS and incubated with Alexa Fluo 488 conjugated Goat anti-Human IgG (Jackson Immune, code: 109-546-098; lot: 108427) 1:400 dilution in antibody dilution buffer, incubate on ice for 45 minutes. Cells were washed three times with PBS and cytospin onto glass slides and mounted with mounting media with DAPI. Pictures were taken by fluorescent microscopy. Anti-PDGF-BB parental and affinity matured mAbs and three DVD-Ig molecules all showed positive staining on PDGFB-RM transient transfected 293 cells (FIG. 2A) and no staining on parental HEK 293 cells except for the slightly positive staining of affinity matured anti-PDGF-BB mAb. It is unclear if parental HEK 293 cells express low level of PDGF-BB endogenously

HUVEC Staining:

HUVEC cells secrete PDGF-BB, and low level of PDGF-BB may be captured on the cell surface as ECM-associated PDGF-BB. Affinity matured anti-PDGF-BB mAb and anti-VEGF/anti-PDGF DVD-Ig built with affinity-matured anti-PDGF-BB mAb was further assessed for its staining on naturally derived ECM-associated PDGF-BB on HUVEC cells. HUVECs (Lonza, cat#: C2519A lot: 181607) were trypsinized, resuspended at 2E4 cells/mL in culture media (Lonza, EGM2 MV Bulletkit: CC-3202). Cells were plated at 10,000 cells/500 μl/well in 8-chamber glass slide and incubated for 16 hours at 37° C., 5% CO₂. After incubation, cells were fixed with 200 μl 4% paraformaldehyde at RT for 10 minutes, washed with PBS and incubated in blocking buffer (10% goat serum in PBS) for one hour on ice. Cells were washed with PBS 3× and incubated with primary antibodies or DVD-Ig molecules at 33 nM in antibody dilution buffer (5% goat serum in PBS) for one hour on ice. Cells were washed three times with PBS and incubated with Alexa Fluo 488 conjugated Goat anti-Human IgG (JacksonImmune, code: 109-546-098; lot: 108427) 1:400 dilution in antibody dilution buffer, incubate on ice for 45 minutes. Cells were washed three times with PBS and mounted with mounting media with DAPI. Pictures were taken by fluorescent microscopy. As shown in FIG. 2B, affinity matured anti-PDGF-BB mAb showed positive staining on HUVEC cells while the staining of parental anti-PDGF-BB mAb on HUVEC cells is not evident (FIG. 2B). Anti-VEGF/anti-PDGF DVD-Ig (PR-1610561) built with affinity-matured anti-PDGF-BB mAb showed positive staining on HUVEC cells but control anti-tetanus toxoid DVD-Ig molecule also showed some weak staining which may be due to the background issue.

Example 13.6

Inhibition of Sprouting in HUVEC/MSC Co-culture Sprouting Assay by Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules

As described in Example 1.28, in early therapeutic treatment mode, Cytodex-3 beads (Sigma-Aldrich, cat# C3275) were coated with HUVEC cells (Lonza) overnight, and then embedded (100 beads/well) with human mesenchymal stem cells (Lonza, 20,000 cells/well) in fibrin gel in 24-well tissue culture plates. A 1:1 mixture of fresh EGM-2 complete media (Lonza) and fibroblast (Lonza) conditioned EGM-2 media were added on top of the fibrin gel along with 2 ng/mL of recombinant human HGF. Medium was replaced every 2-3 days till the end of the experiment. After EC sprouts and pericyte coverings were formed, usually on day 4, anti-VEGF-A (4G8.4), anti-PDGFBB (9E8.) or anti-PDGFBB/VEGF-A DVD-Ig were added to the culture medium at 10 nM. 10 days later cells were fixed in 4% PFA overnight at 4° C. Endothelial cells were stained with anti-PECAM (Abcam, ab32457), followed by fluorescence-conjugated secondary antibody, and pericytes were labeled with anti-aSMA-Cy3 (Sigma, C6198). Cells were then viewed by an inverted fluorescence microscope and 5× images were captured (FIG. 3). As seen in the pictures, DVD-Ig molecules as well as the combination of anti-VEGF and anti-PDGF mAbs are able to prevent sprouting formation greater than that of anti-VEGF mAb alone. Neither anti-PDGF mAb or anti-PDGF aptamer alone appear to have any significant inhibition of sprouting formation (FIG. 3). Similar experiments were also conducted in prophylactic and later therapeutic treatment modes and the results clearly demonstrated that anti-VEGF/anti-PDGF DVD-Ig (PR-1610561) strongly inhibited sprouting formation in this 3D co-culture assay.

Example 13.7

Characterization of FcRn and FcγRs Binding

Anti-VEGF/anti-PDGF DVD-Ig molecules, including 4G8.3-GS-9E8.4, 4G8.3-SL-9E8.4, 4G8.3-GS-9E8.4(g), 4G8.3-SL-9E8.4(g), 9E10.1GS_CL-33675, are human IgG1/κ isotype with L234A, L235A mutations to attenuate FcγRs binding and H435A mutation to eliminate FcRn binding. The binding of DVD-Ig molecules to FcRn from various species and the binding of DVD-Ig molecules to various FcγRs were characterized by Biacore using the method described in Example 1.2. The data is summarized in Tables 70 and 71 below.

TABLE 70
Binding of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules
to FcRn from Different Species, Measured by Biacore
	Steady State	1:1 Binding fit
	huFcRn	cynoFcRn	rabbitFcRn	ratFcRn	muFcRn
	KD	KD	KD	ka	kd	KD	ka	kd	KD
Immobilized	(M)	(M)	(M)	(1/Ms)	(1/s)	(M)	(1/Ms)	(1/s)	(M)
4G8.3-GS-9E8.4(g)	NSB	NSB	NSB	n/a	n/a	NSB	n/a	n/a	NSB
PR-1572102
4G8.3-SL-9E8.4(g)	NSB	NSB	NSB	n/a	n/a	NSB	n/a	n/a	NSB
PR-1572105
9E10.1_GS_C	NSB	NSB	NSB	n/a	n/a	NSB	n/a	n/a	NSB
L-33675 PR-1610561
4G8.3-GS-9E8.4	NSB	NSB	NSB	n/a	n/a	NSB	n/a	n/a	NSB
PR-1569574
4G8.3-SL-9E8.4	NSB	NSB	NSB	n/a	n/a	NSB	n/a	n/a	NSB
PR-1569579
* NSB = No significant binding at the concentration tested;
n/a = not available

TABLE 71
Binding of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules to Various Human FcγRs, Measured by Biacore
		huFcRIIa	huFcRIIa	huFcRIIIa	huFcRIIIa
	huFcRIIb	131H	131R	158F	158V
	KD	KD	KD	KD	ka	kd	KD
Sample	(M)	(M)	(M)	(M)	(1/Ms)	(1/s)	(M)	Fit
4G8.3-GS-9E8.4(g)	NSB	NSB	NSB	NSB	n/a	n/a	7.40E−06	steady state
PR-1572102
4G8.3-SL-9E8.4(g)	NSB	NSB	NSB	NSB	n/a	n/a	6.20E−06	steady state
PR-1572105
9E10.1_GS_CL-33675	NSB	NSB	NSB	NSB	n/a	n/a	1.1E−05*	steady state
PR-1610561
4G8.3-GS-9E8.4	NSB	NSB	NSB	NSB	n/a	n/a	1.6E−05*	steady state
PR-1569574
4G8.3-SL-9E8.4	NSB	NSB	NSB	NSB	n/a	n/a	1.2E−05*	steady state
PR-1569579
*NSB = No significant binding at the concentration tested;
n/a = not available

Example 14

Physicochemical Properties of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules

Example 14.1

Assessment of Physicochemical Properties of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules

Twenty one DVD-Ig molecules were selected for a screen of their solubility and stability profiles. Samples were prepped and evaluated according to Example 2.4. The DVD-Ig proteins were prepared in a formulation buffer and stored at 40° C. and 5° C. for up to 21 days. Samples were pulled and analyzed by SEC to determine changes in aggregation (Table 72). The molecules were evaluated at the listed concentrations. SEC was used to quantitate the aggregation percentage.

TABLE 72
Aggregation and Solubility Screening Of Selected DVD-Ig
Molecules Stored At 40° C. and 5° C. for 21 Days
in a Formulation Buffer
		% Aggregation
	Concentration	Change from T0
DVD-Ig Molecule	(mg/ml)	T21 d 5° C.	T21 d 40° C.
4G8.3-GS-9E8.4	100	0.24	*
4G8.3-SL-9E8.4	100	0.27	*
CL-34565_GS_CL-33675	48.7	0.20	0.25
CL-34565_GS_9E8.4	4.3	−0.30	0.05
CL-34565_GS_3E2.1	10.9	−1.12	−0.89
4G8.5_GS_CL-33675	50	−0.09	*
4G8.5_GS_9E8.4	50	−0.09	12.50
4G8.5_GS_3E2.1	50	0.53	14.63
9E10.1_GS_CL-33675	50	−2.08	−3.09
9E10.1_GS_9E8.4	50.7	2.95	−0.39
9E10.1_GS_3E2.1	43.2	−6.16	−9.05
9E10.6_GS_CL-33675	50	3.17	1.87
9E10.6_GS_3E2.1	34.9	−0.63	−0.65
1B10.1_GS_CL-33675	50	0.72	1.10
1E3.4_GS_3E2.1	50	0.17	*
CL-33675_GS_4G8.5	38.7	0.15	2.34
3E2.1_GS_4G8.5	50	16.15	*
3E2.1_GS_9E10.1	30.4	*	*
3E2.1_GS_9E10.6	50	0.17	5.55
3E2.1_GS_1B10.1	38.6	−6.33	*
3E2.1_GS_1E3.4	50	10.12	*
* Samples were too degraded or compromised to evaluate with SEC (e.g. gelled, precipitated).

Example 14.2

Further Assessment of Physicochemical Properties of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules (Stability During Storage at 40° C., 25° C., and 5° C.)

Based on the physicochemical screen discussed above (Example 14.1), three anti-VEGF-A/anti-PDGF-BB DVD-Ig molecules (4G8.3-GS-9E8.4, 4G8.3-SL-9E8.4, and 9E10.1-GS-33675) were selected for further characterization. Sample prep and analysis was performed according to Example 2.4.

Briefly, the molecules were prepared in a formulation buffer at 100±10 mg/ml and stored at 40° C., 25° C., and 5° C. for 84 days. Samples were periodically pulled for characterization (Tables 73-75 below).

As mentioned in Example 2.4, both 25° C. (room temperature) and 5° C. (storage temperature) are typical temperatures at which the samples would be subjected either during preparation and storage for manufacture or as part of the final drug product presentation. Also, storage at 40° C. is considered an accelerated stability condition which provides an indication of long-term stability prospects.

TABLE 73
Stability of 4G8.3-GS-9E8.4 During Storage. Aggregate, Monomer,
And Fragment Percentages Were Quantitated By SEC
				Area Under SEC
	%	%	%	Chromatogram Signal
	Aggregate	Monomer	Fragment	Relative to T0
T0	1.8	97.3	0.9	1.00
T7 d 40° C.	*	*	*	*
T7 d 25° C.	2.2	97.0	0.9	0.91
T7 d 5° C.	1.9	97.2	0.9	0.92
T21 d 40° C.	*	*	*	*
T21 d 25° C.	3.0	96.4	0.6	0.84
T21 d 5° C.	1.8	97.8	0.5	0.90
T42 d 40° C.	*	*	*	*
T42 d 25° C.	3.4	95.6	1.0	0.88
T42 d 5° C.	2.0	97.3	0.7	1.00
T63 d 40° C.	*	*	*	*
T63 d 25° C.	4.2	94.7	1.0	0.85
T63 d 5° C.	2.1	97.4	0.5	0.92
T84 d 40° C.	*	*	*	*
T84 d 25° C.	5.0	93.7	1.3	0.79
T84 d 5° C.	2.2	97.3	0.6	0.85
* Samples were too degraded or compromised to evaluate with SEC (e.g. gelled, precipitated).

TABLE 74
Stability of 4G8.3-SL-9E8.4 During Storage. Aggregate, Monomer,
And Fragment Percentages Were Quantitated by SEC
				Area Under SEC
	%	%	%	Chromatogram Signal
	Aggregate	Monomer	Fragment	Relative to T0
T0	4.2	94.7	1.1	1.00
T7 d 40° C.	*	*	*	*
T7 d 25° C.	6.6	92.2	1.3	0.86
T7 d 5° C.	4.3	94.7	1.0	0.82
T21 d 40° C.	*	*	*	*
T21 d 25° C.	8.5	90.5	1.1	0.77
T21 d 5° C.	3.9	95.3	0.8	0.87
T42 d 40° C.	*	*	*	*
T42 d 25° C.	13.2	85.6	1.3	0.80
T42 d 5° C.	4.5	94.4	1.1	0.97
T63 d 40° C.	*	*	*	*
T63 d 25° C.	13.2	85.3	1.5	0.73
T63 d 5° C.	4.3	95.0	0.7	0.87
T84 d 40° C.	*	*	*	*
T84 d 25° C.	10.3	88.1	1.6	0.62
T84 d 5° C.	4.5	94.7	0.7	0.80
* Samples were too degraded or compromised to evaluate with SEC (e.g. gelled, precipitated).

TABLE 75
Stability of 9E10.1-GS-33675 During Storage. Aggregate, Monomer,
And Fragment Percentages Were Quantitated by SEC.
				Area Under SEC
	%	%	%	Chromatogram Signal
	Aggregate	Monomer	Fragment	Relative to T0
T0	0.8	98.4	0.7	1.00
T7 d 40° C.	5.3	93.8	0.8	0.84
T7 d 25° C.	4.8	94.6	0.6	0.89
T7 d 5° C.	3.7	95.5	0.8	0.92
T21 d 40° C.	6.1	92.5	1.4	0.77
T21 d 25° C.	4.4	95.0	0.6	0.82
T21 d 5° C.	6.7	92.8	0.5	0.89
T42 d 40° C.	13.8	83.9	2.3	0.76
T42 d 25° C.	4.7	94.6	0.8	0.85
T42 d 5° C.	7.7	91.7	0.5	0.92
T63 d 40° C.	19.8	77.0	3.2	0.77
T63 d 25° C.	4.8	94.4	0.8	0.84
T63 d 5° C.	8.4	91.2	0.4	0.94
T84 d 40° C.	22.8	73.2	4.0	0.68
T84 d 25° C.	5.3	93.7	1.0	0.80
T84 d 5° C.	8.1	91.5	0.4	0.88

Both 4G8.3-GS-9E8.4 and 4G8.3-SL-9E8.4 formed a white precipitate when stored at 40° C. after 7 days and thus could not be analyzed by SEC. The samples are assumed to be completely aggregated. At 25° C., there was an observable increase in aggregation for both molecules. The aggregation was less rapid for 4G8.3-GS-9E8.4 than for 4G8.3-SL-9E8.4. Aggregation of the former increased from 1.8% to 5.0% after 84 days while that of the latter started at 4.2% and reached as high as 13.2% over the course of 84 days. At 5° C., there is no noticeable aggregate increase for the two molecules.

For 9E10.1-GS-33675, aggregation at 5° C. increased from 0.8% to 6.7% by 21 days and levelled off at ˜8% from 42 to 84 days. At 25° C., aggregation increased from 0.8% to 4.7% by 7 days and levelled off at that value up to 84 days. Finally, aggregation at 40° C. increased from 0.8% to 22.8% in an apparently linear fashion over the course of 84 days. The aggregation at 40° C. for 9E10.1-GS-33675 is much less that that observed for the other two DVD-Ig molecules. This may be the result of the universal formulation buffer used.

There was no apparent change in fragmentation for all three DVD-Ig molecules at 25° C. or 5° C. At 40° C., an apparent and expected increase in fragmentation was observed for 9E10.1-GS-33675 after 21 days.

Example 14.3

Further Assessment of Physicochemical Properties of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules (Stability to Freeze-Thaw Stress)

Based on the earlier physicochemical screen (Example 14.1), three anti-VEGF-A/anti-PDGF-BB DVD-Ig molecules (4G8.3-GS-9E8.4, 4G8.3-SL-9E8.4, and 9E10.1-GS-33675) were selected for further characterization. Sample prep, stress, and analysis were performed according to Example 2.5. Briefly, the molecules were prepared in a formulation buffer at concentrations of 100±10 mg/ml or 1 mg/ml and subjected to four cycles of freezing (˜80° C.) and thawing (30° C.). Samples were characterized after the second and fourth thaw (Tables 76-81 below).

As mentioned in Example 2.5, protein samples are typically frozen at −80° C. for long term storage as well as shipping to remote manufacturing sites. The samples are then thawed in order to complete the drug product manufacturing process.

TABLE 76
Stability of 4G8.3-GS-9E8.4 at 100 ± 10 mg/ml When Subjected
To Freeze-Thaw Stress (−80° C./30° C.). Aggregate,
Monomer, And Fragment Percentages Were Quantitated by SEC.
				Area Under SEC
	%	%	%	Chromatogram Signal
	Aggregate	Monomer	Fragment	Relative to T0
F/T 0	1.8	97.3	0.9	1.00
F/T 2	1.8	97.4	0.8	0.90
F/T 4	2.2	96.9	0.9	0.92

TABLE 77
Stability of 4G8.3-SL-9E8.4 at 100 ± 10 mg/ml
When Subjected To Freeze-Thaw stress (−80°
C./30° C.). Aggregate, Monomer, And Fragment
Percentages Were Quantitated by SEC
				Area Under SEC
	%	%	%	Chromatogram Signal
	Aggregate	Monomer	Fragment	Relative to T0
F/T 0	4.2	94.7	1.1	1.00
F/T 2	4.1	95.2	0.7	0.83
F/T 4	4.3	94.4	1.3	0.82

TABLE 78
Stability of 9E10.1-GS-33675 at 100 ± 10 mg/ml
when Subjected To Freeze-Thaw Stress (−80°
C./30° C.). Aggregate, Monomer, And Fragment
Percentages Were Quantitated by SEC.
				Area Under SEC
	%	%	%	Chromatogram Signal
	Aggregate	Monomer	Fragment	Relative to T0
F/T 0	0.8	98.4	0.7	1.00
F/T 2	1.1	98.5	0.4	0.91
F/T 4	1.8	97.6	0.6	0.88

TABLE 79
Stability of 4G8.3-GS-9E8.4 at 1 mg/ml When
Subjected To Freeze-Thaw Stress (−80°
C./30° C.). Aggregate, Monomer, And Fragment
Percentages Were Quantitated by SEC.
				Area Under SEC
	%	%	%	Chromatogram Signal
	Aggregate	Monomer	Fragment	Relative to T0
F/T 0	1.8	97.3	0.9	1.00
F/T 2	1.9	97.5	0.6	0.95
F/T 4	2.0	97.1	0.9	0.96

TABLE 80
Stability of 4G8.3-SL-9E8.4 at 1 mg/When Subjected To
Freeze-Thaw Stress (−80° C./30° C.). Aggregate,
Monomer, And Fragment Percentages Were Quantitated by SEC.
				Area Under SEC
	%	%	%	Chromatogram Signal
	Aggregate	Monomer	Fragment	Relative to T0
F/T 0	4.2	94.7	1.1	1.00
F/T 2	3.9	95.4	0.7	0.94
F/T 4	4.1	94.9	1.0	0.94

TABLE 81
Stability of 9E10.1-GS-33675 at 1 mg/ml When Subjected
To Freeze-Thaw Stress (−80° C./30° C.). Aggregate,
Monomer, And Fragment Percentages Were Quantitated by SEC.
				Area Under SEC
	%	%	%	Chromatogram Signal
	Aggregate	Monomer	Fragment	Relative to T0
F/T 0	0.8	98.4	0.7	1.00
F/T 2	1.0	98.6	0.5	0.98
F/T 4	1.2	98.2	0.6	0.98

For all three DVD-Igs, at either 100±10 mg/ml or 1 mg/ml, no apparent increase in aggregation was observed due to freeze-thaw stress after two cycles.

Example 14.4

Further Assessment of Physicochemical Properties of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules (Viscosity Determination)

Based on the earlier physicochemical screen (Example 14.1), three anti-VEGF-A/anti-PDGF-BB DVD-Ig molecules (4G8.3-GS-9E8.4, 4G8.3-SL-9E8.4, and 9E10.1-GS-33675) were selected for further characterization. The molecules were prepared in a formulation buffer at 100±10 mg/ml and the viscosities were measured at room temperature (Example 2.6). The viscosities were 5.1, 7.2, and 7.2 centipoise, respectively. The values are within the range that enables ease of administration via a small diameter needle attached to a syringe.

Example 14.5

Further Assessment of Physicochemical Properties of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules (Thermal Stability Assessment)

Based on the earlier physicochemical screen (Example 14.1), three anti-VEGF-A/anti-PDGF-BB DVD-Ig molecules (4G8.3-GS-9E8.4, 4G8.3-SL-9E8.4, and 9E10.1-GS-33675) were selected for further characterization. The molecules were prepared in a formulation buffer at 1 mg/ml according to Example 2.3 and the thermal stabilities were determined according to Example 2.2. The midpoint temperatures of the first transition of unfolding are 52° C., 51° C., and 62° C., respectively. The temperatures at which the first transitions began to appear are 44° C., 42° C., and 62° C., respectively. The data indicate that 9E10.1-GS-33675 has a significantly greater thermal stability than the other two DVD-Ig molecules.

Example 14.6

Physicochemical Properties of an Anti-VEGF/anti-PDGF DVD-Ig Molecule (PR-1610561)

Testing of PR-1610561 revealed high thermostability (T_onset=62° C.), solubility at least at 76 mg/ml, and a viscosity at 100 mg/ml at room temperature of 7.2 centipoise, which is within the range that enables ease of administration via a small diameter needle attached to a syringe. PR-1610561 has appropriate storage stability in a universal buffer and freeze-thaw stability.

Example 14.76

Intact and Reduced Molecular Weight Determination

Q-TOF LC-MS can detect mass differences between proteins that can result from mis-sense mutations, post-translational modifications, truncations, and other covalent changes that affect protein molecular weight. Table 82 shows the intact molecular weight and deglycosylated intact molecular weight of all three DVD-Ig molecules. Table 83 shows the molecular weights of light chain, heavy chain and deglycosylated heavy chain. The observed molecular weights of the three DVD-Ig molecules match well with the theoretical values with difference of less than 3 Dalton, which is well within the expected range of the error for the instrument.

TABLE 82
Intact molecular weight
	Intact MW	Deglycosylated Intact MW
	Theoretical	Observed	Theoretical	Observed
PR-1572102	203220	203219	200330	200330
PR-1572105	204350	204348	201460	201460
PR-1610561	202452	202450	199562	199562

TABLE 83
Reduced molecular weight
	Light Chain	Heavy Chain	Deglycosylated
	MW	MW	HC MW
	Theo-	Ob-	Theo-	Ob-	Theo-	Ob-
	retical	served	retical	served	retical	served
PR-1572102	36080	36080	65533	65533	64088	64091
PR-1572105	36735	36734	65444	65444	63999	64002
PR-1610561	36006	36005	65224	65224	63779	63780

Example 14.8

Oligosaccharide Profiles by Fc Molecular Weight

DVD-Ig molecules contain N-linked oligosaccharides in the Fc region of the heavy chain Fc molecular weight measurement can provide a semi-quantitative analysis of the oligosaccharide profiles. Table 84 shows the results of oligosaccharide profiles by Fc molecular weight. The oligosaccharide profiles of all three DVD-Ig molecules were similar to what is normally observed for mAbs, with 70-73% Gal 0F and 21-24% Gal 1F. The level of high mannose species was very low in all three samples. No significant level of aglycosylated species was detected.

TABLE 84
Oligosaccharide Profiles By Fc Molecular Weight
Species	PR-1572102	PR-1572105	PR-1610561
Man 5	1.0	1.1	0.4
Gal 0F-GlcNAc	0.5	0.4	0.0
Gal 0	0.5	0.2	0.7
Gal 0F	73.4	73.4	70.8
Lys-1	0.8	0.3	0.8
Gal 1F	21.0	21.2	23.8
Gal 2F	2.8	3.3	3.6

Example 14.9

Charge Heterogeneity by Weak Cation Exchange Chromatography and Imaged Isoelectric Focusing

Weak cation exchange (WCX) chromatography separates molecules on the basis of the differences in their net surface charge. Variation in the extent of C terminal processing and certain post-translational modifications can lead to different species of an antibody with different charge distributions. Molecules that vary in their charge properties will exhibit different degrees of interaction with ion exchange resins, thus different elution profiles. Each chromatogram is characterized by a predominant peak (“main”) and species eluting before (“acidic”) or after (“basic”). The relative abundances of these species types are shown in Table 85.

TABLE 85
Results of Weak Cation Exchange Chromatography Analysis
	Acidic (%)	Main (%)	Basic (%)
	PR-1572102	9.2	63.9	26.9
	PR-1572105	14.9	52.4	32.7
	PR-1610561	17.7	56.5	25.8

Imaged capillary isoelectric focusing (icIEF) is a technique that separates proteins on the basis of their isoelectric points or pI values. Different proteins have different pI and peak profiles, which makes icIEF an ideal identity assay. In icIEF, proteins with different pI values focus into distinctive bands in a linear pH gradient formed by ampholytes after applying high voltage. Table 86 shows the theoretical pI (calculated based on amino acid sequence) and the observed pI values measured by imaged icIEF. Also shown in Table 86 are the relative abundances of different charge species detected by imaged icIEF.

TABLE 86
Results of Imaged Isoelectric Focusing
		pI by
	Thoe. pI	icIEF	Acidic (%)	Main (%)	Basic (%)
PR- 1572102	6.13	6.78	14.3	71.6	14.1
PR-1572105	6.13	6.74	25.3	60.2	14.4
PR-1610561	6.67	7.27	27.2	63.2	9.6

Example 15

Pharmacokinetic Properties of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules

Example 15.1

Pharmacokinetic Properties of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules Intravenously Administered in huFcRN Transgenic Mice

Studies were conducted in accordance with the AbbVie IACUC guidelines. Anti-VEGF/anti-PDGF DVD-Ig molecules PR-1572102 (lot 2211502), PR-1572105 (lot 2211597), or PR-1610561 (lot 2213329) were administered to huFcRn B6.Cg transgenic mice (5/group) at 5 mg/kg by slow intravenous bolus dose injection. Blood samples were collected from each mouse at 1, 24 and 96 hours and 7, 10, 14 and 21 days post dose. All samples were stored at −80° C. until analysis. DVD-Ig serum concentrations were measured using a Meso Scale Discovery (MSD) electrochemiluminescence (ECL) Ligand Binding Assay. Biotinylated VEGF ligand was coated onto streptavidin MSD plates for capture of anti-VEGF-A/anti-PDGF-BB DVD-Ig molecules from blood samples, and detection was achieved with a sulfo-tag goat anti-human IgG antibody. Concentrations were calculated by four-parameter logistic fit using XLfit4. Pharmacokinetic parameters were calculated with Non-compartmental analysis using Pharmacokinetics Laboratory Automation Software for Management and Analysis (PLASMA) (Version 2.6.12, SParCS, AbbVie).

All three anti-VEGF/PDGF DVD-Ig molecules carrying the H435A substitution had serum concentrations rapidly clear, with measurable concentrations only to 24 hours. These results are in agreement with the rapid clearance observed with other H435A modified antibody and DVD-Ig molecules in human FcRn transgenic mice.

Example 15.2

Pharmacokinetic Properties of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules Intravitreously Administered in Rabbit

Studies were conducted in accordance with the Abbott IACUC guidelines. Female New Zealand White rabbits were used for the ocular pharmacokinetic characterization of Anti-VEGF-A/anti-PDGF-BB DVD-Igs: PR-1572102, PR-1572105 and PR-1610561. Animals (4 animals) were split into two cohorts of two for determination of ocular pharmacokinetics. Samples of aqueous humour were taken at 4, 24, 48, 72, 120, 168, 336 and 504 hours post dosing. With cohort 1 providing samples at 4, 48, 120 and 168 hours, and cohort 2 providing samples at 24, 72, 336 and 504 hours, post dosing. Drug levels in the eye were determined from concentrations in aqueous humour as a surrogate for the vitreous concentrations. Vitreous was harvested from each animal as a terminal sample after their last aqueous humour sample. The proportion of aqueous to vitreous concentration was determined from these terminal time points. Blood samples for the harvest of serum used to estimate systemic exposure after vitreous dosing were also collected at 4, 24, 48, 72, 120, and 168 hours post dosing from all animals, and at 336 and 504 hours from the animals in cohort 2. Test articles were dosed into the vitreous compartment at a range of 0.25 to 0.50 mg per eye with a dose volume of no more than 0.050 mL. Only the right eye of each animal was dosed. Prior to dosing, animals were anesthetized with xylazine/ketamine. The eye was prepared by first applying topical analgesic drops (procaine HCl Ophthalmic solution, 0.5%), then the injections site was swabbed with a saturated povidone-iodine swabstick (10% solution equivalent to 1% available iodine) prior to injection. The intravitreal dose was administered with a 26 gauge needle. The point of entry for the injection was 1-2 mm from the limbus through the sclera. After injection, a sterile cotton eye spear was placed on the injection site and held for 30 seconds to prevent leakage Animals were anesthetized for aqueous fluid collection. At the selected time points after dosing, the aqueous fluid was collected using a 30 gauge needle inserted through the cornea. The needle was advanced just past the bevel and fluid was collected. The samples provided approximately 0.05-0.1 mL of aqueous humour per sampling period. At the selected time points after dosing, blood samples were obtained from an ear vein or artery. Hemostasis following collection was achieved by the application of manual pressure and topical clotting factor or tissue glue as needed. The samples were from 0.5-1 ml in volume, and were allowed to clot for harvest of serum. Aqueous, vitreous and serum samples were stored at −80° C., and submitted for drug level determinations.

All DVD-Ig serum concentrations were measured using a GYROS method employing biotinylated VEGF ligand for capture, and Alexa Flour 647 goat anti-human IgG detection. Concentrations were calculated by four-parameter logistic fit using XLfit4. Pharmacokinetic parameters were calculated with Non-compartmental analysis using Pharmacokinetics Laboratory Automation Software for Management and Analysis (PLASMA) (Version 2.6.12, SParCS, AbbVie).

TABLE 87
Ocular Half Lives in Rabbit from Analysis of Aqueous Humor
Experiment	Test Article	Corporate ID	Half life (hours)
#1	9E10.1_GS_CL-33675	PR-1610561	111
#2	9E10.1_GS_CL-33675	PR-1610561	Pending

Example 15.3

Pharmacokinetic Properties of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules Intravenously Administered in Cynomolgus Monkey

Studies are conducted in accordance with the AbbVie IACUC guidelines. Female cynomolgus are used for the systemic pharmacokinetic characterization of Anti-VEGF-A/anti-PDGF-BB DVD-Igs, including PR-1572102, PR-1572105 and PR-1610561 after intravenous dosing. Monkeys are dosed intravenously at 5 mg/kg by slow bolus into the saphenous vein over approximately 2 minutes with a volume of 0.5 mL/kg. Samples are taken for determination of the pharmacokinetics of the test compounds at 0, 0.08, 4, 8, 24, 72, 168, 240, 336, 504 and 672 hours post dosing. At the selected time points after dosing, blood samples are obtained from a femoral vein. Hemostasis following collection is achieved by the application of manual pressure and topical clotting factor or tissue glue as needed. The samples may be approximately 1 ml in volume, and are allowed to clot for harvest of serum. Serum samples are stored at −80° C., and submitted for drug level determinations.

DVD-Ig serum concentrations are measured using either a GYROS or a MSD method. GYROS employs biotinylated VEGF ligand for capture, and Alexa Flour 647 goat anti-human IgG detection. MSD employs biotinylated VEGF ligand for capture, and Sulfo-tag goat anti-human IgG or sulfo-tag VEGF for detection. Concentrations are calculated by four-parameter logistic fit using XLfit4. Pharmacokinetic parameters are calculated with Non-compartmental analysis using Pharmacokinetics Laboratory Automation Software for Management and Analysis (PLASMA) (Version 2.6.12, SParCS, AbbVie).

Example 15.4

Pharmacokinetic Properties of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules Intravitreously Administered in Cynomolgus Monkey

Studies are conducted in accordance with the AbbVie IACUC guidelines. Female cynomolgus are used for the ocular pharmacokinetic characterization of Anti-VEGF-A/anti-PDGF-BB DVD-Igs, including PR-1572102, PR-1572105 and PR-1610561. Animals (4 animals) are split into two cohorts of two for determination of ocular pharmacokinetics. Samples of aqueous humour are taken at 4, 24, 48, 72, 120, 168, 336 and 504 hours post dosing. With cohort 1 providing samples at 4, 48, 120 and 168 hours, and cohort 2 providing samples at 24, 72, 336 and 504 hours, post dosing. Drug levels in the eye are determined from concentrations in aqueous humour as a surrogate for the vitreous concentrations. Blood samples for the harvest of serum used to estimate systemic exposure after vitreous dosing are also collected at 4, 24, 48, 72, 120, and 168 hours post dosing from all animals, and at 336 and 504 hours from the animals in cohort 2. Test articles are dosed into the vitreous compartment at a range of 0.25 to 0.50 mg per eye with a dose volume of no more than 0.050 mL. Only the right eye of each animal is dosed. Prior to dosing, animals are anesthetized with xylazine/ketamine. The eye is prepared by first applying topical analgesic drops (procaine HCl Ophthalmic solution, 0.5%), then the injections site is swabbed with a saturated povidone-iodine swabstick (10% solution equivalent to 1% available iodine) prior to injection. The intravitreal dose is administered with a 26 gauge needle. The point of entry for the injection is 1-2 mm from the limbus through the sclera. After injection, a sterile cotton eye spear is placed on the injection site and held for 30 seconds to prevent leakage. Animals are anesthetized for aqueous fluid collection. At the selected time points after dosing, the aqueous fluid is collected using a 30 gauge needle inserted through the cornea. The needle is advanced just past the bevel and fluid was collected. The samples provide approximately 0.05-0.1 mL of aqueous humour per sampling period. At the selected time points after dosing, blood samples are obtained from an ear vein or artery. Hemostasis following collection is achieved by the application of manual pressure and topical clotting factor or tissue glue as needed. The samples are approximately 1 ml in volume, and are allowed to clot for harvest of serum. Aqueous, vitreous and serum samples are stored at −80° C., and submitted for drug level determinations.

DVD-Ig serum concentrations are measured using either a GYROS or a MSD method. GYROS employs biotinylated VEGF ligand for capture, and Alexa Flour 647 goat anti-human IgG detection. MSD employs biotinylated VEGF ligand for capture, and Sulfo-tag goat anti-human IgG or sulfo-tag VEGF for detection. Concentrations are calculated by four-parameter logistic fit using XLfit4. Pharmacokinetic parameters are calculated with Non-compartmental analysis using Pharmacokinetics Laboratory Automation Software for Management and Analysis (PLASMA) (Version 2.6.12, SParCS, AbbVie).

Example 16

Efficacy of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules Human VEGF Transgenic Mice

Example 16.1

Efficacy of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules to Inhibit Subretinal Neovascularization in Rho/huVEGF Transgenic Mice

Transgenic mice in which the rhodopsin promoter drives expression of human VEGF₁₆₅ in photoreceptors (Rho-VEGF mice) have onset of VEGF expression at P7 and starting at P10, develop sprouts of NV from the deep capillary bed of the retina that grow through the photoreceptor layer and form an extensive network of new vessels in the subretinal space. Since the new vessels originate from retinal capillaries and not choroidal vessels, it is technically a model of retinal angiomatous proliferation (RAP) which occurs in roughly 30% of patients with neovascular AMD, but in general it mimics critical features of wet AMD. At P14, hemizygous Rho-VEGF mice were given an intraocular injection of test reagents. At P21, the mice were euthanized, and eyes were fixed in 10% phosphate-buffered formalin for 2 hours. Retinas were dissected, blocked with 5% normal swine serum in PBS for 1 hour, stained with FITC-conjugated GSA, a vascular stain, for 2 hours to stain vascular cells, flat mounted with the photoreceptor side up, and examined by fluorescence microscopy. The area of subretinal NV was measured with image analysis by an investigator blinded with respect to treatment group. The other eye will provide information regarding systemic effect of an intraocular injection.

In the study below, nine treatment groups were evaluated: DVD-Ig Control (DVD 889), Eylea, Anti VEGF mAb, Anti PDGF mAb, Anti VEGF+Anti PDGF (combination Ab treatment), Anti-VEGF/anti-PDGF DVD-Ig. Only eye measurements in the experimental eye were analyzed and reported here using one way ANOVA analysis. Posthoc comparison of treatment vs the DVD control groups was analysed by Dunnett's test. Results are shown in See FIG. 4 and in Table 88 below. Further, differences in PDGF neutralization potencies and the molecular size of the DVD-Ig versus IgG did not have an effect in this model.

An overall ANOVA F-test for significance was used and the data was shown to be significant (p<0.0001). Comparison of the test groups to the DVD-Ig control group shows that the difference from all the groups was significant (Dunnet test p<0.0001). PR-1610561 was significantly more effective at inhibiting subretinal neovascularization in Rho/huVEGF transgenic mice than Eylea (Tukey HSD test pvalue=0.0031). PR-1610561 was more effective, but not significantly different from, the anti-VEGF and anti-PDGF (potency matched mAbs) combination group.

TABLE 88
Inhibition Efficacy of Anti-VEGF-A, Anti-PDGF-
BB, Anti-VEGF-A + Anti-PDGF-BB, and Anti-
VEGF-A/Anti-PDGF-BB DVD-Ig Molecules to Subretinal
Neovascularization in Rho/huVEGF Transgenic Mice
	Cor-	N (# of
	porate	ani-		Std	Std	CV
Groups	ID#	mals)	Mean	Dev	Err	(%)
DVD negative	PR-	8	0.0892	0.0665	0.0235	74
control	1250499
Eylea	—	19	0.0198	0.0224	0.0051	113
Anti VEGF	—	7	0.0164	0.0088	0.0033	54
Anti PDGF	—	16	0.0297	0.0265	0.0066	89
Anti VEGF +	—	10	0.0119	0.0182	0.0058	153
Anti PDGF
Anti-VEGF/	PR-	9	0.0033	0.0038	0.0013	115
anti-PDGF	1610561
DVD-Ig

Example 16.2

Efficacy of Anti-VEGF-A/Anti-PDGF-BB DVD-Ig Molecules in Tet-Opsin-Human VEGF₁₆₅ Double-Transgenic Mice

When given injections of doxycycline, Tet-opsin-VEGF double-transgenic mice with Dox-inducible expression of VEGF express 10-fold higher levels of human VEGF₁₆₅ than Rho-VEGF-transgenic mice and develop severe NV and exudative retinal detachments within 3 to 5 days. Tet-opsin-VEGF mice provide a severe model where mice develop exudative retinal detachments and only the most effective agents have a significant impact. Double-hemizygous Tet-opsin-VEGF mice were given intraocular injections of test reagent in the right eyes. For the next 3 days, the mice were also administered a daily subcutaneous injection of 50 mg/kg doxycycline. At the 4th day, mice were euthanized and fundus photographs taken with Micron III retinal imaging microscope (Phoenix Research Laboratories, Pleasanton, Calif.). Also, OCT images were taken by Bioptigen Image-guided OCT (Envisu R4110, Bioptigen Inc. Morrisville, N.C.). Then eyes were frozen in optimal cutting temperature embedding solution. Ten-micron ocular serial sections were cut through the entire eye, stained with H&E stain and examined by light microscopy. After that mean length of the retinal detachment per section was measured with image analysis by an investigator blinded with respect to treatment group. The percentage of the detached retina was computed. Retinal detachment was graded as no detachment (0); partial retinal detachment (1); or total retinal detachment (2).

Anti-VEGF-A, anti-PDGF-BB, and the combination of anti-VEGF-A and anti-PDGF-BB were tested for their ability to suppress retinal detachment (RD) in tet-opsin-VEGF double transgenic mice. Results showed differences among the 3 test groups (P=0.01, Kruskal-Wallis test). Based on the RD number, the combination of anti-VEGF-A and anti-PDGF-BB (7 NRD, 1 PRD, 0 TRD), and the anti-VEGF-A alone (5 NRD, 0 PRD, 0 TRD) groups were more effective than anti-PDGF-BB alone (2 NRD, 2 PRD, 2 TRD) in preventing RD in Tet-opsin-VEGF double transgenic mice.

The differences in efficacy between PR-1610561, Eylea, and control IgG were compared next in tet-opsin-VEGF mice. Differences were also found among the 3 groups (P=0.01, Kruskal-Wallis test). PR-1610561 (10 NRD, 0 PRD, 1 TRD) and Eylea (4 NRD, 3 PRD, 1 TRD) were more effective than IgG control (2 NRD, 2 PRD, 2 TRD) in preventing RD in Tet-opsin-VEGF double transgenic mice. The data is summarized in Table 89 below.

TABLE 89
The efficacy of test articles in tet-
opsin-VEGF double transgenic mice
		Anti-	Anti-	Anti-
	IgG	VEGF	PDGF	VEGF +	PR-
Grade	control	mAb	mAb	Anti-PDGF	1610561	Eylea
0	2	5	2	7	10	4
(NRD)
1	1	0	2	1	0	3
(PRD)
2	6	0	3	0	1	1
(TRD)
Total	9	5	7	8	11	8
eyes

The effects of PR-1610561 in a tet/opsin/huVEGF double transgenic mouse retinal detachment model were also analyzed by another grading system (Table 89A). 1 μl of reagent was injected into one eye, followed by subcutaneous injection of doxycycline at 500 mg/kg once a day for three days, and then fundus images and OCTs were done at day 4. Retinal detachment was graded as no detachment (0); no retinal detachment but at least one sign selected from dilated retinal vessels, retinal edema, or hemorrhage (1); one or less than one quadrant of retinal detachment (2); two or three quandrants of retinal detachment or shallow pan retinal detachment (3); or severe bullous retinal detachment (4).

TABLE 89A
Efficacy of Anti-VEGF, Anti-PDGF, Anti-VEGF + Anti-PDGF, and Anti-
VEGF/Anti-PDGF DVD-Ig Molecules in Tet/Opsin/huVEGF Double Transgenic Mice
Grade	DVD889	Anti-VEGF	Anti-PDGF	Combo	PR-1610561	Aflibercept
0	1	4	1	4	3	1
1	1	1	1	2	7	3
2	1	0	2	0	0	1
3	0	0	0	1	1	1
4	6	0	3	0	0	1
Total eyes	9	5	7	8	11	7
evaluated

The results in the tables above show that PR-1610561 has similar efficacy to a combination of anti-VEGF-A and anti-PDGF-BB, and is superior to Aflibercept alone in suppressing subretinal neovascularization in Rho/huVEGF transgenic mice. PR-1610561 is also superior to the combination of Aflibercept and anti-PDGF-BB in the prevention of vascular leakage in Rho/huVEGF transgenic mice.

Example 16.3

Effects of Anti-VEGF/Anti-PDGF on Ocular Neovascularization and Vascular Permeability/Perfusion

This study compared the effects of intraocular injections of anti-VEGF/anti-PDGF DVD-Ig molecules, anti-VEGF mAb alone, anti-PDGF alone, and a combination of antibodies.

DVD-Ig molecules and DVD-Ig Fab fragments were selected for evaluation, first in Rho/VEGF mice and then in Tet/opsin/VEGF double transgenic mice.

Studies used rho/VEGF and Tet/opsin/VEGF mouse models as described in Example 16.1. The compounds evaluated are shown in Table 90 below. About 20 mice were included per experiment, where one eye was injected with agent and the other eye was not injected.

TABLE 90
Study Agents
4G8.3-GS-9E8.4 (PR-1572102; DVD-Ig-1)
4G8.3-LS-9E8.4 (PR-PR-1575573; DVD-Ig-2)
4G8.3-SL-9E8.4 (PR-1572105; DVD-Ig-3)
DVD 889(IgG control)
Anti-VEGF IgG 4G83
Anti-PDGF-BB IgG 9E8.4
Anti-VEGF IgG 24 μg + Anti-PDGF-BB IgG
Avastin 24 μg
Anti-PDGF-BB aptamer E10030.1
Avastin 24 μg + Anti-PDGF-BB aptamer

Transgenic mice in which the rhodopsin promoter drives expression of VEGF in photoreceptors (rho/VEGF mice) develop retinal angiomatous proliferation (RAP) which originates from the deep capillary bed of the retina and grows through the photoreceptor layer to reach the subretinal spaces. The transgenic mice were utilized to determine the effects of DVD-Ig molecules on subretinal neovascularization. The rho/VEGF mice have an onset of VEGF expression at P7 and, starting at P10, develop sprouts of NV from the deep capillary bed of the retina that grow through the photoreceptor layer and form an extensive network of new vessels in the subretinal space. At P14, hemizygous Rho-VEGF mice were given an intraocular injection of test reagents. At P21, the mice were euthanized, and eyes were fixed in 10% phosphate-buffered formalin for 2 hours. Retinas were dissected, blocked with 5% normal swine serum in PBS for 1 hour, stained with FITC-conjugated GSA for 2 hours to stain vascular cells, flat mounted with the photoreceptor side up, and examined by fluorescence microscopy. The area of subretinal NV was measured with image analysis by an investigator blinded with respect to treatment group.

Compared with the control DVD-Ig molecule, DVD-Ig-1 and DVD-Ig-3 significantly decreased choroidal neovascularization (CNV) (p=0.02, 0.04), whereas DVD-Ig-2 did not show much effect. Compared with the IgG control, the combined administration of anti-VEGF IgG and anti-PDGF-BB IgG significantly decreased CNV (p=0.045), while administration of anti-VEGF IgG or anti-PDGF IgG alone did not significantly reduce subretinal NV. No other difference was observed in eyes injected with Avastin, anti-PDGF-BB aptamer, or a mixture of Avastin and anti-PDGF-BB aptamer. Significantly decreased subretinal NV was found after administration of DVD-Ig-1 and DVD-Ig-3, when compared to the mixture of Avastin and the anti-PDGF-BB aptamer. No other difference was found between DVD-Ig reagents and the combined administration of anti-VEGF-IgG and anti-PDGF IgG. FIG. 5.

No difference was found in the untreated eyes of mice injected with anti-VEGF/anti-PDGF DVD-Ig molecules, control DVD-Ig, anti-VEGF mAb alone, anti-PDGF alone, and a combination of antibodies (ANOVA, P>0.05), indicating there was no clear systemic effect of intraocular injection. FIG. 6.

Tet/opsin/VEGF mice express higher levels of VEGF in photoreceptors than rho/VEGF mice, resulting in severe NV and vascular leakage with exudative retinal detachment. The efficacy of intraocular injections of anti-VEGF/anti-PDGF DVD-Ig molecules in this transgenic mouse was also evaluated. Mice were given intraocular injections of test reagent in the right eye. For the next 3 days, the mice were also administered a daily subcutaneous injection of 50 mg/kg doxycycline. At the 4th days, mice were euthanized and fundus photographs were taken with Micron III retinal imaging microscope (Phoenix Research Laboratories, Pleasanton, Calif.). OCT images were taken by Bioptigen Image-guided OCT (Envisu R4110, Bioptigen Inc. Morrisville, N.C.). Then eyes were frozen in optimal cutting temperature embedding solution. Ten-micron ocular serial sections were cut through the entire eye, stained with H&E stain and examined by light microscopy. Mean length of the retinal detachment per section was measured with image analysis by an investigator blinded with respect to treatment group. The percentage of the retina that was detached was computed.

Five mice in each test group were injected with DVD-Ig reagents separately. In DVD-Ig-1 injected eyes, two were not detached and three were partially detached, while three eyes were totally detached and two partially detached in the uninjected eye. In DVD-Ig-3 injected eyes, one was not detached, two were partially detached, and two were totally detached, while all the uninjected eyes were totally detached. In the DVD-Ig-2 injected eyes, one was not detached and four were totally detached, while one eye was partially detached and four eyes were totally detached in the uninjected eye. In the IgG control group, one injected eye was not detached, one eye was partially detached, and three eyes were totally detached, while all eyes were totally detached in the uninjected eye. FIG. 7.

Thus, DVD-Ig-1 and DVD-Ig-3 appeared to perform at least as well as a combination of anti-VEGF mAb and anti-PDGF mAb for the measured parameters, while requiring the administration of only one compound.

Example 17

Generation and Identification of Various Molecular Formats Optimal for Applications in Ocular Diseases

Several attributes were considered in the design of a therapeutic biologic for the treatment of wet AMD:

PK, Efficacy and Frequency of Administration:

Longer ocular duration may support less frequent intravitreous injection. The size of the administered molecule may play a role in determining ocular half-life. This is supported by consistently longer ocular half-life for the current anti-VEGF agents with larger molecular size in humans and in experimental animals. Bevacizumab, which has a larger molecular size (150 kDa) than ranibizumab (49 kDa), also seems to have more robust duration of efficacy in both Rho/huVEGF and tet/huVEGF transgenic mice, the two models used for preclinical efficacy.

FcRn and FcγR Binding and Safety:

Fc neonatal receptor (FcRn), which plays a role for long circulating half-life of IgG molecules in serum, may or may not play an important role in determining ocular half-life. The molecules with wild type FcRn binding, however, will have long systemic half-life and may increase safety risk due to unnecessary systemic exposure of intravitreously injected molecules. FcRn is also perceived to play a role in active efflux of IgGs across blood-retina barrier. This may lead to shortened ocular retention time for the intravitreously inject molecules. Effector functions are not needed for the efficacy of anti-wet AMD agents. But both VEGF-A and PDGF-BB may be associated with extracellular matrix when they are initially synthesized and secreted. The ECM-associated VEGF-A and PDGF-BB therefore may potentially mediate effector functions.

Affinity, Valency and Potency:

Both VEGF-A and PDGF-BB are homodimeric molecules. If a monovalent molecular format similar to that of ranibizumab (Fab) is used for bispecific molecules targeting VEGF and PDGF for the treatment of wet AMD, high affinity may be needed to maintain binding and potent neutralization of both VEGF-A and PDGF-BB.

Manufacturability:

Any viable format needs to have acceptable expression, purification, formulation properties to accommodate DS and DP manufacturing.

Various binding protein formats disclosed herein may satisfy these characteristics:

(1) Full length DVD-Ig [L234A, L235A] (200 kDa, lacks binding to FcgRs)(2) Full length DVD-Ig [L234A, L235A, H435A] (200 kDa, lacks binding to FcgRs and FcRn)(3) Half DVD-Ig (100 kDa, lacks binding to FcgRs and FcRn)(4) DVD-Fab (75 kDa, no Fc)

Example 17.1

Generation of Various Molecular Formats Including DVD-Ig [L234A, L235A], DVD-Ig [L234A, L235A and H435A], DVD-Ig [L234A, L235A and H435R], Half DVD-Ig and DVD-Fab

This example evaluates the impact of Fc mutations on the PK properties of DVD-Ig binding proteins. DVD-038 was used a tool molecule to study various DVD-Ig formats, including a half-DVD-Ig (DVD038 [L234A, L235A] Half-DVD), full DVD-Ig binding proteins having three constant domain mutations (DVD038 [L234A, L235A and H435A] and DVD038 [L234A, L235A and H435R]), and a full DVD-Ig binding protein having two constant domain mutations (DVD038 [L234A, L235A]). The data below was used to evaluate options for producing a VEGF/PDGF binding protein structure with good drug-like properties and exhibiting high ocular duration but low systemic circulation. DVD038 is a dual variable domain binding protein that binds HER2 and VEGF.

To prepare mutants of DVD038, overlapping PCR was used with primers designed to include the desired mutations. PCR products were digested and ligated into the cloning vector. Bacterial transformation was performed to identify positive clones and constructs were harvested and purified for use in mammalian transfection using standard protocols known in the art.

All variants were transiently transfected into 10 L of HEK 293 6E suspension cell cultures in a Wave-bag with a ratio of 60% to 40% light to heavy chain construct. 0.5 mg/mL PEI was used to transfect the cells. Supernatants were harvested after 11 days by centrifugation at 16000 g for 20 minutes followed by filtration using Pall Serum Capsule and Pall AcroPak 1000. All except DVD-Fab were purified on MabSelectSuRe resin (GE Healthcare, 17-5438-04). Following equilibration with PBS pH 7.4, the supernatant was loaded on the resin and washed with PBS pH 7.4. DVD-Ig protein was eluted with 50 mM Glycine, 50 mM NaCl pH 3.5. DVD-Fab was purified using Protein G Sepharose 4 FF resin (GE Healthcare, 17-0618-04). Elution was performed with Immunopure IgG elution buffer (Pierce, 185 1520). Fractions containing DVD-Ig were pooled and dialyzed in 30 mM Histidine pH 6, 8% sucrose overnight at 4° C.

Example 17.2

Binding of Various Formats to FcRns from Different Species

As described in Example 1.2, all variants of DVD038, except for DVD038 Fab which does not have an Fc region, were analyzed for their binding to FcRns from different species. The data is summarized in Table 91 below.

TABLE 91
Binding of Various Formats to FcRns from Different Species
		Hu	Cyno	Rabbit
	Corporate	FcRn	FcRn	FcRn	Rat FcRn
Test Articles	ID	KD (M)	KD (M)	KD (M)	ka (1/Ms)	kd (1/s)	KD (M)
DVD038 (L234A,	PR-1578399	6.26E−06	3.13E−06	6.76E−07	3.06E+04	2.57E−02	8.40E−07
L235A) Half DVD-Ig
DVD038 (L234A,	PR-1564681	7.96E−06	2.57E−06	3.98E−07	5.15E+04	5.53E−02	1.07E−06
L235A, H435R)
DVD038 (L234A,	PR-1565009	4.90E−06	1.74E−06	2.75E−07	3.66E+04	1.94E−02	5.31E−07
L235A)
DVD038 (L234A,	PR-1565689	NSB	NSB	NSB	NSB
L235A, H435A)
HERCEPTIN	—	4.53E−06	2.62E−06	4.69E−07	3.27E+04	1.81E−02	5.55E−07
* NSB = no significant binding

Example 17.3

Pharmacokinetic Properties of Different Formats in huFcRn Transgenic Mice Administered Intravenously

Studies were conducted in accordance with the Abbott IACUC guidelines. DVD038 (L234A, L235A) (PR-1565009), DVD038 (L234A, L235A, H435R) (PR-1564681), and DVD038 (L234A, L235A, H435A) (PR-1565689) were administered to huFcRn transgenic mice (5/group) at 6.7 mg/kg by slow intravenous bolus dose injection. Blood samples were collected from each mouse at 1, 24 and 96 hours and 7, 10, 14 and 21 days post dose. All samples were stored at −80° C. until analysis. DVD-Ig serum concentrations were measured using a Meso Scale Discovery (MSD) electrochemiluminescence (ECL) Ligand Binding Assay. Biotinylated VEGF ligand was coated onto streptavidin MSD plates for capture of anti-VEGF-A/anti-PDGF-BB DVD-Ig molecules from blood samples, and detection was achieved with a sulfo-tag goat anti-human IgG antibody. Concentrations were calculated by four-parameter logistic fit using XLfit4.

Pharmacokinetic parameters were calculated with Non-compartmental analysis using Pharmacokinetics Laboratory Automation Software for Management and Analysis (PLASMA) (Version 2.6.12, SParCS, AbbVie).

TABLE 92
PK in huFcRn Transgenic Mice
			CL
Test Articles	Corporate ID	T½ (d)	(mL/h/kg)
DVD038 (L234A, L235A)	PR-1565009	2.8	0.81
DVD038 (L234A, L235A, H435R)	PR-1564681	1.8	1.25
DVD038 (L234A, L235A, H435A)	PR-1565689	0.6	1.58

The results demonstrate a trend for increased clearance and shorter half-life for DVD constructs with reduced or lack of Fc binding in huFcRn transgenic mice.

Example 17.4

Pharmacokinetic Properties of Different Formats in CD-1 Mice Administered Intravenously

Studies were conducted in accordance with the Abbott IACUC guidelines. DVD038 (L234A, L235A) (PR-1565009), DVD038 (L234A, L235A, H435R) (PR-1564681), DVD038 (L234A, L235A, H435A) (PR-1565689), DVD038 half DVD-Ig (L234A, L235A) (PR-1578399) and DVD-Fab (PR-1574215) were administered to CD-1 mice (5/group) at 6.7 mg/kg by slow intravenous bolus dose injection. Blood samples were collected from each mouse at 1, 24 and 96 hours and 7, 10, 14 and 21 days post dose. All samples were stored at −80° C. until analysis. DVD-Ig serum concentrations were measured using a Meso Scale Discovery (MSD) electrochemiluminescence (ECL) Ligand Binding Assay. Biotinylated VEGF ligand was coated onto streptavidin MSD plates for capture of anti-VEGF-A/anti-PDGF-BB DVD-Ig molecules from blood samples, and detection was achieved with a sulfo-tag goat anti-human IgG antibody. Concentrations were calculated by four-parameter logistic fit using XLfit4. Pharmacokinetic parameters were calculated with Non-compartmental analysis using Pharmacokinetics Laboratory Automation Software for Management and Analysis (PLASMA) (Version 2.6.12, SParCS, AbbVie).

TABLE 93
PK in CD-1 Mice
			CL
Test Articles	Corporate ID	T½ (d)	(mL/h/kg)
DVD038 (L234A, L235A)	PR-1565009	7.6	0.46
DVD038 (L234A, L235A, H435R)	PR-1564681	6.4	0.29
DVD038 (L234A, L235A, H435A)	PR-1565689	2.7	0.73
DVD038 Half DVD-Ig (L234A,	PR-1578399	0.4	8.86
L235A)
DVD038 DVD-Fab	PR-1574215	0.2	20.76

Results demonstrate a trend for increased clearance and shorter half-life for DVD constructs with reduced or lack of Fc binding in CD-1 mice. Molecules composed of a fragment of immunoglobulin structure are cleared fastest.

Example 17.5

Pharmacokinetic Properties of Different Formats in Rabbits Administered Intravitreously

Studies were conducted in accordance with the AbbVie IACUC guidelines. Female New Zealand White rabbits were used for the ocular pharmacokinetic characterization of formats DVD038 (PR-1565009, lot 2131983), DVD038 H435A (PR-1565689, lot 2131481), DVD038 Dhab (PR-1578399, lot 2149586) and DVDFab (PR-1574215, lot 2143755). Animals (4 animals) were split into two cohorts of two for determination of ocular pharmacokinetics. Samples of aqueous humour were taken at 48, 168, 336 and 504 hours post dosing. With cohort 1 providing samples at 48 and 168 hours, and cohort 2 providing samples at 336 and 504 hours, post dosing. Drug levels in the eye were determined from concentrations in aqueous humour. Blood samples for the harvest of serum used to estimate systemic exposure after vitreous dosing were also collected at 4, 24, 48, 72, 120, 168 hours post dosing from all animals, and at 336 and 504 hours from the animals in cohort 2. Test articles were dosed into the vitreous compartment at 0.50 mg per eye with a volume of no more than 0.050 mL. Only the right eye of each animal was dosed. Prior to dosing, animals were anesthetized with xylazine/ketamine. The eye was prepared by first applying topical analgesic drops (procaine HCl Ophthalmic solution, 0.5%), then the injections site was swabbed with a saturated povidone-iodine swab stick (10% solution equivalent to 1% available iodine) prior to injection. The intravitreal dose was administered with a 26 gauge needle. The point of entry for the injection was 1-2 mm from the limbus through the sclera. After injection, a sterile cotton eye spear was placed on the injection site and held for 30 seconds to prevent leakage. Animals were anesthetized for aqueous fluid collection. At the selected time points after dosing, the aqueous fluid was collected using a 30 gauge needle inserted through the cornea. The needle was advanced just past the bevel and fluid was collected. The samples provided approximately 0.05-0.1 mL of aqueous humour per sampling period. At the selected time points after dosing, blood samples were obtained from an ear vein or artery. Hemostasis following collection was achieved by the application of manual pressure and topical clotting factor or tissue glue as needed. The samples were from 0.5-1 ml in volume, and were allowed to clot for harvest of serum. Aqueous, vitreous and serum samples were stored at −80° C., and submitted for drug level determinations.

The serum, and aqueous humour concentrations for these molecules were measured using either a GYROS or a MSD method. GYROS employs a biotinylated VEGF ligand for capture, and Alexa Flour 647 goat anti-human IgG detection. MSD employs biotinylated VEGF ligand for capture, and Sulfo-tag goat anti-human IgG or sulfo-tag VEGF for detection. Results were comparable between the two methods. Concentrations were calculated by four-parameter logistic fit using XLfit4. Pharmacokinetic parameters were calculated with Non-compartmental analysis using Pharmacokinetics Laboratory Automation Software for Management and Analysis (PLASMA) (Version 2.6.12, SParCS, AbbVie). Results from the experiment are shown in Table 94.

TABLE 94
Ocular Half Lives in Rabbit from Analysis of Aqueous Humor
Test Articles	Corporate ID	Half life
DVD038 (L234A, L235A)	PR-1565009	151
DVD038 (L234A, L235A, H435A)	PR-1565689	157
DVD038 Half DVD-Ig (L234A, L235A)	PR-1578399	90
DVD038 DVD-Fab	PR-1574215	110

Population analysis of the pooled data sets was performed on the composite profile from multiple animals at each dose level. The analysis provided parameter estimates with reasonable variability (CV<30%). The larger molecular weight constructs show a weak trend towards a longer ocular half-life.

TABLE 95
Exemplary DVD-Ig Binding Proteins And Component Subunits
SEQ
ID NO	DVD-Ig	Outer VD name	Linker	Inner VD name
45	PR-1563988H	hBDI-9E8.4 VH (PDGF)	GS-H10	hBDB-4G8.3 VH (VEGF)
		(SEQ ID NO: 1)		(SEQ ID NO: 17)
46	PR-1563988L	hBDI-9E8.4 VL (PDGF)	GS-L10	hBDB-4G8.3 VL (VEGF)
		(SEQ ID NO: 2)		(SEQ ID NO: 18)
47	PR-1563990H	hBDI-9E8.4 VH (PDGF)	HG-short	hBDB-4G8.3 VH (VEGF)
		(SEQ ID NO: 1)		(SEQ ID NO: 17)
48	PR-1563990L	hBDI-9E8.4 VL (PDGF)	LK-short	hBDB-4G8.3 VL (VEGF)
		(SEQ ID NO: 2)		(SEQ ID NO: 18)
49	PR-1563998H	hBDI-9E8.4 VH (PDGF)	HG-short	hBDB-4G8.3 VH (VEGF)
		(SEQ ID NO: 1)		(SEQ ID NO: 17)
50	PR-1563998L	hBDI-9E8.4 VL (PDGF)	LK-long	hBDB-4G8.3 VL (VEGF)
		(SEQ ID NO: 2)		(SEQ ID NO: 18)
51	PR-1564009H	hBDI-9E8.4 VH (PDGF)	HG-long	hBDB-4G8.3 VH (VEGF)
		(SEQ ID NO: 1)		(SEQ ID NO: 17)
51	PR-1564009L	hBDI-9E8.4 VL (PDGF)	LK-short	hBDB-4G8.3 VL (VEGF)
		(SEQ ID NO: 2)		(SEQ ID NO: 18)
53	PR-1564010H	hBDB-4G8.3 VH (VEGF)	GS-H10	hBDI-9E8.4 VH (PDGF)
		(SEQ ID NO: 17)		(SEQ ID NO: 1)
54	PR-1564010L	hBDB-4G8.3 VL (VEGF)	GS-L10	hBDI-9E8.4 VL (PDGF)
		(SEQ ID NO: 18)		(SEQ ID NO: 2)
55	PR-1564011H	hBDB-4G8.3 VH (VEGF)	HG-short	hBDI-9E8.4 VH (PDGF)
		(SEQ ID NO: 17)		(SEQ ID NO: 1)
56	PR-1564011L	hBDB-4G8.3 VL (VEGF)	LK-short	hBDI-9E8.4 VL (PDGF)
		(SEQ ID NO: 18)		(SEQ ID NO: 2)
57	PR-1564012H	hBDB-4G8.3 VH (VEGF)	HG-short	hBDI-9E8.4 VH (PDGF)
		(SEQ ID NO: 17)		(SEQ ID NO: 1)
58	PR-1564012L	hBDB-4G8.3 VL (VEGF)	LK-long	hBDI-9E8.4 VL (PDGF)
		(SEQ ID NO: 18)		(SEQ ID NO: 2)
59	PR-1564013H	hBDB-4G8.3 VH (VEGF)	HG-long	hBDI-9E8.4 VH (PDGF)
		(SEQ ID NO: 17)		(SEQ ID NO: 1)
60	PR-1564013L	hBDB-4G8.3 VL (VEGF)	LK-short	hBDI-9E8.4 VL (PDGF)
		(SEQ ID NO: 18)		(SEQ ID NO: 2)
61	PR-1564883H	hBDI-5H1.9 VH (PDGF)	HG-short	hBDB-4G8.13 VH (VEGF)
	(DVD3896H)a	(SEQ ID NO: 3)		(SEQ ID NO: 19)
62	PR-1564883L	hBDI-5H1.9 VL (PDGF)	LK-long	hBDB-4G8.13 VL (VEGF)
	(DVD3896L)a	(SEQ ID NO: 4)		(SEQ ID NO: 20)
63	PR-1564893H	hBDI-5H1.9 VH (PDGF)	HG-short	hBDB-4G8.14 VH (VEGF)
	(DVD3897H)a	(SEQ ID NO: 3)		(SEQ ID NO: 21)
64	PR-1564893L	hBDI-5H1.9 VL (PDGF)	LK-long	hBDB-4G8.14 VL (VEGF)
	(DVD3897L)a	(SEQ ID NO: 4)		(SEQ ID NO: 22)
209	PR-1564896H	hBDI-5H1.9 VH (PDGF)	HG-short	hBDB-4G8.15 VH (VEGF)
	(DVD3898H)a	(SEQ ID NO: 3)		(SEQ ID NO: 23)
65	PR-1564896L	hBDI-5H1.9 VL (PDGF)	LK-long	hBDB-4G8.15 VL (VEGF)
	(DVD3898L)a	(SEQ ID NO: 4)		(SEQ ID NO: 24)
66	PR-1564898H	hBDI-5H1.12 VH (PDGF)	HG-short	hBDB-4G8.14 VH (VEGF)
	(DVD3899H)a	(SEQ ID NO: 211)		(SEQ ID NO: 21)
67	PR-1564898L	hBDI-5H1.12 VL (PDGF)	LK-long	hBDB-4G8.14 VL (VEGF)
	(DVD3899L)a	(SEQ ID NO: 212)		(SEQ ID NO: 22)
68	PR-1564899H	hBDI-5H1.12 VH (PDGF)	HG-short	hBDB-4G8.15 VH (VEGF)
	(DVD3900H)a	(SEQ ID NO: 211)		(SEQ ID NO: 23)
69	PR-1564899L	hBDI-5H1.12 VL (PDGF)	LK-long	hBDB-4G8.15 VL (VEGF)
	(DVD3900L)a	(SEQ ID NO: 212)		(SEQ ID NO: 24)
70	PR-1565023H	hBDI-9E8.9 VH (PDGF)	HG-short	hBDB-4G8.13 VH (VEGF)
	(DVD3901H)a	(SEQ ID NO: 7)		(SEQ ID NO: 19)
71	PR-1565023L	hBDI-9E8.9 VL (PDGF)	LK-long	hBDB-4G8.13 VL (VEGF)
	(DVD3901L)a	(SEQ ID NO: 8)		(SEQ ID NO: 20)
72	PR-1565029H	hBDI-9E8.9 VH (PDGF)	HG-short	hBDB-4G8.14 VH (VEGF)
	(DVD3902H)a	(SEQ ID NO: 7)		(SEQ ID NO: 21)
73	PR-1565029L	hBDI-9E8.9 VL (PDGF)	LK-long	hBDB-4G8.14 VL (VEGF)
	(DVD3902L)a	(SEQ ID NO: 8)		(SEQ ID NO: 22)
74	PR-1565030H	hBDI-9E8.9 VH (PDGF)	HG-short	hBDB-4G8.15 VH (VEGF)
	(DVD3903H)a	(SEQ ID NO: 7)		(SEQ ID NO: 23)
75	PR-1565030L	hBDI-9E8.9 VL (PDGF)	LK-long	hBDB-4G8.15 VL (VEGF)
	(DVD3903L)a	(SEQ ID NO: 8)		(SEQ ID NO: 24)
76	PR-1565031H	hBDI-9E8.12 VH (PDGF)	HG-short	hBDB-4G8.14 VH (VEGF)
	(DVD3904H)a	(SEQ ID NO: 9)		(SEQ ID NO: 21)
77	PR-1565031L	hBDI-9E8.12 VL (PDGF)	LK-long	hBDB-4G8.14 VL (VEGF)
	(DVD3904L)a	(SEQ ID NO: 10)		(SEQ ID NO: 22)
78	PR-1565032H	hBDI-9E8.12 VH (PDGF)	HG-short	hBDB-4G8.15 VH (VEGF)
	(DVD3905H)a	(SEQ ID NO: 5)		(SEQ ID NO: 23)
79	PR-1565032L	hBDI-9E8.12 VL (PDGF)	LK-long	hBDB-4G8.15 VL (VEGF)
	(DVD3905L)a	(SEQ ID NO: 6)		(SEQ ID NO: 24)
80	PR-1565035H	hBDI-5H1.10 VH (PDGF)	HG-short	hBDB-4G8.15 VH (VEGF)
	(DVD3906H)a	(SEQ ID NO: 9)		(SEQ ID NO: 23)
81	PR-1565035L	hBDI-5H1.10 VL (PDGF)	LK-long	hBDB-4G8.15 VL (VEGF)
	(DVD3906L)a	(SEQ ID NO: 10)		(SEQ ID NO: 24)
82	PR-1565033H	hBDI-9E8.10 VH (PDGF)	HG-short	hBDB-4G8.15 VH (VEGF)
	(DVD3907H)a	(SEQ ID NO: 9)		(SEQ ID NO: 23)
83	PR-1565033L	hBDI-9E8.10 VL (PDGF)	LK-long	hBDB-4G8.15 VL (VEGF)
	(DVD3907L)a	(SEQ ID NO: 10)		(SEQ ID NO: 24)
84	PR-1569574H	hBDI-9E8.4 VH (PDGF)	GS-H10	hBDB-4G8.3 VH (VEGF)
		(SEQ ID NO: 1)		(SEQ ID NO: 17)
85	PR-1569574L	hBDI-9E8.4 VL (PDGF)	GS-L10	hBDB-4G8.3 VL (VEGF)
		(SEQ ID NO: 2)		(SEQ ID NO: 18)
86	PR-1569579H	hBDI-9E8.4 VH (PDGF)	HG-short	hBDB-4G8.3 VH (VEGF)
		(SEQ ID NO: 1)		(SEQ ID NO: 17)
87	PR-1569579L	hBDI-9E8.4 VL (PDGF)	LK-long	hBDB-4G8.3 VL (VEGF)
		(SEQ ID NO: 2)		(SEQ ID NO: 18)
88	PR-1572102H	hBDB-4G8.3 VH (VEGF)	GS-H10	hBDI-9E8.4 VH (PDGF)
		(SEQ ID NO: 17)		(SEQ ID NO: 1)
89	PR-1572102L	hBDB-4G8.3 VL (VEGF)	GS-L10	hBDI-9E8.4 VL (PDGF)
		(SEQ ID NO: 18)		(SEQ ID NO: 2)
90	PR-1572103H	hBDB-4G8.3 VH (VEGF)	GS-H10	hBDI-9E8.4 VH (PDGF)
		(SEQ ID NO: 17)		(SEQ ID NO: 1)
91	PR-1572103L	hBDB-4G8.3 VL (VEGF)	GS-L11	hBDI-9E8.4 VL (PDGF)
		(SEQ ID NO: 18)		(SEQ ID NO: 2)
92	PR-1572104H	hBDB-4G8.3 VH (VEGF)	GS-H10	hBDI-9E8.4 VH (PDGF)
		(SEQ ID NO: 17)		(SEQ ID NO: 1)
93	PR-1572104L	hBDB-4G8.3 VL (VEGF)	GS-L10(dR)	hBDI-9E8.4 VL (PDGF)
		(SEQ ID NO: 18)		(SEQ ID NO: 2)
94	PR-1572105H	hBDB-4G8.3 VH (VEGF)	HG-short	hBDI-9E8.4 VH (PDGF)
		(SEQ ID NO: 17)		(SEQ ID NO: 1)
95	PR-1572105L	hBDB-4G8.3 VL (VEGF)	LK-long	hBDI-9E8.4 VL (PDGF)
		(SEQ ID NO: 18)		(SEQ ID NO: 2)
96	PR-1572106H	hBDB-4G8.3 VH (VEGF)	HG-long	hBDI-9E8.4 VH (PDGF)
		(SEQ ID NO: 17)		(SEQ ID NO: 1)
97	PR-1572106L	hBDB-4G8.3 VL (VEGF)	LK-short	hBDI-9E8.4 VL (PDGF)
		(SEQ ID NO: 18)		(SEQ ID NO: 2)
210	PR-1575573H	hBDI-9E8.4 VH (PDGF)	HG-long	hBDB-4G8.3 VH (VEGF)
		(SEQ ID NO: 1)		(SEQ ID NO: 17)
98	PR-1575573L	hBDI-9E8.4 VL (PDGF)	LK-short	hBDB-4G8.3 VL (VEGF)
		(SEQ ID NO: 2)		(SEQ ID NO: 18)
99	PR-1575832H	hBDB-4G8.3 VH (VEGF)	GS-H10	hBDI-9E8.4E VH (PDGF)
		(SEQ ID NO: 17)		(SEQ ID NO: 11)
100	PR-1575832L	hBDB-4G8.3 VL (VEGF)	GS-L10	hBDI-9E8.4E VL (PDGF)
		(SEQ ID NO: 18)		(SEQ ID NO: 12)
101	PR-1575834H	hBDB-4G8.3 VH (VEGF)	HG-short	hBDI-9E8.4E VH (PDGF)
		(SEQ ID NO: 17)		(SEQ ID NO: 11)
102	PR-1575834L	hBDB-4G8.3 VL (VEGF)	LK-long	hBDI-9E8.4E VL (PDGF)
		(SEQ ID NO: 18)		(SEQ ID NO: 12)
103	PR-1575835H	hBDB-4G8.3 VH (VEGF)	HG-long	hBDI-9E8.4E VH (PDGF)
		(SEQ ID NO: 17)		(SEQ ID NO: 11)
104	PR-1575835L	hBDB-4G8.3 VL (VEGF)	LK-short	hBDI-9E8.4E VL (PDGF)
		(SEQ ID NO: 18)		(SEQ ID NO: 12)
105	PR-1577165H	hBEW-9A8.12 VH (VEGF)	GS-H10	hBDI-9E8.4E VH (PDGF)
		(SEQ ID NO: 25)		(SEQ ID NO: 11)
106	PR-1577165L	hBEW-9A8.12 VL (VEGF)	GS-L10	hBDI-9E8.4E VL (PDGF)
		(SEQ ID NO: 26)		(SEQ ID NO: 12)
107	PR-1577166H	hBEW-9A8.12 VH (VEGF)	HG-short	hBDI-9E8.4E VH (PDGF)
		(SEQ ID NO: 25)		(SEQ ID NO: 11)
108	PR-1577166L	hBEW-9A8.12 VL (VEGF)	LK-long	hBDI-9E8.4E VL (PDGF)
		(SEQ ID NO: 26)		(SEQ ID NO: 12)
109	PR-1577547H	hBEW-9A8.12 VH (VEGF)	HG-long	hBDI-9E8.4E VH (PDGF)
		(SEQ ID NO: 25)		(SEQ ID NO: 11)
110	PR-1577547L	hBEW-9A8.12 VL (VEGF)	LK-short	hBDI-9E8.4E VL (PDGF)
		(SEQ ID NO: 26)		(SEQ ID NO: 12)
111	PR-1577548H	hBDI-9E8.4E VH (PDGF)	HG-short	hBEW-9A8.12 VH (VEGF)
		(SEQ ID NO: 11)		(SEQ ID NO: 25)
112	PR-1577548L	hBDI-9E8.4E VL (PDGF)	LK-long	hBEW-9A8.12 VL (VEGF)
		(SEQ ID NO: 12)		(SEQ ID NO: 26)
113	PR-1577550H	hBDI-9E8.4E VH (PDGF)	HG-long	hBEW-9A8.12 VH (VEGF)
		(SEQ ID NO: 11)		(SEQ ID NO: 25)
114	PR-1577550L	hBDI-9E8.4E VL (PDGF)	LK-short	hBEW-9A8.12 VL (VEGF)
		(SEQ ID NO: 12)		(SEQ ID NO: 26)
115	PR-1578137H	hBDI-9E8.4E VH (PDGF)	GS-H10	hBEW-9A8.12 VH (VEGF)
		(SEQ ID NO: 11)		(SEQ ID NO: 25)
116	PR-1578137L	hBDI-9E8.4E VL (PDGF)	GS-L10	hBEW-9A8.12 VL (VEGF)
		(SEQ ID NO: 12)		(SEQ ID NO: 26)
117	PR-1598261H	hBDB-4G8.2 VH (VEGF)	GS-H10	hBDI-9E8.4 VH (PDGF)
		(SEQ ID NO: 27)		(SEQ ID NO: 1)
118	PR-1598261L	hBDB-4G8.2 VL (VEGF)	GS-L10	hBDI-9E8.4 VL (PDGF)
		(SEQ ID NO: 28)		(SEQ ID NO: 2)
119	PR-1598262H	hBDB-4G8.4 VH (VEGF)	GS-H10	hBDI-9E8.4 VH (PDGF)
		(SEQ ID NO: 29)		(SEQ ID NO: 1)
120	PR-1598262L	hBDB-4G8.4 VL (VEGF)	GS-L10	hBDI-9E8.4 VL (PDGF)
		(SEQ ID NO: 30)		(SEQ ID NO: 2)
121	PR-1598263H	hBDB-4G8.5 VH (VEGF)	GS-H10	hBDI-9E8.4 VH (PDGF)
		(SEQ ID NO: 31)		(SEQ ID NO: 1)
122	PR-1598263L	hBDB-4G8.5 VL (VEGF)	GS-L10	hBDI-9E8.4 VL (PDGF)
		(SEQ ID NO: 32)		(SEQ ID NO: 2)
123	PR-1598264H	hBDB-4G8.12 VH (VEGF)	GS-H10	hBDI-9E8.4 VH (PDGF)
		(SEQ ID NO: 33)		(SEQ ID NO: 1)
124	PR-1598264L	hBDB-4G8.12 VL (VEGF)	GS-L10	hBDI-9E8.4 VL (PDGF)
		(SEQ ID NO: 34)		(SEQ ID NO: 2)
125	PR-1598265H	hBDB-4G8.13 VH (VEGF)	GS-H10	hBDI-9E8.4 VH (PDGF)
		(SEQ ID NO: 19)		(SEQ ID NO: 1)
126	PR-1598265L	hBDB-4G8.13 VL (VEGF)	GS-L10	hBDI-9E8.4 VL (PDGF)
		(SEQ ID NO: 20)		(SEQ ID NO: 2)
127	PR-1598266H	hBDB-4G8.14 VH (VEGF)	GS-H10	hBDI-9E8.4 VH (PDGF)
		(SEQ ID NO: 21)		(SEQ ID NO: 1)
128	PR-1598266L	hBDB-4G8.14 VL (VEGF)	GS-L10	hBDI-9E8.4 VL (PDGF)
		(SEQ ID NO: 22)		(SEQ ID NO: 2)
129	PR-1610560H	hBDB-4G8.5 VH (VEGF)	GS-H10	hBFU-3E2.1 VH (PDGF)
		(SEQ ID NO: 31)		(SEQ ID NO: 13)
130	PR-1610560L	hBDB-4G8.5 VL (VEGF)	GS-L10(dR)	hBFU-3E2.1 VL (PDGF)
		(SEQ ID NO: 32)		(SEQ ID NO: 14)
131	PR-1610561H	hBEW-9E10.1 VH (VEGF)	GS-H10	CL-33675 VH (PDGF)
		(SEQ ID NO: 35)		(SEQ ID NO: 15)
132	PR-1610561L	hBEW-9E10.1 VL (VEGF)	GS-L10(dR)	CL-33675 VL (PDGF)
		(SEQ ID NO: 36)		(SEQ ID NO: 16)
133	PR-1610562H	hBEW-9E10.1 VH (VEGF)	GS-H10	hBFU-3E2.1 VH (PDGF)
		(SEQ ID NO: 35)		(SEQ ID NO: 13)
134	PR-1610562L	hBEW-9E10.1 VL (VEGF)	GS-L10(dR)	hBFU-3E2.1 VL (PDGF)
		(SEQ ID NO: 36)		(SEQ ID NO: 14)
135	PR-1610563H	hBEW-9E10.6 VH (VEGF)	GS-H10	hBFU-3E2.1 VH (PDGF)
		(SEQ ID NO: 37)		(SEQ ID NO: 13)
136	PR-1610563L	hBEW-9E10.6 VL (VEGF)	GS-L10(dR)	hBFU-3E2.1 VL (PDGF)
		(SEQ ID NO: 38)		(SEQ ID NO: 14)
137	PR-1610564H	hBEW-1B10.1 VH (VEGF)	GS-H10	hBFU-3E2.1 VH (PDGF)
		(SEQ ID NO: 39)		(SEQ ID NO: 13)
138	PR-1610564L	hBEW-1B10.1 VL (VEGF)	GS-L10(dR)	hBFU-3E2.1 VL (PDGF)
		(SEQ ID NO: 40)		(SEQ ID NO: 14)
139	PR-1611291H	hBDB-4G8.5 VH (VEGF)	GS-H10	CL-33675 VH (PDGF)
		(SEQ ID NO: 31)		(SEQ ID NO: 15)
140	PR-1611291L	hBDB-4G8.5 VL (VEGF)	GS-L10(dR)	CL-33675 VL (PDGF)
		(SEQ ID NO: 32)		(SEQ ID NO: 16)
141	PR-1611292H	hBEW-1B10.1 VH (VEGF)	GS-H10	CL-33675 VH (PDGF)
		(SEQ ID NO: 39)		(SEQ ID NO: 15)
142	PR-1611292L	hBEW-1B10.1 VL (VEGF)	GS-L10(dR)	CL-33675 VL (PDGF)
		(SEQ ID NO: 40)		(SEQ ID NO: 16)
143	PR-1611293H	hBEW-1E3.4 VH (VEGF)	GS-H10	CL-33675 VH (PDGF)
		(SEQ ID NO: 41)		(SEQ ID NO: 15)
144	PR-1611293L	hBEW-1E3.4 VL (VEGF)	GS-L10(dR)	CL-33675 VL (PDGF)
		(SEQ ID NO: 42)		(SEQ ID NO: 16)
145	PR-1611294H	hBEW-1E3.4 VH (VEGF)	GS-H10	hBDI-9E8.4 VH (PDGF)
		(SEQ ID NO: 41)		(SEQ ID NO: 1)
146	PR-1611294L	hBEW-1E3.4 VL (VEGF)	GS-L10(dR)	hBDI-9E8.4 VL (PDGF)
		(SEQ ID NO: 42)		(SEQ ID NO: 2)
147	PR-1611295H	CL-33675 VH (PDGF)	GS-H10	hBEW-9E10.1 VH (VEGF)
		(SEQ ID NO: 15)		(SEQ ID NO: 35)
148	PR-1611295L	CL-33675 VL (PDGF)	GS-L10(dR)	hBEW-9E10.1 VL (VEGF)
		(SEQ ID NO: 16)		(SEQ ID NO: 36)
149	PR-1611296H	CL-33675 VH (PDGF)	GS-H10	hBEW-9E10.6 VH (VEGF)
		(SEQ ID NO: 15)		(SEQ ID NO: 37)
150	PR-1611296L	CL-33675 VL (PDGF)	GS-L10(dR)	hBEW-9E10.6 VL (VEGF)
		(SEQ ID NO: 16)		(SEQ ID NO: 38)
151	PR-1611297H	CL-33675 VH (PDGF)	GS-H10	hBEW-1E3.4 VH (VEGF)
		(SEQ ID NO: 15)		(SEQ ID NO: 41)
152	PR-1611297L	CL-33675 VL (PDGF)	GS-L10(dR)	hBEW-1E3.4 VL (VEGF)
		(SEQ ID NO: 16)		(SEQ ID NO: 42)
153	PR-1611298H	hBDI-9E8.4 VH (PDGF)	GS-H10	hBEW-9E10.1 VH (VEGF)
		(SEQ ID NO: 1)		(SEQ ID NO: 35)
154	PR-1611298L	hBDI-9E8.4 VL (PDGF)	GS-L10(dR)	hBEW-9E10.1 VL (VEGF)
		(SEQ ID NO: 2)		(SEQ ID NO: 36)
155	PR-1611299H	hBDI-9E8.4 VH (PDGF)	GS-H10	hBEW-9E10.6 VH (VEGF)
		(SEQ ID NO: 1)		(SEQ ID NO: 37)
156	PR-1611299L	hBDI-9E8.4 VL (PDGF)	GS-L10(dR)	hBEW-9E10.6 VL (VEGF)
		(SEQ ID NO: 2)		(SEQ ID NO: 38)
157	PR-1611300H	hBDI-9E8.4 VH (PDGF)	GS-H10	hBEW-1B10.1 VH (VEGF)
		(SEQ ID NO: 1)		(SEQ ID NO: 39)
158	PR-1611300L	hBDI-9E8.4 VL (PDGF)	GS-L10(dR)	hBEW-1B10.1 VL (VEGF)
		(SEQ ID NO: 2)		(SEQ ID NO: 40)
159	PR-1611301H	hBDI-9E8.4 VH (PDGF)	GS-H10	hBEW-1E3.4 VH (VEGF)
		(SEQ ID NO: 1)		(SEQ ID NO: 41)
160	PR-1611301L	hBDI-9E8.4 VL (PDGF)	GS-L10(dR)	hBEW-1E3.4 VH (VEGF)
		(SEQ ID NO: 2)		(SEQ ID NO: 42)
161	PR-1612489H	hBDB-4G8.5 VH (VEGF)	GS-H10	hBDI-9E8.4 VH (PDGF)
		(SEQ ID NO: 31)		(SEQ ID NO: 1)
162	PR-1612489L	hBDB-4G8.5 VL (VEGF)	GS-L10(dR)	hBDI-9E8.4 VL (PDGF)
		(SEQ ID NO: 32)		(SEQ ID NO: 2)
163	PR-1612491H	hBEW-9E10.1 VH (VEGF)	GS-H10	hBDI-9E8.4 VH (PDGF)
		(SEQ ID NO: 35)		(SEQ ID NO: 1)
164	PR-1612491L	hBEW-9E10.1 VL (VEGF)	GS-L10(dR)	hBDI-9E8.4 VL (PDGF)
		(SEQ ID NO: 36)		(SEQ ID NO: 2)
165	PR-1612492H	hBEW-9E10.6 VH (VEGF)	GS-H10	CL-33675 VH (PDGF)
		(SEQ ID NO: 37)		(SEQ ID NO: 15)
166	PR-1612492L	hBEW-9E10.6 VL (VEGF)	GS-L10(dR)	CL-33675 VL (PDGF)
		(SEQ ID NO: 38)		(SEQ ID NO: 16)
167	PR-1612493H	hBEW-9E10.6 VH (VEGF)	GS-H10	hBDI-9E8.4 VH (PDGF)
		(SEQ ID NO: 37)		(SEQ ID NO: 1)
168	PR-1612493L	hBEW-9E10.6 VL (VEGF)	GS-L10(dR)	hBDI-9E8.4 VL (PDGF)
		(SEQ ID NO: 38)		(SEQ ID NO: 2)
169	PR-1612494H	hBEW-1B10.1 VH (VEGF)	GS-H10	hBDI-9E8.4 VH (PDGF)
		(SEQ ID NO: 39)		(SEQ ID NO: 1)
170	PR-1612494L	BEW-1B10.1 VL (VEGF)	GS-L10(dR)	hBDI-9E8.4 VL (PDGF)
		(SEQ ID NO: 40)		(SEQ ID NO: 2)
171	PR-1612495H	hBEW-1E3.4 VH (VEGF)	GS-H10	hBFU-3E2.1 VH (PDGF)
		(SEQ ID NO: 41)		(SEQ ID NO: 13)
172	PR-1612495L	hBEW-1E3.4 VL (VEGF)	GS-L10(dR)	hBFU-3E2.1 VL (PDGF)
		(SEQ ID NO: 42)		(SEQ ID NO: 14)
173	PR-1612496H	CL-33675 VH (PDGF)	GS-H10	hBDB-4G8.5 VH (VEGF)
		(SEQ ID NO: 15)		(SEQ ID NO: 31)
174	PR-1612496L	CL-33675 VL (PDGF)	GS-L10(dR)	hBDB-4G8.5 VL (VEGF)
		(SEQ ID NO: 16)		(SEQ ID NO: 32)
175	PR-1612498H	CL-33675 VH (PDGF)	GS-H10	hBEW-1B10.1 VH (VEGF)
		(SEQ ID NO: 15)		(SEQ ID NO: 39)
176	PR-1612498L	CL-33675 VL (PDGF)	GS-L10(dR)	hBEW-1B10.1 VL (VEGF)
		(SEQ ID NO: 16)		(SEQ ID NO: 40)
177	PR-1612499H	hBFU-3E2.1 VH (PDGF)	GS-H10	hBDB-4G8.5 VH (VEGF)
		(SEQ ID NO: 13)		(SEQ ID NO: 31)
178	PR-1612499L	hBFU-3E2.1 VL (PDGF)	GS-L10(dR)	hBDB-4G8.5 VL (VEGF)
		(SEQ ID NO: 14)		(SEQ ID NO: 32)
179	PR-1612500H	hBFU-3E2.1 VH (PDGF)	GS-H10	hBEW-9E10.1 VH (VEGF)
		(SEQ ID NO: 13)		(SEQ ID NO: 35)
180	PR-1612500L	hBFU-3E2.1 VL (PDGF)	GS-L10(dR)	hBEW-9E10.1 VL (VEGF)
		(SEQ ID NO: 14)		(SEQ ID NO: 36)
181	PR-1612501H	hBFU-3E2.1 VH (PDGF)	GS-H10	hBEW-9E10.6 VH (VEGF)
		(SEQ ID NO: 13)		(SEQ ID NO: 37)
182	PR-1612501L	hBFU-3E2.1 VL (PDGF)	GS-L10(dR)	hBEW-9E10.6 VL (VEGF)
		(SEQ ID NO: 14)		(SEQ ID NO: 38)
183	PR-1612502H	hBFU-3E2.1 VH (PDGF)	GS-H10	hBEW-1B10.1 VH (VEGF)
		(SEQ ID NO: 13)		(SEQ ID NO: 39)
184	PR-1612502L	hBFU-3E2.1 VL (PDGF)	GS-L10(dR)	hBEW-1B10.1 VL (VEGF)
		(SEQ ID NO: 14)		(SEQ ID NO: 40)
185	PR-1613183H	CL-34565 VH (VEGF)	GS-H10	CL-33675 VH (PDGF)
		(SEQ ID NO: 43)		(SEQ ID NO: 15)
186	PR-1613183L	CL-34565 VL (VEGF)	GS-L10(dR)	CL-33675 VL (PDGF)
		(SEQ ID NO: 44)		(SEQ ID NO: 16)
187	PR-1613184H	CL-34565 VH (VEGF)	GS-H10	hBDI-9E8.4 VH (PDGF)
		(SEQ ID NO: 43)		(SEQ ID NO: 1)
188	PR-1613184L	CL-34565 VL (VEGF)	GS-L10(dR)	hBDI-9E8.4 VL (PDGF)
		(SEQ ID NO: 44)		(SEQ ID NO: 2)
189	PR-1613185H	CL-34565 VH (VEGF)	GS-H10	hBFU-3E2.1 VH (PDGF)
		(SEQ ID NO: 43)		(SEQ ID NO: 13)
190	PR-1613185L	CL-34565 VL (VEGF)	GS-L10(dR)	hBFU-3E2.1 VL (PDGF)
		(SEQ ID NO: 44)		(SEQ ID NO: 14)
191	PR-1613186H	CL-33675 VH (PDGF)	GS-H10	CL-34565 VH (VEGF)
		(SEQ ID NO: 15)		(SEQ ID NO: 43)
192	PR-1613186L	CL-33675 VL (PDGF)	GS-L10(dR)	CL-34565 VL (VEGF)
		(SEQ ID NO: 16)		(SEQ ID NO: 44)
193	PR-1613187H	hBDI-9E8.4 VH (PDGF)	GS-H10	CL-34565 VH (VEGF)
		(SEQ ID NO: 1)		(SEQ ID NO: 43)
194	PR-1613187L	hBDI-9E8.4 VL (PDGF)	GS-L10(dR)	CL-34565 VL (VEGF)
		(SEQ ID NO: 2)		(SEQ ID NO: 44)
195	PR-1613188H	hBDI-9E8.4 VH (PDGF)	GS-H10	hBDB-4G8.5 VH (VEGF)
		(SEQ ID NO: 1)		(SEQ ID NO: 31)
196	PR-1613188L	hBDI-9E8.4 VL (PDGF)	GS-L10(dR)	hBDB-4G8.5 VL (VEGF)
		(SEQ ID NO: 2)		(SEQ ID NO: 32)
197	PR-1613189H	hBFU-3E2.1 VH (PDGF)	GS-H10	CL-34565 VH (VEGF)
		(SEQ ID NO: 13)		(SEQ ID NO: 43)
198	PR-1613189L	hBFU-3E2.1 VL (PDGF)	GS-L10(dR)	CL-34565 VL (VEGF)
		(SEQ ID NO: 14)		(SEQ ID NO: 44)
199	PR-1613190H	hBFU-3E2.1 VH (PDGF)	GS-H10	hBEW-1E3.4 VH (VEGF)
		(SEQ ID NO: 13)		(SEQ ID NO: 41)
200	PR-1613190L	hBFU-3E2.1 VL (PDGF)	GS-L10(dR)	hBEW-1E3.4 VL (VEGF)
		(SEQ ID NO: 14)		(SEQ ID NO: 42)
201	PR-1629646H	hBEW-9E10.1 VH (VEGF)	HG-short	CL-33675 VH (PDGF)
		(SEQ ID NO: 35)		(SEQ ID NO: 15)
202	PR-1629646L	hBEW-9E10.1 VL (VEGF)	LK-long	CL-33675 VL (PDGF)
		(SEQ ID NO: 36)		(SEQ ID NO: 16)
203	PR-1629647H	hBEW-1B10.1 VH (VEGF)	HG-short	CL-33675 VH (PDGF)
		(SEQ ID NO: 39)		(SEQ ID NO: 15)
204	PR-1629647L	hBEW-1B10.1 VL (VEGF)	LK-long	CL-33675 VL (PDGF)
		(SEQ ID NO: 40)		(SEQ ID NO: 16)
205	PR-1629648H	hBEW-9E10.1 VH (VEGF)	HG-long	CL-33675 VH (PDGF)
		(SEQ ID NO: 35)		(SEQ ID NO: 15)
206	PR-1629648L	hBEW-9E10.1 VL (VEGF)	LK-short	CL-33675 VL (PDGF)
		(SEQ ID NO: 36)		(SEQ ID NO: 16)
207	PR-1629649H	hBEW-1B10.1 VH (VEGF)	HG-long	CL-33675 VH (PDGF)
		(SEQ ID NO: 39)		(SEQ ID NO: 15)
208	PR-1629649L	hBEW-1B10.1 VL (VEGF)	LK-short	CL-33675 VL (PDGF)
		(SEQ ID NO: 40)		(SEQ ID NO: 16)

TABLE 96
Sequences of Exemplary DVD-Ig Binding Proteins
SEQ
ID NO	DVD-Ig	Sequence
45	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1563988H	DDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIESIGTTYSFDYW
		GQGTMVTVSSGGGGSGGGGSEVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMY
		WVRQAPGQGLEWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDT
		AVYYCARTNYYYRSYIFYFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAA
		LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
		CNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTP
		EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNHYTQKSLSLSPGK
46	PR-	EFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRPS
	1563988L	GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKGGGSGGG
		GSGDTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGASNL
		ESGVPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKRTVAA
		PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
		DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
47	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1563990H	DDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIESIGTTYSFDYW
		GQGTMVTVSSASTKGPEVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQ
		APGQGLEWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYY
		CARTNYYYRSYIFYFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
		KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
		KPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCV
		VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP
		SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
		ALHNHYTQKSLSLSPGK
48	PR-	EFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRPS
	1563990L	GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKGTVAAPDT
		VLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGASNLESGVP
		ARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKRTVAAPSVFIF
		PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS
		LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
49	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1563998H	DDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIESIGTTYSFDYW
		GQGTMVTVSSASTKGPEVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQ
		APGQGLEWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYY
		CARTNYYYRSYIFYFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
		KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
		KPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCV
		VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP
		SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
		ALHNHYTQKSLSLSPGK
50	PR-	EFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRPS
	1563998L	GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKGTVAAPSV
		FIFPPDTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGASN
		LESGVPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKRTVA
		APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS
		KDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
51	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1564009H	DDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIESIGTTYSFDYW
		GQGTMVTVSSASTKGPSVFPLAPEVQLVQSGSELKKPGASVKVSCKASGYTFTNYG
		MYWVRQAPGQGLEWMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAE
		DTAVYYCARTNYYYRSYIFYFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
		TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMIS
		RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL
		HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT
		CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV
		FSCSVMHEALHNHYTQKSLSLSPGK
51	PR-	EFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRPS
	1564009L	GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKGTVAAPDT
		VLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGASNLESGVP
		ARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKRTVAAPSVFIF
		PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS
		LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
53	PR-	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWINTE
	1564010H	TGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYIFYFD
		YWGQGTMVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGM
		GVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDP
		VDTATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAAL
		GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
		NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE
		VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNHYTQKSLSLSPGK
54	PR-	DTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGASNLESG
	1564010L	VPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKRGGSGGGG
		SGEFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQR
		PSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKGTVAAP
		SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
		STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
55	PR-	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWINTE
	1564011H	TGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYIFYFD
		YWGQGTMVTVSSASTKGPEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWI
		RQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTAT
		YYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
		KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
		KPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCV
		VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP
		SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
		ALHNHYTQKSLSLSPGK
56	PR-	DTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGASNLESG
	1564011L	VPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKRTVAAPEF
		VLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRPSGI
		PDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKGTVAAPSVFI
		FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY
		SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
57	PR-	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWINTE
	1564012H	TGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYIFYFD
		YWGQGTMVTVSSASTKGPEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWI
		RQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTAT
		YYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
		KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
		KPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCV
		VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP
		SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
		ALHNHYTQKSLSLSPGK
58	PR-	DTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGASNLESG
	1564012L	VPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKRTVAAPSVF
		IFPPEFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQ
		RPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKGTVAA
		PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
		DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
59	PR-	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWINTE
	1564013H	TGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYIFYFD
		YWGQGTMVTVSSASTKGPSVFPLAPEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYG
		MGVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNM
		DPVDTATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTA
		ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
		YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISR
		TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
		QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC
		LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS
		CSVMHEALHNHYTQKSLSLSPGK
60	PR-	DTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGASNLESG
	1564013L	VPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKRTVAAPEF
		VLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRPSGI
		PDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKGTVAAPSVFI
		FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY
		SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
61	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTFGMGVGWIRQPPGKALEWLANIWWDD
	1564883H	DKYYNPSLKNRLTISKDTSKNQAVLTITNMDPVDTATYYCARISTGISSYYVMDAWG
	(DVD3896H)a	QGTTVTVSSASTKGPEIQLVQSGTEVKKPGESLKISCKASGYTFTNYGMYWVKQMP
		GKGLEYMGWINTETGKPTYADDFKGRFTFSLDKSFNTAFLQWSSLKASDTAMYFCA
		RTNYYYRSYIFYFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
		YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP
		SNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVV
		DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
		YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSD
		IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
		HNHYTQKSLSLSPGK
62	PR-	DFVLTQSPDSLAVSLGERATINCERSSGDIGDTYVSWYQQKPGQPPKNVIYGNDQRP
	1564883L	SGVPDRFSGSGSGNSATLTISSLQAEDVAVYFCQSYDSDIDIVFGGGTKVEIKGTVAA
	(DVD3896L)a	PSVFIFPPETVLTQSPATLSVSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYG
		ASNLESGVPARFSGSGSGTDFTLTISSLQSEDFAVYFCQQSWNDPFTFGQGTRLEIKRT
		VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
		DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
63	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTFGMGVGWIRQPPGKALEWLANIWWDD
	1564893H	DKYYNPSLKNRLTISKDTSKNQAVLTITNMDPVDTATYYCARISTGISSYYVMDAWG
	(DVD3897H)a	QGTTVTVSSASTKGPEIQLVQSGGGVVQPGGSLRLSCAASGYTFTNYGMYWVKQAP
		GKGLEYMGWINTETGKPTYADDFKGRFTFSLDTSKSTAYLQLNSLRAEDTAVYFCA
		RTNYYYRSYIFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
		YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP
		SNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVV
		DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
		YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSD
		IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
		HNHYTQKSLSLSPGK
64	PR-	DFVLTQSPDSLAVSLGERATINCERSSGDIGDTYVSWYQQKPGQPPKNVIYGNDQRP
	1564893L	SGVPDRFSGSGSGNSATLTISSLQAEDVAVYFCQSYDSDIDIVFGGGTKVEIKGTVAA
	(DVD3897L)a	PSVFIFPPDTVLTQSPSTLSASPGERATISCRASESVSTHMHWYQQKPGQAPKLLIYGA
		SNLESGVPSRFSGSRSGTDFTLTISSLQPEDFAVYFCQQSWNDPFTFGQGTKVEIKRTV
		AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
		SKDSTYSLSSTLTLSKADYEK
209	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTFGMGVGWIRQPPGKALEWLANIWWDD
	1564896H	DKYYNPSLKNRLTISKDTSKNQAVLTITNMDPVDTATYYCARISTGISSYYVMDAWG
	(DVD3898H)a	QGTTVTVSSASTKGPEVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMYWVKQAP
		GKGLEYMGWINTETGKPTYADDFKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYFCA
		RTNYYYRSYIFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
		YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP
		SNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVV
		DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
		YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSD
		IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
		HNHYTQKSLSLSPGK
65	PR-	DFVLTQSPDSLAVSLGERATINCERSSGDIGDTYVSWYQQKPGQPPKNVIYGNDQRP
	1564896L	SGVPDRFSGSGSGNSATLTISSLQAEDVAVYFCQSYDSDIDIVFGGGTKVEIKGTVAA
	(DVD3898L)a	PSVFIFPPDTQLTQSPSSLSASVGDRVTISCRASESVSTHMHWYQQKPGKAPKLLIYG
		ASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSWNDPFTFGQGTKVEIKRT
		VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
		DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
66	PR-	EVQLVESGGGLVQPGGSLRLSCAFSGFSLSTFGMGVGWIRQAPGKGLEWLANIWWD
	1564898H	DDKYYNPSLKNRLTISKDTSKNQAYLQINSLRAEDTAVYYCARISTGISSYYVMDAW
	(DVD3899H)a	GQGTLVTVSSASTKGPEIQLVQSGGGVVQPGGSLRLSCAASGYTFTNYGMYWVKQA
		PGKGLEYMGWINTETGKPTYADDFKGRFTFSLDTSKSTAYLQLNSLRAEDTAVYFC
		ARTNYYYRSYIFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
		DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK
		PSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVV
		VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK
		EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS
		DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA
		LHNHYTQKSLSLSPGK
67	PR-	DFQLTQSPSSLSASVGDRVTITCERSSGDIGDTYVSWYQQKPGKAPKNVIYGNDQRP
	1564898L	SGVPSRFSGSGSGNSATLTISSLQPEDFATYFCQSYDSDIDIVFGQGTKVEIKGTVAAP
	(DVD3899L)a	SVFIFPPDTVLTQSPSTLSASPGERATISCRASESVSTHMHWYQQKPGQAPKLLIYGAS
		NLESGVPSRFSGSRSGTDFTLTISSLQPEDFAVYFCQQSWNDPFTFGQGTKVEIKRTV
		AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
		SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
68	PR-	EVQLVESGGGLVQPGGSLRLSCAFSGFSLSTFGMGVGWIRQAPGKGLEWLANIWWD
	1564899H	DDKYYNPSLKNRLTISKDTSKNQAYLQINSLRAEDTAVYYCARISTGISSYYVMDAW
	(DVD3900H)a	GQGTLVTVSSASTKGPEVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMYWVKQ
		APGKGLEYMGWINTETGKPTYADDFKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYF
		CARTNYYYRSYIFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
		KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
		KPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCV
		VVDVSHEDPEVKTNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP
		SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
		ALHNHYTQKSLSLSPGK
69	PR-	DFQLTQSPSSLSASVGDRVTITCERSSGDIGDTYVSWYQQKPGKAPKNVIYGNDQRP
	1564899L	SGVPSRFSGSGSGNSATLTISSLQPEDFATYFCQSYDSDIDIVFGQGTKVEIKGTVAAP
	(DVD3900L)a	SVFIFPPDTQLTQSPSSLSASVGDRVTISCRASESVSTHMHWYQQKPGKAPKLLIYGA
		SNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSWNDPFTFGQGTKVEIKRTV
		AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
		SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
70	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1565023H	DDKYYNPSLKNRLTISKDTSKNQAVLTITNMDPVDTATYYCARIESIGTTYSFDYWG
	(DVD3901H)a	QGTTVTVSSASTKGPEIQLVQSGTEVKKPGESLKISCKASGYTFTNYGMYWVKQMP
		GKGLEYMGWINTETGKPTYADDFKGRFTFSLDKSFNTAFLQWSSLKASDTAMYFCA
		RTNYYYRSYIFYFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
		YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP
		SNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVV
		DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
		YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSD
		IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
		HNHYTQKSLSLSPGK
71	PR-	DFVLTQSPDSLAVSLGERATINCERSSGDIGDSYVSWYQQKPGQPPKNVIYADDQRP
	1565023L	SGVPDRFSGSGSGNSASLTISSLQAEDVAVYFCQSYDINIDIVFGGGTKVEIKGTVAAP
	(DVD3901L)a	SVFIFPPETVLTQSPATLSVSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGA
		SNLESGVPARFSGSGSGTDFTLTISSLQSEDFAVYFCQQSWNDPFTFGQGTRLEIKRTV
		AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
		SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
72	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1565029H	DDKYYNPSLKNRLTISKDTSKNQAVLTITNMDPVDTATYYCARIESIGTTYSFDYWG
	(DVD3902H)a	QGTTVTVSSASTKGPEIQLVQSGGGVVQPGGSLRLSCAASGYTFTNYGMYWVKQAP
		GKGLEYMGWINTETGKPTYADDFKGRFTFSLDTSKSTAYLQLNSLRAEDTAVYFCA
		RTNYYYRSYIFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
		YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP
		SNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVV
		DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
		YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSD
		IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
		HNHYTQKSLSLSPGK
73	PR-	DFVLTQSPDSLAVSLGERATINCERSSGDIGDSYVSWYQQKPGQPPKNVIYADDQRP
	1565029L	SGVPDRFSGSGSGNSASLTISSLQAEDVAVYFCQSYDINIDIVFGGGTKVEIKGTVAAP
	(DVD3902L)a	SVFIFPPDTVLTQSPSTLSASPGERATISCRASESVSTHMHWYQQKPGQAPKLLIYGAS
		NLESGVPSRFSGSRSGTDFTLTISSLQPEDFAVYFCQQSWNDPFTFGQGTKVEIKRTV
		AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
		SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
74	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1565030H	DDKYYNPSLKNRLTISKDTSKNQAVLTITNMDPVDTATYYCARIESIGTTYSFDYWG
	(DVD3903H)a	QGTTVTVSSASTKGPEVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMYWVKQAP
		GKGLEYMGWINTETGKPTYADDFKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYFCA
		RTNYYYRSYIFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
		YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP
		SNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVV
		DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
		YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSD
		IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
		HNHYTQKSLSLSPGK
75	PR-	DFVLTQSPDSLAVSLGERATINCERSSGDIGDSYVSWYQQKPGQPPKNVIYADDQRP
	1565030L	SGVPDRFSGSGSGNSASLTISSLQAEDVAVYFCQSYDINIDIVFGGGTKVEIKGTVAAP
	(DVD3903L)a	SVFIFPPDTQLTQSPSSLSASVGDRVTISCRASESVSTHMHWYQQKPGKAPKLLIYGA
		SNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSWNDPFTFGQGTKVEIKRTV
		AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
		SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
76	PR-	EVQLVESGGGLVQPGGSLRLSCAFSGFSLSTYGMGVGWIRQAPGKGLEWLANIWW
	1565031H	DDDKYYNPSLKNRLTISKDTSKNQAYLQINSLRAEDTAVYYCARIESIGTTYSFDYW
	(DVD3904H)a	GQGTLVTVSSASTKGPEIQLVQSGGGVVQPGGSLRLSCAASGYTFTNYGMYWVKQA
		PGKGLEYMGWINTETGKPTYADDFKGRFTFSLDTSKSTAYLQLNSLRAEDTAVYFC
		ARTNYYYRSYIFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
		DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK
		PSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVV
		VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK
		EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS
		DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA
		LHNHYTQKSLSLSPGK
77	PR-	DFQLTQSPSSLSASVGDRVTITCERSSGDIGDSYVSWYQQKPGKAPKNVIYADDQRPS
	1565031L	GVPSRFSGSGSGNSASLTISSLQPEDFATYFCQSYDINIDIVFGQGTKVEIKGTVAAPSV
	(DVD3904L)a	FIFPPDTVLTQSPSTLSASPGERATISCRASESVSTHMHWYQQKPGQAPKLLIYGASNL
		ESGVPSRFSGSRSGTDFTLTISSLQPEDFAVYFCQQSWNDPFTFGQGTKVEIKRTVAA
		PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
		DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
78	PR-	EVQLVESGGGLVQPGGSLRLSCAFSGFSLSTYGMGVGWIRQAPGKGLEWLANIWW
	1565032H	DDDKYYNPSLKNRLTISKDTSKNQAYLQINSLRAEDTAVYYCARIESIGTTYSFDYW
	(DVD3905H)a	GQGTLVTVSSASTKGPEVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMYWVKQ
		APGKGLEYMGWINTETGKPTYADDFKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYF
		CARTNYYYRSYIFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
		KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
		KPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCV
		VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP
		SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
		ALHNHYTQKSLSLSPGK
79	PR-	DFQLTQSPSSLSASVGDRVTITCERSSGDIGDSYVSWYQQKPGKAPKNVIYADDQRPS
	1565032L	GVPSRFSGSGSGNSASLTISSLQPEDFATYFCQSYDINIDIVFGQGTKVEIKGTVAAPSV
	(DVD3905L)a	FIFPPDTQLTQSPSSLSASVGDRVTISCRASESVSTHMHWYQQKPGKAPKLLIYGASN
		LESGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSWNDPFTFGQGTKVEIKRTVA
		APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS
		KDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
80	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTFGMGVGWIRQPPGKALEWLANIWWDD
	1565035H	DKYYNPSLKNRLTISKDTSKNQAVLTITNMDPVDTATYYCARISTGISSYYVMDAWG
	(DVD3906H)a	QGTTVTVSSASTKGPEVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMYWVKQAP
		GKGLEYMGWINTETGKPTYADDFKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYFCA
		RTNYYYRSYIFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
		YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP
		SNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVV
		DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
		YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSD
		IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
		HNHYTQKSLSLSPGK
81	PR-	DFQLTQSPSSLSASVGDRVTITCERSSGDIGDTYVSWYQQKPGKAPKNVIYGNDQRP
	1565035L	SGVPSRFSGSGSGNSATLTISSLQPEDFATYFCQSYDSDIDIVFGQGTKVEIKGTVAAP
	(DVD3906L)a	SVFIFPPDTQLTQSPSSLSASVGDRVTISCRASESVSTHMHWYQQKPGKAPKLLIYGA
		SNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSWNDPFTFGQGTKVEIKRTV
		AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
		SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
82	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1565033H	DDKYYNPSLKNRLTISKDTSKNQAVLTITNMDPVDTATYYCARIESIGTTYSFDYWG
	(DVD3907H)a	QGTTVTVSSASTKGPEVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMYWVKQAP
		GKGLEYMGWINTETGKPTYADDFKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYFCA
		RTNYYYRSYIFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
		YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP
		SNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVV
		DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
		YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSD
		IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
		HNHYTQKSLSLSPGK
83	PR-	DFQLTQSPSSLSASVGDRVTITCERSSGDIGDSYVSWYQQKPGKAPKNVIYADDQRPS
	1565033L	GVPSRFSGSGSGNSASLTISSLQPEDFATYFCQSYDINIDIVFGQGTKVEIKGTVAAPSV
	(DVD3907L)a	FIFPPDTVLTQSPSTLSASPGERATISCRASESVSTHMHWYQQKPGQAPKLLIYGASNL
		ESGVPSRFSGSRSGTDFTLTISSLQPEDFAVYFCQQSWNDPFTFGQGTKVEIKRTVAA
		PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
		DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
84	PR-	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWINTE
	1569574H	TGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYIFYFD
		YWGQGTMVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGM
		GVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDP
		VDTATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAAL
		GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
		NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE
		VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNAYTQKSLSLSPGK
85	PR-	DTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGASNLESG
	1569574L	VPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKRGGSGGGG
		SGEFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQR
		PSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKGTVAAP
		SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
		STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
86	PR-	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWINTE
	1569579H	TGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYIFYFD
		YWGQGTMVTVSSASTKGPEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWI
		RQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTAT
		YYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
		KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
		KPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCV
		VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP
		SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
		ALHNAYTQKSLSLSPGK
87	PR-	DTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGASNLESG
	1569579L	VPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKRTVAAPSVF
		IFPPEFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQ
		RPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKGTVAA
		PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
		DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
88	PR-	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWINTE
	1572102H	TGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYIFYFD
		YWGQGTMVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGM
		GVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDP
		VDTATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAAL
		GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
		NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE
		VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNAYTQKSLSLSPGK
89	PR-	DTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGASNLESG
	1572102L	VPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKRGGSGGGG
		SGEFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQR
		PSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAAP
		SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
		STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
90	PR-	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWINTE
	1572103H	TGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYIFYFD
		YWGQGTMVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGM
		GVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDP
		VDTATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAAL
		GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
		NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE
		VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNAYTQKSLSLSPGK
91	PR-	DTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGASNLESG
	1572103L	VPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKRGGSGGGG
		SGGEFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQ
		RPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAA
		PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
		DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
92	PR-	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWINTE
	1572104H	TGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYIFYFD
		YWGQGTMVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGM
		GVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDP
		VDTATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAAL
		GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
		NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE
		VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNAYTQKSLSLSPGK
93	PR-	DTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGASNLESG
	1572104L	VPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKGGSGGGGS
		GGEFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQ
		RPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAA
		PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
		DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
94	PR-	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWINTE
	1572105H	TGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYIFYFD
		YWGQGTMVTVSSASTKGPEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWI
		RQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTAT
		YYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
		KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
		KPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCV
		VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP
		SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
		ALHNAYTQKSLSLSPGK
95	PR-	DTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGASNLESG
	1572105L	VPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKRTVAAPSVF
		IFPPEFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQ
		RPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAA
		PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
		DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
96	PR-	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWINTE
	1572106H	TGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYIFYFD
		YWGQGTMVTVSSASTKGPSVFPLAPEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYG
		MGVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNM
		DPVDTATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTA
		ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
		YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISR
		TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
		QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC
		LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS
		CSVMHEALHNAYTQKSLSLSPGK
97	PR-	DTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGASNLESG
	1572106L	VPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKRTVAAPEF
		VLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRPSGI
		PDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAAPSVFI
		FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY
		SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
210	PR-	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWINTE
	1575573H	TGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYIFYFD
		YWGQGTMVTVSSASTKGPSVFPLAPEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYG
		MGVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNM
		DPVDTATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTA
		ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
		YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISR
		TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
		QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC
		LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS
		CSVMHEALHNAYTQKSLSLSPGK
98	PR-	DTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGASNLESG
	1575573L	VPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKRTVAAPEF
		VLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRPSGI
		PDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKGTVAAPSVFI
		FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY
		SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
99	PR-	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWINTE
	1575832H	TGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYIFYFD
		YWGQGTMVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGM
		GVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDP
		VDTATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAAL
		GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
		NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE
		VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNAYTQKSLSLSPGK
100	PR-	DTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGASNLESG
	1575832L	VPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKRGGSGGGG
		SGEFVLTQSPGTLSLSPGERATLSCERSSGDIGESYVSWYQQKPGQAPRLVIYADDQR
		PSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAAP
		SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
		STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
101	PR-	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWINTE
	1575834H	TGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYIFYFD
		YWGQGTMVTVSSASTKGPEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWI
		RQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTAT
		YYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
		KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
		KPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCV
		VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP
		SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
		ALHNAYTQKSLSLSPGK
102	PR-	DTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGASNLESG
	1575834L	VPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKRTVAAPSVF
		IFPPEFVLTQSPGTLSLSPGERATLSCERSSGDIGESYVSWYQQKPGQAPRLVIYADDQ
		RPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAA
		PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
		DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
103	PR-	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWINTE
	1575835H	TGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYIFYFD
		YWGQGTMVTVSSASTKGPSVFPLAPEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYG
		MGVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNM
		DPVDTATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTA
		ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
		YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISR
		TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
		QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC
		LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS
		CSVMHEALHNAYTQKSLSLSPGK
104	PR-	DTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGASNLESG
	1575835L	VPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKRTVAAPEF
		VLTQSPGTLSLSPGERATLSCERSSGDIGESYVSWYQQKPGQAPRLVIYADDQRPSGI
		PDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAAPSVFI
		FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY
		SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
105	PR-	EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWINTE
	1577165H	TGKPIYADDFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVDYDGSFWFAY
		WGQGTLVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGV
		GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVD
		TATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
		LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV
		NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVT
		CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL
		NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG
		FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
		MHEALHNAYTQKSLSLSPGK
106	PR-	DTQLTQSPSSLSASVGDRVTITCRASESVSTVIHWYQQKPGKQPKLLIHGASNLESGV
	1577165L	PSRFSGSGSGTDFTLTISSLQPEDFATYFCQQHWNDPPTFGQGTKLEIKRGGSGGGGS
		GEFVLTQSPGTLSLSPGERATLSCERSSGDIGESYVSWYQQKPGQAPRLVIYADDQRP
		SGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAAPS
		VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
		TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
107	PR-	EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWINTE
	1577166H	TGKPIYADDFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVDYDGSFWFAY
		WGQGTLVTVSSASTKGPEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIR
		QPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATY
		YCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
		DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK
		PSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVV
		VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK
		EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS
		DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA
		LHNAYTQKSLSLSPGK
108	PR-	DTQLTQSPSSLSASVGDRVTITCRASESVSTVIHWYQQKPGKQPKLLIHGASNLESGV
	1577166L	PSRFSGSGSGTDFTLTISSLQPEDFATYFCQQHWNDPPTFGQGTKLEIKRTVAAPSVFI
		FPPEFVLTQSPGTLSLSPGERATLSCERSSGDIGESYVSWYQQKPGQAPRLVIYADDQ
		RPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAA
		PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
		DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
109	PR-	EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWINTE
	1577547H	TGKPIYADDFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVDYDGSFWFAY
		WGQGTLVTVSSASTKGPSVFPLAPEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGM
		GVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDP
		VDTATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAAL
		GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
		NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE
		VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNAYTQKSLSLSPGK
110	PR-	DTQLTQSPSSLSASVGDRVTITCRASESVSTVIHWYQQKPGKQPKLLIHGASNLESGV
	1577547L	PSRFSGSGSGTDFTLTISSLQPEDFATYFCQQHWNDPPTFGQGTKLEIKRTVAAPEFVL
		TQSPGTLSLSPGERATLSCERSSGDIGESYVSWYQQKPGQAPRLVIYADDQRPSGIPD
		RFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAAPSVFIFP
		PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL
		SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
111	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1577548H	DDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIESIGTTYSFDYW
		GQGTMVTVSSASTKGPEVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMYWVRQ
		APGQGLEWMGWINTETGKPIYADDFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYY
		CARVDYDGSFWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
		YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP
		SNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVV
		DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
		YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSD
		IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
		HNAYTQKSLSLSPGK
112	PR-	EFVLTQSPGTLSLSPGERATLSCERSSGDIGESYVSWYQQKPGQAPRLVIYADDQRPS
	1577548L	GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAAPSV
		FIFPPDTQLTQSPSSLSASVGDRVTITCRASESVSTVIHWYQQKPGKQPKLLIHGASNL
		ESGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQHWNDPPTFGQGTKLEIKRTVAA
		PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
		DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
113	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1577550H	DDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIESIGTTYSFDYW
		GQGTMVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGASVKVSCKASGYTFTNYG
		MYWVRQAPGQGLEWMGWINTETGKPIYADDFKGRVTMTTDTSTSTAYMELRSLRS
		DDTAVYYCARVDYDGSFWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAA
		LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
		CNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTP
		EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNAYTQKSLSLSPGK
114	PR-	EFVLTQSPGTLSLSPGERATLSCERSSGDIGESYVSWYQQKPGQAPRLVIYADDQRPS
	1577550L	GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAAPDT
		QLTQSPSSLSASVGDRVTITCRASESVSTVIHWYQQKPGKQPKLLIHGASNLESGVPS
		RFSGSGSGTDFTLTISSLQPEDFATYFCQQHWNDPPTFGQGTKLEIKRTVAAPSVFIFP
		PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL
		SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
115	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1578137H	DDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIESIGTTYSFDYW
		GQGTMVTVSSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMY
		WVRQAPGQGLEWMGWINTETGKPIYADDFKGRVTMTTDTSTSTAYMELRSLRSDD
		TAVYYCARVDYDGSFWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG
		CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEV
		TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW
		LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK
		GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
		MHEALHNAYTQKSLSLSPGK
116	PR-	EFVLTQSPGTLSLSPGERATLSCERSSGDIGESYVSWYQQKPGQAPRLVIYADDQRPS
	1578137L	GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRGGSGGG
		GSGDTQLTQSPSSLSASVGDRVTITCRASESVSTVIHWYQQKPGKQPKLLIHGASNLE
		SGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQHWNDPPTFGQGTKLEIKRTVAAPS
		VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
		TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
117	PR-	EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWINTE
	1598261H	TGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARTNYYYRSYIFYFD
		YWGQGTMVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGM
		GVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDP
		VDTATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAAL
		GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
		NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE
		VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNHYTQKSLSLSPGK
118	PR-	ATQLTQSPSLSASVGDRVTITCRASESVSTHMHWYQQKPGKQPKLLIYGASNLESGV
	1598261L	PSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSWNDPFTFGQGTKLEIKRGGSGGGGS
		GEFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRP
		SGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAAPS
		VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
		TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
119	PR-	EIQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEYMGWINTET
	1598262H	GKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCARTNYYYRSYIFYFDY
		WGQGTMVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMG
		VGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALG
		CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEV
		TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW
		LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK
		GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
		MHEALHNHYTQKSLSLSPGK
120	PR-	AIQLTQSPSSLSASVGDRVTITCRASESVSTHMHWYQQKPGKAPKLLIYGASNLESGV
	1598262L	PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSWNDPFTFGQGTKLEIKRGGSGGGGS
		GEFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRP
		SGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAAPS
		VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
		TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
121	PR-	EIQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEYMGWINTET
	1598263H	GKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCARTNYYYRSYIFYFDY
		WGQGTMVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMG
		VGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALG
		CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEV
		TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW
		LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK
		GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
		MHEALHNHYTQKSLSLSPGK
122	PR-	ATQLTQSPSLSASVGDRVTITCRASESVSTHMHWYQQKPGKQPKLLIYGASNLESGV
	1598263L	PSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSWNDPFTFGQGTKLEIKRGGSGGGGS
		GEFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRP
		SGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAAPS
		VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
		TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
123	PR-	EIQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEYMGWINTET
	1598264H	GKPTYADDFKGRFTFTLDTSTSTAYMELRSLRSDDTAVYFCARTNYYYRSYIFYFDY
		WGQGTMVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMG
		VGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALG
		CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEV
		TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW
		LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK
		GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
		MHEALHNHYTQKSLSLSPGK
124	PR-	DTVLTQSPATLSLSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGASNLESG
	1598264L	VPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPFTFGQGTKLEIKRGGSGGGG
		SGEFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQR
		PSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAAP
		SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
		STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
125	PR-	EIQLVQSGTEVKKPGESLKISCKASGYTFTNYGMYWVKQMPGKGLEYMGWINTETG
	1598265H	KPTYADDFKGRFTFSLDKSFNTAFLQWSSLKASDTAMYFCARTNYYYRSYIFYFDY
		WGQGTMVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMG
		VGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALG
		CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEV
		TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW
		LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK
		GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
		MHEALHNHYTQKSLSLSPGK
126	PR-	ETVLTQSPATLSVSPGERATLSCRASESVSTHMHWYQQKPGQAPRLLIYGASNLESG
	1598265L	VPARFSGSGSGTDFTLTISSLQSEDFAVYFCQQSWNDPFTFGQGTRLEIKRGGSGGGG
		SGEFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQR
		PSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAAP
		SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
		STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
127	PR-	EIQLVQSGGGVVQPGGSLRLSCAASGYTFTNYGMYWVKQAPGKGLEYMGWINTET
	1598266H	GKPTYADDFKGRFTFSLDTSKSTAYLQLNSLRAEDTAVYFCARTNYYYRSYIFYFDY
		WGQGTLVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGV
		GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVD
		TATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
		LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV
		NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVT
		CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL
		NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG
		FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
		MHEALHNHYTQKSLSLSPGK
128	PR-	DTVLTQSPSTLSASPGERATISCRASESVSTHMHWYQQKPGQAPKLLIYGASNLESGV
	1598266L	PSRFSGSRSGTDFTLTISSLQPEDFAVYFCQQSWNDPFTFGQGTKVEIKRGGSGGGGS
		GEFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRP
		SGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAAPS
		VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
		TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
129	PR-	EIQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEYMGWINTET
	1610560H	GKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCARTNYYYRSYIFYFDY
		WGQGTMVTVSSGGGGSGGGGSEVQLVQSGAEVKKPGSSVKVSCKASGYTFTESYM
		YWVKQAPGQGLELIGRIDPEDGSTDYVEKFKNKATLTADKSTSTAYMELSSLRSEDT
		AVYFCARFGARSYFYPMDAWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALG
		CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEV
		TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW
		LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK
		GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
		MHEALHNAYTQKSLSLSPGK
130	PR-	ATQLTQSPSLSASVGDRVTITCRASESVSTHMHWYQQKPGKQPKLLIYGASNLESGV
	1610560L	PSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSWNDPFTFGQGTKLEIKGGSGGGGSG
		GETVLTQSPATLSLSPGERATLSCRASESVSTLMHWYQQKPGQQPRLLIYGASNLESG
		VPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPWTFGGGTKVEIKRTVAAPSV
		FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
		YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
131	PR-	EIQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVKQAPGQGLEYMGWIDTET
	1610561H	GRPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCARWSGDTTGIRGPWFA
		YWGQGTLVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMG
		VGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSGPKYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAAL
		GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
		NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE
		VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNAYTQKSLSLSPGK
132	PR-	DIRMTQSPSSLSASVGDRVTIECLASEDIYSDLAWYQQKPGKSPKLLIYNANGLQNGV
	1610561L	PSRFSGSGSGTDYSLTISSLQPEDVATYFCQQYNYFPGTFGQGTKLEIKGGSGGGGSG
		GEIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQAPRLLIYADDQRA
		SGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYGINIDVVFGGGTKVEIKRTVAAP
		SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
		STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
133	PR-	EIQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVKQAPGQGLEYMGWIDTET
	1610562H	GRPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCARWSGDTTGIRGPWFA
		YWGQGTLVTVSSGGGGSGGGGSEVQLVQSGAEVKKPGSSVKVSCKASGYTFTESY
		MYWVKQAPGQGLELIGRIDPEDGSTDYVEKFKNKATLTADKSTSTAYMELSSLRSE
		DTAVYFCARFGARSYFYPMDAWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAAL
		GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
		NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE
		VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNAYTQKSLSLSPGK
134	PR-	DIRMTQSPSSLSASVGDRVTIECLASEDIYSDLAWYQQKPGKSPKLLIYNANGLQNGV
	1610562L	PSRFSGSGSGTDYSLTISSLQPEDVATYFCQQYNYFPGTFGQGTKLEIKGGSGGGGSG
		GETVLTQSPATLSLSPGERATLSCRASESVSTLMHWYQQKPGQQPRLLIYGASNLESG
		VPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPWTFGGGTKVEIKRTVAAPSV
		FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
		YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
135	PR-	EVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWIDTE
	1610563H	TGRPTYADDFKGRFTFTADKSTSTAYMELSSLRSEDTAVYYCARWSGDTTGIRGPWF
		AYWGQGTLVTVSSGGGGSGGGGSEVQLVQSGAEVKKPGSSVKVSCKASGYTFTESY
		MYWVKQAPGQGLELIGRIDPEDGSTDYVEKFKNKATLTADKSTSTAYMELSSLRSE
		DTAVYFCARFGARSYFYPMDAWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAAL
		GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
		NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE
		VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNAYTQKSLSLSPGK
136	PR-	DIRMTQSPSSLSASVGDRVTITCLASEDIYSDLAWYQQKPGKSPKLLIYNANGLQNGV
	1610563L	PSRFSGSGSGTDYTLTISSLQPEDVATYFCQQYNYFPGTFGQGTKLEIKGGSGGGGSG
		GETVLTQSPATLSLSPGERATLSCRASESVSTLMHWYQQKPGQQPRLLIYGASNLESG
		VPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPWTFGGGTKVEIKRTVAAPSV
		FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
		YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
137	PR-	EVQLVESGGGLVQPGGSLRLSCAASGFSFSKYDMAWFRQAPGKGLEWVASITTSGV
	1610564H	GTYYRDSVKGRFTVSRDNAKSTLYLQMNSLRAEDTAVYYCARGYGAMDAWGQGT
		TVTVSSGGGGSGGGGSEVQLVQSGAEVKKPGSSVKVSCKASGYTFTESYMYWVKQ
		APGQGLELIGRIDPEDGSTDYVEKFKNKATLTADKSTSTAYMELSSLRSEDTAVYFC
		ARFGARSYFYPMDAWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
		YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP
		SNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVV
		DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
		YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSD
		IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
		HNAYTQKSLSLSPGK
138	PR-	DIQMTQSPSSLSASVGDRVTITCKASQDIDDYLSWYQQKPGKSPKLVIYAATRLADG
	1610564L	VPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQSSSTPWTFGGGTKVEIKGGSGGGGS
		GGETVLTQSPATLSLSPGERATLSCRASESVSTLMHWYQQKPGQQPRLLIYGASNLES
		GVPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPWTFGGGTKVEIKRTVAAPS
		VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
		TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
139	PR-	EIQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEYMGWINTET
	1611291H	GKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCARTNYYYRSYIFYFDY
		WGQGTMVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMG
		VGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESSGPKYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAAL
		GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
		NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE
		VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNAYTQKSLSLSPGK
140	PR-	ATQLTQSPSLSASVGDRVTITCRASESVSTHMHWYQQKPGKQPKLLIYGASNLESGV
	1611291L	PSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSWNDPFTFGQGTKLEIKGGSGGGGSG
		GEIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQAPRLLIYADDQRA
		SGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYGINIDVVFGGGTKVEIKRTVAAP
		SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
		STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
141	PR-	EVQLVESGGGLVQPGGSLRLSCAASGFSFSKYDMAWFRQAPGKGLEWVASITTSGV
	1611292H	GTYYRDSVKGRFTVSRDNAKSTLYLQMNSLRAEDTAVYYCARGYGAMDAWGQGT
		TVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQ
		PPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYY
		CARIESSGPKYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
		YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP
		SNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVV
		DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
		YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSD
		IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
		HNAYTQKSLSLSPGK
142	PR-	DIQMTQSPSSLSASVGDRVTITCKASQDIDDYLSWYQQKPGKSPKLVIYAATRLADG
	1611292L	VPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQSSSTPWTFGGGTKVEIKGGSGGGGS
		GGEIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQAPRLLIYADDQR
		ASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYGINIDVVFGGGTKVEIKRTVAA
		PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
		DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
143	PR-	EIQLVQSGSELKKPGASVKVSCKASGYPFTNSGMYWVKQAPGQGLEYMGWINTEA
	1611293H	GKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCARWGYISDNSYGWFDY
		WGQGTLVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGV
		GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVD
		TATYYCARIESSGPKYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALG
		CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEV
		TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW
		LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK
		GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
		MHEALHNAYTQKSLSLSPGK
144	PR-	ATQLTQSPSSLSASVGDRVTISCRASEGVYSYMHWYQQKPGKQPKLLIYKASNLASG
	1611293L	VPSRFSGSGSGTDFTLTISSLQPEDFATYFCHQNWNDPLTFGQGTKLEIKGGSGGGGS
		GGEIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQAPRLLIYADDQR
		ASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYGINIDVVFGGGTKVEIKRTVAA
		PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
		DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
145	PR-	EIQLVQSGSELKKPGASVKVSCKASGYPFTNSGMYWVKQAPGQGLEYMGWINTEA
	1611294H	GKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCARWGYISDNSYGWFDY
		WGQGTLVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGV
		GWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVD
		TATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
		LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV
		NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVT
		CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL
		NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG
		FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
		MHEALHNAYTQKSLSLSPGK
146	PR-	ATQLTQSPSSLSASVGDRVTISCRASEGVYSYMHWYQQKPGKQPKLLIYKASNLASG
	1611294L	VPSRFSGSGSGTDFTLTISSLQPEDFATYFCHQNWNDPLTFGQGTKLEIKGGSGGGGS
		GGEFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQ
		RPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAA
		PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
		DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
147	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1611295H	DDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIESSGPKYSFDYW
		GQGTMVTVSSGGGGSGGGGSEIQLVQSGSELKKPGASVKVSCKASGYTFTNYGMY
		WVKQAPGQGLEYMGWIDTETGRPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDT
		AVYFCARWSGDTTGIRGPWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTA
		ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
		YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISR
		TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
		QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC
		LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS
		CSVMHEALHNAYTQKSLSLSPGK
148	PR-	EIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQAPRLLIYADDQRAS
	1611295L	GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYGINIDVVFGGGTKVEIKGGSGGGG
		SGGDIRMTQSPSSLSASVGDRVTIECLASEDIYSDLAWYQQKPGKSPKLLIYNANGLQ
		NGVPSRFSGSGSGTDYSLTISSLQPEDVATYFCQQYNYFPGTFGQGTKLEIKRTVAAP
		SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
		STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
149	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1611296H	DDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIESSGPKYSFDYW
		GQGTMVTVSSGGGGSGGGGSEVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYGMY
		WVRQAPGQGLEWMGWIDTETGRPTYADDFKGRFTFTADKSTSTAYMELSSLRSEDT
		AVYYCARWSGDTTGIRGPWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTA
		ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
		YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISR
		TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
		QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC
		LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS
		CSVMHEALHNAYTQKSLSLSPGK
150	PR-	EIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQAPRLLIYADDQRAS
	1611296L	GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYGINIDVVFGGGTKVEIKGGSGGGG
		SGGDIRMTQSPSSLSASVGDRVTITCLASEDIYSDLAWYQQKPGKSPKLLIYNANGLQ
		NGVPSRFSGSGSGTDYTLTISSLQPEDVATYFCQQYNYFPGTFGQGTKLEIKRTVAAP
		SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
		STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
151	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1611297H	DDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIESSGPKYSFDYW
		GQGTMVTVSSGGGGSGGGGSEIQLVQSGSELKKPGASVKVSCKASGYPFTNSGMY
		WVKQAPGQGLEYMGWINTEAGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDT
		AVYFCARWGYISDNSYGWFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAA
		LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
		CNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTP
		EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNAYTQKSLSLSPGK
152	PR-	EIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQAPRLLIYADDQRAS
	1611297L	GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYGINIDVVFGGGTKVEIKGGSGGGG
		SGGATQLTQSPSSLSASVGDRVTISCRASEGVYSYMHWYQQKPGKQPKLLIYKASNL
		ASGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCHQNWNDPLTFGQGTKLEIKRTVAA
		PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
		DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
153	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1611298H	DDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIESIGTTYSFDYW
		GQGTMVTVSSGGGGSGGGGSEIQLVQSGSELKKPGASVKVSCKASGYTFTNYGMY
		WVKQAPGQGLEYMGWIDTETGRPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDT
		AVYFCARWSGDTTGIRGPWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTA
		ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
		YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISR
		TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
		QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC
		LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS
		CSVMHEALHNAYTQKSLSLSPGK
154	PR-	EFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRPS
	1611298L	GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKGGSGGGG
		SGGDIRMTQSPSSLSASVGDRVTIECLASEDIYSDLAWYQQKPGKSPKLLIYNANGLQ
		NGVPSRFSGSGSGTDYSLTISSLQPEDVATYFCQQYNYFPGTFGQGTKLEIKRTVAAP
		SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
		STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
155	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1611299H	DDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIESIGTTYSFDYW
		GQGTMVTVSSGGGGSGGGGSEVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYGMY
		WVRQAPGQGLEWMGWIDTETGRPTYADDFKGRFTFTADKSTSTAYMELSSLRSEDT
		AVYYCARWSGDTTGIRGPWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTA
		ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
		YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISR
		TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
		QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC
		LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS
		CSVMHEALHNAYTQKSLSLSPGK
156	PR-	EFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRPS
	1611299L	GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKGGSGGGG
		SGGDIRMTQSPSSLSASVGDRVTITCLASEDIYSDLAWYQQKPGKSPKLLIYNANGLQ
		NGVPSRFSGSGSGTDYTLTISSLQPEDVATYFCQQYNYFPGTFGQGTKLEIKRTVAAP
		SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
		STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
157	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1611300H	DDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIESIGTTYSFDYW
		GQGTMVTVSSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFSFSKYDMA
		WFRQAPGKGLEWVASITTSGVGTYYRDSVKGRFTVSRDNAKSTLYLQMNSLRAEDT
		AVYYCARGYGAMDAWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
		DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK
		PSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVV
		VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK
		EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS
		DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA
		LHNAYTQKSLSLSPGK
158	PR-	EFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRPS
	1611300L	GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKGGSGGGG
		SGGDIQMTQSPSSLSASVGDRVTITCKASQDIDDYLSWYQQKPGKSPKLVIYAATRL
		ADGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQSSSTPWTFGGGTKVEIKRTVAA
		PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
		DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
159	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1611301H	DDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIESIGTTYSFDYW
		GQGTMVTVSSGGGGSGGGGSEIQLVQSGSELKKPGASVKVSCKASGYPFTNSGMY
		WVKQAPGQGLEYMGWINTEAGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDT
		AVYFCARWGYISDNSYGWFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAA
		LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
		CNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTP
		EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNAYTQKSLSLSPGK
160	PR-	EFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRPS
	1611301L	GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKGGSGGGG
		SGGATQLTQSPSSLSASVGDRVTISCRASEGVYSYMHWYQQKPGKQPKLLIYKASNL
		ASGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCHQNWNDPLTFGQGTKLEIKRTVAA
		PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
		DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
161	PR-	EIQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVRQAPGQGLEYMGWINTET
	1612489H	GKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCARTNYYYRSYIFYFDY
		WGQGTMVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMG
		VGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALG
		CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEV
		TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW
		LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK
		GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
		MHEALHNAYTQKSLSLSPGK
162	PR-	ATQLTQSPSLSASVGDRVTITCRASESVSTHMHWYQQKPGKQPKLLIYGASNLESGV
	1612489L	PSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSWNDPFTFGQGTKLEIKGGSGGGGSG
		GEFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRP
		SGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAAPS
		VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
		TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
163	PR-	EIQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVKQAPGQGLEYMGWIDTET
	1612491H	GRPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCARWSGDTTGIRGPWFA
		YWGQGTLVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMG
		VGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPV
		DTATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALG
		CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEV
		TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW
		LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK
		GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
		MHEALHNAYTQKSLSLSPGK
164	PR-	DIRMTQSPSSLSASVGDRVTIECLASEDIYSDLAWYQQKPGKSPKLLIYNANGLQNGV
	1612491L	PSRFSGSGSGTDYSLTISSLQPEDVATYFCQQYNYFPGTFGQGTKLEIKGGSGGGGSG
		GEFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRP
		SGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAAPS
		VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
		TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
165	PR-	EVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWIDTE
	1612492H	TGRPTYADDFKGRFTFTADKSTSTAYMELSSLRSEDTAVYYCARWSGDTTGIRGPWF
		AYWGQGTLVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGM
		GVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDP
		VDTATYYCARIESSGPKYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAA
		LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
		CNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTP
		EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNAYTQKSLSLSPGK
166	PR-	DIRMTQSPSSLSASVGDRVTITCLASEDIYSDLAWYQQKPGKSPKLLIYNANGLQNGV
	1612492L	PSRFSGSGSGTDYTLTISSLQPEDVATYFCQQYNYFPGTFGQGTKLEIKGGSGGGGSG
		GEIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQAPRLLIYADDQRA
		SGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYGINIDVVFGGGTKVEIKRTVAAP
		SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
		STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
167	PR-	EVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYGMYWVRQAPGQGLEWMGWIDTE
	1612493H	TGRPTYADDFKGRFTFTADKSTSTAYMELSSLRSEDTAVYYCARWSGDTTGIRGPWF
		AYWGQGTLVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGM
		GVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDP
		VDTATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAAL
		GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
		NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE
		VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNAYTQKSLSLSPGK
168	PR-	DIRMTQSPSSLSASVGDRVTITCLASEDIYSDLAWYQQKPGKSPKLLIYNANGLQNGV
	1612493L	PSRFSGSGSGTDYTLTISSLQPEDVATYFCQQYNYFPGTFGQGTKLEIKGGSGGGGSG
		GEFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRP
		SGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAAPS
		VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
		TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
169	PR-	EVQLVESGGGLVQPGGSLRLSCAASGFSFSKYDMAWFRQAPGKGLEWVASITTSGV
	1612494H	GTYYRDSVKGRFTVSRDNAKSTLYLQMNSLRAEDTAVYYCARGYGAMDAWGQGT
		TVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQ
		PPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYY
		CARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
		YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP
		SNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVV
		DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
		YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSD
		IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
		HNAYTQKSLSLSPGK
170	PR-	DIQMTQSPSSLSASVGDRVTITCKASQDIDDYLSWYQQKPGKSPKLVIYAATRLADG
	1612494L	VPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQSSSTPWTFGGGTKVEIKGGSGGGGS
		GGEFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQ
		RPSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAA
		PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
		DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
171	PR-	EIQLVQSGSELKKPGASVKVSCKASGYPFTNSGMYWVKQAPGQGLEYMGWINTEA
	1612495H	GKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCARWGYISDNSYGWFDY
		WGQGTLVTVSSGGGGSGGGGSEVQLVQSGAEVKKPGSSVKVSCKASGYTFTESYM
		YWVKQAPGQGLELIGRIDPEDGSTDYVEKFKNKATLTADKSTSTAYMELSSLRSEDT
		AVYFCARFGARSYFYPMDAWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALG
		CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEV
		TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW
		LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK
		GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
		MHEALHNAYTQKSLSLSPGK
172	PR-	ATQLTQSPSSLSASVGDRVTISCRASEGVYSYMHWYQQKPGKQPKLLIYKASNLASG
	1612495L	VPSRFSGSGSGTDFTLTISSLQPEDFATYFCHQNWNDPLTFGQGTKLEIKGGSGGGGS
		GGETVLTQSPATLSLSPGERATLSCRASESVSTLMHWYQQKPGQQPRLLIYGASNLES
		GVPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPWTFGGGTKVEIKRTVAAPS
		VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
		TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
173	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1612496H	DDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIESSGPKYSFDYW
		GQGTMVTVSSGGGGSGGGGSEIQLVQSGSELKKPGASVKVSCKASGYTFTNYGMY
		WVRQAPGQGLEYMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDT
		AVYFCARTNYYYRSYIFYFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAAL
		GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
		NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE
		VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNAYTQKSLSLSPGK
174	PR-	EIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQAPRLLIYADDQRAS
	1612496L	GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYGINIDVVFGGGTKVEIKGGSGGGG
		SGGATQLTQSPSLSASVGDRVTITCRASESVSTHMHWYQQKPGKQPKLLIYGASNLE
		SGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSWNDPFTFGQGTKLEIKRTVAAPS
		VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
		TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
175	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1612498H	DDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIESSGPKYSFDYW
		GQGTMVTVSSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFSFSKYDMA
		WFRQAPGKGLEWVASITTSGVGTYYRDSVKGRFTVSRDNAKSTLYLQMNSLRAEDT
		AVYYCARGYGAMDAWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
		DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK
		PSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVV
		VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK
		EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS
		DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA
		LHNAYTQKSLSLSPGK
176	PR-	EIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQAPRLLIYADDQRAS
	1612498L	GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYGINIDVVFGGGTKVEIKGGSGGGG
		SGGDIQMTQSPSSLSASVGDRVTITCKASQDIDDYLSWYQQKPGKSPKLVIYAATRL
		ADGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQSSSTPWTFGGGTKVEIKRTVAA
		PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
		DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
177	PR-	EVQLVQSGAEVKKPGSSVKVSCKASGYTFTESYMYWVKQAPGQGLELIGRIDPEDG
	1612499H	STDYVEKFKNKATLTADKSTSTAYMELSSLRSEDTAVYFCARFGARSYFYPMDAWG
		QGTTVTVSSGGGGSGGGGSEIQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWV
		RQAPGQGLEYMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVY
		FCARTNYYYRSYIFYFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
		VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN
		HKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTC
		VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN
		GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF
		YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM
		HEALHNAYTQKSLSLSPGK
178	PR-	ETVLTQSPATLSLSPGERATLSCRASESVSTLMHWYQQKPGQQPRLLIYGASNLESGV
	1612499L	PARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPWTFGGGTKVEIKGGSGGGGS
		GGATQLTQSPSLSASVGDRVTITCRASESVSTHMHWYQQKPGKQPKLLIYGASNLES
		GVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSWNDPFTFGQGTKLEIKRTVAAPSV
		FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
		YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
179	PR-	EVQLVQSGAEVKKPGSSVKVSCKASGYTFTESYMYWVKQAPGQGLELIGRIDPEDG
	1612500H	STDYVEKFKNKATLTADKSTSTAYMELSSLRSEDTAVYFCARFGARSYFYPMDAWG
		QGTTVTVSSGGGGSGGGGSEIQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWV
		KQAPGQGLEYMGWIDTETGRPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVY
		FCARWSGDTTGIRGPWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
		LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV
		NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVT
		CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL
		NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG
		FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
		MHEALHNAYTQKSLSLSPGK
180	PR-	ETVLTQSPATLSLSPGERATLSCRASESVSTLMHWYQQKPGQQPRLLIYGASNLESGV
	1612500L	PARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPWTFGGGTKVEIKGGSGGGGS
		GGDIRMTQSPSSLSASVGDRVTIECLASEDIYSDLAWYQQKPGKSPKLLTYNANGLQN
		GVPSRFSGSGSGTDYSLTISSLQPEDVATYFCQQYNYFPGTFGQGTKLEIKRTVAAPS
		VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
		TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
181	PR-	EVQLVQSGAEVKKPGSSVKVSCKASGYTFTESYMYWVKQAPGQGLELIGRIDPEDG
	1612501H	STDYVEKFKNKATLTADKSTSTAYMELSSLRSEDTAVYFCARFGARSYFYPMDAWG
		QGTTVTVSSGGGGSGGGGSEVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYGMYW
		VRQAPGQGLEWMGWIDTETGRPTYADDFKGRFTFTADKSTSTAYMELSSLRSEDTA
		VYYCARWSGDTTGIRGPWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAA
		LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
		CNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTP
		EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNAYTQKSLSLSPGK
182	PR-	ETVLTQSPATLSLSPGERATLSCRASESVSTLMHWYQQKPGQQPRLLIYGASNLESGV
	1612501L	PARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPWTFGGGTKVEIKGGSGGGGS
		GGDIRMTQSPSSLSASVGDRVTITCLASEDIYSDLAWYQQKPGKSPKLLTYNANGLQN
		GVPSRFSGSGSGTDYTLTISSLQPEDVATYFCQQYNYFPGTFGQGTKLEIKRTVAAPS
		VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
		TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
183	PR-	EVQLVQSGAEVKKPGSSVKVSCKASGYTFTESYMYWVKQAPGQGLELIGRIDPEDG
	1612502H	STDYVEKFKNKATLTADKSTSTAYMELSSLRSEDTAVYFCARFGARSYFYPMDAWG
		QGTTVTVSSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFSFSKYDMAWF
		RQAPGKGLEWVASITTSGVGTYYRDSVKGRFTVSRDNAKSTLYLQMNSLRAEDTAV
		YYCARGYGAMDAWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF
		PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN
		TKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVD
		VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
		KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDI
		AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
		NAYTQKSLSLSPGK
184	PR-	ETVLTQSPATLSLSPGERATLSCRASESVSTLMHWYQQKPGQQPRLLIYGASNLESGV
	1612502L	PARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPWTFGGGTKVEIKGGSGGGGS
		GGDIQMTQSPSSLSASVGDRVTITCKASQDIDDYLSWYQQKPGKSPKLVIYAATRLA
		DGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQSSSTPWTFGGGTKVEIKRTVAAP
		SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
		STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
185	PR-	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGLEWMGWIDTE
	1613183H	TGDPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARTNYYYRNYMFYF
		DYWGQGTMVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYG
		MGVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNM
		DPVDTATYYCARIESSGPKYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
		TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMIS
		RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL
		HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT
		CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV
		FSCSVMHEALHNAYTQKSLSLSPGK
186	PR-	EIVLTQSPATLSLSPGERATLFCRASQSVSNHMHWYQQKPGQAPRLLIYGASILESGV
	1613183L	PARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSWYDPITFGQGTKLEIKGGSGGGGSG
		GEIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQAPRLLIYADDQRA
		SGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYGINIDVVFGGGTKVEIKRTVAAP
		SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
		STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
187	PR-	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGLEWMGWIDTE
	1613184H	TGDPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARTNYYYRNYMFYF
		DYWGQGTMVTVSSGGGGSGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYG
		MGVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNM
		DPVDTATYYCARIESIGTTYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTA
		ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
		YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISR
		TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
		QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC
		LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS
		CSVMHEALHNAYTQKSLSLSPGK
188	PR-	EIVLTQSPATLSLSPGERATLFCRASQSVSNHMHWYQQKPGQAPRLLIYGASILESGV
	1613184L	PARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSWYDPITFGQGTKLEIKGGSGGGGSG
		GEFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRP
		SGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKRTVAAPS
		VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
		TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
189	PR-	EVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYWVRQAPGQGLEWMGWIDTE
	1613185H	TGDPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARTNYYYRNYMFYF
		DYWGQGTMVTVSSGGGGSGGGGSEVQLVQSGAEVKKPGSSVKVSCKASGYTFTES
		YMYWVKQAPGQGLELIGRIDPEDGSTDYVEKFKNKATLTADKSTSTAYMELSSLRS
		EDTAVYFCARFGARSYFYPMDAWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAA
		LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
		CNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTP
		EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNAYTQKSLSLSPGK
190	PR-	EIVLTQSPATLSLSPGERATLFCRASQSVSNHMHWYQQKPGQAPRLLIYGASILESGV
	1613185L	PARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSWYDPITFGQGTKLEIKGGSGGGGSG
		GETVLTQSPATLSLSPGERATLSCRASESVSTLMHWYQQKPGQQPRLLIYGASNLESG
		VPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPWTFGGGTKVEIKRTVAAPSV
		FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
		YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
191	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1613186H	DDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIESSGPKYSFDYW
		GQGTMVTVSSGGGGSGGGGSEVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMY
		WVRQAPGQGLEWMGWIDTETGDPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDT
		AVYYCARTNYYYRNYMFYFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTA
		ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
		YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISR
		TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
		QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC
		LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS
		CSVMHEALHNAYTQKSLSLSPGK
192	PR-	EIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQAPRLLIYADDQRAS
	1613186L	GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYGINIDVVFGGGTKVEIKGGSGGGG
		SGGEIVLTQSPATLSLSPGERATLFCRASQSVSNHMHWYQQKPGQAPRLLIYGASILE
		SGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSWYDPITFGQGTKLEIKRTVAAPS
		VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
		TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
193	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1613187H	DDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIESIGTTYSFDYW
		GQGTMVTVSSGGGGSGGGGSEVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMY
		WVRQAPGQGLEWMGWIDTETGDPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDT
		AVYYCARTNYYYRNYMFYFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTA
		ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
		YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISR
		TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
		QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC
		LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS
		CSVMHEALHNAYTQKSLSLSPGK
194	PR-	EFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRPS
	1613187L	GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKGGSGGGG
		SGGEIVLTQSPATLSLSPGERATLFCRASQSVSNHMHWYQQKPGQAPRLLIYGASILE
		SGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSWYDPITFGQGTKLEIKRTVAAPS
		VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
		TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
195	PR-	EVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWD
	1613188H	DDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIESIGTTYSFDYW
		GQGTMVTVSSGGGGSGGGGSEIQLVQSGSELKKPGASVKVSCKASGYTFTNYGMY
		WVRQAPGQGLEYMGWINTETGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDT
		AVYFCARTNYYYRSYIFYFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAAL
		GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
		NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE
		VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNAYTQKSLSLSPGK
196	PR-	EFVLTQSPGTLSLSPGERATLSCERSSGDIGDSYVSWYQQKPGQAPRLVIYADDQRPS
	1613188L	GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYDINIDIVFGGGTKVEIKGGSGGGG
		SGGATQLTQSPSLSASVGDRVTITCRASESVSTHMHWYQQKPGKQPKLLIYGASNLE
		SGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSWNDPFTFGQGTKLEIKRTVAAPS
		VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
		TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
197	PR-	EVQLVQSGAEVKKPGSSVKVSCKASGYTFTESYMYWVKQAPGQGLELIGRIDPEDG
	1613189H	STDYVEKFKNKATLTADKSTSTAYMELSSLRSEDTAVYFCARFGARSYFYPMDAWG
		QGTTVTVSSGGGGSGGGGSEVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMYW
		VRQAPGQGLEWMGWIDTETGDPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTA
		VYYCARTNYYYRNYMFYFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAA
		LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
		CNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTP
		EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
		WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNAYTQKSLSLSPGK
198	PR-	ETVLTQSPATLSLSPGERATLSCRASESVSTLMHWYQQKPGQQPRLLIYGASNLESGV
	1613189L	PARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPWTFGGGTKVEIKGGSGGGGS
		GGEIVLTQSPATLSLSPGERATLFCRASQSVSNHMHWYQQKPGQAPRLLIYGASILES
		GVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSWYDPITFGQGTKLEIKRTVAAPS
		VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
		TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
199	PR-	EVQLVQSGAEVKKPGSSVKVSCKASGYTFTESYMYWVKQAPGQGLELIGRIDPEDG
	1613190H	STDYVEKFKNKATLTADKSTSTAYMELSSLRSEDTAVYFCARFGARSYFYPMDAWG
		QGTTVTVSSGGGGSGGGGSEIQLVQSGSELKKPGASVKVSCKASGYPFTNSGMYWV
		KQAPGQGLEYMGWINTEAGKPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAV
		YFCARWGYISDNSYGWFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG
		CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEV
		TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW
		LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK
		GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
		MHEALHNAYTQKSLSLSPGK
200	PR-	ETVLTQSPATLSLSPGERATLSCRASESVSTLMHWYQQKPGQQPRLLIYGASNLESGV
	1613190L	PARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSWNDPWTFGGGTKVEIKGGSGGGGS
		GGATQLTQSPSSLSASVGDRQVTISCRASEGVYSYMHWYQQKPGKQPKLLIYKASNLA
		SGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCHQNWNDPLTFGQGTKLEIKRTVAAP
		SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
		STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
201	PR-	EIQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVKQAPGQGLEYMGWIDTET
	1629646H	GRPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCARWSGDTTGIRGPWFA
		YWGQGTLVTVSSASTKGPEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWI
		RQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTAT
		YYCARIESSGPKYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
		KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
		KPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCV
		VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP
		SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
		ALHNAYTQKSLSLSPGK
202	PR-	DIRMTQSPSSLSASVGDRVTIECLASEDIYSDLAWYQQKPGKSPKLLIYNANGLQNGV
	1629646L	PSRFSGSGSGTDYSLTISSLQPEDVATYFCQQYNYFPGTFGQGTKLEIKRTVAAPSVFI
		FPPEIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQAPRLLIYADDQR
		ASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYGINIDVVFGGGTKVEIKRTVAA
		PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
		DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
203	PR-	EVQLVESGGGLVQPGGSLRLSCAASGFSFSKYDMAWFRQAPGKGLEWVASITTSGV
	1629647H	GTYYRDSVKGRFTVSRDNAKSTLYLQMNSLRAEDTAVYYCARGYGAMDAWGQGT
		TVTVSSASTKGPEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKA
		LEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIE
		SSGPKYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
		VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTK
		VDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS
		HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
		KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV
		EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNA
		YTQKSLSLSPGK
204	PR-	DIQMTQSPSSLSASVGDRVTITCKASQDIDDYLSWYQQKPGKSPKLVIYAATRLADG
	1629647L	VPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQSSSTPWTFGGGTKVEIKRTVAAPSVF
		IFPPEIVLTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQAPRLLIYADDQ
		RASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYGINIDVVFGGGTKVEIKRTVA
		APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS
		KDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
205	PR-	EIQLVQSGSELKKPGASVKVSCKASGYTFTNYGMYWVKQAPGQGLEYMGWIDTET
	1629648H	GRPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCARWSGDTTGIRGPWFA
		YWGQGTLVTVSSASTKGPSVFPLAPEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYG
		MGVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNM
		DPVDTATYYCARIESSGPKYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
		TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMIS
		RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL
		HQDWLNGKEYKCKVSNKALPAPIEKTIMISKAKGQPREPQVYTLPPSREEMTKNQVSLT
		CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV
		FSCSVMHEALHNAYTQKSLSLSPGK
206	PR-	DIRMTQSPSSLSASVGDRVTIECLASEDIYSDLAWYQQKPGKSPKLLIYNANGLQNGV
	1629648L	PSRFSGSGSGTDYSLTISSLQPEDVATYFCQQYNYFPGTFGQGTKLEIKRTVAAPEIVL
		TQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQAPRLLIYADDQRASGIPD
		RFSGSGSGTDFTLTISRLEPEDFAVYYCQSYGINIDVVFGGGTKVEIKRTVAAPSVFIFP
		PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL
		SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
207	PR-	EVQLVESGGGLVQPGGSLRLSCAASGFSFSKYDMAWFRQAPGKGLEWVASITTSGV
	1629649H	GTYYRDSVKGRFTVSRDNAKSTLYLQMNSLRAEDTAVYYCARGYGAMDAWGQGT
		TVTVSSASTKGPSVFPLAPEVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGMGVGWI
		RQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTAT
		YYCARIESSGPKYSFDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
		KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
		KPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCV
		VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP
		SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
		ALHNAYTQKSLSLSPGK
208	PR-	DIQMTQSPSSLSASVGDRVTITCKASQDIDDYLSWYQQKPGKSPKLVIYAATRLADG
	1629649L	VPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQSSSTPWTFGGGTKVEIKRTVAAPEIV
		LTQSPGTLSLSPGERATLSCRASSGSIWYSFVSWYQQKPGQAPRLLIYADDQRASGIP
		DRFSGSGSGTDFTLTISRLEPEDFAVYYCQSYGINIDVVFGGGTKVEIKRTVAAPSVFI
		FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY
		SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Example 18

PR-1610561 Cell Lines

Chimeric, humanized, and affinity matured antibodies, and DVD-Ig binding proteins were expressed using pHybE vectors. Transient expression of PR-1610561 in HEK cells was also achieved using a vector similar to pHybE-hCg1,z,non-a,mut(234,235) V2. See U.S. Pat. No. 8,187,836.

CHO cell lines producing PR-1610561 have been generated. The growth and productivity of the CHO cell lines were similar to those of other DVD-Ig molecules. All cell lines passed a screening for acceptable product quality by MS, SEC, and CIEX. CHO cell lines were produced using pBJ and pCD plasmid vectors encoding the amino acid sequences of PR-1610561. See US 2014/0295497.

Example 19

Epitope Binning

Antibodies and binding proteins disclosed herein are tested in a label-free cell-based competition assay in order to determine which antibodies and binding proteins are capable of binding to the same antigen (e.g., VEGF, PDGF, or one of their receptors) simultaneously. If antibodies or binding proteins are not able to bind simultaneously (therefore possibly competing for the same or similar epitope), those antibodies or binding proteins are assigned to the same “epitope bin.” If antibodies or binding proteins are capable of binding simultaneously and therefore do not compete for antigen binding, those antibodies or binding proteins are assigned to different epitope bins.

INCORPORATION BY REFERENCE

The contents of all cited references (including literature references, patents, patent applications, and websites) that maybe cited throughout this application are hereby expressly incorporated by reference in their entirety for any purpose, as are the references cited therein. To the extent those references contradict or are inconsistent with any statements in this application, the text of the application will control. The disclosure will employ, unless otherwise indicated, conventional techniques of immunology, molecular biology and cell biology, and pathology, which are well known in the art.

EQUIVALENTS

The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting of the inventions described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are therefore intended to be embraced herein.

Claims

1-155. (canceled)

156. An antibody or antigen binding fragment thereof capable of binding VEGF, wherein the antibody or antigen binding fragment comprises: a) CDRs 1-3 from SEQ ID NO: 17 and CDRs-1-3 from SEQ ID NO: 18,b) CDRs 1-3 from SEQ ID NO: 19 and CDRs-1-3 from SEQ ID NO: 20,c) CDRs 1-3 from SEQ ID NO: 21 and CDRs-1-3 from SEQ ID NO: 22,d) CDRs 1-3 from SEQ ID NO: 23 and CDRs-1-3 from SEQ ID NO: 24,e) CDRs 1-3 from SEQ ID NO: 25 and CDRs-1-3 from SEQ ID NO: 26,f) CDRs 1-3 from SEQ ID NO: 27 and CDRs-1-3 from SEQ ID NO: 28,g) CDRs 1-3 from SEQ ID NO: 29 and CDRs-1-3 from SEQ ID NO: 30,h) CDRs 1-3 from SEQ ID NO: 31 and CDRs-1-3 from SEQ ID NO: 32,i) CDRs 1-3 from SEQ ID NO: 33 and CDRs-1-3 from SEQ ID NO: 34,j) CDRs 1-3 from SEQ ID NO: 35 and CDRs-1-3 from SEQ ID NO: 36,k) CDRs 1-3 from SEQ ID NO: 37 and CDRs-1-3 from SEQ ID NO: 38,l) CDRs 1-3 from SEQ ID NO: 39 and CDRs-1-3 from SEQ ID NO: 40,m) CDRs 1-3 from SEQ ID NO: 41 and CDRs-1-3 from SEQ ID NO: 42, orn) CDRs 1-3 from SEQ ID NO: 43 and CDRs-1-3 from SEQ ID NO: 44.

157. The antibody or antigen binding fragment of claim 156, wherein the antibody or antigen binding fragment comprises: a) SEQ ID NO: 17 and SEQ ID NO: 18,b) SEQ ID NO: 19 and SEQ ID NO: 20,c) SEQ ID NO: 21 and SEQ ID NO: 22,d) SEQ ID NO: 23 and SEQ ID NO: 24,e) SEQ ID NO: 25 and SEQ ID NO: 26,f) SEQ ID NO: 27 and SEQ ID NO: 28,g) SEQ ID NO: 29 and SEQ ID NO: 30,h) SEQ ID NO: 31 and SEQ ID NO: 32,i) SEQ ID NO: 33 and SEQ ID NO: 34,j) SEQ ID NO: 35 and SEQ ID NO: 36,k) SEQ ID NO: 37 and SEQ ID NO: 38,l) SEQ ID NO: 39 and SEQ ID NO: 40,m) SEQ ID NO: 41 and SEQ ID NO: 42, orn) SEQ ID NO: 43 and SEQ ID NO: 44.

158. The antibody or antigen binding fragment of claim 156, wherein the antibody or antigen binding fragment comprises CDRs 1-3 from SEQ ID NO: 35 and CDRs 1-3 from SEQ ID NO: 36, or comprises SEQ ID NO: 35 and SEQ ID NO: 36.

159. The antibody or antigen binding fragment of claim 156, wherein the antibody or antigen binding fragment comprises CDRs 1-3 from SEQ ID NO: 17 and CDRs 1-3 from SEQ ID NO: 18, or comprises SEQ ID NO: 17 and SEQ ID NO: 18.

160. The antibody or antigen binding fragment of claim 156, wherein the antibody or antigen binding fragment comprises CDRs 1-3 from SEQ ID NO: 39 and CDRs 1-3 from SEQ ID NO: 40, or comprises SEQ ID NO: 39 and SEQ ID NO: 40.

161. The antibody or antigen binding fragment of claim 156, further comprising heavy and light chain constant domains selected from Table 3.

162. The antibody or antigen binding fragment of claim 158, further comprising: a) a heavy chain constant region on the first polypeptide chain comprising a human IgG1 heavy chain sequence modified by one or more amino acid changes, wherein the changes comprise substitution of leucines at positions 234 and 235 with alanines, and optionally also comprise a substitution of histidine at position 435 with alanine, wherein the amino acid positions are numbered using EU index numbering; and(b) a light chain constant region on the second polypeptide chain comprising a human kappa light chain constant region sequence.

163. An antibody or antigen binding fragment that competes with the antibody or antigen binding fragment of claim 156 for binding to VEGF.

164. An antibody or antigen binding fragment that binds to the same epitope of VEGF as the antibody or antigen binding fragment of claim 156.

165. An antibody conjugate comprising the antibody or antigen binding fragment of claim 156, the antibody conjugate further comprising an immunoadhesion molecule, an imaging agent, a therapeutic agent, or a cytotoxic agent, wherein the imaging agent is a radiolabel, an enzyme, a fluorescent label, a luminescent label, a bioluminescent label, a magnetic label, or biotin, wherein the radiolabel is 3H, 14C, 35S, 90Y, 99Tc, 111In, 125I, 131I, 177Lu, 166Ho, or 153Sm, and wherein the therapeutic or cytotoxic agent is an anti-metabolite, an alkylating agent, an antibiotic, a growth factor, a cytokine, an anti-angiogenic agent, an anti-mitotic agent, an anthracycline, toxin, or an apoptotic agent.

166. An isolated nucleic acid encoding the antibody or antigen binding fragment of claim 156.

167. A vector comprising the isolated nucleic acid of claim 166.

168. A host cell comprising the vector of claim 167.

169. A method of producing an antibody or antigen binding fragment, comprising culturing the host cell of claim 168 in culture medium under conditions sufficient to produce the antibody or antigen binding fragment.

170. A pharmaceutical composition comprising the antibody or antigen binding fragment of claim 156, and a pharmaceutically acceptable carrier.

171. The pharmaceutical composition of claim 170, further comprising at least one additional therapeutic agent.

172. A method of treating a subject for a disease or disorder by administering the antibody or antigen binding fragment of claim 156 to the subject.

173. An antibody or antigen binding fragment thereof capable of binding PDGF, wherein the antibody or antigen binding fragment comprises: a) CDRs 1-3 from SEQ ID NO: 1 and CDRs-1-3 from SEQ ID NO: 2,b) CDRs 1-3 from SEQ ID NO: 3 and CDRs-1-3 from SEQ ID NO: 4,c) CDRs 1-3 from SEQ ID NO: 5 and CDRs-1-3 from SEQ ID NO: 6,d) CDRs 1-3 from SEQ ID NO: 7 and CDRs-1-3 from SEQ ID NO: 8,e) CDRs 1-3 from SEQ ID NO: 9 and CDRs-1-3 from SEQ ID NO: 10,f) CDRs 1-3 from SEQ ID NO: 11 and CDRs-1-3 from SEQ ID NO: 12,g) CDRs 1-3 from SEQ ID NO: 13 and CDRs-1-3 from SEQ ID NO: 14,h) CDRs 1-3 from SEQ ID NO: 15 and CDRs-1-3 from SEQ ID NO: 16, ori) CDRs 1-3 from SEQ ID NO: 211 and CDRs-1-3 from SEQ ID NO: 212.

174. The antibody or antigen binding fragment of claim 173, wherein the antibody or antigen binding fragment comprises: a) SEQ ID NO: 1 and SEQ ID NO: 2,b) SEQ ID NO: 3 and SEQ ID NO: 4,c) SEQ ID NO: 5 and SEQ ID NO: 6,d) SEQ ID NO: 7 and SEQ ID NO: 8,e) SEQ ID NO: 9 and SEQ ID NO: 10,f) SEQ ID NO: 11 and SEQ ID NO: 12,g) SEQ ID NO: 13 and SEQ ID NO: 14,h) SEQ ID NO: 15 and SEQ ID NO: 16, ori) SEQ ID NO: 211 and SEQ ID NO: 212.

175. The antibody or antigen binding fragment of claim 173, wherein the antibody or antigen binding fragment comprises CDRs 1-3 from SEQ ID NO: 1 and CDRs 1-3 from SEQ ID NO: 2, or comprise SEQ ID NO: 1 and SEQ ID NO: 2.

176. The antibody or antigen binding fragment of claim 173, wherein the antibody or antigen binding fragment comprises CDRs 1-3 from SEQ ID NO: 15 and CDRs 1-3 from SEQ ID NO: 16, or comprise SEQ ID NO: 15 and SEQ ID NO: 16.

177. The antibody or antigen binding fragment of claim 173, further comprising heavy and light chain constant domains selected from Table 3.

178. The antibody or antigen binding fragment of claim 176, further comprising: a) a heavy chain constant region on the first polypeptide chain comprising a human IgG1 heavy chain sequence modified by one or more amino acid changes, wherein the changes comprise substitution of leucines at positions 234 and 235 with alanines, and optionally also comprise a substitution of histidine at position 435 with alanine, wherein the amino acid positions are numbered using EU index numbering; and(b) a light chain constant region on the second polypeptide chain comprising a human kappa light chain constant region sequence.

179. An antibody or antigen binding fragment that competes with the antibody or antigen binding fragment of claim 173 for binding to PDGF.

180. An antibody or antigen binding fragment that binds to the same epitope of PDGF as the antibody or antigen binding fragment of claim 173.

181. An antibody conjugate comprising the antibody or antigen binding fragment of claim 173, the antibody conjugate further comprising an immunoadhesion molecule, an imaging agent, a therapeutic agent, or a cytotoxic agent, wherein the imaging agent is a radiolabel, an enzyme, a fluorescent label, a luminescent label, a bioluminescent label, a magnetic label, or biotin, wherein the radiolabel is 3H, 14C, 35S, 90Y, 99Tc, 111In, 125I, 131I, 177Lu, 166Ho, or 153Sm, and wherein the therapeutic or cytotoxic agent is an anti-metabolite, an alkylating agent, an antibiotic, a growth factor, a cytokine, an anti-angiogenic agent, an anti-mitotic agent, an anthracycline, toxin, or an apoptotic agent.

182. An isolated nucleic acid encoding the antibody or antigen binding fragment of claim 173.

183. A vector comprising the isolated nucleic acid of claim 182.

184. A host cell comprising the vector of claim 183.

185. A method of producing an antibody or antigen binding fragment, comprising culturing the host cell of claim 184 in culture medium under conditions sufficient to produce the antibody or antigen binding fragment.

186. A pharmaceutical composition comprising the antibody or antigen binding fragment of claim 173, and a pharmaceutically acceptable carrier.

187. The pharmaceutical composition of claim 186, further comprising at least one additional therapeutic agent.

188. A method of treating a subject for a disease or disorder by administering the antibody or antigen binding fragment of claim 173 to the subject.

189. A multispecific binding protein capable of binding VEGF and PDGF, wherein: i) the variable domains that form a functional binding site for VEGF comprise; a) CDRs 1-3 from SEQ ID NO: 17 and CDRs-1-3 from SEQ ID NO: 18,b) CDRs 1-3 from SEQ ID NO: 19 and CDRs-1-3 from SEQ ID NO: 20,c) CDRs 1-3 from SEQ ID NO: 21 and CDRs-1-3 from SEQ ID NO: 22,d) CDRs 1-3 from SEQ ID NO: 23 and CDRs-1-3 from SEQ ID NO: 24,e) CDRs 1-3 from SEQ ID NO: 25 and CDRs-1-3 from SEQ ID NO: 26,f) CDRs 1-3 from SEQ ID NO: 27 and CDRs-1-3 from SEQ ID NO: 28,g) CDRs 1-3 from SEQ ID NO: 29 and CDRs-1-3 from SEQ ID NO: 30,h) CDRs 1-3 from SEQ ID NO: 31 and CDRs-1-3 from SEQ ID NO: 32,i) CDRs 1-3 from SEQ ID NO: 33 and CDRs-1-3 from SEQ ID NO: 34,j) CDRs 1-3 from SEQ ID NO: 35 and CDRs-1-3 from SEQ ID NO: 36,k) CDRs 1-3 from SEQ ID NO: 37 and CDRs-1-3 from SEQ ID NO: 38,l) CDRs 1-3 from SEQ ID NO: 39 and CDRs-1-3 from SEQ ID NO: 40,m) CDRs 1-3 from SEQ ID NO: 41 and CDRs-1-3 from SEQ ID NO: 42, orn) CDRs 1-3 from SEQ ID NO: 43 and CDRs-1-3 from SEQ ID NO: 44; andii) the variable domains that form a functional binding site for PDGF comprise; a) CDRs 1-3 from SEQ ID NO: 1 and CDRs-1-3 from SEQ ID NO: 2,b) CDRs 1-3 from SEQ ID NO: 3 and CDRs-1-3 from SEQ ID NO: 4,c) CDRs 1-3 from SEQ ID NO: 5 and CDRs-1-3 from SEQ ID NO: 6,d) CDRs 1-3 from SEQ ID NO: 7 and CDRs-1-3 from SEQ ID NO: 8,e) CDRs 1-3 from SEQ ID NO: 9 and CDRs-1-3 from SEQ ID NO: 10,f) CDRs 1-3 from SEQ ID NO: 11 and CDRs-1-3 from SEQ ID NO: 12,g) CDRs 1-3 from SEQ ID NO: 13 and CDRs-1-3 from SEQ ID NO: 14,h) CDRs 1-3 from SEQ ID NO: 15 and CDRs-1-3 from SEQ ID NO: 16, ori) CDRs 1-3 from SEQ ID NO: 211 and CDRs-1-3 from SEQ ID NO: 212.

190. The multispecific binding protein of claim 189, wherein: i) the variable domains that form a functional binding site for VEGF comprise; a) SEQ ID NO: 17 and SEQ ID NO: 18,b) SEQ ID NO: 19 and SEQ ID NO: 20,c) SEQ ID NO: 21 and SEQ ID NO: 22,d) SEQ ID NO: 23 and SEQ ID NO: 24,e) SEQ ID NO: 25 and SEQ ID NO: 26,f) SEQ ID NO: 27 and SEQ ID NO: 28,g) SEQ ID NO: 29 and SEQ ID NO: 30,h) SEQ ID NO: 31 and SEQ ID NO: 32,i) SEQ ID NO: 33 and SEQ ID NO: 34,j) SEQ ID NO: 35 and SEQ ID NO: 36,k) SEQ ID NO: 37 and SEQ ID NO: 38,l) SEQ ID NO: 39 and SEQ ID NO: 40,m) SEQ ID NO: 41 and SEQ ID NO: 42, orn) SEQ ID NO: 43 and SEQ ID NO: 44; andii) the variable domains that form a functional binding site for PDGF comprise: a) SEQ ID NO: 1 and SEQ ID NO: 2,b) SEQ ID NO: 3 and SEQ ID NO: 4,c) SEQ ID NO: 5 and SEQ ID NO: 6,d) SEQ ID NO: 7 and SEQ ID NO: 8,e) SEQ ID NO: 9 and SEQ ID NO: 10,f) SEQ ID NO: 11 and SEQ ID NO: 12,g) SEQ ID NO: 13 and SEQ ID NO: 14,h) SEQ ID NO: 15 and SEQ ID NO: 16, ori) SEQ ID NO: 211 and SEQ ID NO: 212.

191. The multispecific binding protein of claim 189, wherein the variable domains that form a functional binding site for VEGF comprise: a) CDRs 1-3 from SEQ ID NO: 35 and CDRs 1-3 from SEQ ID NO: 36;b) CDRs 1-3 from SEQ ID NO: 17 and CDRs 1-3 from SEQ ID NO: 18; orc) CDRs 1-3 from SEQ ID NO: 39 and CDRs 1-3 from SEQ ID NO: 40.

192. The multispecific binding protein of claim 190, wherein the variable domains that form a functional binding site for VEGF comprise: a) SEQ ID NO: 35 and SEQ ID NO: 36;b) SEQ ID NO: 17 and SEQ ID NO: 18; orc) SEQ ID NO: 39 and SEQ ID NO: 40.

193. The multispecific binding protein of claim 189, wherein the variable domains that form a functional binding site for PDGF comprise: a) CDRs 1-3 from SEQ ID NO: 1 and CDRs 1-3 from SEQ ID NO: 2; orb) CDRs 1-3 from SEQ ID NO: 15 and CDRs 1-3 from SEQ ID NO: 16.

194. The multispecific binding protein of claim 190, wherein the variable domains that form a functional binding site for PDGF comprise: a) SEQ ID NO: 1 and SEQ ID NO: 2; orb) SEQ ID NO: 15 and SEQ ID NO: 16.

195. The multispecific binding protein of claim 189, wherein: (a) the variable domains that form a functional binding site for VEGF comprise CDRs 1-3 from SEQ ID NO: 35 and CDRs 1-3 from SEQ ID NO: 36 and the variable domains that form a functional binding site for PDGF comprise CDRs 1-3 from SEQ ID NO: 15 and CDRs 1-3 from SEQ ID NO: 16;(b) the variable domains that form a functional binding site for VEGF comprise CDRs 1-3 from SEQ ID NO: 17 and CDRs 1-3 from SEQ ID NO: 18 and the variable domains that form a functional binding site for PDGF comprise CDRs 1-3 from SEQ ID NO: 1 and CDRs 1-3 from SEQ ID NO: 2; or(c) the variable domains that form a functional binding site for VEGF comprise CDRs 1-3 from SEQ ID NO: 39 and CDRs 1-3 from SEQ ID NO: 40 and the variable domains that form a functional binding site for PDGF comprise CDRs 1-3 from SEQ ID NO: 15 and CDRs 1-3 from SEQ ID NO: 16.

196. The multispecific binding protein of claim 190, wherein: (a) the variable domains that form a functional binding site for VEGF comprise SEQ ID NO: 35 and SEQ ID NO: 36 and the variable domains that form a functional binding site for PDGF comprise SEQ ID NO: 15 and SEQ ID NO: 16;(b) the variable domains that form a functional binding site for VEGF comprise SEQ ID NO: 17 and SEQ ID NO: 18 and the variable domains that form a functional binding site for PDGF comprise SEQ ID NO: 1 and SEQ ID NO: 2; or(c) the variable domains that form a functional binding site for VEGF comprise SEQ ID NO: 39 and SEQ ID NO: 40 and the variable domains that form a functional binding site for PDGF comprise SEQ ID NO: 15 and SEQ ID NO: 16.

197. The multispecific binding protein of claim 189, further comprising heavy and light chain constant domains selected from Table 3.

198. The multispecific binding protein of claim 195, further comprising: a) a heavy chain constant region on the first polypeptide chain comprising a human IgG1 heavy chain sequence modified by one or more amino acid changes, wherein the changes comprise substitution of leucines at positions 234 and 235 with alanines, and optionally also comprise a substitution of histidine at position 435 with alanine, wherein the amino acid positions are numbered using EU index numbering; and(b) a light chain constant region on the second polypeptide chain comprising a human kappa light chain constant region sequence.

199. The multispecific binding protein of claim 189, wherein the binding protein is: a) a dual variable domain immunoglobulin (DVD-Ig) binding protein;b) a CrossMab binding protein;c) a diabody;d) a tandem single-chain Fv molecule;e) a single-chain diabody; orf) a di-diabody.

200. The multispecific binding protein of claim 199, wherein the binding protein is a DVD-Ig binding protein comprising first and second polypeptide chains, each independently comprising VD1-(X1)n-VD2-C-X2, wherein VD1 is a first variable domain;VD2 is a second variable domain;C is a constant domain;X1 is a linker;X2 is an Fc region; andn is 0 or 1,

201. The multispecific binding protein of claim 200, wherein the DVD-Ig binding protein comprises any one of: PR-1563988 (comprising SEQ ID NOs: 45 and 46),PR-1563990 (comprising SEQ ID NOs: 47 and 48),PR-1563998 (comprising SEQ ID NOs: 49 and 50),PR-1564009 (comprising SEQ ID NOs: 51 and 52),PR-1564010 (comprising SEQ ID NOs: 53 and 54),PR-1564011 (comprising SEQ ID NOs: 55 and 56),PR-1564012 (comprising SEQ ID NOs: 57 and 58),PR-1564013 (comprising SEQ ID NOs: 59 and 60),PR-1564896 (comprising SEQ ID NOs: 209 and 65),PR-1565031 (comprising SEQ ID NOs: 76 and 77),PR-1565032 (comprising SEQ ID NOs: 78 and 79),PR-1565035 (comprising SEQ ID NOs: 80 and 81),PR-1572102 (comprising SEQ ID NOs: 88 and 89),PR-1572103 (comprising SEQ ID NOs: 90 and 91),PR-1572104 (comprising SEQ ID NOs: 92 and 93),PR-1572105 (comprising SEQ ID NOs: 94 and 95),PR-1572106 (comprising SEQ ID NOs: 96 and 97),PR-1575573 (comprising SEQ ID NOs: 210 and 98),PR-1575832 (comprising SEQ ID NOs: 99 and 100),PR-1575834 (comprising SEQ ID NOs: 101 and 102),PR-1575835 (comprising SEQ ID NOs: 103 and 104),PR-1577165 (comprising SEQ ID NOs: 105 and 106),PR-1577166 (comprising SEQ ID NOs: 107 and 108),PR-1577547 (comprising SEQ ID NOs: 109 and 110),PR-1577548 (comprising SEQ ID NOs: 111 and 112),PR-1577550 (comprising SEQ ID NOs: 113 and 114),PR-1578137 (comprising SEQ ID NOs: 116 and 117),PR-1610560 (comprising SEQ ID NOs: 129 and 130),PR-1610561 (comprising SEQ ID NOs: 131 and 132),PR-1610562 (comprising SEQ ID NOs: 133 and 134),PR-1610563 (comprising SEQ ID NOs: 135 and 136),PR-1611291 (comprising SEQ ID NOs: 139 and 140),PR-1611292 (comprising SEQ ID NOs: 141 and 142),PR-1612489 (comprising SEQ ID NOs: 161 and 162),PR-1612491 (comprising SEQ ID NOs: 163 and 164),PR-1612492 (comprising SEQ ID NOs: 165 and 166),PR-1612495 (comprising SEQ ID NOs: 171 and 172),PR-1612496 (comprising SEQ ID NOs: 173 and 174),PR-1612499 (comprising SEQ ID NOs: 177 and 178),PR-1612500 (comprising SEQ ID NOs: 179 and 180),PR-1612501 (comprising SEQ ID NOs: 181 and 182),PR-1612502 (comprising SEQ ID NOs: 183 and 184),PR-1613183 (comprising SEQ ID NOs: 185 and 186),PR-1613184 (comprising SEQ ID NOs: 187 and 188),PR-1613185 (comprising SEQ ID NOs: 189 and 190),PR-1613190 (comprising SEQ ID NOs: 199 and 200),PR-1565040 (comprising SEQ ID NOs: 3844 and 3845),PR-1565042 (comprising SEQ ID NOs: 3837 and 3838),PR-1565044 (comprising SEQ ID NOs: 213 and 214),PR-1565051 (comprising SEQ ID NOs: 215 and 216),PR-1565083 (comprising SEQ ID NOs: 217 and 218),PR-1565084 (comprising SEQ ID NOs: 219 and 220),PR-1565085 (comprising SEQ ID NOs: 221 and 222),PR-1565086 (comprising SEQ ID NOs: 223 and 224),PR-1571821 (comprising SEQ ID NOs: 225 and 226),PR-1571823 (comprising SEQ ID NOs: 227 and 228),PR-1575521 (comprising SEQ ID NOs: 229 and 230),PR-1571824 (comprising SEQ ID NOs: 231 and 232),PR-1571825 (comprising SEQ ID NOs: 233 and 234),PR-1571826 (comprising SEQ ID NOs: 235 and 236),PR-1571827 (comprising SEQ ID NOs: 237 and 238),PR-1571828 (comprising SEQ ID NOs: 239 and 240),PR-1571830 (comprising SEQ ID NOs: 241 and 242),PR-1571831 (comprising SEQ ID NOs: 243 and 244),PR-1571832 (comprising SEQ ID NOs: 245 and 246),PR-1571836 (comprising SEQ ID NOs: 247 and 248),PR-1577053 (comprising SEQ ID NOs: 249 and 250), orPR-1577056 (comprising SEQ ID NOs: 251 and 252).

202. The multispecific binding protein of claim 200, wherein the DVD-Ig binding protein comprises any one of: a) PR-1610561 (comprising SEQ ID NOs: 131 and 132);b) PR-1572102 (comprising SEQ ID NOs: 88 and 89);c) PR-1572105 (comprising SEQ ID NOs: 94 and 95); ord) PR-1611292 (comprising SEQ ID NOs: 141 and 142).

203. The multispecific binding protein of claim 202, further comprising: a) a heavy chain constant region on the first polypeptide chain comprising a human IgG1 heavy chain sequence modified by one or more amino acid changes, wherein the changes comprise substitution of leucines at positions 234 and 235 with alanines, and optionally also comprise a substitution of histidine at position 435 with alanine, wherein the amino acid positions are numbered using EU index numbering; and(b) a light chain constant region on the second polypeptide chain comprising a human kappa light chain constant region sequence.

204. The multispecific binding protein of claim 200, wherein the DVD-Ig binding protein comprises two first polypeptide chains and two second polypeptide chains, and four functional target binding sites.

205. The multispecific binding protein of claim 200, wherein the linker X1 comprises any one of the linkers listed in Table 55.

206. The multispecific binding protein of claim 200, wherein the Fc region is an Fc region from an IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD, or a variant thereof.

207. A multispecific binding protein that competes with the binding protein of claim 189 for binding to VEGF and/or PDGF.

208. A multispecific binding protein that binds to the same epitope of VEGF and/or PDGF as the binding protein of claim 189.

209. A conjugate comprising the multispecific binding protein of claim 189, the conjugate further comprising an immunoadhesion molecule, an imaging agent, a therapeutic agent, or a cytotoxic agent, wherein the imaging agent is a radiolabel, an enzyme, a fluorescent label, a luminescent label, a bioluminescent label, a magnetic label, or biotin, wherein the radiolabel is 3H, 14C, 35S, 90Y, 99Tc, 111In, 125I, 131I, 177Lu, 166Ho, or 153Sm, and wherein the therapeutic or cytotoxic agent is an anti-metabolite, an alkylating agent, an antibiotic, a growth factor, a cytokine, an anti-angiogenic agent, an anti-mitotic agent, an anthracycline, toxin, or an apoptotic agent.

210. An isolated nucleic acid encoding the multispecific binding protein of claim 189.

211. A vector comprising the isolated nucleic acid of claim 210.

212. A host cell comprising the vector of claim 211.

213. A method of producing a multispecific binding protein, comprising culturing the host cell of claim 212 in culture medium under conditions sufficient to produce the multispecific binding protein.

214. A pharmaceutical composition comprising the multispecific binding protein of claim 189, and a pharmaceutically acceptable carrier.

215. The pharmaceutical composition of claim 214, further comprising at least one additional therapeutic agent.

216. A method of treating a subject for a disease or disorder by administering the multispecific binding protein of claim 189 to the subject.

217. The multispecific binding protein of claim 200, wherein the DVD-Ig binding protein comprises PR-1610561 (comprising SEQ ID NOs: 131 and 132).

218. The multispecific binding protein of claim 200, wherein the DVD-Ig binding protein comprises PR-1572102 (comprising SEQ ID NOs: 88 and 89).

219. The multispecific binding protein of claim 200, wherein the DVD-Ig binding protein comprises PR-1572105 (comprising SEQ ID NOs: 94 and 95).

220. The multispecific binding protein of claim 200, wherein the DVD-Ig binding protein comprises PR-1611292 (comprising SEQ ID NOs: 141 and 142).